{"81ce440540188d860e44b25dbbf288393a815e02": [["Over the last 100 years, immense efforts have been devoted to understanding influenza viruses, yielding deeper understanding of viral pathogenesis, animal models of infection, innate and adaptive immune responses to the virus, original antigenic sin, immunodominance, and antigenic imprinting.", [["influenza viruses", "DISEASE", 76, 93], ["infection", "DISEASE", 165, 174], ["influenza viruses", "ORGANISM", 76, 93], ["influenza viruses", "PROBLEM", 76, 93], ["viral pathogenesis", "PROBLEM", 128, 146], ["infection", "PROBLEM", 165, 174], ["the virus", "PROBLEM", 216, 225], ["viral pathogenesis", "OBSERVATION", 128, 146], ["infection", "OBSERVATION", 165, 174]]], ["Among a number of achievements, the deployment of influenza vaccines has been the most important milestone and has saved countless lives to date.", [["influenza", "DISEASE", 50, 59], ["influenza vaccines", "TREATMENT", 50, 68]]], ["A major breakthrough in our knowledge of humoral immune responses to influenza virus has been the discovery of broadly neutralizing antibodies (bNAbs) that target structurally and functionally conserved sites of vulnerability on the viral hemagglutinin (HA).", [["influenza virus", "DISEASE", 69, 84], ["influenza virus", "ORGANISM", 69, 84], ["bNAbs", "GENE_OR_GENE_PRODUCT", 144, 149], ["viral hemagglutinin", "ORGANISM", 233, 252], ["HA", "GENE_OR_GENE_PRODUCT", 254, 256], ["broadly neutralizing antibodies", "PROTEIN", 111, 142], ["bNAbs", "PROTEIN", 144, 149], ["viral hemagglutinin", "PROTEIN", 233, 252], ["HA", "PROTEIN", 254, 256], ["influenza virus", "SPECIES", 69, 84], ["A major breakthrough", "PROBLEM", 0, 20], ["humoral immune responses", "PROBLEM", 41, 65], ["influenza virus", "PROBLEM", 69, 84], ["broadly neutralizing antibodies", "TREATMENT", 111, 142], ["the viral hemagglutinin (HA)", "PROBLEM", 229, 257], ["major", "OBSERVATION_MODIFIER", 2, 7], ["breakthrough", "OBSERVATION_MODIFIER", 8, 20]]], ["Furthermore, several apparently common lineages of bNAbs have been identified across multiple individuals.", [["bNAbs", "GENE_OR_GENE_PRODUCT", 51, 56], ["bNAbs", "PROTEIN", 51, 56], ["bNAbs", "PROBLEM", 51, 56], ["common", "OBSERVATION_MODIFIER", 32, 38], ["lineages", "OBSERVATION", 39, 47], ["bNAbs", "OBSERVATION", 51, 56], ["multiple", "OBSERVATION_MODIFIER", 85, 93], ["individuals", "OBSERVATION_MODIFIER", 94, 105]]], ["These findings have instructed us on the developmental pathways that could lead to bNAb responses to influenza and have breathed new life into efforts to design vaccines that protect against a wide variety of virus strains: universal influenza vaccines.", [["influenza", "DISEASE", 101, 110], ["influenza", "DISEASE", 234, 243], ["bNAb", "GENE_OR_GENE_PRODUCT", 83, 87], ["bNAb responses", "PROBLEM", 83, 97], ["influenza", "PROBLEM", 101, 110], ["design vaccines", "TREATMENT", 154, 169], ["a wide variety of virus strains", "PROBLEM", 191, 222], ["universal influenza vaccines", "TREATMENT", 224, 252]]], ["These efforts are driven by technological revolutions in several fields that have made possible new approaches to vaccine design and delivery.", [["vaccine design", "TREATMENT", 114, 128], ["delivery", "TREATMENT", 133, 141]]], ["Here we provide our perspective on the prospects for a next generation of influenza vaccines based on these new approaches and concepts.NEW CONCEPTS IN TRADITIONAL VACCINE PLATFORMSAlthough the majority of universal influenza vaccine efforts are directed at subunit vaccines or alternative platforms, several new concepts in virus manipulation are currently being evaluated in the live-attenuated vaccine format.", [["a next generation of influenza vaccines", "TREATMENT", 53, 92], ["TRADITIONAL VACCINE", "TREATMENT", 152, 171], ["universal influenza vaccine efforts", "TREATMENT", 206, 241], ["subunit vaccines", "TREATMENT", 258, 274], ["alternative platforms", "TREATMENT", 278, 299], ["virus manipulation", "TREATMENT", 325, 343]]], ["Orthodox approaches to generate attenuated virus vaccines often involve serial passage of viruses in vitro or in vivo.", [["Orthodox approaches", "TREATMENT", 0, 19], ["attenuated virus vaccines", "TREATMENT", 32, 57]]], ["For example, the first reported live-attenuated influenza vaccine was generated by adapting virus to successively lower temperatures [1] .", [["influenza", "DISEASE", 48, 57], ["influenza", "ORGANISM", 48, 57], ["live-attenuated influenza vaccine", "TREATMENT", 32, 65]]], ["The resultant cold-adapted virus remains the basis of current commercial live-attenuated influenza vaccines.", [["influenza", "DISEASE", 89, 98], ["The resultant cold-adapted virus", "PROBLEM", 0, 32], ["attenuated influenza vaccines", "TREATMENT", 78, 107], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["cold", "OBSERVATION", 14, 18], ["influenza", "OBSERVATION", 89, 98]]], ["However, several orthogonal approaches to synthetically attenuate viruses are being explored.NEW CONCEPTS IN TRADITIONAL VACCINE PLATFORMSFor example, introduction of a conditional defect in influenza HA by engineering its posttranslational processing and maturation was demonstrated as an effective virus attenuation strategy [2] .", [["influenza", "DISEASE", 191, 200], ["influenza HA", "ORGANISM", 191, 203], ["viruses", "PROBLEM", 66, 73], ["a conditional defect", "PROBLEM", 167, 187], ["influenza HA", "PROBLEM", 191, 203], ["an effective virus attenuation strategy", "TREATMENT", 287, 326], ["viruses", "OBSERVATION", 66, 73], ["defect", "OBSERVATION", 181, 187], ["influenza", "OBSERVATION", 191, 200]]], ["The engineered HA possesses a proteolytic cleavage site recognized by pancreatic elastase instead of trypsin-like serine proteases, and the resultant virus is highly attenuated while remaining immunogenic.", [["pancreatic", "ANATOMY", 70, 80], ["HA", "CHEMICAL", 15, 17], ["serine", "CHEMICAL", 114, 120], ["HA", "GENE_OR_GENE_PRODUCT", 15, 17], ["pancreatic elastase", "GENE_OR_GENE_PRODUCT", 70, 89], ["trypsin", "GENE_OR_GENE_PRODUCT", 101, 108], ["proteolytic cleavage site", "PROTEIN", 30, 55], ["pancreatic elastase", "PROTEIN", 70, 89], ["trypsin", "PROTEIN", 101, 108], ["serine proteases", "PROTEIN", 114, 130], ["The engineered HA", "PROBLEM", 0, 17], ["a proteolytic cleavage site", "PROBLEM", 28, 55], ["pancreatic elastase", "PROBLEM", 70, 89], ["trypsin", "PROBLEM", 101, 108], ["serine proteases", "PROBLEM", 114, 130], ["the resultant virus", "PROBLEM", 136, 155], ["pancreatic", "ANATOMY", 70, 80], ["elastase", "OBSERVATION", 81, 89], ["virus", "OBSERVATION", 150, 155], ["attenuated", "OBSERVATION_MODIFIER", 166, 176], ["immunogenic", "OBSERVATION", 193, 204]]], ["Virus attenuation by genome-wide modifications in codon pair bias, in which adjacent codon usage is deoptimized without introducing nonsynonymous mutations, was initially demonstrated in poliovirus [3] and later proven efficacious in influenza viruses [4] .", [["influenza viruses", "DISEASE", 234, 251], ["Virus", "ORGANISM", 0, 5], ["poliovirus", "ORGANISM", 187, 197], ["influenza viruses", "ORGANISM", 234, 251], ["Virus attenuation", "PROBLEM", 0, 17], ["wide modifications in codon pair bias", "PROBLEM", 28, 65], ["introducing nonsynonymous mutations", "PROBLEM", 120, 155], ["poliovirus", "PROBLEM", 187, 197], ["influenza viruses", "PROBLEM", 234, 251], ["attenuation", "OBSERVATION_MODIFIER", 6, 17], ["wide", "OBSERVATION_MODIFIER", 28, 32], ["pair bias", "OBSERVATION", 56, 65], ["codon usage", "OBSERVATION", 85, 96], ["influenza viruses", "OBSERVATION", 234, 251]]], ["The precise mechanism of this approach to virus attenuation may relate to inefficient translation of disfavored codon pairs, triggering of innate immune sensors by coincidental increases in the frequency of CpG/UpA dinucleotides [5] , or a combination of the two.", [["CpG", "CHEMICAL", 207, 210], ["dinucleotides", "CHEMICAL", 215, 228], ["CpG", "DNA", 207, 210], ["virus attenuation", "PROBLEM", 42, 59], ["disfavored codon pairs", "PROBLEM", 101, 123], ["innate immune sensors", "TREATMENT", 139, 160], ["coincidental increases", "PROBLEM", 164, 186], ["CpG/UpA dinucleotides", "TREATMENT", 207, 228], ["disfavored codon", "OBSERVATION", 101, 117], ["increases", "OBSERVATION_MODIFIER", 177, 186]]], ["Incorporation of microRNAs (miRNAs) and their response elements into the viral genome to alter tissue tropism and/or restrict host species range has also been explored as an attenuation strategy [6] [7] [8] .", [["tissue", "ANATOMY", 95, 101], ["tissue", "TISSUE", 95, 101], ["microRNAs", "DNA", 17, 26], ["miRNAs", "DNA", 28, 34], ["response elements", "DNA", 46, 63], ["viral genome", "DNA", 73, 85], ["Incorporation of microRNAs (miRNAs)", "PROBLEM", 0, 35], ["the viral genome", "PROBLEM", 69, 85], ["alter tissue tropism", "PROBLEM", 89, 109], ["an attenuation strategy", "TEST", 171, 194], ["microRNAs", "OBSERVATION", 17, 26], ["viral genome", "OBSERVATION", 73, 85]]], ["Another approach is to recode the influenza genome to include amber codons (TAG) which, under certain circumstances, can be translated as unnatural amino acids (UAAs; eg, N \u03b5 -2-azidoethyloxycarbonyl-l-lysine) [9] .", [["amino acids", "CHEMICAL", 148, 159], ["UAAs", "CHEMICAL", 161, 165], ["N \u03b5 -2-azidoethyloxycarbonyl-l-lysine", "CHEMICAL", 171, 208], ["TAG", "CHEMICAL", 76, 79], ["amino acids", "CHEMICAL", 148, 159], ["UAAs", "CHEMICAL", 161, 165], ["N \u03b5 -2-azidoethyloxycarbonyl-l-lysine", "CHEMICAL", 171, 208], ["TAG", "SIMPLE_CHEMICAL", 76, 79], ["amino acids", "AMINO_ACID", 148, 159], ["UAAs", "SIMPLE_CHEMICAL", 161, 165], ["N \u03b5 -2-azidoethyloxycarbonyl-l-lysine", "SIMPLE_CHEMICAL", 171, 208], ["influenza genome", "DNA", 34, 50], ["amber codons", "DNA", 62, 74], ["the influenza genome", "PROBLEM", 30, 50], ["amber codons", "PROBLEM", 62, 74], ["unnatural amino acids", "TREATMENT", 138, 159], ["UAAs", "TEST", 161, 165], ["azidoethyloxycarbonyl-l-lysine)", "TREATMENT", 178, 209], ["amber codons", "OBSERVATION", 62, 74]]], ["The virus with these modifications can only be propagated in engineered cell lines expressing tRNA CUA and UAA, yet is fully immunogenic.", [["cell lines", "ANATOMY", 72, 82], ["cell lines", "CELL", 72, 82], ["UAA", "SIMPLE_CHEMICAL", 107, 110], ["engineered cell lines", "CELL_LINE", 61, 82], ["The virus", "PROBLEM", 0, 9], ["these modifications", "TREATMENT", 15, 34], ["engineered cell lines", "TREATMENT", 61, 82], ["tRNA CUA", "TEST", 94, 102], ["UAA", "PROBLEM", 107, 110], ["virus", "OBSERVATION", 4, 9], ["cell lines", "OBSERVATION", 72, 82], ["tRNA CUA", "OBSERVATION", 94, 102], ["immunogenic", "OBSERVATION", 125, 136]]], ["The error-prone nature of viral RNAdependent RNA polymerases offers another sophisticated way to attenuate viruses via redirected evolution in sequence space.", [["viral RNAdependent RNA polymerases", "PROTEIN", 26, 60], ["viral RNAdependent RNA polymerases", "TREATMENT", 26, 60], ["attenuate viruses", "PROBLEM", 97, 114], ["viral RNAdependent", "OBSERVATION", 26, 44]]], ["In a recent example, Coxsackie B3 and influenza viruses were recoded to include codons that are only a single nucleotide substitution away from stop codons [10] .", [["influenza viruses", "DISEASE", 38, 55], ["nucleotide", "CHEMICAL", 110, 120], ["nucleotide", "CHEMICAL", 110, 120], ["Coxsackie B3", "ORGANISM", 21, 33], ["influenza viruses", "ORGANISM", 38, 55], ["Coxsackie B3", "SPECIES", 21, 33], ["Coxsackie B3", "PROBLEM", 21, 33], ["influenza viruses", "PROBLEM", 38, 55], ["a single nucleotide substitution", "TREATMENT", 101, 133]]], ["The recoded viruses were highly sensitive to mutagenic conditions and highly attenuated in vivo while retaining their capacity for immune induction.", [["The recoded viruses", "PROBLEM", 0, 19], ["mutagenic conditions", "TEST", 45, 65], ["immune induction", "TREATMENT", 131, 147], ["viruses", "OBSERVATION", 12, 19]]], ["The most advanced candidates using orthogonal viral attenuation methods incorporate specific mutations known to disrupt viral interferon suppression mechanisms, resulting in stronger type I interferon (IFN-I) responses in infected cells [11] [12] [13] .", [["cells", "ANATOMY", 231, 236], ["type I interferon", "GENE_OR_GENE_PRODUCT", 183, 200], ["IFN-I", "GENE_OR_GENE_PRODUCT", 202, 207], ["cells", "CELL", 231, 236], ["interferon", "PROTEIN", 126, 136], ["IFN", "PROTEIN", 202, 205], ["orthogonal viral attenuation methods", "TREATMENT", 35, 71], ["specific mutations", "PROBLEM", 84, 102], ["viral interferon suppression mechanisms", "TREATMENT", 120, 159], ["infected cells", "PROBLEM", 222, 236]]], ["It is important to note that these concepts not only make the virus more susceptible to innate immunity and hence attenuate virulence, but also enhance their immunogenicity by providing the transient IFN-\u03b2 milieu in the absence of other inflammatory cytokines that helps to enhance adaptive immunity [14, 15] .NEW APPROACHES TO ANTIGEN DESIGNMany recent advances in vaccine development have been driven by structures of antibodies and their targets, often in complex, which inform approaches aimed at eliciting desired responses using designed immunogens [16] [17] [18] [19] [20] (Figure 1 ).", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 200, 205], ["[16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 555, 579], ["IFN", "PROTEIN", 200, 203], ["inflammatory cytokines", "PROTEIN", 237, 259], ["antibodies", "PROTEIN", 420, 430], ["the virus", "PROBLEM", 58, 67], ["virulence", "PROBLEM", 124, 133], ["the transient IFN-\u03b2 milieu", "PROBLEM", 186, 212], ["other inflammatory cytokines", "PROBLEM", 231, 259], ["advances in vaccine", "TREATMENT", 354, 373], ["designed immunogens", "TREATMENT", 535, 554]]], ["However, there is no single \"best\" solution for designing immunogens for any disease.", [["designing immunogens", "TREATMENT", 48, 68], ["any disease", "PROBLEM", 73, 84], ["no", "UNCERTAINTY", 18, 20]]], ["Because different pathogens use diverse strategies to evade protective immune responses, vaccine design strategies must be tailored to our knowledge of how protective antibodies function in each disease and why particular antigens may or may not elicit them.NEW APPROACHES TO ANTIGEN DESIGNMany antigens adopt multiple conformational states throughout the life cycle of the pathogen, either as part of their natural function or as an explicit strategy for immune evasion.", [["protective antibodies", "PROTEIN", 156, 177], ["different pathogens", "PROBLEM", 8, 27], ["diverse strategies", "TREATMENT", 32, 50], ["protective immune responses", "TREATMENT", 60, 87], ["vaccine design strategies", "TREATMENT", 89, 114], ["each disease", "PROBLEM", 190, 202], ["ANTIGEN DESIGNMany antigens", "TREATMENT", 276, 303], ["multiple conformational states", "PROBLEM", 310, 340], ["the pathogen", "PROBLEM", 370, 382], ["immune evasion", "TREATMENT", 456, 470]]], ["For such antigens, stabilization of a desired antigenic state is a conceptually straightforward approach for improving the quality of antibody responses.", [["such antigens", "PROBLEM", 4, 17]]], ["A common problem encountered when expressing antigens outside their native context is that they fail to adopt the correct quaternary structure (eg, the ectodomains of enveloped virus glycoproteins expressed without their native transmembrane domains).", [["transmembrane", "ANATOMY", 228, 241], ["enveloped virus glycoproteins", "ORGANISM", 167, 196], ["ectodomains", "PROTEIN", 152, 163], ["enveloped virus glycoproteins", "PROTEIN", 167, 196], ["native transmembrane domains", "PROTEIN", 221, 249], ["A common problem", "PROBLEM", 0, 16], ["enveloped virus glycoproteins", "TREATMENT", 167, 196]]], ["Genetic fusion to multimeric protein scaffolds with higher stability has proven to be a general method for quaternary stabilization of such antigens.", [["antigens", "PROTEIN", 140, 148], ["Genetic fusion", "TREATMENT", 0, 14], ["multimeric protein scaffolds", "TREATMENT", 18, 46], ["a general method", "TREATMENT", 86, 102], ["quaternary stabilization", "TREATMENT", 107, 131], ["such antigens", "PROBLEM", 135, 148], ["fusion", "OBSERVATION", 8, 14], ["protein scaffolds", "OBSERVATION", 29, 46], ["higher stability", "OBSERVATION_MODIFIER", 52, 68]]], ["This is usually performed using protein complexes with symmetries matching that of the antigen, and can range from small scaffolds such as the foldon trimerization domain from T4 fibritin [22, 23] to larger multimers such as ferritin [24] that display multiple copies of the oligomeric antigen.", [["T4 fibritin", "SIMPLE_CHEMICAL", 176, 187], ["ferritin", "GENE_OR_GENE_PRODUCT", 225, 233], ["protein complexes", "PROTEIN", 32, 49], ["foldon trimerization domain", "PROTEIN", 143, 170], ["T4 fibritin", "PROTEIN", 176, 187], ["ferritin", "PROTEIN", 225, 233], ["oligomeric antigen", "PROTEIN", 275, 293], ["the antigen", "TEST", 83, 94], ["small scaffolds", "PROBLEM", 115, 130], ["the foldon trimerization domain", "TREATMENT", 139, 170], ["T4 fibritin", "TEST", 176, 187], ["ferritin", "TEST", 225, 233], ["the oligomeric antigen", "PROBLEM", 271, 293], ["small scaffolds", "OBSERVATION", 115, 130], ["oligomeric antigen", "OBSERVATION", 275, 293]]], ["While often required for the production of stable antigens, heterologous multimerization domains generally do not address sources of instability unrelated to quaternary structure.", [["heterologous multimerization domains", "PROTEIN", 60, 96], ["heterologous multimerization domains", "PROBLEM", 60, 96], ["instability", "PROBLEM", 133, 144], ["instability", "OBSERVATION", 133, 144], ["quaternary structure", "OBSERVATION", 158, 178]]], ["For example, many viral glycoproteins that [25] .", [["viral glycoproteins", "PROTEIN", 18, 37], ["many viral glycoproteins", "PROBLEM", 13, 37]]], ["This type of conformational heterogeneity can be problematic if the metastable prefusion state is desired antigenically [22, 26, 27] , and it can be exaggerated when antigens are recombinantly expressed and purified in isolation.", [["antigens", "PROTEIN", 166, 174], ["conformational heterogeneity", "PROBLEM", 13, 41], ["the metastable prefusion state", "PROBLEM", 64, 94], ["metastable", "OBSERVATION_MODIFIER", 68, 78], ["prefusion", "OBSERVATION", 79, 88]]], ["With detailed knowledge of desired and undesired structural states, more precise techniques in protein engineering and design can be used to favor or disfavor specific conformations of target proteins.", [["target proteins", "PROTEIN", 185, 200], ["target proteins", "PROBLEM", 185, 200]]], ["Common strategies include designing disulfide bonds to immobilize linked domains [28] [29] [30] [31] [32] , improved hydrophobic packing to stabilize a particular conformational state [22, 33] , proline mutations to constrain conformational flexibility, and proline/glycine mutations to discourage helix formation [32, 34, 35] .", [["proline", "CHEMICAL", 258, 265], ["glycine", "CHEMICAL", 266, 273], ["disulfide", "CHEMICAL", 36, 45], ["proline", "CHEMICAL", 195, 202], ["proline", "CHEMICAL", 258, 265], ["glycine", "CHEMICAL", 266, 273], ["[28] [29] [30] [31] [32]", "SIMPLE_CHEMICAL", 81, 105], ["proline", "AMINO_ACID", 195, 202], ["proline", "AMINO_ACID", 258, 265], ["glycine", "AMINO_ACID", 266, 273], ["Common strategies", "TREATMENT", 0, 17], ["designing disulfide bonds", "TREATMENT", 26, 51], ["hydrophobic packing", "TREATMENT", 117, 136], ["proline mutations", "PROBLEM", 195, 212], ["conformational flexibility", "TEST", 226, 252], ["proline/glycine mutations", "TREATMENT", 258, 283]]], ["In one well-characterized example, the Fab of a potent, prefusion-specific neutralizing antibody against the fusion glycoprotein of respiratory syncytial virus (RSV F) was used in combination with a foldon trimerization domain at the C terminus to maintain F in its metastable prefusion conformation and prevent irreversible transition to the postfusion state.", [["Fab", "GENE_OR_GENE_PRODUCT", 39, 42], ["respiratory syncytial virus", "ORGANISM", 132, 159], ["RSV", "ORGANISM", 161, 164], ["Fab", "PROTEIN", 39, 42], ["prefusion-specific neutralizing antibody", "PROTEIN", 56, 96], ["fusion glycoprotein", "PROTEIN", 109, 128], ["foldon trimerization domain", "PROTEIN", 199, 226], ["C terminus", "PROTEIN", 234, 244], ["respiratory syncytial virus", "SPECIES", 132, 159], ["respiratory syncytial virus", "SPECIES", 132, 159], ["RSV", "SPECIES", 161, 164], ["prefusion-specific neutralizing antibody", "TREATMENT", 56, 96], ["the fusion glycoprotein", "TREATMENT", 105, 128], ["respiratory syncytial virus", "PROBLEM", 132, 159], ["a foldon trimerization domain", "TREATMENT", 197, 226], ["the C terminus", "TREATMENT", 230, 244], ["irreversible transition to the postfusion state", "PROBLEM", 312, 359], ["respiratory syncytial virus", "OBSERVATION", 132, 159], ["metastable", "OBSERVATION", 266, 276], ["prefusion conformation", "OBSERVATION", 277, 299], ["irreversible", "OBSERVATION_MODIFIER", 312, 324]]], ["After solving the structure of the prefusion state in complex with the Fab [36] , mutations that introduced a disulfide bond and cavity-filling hydrophobic side chains were made to F to stabilize the protein in this conformation.", [["disulfide", "CHEMICAL", 110, 119], ["prefusion state", "PROTEIN", 35, 50], ["F", "PROTEIN", 181, 182], ["mutations", "PROBLEM", 82, 91], ["a disulfide bond and cavity-filling hydrophobic side chains", "TREATMENT", 108, 167], ["prefusion state", "OBSERVATION", 35, 50]]], ["The designed prefusion-stabilized antigen, DS-Cav1, elicits much stronger neutralizing antibody responses than postfusion F [22] and is currently being evaluated in a phase I clinical trial (NCT03049488).", [["DS-Cav1", "GENE_OR_GENE_PRODUCT", 43, 50], ["prefusion-stabilized antigen", "PROTEIN", 13, 41], ["DS", "PROTEIN", 43, 45], ["Cav1", "PROTEIN", 46, 50], ["The designed prefusion", "TEST", 0, 22], ["DS", "TEST", 43, 45], ["Cav1", "ANATOMY", 46, 50]]], ["Additional prefusion-stabilized RSV F antigens have been generated by introducing proline mutations in between discontinuous helices that form a continuous helix upon transition to the postfusion structure [34] , and this approach has also been used to stabilize other viral glycoproteins such as the spike (S) proteins of Middle East respiratory syndrome coronavirus (MERS CoV), severe acute respiratory syndrome (SARS) CoV, and human CoV HKU-1 [35] .", [["proline", "CHEMICAL", 82, 89], ["respiratory syndrome coronavirus", "DISEASE", 335, 367], ["acute respiratory syndrome (SARS) CoV", "DISEASE", 387, 424], ["proline", "CHEMICAL", 82, 89], ["RSV", "ORGANISM", 32, 35], ["F antigens", "GENE_OR_GENE_PRODUCT", 36, 46], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 323, 367], ["MERS CoV", "ORGANISM", 369, 377], ["human", "ORGANISM", 430, 435], ["RSV F antigens", "PROTEIN", 32, 46], ["viral glycoproteins", "PROTEIN", 269, 288], ["spike (S) proteins", "PROTEIN", 301, 319], ["human", "SPECIES", 430, 435], ["RSV", "SPECIES", 32, 35], ["Middle East respiratory syndrome coronavirus", "SPECIES", 323, 367], ["MERS CoV", "SPECIES", 369, 377], ["severe acute respiratory syndrome (SARS) CoV", "SPECIES", 380, 424], ["human CoV HKU-1", "SPECIES", 430, 445], ["Additional prefusion-stabilized RSV F antigens", "TREATMENT", 0, 46], ["introducing proline mutations", "TREATMENT", 70, 99], ["discontinuous helices", "TREATMENT", 111, 132], ["a continuous helix", "PROBLEM", 143, 161], ["other viral glycoproteins", "PROBLEM", 263, 288], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 323, 367], ["severe acute respiratory syndrome", "PROBLEM", 380, 413], ["CoV", "TEST", 421, 424], ["human CoV HKU", "TEST", 430, 443], ["Middle", "ANATOMY_MODIFIER", 323, 329], ["respiratory syndrome", "OBSERVATION", 335, 355], ["severe", "OBSERVATION_MODIFIER", 380, 386], ["acute", "OBSERVATION_MODIFIER", 387, 392], ["respiratory syndrome", "OBSERVATION", 393, 413]]], ["For HIV, combining disulfide and proline mutations has been shown to stabilize soluble versions of the Env glycoprotein in trimeric, native-like, prefusion conformations [32] .", [["disulfide", "CHEMICAL", 19, 28], ["proline", "CHEMICAL", 33, 40], ["disulfide", "CHEMICAL", 19, 28], ["proline", "CHEMICAL", 33, 40], ["proline", "AMINO_ACID", 33, 40], ["Env glycoprotein", "GENE_OR_GENE_PRODUCT", 103, 119], ["Env glycoprotein", "PROTEIN", 103, 119], ["HIV", "SPECIES", 4, 7], ["HIV", "SPECIES", 4, 7], ["HIV", "PROBLEM", 4, 7], ["combining disulfide and proline mutations", "TREATMENT", 9, 50], ["Env glycoprotein", "OBSERVATION", 103, 119]]], ["Extensions of this design strategy have been generalized across the Env glycoproteins of many different strains and have become an invaluable tool for vaccine development and the study of humoral responses against the virus [37] [38] [39] .", [["Env glycoproteins", "PROTEIN", 68, 85], ["this design strategy", "PROBLEM", 14, 34], ["many different strains", "PROBLEM", 89, 111], ["vaccine development", "TREATMENT", 151, 170], ["the study", "TEST", 175, 184], ["humoral responses", "TEST", 188, 205], ["the virus", "PROBLEM", 214, 223]]], ["These stabilization strategies have proven immensely useful for generating conformationally homogeneous, antigenically intact molecules; continued development and application of these methods will be applicable in many vaccine design contexts.", [["These stabilization strategies", "TREATMENT", 0, 30], ["generating conformationally homogeneous, antigenically intact molecules", "PROBLEM", 64, 135], ["these methods", "TREATMENT", 178, 191]]], ["Another major challenge in antigen design is the development of strategies to elicit broadly protective responses against antigenically variable viruses such as influenza or HIV.", [["influenza or HIV", "DISEASE", 161, 177], ["HIV", "ORGANISM", 174, 177], ["HIV", "SPECIES", 174, 177], ["HIV", "SPECIES", 174, 177], ["antigenically variable viruses", "PROBLEM", 122, 152], ["influenza", "PROBLEM", 161, 170], ["HIV", "PROBLEM", 174, 177]]], ["One intuitively appealing approach is to focus immune responses on epitopes that are conserved across multiple virus strains, subtypes, clades, or species.", [["epitopes", "PROTEIN", 67, 75], ["immune responses", "PROBLEM", 47, 63], ["epitopes", "PROBLEM", 67, 75], ["multiple virus strains", "PROBLEM", 102, 124], ["species", "PROBLEM", 147, 154]]], ["This concept is supported by the observation that bNAbs against many pathogens target precisely these epitopes [40] .", [["bNAbs", "SIMPLE_CHEMICAL", 50, 55], ["bNAbs", "PROTEIN", 50, 55], ["epitopes", "PROTEIN", 102, 110], ["bNAbs", "TREATMENT", 50, 55], ["many pathogens", "PROBLEM", 64, 78]]], ["However, design strategies must overcome the presence of less conserved, distracting epitopes that are either strain-specific or incapable of eliciting protective responses [41, 42] .", [["epitopes", "PROTEIN", 85, 93], ["distracting epitopes", "PROBLEM", 73, 93]]], ["Inspired by a widespread viral immune evasion mechanism, physically masking antigen surfaces (such as the immunodominant head domain of influenza HA) using hyperglycosylation has been shown to redirect antibody responses to desired epitopes in some cases [43] [44] [45] .NEW APPROACHES TO ANTIGEN DESIGNSubdomain-based approaches that remove elements containing undesired epitopes from the antigen entirely have also been widely employed to focus immune responses.", [["head", "ANATOMY", 121, 125], ["hyperglycosylation", "CHEMICAL", 156, 174], ["influenza HA", "ORGANISM", 136, 148], ["immunodominant head domain", "PROTEIN", 106, 132], ["epitopes", "PROTEIN", 232, 240], ["epitopes", "PROTEIN", 372, 380], ["a widespread viral immune evasion mechanism", "PROBLEM", 12, 55], ["physically masking antigen surfaces", "PROBLEM", 57, 92], ["influenza HA", "PROBLEM", 136, 148], ["hyperglycosylation", "TREATMENT", 156, 174], ["ANTIGEN DESIGNSubdomain", "TREATMENT", 289, 312], ["undesired epitopes", "PROBLEM", 362, 380], ["widespread", "OBSERVATION_MODIFIER", 14, 24], ["viral immune evasion", "OBSERVATION", 25, 45]]], ["In some cases, simple elimination of undesired portions of the antigen, usually along domain boundaries, can be used to produce minimal antigens that are both structurally and antigenically intact [46] [47] [48] [49] .", [["minimal antigens", "PROTEIN", 128, 144], ["the antigen", "PROBLEM", 59, 70], ["minimal antigens", "PROBLEM", 128, 144]]], ["In other cases more complex manipulations such as novel loop connections and stabilizing mutations have been required; \"headless\" or \"stabilized stem\" HAs lacking the immunodominant head region are a successful example that have been shown to induce responses to the immunologically subdominant stem with broader cross-reactivity [29, 33, [50] [51] [52] .", [["stem", "ANATOMY", 145, 149], ["head region", "ANATOMY", 182, 193], ["stem", "ANATOMY", 295, 299], ["stem", "CELL", 145, 149], ["stem", "CELL", 295, 299], ["immunodominant head region", "PROTEIN", 167, 193], ["novel loop connections", "TREATMENT", 50, 72], ["stabilizing mutations", "PROBLEM", 77, 98], ["broader cross-reactivity", "TEST", 305, 329], ["head", "ANATOMY", 182, 186]]], ["Similarly, radical deletions, loop connections, and stabilizing mutations were used to produce a minimal version of the CD4 binding site of HIV Env called eOD [53] that has proven to be a robust platform for further engineering, as discussed below.", [["CD4", "GENE_OR_GENE_PRODUCT", 120, 123], ["HIV Env", "ORGANISM", 140, 147], ["CD4 binding site", "DNA", 120, 136], ["HIV Env", "PROTEIN", 140, 147], ["HIV", "SPECIES", 140, 143], ["radical deletions", "PROBLEM", 11, 28], ["loop connections", "TREATMENT", 30, 46], ["stabilizing mutations", "PROBLEM", 52, 73], ["radical deletions", "OBSERVATION", 11, 28], ["loop", "OBSERVATION_MODIFIER", 30, 34], ["minimal", "OBSERVATION_MODIFIER", 97, 104]]], ["A more extreme variation on the subdomain approach known as epitope-focused vaccine design has been used to generate antigens that present only specific, well-defined epitopes known to be targeted by neutralizing antibodies.", [["epitope", "PROTEIN", 60, 67], ["antigens", "PROTEIN", 117, 125], ["epitopes", "PROTEIN", 167, 175], ["neutralizing antibodies", "PROTEIN", 200, 223], ["A more extreme variation", "PROBLEM", 0, 24], ["the subdomain approach", "TREATMENT", 28, 50], ["epitope-focused vaccine", "TREATMENT", 60, 83], ["more extreme", "OBSERVATION_MODIFIER", 2, 14], ["variation", "OBSERVATION_MODIFIER", 15, 24]]], ["Several examples have demonstrated that computational protein design can be used to incorporate such epitopes into unrelated scaffold proteins with high structural fidelity.", [["epitopes", "PROTEIN", 101, 109], ["scaffold proteins", "PROTEIN", 125, 142], ["computational protein design", "TREATMENT", 40, 68], ["such epitopes into unrelated scaffold proteins", "PROBLEM", 96, 142], ["high structural fidelity", "PROBLEM", 148, 172], ["high structural fidelity", "OBSERVATION", 148, 172]]], ["These \"epitope scaffolds\" bind to their target antibodies with high affinity and, upon immunization, induce antibodies that bind to the native antigen and in some cases neutralize the pathogen [54-58].", [["antibodies", "PROTEIN", 47, 57], ["antibodies", "PROTEIN", 108, 118], ["native antigen", "PROTEIN", 136, 150], ["These \"epitope scaffolds", "TREATMENT", 0, 24], ["high affinity", "PROBLEM", 63, 76], ["immunization", "TREATMENT", 87, 99], ["induce antibodies", "PROBLEM", 101, 118], ["the pathogen", "TEST", 180, 192]]], ["In another flavor of epitope-focused vaccine design, conserved linear epitopes targeted by neutralizing antibodies, such as the fusion peptide of HIV Env, can be presented as antigens on multivalent display platforms in a structure-agnostic manner [59, 60].", [["HIV Env", "ORGANISM", 146, 153], ["conserved linear epitopes", "PROTEIN", 53, 78], ["neutralizing antibodies", "PROTEIN", 91, 114], ["HIV Env", "PROTEIN", 146, 153], ["antigens", "PROTEIN", 175, 183], ["HIV", "SPECIES", 146, 149], ["HIV", "SPECIES", 146, 149], ["epitope-focused vaccine design", "TREATMENT", 21, 51], ["conserved linear epitopes", "TREATMENT", 53, 78], ["neutralizing antibodies", "TREATMENT", 91, 114], ["the fusion peptide", "TREATMENT", 124, 142], ["HIV Env", "PROBLEM", 146, 153]]], ["While epitope-focused vaccine design offers a conceptual framework for targeting a desired epitope with high precision, inducing high levels of neutralizing antibodies with minimal, epitope-based antigens has been challenging and there is a risk of immune evasion as this approach typically targets a single vulnerable epitope.", [["neutralizing antibodies", "PROTEIN", 144, 167], ["minimal, epitope-based antigens", "PROTEIN", 173, 204], ["a desired epitope", "TREATMENT", 81, 98], ["high levels of neutralizing antibodies", "PROBLEM", 129, 167], ["epitope-based antigens", "TREATMENT", 182, 204], ["immune evasion", "TREATMENT", 249, 263], ["this approach", "TREATMENT", 267, 280], ["a single vulnerable epitope", "PROBLEM", 299, 326]]], ["Combining epitope-focused design with continued exploration and optimization of multivalent presentation platforms, discussed below, could help address these issues.NEW APPROACHES TO ANTIGEN DESIGNThe controlled use of antigenic variation is another strategy for highlighting a conserved region for immune responses.NEW APPROACHES TO ANTIGEN DESIGNFor example, heterologous prime-boost strategies have been used to administer antigens that significantly vary in off-target regions with undesired epitopes while keeping the desired epitope invariant across all antigens to maximize the response against that region [59, 61-63].", [["antigens", "PROTEIN", 426, 434], ["epitopes", "PROTEIN", 496, 504], ["antigens", "PROTEIN", 560, 568], ["continued exploration", "TEST", 38, 59], ["antigenic variation", "TREATMENT", 219, 238], ["heterologous prime", "TREATMENT", 361, 379], ["boost strategies", "TREATMENT", 380, 396], ["antigens", "TREATMENT", 426, 434], ["undesired epitopes", "PROBLEM", 486, 504], ["the desired epitope invariant across all antigens", "TREATMENT", 519, 568], ["antigenic variation", "OBSERVATION", 219, 238]]], ["This process can be enhanced by designing antigens optimized for this purpose, as exemplified by chimeric HA antigens in which the head region of HA from a seasonally circulating virus is replaced with the corresponding region of exotic subtypes that most humans have never encountered [63] .", [["head region", "ANATOMY", 131, 142], ["HA antigens", "GENE_OR_GENE_PRODUCT", 106, 117], ["head", "ORGANISM_SUBDIVISION", 131, 135], ["HA", "GENE_OR_GENE_PRODUCT", 146, 148], ["humans", "ORGANISM", 256, 262], ["antigens", "PROTEIN", 42, 50], ["chimeric HA antigens", "PROTEIN", 97, 117], ["humans", "SPECIES", 256, 262], ["humans", "SPECIES", 256, 262], ["chimeric HA antigens", "PROBLEM", 97, 117], ["HA", "PROBLEM", 146, 148], ["a seasonally circulating virus", "PROBLEM", 154, 184], ["head", "ANATOMY", 131, 135], ["HA", "OBSERVATION", 146, 148], ["virus", "OBSERVATION", 179, 184], ["exotic subtypes", "OBSERVATION", 230, 245]]], ["Through a combination of low-level preexisting immunity against conserved stem epitopes and sequential administration of antigens with distinct head regions for which no preexisting immunity exists, this strategy aims to maximize stem-directed responses and is currently being evaluated in clinical trials (NCT03300050).NEW APPROACHES TO ANTIGEN DESIGNWhile targeting conserved epitopes is a promising strategy for eliciting broadly protective responses, differences in surrounding motifs or epitope conformations between strains can impede cross-reactive immunity.", [["head", "ANATOMY", 144, 148], ["stem", "ANATOMY", 230, 234], ["head", "ORGANISM_SUBDIVISION", 144, 148], ["stem", "CELL", 230, 234], ["conserved stem epitopes", "PROTEIN", 64, 87], ["antigens", "PROTEIN", 121, 129], ["low-level preexisting immunity", "TREATMENT", 25, 55], ["conserved stem epitopes", "TREATMENT", 64, 87], ["sequential administration of antigens", "TREATMENT", 92, 129], ["distinct head regions", "PROBLEM", 135, 156], ["a promising strategy", "TREATMENT", 390, 410], ["epitope conformations between strains", "PROBLEM", 492, 529], ["stem epitopes", "OBSERVATION", 74, 87], ["head", "ANATOMY", 144, 148]]], ["In influenza, this is particularly true for the receptor-binding site (RBS), as many mutations near the RBS significantly limit the breadth of all known cross-reactive antibodies against this region [64-66].", [["influenza", "DISEASE", 3, 12], ["receptor-binding site", "DNA", 48, 69], ["RBS", "DNA", 71, 74], ["RBS", "DNA", 104, 107], ["cross-reactive antibodies", "PROTEIN", 153, 178], ["influenza", "PROBLEM", 3, 12], ["many mutations near the RBS", "PROBLEM", 80, 107], ["influenza", "OBSERVATION", 3, 12], ["cross-reactive antibodies", "OBSERVATION", 153, 178]]], ["Stemdirected responses are inherently broader due to the higher conservation of this region of HA, yet it remains challenging to elicit strong anti-stem responses that span group 1 and group 2 influenza A viruses, or ideally protect against both influenza A and B viruses.", [["influenza A and B viruses", "DISEASE", 246, 271], ["HA", "GENE_OR_GENE_PRODUCT", 95, 97], ["influenza A viruses", "ORGANISM", 193, 212], ["influenza A", "ORGANISM", 246, 257], ["B viruses", "ORGANISM", 262, 271], ["B viruses", "SPECIES", 262, 271], ["HA", "PROBLEM", 95, 97], ["2 influenza A viruses", "PROBLEM", 191, 212], ["both influenza A and B viruses", "PROBLEM", 241, 271]]], ["To achieve universal protection from such a diverse collection of viruses, epitope-focused strategies must be optimized to cater towards maximal breadth.NEW APPROACHES TO ANTIGEN DESIGNA different approach to inducing bNAbs by immunization, referred to as germline-targeting or lineage-based vaccine design, has been inspired by the ever-growing collection of bNAbs against HIV and influenza.", [["bNAbs", "CHEMICAL", 218, 223], ["HIV and influenza", "DISEASE", 374, 391], ["bNAbs", "GENE_OR_GENE_PRODUCT", 218, 223], ["bNAbs", "GENE_OR_GENE_PRODUCT", 360, 365], ["HIV", "ORGANISM", 374, 377], ["bNAbs", "DNA", 218, 223], ["germline", "DNA", 256, 264], ["HIV", "SPECIES", 374, 377], ["HIV", "SPECIES", 374, 377], ["universal protection", "TREATMENT", 11, 31], ["a diverse collection of viruses", "PROBLEM", 42, 73], ["epitope-focused strategies", "TREATMENT", 75, 101], ["immunization", "TREATMENT", 227, 239], ["bNAbs", "PROBLEM", 360, 365], ["HIV", "PROBLEM", 374, 377], ["influenza", "PROBLEM", 382, 391], ["viruses", "OBSERVATION", 66, 73]]], ["The identification of structural and genetic constraints on bNAb development that are commonly found across multiple individuals, enabled by high-throughput antibody sequencing technologies, provides a system for classifying bNAbs and has made the idea of targeting particular classes a viable option for vaccine design.", [["bNAb", "CANCER", 60, 64], ["bNAbs", "CANCER", 225, 230], ["structural and genetic constraints", "PROBLEM", 22, 56], ["vaccine design", "TREATMENT", 305, 319]]], ["The central concept of lineage-based vaccine design is that designing antigens that strongly bind to inferred unmutated precursors of known classes of bNAbs has the potential to drive direct elicitation of bNAb responses [67, 68] .", [["lineage", "CELL", 23, 30], ["bNAbs", "GENE_OR_GENE_PRODUCT", 151, 156], ["bNAb", "GENE_OR_GENE_PRODUCT", 206, 210], ["bNAbs", "PROTEIN", 151, 156], ["bNAb", "PROTEIN", 206, 210], ["lineage-based vaccine design", "TREATMENT", 23, 51], ["bNAbs", "PROBLEM", 151, 156], ["central", "ANATOMY_MODIFIER", 4, 11], ["lineage", "OBSERVATION_MODIFIER", 23, 30]]], ["This strategy is most established in the context of HIV vaccine research, where it is primarily (though not only [61, 62]) focused on eliciting bNAbs against the CD4 binding site of HIV Env [49, 62, [69] [70] [71] .", [["HIV", "ORGANISM", 52, 55], ["bNAbs", "GENE_OR_GENE_PRODUCT", 144, 149], ["CD4", "GENE_OR_GENE_PRODUCT", 162, 165], ["HIV Env", "ORGANISM", 182, 189], ["bNAbs", "PROTEIN", 144, 149], ["CD4 binding site", "DNA", 162, 178], ["HIV", "SPECIES", 52, 55], ["HIV vaccine", "TREATMENT", 52, 63], ["HIV Env", "TEST", 182, 189]]], ["A leading example is the eOD-GT8 antigen, which has been extensively engineered to have high affinity to the unmutated common ancestor of VRC01-class bNAbs. eOD-GT8, when displayed in multivalent fashion on a self-assembling protein scaffold, has successfully activated target precursor B cells in knock-in mouse models [62, 72] and has recently advanced into proof-of-concept studies in humans (NCT03547245).", [["precursor B cells", "ANATOMY", 277, 294], ["eOD-GT8", "CHEMICAL", 157, 164], ["eOD-GT8 antigen", "GENE_OR_GENE_PRODUCT", 25, 40], ["VRC01-class bNAbs", "GENE_OR_GENE_PRODUCT", 138, 155], ["eOD-GT8", "SIMPLE_CHEMICAL", 157, 164], ["precursor B cells", "CELL", 277, 294], ["mouse", "ORGANISM", 307, 312], ["humans", "ORGANISM", 388, 394], ["eOD", "PROTEIN", 25, 28], ["GT8 antigen", "PROTEIN", 29, 40], ["VRC01-class bNAbs", "DNA", 138, 155], ["eOD", "PROTEIN", 157, 160], ["GT8", "PROTEIN", 161, 164], ["target precursor B cells", "CELL_TYPE", 270, 294], ["mouse", "SPECIES", 307, 312], ["humans", "SPECIES", 388, 394], ["mouse", "SPECIES", 307, 312], ["humans", "SPECIES", 388, 394], ["high affinity", "PROBLEM", 88, 101], ["eOD", "TEST", 157, 160], ["a self-assembling protein scaffold", "TREATMENT", 207, 241]]], ["There is significant room to explore the application of this strategy to viruses other than HIV, and particularly for influenza where there is growing knowledge of multidonor classes of bNAbs that could be targeted [73] [74] [75] [76] .NEW APPROACHES TO ANTIGEN DESIGNWhile lineage-based approaches may enable elicitation of very specific classes of antibodies, designed antigens can be tailored to bias the specificity of antibody response patterns at a polyclonal level as well.", [["influenza", "DISEASE", 118, 127], ["HIV", "ORGANISM", 92, 95], ["bNAbs", "SIMPLE_CHEMICAL", 186, 191], ["[73] [74] [75] [76]", "SIMPLE_CHEMICAL", 215, 234], ["antibodies", "PROTEIN", 350, 360], ["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 92, 95], ["this strategy", "TREATMENT", 56, 69], ["viruses", "PROBLEM", 73, 80], ["HIV", "PROBLEM", 92, 95], ["influenza", "PROBLEM", 118, 127], ["bNAbs", "PROBLEM", 186, 191], ["very specific classes of antibodies", "PROBLEM", 325, 360], ["antibody response patterns", "PROBLEM", 423, 449]]], ["In the case of complex antigens with a variety of epitopes that could mediate neutralization or protection, approaches that combine multiple sequences from diverse strains into a consensus or genetic-mosaic sequence by presenting epitopes from all included strains have the potential to induce broad responses.", [["complex antigens", "PROTEIN", 15, 31], ["epitopes", "PROTEIN", 50, 58], ["consensus or genetic-mosaic sequence", "DNA", 179, 215], ["epitopes", "PROTEIN", 230, 238], ["diverse strains", "PROBLEM", 156, 171]]], ["For influenza, this concept has been evaluated using \"computationally optimized broadly reactive antigens\" [77, 78] .", [["influenza", "DISEASE", 4, 13], ["influenza", "PROBLEM", 4, 13]]], ["The design strategy focuses on the head region of HA with the intention of maximizing the breadth of hemagglutination inhibition (HAI) titers, and has been successful at improving cross-reactivity within individual subtypes of influenza.", [["head region", "ANATOMY", 35, 46], ["influenza", "DISEASE", 227, 236], ["head", "ORGANISM_SUBDIVISION", 35, 39], ["HA", "PROBLEM", 50, 52], ["influenza", "PROBLEM", 227, 236], ["head", "ANATOMY", 35, 39], ["influenza", "OBSERVATION", 227, 236]]], ["Similar approaches have been used in HIV vaccine development to produce Env gp140 trimers that are composed of a variety of sequences from diverse [79], and a polyclonal-centered strategy has been recently combined with lineage-based vaccine design [71] .", [["HIV", "ORGANISM", 37, 40], ["Env", "ORGANISM", 72, 75], ["Env gp140 trimers", "PROTEIN", 72, 89], ["HIV", "SPECIES", 37, 40], ["HIV", "SPECIES", 37, 40], ["HIV vaccine", "TREATMENT", 37, 48], ["Env gp140 trimers", "TREATMENT", 72, 89], ["a polyclonal-centered strategy", "TREATMENT", 157, 187], ["lineage-based vaccine", "TREATMENT", 220, 241]]], ["In that case, germline-targeting mutations were added to two distinct epitopes on a SOSIP trimer to activate the unmutated common ancestors of two classes of bNAbs, a strategy that was validated in knock-in mice.NEW APPROACHES TO ANTIGEN DESIGNLooking ahead, the coordinated design and coadministration of multiple antigens could be a promising approach to increasing breadth against viruses exhibiting extreme structural and antigenic diversity, such as influenza and HIV.", [["influenza and HIV", "DISEASE", 455, 472], ["SOSIP", "GENE_OR_GENE_PRODUCT", 84, 89], ["bNAbs", "GENE_OR_GENE_PRODUCT", 158, 163], ["mice", "ORGANISM", 207, 211], ["HIV", "ORGANISM", 469, 472], ["germline", "DNA", 14, 22], ["epitopes", "PROTEIN", 70, 78], ["SOSIP trimer", "PROTEIN", 84, 96], ["bNAbs", "PROTEIN", 158, 163], ["mice", "SPECIES", 207, 211], ["HIV", "SPECIES", 469, 472], ["mice", "SPECIES", 207, 211], ["HIV", "SPECIES", 469, 472], ["germline-targeting mutations", "PROBLEM", 14, 42], ["a SOSIP trimer", "TREATMENT", 82, 96], ["coadministration of multiple antigens", "TREATMENT", 286, 323], ["increasing breadth against viruses", "PROBLEM", 357, 391], ["extreme structural and antigenic diversity", "PROBLEM", 403, 445], ["influenza", "PROBLEM", 455, 464], ["HIV", "PROBLEM", 469, 472], ["antigenic diversity", "OBSERVATION", 426, 445]]], ["In particular, designing antigens that are specifically intended to be codelivered or multimerically displayed may be a promising avenue for future investigation.ANTIGEN DISPLAY AND DELIVERY PLATFORMSThe manner in which antigens are presented to the immune system profoundly influences the ensuing response [80].", [["immune system", "ANATOMY", 250, 263], ["antigens", "PROTEIN", 25, 33], ["antigens", "PROTEIN", 220, 228], ["future investigation", "TEST", 141, 161]]], ["Recent technological advances have enabled new approaches to antigen display and delivery that are increasing the potency and durability of vaccine responses and optimizing the balance between humoral and cellular immunity (Figure 2 ).", [["cellular", "ANATOMY", 205, 213], ["cellular", "CELL", 205, 213], ["delivery", "TREATMENT", 81, 89], ["vaccine responses", "TREATMENT", 140, 157]]], ["We focus here on two such technologies: self-assembling proteins as multivalent antigen display platforms and genetic immunization via mRNA vaccines. , although in ways that may be specific to each material or platform.", [["self-assembling proteins", "PROTEIN", 40, 64], ["genetic immunization", "TREATMENT", 110, 130], ["mRNA vaccines", "TREATMENT", 135, 148]]], ["A significant limitation of early display platforms was their inability to scaffold complex antigens such as the intact ectodomains of viral glycoproteins.", [["scaffold complex antigens", "PROTEIN", 75, 100], ["ectodomains", "PROTEIN", 120, 131], ["viral glycoproteins", "PROTEIN", 135, 154], ["their inability to scaffold complex antigens", "PROBLEM", 56, 100], ["viral glycoproteins", "PROBLEM", 135, 154], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["viral glycoproteins", "OBSERVATION", 135, 154]]], ["The discovery that nonviral self-assembling proteins such as ferritin and lumazine synthase can form monodisperse immunogens that present large, complex antigens has recently moved the field beyond this limitation [24, 69] .", [["lumazine", "CHEMICAL", 74, 82], ["lumazine", "CHEMICAL", 74, 82], ["ferritin", "GENE_OR_GENE_PRODUCT", 61, 69], ["lumazine synthase", "GENE_OR_GENE_PRODUCT", 74, 91], ["nonviral self-assembling proteins", "PROTEIN", 19, 52], ["ferritin", "PROTEIN", 61, 69], ["lumazine synthase", "PROTEIN", 74, 91], ["complex antigens", "PROTEIN", 145, 161], ["nonviral self-assembling proteins", "PROBLEM", 19, 52], ["ferritin and lumazine synthase", "TREATMENT", 61, 91], ["monodisperse immunogens", "TREATMENT", 101, 124], ["large, complex antigens", "PROBLEM", 138, 161], ["large", "OBSERVATION_MODIFIER", 138, 143]]], ["A small set of such proteins has been used to present a wide variety of antigens, including those derived from influenza [24, 33] , HIV [49, 70, 72, [89] [90] [91] [92] , and Epstein-Barr virus [48] .", [["influenza", "DISEASE", 111, 120], ["influenza", "ORGANISM", 111, 120], ["HIV", "ORGANISM", 132, 135], ["Epstein-Barr virus", "ORGANISM", 175, 193], ["antigens", "PROTEIN", 72, 80], ["HIV", "SPECIES", 132, 135], ["HIV", "SPECIES", 132, 135], ["Epstein-Barr virus", "SPECIES", 175, 193], ["A small set of such proteins", "PROBLEM", 0, 28], ["influenza", "PROBLEM", 111, 120], ["HIV", "TEST", 132, 135], ["Epstein", "TEST", 175, 182], ["Barr virus", "TEST", 183, 193], ["small", "OBSERVATION_MODIFIER", 2, 7]]], ["In these studies, multivalent display consistently and robustly enhanced the potency of the antigen-specific response.", [["these studies", "TEST", 3, 16], ["the antigen", "TEST", 88, 99]]], ["In some cases, self-assembling scaffolds were successfully combined with antigens designed to focus the response on specific epitopes and therefore improve neutralization potency or breadth [33, 44, 48] .", [["antigens", "PROTEIN", 73, 81], ["epitopes", "PROTEIN", 125, 133], ["self-assembling scaffolds", "TREATMENT", 15, 40], ["specific epitopes", "TREATMENT", 116, 133]]], ["A first-in-class clinical trial of a self-assembling nanoparticle-based influenza vaccine has recently been started (NCT03186781).ANTIGEN DISPLAY AND DELIVERY PLATFORMSSelf-assembling proteins have several advantages over other multivalent antigen presentation platforms [82] .", [["nanoparticle", "CHEMICAL", 53, 65], ["DELIVERY PLATFORMSSelf-assembling proteins", "PROTEIN", 150, 192], ["a self-assembling nanoparticle-based influenza vaccine", "TREATMENT", 35, 89]]], ["Seamless integration of the antigen and self-assembling scaffold via genetic fusion-an approach unique to self-assembling protein scaffolds-facilitates immunogen production because, for recombinant antigens, production of both the antigen and the scaffold can be accomplished in a single molecule.", [["antigen", "GENE_OR_GENE_PRODUCT", 28, 35], ["recombinant antigens", "PROTEIN", 186, 206], ["self-assembling scaffold via genetic fusion", "TREATMENT", 40, 83], ["self-assembling protein scaffolds", "TREATMENT", 106, 139], ["immunogen production", "PROBLEM", 152, 172], ["recombinant antigens", "PROBLEM", 186, 206]]], ["Alternatively, simple, robust, and gentle protein-based conjugation systems such as SpyCatcher/SpyTag [93] enable rapid prototyping of many different antigens on self-assembling protein scaffolds in an approach that has been dubbed \"plug-and-display\" [94, 95] .", [["SpyCatcher", "PROTEIN", 84, 94], ["antigens", "PROTEIN", 150, 158], ["gentle protein", "TEST", 35, 49], ["rapid prototyping", "TREATMENT", 114, 131], ["self-assembling protein scaffolds", "TREATMENT", 162, 195], ["simple", "OBSERVATION_MODIFIER", 15, 21], ["robust", "OBSERVATION_MODIFIER", 23, 29]]], ["Because most functional proteins fold and assemble to well-defined and unique low energy states, self-assembling protein immunogens tend to be highly ordered and monodisperse, making them easier to characterize for quality and potency than more heterogeneous materials.", [["most functional proteins fold", "PROBLEM", 8, 37], ["unique low energy states", "PROBLEM", 71, 95], ["self-assembling protein immunogens", "TREATMENT", 97, 131], ["heterogeneous", "OBSERVATION_MODIFIER", 245, 258]]], ["As noted above, self-assembling scaffolds can also stabilize antigens in their native oligomeric state.", [["antigens", "PROTEIN", 61, 69], ["self-assembling scaffolds", "TREATMENT", 16, 41], ["oligomeric state", "OBSERVATION", 86, 102]]], ["Furthermore, the fact that self-assembling proteins are genetically encoded opens up the possibility of deploying potent nanoparticle immunogens via genetic immunization (eg, viral vectors or nucleic acid vaccines; see below).ANTIGEN DISPLAY AND DELIVERY PLATFORMSHowever, unlike polymeric systems or liposomes, a potential liability of using self-assembling proteins as scaffolds is that the resultant immunogens tend to induce antibody responses against the scaffolds themselves [24, 96] .", [["nucleic acid", "CHEMICAL", 192, 204], ["liposomes", "SIMPLE_CHEMICAL", 301, 310], ["self-assembling proteins", "PROTEIN", 27, 51], ["self-assembling proteins", "PROTEIN", 343, 367], ["deploying potent nanoparticle immunogens", "TREATMENT", 104, 144], ["genetic immunization (eg", "TREATMENT", 149, 173], ["viral vectors", "TREATMENT", 175, 188], ["nucleic acid vaccines", "TREATMENT", 192, 213], ["self-assembling proteins", "TREATMENT", 343, 367], ["scaffolds", "TREATMENT", 371, 380], ["the resultant immunogens", "TREATMENT", 389, 413], ["antibody responses", "TEST", 429, 447]]], ["While this has generally not prevented the elicitation of potent antigen-specific responses, it remains to be seen whether engineering mechanisms to dampen or avoid anti-scaffold responses into these systems [97, 98] might further improve antigen-specific, protective responses.ANTIGEN DISPLAY AND DELIVERY PLATFORMSLooking ahead, the limited number of existing self-assembling protein scaffolds and the fact that their structural properties are essentially fixed severely constrains the design space that may be explored.", [["these systems", "TEST", 194, 207], ["self-assembling protein scaffolds", "TREATMENT", 362, 395], ["may be", "UNCERTAINTY", 506, 512]]], ["Recently, new computational methods have been developed for designing novel self-assembling proteins with atomic-level accuracy [99-103].", [["atomic-level accuracy", "TEST", 106, 127]]], ["These methods have enabled the generation of new protein scaffolds in which structural features such as size, shape, number of subunits, and the location and orientation of displayed antigen can be systematically and precisely controlled.", [["new protein scaffolds", "TREATMENT", 45, 66], ["size", "OBSERVATION_MODIFIER", 104, 108], ["shape", "OBSERVATION_MODIFIER", 110, 115]]], ["We expect such studies to improve our understanding of the structural correlates of immunogenicity and generate potent new vaccine candidates.ANTIGEN DISPLAY AND DELIVERY PLATFORMSThe first examples of the use of these computationally designed self-assembling proteins as vaccine scaffolds have recently been reported [95, 104] .", [["self-assembling proteins", "PROTEIN", 244, 268], ["such studies", "TEST", 10, 22], ["self-assembling proteins", "TREATMENT", 244, 268], ["vaccine scaffolds", "TREATMENT", 272, 289]]], ["In both cases, highly ordered, monodisperse immunogens notable for their extreme stability were found to induce potent immune responses.ANTIGEN DISPLAY AND DELIVERY PLATFORMSAn emerging concept in antigen presentation and delivery that exploits several advantages of recombinant approaches is the codisplay of multiple antigenic variants on a single continuous surface [92, 105] .", [["surface", "ANATOMY", 361, 368], ["monodisperse immunogens", "TREATMENT", 31, 54], ["their extreme stability", "PROBLEM", 67, 90], ["delivery", "TREATMENT", 222, 230], ["recombinant approaches", "TREATMENT", 267, 289], ["multiple antigenic variants", "PROBLEM", 310, 337], ["multiple", "OBSERVATION_MODIFIER", 310, 318], ["antigenic variants", "OBSERVATION", 319, 337]]], ["For antigenically variable targets such as influenza HA and HIV Env, codisplay could provide a mechanism for improving the breadth of vaccine responses by focusing them on conserved epitopes known to be targeted by bNAbs.", [["influenza HA", "ORGANISM", 43, 55], ["HIV Env", "ORGANISM", 60, 67], ["bNAbs", "GENE_OR_GENE_PRODUCT", 215, 220], ["bNAbs", "PROTEIN", 215, 220], ["HIV", "SPECIES", 60, 63], ["HIV", "SPECIES", 60, 63], ["antigenically variable targets", "PROBLEM", 4, 34], ["influenza HA", "PROBLEM", 43, 55], ["HIV Env", "PROBLEM", 60, 67]]], ["The hypothesis is that antigen presentation in a heterogeneous array would alter the hierarchy of B-cell activation by providing a selective advantage to cross-reactive B cells targeting conserved epitopes through nanoparticle-mediated BCRMultivalent Display Multivalent DisplayC o-display Co-display Immunomodulation Immunomodulation Genetic Delivery Genetic Delivery Figure 2 .", [["B-cell", "ANATOMY", 98, 104], ["B cells", "ANATOMY", 169, 176], ["B-cell", "CELL", 98, 104], ["B cells", "CELL", 169, 176], ["cross-reactive B cells", "CELL_TYPE", 154, 176], ["antigen presentation", "PROBLEM", 23, 43], ["B-cell activation", "TREATMENT", 98, 115], ["a selective advantage to cross-reactive B cells targeting conserved epitopes through nanoparticle", "TREATMENT", 129, 226], ["Co-display Immunomodulation Immunomodulation", "TREATMENT", 290, 334]]], ["Antigen display and delivery methods.", [["delivery methods", "TREATMENT", 20, 36]]], ["Antigen presentation on selfassembling nanoparticles (either natural or designed) has proven to be a robust method for enhancing humoral responses (upper left).", [["upper left", "ANATOMY", 148, 158], ["upper left", "ORGANISM_SUBDIVISION", 148, 158], ["selfassembling nanoparticles", "TREATMENT", 24, 52], ["upper", "ANATOMY_MODIFIER", 148, 153], ["left", "ANATOMY_MODIFIER", 154, 158]]], ["Codisplay of related antigens (antigenic variants, colored uniquely) on individual nanoparticles offers a customizable strategy for altering the profile of the vaccine-induced antibody response (upper right).", [["upper right", "ORGANISM_SUBDIVISION", 195, 206], ["antigens", "PROTEIN", 21, 29], ["antigenic variants", "PROTEIN", 31, 49], ["related antigens (antigenic variants", "PROBLEM", 13, 49], ["individual nanoparticles", "TREATMENT", 72, 96], ["a customizable strategy", "TREATMENT", 104, 127], ["the vaccine", "TREATMENT", 156, 167], ["upper", "ANATOMY_MODIFIER", 195, 200], ["right", "ANATOMY_MODIFIER", 201, 206]]], ["Immunomodulation can be achieved by colocalizing antigens and immunomodulatory molecules (silver blobs) on the same nanoparticle (lower left).", [["lower left", "ANATOMY", 130, 140], ["silver", "CHEMICAL", 90, 96], ["silver blobs", "SIMPLE_CHEMICAL", 90, 102], ["immunomodulatory molecules", "PROTEIN", 62, 88], ["Immunomodulation", "TREATMENT", 0, 16], ["immunomodulatory molecules (silver blobs", "PROBLEM", 62, 102], ["lower", "ANATOMY_MODIFIER", 130, 135], ["left", "ANATOMY_MODIFIER", 136, 140]]], ["Genetic delivery involves administration of a nucleic acid to produce immunogens in situ, offering a versatile strategy for vaccine production that may also improve immunogenicity (lower right).Multivalent Display Multivalent Displayclustering and potentially bivalent BCR ligation.", [["nucleic acid", "CHEMICAL", 46, 58], ["BCR", "GENE_OR_GENE_PRODUCT", 269, 272], ["BCR", "PROTEIN", 269, 272], ["Genetic delivery", "TREATMENT", 0, 16], ["a nucleic acid", "TREATMENT", 44, 58], ["immunogens", "TREATMENT", 70, 80], ["a versatile strategy", "TREATMENT", 99, 119], ["vaccine production", "TREATMENT", 124, 142], ["potentially bivalent BCR ligation", "TREATMENT", 248, 281], ["lower", "ANATOMY_MODIFIER", 181, 186], ["right", "ANATOMY_MODIFIER", 187, 192], ["Multivalent Displayclustering", "OBSERVATION", 214, 243], ["bivalent BCR ligation", "OBSERVATION", 260, 281]]], ["In contrast, B cells expressing BCRs with narrow, strain-specific binding would not receive the advantages offered by the particulate antigen and would be relatively poorly activated.", [["B cells", "ANATOMY", 13, 20], ["B cells", "CELL", 13, 20], ["BCRs", "GENE_OR_GENE_PRODUCT", 32, 36], ["B cells", "CELL_TYPE", 13, 20], ["BCRs", "PROTEIN", 32, 36], ["particulate antigen", "PROTEIN", 122, 141], ["BCRs", "PROBLEM", 32, 36], ["narrow, strain-specific binding", "PROBLEM", 42, 73], ["narrow", "OBSERVATION_MODIFIER", 42, 48]]], ["While this type of \"mosaic antigen array\" does not exist in nature, it can be generated on the surface of self-assembling protein scaffolds, as reported in a recent study in which multiple monomeric HA receptor binding domains (RBDs) were displayed on ferritin to generate a series of antigenically variable nanoparticle immunogens [106] .", [["surface", "ANATOMY", 95, 102], ["surface", "CELLULAR_COMPONENT", 95, 102], ["ferritin", "GENE_OR_GENE_PRODUCT", 252, 260], ["monomeric HA receptor binding domains", "PROTEIN", 189, 226], ["RBDs", "PROTEIN", 228, 232], ["ferritin", "PROTEIN", 252, 260], ["\"mosaic antigen array", "PROBLEM", 19, 40], ["a recent study", "TEST", 156, 170], ["multiple monomeric HA receptor binding domains (RBDs)", "PROBLEM", 180, 233], ["ferritin", "TEST", 252, 260], ["antigenically variable nanoparticle immunogens", "TREATMENT", 285, 331], ["protein scaffolds", "OBSERVATION", 122, 139]]], ["Intriguingly, the breadth of the immune response induced by these immunogens correlated with the complexity of the mosaic antigen array (ie, the number of antigenically distinct RBDs displayed on the nanoparticle immunogen), and was superior to that induced by cocktails of nanoparticles individually displaying each of the RBDs.", [["RBDs", "CANCER", 178, 182], ["RBDs", "PROTEIN", 178, 182], ["these immunogens", "TREATMENT", 60, 76], ["the nanoparticle immunogen", "TREATMENT", 196, 222], ["nanoparticles", "TREATMENT", 274, 287], ["the RBDs", "PROBLEM", 320, 328], ["immune response", "OBSERVATION", 33, 48]]], ["It will be interesting to determine whether this concept is applicable to other antigenically diverse, \"hard-to-hit\" targets like HIV.", [["HIV", "ORGANISM", 130, 133], ["HIV", "SPECIES", 130, 133], ["HIV", "SPECIES", 130, 133], ["HIV", "PROBLEM", 130, 133]]], ["Given suitable scaffolds, codisplay could also be used to present heteromeric protein complexes (eg, the human cytomegalovirus glycoprotein pentamer) or multiple proteins that associate on pathogen surfaces (eg, herpesvirus gB and gH/gL).", [["human", "ORGANISM", 105, 110], ["cytomegalovirus", "ORGANISM", 111, 126], ["herpesvirus gB", "ORGANISM", 212, 226], ["gH", "GENE_OR_GENE_PRODUCT", 231, 233], ["gL", "GENE_OR_GENE_PRODUCT", 234, 236], ["heteromeric protein complexes", "PROTEIN", 66, 95], ["human cytomegalovirus glycoprotein pentamer", "PROTEIN", 105, 148], ["multiple proteins", "PROTEIN", 153, 170], ["herpesvirus gB", "PROTEIN", 212, 226], ["gH", "PROTEIN", 231, 233], ["gL", "PROTEIN", 234, 236], ["human", "SPECIES", 105, 110], ["human cytomegalovirus", "SPECIES", 105, 126], ["suitable scaffolds", "TREATMENT", 6, 24], ["codisplay", "TREATMENT", 26, 35], ["heteromeric protein complexes", "PROBLEM", 66, 95], ["the human cytomegalovirus glycoprotein pentamer", "TREATMENT", 101, 148], ["multiple proteins", "PROBLEM", 153, 170], ["pathogen surfaces", "TEST", 189, 206], ["eg", "TEST", 208, 210], ["herpesvirus gB", "TEST", 212, 226], ["gH", "TEST", 231, 233]]], ["In these contexts, codisplay could simplify vaccine manufacturing and characterization in addition to offering the enhanced potency that is typically obtained through multivalent display.", [["vaccine manufacturing", "TREATMENT", 44, 65]]], ["Immunogens targeting certain types of cells induce stronger immune responses than nontargeted counterparts [88, 107] .", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["Immunogens", "TREATMENT", 0, 10]]], ["New approaches to modulating antigen trafficking, uptake, or transport by manipulating size, surface chemistry, or through accessory molecules could enhance antigen availability in lymph nodes for cognate immune cells (ie, B and T cells).", [["surface", "ANATOMY", 93, 100], ["lymph nodes", "ANATOMY", 181, 192], ["immune cells", "ANATOMY", 205, 217], ["B", "ANATOMY", 223, 224], ["T cells", "ANATOMY", 229, 236], ["antigen", "GENE_OR_GENE_PRODUCT", 29, 36], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 181, 192], ["immune cells", "CELL", 205, 217], ["ie", "CELL", 219, 221], ["B", "CELL", 223, 224], ["T cells", "CELL", 229, 236], ["accessory molecules", "PROTEIN", 123, 142], ["cognate immune cells", "CELL_TYPE", 197, 217], ["B and T cells", "CELL_TYPE", 223, 236], ["surface chemistry", "TEST", 93, 110], ["accessory molecules", "PROBLEM", 123, 142], ["lymph nodes", "TEST", 181, 192], ["cognate immune cells", "TEST", 197, 217], ["uptake", "OBSERVATION_MODIFIER", 50, 56], ["size", "OBSERVATION_MODIFIER", 87, 91], ["lymph nodes", "OBSERVATION", 181, 192]]], ["Accessory molecules could also be used to potentiate immune responses by exploiting immune signaling pathways.", [["Accessory molecules", "PROBLEM", 0, 19], ["immune responses", "PROBLEM", 53, 69], ["immune signaling pathways", "PROBLEM", 84, 109], ["molecules", "OBSERVATION", 10, 19]]], ["For example, complement C3d, a classical opsonin, is recognized by complement receptors 2 (CR2, CD21) expressed on B cells and follicular dendritic cells.", [["B cells", "ANATOMY", 115, 122], ["follicular dendritic cells", "ANATOMY", 127, 153], ["complement C3d", "GENE_OR_GENE_PRODUCT", 13, 27], ["opsonin", "GENE_OR_GENE_PRODUCT", 41, 48], ["complement receptors 2", "GENE_OR_GENE_PRODUCT", 67, 89], ["CR2", "GENE_OR_GENE_PRODUCT", 91, 94], ["CD21", "GENE_OR_GENE_PRODUCT", 96, 100], ["B cells", "CELL", 115, 122], ["follicular dendritic cells", "CELL", 127, 153], ["complement C3d", "PROTEIN", 13, 27], ["classical opsonin", "PROTEIN", 31, 48], ["complement receptors 2", "PROTEIN", 67, 89], ["CR2", "PROTEIN", 91, 94], ["CD21", "PROTEIN", 96, 100], ["B cells", "CELL_TYPE", 115, 122], ["follicular dendritic cells", "CELL_TYPE", 127, 153], ["a classical opsonin", "PROBLEM", 29, 48], ["complement receptors", "TEST", 67, 87], ["CR2", "TEST", 91, 94], ["follicular dendritic cells", "PROBLEM", 127, 153], ["opsonin", "OBSERVATION", 41, 48], ["B cells", "OBSERVATION", 115, 122], ["follicular dendritic cells", "OBSERVATION", 127, 153]]], ["On B cells, CR2 forms a trimolecular complex with CD19 and CD81 (TAPA-1), and signaling through this complex amplifies and compensates for low levels of BCR signaling [108, 109].", [["B cells", "ANATOMY", 3, 10], ["B cells", "CELL", 3, 10], ["CR2", "GENE_OR_GENE_PRODUCT", 12, 15], ["CD19", "GENE_OR_GENE_PRODUCT", 50, 54], ["CD81", "GENE_OR_GENE_PRODUCT", 59, 63], ["TAPA-1", "GENE_OR_GENE_PRODUCT", 65, 71], ["BCR", "GENE_OR_GENE_PRODUCT", 153, 156], ["B cells", "CELL_TYPE", 3, 10], ["CR2", "PROTEIN", 12, 15], ["trimolecular complex", "PROTEIN", 24, 44], ["CD19", "PROTEIN", 50, 54], ["CD81", "PROTEIN", 59, 63], ["TAPA", "PROTEIN", 65, 69], ["BCR", "PROTEIN", 153, 156], ["CD19", "TEST", 50, 54], ["CD81", "TEST", 59, 63], ["TAPA", "TEST", 65, 69], ["low levels of BCR signaling", "PROBLEM", 139, 166]]], ["Therefore, targeting this trimolecular complex may act as a molecular adjuvant [110] .", [["trimolecular complex", "PROTEIN", 26, 46], ["this trimolecular complex", "PROBLEM", 21, 46]]], ["The key for successful targeting/ adjuvanting is to colocalize the targeting/adjuvanting molecules on the same surface where the vaccine antigens are located.", [["surface", "ANATOMY", 111, 118], ["surface", "CELLULAR_COMPONENT", 111, 118], ["adjuvanting molecules", "PROTEIN", 77, 98], ["vaccine antigens", "PROTEIN", 129, 145], ["successful targeting/ adjuvanting", "TREATMENT", 12, 45], ["the targeting/adjuvanting molecules", "TREATMENT", 63, 98], ["the vaccine antigens", "TREATMENT", 125, 145]]], ["This should provide maximal enhancement of the antigen-specific immune response and mitigate potential off-target effects [111] .", [["antigen", "GENE_OR_GENE_PRODUCT", 47, 54], ["the antigen", "TEST", 43, 54]]], ["While the recent development of highly customizable nanoparticle platforms capable of codisplaying multiple molecules has enabled new approaches to modulating targeting or immune signaling, these concepts are still in their infancy and need to be rigorously tested.", [["codisplaying multiple molecules", "PROBLEM", 86, 117], ["immune signaling", "PROBLEM", 172, 188], ["highly", "OBSERVATION_MODIFIER", 32, 38], ["customizable", "OBSERVATION_MODIFIER", 39, 51], ["nanoparticle platforms", "OBSERVATION", 52, 74]]], ["Nevertheless, in the near future, we anticipate that it will become possible to reconstitute immunological synapses with tailored functions by codisplaying a variety of costimulatory, inhibitory, regulatory, accessory, and immunomodulatory molecules in addition to vaccine antigen all on the same surface to maximize or fine-tune immune stimulation by design.Multivalent Display Multivalent DisplayImmunization with mRNA for in situ translation has many potential advantages as a method of antigen delivery.", [["surface", "ANATOMY", 297, 304], ["immunomodulatory molecules", "PROTEIN", 223, 249], ["vaccine antigen", "PROTEIN", 265, 280], ["mRNA", "RNA", 416, 420], ["immunological synapses", "PROBLEM", 93, 115], ["immunomodulatory molecules", "TREATMENT", 223, 249], ["vaccine antigen", "TREATMENT", 265, 280], ["a method of antigen delivery", "TREATMENT", 478, 506], ["Multivalent DisplayImmunization", "OBSERVATION", 379, 410]]], ["Like other approaches to genetic immunization, such as DNA vaccines [112] and viral vectors [113] , the production of antigen from a delivered mRNA mimics the replication of infectious agents in three key ways.", [["DNA", "CELLULAR_COMPONENT", 55, 58], ["antigen", "GENE_OR_GENE_PRODUCT", 118, 125], ["delivered mRNA", "RNA", 133, 147], ["genetic immunization", "TREATMENT", 25, 45], ["DNA vaccines", "TREATMENT", 55, 67], ["viral vectors", "TREATMENT", 78, 91], ["the production of antigen", "PROBLEM", 100, 125], ["infectious agents", "TREATMENT", 174, 191], ["infectious", "OBSERVATION", 174, 184]]], ["First, antigen is provided continuously for a period of time, in contrast to the bolus of antigen delivered by protein-based subunit vaccines.", [["protein-based subunit vaccines", "TREATMENT", 111, 141]]], ["Several recent studies have demonstrated that prolonged antigen exposure can improve the magnitude and quality of vaccine-induced responses [114] [115] [116] [117] .", [["Several recent studies", "TEST", 0, 22], ["prolonged antigen exposure", "PROBLEM", 46, 72]]], ["Second, antigen is synthesized, posttranslationally modified, processed, and presented to B cells and T cells the same way it is during natural infection, including antigen presentation on MHC class I, which results in stronger cellular responses than are typically achieved with subunit vaccines [118] .", [["B cells", "ANATOMY", 90, 97], ["T cells", "ANATOMY", 102, 109], ["cellular", "ANATOMY", 228, 236], ["infection", "DISEASE", 144, 153], ["B cells", "CELL", 90, 97], ["T cells", "CELL", 102, 109], ["MHC class I", "GENE_OR_GENE_PRODUCT", 189, 200], ["cellular", "CELL", 228, 236], ["B cells", "CELL_TYPE", 90, 97], ["T cells", "CELL_TYPE", 102, 109], ["MHC class I", "PROTEIN", 189, 200], ["natural infection", "PROBLEM", 136, 153], ["subunit vaccines", "TREATMENT", 280, 296], ["infection", "OBSERVATION", 144, 153]]], ["Third, various types of antigens can be expressed, including cytoplasmic, transmembrane, or secreted proteins as well as engineered antigens that are highly immunogenic yet incompatible with the manufacture of live or inactivated whole-pathogen vaccines because they do not support viral replication (eg, prefusion-stabilized RSV F [119]).", [["cytoplasmic", "ANATOMY", 61, 72], ["transmembrane", "ANATOMY", 74, 87], ["cytoplasmic", "ORGANISM_SUBSTANCE", 61, 72], ["transmembrane", "CELLULAR_COMPONENT", 74, 87], ["RSV", "ORGANISM", 326, 329], ["antigens", "PROTEIN", 24, 32], ["cytoplasmic, transmembrane, or secreted proteins", "PROTEIN", 61, 109], ["engineered antigens", "PROTEIN", 121, 140], ["RSV", "SPECIES", 326, 329], ["cytoplasmic, transmembrane, or secreted proteins", "PROBLEM", 61, 109], ["whole-pathogen vaccines", "TREATMENT", 230, 253], ["viral replication", "TREATMENT", 282, 299]]], ["A major advantage that mRNA vaccines have over other genetic immunization platforms is that there is no risk of infection or genome integration, resulting in a better safety profile.", [["infection", "DISEASE", 112, 121], ["mRNA vaccines", "TREATMENT", 23, 36], ["genetic immunization platforms", "TREATMENT", 53, 83], ["infection", "PROBLEM", 112, 121], ["no risk of", "UNCERTAINTY", 101, 111], ["infection", "OBSERVATION", 112, 121]]], ["Manufacturing can be done synthetically, eliminating the need for cell culture and potential contamination by animal products.", [["cell", "ANATOMY", 66, 70], ["cell", "CELL", 66, 70], ["cell culture", "TEST", 66, 78], ["potential contamination", "PROBLEM", 83, 106], ["animal products", "TREATMENT", 110, 125]]], ["Furthermore, manufacturing is rapid and for the most part independent of sequence, making this vaccine modality particularly well-suited to the development of rapid response platforms to protect against periodic outbreaks or pandemics.", [["this vaccine modality", "TREATMENT", 90, 111], ["rapid response platforms", "TREATMENT", 159, 183], ["periodic outbreaks", "PROBLEM", 203, 221], ["pandemics", "PROBLEM", 225, 234], ["rapid", "OBSERVATION_MODIFIER", 30, 35]]], ["Finally, unlike viral vectors [120], antivector immunity tends not to be an issue with existing delivery platforms, which could help enable repeated dosing.Multivalent Display Multivalent DisplayWhile early approaches to genetic immunization focused on DNA vaccines and viral vectors due to concerns about mRNA instability and immunogenicity, recent technological breakthroughs have made mRNA a plausible commercial vaccine modality.", [["DNA", "CELLULAR_COMPONENT", 253, 256], ["mRNA", "RNA", 388, 392], ["antivector immunity", "TREATMENT", 37, 56], ["existing delivery platforms", "TREATMENT", 87, 114], ["genetic immunization", "TREATMENT", 221, 241], ["DNA vaccines", "TREATMENT", 253, 265], ["viral vectors", "TREATMENT", 270, 283], ["mRNA instability", "PROBLEM", 306, 322], ["a plausible commercial vaccine modality", "TREATMENT", 393, 432]]], ["Decades of investigation into the basic biology of mRNA have defined sequence elements (eg, 5\u2032 and 3\u2032 UTRs [121, 122] ) and optimization strategies (eg, codon optimization [123]) that enable modulation of intracellular stability and translational efficiency.", [["intracellular", "ANATOMY", 205, 218], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 218], ["mRNA", "RNA", 51, 55], ["sequence elements", "DNA", 69, 86], ["5\u2032 and 3\u2032 UTRs", "DNA", 92, 106], ["eg", "TEST", 88, 90], ["UTRs", "TEST", 102, 106], ["optimization strategies (eg, codon optimization", "TREATMENT", 124, 171], ["intracellular stability", "PROBLEM", 205, 228], ["translational efficiency", "PROBLEM", 233, 257], ["intracellular stability", "OBSERVATION", 205, 228], ["translational efficiency", "OBSERVATION", 233, 257]]], ["Improvements in potency have also been obtained by minimizing the intrinsic immunogenicity of nonendogenous mRNA, which can trigger innate immune responses that suppress translation of the encoded antigen.", [["nonendogenous mRNA", "RNA", 94, 112], ["encoded antigen", "PROTEIN", 189, 204], ["nonendogenous mRNA", "PROBLEM", 94, 112], ["the encoded antigen", "PROBLEM", 185, 204]]], ["For example, the related discoveries that mRNAs containing modified nucleosides such as pseudouridine are weaker activators of RNA-sensing pattern recognition receptors [124] and that they therefore yield higher levels of translated protein for a longer period of time in cells and in vivo [125] were major steps forward.", [["cells", "ANATOMY", 272, 277], ["pseudouridine", "CHEMICAL", 88, 101], ["nucleosides", "CHEMICAL", 68, 79], ["pseudouridine", "CHEMICAL", 88, 101], ["pseudouridine", "SIMPLE_CHEMICAL", 88, 101], ["RNA-sensing pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 127, 168], ["cells", "CELL", 272, 277], ["mRNAs", "RNA", 42, 47], ["RNA-sensing pattern recognition receptors", "PROTEIN", 127, 168], ["translated protein", "PROTEIN", 222, 240], ["modified nucleosides", "TREATMENT", 59, 79], ["pseudouridine", "TREATMENT", 88, 101], ["weaker activators of RNA", "PROBLEM", 106, 130]]], ["The subsequent observation that mRNA preparations free of double-stranded RNA contaminants further reduce innate immune activation and increase translation efficiency [126] has made high-level expression of delivered antigen without undesired immune activation possible.", [["mRNA preparations", "TREATMENT", 32, 49], ["double-stranded RNA contaminants", "TREATMENT", 58, 90], ["innate immune activation", "PROBLEM", 106, 130], ["increase translation efficiency", "PROBLEM", 135, 166], ["delivered antigen", "PROBLEM", 207, 224], ["undesired immune activation", "PROBLEM", 233, 260]]], ["Antigen-encoding viral replicons are an alternative approach to obtaining high-level antigen expression [127] .", [["Antigen-encoding viral replicons", "DNA", 0, 32], ["Antigen", "TEST", 0, 7], ["encoding viral replicons", "TREATMENT", 8, 32], ["an alternative approach", "TREATMENT", 37, 60], ["viral replicons", "OBSERVATION", 17, 32]]], ["In addition to antigen, the self-amplifying mRNA encodes a viral replicase that makes copies of the mRNA vector itself [128], leading to robust antigen production and potent immune responses from very small doses of mRNA.", [["self-amplifying mRNA", "RNA", 28, 48], ["mRNA vector", "DNA", 100, 111], ["mRNA", "RNA", 216, 220], ["a viral replicase", "TREATMENT", 57, 74], ["robust antigen production", "PROBLEM", 137, 162], ["potent immune responses", "PROBLEM", 167, 190], ["viral replicase", "OBSERVATION", 59, 74]]], ["One potential drawback of self-amplifying mRNAs is that they intrinsically activate innate immunity, which, while likely contributing to their potency, eliminates control over this important aspect of mRNA vaccine design and limits the duration of antigen production.Multivalent Display Multivalent DisplayDelivery systems that can transport nucleic acids into the cytoplasm are required for mRNA vaccines to be effective.", [["cytoplasm", "ANATOMY", 365, 374], ["nucleic acids", "CHEMICAL", 342, 355], ["antigen", "GENE_OR_GENE_PRODUCT", 248, 255], ["cytoplasm", "ORGANISM_SUBSTANCE", 365, 374], ["self-amplifying mRNAs", "RNA", 26, 47], ["mRNA vaccine", "TREATMENT", 201, 213], ["antigen production", "PROBLEM", 248, 266], ["nucleic acids", "TREATMENT", 342, 355], ["mRNA vaccines", "TREATMENT", 392, 405]]], ["While ex vivo loading of dendritic cells is being pursued for cancer vaccines [129], direct immunization with formulated mRNA will likely be the only viable approach for infectious disease in the near future.", [["dendritic cells", "ANATOMY", 25, 40], ["cancer", "ANATOMY", 62, 68], ["cancer", "DISEASE", 62, 68], ["infectious disease", "DISEASE", 170, 188], ["dendritic cells", "CELL", 25, 40], ["cancer", "CANCER", 62, 68], ["dendritic cells", "CELL_TYPE", 25, 40], ["formulated mRNA", "RNA", 110, 125], ["dendritic cells", "PROBLEM", 25, 40], ["cancer vaccines", "TREATMENT", 62, 77], ["direct immunization", "TREATMENT", 85, 104], ["infectious disease", "PROBLEM", 170, 188], ["dendritic cells", "OBSERVATION", 25, 40]]], ["Although substantial progress has been made, biologics delivery generally remains an unsolved problem and many strategies are being evaluated preclinically.", [["biologics delivery", "TREATMENT", 45, 63], ["an unsolved problem", "PROBLEM", 82, 101], ["substantial", "OBSERVATION_MODIFIER", 9, 20]]], ["To date, there are at least 3 delivery platforms under clinical investigation for mRNA vaccines, including uncomplexed mRNAs mixed with mRNA-protamine complexes that stimulate innate immunity through TLR7 signaling [130, 131], mRNA-decorated cationic lipid nanoemulsions [132], and mRNA-encapsidating lipid nanoparticles [118, [133] [134] [135] .", [["protamine", "GENE_OR_GENE_PRODUCT", 141, 150], ["TLR7", "GENE_OR_GENE_PRODUCT", 200, 204], ["cationic lipid nanoemulsions", "SIMPLE_CHEMICAL", 242, 270], ["encapsidating lipid nanoparticles", "SIMPLE_CHEMICAL", 287, 320], ["uncomplexed mRNAs", "RNA", 107, 124], ["mRNA", "RNA", 136, 140], ["protamine complexes", "PROTEIN", 141, 160], ["TLR7", "PROTEIN", 200, 204], ["mRNA", "RNA", 227, 231], ["mRNA", "RNA", 282, 286], ["clinical investigation", "TEST", 55, 77], ["mRNA vaccines", "TREATMENT", 82, 95], ["mRNA-protamine complexes", "TREATMENT", 136, 160], ["TLR7 signaling", "TEST", 200, 214], ["mRNA", "TEST", 227, 231], ["decorated cationic lipid nanoemulsions", "TEST", 232, 270], ["mRNA", "TEST", 282, 286], ["lipid nanoparticles", "TEST", 301, 320]]], ["The latter systems were pioneered for intravenous delivery of siRNA therapeutics, which results primarily in delivery to the liver.", [["intravenous", "ANATOMY", 38, 49], ["liver", "ANATOMY", 125, 130], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 49], ["liver", "ORGAN", 125, 130], ["intravenous delivery of siRNA therapeutics", "TREATMENT", 38, 80], ["liver", "ANATOMY", 125, 130]]], ["However, intradermal, intramuscular, and subcutaneous administration of mRNA vaccines formulated in lipid nanoparticles results in robust local expression at the injection site [136] .", [["intramuscular", "ANATOMY", 22, 35], ["subcutaneous", "ANATOMY", 41, 53], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["lipid nanoparticles", "SIMPLE_CHEMICAL", 100, 119], ["intradermal", "TREATMENT", 9, 20], ["intramuscular", "TREATMENT", 22, 35], ["mRNA vaccines", "TREATMENT", 72, 85], ["lipid nanoparticles", "TREATMENT", 100, 119], ["intramuscular", "ANATOMY", 22, 35], ["subcutaneous", "ANATOMY", 41, 53], ["robust", "OBSERVATION_MODIFIER", 131, 137], ["local expression", "OBSERVATION", 138, 154]]], ["Encouragingly, mRNA vaccines have provided impressive results in preclinical animal models.Multivalent Display Multivalent DisplayData are just beginning to emerge from phase I clinical trials of mRNA vaccines for infectious diseases.", [["infectious diseases", "DISEASE", 214, 233], ["mRNA vaccines", "TREATMENT", 15, 28], ["mRNA vaccines", "TREATMENT", 196, 209], ["infectious diseases", "PROBLEM", 214, 233], ["Multivalent DisplayData", "OBSERVATION", 111, 134]]], ["A clinical trial of an mRNA/mRNA-protamine complex vaccine encoding the rabies virus glycoprotein induced neutralizing antibodies and virus-specific T cells and demonstrated an acceptable safety profile [137] .", [["T cells", "ANATOMY", 149, 156], ["protamine", "CHEMICAL", 33, 42], ["protamine", "GENE_OR_GENE_PRODUCT", 33, 42], ["rabies virus", "ORGANISM", 72, 84], ["T cells", "CELL", 149, 156], ["rabies virus glycoprotein", "PROTEIN", 72, 97], ["neutralizing antibodies", "PROTEIN", 106, 129], ["virus-specific T cells", "CELL_TYPE", 134, 156], ["rabies virus", "SPECIES", 72, 84], ["rabies virus", "SPECIES", 72, 84], ["an mRNA/mRNA", "TREATMENT", 20, 32], ["protamine complex vaccine", "TREATMENT", 33, 58], ["the rabies virus glycoprotein", "TEST", 68, 97], ["neutralizing antibodies", "TEST", 106, 129], ["virus", "PROBLEM", 134, 139]]], ["However, the potency and durability of the immune response were lower than in preclinical animal models and required the use of needle-free injection devices.", [["needle-free injection devices", "TREATMENT", 128, 157]]], ["Similarly, an mRNA vaccine with modified nucleosides formulated in lipid nanoparticles encoding influenza HA induced HAI titers in humans that were above the protective threshold and similar to conventional, commercially available influenza vaccines, yet below the levels induced in animal models [133] .", [["nucleosides", "CHEMICAL", 41, 52], ["nucleosides", "CHEMICAL", 41, 52], ["nucleosides", "SIMPLE_CHEMICAL", 41, 52], ["lipid nanoparticles", "SIMPLE_CHEMICAL", 67, 86], ["influenza HA", "ORGANISM", 96, 108], ["humans", "ORGANISM", 131, 137], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["an mRNA vaccine", "TREATMENT", 11, 26], ["modified nucleosides", "TREATMENT", 32, 52], ["lipid nanoparticles", "TREATMENT", 67, 86], ["influenza HA induced HAI titers in humans", "PROBLEM", 96, 137], ["influenza vaccines", "TREATMENT", 231, 249]]], ["These early data, while encouraging, suggest that additional improvements to mRNA vaccines will be required to realize the full potential of this promising delivery platform.", [["mRNA vaccines", "TREATMENT", 77, 90], ["this promising delivery platform", "TREATMENT", 141, 173]]], ["Better delivery systems and innovative approaches to triggering innate immunity without sacrificing antigen expression are two areas where substantial improvements could be made.", [["Better delivery systems", "TREATMENT", 0, 23], ["innovative approaches", "TREATMENT", 28, 49]]], ["Improving the design of the encoded antigens-for example, using the self-assembling nanoparticle immunogens discussed earlier-is also likely to enhance performance.Multivalent Display Multivalent DisplayIn addition to these technologies, the goal of single-injection subunit vaccines continues to drive the exploration of controlled release formulations based on synthetic or biological polymers [117, 138, 139] .", [["encoded antigens", "PROTEIN", 28, 44], ["the self-assembling nanoparticle immunogens", "TREATMENT", 64, 107], ["these technologies", "TREATMENT", 218, 236], ["single-injection subunit vaccines", "TREATMENT", 250, 283], ["the exploration of controlled release formulations", "TREATMENT", 303, 353]]], ["For more detail, the reader is referred to excellent recent reviews [86, 88] .CONCLUDING REMARKS-TOWARDS A UNIVERSAL INFLUENZA VACCINEOne hundred years after the 1918 Spanish flu pandemic, influenza remains a massive burden to public health.", [["flu pandemic", "DISEASE", 175, 187], ["influenza", "DISEASE", 189, 198], ["influenza", "PROBLEM", 189, 198]]], ["In recent years, methods developed for immunogen design have resulted in significant preclinical progress towards a universal influenza vaccine.", [["methods", "TREATMENT", 17, 24], ["immunogen design", "TREATMENT", 39, 55], ["a universal influenza vaccine", "TREATMENT", 114, 143]]], ["Even though such a vaccine has not yet been deployed, many recently developed approaches could nonetheless provide substantial improvements in breadth of protection over existing licensed vaccines.", [["a vaccine", "TREATMENT", 17, 26], ["existing licensed vaccines", "TREATMENT", 170, 196], ["substantial", "OBSERVATION_MODIFIER", 115, 126], ["improvements", "OBSERVATION_MODIFIER", 127, 139], ["breadth", "OBSERVATION_MODIFIER", 143, 150]]], ["In aiming for universal protection, it will be vital to determine the best possible ways to redirect immune responses towards conserved regions of influenza antigens, including the RBS and stem of HA and possibly more unexplored regions on the neuraminidase and M2 proteins.", [["RBS", "GENE_OR_GENE_PRODUCT", 181, 184], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 244, 257], ["M2", "GENE_OR_GENE_PRODUCT", 262, 264], ["influenza antigens", "PROTEIN", 147, 165], ["RBS", "PROTEIN", 181, 184], ["neuraminidase and M2 proteins", "PROTEIN", 244, 273], ["universal protection", "TREATMENT", 14, 34], ["influenza antigens", "PROBLEM", 147, 165], ["the RBS", "TEST", 177, 184], ["HA", "PROBLEM", 197, 199], ["the neuraminidase", "TREATMENT", 240, 257], ["influenza", "OBSERVATION", 147, 156]]], ["New approaches to immunogen design, enabled by the development of new technologies, will be needed to achieve the breadth of responses against these conserved regions required to provide universal protection.", [["these conserved regions", "PROBLEM", 143, 166], ["universal protection", "TREATMENT", 187, 207]]], ["Better knowledge of convergent antibody lineages and additional experience designing antigens that target them to give rise to bNAbs is expected to improve current approaches.", [["antigens", "PROTEIN", 85, 93], ["convergent antibody lineages", "PROBLEM", 20, 48], ["bNAbs", "PROBLEM", 127, 132], ["antibody lineages", "OBSERVATION", 31, 48]]], ["Rigorous exploration of new methods for antigen display using self-assembling scaffolds has the potential to further amplify responses targeting these conserved regions, and the ability to design novel self-assembling protein platforms should make it possible to tailor them to maximize the potency and durability of humoral responses.", [["Rigorous exploration", "TEST", 0, 20], ["new methods", "TREATMENT", 24, 35], ["self-assembling scaffolds", "TREATMENT", 62, 87]]], ["These challenges and opportunities represent a novel space to explore in conjunction with antigen design and the development of delivery technologies to induce CD8 + T cell responses or mucosal immunity in addition to targeted antibody responses.", [["CD8 + T cell", "ANATOMY", 160, 172], ["mucosal", "ANATOMY", 186, 193], ["CD8", "GENE_OR_GENE_PRODUCT", 160, 163], ["mucosal", "ORGAN", 186, 193], ["CD8", "PROTEIN", 160, 163], ["a novel space", "PROBLEM", 45, 58], ["antigen design", "TREATMENT", 90, 104], ["delivery technologies", "TREATMENT", 128, 149], ["CD8", "TEST", 160, 163]]], ["With respect to influenza in particular, it will be essential to understand how preexisting immunity influences responses to novel immunogens, and how the vaccine design process can best accommodate these effects.CONCLUDING REMARKS-TOWARDS A UNIVERSAL INFLUENZA VACCINEThe novel strategies and technologies developed in response to the challenges presented by a universal influenza vaccine will be applicable to the structure-based design of vaccines for a wide range of pathogens.", [["influenza", "DISEASE", 16, 25], ["influenza", "PROBLEM", 16, 25], ["novel immunogens", "TREATMENT", 125, 141], ["the vaccine design process", "TREATMENT", 151, 177], ["A UNIVERSAL INFLUENZA VACCINE", "TREATMENT", 240, 269], ["a universal influenza vaccine", "TREATMENT", 360, 389], ["vaccines", "TREATMENT", 442, 450], ["pathogens", "PROBLEM", 471, 480], ["influenza", "OBSERVATION", 16, 25]]], ["It is an incredibly exciting time for the field of vaccine development, and we predict a structure-based, design-driven renaissance that recalls or even surpasses the original golden age of vaccines.Supplementary DataSupplementary materials are available at The Journal of Infectious Diseases online.", [["Infectious Diseases", "DISEASE", 273, 292], ["vaccine development", "TREATMENT", 51, 70], ["Supplementary DataSupplementary materials", "TREATMENT", 199, 240], ["incredibly", "OBSERVATION_MODIFIER", 9, 19]]]], "e42e38806843cc44593445984f57fb81d46e0c41": [["The news is rarely positive-from predicting an increasing frequency of el Nino events (Cai et al., 2014) to reduction in biodiversity (Mantyka-Pringle et al., 2015) and reduced wheat production (Asseng et al., 2015) .", [["wheat", "SPECIES", 177, 182], ["wheat", "SPECIES", 177, 182], ["reduced wheat production", "PROBLEM", 169, 193], ["positive", "OBSERVATION", 19, 27], ["increasing", "OBSERVATION_MODIFIER", 47, 57], ["biodiversity", "OBSERVATION_MODIFIER", 121, 133]]], ["There are likely to be substantial effects on illness and mortality statistics, disproportionately affecting poorer regions (Patz et al., 2005) .", [["illness", "DISEASE", 46, 53], ["illness", "PROBLEM", 46, 53], ["likely to be", "UNCERTAINTY", 10, 22], ["substantial", "OBSERVATION_MODIFIER", 23, 34], ["effects", "OBSERVATION", 35, 42]]], ["The consensus now rests with those who consider the anticipated change to be anthropogenic in nature.", [["anthropogenic", "OBSERVATION", 77, 90]]], ["Despite this consensus, however, there is still much uncertainty about what the future holds for wider aspects of human health (Wardekker et al., 2012) .INTRODUCTIONWithin the wider domain of climate and health, the neglected tropical diseases (Hotez et al., 2006) , often abbreviated to NTDs, are a collection of infectious diseases affecting hundreds of millions of individuals living in tropical countries.", [["NTDs", "DISEASE", 288, 292], ["infectious diseases", "DISEASE", 314, 333], ["human", "ORGANISM", 114, 119], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["the neglected tropical diseases", "PROBLEM", 212, 243], ["NTDs", "PROBLEM", 288, 292], ["infectious diseases", "PROBLEM", 314, 333], ["infectious", "OBSERVATION", 314, 324]]], ["In recent years, there has been considerable increase in investment towards reducing the burden of several NTDs , but they still collectively contribute to productivity loss (reviewed by Conteh et al., 2010) , illness and suffering in many countries, including several within the G20 .", [["NTDs", "DISEASE", 107, 111], ["illness", "DISEASE", 210, 217], ["several NTDs", "PROBLEM", 99, 111], ["productivity loss", "PROBLEM", 156, 173], ["illness", "PROBLEM", 210, 217], ["considerable", "OBSERVATION_MODIFIER", 32, 44], ["increase", "OBSERVATION_MODIFIER", 45, 53]]], ["Recent estimates of their overall burden suggest NTD kill over 350,000 people per annum and cause the loss of between 27 and 56 million disability-adjusted life years .INTRODUCTIONClimate change projections are typically associated looking forward several decades, often reaching out as far as 100 years or more (Collins et al., 2013) .", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77]]], ["NTDs are a contemporary issue and are subject to attempts to eliminate them as a public health problem, or even eradicate them from the planet.", [["NTDs", "DISEASE", 0, 4], ["NTDs", "PROBLEM", 0, 4]]], ["At the time of writing, the dates 2020 and 2030 feature prominently in documents including the WHO roadmaps (World Health Organisation, 2012 , 2013a , 2016a .INTRODUCTIONThe latest WHO documents regarding the roadmap for NTD control also mentions climate change in a number of places (World Health Organisation, 2017) .", [["NTD control", "TREATMENT", 221, 232]]], ["There exists a 'Climate and Health atlas ', published in 2012 (World Health Organisation, 2013b ) that is referred to by the WHO literature, and 'which explores the numerous and variable effects of climate change on infectious diseases, including NTDs'.", [["infectious diseases", "DISEASE", 216, 235], ["NTDs", "DISEASE", 247, 251], ["infectious diseases", "PROBLEM", 216, 235], ["NTDs", "PROBLEM", 247, 251], ["infectious", "OBSERVATION", 216, 226]]], ["On closer inspection, however, the Climate and Health Atlas contains only material on meningitis, dengue, malaria and diarrhoea.INTRODUCTIONSimultaneous to the technical and targeted approaches being recommended by WHO are much wider attempts at sustainable development, most visible through the lens of the sustainable development goals (Griggs et al., 2013) .", [["meningitis", "DISEASE", 86, 96], ["dengue", "DISEASE", 98, 104], ["malaria", "DISEASE", 106, 113], ["diarrhoea", "DISEASE", 118, 127], ["closer inspection", "TEST", 3, 20], ["meningitis", "PROBLEM", 86, 96], ["dengue", "PROBLEM", 98, 104], ["malaria", "PROBLEM", 106, 113], ["diarrhoea", "PROBLEM", 118, 127], ["meningitis", "OBSERVATION", 86, 96], ["malaria", "OBSERVATION", 106, 113], ["diarrhoea", "OBSERVATION", 118, 127], ["sustainable", "OBSERVATION_MODIFIER", 308, 319]]], ["Aspects of the NTD impact on health and productivity permeate many SDG themes (Bangert et al., 2017) , including Goal 3 (Health), which even contains a target for NTDs, namely Target 3.3: 'By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases' (Fitzpatrick and Engels, 2016) .INTRODUCTIONSuccess in implementing the WHO plans and the SDGs could spell the end for some or all the NTDs.", [["NTDs", "DISEASE", 163, 167], ["AIDS", "DISEASE", 219, 223], ["tuberculosis", "DISEASE", 225, 237], ["malaria", "DISEASE", 239, 246], ["tropical diseases", "DISEASE", 261, 278], ["hepatitis", "DISEASE", 290, 299], ["water-borne diseases", "DISEASE", 301, 321], ["communicable diseases", "DISEASE", 332, 353], ["NTDs", "DISEASE", 490, 494], ["AIDS", "PROBLEM", 219, 223], ["tuberculosis", "PROBLEM", 225, 237], ["malaria", "PROBLEM", 239, 246], ["neglected tropical diseases", "PROBLEM", 251, 278], ["combat hepatitis", "PROBLEM", 283, 299], ["water-borne diseases", "PROBLEM", 301, 321], ["other communicable diseases'", "PROBLEM", 326, 354], ["tuberculosis", "OBSERVATION", 225, 237], ["malaria", "OBSERVATION", 239, 246], ["tropical diseases", "OBSERVATION", 261, 278]]], ["But considerable literature exists, primarily derived from studies of parasites affecting wildlife that global environmental change may lead to responses by hosts, vectors and parasites themselves that could affect the outcome of interventions (Cable et al., 2017) .", [["parasites", "PROBLEM", 70, 79]]], ["Thus, it will be important to consider not just meeting targets set within the SDG and WHO documents, but how those targets are met.INTRODUCTIONIn reviewing how decadal climate change may impact on the future transmission of the NTDs, it is necessary to be somewhat pessimistic and assume that most NTDs are not going to be eliminated or eradicated by 2030.", [["NTDs", "DISEASE", 229, 233], ["NTDs", "DISEASE", 299, 303]]], ["This includes assuming that policy change associated with SDG Goal 13 'Action on Climate' does not result in returning the climate to preindustrial levels-a target that at the time of writing looked increasingly unreachable (UNEP, 2017) .INTRODUCTIONThe tension between contemporary knowledge and future projections can be resolved partially by deploying a universal caveat-namely by stating that future projections may be valid, 'all other things being equal'.", [["preindustrial levels", "TEST", 134, 154], ["tension", "OBSERVATION_MODIFIER", 254, 261]]], ["Given future uncertainties in terms of climate change scenarios (described below), it is highly unlikely that anything will remain equal over the coming decades.", [["climate change scenarios", "PROBLEM", 39, 63], ["highly unlikely", "UNCERTAINTY", 89, 104]]], ["Anthropogenic activities connected to, or independent of, climate change will also have an impact, e.g., through early case detection combined with equal access to medicines.", [["medicines", "TREATMENT", 164, 173]]], ["The point of existing research into climate change and health is therefore not to give definitive conclusions but to reach interim conclusions that feed into the next round of projections which can consider a range of natural and anthropogenic interventions.INTRODUCTIONThe 'precautionary principle' as applied widely to environmental science (Kriebel et al., 2001) , and specifically to climate change (Hallegatte, 2009 ) is also relevant in terms of understanding why climate change research is important.", [["natural and anthropogenic interventions", "TREATMENT", 218, 257]]], ["Thus, applying the precautionary principle in terms of action against climate change, or any other domain contained within the SDGs, may not sufficient to guarantee a future free of NTDs.AIMSThe main aims of this chapter are (1) to review crosscutting issues that are likely to affect future transmission of NTDs, (2) to provide information about the current state of the art with respect to investigations into climate change and NTD transmission and (3) to identify gaps in knowledge with a view to identifying potential areas of research activity.", [["NTDs", "DISEASE", 182, 186], ["NTDs", "DISEASE", 308, 312], ["the precautionary principle", "TREATMENT", 15, 42], ["any other domain", "PROBLEM", 89, 105], ["NTDs", "PROBLEM", 182, 186], ["NTD transmission", "TEST", 431, 447]]], ["The review considers 34 different species of established or emerging public health importance, drawn from the WHO list of NTDs and the WHO blueprint list of priority diseases.", [["priority diseases", "PROBLEM", 157, 174]]], ["Infections are listed in Table 1 along with brief descriptions of their climate-sensitive life stages.A PARASITOLOGIST'S GUIDE TO CLIMATE CHANGEDetailed insights into the causes and drivers of climate change are available elsewhere (IPCC, 2013) .", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10]]], ["To understand how climate change may change the landscape of transmission for NTDs, I begin with some macroscale considerations of the underpinning physics of climate change and a description of how we interpret the climate change vernacular.", [["NTDs", "DISEASE", 78, 82], ["NTDs", "PROBLEM", 78, 82]]], ["Historic observations support the basic tenet of climate change which is that increasing levels of so-called greenhouse gases have driven upwards the global mean surface temperature (Hartmann et al., 2013) .", [["surface", "ANATOMY", 162, 169], ["increasing levels", "PROBLEM", 78, 95], ["greenhouse gases", "TEST", 109, 125], ["increasing", "OBSERVATION_MODIFIER", 78, 88]]], ["The characteristic of a greenhouse gas is that it influences 'radiative forcing' towards a more positive value.", [["a greenhouse gas", "PROBLEM", 22, 38], ["greenhouse gas", "OBSERVATION", 24, 38]]], ["Radiative forcing is defined as a rate of change in energy per unit area (measured in W/m 2 ) of the upper atmosphere.", [["Radiative forcing", "PROBLEM", 0, 17], ["upper", "ANATOMY_MODIFIER", 101, 106]]], ["As greenhouse gasses (also known as radiative forcing components or climate sensitivities) trap more of the incoming energy from the sun, so the ratio of incoming vs reflected energy gets greater and the radiative forcing value increases (Fig. 1) .A PARASITOLOGIST'S GUIDE TO CLIMATE CHANGEThe Intergovernmental Panel on Climate Change (IPCC) has adopted several representative climate change scenarios throughout its working history.", [["greenhouse gasses", "TEST", 3, 20], ["radiative forcing components", "PROBLEM", 36, 64], ["Intergovernmental Panel", "TEST", 294, 317], ["Climate Change (IPCC", "TREATMENT", 321, 341], ["radiative forcing", "OBSERVATION", 204, 221]]], ["They are known as A1, B1, Fig. 1 The role of greenhouses in terms of climate change is to affect the balance between surface and atmospheric energy absorption and emission (the energy budget).", [["surface", "ANATOMY", 117, 124], ["A1", "PROTEIN", 18, 20], ["B1", "PROTEIN", 22, 24]]], ["Increasing the back radiation will affect global temperature changes, the carbon and water cycles and have both direct and indirect effects at various scales across multiple domains of organisation as illustrated in Fig. 2.", [["carbon", "CHEMICAL", 74, 80], ["carbon", "SIMPLE_CHEMICAL", 74, 80], ["the back radiation", "TREATMENT", 11, 29], ["global temperature changes", "PROBLEM", 42, 68], ["the carbon and water cycles", "TREATMENT", 70, 97]]], ["A2 and B2.", [["A2", "GENE_OR_GENE_PRODUCT", 0, 2], ["B2", "GENE_OR_GENE_PRODUCT", 7, 9], ["A2", "PROTEIN", 0, 2], ["B2", "DNA", 7, 9], ["B2", "ANATOMY", 7, 9]]], ["The A1 scenario predicts a future world that converges in terms of rapid economic growth, and rapid introduction of more efficient technologies.", [["rapid economic growth", "PROBLEM", 67, 88]]], ["The A2 scenario indicates a more fragmented world with slower rates of development.", [["A2", "PROTEIN", 4, 6], ["A2 scenario", "OBSERVATION", 4, 15], ["more", "OBSERVATION_MODIFIER", 28, 32], ["fragmented", "OBSERVATION", 33, 43], ["slower", "OBSERVATION_MODIFIER", 55, 61], ["rates", "OBSERVATION_MODIFIER", 62, 67]]], ["The B1 scenario describes a convergent world with a static population, and the B2 scenario describes a world with intermediate population growth and technological development.A PARASITOLOGIST'S GUIDE TO CLIMATE CHANGEThe so-called relative concentration pathways (RCPs), rather than being based on socioeconomic scenarios, use radiative forcing narratives to project global warming trends over the coming decades.", [["radiative forcing narratives", "TREATMENT", 327, 355]]], ["They differ from the SRES family by decoupling climate modelling from scenario development and thereby allow for independent modelling of specific interventions, rather than having them built in at the onset.", [["SRES family", "PROTEIN", 21, 32], ["specific interventions", "TREATMENT", 138, 160]]], ["The nomenclature of these pathways corresponds specifically to the anticipated change in the global average level of radiative forcing in the year 2100 compared to preindustrial levels.", [["preindustrial levels", "TEST", 164, 184], ["anticipated", "OBSERVATION_MODIFIER", 67, 78], ["change", "OBSERVATION_MODIFIER", 79, 85], ["global", "OBSERVATION_MODIFIER", 93, 99], ["average", "OBSERVATION_MODIFIER", 100, 107], ["radiative forcing", "OBSERVATION", 117, 134]]], ["So, for example, RCP2.6 represents a change of 2.6 W/m 2 over this time period.A PARASITOLOGIST'S GUIDE TO CLIMATE CHANGEThe RCPs have been developed over several years by research teams that modelled changes to the atmosphere based on projected anthropogenic drivers of greenhouse gasses.", [["greenhouse gasses", "OBSERVATION", 271, 288]]], ["Each RCP imagines a particular future where levels of CO 2 and other gasses are either reduced or increased by changes in the drivers of emissions.", [["CO 2", "CHEMICAL", 54, 58], ["CO 2", "GENE_OR_GENE_PRODUCT", 54, 58], ["levels of CO", "TEST", 44, 56], ["other gasses", "TEST", 63, 75], ["reduced", "OBSERVATION_MODIFIER", 87, 94], ["increased", "OBSERVATION_MODIFIER", 98, 107]]], ["For example, RCP2.6 is the output of models that combine reforestation programmes, reduced methane emissions and moderate population growth.", [["methane", "CHEMICAL", 91, 98], ["methane", "CHEMICAL", 91, 98], ["methane", "SIMPLE_CHEMICAL", 91, 98], ["reduced methane emissions", "PROBLEM", 83, 108], ["moderate population growth", "PROBLEM", 113, 139], ["output", "OBSERVATION_MODIFIER", 27, 33], ["reduced", "OBSERVATION_MODIFIER", 83, 90], ["methane emissions", "OBSERVATION", 91, 108], ["moderate", "OBSERVATION_MODIFIER", 113, 121], ["population", "OBSERVATION_MODIFIER", 122, 132], ["growth", "OBSERVATION_MODIFIER", 133, 139]]], ["Conversely, RCP8.5 considers a future where methane emissions increase substantially, there is considerable population growth and continued heavy reliance on fossil fuels.", [["methane", "CHEMICAL", 44, 51], ["methane", "CHEMICAL", 44, 51], ["methane", "SIMPLE_CHEMICAL", 44, 51], ["methane emissions", "PROBLEM", 44, 61], ["considerable population growth", "PROBLEM", 95, 125], ["considerable", "OBSERVATION_MODIFIER", 95, 107], ["population", "OBSERVATION_MODIFIER", 108, 118], ["growth", "OBSERVATION_MODIFIER", 119, 125], ["fossil fuels", "OBSERVATION", 158, 170]]], ["RCP2.6 is considered to be 'reversible' and in the underpinning models it is suggested that emissions will peak in 2050 before returning to historically normal values by 2100.", [["RCP2.6", "CHEMICAL", 0, 6], ["considered to be", "UNCERTAINTY", 10, 26], ["reversible", "OBSERVATION", 28, 38]]], ["Conversely, RCP8.5 summarises a future of no climate policies and no possibility of return to historic levels of emission.A PARASITOLOGIST'S GUIDE TO CLIMATE CHANGERCPs are associated with integrated assessment models (van Vuuren et al., 2011b) to produce time series data of emissions that act as inputs into more complex Atmosphere-Ocean Global Circulation models (AOGCMs).", [["integrated assessment models", "TEST", 189, 217], ["no possibility", "UNCERTAINTY", 66, 80]]], ["The next step in producing state-of-the-art projections is to develop earth system models (ESMs) that include both land and ocean biogeochemistry.", [["ocean biogeochemistry", "OBSERVATION", 124, 145]]], ["Combining AOGCMs and ESMs leads to multimodel 'experiments' that project global temperature, precipitation and other variables over coming decades.", [["Combining AOGCMs and ESMs", "PROBLEM", 0, 25]]], ["The experiment known as CMIP5 is capable of producing dozens of different simulated output variables (Taylor et al., 2012) including snowfall flux, zooplankton carbon concentration, near-surface wind speed, evaporation, soil temperature and water content.", [["surface", "ANATOMY", 187, 194], ["carbon", "CHEMICAL", 160, 166], ["carbon", "CHEMICAL", 160, 166], ["carbon", "SIMPLE_CHEMICAL", 160, 166], ["water", "SIMPLE_CHEMICAL", 241, 246], ["snowfall flux", "TREATMENT", 133, 146], ["zooplankton carbon concentration", "TREATMENT", 148, 180], ["water content", "OBSERVATION_MODIFIER", 241, 254]]], ["The spatial and temporal resolutions of these outputs can be specified depending on need and within the limits of the available IT infrastructure.", [["spatial", "OBSERVATION_MODIFIER", 4, 11], ["temporal", "OBSERVATION_MODIFIER", 16, 24], ["resolutions", "OBSERVATION_MODIFIER", 25, 36]]], ["Daily estimates of precipitation and temperature are now available, for example through the NASA Earth Exchange Global Daily Downscaled Projections (NEX-GDDP) at a temporal resolution of 1 day and a spatial resolution of 0.25 degree (approximately 25 \u00c2 25 km).", [["temperature", "TEST", 37, 48]]], ["One of the criticisms of highly detailed models is that as they become more realistic, they become more uncertain (Maslin and Austin, 2012) .CROSSCUTTING ENVIRONMENTAL AND ANTHROPOCENTRIC ISSUESEvidence suggests that recent climate change is already affecting the phenology of a wide range of organisms across the globe (Walther et al., 2002) .", [["recent climate change", "PROBLEM", 217, 238], ["climate", "OBSERVATION", 224, 231], ["globe", "ANATOMY", 314, 319]]], ["From the relatively simple concept of climate forcing springs a hugely complex and interactive web of interacting ecosystems that might impact on the ecology of hosts, parasites and vectors over both time and space.", [["parasites and vectors", "TREATMENT", 168, 189]]], ["Below I summarise some important elements of anticipated change that evidence suggests may impact on NTD ecology.AsynchronyLife cycles of several parasitic infections, particularly those with a life cycle involving a vector or intermediate host, rely on circadian rhythms to ensure that transmission stages are available at the same time as the host is exposed to the intermediate host or vector.", [["parasitic infections", "DISEASE", 146, 166], ["AsynchronyLife cycles", "TREATMENT", 113, 134], ["several parasitic infections", "PROBLEM", 138, 166], ["a vector", "TREATMENT", 215, 223], ["circadian rhythms", "TEST", 254, 271], ["several", "OBSERVATION_MODIFIER", 138, 145], ["parasitic", "OBSERVATION_MODIFIER", 146, 155], ["infections", "OBSERVATION", 156, 166]]], ["For example, it has been long established that malaria parasites exhibit circadian patterns in emergence from red-blood cells (Mideo et al., 2013) , and also well known that schistosome cercariae exhibit a circadian pattern of emergence from snail hosts (Mintsa-Ngu ema et al., 2014) .", [["red-blood cells", "ANATOMY", 110, 125], ["malaria parasites", "DISEASE", 47, 64], ["schistosome cercariae", "DISEASE", 174, 195], ["red-blood cells", "CELL", 110, 125], ["schistosome cercariae", "ORGANISM", 174, 195], ["red-blood cells", "CELL_TYPE", 110, 125], ["malaria parasites", "PROBLEM", 47, 64], ["circadian patterns", "PROBLEM", 73, 91], ["red-blood cells", "TEST", 110, 125], ["schistosome cercariae", "PROBLEM", 174, 195], ["malaria", "OBSERVATION", 47, 54], ["schistosome", "OBSERVATION", 174, 185]]], ["Less well known is that humans excrete eggs of schistosome parasites in a circadian pattern, with peak excretion late morning (Doehring et al., 1983; Hawking, 1975) .", [["schistosome parasites", "DISEASE", 47, 68], ["humans", "ORGANISM", 24, 30], ["schistosome", "ORGANISM", 47, 58], ["humans", "SPECIES", 24, 30], ["humans", "SPECIES", 24, 30], ["schistosome parasites", "PROBLEM", 47, 68], ["schistosome parasites", "OBSERVATION", 47, 68]]], ["Climate change has the potential to create asynchrony by either changing host behaviour (e.g. time of faecal expulsion change as a result of abiotic and biotic pressures on host behaviour), or by disrupting the availability of hosts at the time required to complete the life cycle (e.g., by forcing a range shift).", [["faecal", "ORGANISM_SUBDIVISION", 102, 108], ["faecal expulsion change", "PROBLEM", 102, 125], ["abiotic and biotic pressures", "TREATMENT", 141, 169], ["asynchrony", "OBSERVATION", 43, 53]]], ["Evidence for this occurring already has emerged from studies of livestock carrying Nematodirus battus (Gethings et al., 2015) .AsynchronyThe net result of asynchrony may be to reduce disease in the short term, but it may also place a selection pressure on the parasites, selecting those variants that induce the host to expel transmission stages at a time appropriate to the new system.", [["Nematodirus battus", "ORGANISM", 83, 101], ["Nematodirus battus", "SPECIES", 83, 101], ["Nematodirus battus", "SPECIES", 83, 101], ["Asynchrony", "PROBLEM", 127, 137], ["asynchrony", "PROBLEM", 155, 165], ["disease", "PROBLEM", 183, 190], ["short term", "OBSERVATION_MODIFIER", 198, 208], ["pressure", "OBSERVATION_MODIFIER", 244, 252]]], ["Variation in the timing of peak output of schistosome cercariae from snails has been recorded across different species of definitive host (Th eron, 2015)-indicating that selection pressures can alter circadian emergence patterns.", [["schistosome cercariae", "ORGANISM", 42, 63], ["Th eron", "CELL", 139, 146], ["peak output", "TEST", 27, 38], ["schistosome cercariae", "PROBLEM", 42, 63], ["selection pressures", "TEST", 170, 189], ["peak output", "OBSERVATION", 27, 38], ["schistosome cercariae", "OBSERVATION", 42, 63]]], ["It remains to be seen whether the selection pressure will be sufficiently strong to produce new timing peaks in the future, and whether the potential for reducing disease will be offset by increased abundance of both vectors and hosts.ScaleNTD is so called because their geographical distribution is bounded by environmental conditions normally encountered between the lines of latitude denoted as the tropic of Cancer and Capricorn.", [["Cancer", "ANATOMY", 412, 418], ["Cancer", "DISEASE", 412, 418], ["Cancer", "CANCER", 412, 418], ["the selection pressure", "TEST", 30, 52], ["reducing disease", "PROBLEM", 154, 170], ["Cancer", "PROBLEM", 412, 418], ["Capricorn", "TREATMENT", 423, 432], ["increased", "OBSERVATION_MODIFIER", 189, 198], ["abundance", "OBSERVATION", 199, 208], ["Cancer", "OBSERVATION", 412, 418]]], ["There is some evidence that the width of the tropics, or at least the arid tropical edge, is increasing northwards and southwards at a rate of between 0.5 and 1 degrees latitude in each direction each decade (Lucas et al., 2014) , possibly in part due to stratospheric ozone depletion at the poles (Kang et al., 2011) .", [["ozone", "CHEMICAL", 269, 274], ["ozone", "CHEMICAL", 269, 274], ["ozone", "SIMPLE_CHEMICAL", 269, 274], ["stratospheric ozone depletion", "PROBLEM", 255, 284], ["width", "OBSERVATION_MODIFIER", 32, 37], ["tropics", "OBSERVATION_MODIFIER", 45, 52], ["arid", "OBSERVATION_MODIFIER", 70, 74], ["tropical edge", "OBSERVATION", 75, 88], ["increasing", "OBSERVATION_MODIFIER", 93, 103], ["stratospheric ozone depletion", "OBSERVATION", 255, 284], ["poles", "ANATOMY_MODIFIER", 292, 297]]], ["What remains unclear is not just how best to measure changes in the area constituting the tropics and subtropics (reviewed by Lucas et al., 2014) , but also how individual vegetation and other zones within the geographic tropics will vary locally in their biotic and abiotic characteristics.ScaleClimate change is likely to have an effect at every scale of biological, social, ecological and geographical organisation (Fig. 2) .", [["individual vegetation and other zones", "PROBLEM", 161, 198], ["ScaleClimate change", "PROBLEM", 291, 310], ["vegetation", "OBSERVATION", 172, 182], ["zones", "ANATOMY_MODIFIER", 193, 198], ["abiotic characteristics", "OBSERVATION", 267, 290]]], ["Local scale considerations are important in terms understanding the effects of climate change on NTDs because the life history traits of many species of organism involved in NTD life cycles are tied to a particular environmental envelope.", [["NTDs", "DISEASE", 97, 101], ["Local scale considerations", "TREATMENT", 0, 26], ["climate change on NTDs", "PROBLEM", 79, 101], ["many species of organism", "PROBLEM", 137, 161], ["NTD life cycles", "TREATMENT", 174, 189]]], ["Ecologists continue to debate whether or not heterogeneity in abiotic resources at a particular scale is associated with diversity of organisms (Lundholm, 2009 ), but it remains true that microclimatic variation is a driver of species abundance at a very local level.", [["heterogeneity in abiotic resources", "PROBLEM", 45, 79], ["diversity of organisms", "PROBLEM", 121, 143], ["species abundance", "PROBLEM", 227, 244], ["microclimatic variation", "OBSERVATION", 188, 211]]], ["The availability of specific habitats is a requirement for many vector and intermediate host species.", [["many vector", "TREATMENT", 59, 70], ["host species", "OBSERVATION", 88, 100]]], ["For example, eggs of helminth species require specific abiotic and biotic conditions to thrive.", [["helminth species", "PROBLEM", 21, 37], ["biotic conditions", "TREATMENT", 67, 84]]], ["Intermediate snail hosts require vegetation that is anchored in a substrate that will supply appropriate nutrients.ScaleThe relationship between spatial diversity in abiotic, biotic resources, host availability and parasite distribution remains poorly understood in the NTD context.", [["vegetation", "PROBLEM", 33, 43], ["vegetation", "OBSERVATION", 33, 43]]], ["Studies of wildlife populations offer some insights into the drivers of current relationships (Ellis et al., 2015) , pointing to a complex system of host-switching and localised adaption driven by host availability at specific locations.ScaleAs the local soil and water chemistry alters as a result of changes to the local climate, it can be expected that current patterns of heterogeneous transmission will change in the future.", [["local", "OBSERVATION_MODIFIER", 249, 254], ["soil", "OBSERVATION_MODIFIER", 255, 259], ["heterogeneous", "OBSERVATION_MODIFIER", 376, 389]]], ["Areas that are currently unsuitable for transmission, perhaps because of a lack of suitable vegetation to support an intermediate or zoonotic host, may become more suitable at some point in the future.Population Movement, Urbanisation and GrowthWhile considering the effects of changing temperature and precipitation patterns is a vital component of understanding climate change and NTDs, it is also necessary to take a step sideways to consider other anthropocentric aspects of global environmental change that are directly or indirectly connected to climate change.Population Movement, Urbanisation and GrowthPopulation movement for reasons ranging from tourism to labour migration is an important component in the epidemiology of several NTDs Fig. 2 Illustration of the range of scales within ecological, biogeographical, social and geographical domains of organisation that will be affected directly or indirectly by climate change.", [["NTDs", "DISEASE", 383, 387], ["NTDs", "DISEASE", 741, 745], ["suitable vegetation", "PROBLEM", 83, 102], ["an intermediate or zoonotic host", "PROBLEM", 114, 146], ["changing temperature", "TREATMENT", 278, 298], ["labour migration", "PROBLEM", 667, 683], ["several NTDs Fig", "PROBLEM", 733, 749], ["vegetation", "OBSERVATION", 92, 102]]], ["Urbanisation, as a major subdomain of population movement is now considered to be not just a driver of climate change (Kalnay and Cai, 2003) , but also a consequence of climate change (Barrios et al., 2006) .", [["population movement", "OBSERVATION", 38, 57]]], ["As people move to the cities because of, e.g., failing crops due to prolonged drought (Barrios et al., 2006) , they will contribute to increased emissions and potentially expose themselves to NTDs that thrive in urban situations, including Dengue (Were, 2012) .Population Movement, Urbanisation and GrowthWater demand.", [["NTDs", "DISEASE", 192, 196], ["Dengue", "DISEASE", 240, 246], ["people", "ORGANISM", 3, 9], ["people", "SPECIES", 3, 9], ["prolonged drought", "PROBLEM", 68, 85], ["increased emissions", "PROBLEM", 135, 154]]], ["Global water demand is projected to increase significantly, particularly in terms of water needs for irrigation (reviewed by Wang et al., 2017) .", [["Global water demand", "PROBLEM", 0, 19], ["irrigation", "TREATMENT", 101, 111], ["water demand", "OBSERVATION", 7, 19], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["significantly", "OBSERVATION_MODIFIER", 45, 58]]], ["Globally, water scarcity is expected to increase (Gosling and Arnell, 2016) .", [["water scarcity", "OBSERVATION", 10, 24], ["increase", "OBSERVATION_MODIFIER", 40, 48]]], ["The fragmented nature of the change (van Vliet et al., 2013 ) may lead to selective national or international population migration from at risk areas, as has been observed in various countries (reviewed by Obokata et al., 2014) , including Ethiopia (Gray and Mueller, 2012) , Mexico (Nawrotzki et al., 2015) and South Africa (Mastrorillo et al., 2016) .", [["fragmented", "OBSERVATION_MODIFIER", 4, 14], ["change", "OBSERVATION_MODIFIER", 29, 35]]], ["This occurs alongside and in addition to internal and crossborder migration, often temporary, which has a multitude of environmental causes (Reuveny and Moore, 2009) .", [["internal and crossborder migration", "TREATMENT", 41, 75], ["internal", "OBSERVATION_MODIFIER", 41, 49], ["migration", "OBSERVATION", 66, 75]]], ["Understanding the role of climate-associated migration is important as individuals who migrate may carry parasites and cause new outbreaks, as has been observed recently in Corsica, where Schistosoma hybrids have been observed and attributed to the mixing of imported Schistosoma haematobium and local Schistosoma bovis (Boissier et al., 2016) .Population Movement, Urbanisation and GrowthUrbanisation is associated with population growth (Cohen, 2006) , but not necessarily in a readily predictable or linear manner.", [["Schistosoma hybrids", "DISEASE", 188, 207], ["Schistosoma haematobium", "DISEASE", 268, 291], ["Schistosoma bovis", "DISEASE", 302, 319], ["GrowthUrbanisation", "DISEASE", 383, 401], ["Schistosoma hybrids", "ORGANISM", 188, 207], ["Schistosoma haematobium", "ORGANISM", 268, 291], ["Schistosoma bovis", "ORGANISM", 302, 319], ["Schistosoma haematobium", "SPECIES", 268, 291], ["Schistosoma bovis", "SPECIES", 302, 319], ["Schistosoma haematobium", "SPECIES", 268, 291], ["Schistosoma bovis", "SPECIES", 302, 319], ["parasites", "PROBLEM", 105, 114], ["Schistosoma hybrids", "PROBLEM", 188, 207], ["imported Schistosoma haematobium", "PROBLEM", 259, 291], ["local Schistosoma bovis", "PROBLEM", 296, 319], ["new", "OBSERVATION_MODIFIER", 125, 128], ["outbreaks", "OBSERVATION", 129, 138], ["Schistosoma hybrids", "OBSERVATION", 188, 207], ["Schistosoma haematobium", "OBSERVATION", 268, 291], ["Schistosoma bovis", "OBSERVATION", 302, 319], ["Movement", "OBSERVATION_MODIFIER", 356, 364]]], ["Within Africa alone, the population is expected to double to 2 billion by 2050 (United Nations, 2015) , but several models and observations suggest complex patterns of migration and countermigration depending on the motives and opportunities (Geyer and Geyer, 2015) .", [["migration and countermigration", "PROBLEM", 168, 198], ["complex", "OBSERVATION_MODIFIER", 148, 155], ["migration", "OBSERVATION", 168, 177]]], ["Increasing levels of urbanisation associated with population increase (Satterthwaite, 2009) is nonetheless likely to impact on the climate substantially-e.g., as land-use changes are enacted (Pielke, 2005) , as habitats are altered and fragmented (Haddad et al., 2015) , as biodiversity decreases (Mooney et al., 2009) .", [["Increasing levels of urbanisation", "PROBLEM", 0, 33], ["urbanisation", "OBSERVATION_MODIFIER", 21, 33], ["fragmented", "OBSERVATION_MODIFIER", 236, 246]]], ["Human-wildlife interactions in both rural (Aryal et al., 2014) and urban (Becker et al., 2015) locations will inevitably change over the coming decades as a result of these and other changes.Agriculture and FarmingA large fraction of people exposed to NTDs is smallholders or subsistence farmers dependent on natural water cycles to support crops and/or livestock.", [["FarmingA", "CHEMICAL", 207, 215], ["NTDs", "DISEASE", 252, 256], ["Human", "ORGANISM", 0, 5], ["people", "ORGANISM", 234, 240], ["Human", "SPECIES", 0, 5], ["people", "SPECIES", 234, 240], ["NTDs", "PROBLEM", 252, 256], ["natural water cycles", "TREATMENT", 309, 329], ["large", "OBSERVATION_MODIFIER", 216, 221], ["fraction", "OBSERVATION_MODIFIER", 222, 230], ["subsistence", "OBSERVATION_MODIFIER", 276, 287], ["farmers", "OBSERVATION_MODIFIER", 288, 295], ["dependent", "OBSERVATION_MODIFIER", 296, 305]]], ["Evidence suggests that climate-associated events such as prolonged drought, delayed onset of rains, or above normal precipitation can adversely affect a range of livelihood assets (Ziervogel and Calder, 2003) .", [["climate-associated events", "PROBLEM", 23, 48], ["prolonged drought", "PROBLEM", 57, 74], ["rains", "PROBLEM", 93, 98]]], ["Small holders and poorer farmers are more likely to be concerned about heavy rainfall, but may have no livelihood response due to a lack of assets and entitlements (Cooper and Wheeler, 2017) .", [["holders", "OBSERVATION_MODIFIER", 6, 13]]], ["This effect may not be universal, as there is also evidence that farming communities have adapted to harsh environments over many generations (Kassie et al., 2013; Mortimore and Adams, 2001) to include allocating labour differentially across seasons to mitigate unpredictable precipitation patterns, increasing biodiversity and diversifying livelihoods.Agriculture and FarmingFood demand and production are likely to change considerably in coming decades due to population growth, direct and indirect effects of climate change (Valin et al., 2014) .", [["unpredictable precipitation patterns", "PROBLEM", 262, 298], ["increasing biodiversity", "PROBLEM", 300, 323], ["population growth", "PROBLEM", 462, 479], ["increasing", "OBSERVATION_MODIFIER", 300, 310], ["biodiversity", "OBSERVATION_MODIFIER", 311, 323], ["diversifying livelihoods", "OBSERVATION", 328, 352]]], ["Various large-scale effects have been speculated including risks to global food security (Wheeler and von Braun, 2013) through, e.g., loss of freshwater for irrigation (Elliott et al., 2014) .", [["Various large-scale effects", "PROBLEM", 0, 27], ["irrigation", "TREATMENT", 157, 167], ["large", "OBSERVATION_MODIFIER", 8, 13], ["-scale", "OBSERVATION_MODIFIER", 13, 19]]], ["Simultaneously, the demand for water for aquaculture is rising, bringing the potential for food-borne diseases to become a major issue in coming decades.", [["food-borne diseases", "DISEASE", 91, 110], ["aquaculture", "TREATMENT", 41, 52], ["borne diseases", "PROBLEM", 96, 110]]], ["Almost 60 species of fish-borne trematode have been described (Hung et al., 2013) .", [["fish-borne trematode", "DISEASE", 21, 41], ["fish", "ORGANISM", 21, 25]]], ["Infections among farmed fish have been associated with aquaculture practices in several SE Asian countries (reviewed by Lima dos Santos and Howgate, 2011).", [["Infections", "DISEASE", 0, 10], ["SE", "DISEASE", 88, 90], ["fish", "ORGANISM", 24, 28], ["Infections", "PROBLEM", 0, 10]]], ["Concerns have also been raised regarding potential spillover from wildlife populations into tilapia productions in China .", [["tilapia", "ORGANISM", 92, 99]]], ["The encroachment of wildlife into human communities is also expected to increase with increased urbanisation, habitat encroachment, loss and fragmentation (Hassell et al., 2017.)", [["human", "ORGANISM", 34, 39], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["increased urbanisation", "PROBLEM", 86, 108], ["habitat encroachment", "PROBLEM", 110, 130], ["loss and fragmentation", "PROBLEM", 132, 154], ["encroachment", "OBSERVATION", 4, 16], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["urbanisation", "OBSERVATION_MODIFIER", 96, 108], ["habitat", "OBSERVATION_MODIFIER", 110, 117], ["encroachment", "OBSERVATION_MODIFIER", 118, 130], ["loss", "OBSERVATION_MODIFIER", 132, 136], ["fragmentation", "OBSERVATION_MODIFIER", 141, 154]]], ["For NTDs with a zoonotic life cycle that can involve domesticated animals, the potential effects of climate change cannot be ignored.", [["NTDs", "DISEASE", 4, 8], ["NTDs", "PROBLEM", 4, 8], ["a zoonotic life cycle", "TREATMENT", 14, 35], ["climate change", "TREATMENT", 100, 114]]], ["Livestock is a driver of climate change due to the emissions of greenhouse gasses within the system (Gill et al., 2010) .", [["Livestock", "DISEASE", 0, 9]]], ["Thornton et al. (2009) consider various potential effects including change in quality and quantity of feed, heat stress and water security.", [["change in quality and quantity of feed", "TREATMENT", 68, 106], ["heat stress and water security", "TREATMENT", 108, 138]]], ["Potential effects on transmission of infections in livestock animals have been reviewed by Baylis and Githeko (2006) , who suggest that climate change is likely to have been responsible for the introduction of several infectious diseases into new areas including bluetongue virus in the United Kingdom, but also suggest that Fasciola infections in the United Kingdom may decline due to lower levels of summer rainfall.Exposure, Vulnerability and RiskThis review concentrates largely on the ecology and natural history of infections, as this where most of the literature on NTDS and environmental change is located.", [["infections", "DISEASE", 37, 47], ["infectious diseases", "DISEASE", 218, 237], ["bluetongue virus", "DISEASE", 263, 279], ["Fasciola infections", "DISEASE", 325, 344], ["infections", "DISEASE", 521, 531], ["NTDS", "CHEMICAL", 573, 577], ["bluetongue virus", "ORGANISM", 263, 279], ["Fasciola", "ORGANISM", 325, 333], ["bluetongue virus", "SPECIES", 263, 279], ["bluetongue virus", "SPECIES", 263, 279], ["infections", "PROBLEM", 37, 47], ["several infectious diseases", "PROBLEM", 210, 237], ["bluetongue virus", "PROBLEM", 263, 279], ["Fasciola infections", "PROBLEM", 325, 344], ["infections", "PROBLEM", 521, 531], ["NTDS", "PROBLEM", 573, 577], ["infections", "OBSERVATION", 37, 47], ["several", "OBSERVATION_MODIFIER", 210, 217], ["infectious", "OBSERVATION", 218, 228], ["bluetongue virus", "OBSERVATION", 263, 279], ["Fasciola", "OBSERVATION_MODIFIER", 325, 333], ["infections", "OBSERVATION", 334, 344], ["infections", "OBSERVATION", 521, 531]]], ["In the IPCC framework on vulnerability and adaptation (IPCC, 2014) , the information contained herein would contribute to understanding future hazards, as distinct from exposures or vulnerability.", [["vulnerability", "PROBLEM", 182, 195]]], ["The term 'Hazard', quoting directly from IPCC (2014), refers to 'The potential occurrence of a natural or human-induced physical event or trend or physical impact that may cause loss of life, injury, or other health impacts, as well as damage and loss to property, infrastructure, livelihoods, service provision, ecosystems, and environmental resources'.", [["injury", "DISEASE", 192, 198], ["human", "ORGANISM", 106, 111], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["loss of life", "PROBLEM", 178, 190], ["injury", "PROBLEM", 192, 198]]], ["The term 'Exposure' refers to 'The presence of people, livelihoods, species or ecosystems, environmental functions, services, and resources, infrastructure'.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53]]], ["Vulnerability encompasses a variety of concepts and elements including sensitivity or susceptibility to harm and lack of capacity to cope and adapt'.", [["sensitivity", "PROBLEM", 71, 82], ["lack of capacity", "PROBLEM", 113, 129], ["variety", "OBSERVATION_MODIFIER", 28, 35]]], ["The term 'Risk' refers to the '\u2026 probability of occurrence of hazardous events or trends multiplied by the impacts if these events or trends occur.", [["hazardous events", "PROBLEM", 62, 78], ["these events", "PROBLEM", 118, 130]]], ["Fig. 4 illustrates how these issues are connected and interact in the context of climate change and NTDs.Exposure, Vulnerability and RiskVulnerability is a contested term in the risk-reduction community (F\u20ac ussel, 2007) but has its roots in geography and social sciences, often referring to indicators such as socioeconomic status, the political economy, human agency and social capital.", [["roots", "ANATOMY", 232, 237], ["NTDs", "DISEASE", 100, 104], ["RiskVulnerability", "DISEASE", 133, 150], ["human", "ORGANISM", 355, 360], ["human", "SPECIES", 355, 360], ["human", "SPECIES", 355, 360], ["NTDs", "PROBLEM", 100, 104]]], ["In relation to infectious diseases, vulnerability has been historically assessed in these contexts for HIV, TB and Malaria in Europe (Bates et al., 2004) .", [["infectious diseases", "DISEASE", 15, 34], ["HIV,", "DISEASE", 103, 107], ["TB", "DISEASE", 108, 110], ["Malaria", "DISEASE", 115, 122], ["HIV", "SPECIES", 103, 106], ["HIV", "SPECIES", 103, 106], ["infectious diseases", "PROBLEM", 15, 34], ["vulnerability", "PROBLEM", 36, 49], ["HIV", "PROBLEM", 103, 106], ["TB", "PROBLEM", 108, 110], ["Malaria", "PROBLEM", 115, 122], ["infectious", "OBSERVATION", 15, 25], ["Malaria", "OBSERVATION", 115, 122]]], ["The EU funded Healthy Futures programme (www.healthyfutures.eu) adopted the IPCC vulnerability-hazard-risk framework to produce risk maps related to decadal climate change in the context of Rift Valley Fever, Malaria and S. mansoni in East Africa (Taylor et al., 2016) .", [["Rift Valley Fever", "DISEASE", 190, 207], ["Malaria and S. mansoni", "DISEASE", 209, 231], ["Rift Valley Fever", "ORGANISM", 190, 207], ["S. mansoni", "ORGANISM", 221, 231], ["S. mansoni", "SPECIES", 221, 231], ["Rift Valley Fever", "SPECIES", 190, 207], ["S. mansoni", "SPECIES", 221, 231], ["risk maps", "PROBLEM", 128, 137], ["decadal climate change", "PROBLEM", 149, 171], ["Rift Valley Fever", "PROBLEM", 190, 207], ["Malaria", "PROBLEM", 209, 216], ["S. mansoni", "PROBLEM", 221, 231]]], ["In that project, stakeholder analysis and expert consultation were deployed to provide weighted indicators that could be included in the vulnerability domain.", [["stakeholder analysis", "TEST", 17, 37]]], ["A comparative approach to estimating vulnerability that compared the expert-weighting approach to statistical modelling found high concordance in the context of modelling vulnerability to Dengue (Hagenlocher et al., 2013) .SoilSoil is the upper covering layer of the earth, consisting of three subphases (water, gas and solids) which combine to describe the overall mechanics and other properties.", [["Dengue", "DISEASE", 188, 194], ["SoilSoil", "CHEMICAL", 223, 231], ["water", "SIMPLE_CHEMICAL", 305, 310], ["statistical modelling", "TEST", 98, 119], ["three subphases (water, gas and solids", "TREATMENT", 288, 326], ["upper", "ANATOMY_MODIFIER", 239, 244]]], ["Typically, soil properties vary in terms of texture (particle size and distribution), chemical and mineralogical properties, surface area and particle aggregation (related to aeration, compaction, temperature and water retention).", [["surface", "ANATOMY", 125, 132], ["particle aggregation", "PROBLEM", 142, 162], ["temperature and water retention", "TREATMENT", 197, 228], ["soil properties vary", "OBSERVATION_MODIFIER", 11, 31], ["texture", "OBSERVATION_MODIFIER", 44, 51], ["particle", "OBSERVATION_MODIFIER", 53, 61], ["size", "OBSERVATION_MODIFIER", 62, 66], ["mineralogical properties", "OBSERVATION", 99, 123], ["surface", "OBSERVATION_MODIFIER", 125, 132], ["particle aggregation", "OBSERVATION", 142, 162], ["aeration", "OBSERVATION_MODIFIER", 175, 183]]], ["The overall structure, mechanics and properties of a soil matrix are also influenced by a range of other factors such as the amount and properties of organic matter (detritus), oxides, clays, living vegetation, bacteria and fungi.SoilRecent theoretical and empirical studies have improved understanding of soil processes, mainly from the viewpoint of ensuring 'soil security' (Amundson et al., 2015) .", [["soil matrix", "ANATOMY", 53, 64], ["oxides", "CHEMICAL", 177, 183], ["oxides", "SIMPLE_CHEMICAL", 177, 183], ["a soil matrix", "TREATMENT", 51, 64], ["organic matter", "PROBLEM", 150, 164], ["oxides, clays", "TREATMENT", 177, 190], ["living vegetation", "PROBLEM", 192, 209], ["bacteria", "PROBLEM", 211, 219], ["fungi", "PROBLEM", 224, 229], ["empirical studies", "TEST", 257, 274], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21], ["mechanics", "OBSERVATION_MODIFIER", 23, 32], ["soil matrix", "OBSERVATION", 53, 64], ["organic matter", "OBSERVATION", 150, 164]]], ["However, there are still many gaps in knowledge Fig. 4 A core concept of the IPCC (2014) report on vulnerability and adaptations is that risks to populations are formed by interactions between sources of hazard, vulnerability and exposure.", [["many", "OBSERVATION_MODIFIER", 25, 29], ["gaps", "OBSERVATION", 30, 34]]], ["In the context of NTDs, natural and anthropogenic inputs-including interventions such as WASH and vector control-combine to affect the life cycles of climate-sensitive stages (the hazard).", [["NTDs", "DISEASE", 18, 22], ["NTDs", "PROBLEM", 18, 22], ["natural and anthropogenic inputs", "TREATMENT", 24, 56], ["interventions", "TREATMENT", 67, 80], ["WASH and vector control", "TREATMENT", 89, 112]]], ["Simultaneously a wide variety of societal inputs can affect vulnerability and exposure levels, and can lead to mitigations that modify emissions and habitats to affect the NTD-associated hazard.", [["societal inputs", "TREATMENT", 33, 48], ["the NTD", "PROBLEM", 168, 175], ["wide", "OBSERVATION_MODIFIER", 17, 21]]], ["A lack of adaptive inputs is likely to lead to higher exposure, vulnerability, hazards and risk.Soilof how a changing climates might affect 'soil health'-defined as 'the capacity of a specific kind of soil to function, within natural or managed ecosystem boundaries, to sustain plant and animal productivity, maintain or enhance water and air quality, and support human health and habitation' (Doran and Zeiss, 2000) .SoilSoil is essential to the natural history of many parasites and/or their vectors; examples include eggs of geohelminths (Steinbaum et al., 2016) , larvae of Tsetse flies (Leak, 1999) and burrows of mammals fed on by triatominae insects (Miles et al., 1981) .", [["SoilSoil", "CHEMICAL", 418, 426], ["human", "ORGANISM", 364, 369], ["Tsetse flies", "ORGANISM", 578, 590], ["human", "SPECIES", 364, 369], ["human", "SPECIES", 364, 369], ["Tsetse flies", "SPECIES", 578, 590], ["adaptive inputs", "TREATMENT", 10, 25], ["Leak", "PROBLEM", 592, 596]]], ["Part of this process is likely to include a better understanding of how microgeographical variation in soil chemistry affects herb-layer vegetation (Bruelheide and Udelhoven, 2005) .WaterA central tenet of climate change is rising temperatures in the water phase, including freshwater and marine domains (see above).", [["soil chemistry", "TEST", 103, 117], ["layer vegetation", "PROBLEM", 131, 147], ["rising temperatures", "PROBLEM", 224, 243], ["is likely to", "UNCERTAINTY", 21, 33], ["layer vegetation", "OBSERVATION", 131, 147], ["central", "OBSERVATION_MODIFIER", 189, 196], ["tenet", "OBSERVATION_MODIFIER", 197, 202], ["climate change", "OBSERVATION", 206, 220], ["rising", "OBSERVATION_MODIFIER", 224, 230], ["temperatures", "OBSERVATION_MODIFIER", 231, 243], ["water phase", "OBSERVATION_MODIFIER", 251, 262]]], ["Temperature change, combined with population growth, and many other factors related to future aspects of landscape, hydrology, human behaviour, water and sanitation infrastructure, water-and land-use, is likely to have profound effects on many aspects of the water budget.", [["human", "ORGANISM", 127, 132], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["Temperature change", "PROBLEM", 0, 18], ["population growth", "PROBLEM", 34, 51], ["many other factors", "PROBLEM", 57, 75], ["the water budget", "TREATMENT", 255, 271]]], ["The global hydrological cycle is thereby expected to undergo potentially profound changes (Held and Soden, 2006) .", [["profound changes", "PROBLEM", 73, 89], ["global", "OBSERVATION_MODIFIER", 4, 10], ["hydrological cycle", "OBSERVATION", 11, 29], ["profound", "OBSERVATION_MODIFIER", 73, 81]]], ["Here I summarise some of the key aspects that are relevant to NTD natural history.PrecipitationIt is likely that anthropogenic influences differentially affected precipitation during the 20th century depending on region-with increase precipitation in (very broadly speaking) northern latitudes and decreased precipitation in southern latitudes (Zhang et al., 2007) .", [["increase precipitation", "PROBLEM", 225, 247], ["decreased precipitation", "PROBLEM", 298, 321], ["likely", "UNCERTAINTY", 101, 107], ["anthropogenic", "OBSERVATION", 113, 126], ["decreased", "OBSERVATION_MODIFIER", 298, 307], ["precipitation", "OBSERVATION_MODIFIER", 308, 321]]], ["Consensus is emerging that extremes of precipitation are likely to increase in frequency (Knapp et al., 2015) .", [["likely to", "UNCERTAINTY", 57, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75]]], ["Also of concern is increased frequency of drought (Dewes et al., 2017) and flooding (Hirabayashi et al., 2013) , although there is still considerable debate on the role of anthropogenic drivers underpinning these changes (Kundzewicz et al., 2014) .", [["increased", "OBSERVATION_MODIFIER", 19, 28], ["frequency", "OBSERVATION_MODIFIER", 29, 38]]], ["This alteration in hydrological stability may nonetheless impact on not just aquatic habitats (Marino et al., 2017) , groundwater and streamflow (Taylor et al., 2013) but also the carbon cycle (Haverd et al., 2017) , soil moisture and vegetation phenology (Richardson et al., 2013) .", [["carbon", "CHEMICAL", 180, 186], ["This alteration in hydrological stability", "PROBLEM", 0, 41], ["hydrological stability", "OBSERVATION", 19, 41]]], ["Effects may include fragmented changes to freshwater systems, due to, for example, changes to location-specific river discharges (Schewe et al., 2014) and recharges (Hartmann et al., 2017) .PrecipitationIncreased precipitation in urban areas without adequate capacity to adapt or mitigate the situation has been associated with outbreaks of Dengue in several countries, including India (Mutheneni et al., 2017) and Bangladesh (Karim et al., 2012) .", [["Dengue", "DISEASE", 341, 347], ["fragmented changes to freshwater systems", "PROBLEM", 20, 60], ["Increased precipitation", "PROBLEM", 203, 226], ["fragmented", "OBSERVATION", 20, 30], ["precipitation", "OBSERVATION_MODIFIER", 213, 226]]], ["Similarly, abundance of freshwater snails acting as intermediate hosts in the schistosome life cycle, as well as transmission of the parasite, are known to peak at specific times of year, depending on location (reviewed by Rollinson, 2011) and driven by climatic factors including rainfall (e.g. Moser et al., 2014) .PrecipitationClimate change-driven changes to the water balance, such that affect soil moisture conditions, are also likely to affect suitability of specific habitats for soil-transmitted helminths.", [["helminths", "DISEASE", 505, 514], ["freshwater snails", "ORGANISM", 24, 41], ["schistosome", "ORGANISM", 78, 89], ["freshwater snails", "PROBLEM", 24, 41], ["PrecipitationClimate change", "PROBLEM", 317, 344], ["freshwater snails", "OBSERVATION", 24, 41]]], ["Seasonality of hookworm transmission in several countries including South Africa (Mabaso et al., 2003) , Nigeria (Nwosu and Anya, 1980) and Timor Leste (Wardell et al., 2017) has been at least partly attributed to seasonal precipitation.Thermal ToleranceThermal tolerance may be a critical issue for many water-based, or semiaquatic organisms involved in the life cycles of NTDS-including insects, freshwater snails, fish, crabs, copepods, crayfish and insects.", [["crabs", "ANATOMY", 423, 428], ["hookworm transmission", "DISEASE", 15, 36], ["NTDS", "CHEMICAL", 374, 378], ["NTDS", "SIMPLE_CHEMICAL", 374, 378], ["fish", "ORGANISM_SUBDIVISION", 417, 421], ["crabs", "ORGANISM_SUBDIVISION", 423, 428], ["crayfish", "ORGANISM_SUBDIVISION", 440, 448], ["seasonal precipitation", "PROBLEM", 214, 236], ["semiaquatic organisms", "PROBLEM", 321, 342], ["NTDS", "PROBLEM", 374, 378], ["hookworm", "OBSERVATION", 15, 23], ["seasonal precipitation", "OBSERVATION", 214, 236]]], ["Poikilothermic ectotherms such as these consume oxygen based on the water or temperature until some threshold temperature where ATP supply and demand is overwhelmingly disrupted and the organism dies (Poertner, 2001) .", [["oxygen", "CHEMICAL", 48, 54], ["ATP", "CHEMICAL", 128, 131], ["oxygen", "CHEMICAL", 48, 54], ["ATP", "CHEMICAL", 128, 131], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["ATP", "SIMPLE_CHEMICAL", 128, 131], ["Poikilothermic ectotherms", "TREATMENT", 0, 25], ["these consume oxygen", "TREATMENT", 34, 54], ["ATP supply", "TREATMENT", 128, 138]]], ["Tropical species may have relatively wide tolerances, but may also be more vulnerable to increases in temperature due to already inhabiting water bodies with temperatures close to their thermal limits (Sunday et al., 2012) .", [["Tropical species", "PROBLEM", 0, 16]]], ["Whether mean increases in temperature are more important than changes in diurnal variation is being debated in the literature (Vasseur et al., 2014) .StratificationThe life cycles of several NTDs including Schistosoma, the food-borne trematodes and Dracuncula involve intermediate hosts that may inhabit and reproduce in water bodies with thermal stratification, such as lakes.", [["NTDs", "DISEASE", 191, 195], ["Schistosoma", "ORGANISM", 206, 217], ["mean increases in temperature", "PROBLEM", 8, 37], ["several NTDs", "PROBLEM", 183, 195], ["Schistosoma", "PROBLEM", 206, 217], ["thermal stratification", "TREATMENT", 339, 361], ["mean", "OBSERVATION_MODIFIER", 8, 12], ["increases", "OBSERVATION_MODIFIER", 13, 22], ["diurnal variation", "OBSERVATION", 73, 90], ["Schistosoma", "OBSERVATION", 206, 217]]], ["Analysis of historic data indicates that global warming is associated with changes to lake stratification that are dependent on lake morphometry (Kraemer et al., 2015a) .", [["historic data", "TEST", 12, 25], ["global warming", "PROBLEM", 41, 55], ["global", "OBSERVATION_MODIFIER", 41, 47], ["warming", "OBSERVATION", 48, 55]]], ["Evidence of the effects on ecosystems is emerging in the literature.", [["ecosystems", "OBSERVATION", 27, 37]]], ["For example, saltwater intrusion into tropical rivers can affect the bacteria of floodplain soils by altering both the salinity and pH (Nelson et al., 2016) .", [["saltwater intrusion into tropical rivers", "PROBLEM", 13, 53], ["the bacteria of floodplain soils", "PROBLEM", 65, 97]]], ["Increase in the influx of brackish water in coastal areas due to sea level changes has been implicated as the reason behind an increase in the abundance of salinity-tolerant Aedes mosquitoes in the Sri Lankan context (Ramasamy and Surendran, 2012) .MitigationMitigating the challenges outlined above through providing sustainable water resources forms part of SDG Goal 6-the other key component for NTDs being access to sanitation and hygiene 'for all' by 2030.", [["salinity", "CHEMICAL", 156, 164], ["Aedes mosquitoes", "ORGANISM", 174, 190], ["Aedes mosquitoes", "SPECIES", 174, 190], ["sea level changes", "PROBLEM", 65, 82], ["MitigationMitigating the challenges", "TREATMENT", 249, 284], ["sustainable water resources", "TREATMENT", 318, 345], ["NTDs", "PROBLEM", 399, 403], ["influx", "OBSERVATION_MODIFIER", 16, 22], ["brackish water", "OBSERVATION", 26, 40], ["sea level", "OBSERVATION", 65, 74], ["increase", "OBSERVATION_MODIFIER", 127, 135]]], ["This latter aspect, commonly termed water, sanitation and hygiene (WASH) is considered crucial in reducing transmission of STH (Freeman et al., 2013) , trachoma (Stocks et al., 2014) , schistosomiasis (Grimes et al., 2014) and Entamoeba (Speich et al., 2016) .MitigationOur warning from history on this subject is quite clear.", [["STH", "DISEASE", 123, 126], ["trachoma", "DISEASE", 152, 160], ["schistosomiasis", "DISEASE", 185, 200], ["hygiene (WASH)", "TREATMENT", 58, 72], ["trachoma", "PROBLEM", 152, 160], ["schistosomiasis", "PROBLEM", 185, 200], ["clear", "OBSERVATION", 320, 325]]], ["Development projects with all good intentions, related to water infrastructure in particular, have themselves been associated with increased transmission of parasitic infections including malaria in unstable areas (Ijumba and Lindsay, 2001; Kibret et al., 2017) , filariasis (Erlanger et al., 2005) and schistosomiasis (e.g. N' Goran et al., 1997) .", [["parasitic infections", "DISEASE", 157, 177], ["malaria", "DISEASE", 188, 195], ["filariasis", "DISEASE", 264, 274], ["schistosomiasis", "DISEASE", 303, 318], ["parasitic infections", "PROBLEM", 157, 177], ["malaria in unstable areas", "PROBLEM", 188, 213], ["filariasis", "PROBLEM", 264, 274], ["schistosomiasis", "PROBLEM", 303, 318], ["parasitic", "OBSERVATION_MODIFIER", 157, 166], ["infections", "OBSERVATION", 167, 177], ["unstable", "OBSERVATION_MODIFIER", 199, 207], ["filariasis", "ANATOMY", 264, 274], ["schistosomiasis", "OBSERVATION", 303, 318]]], ["In the latter case, concerns have been raised recently about how a large-scale water conservation project could translocate Oncomelania hupensis (an intermediate host snail of S. japonica) in China (Liang et al., 2012; Zhu et al., 2017) , how migration of seasonal workers related to dam construction might have led to admixture of S. mansoni populations in Senegal ( Van den Broeck et al., 2015) , how dam construction could affect the transmission of Schistosoma mekongi in Laos (Attwood and Upatham, 2012) and prevent the migration of snail-eating prawns across sub-Saharan Africa (Sokolow et al., 2017) .", [["S. mansoni", "DISEASE", 332, 342], ["Schistosoma mekongi", "DISEASE", 453, 472], ["Oncomelania hupensis", "ORGANISM", 124, 144], ["S. japonica", "ORGANISM", 176, 187], ["S. mansoni", "ORGANISM", 332, 342], ["Schistosoma mekongi", "ORGANISM", 453, 472], ["Oncomelania hupensis", "SPECIES", 124, 144], ["S. japonica", "SPECIES", 176, 187], ["S. mansoni", "SPECIES", 332, 342], ["Schistosoma mekongi", "SPECIES", 453, 472], ["Oncomelania hupensis", "SPECIES", 124, 144], ["S. japonica", "SPECIES", 176, 187], ["S. mansoni", "SPECIES", 332, 342], ["Schistosoma mekongi", "SPECIES", 453, 472], ["a large-scale water conservation", "TREATMENT", 65, 97], ["Oncomelania hupensis", "PROBLEM", 124, 144], ["dam construction", "TREATMENT", 284, 300], ["Schistosoma mekongi", "PROBLEM", 453, 472], ["the migration of snail", "PROBLEM", 521, 543], ["Oncomelania hupensis", "OBSERVATION", 124, 144], ["Schistosoma", "OBSERVATION", 453, 464]]], ["These and other examples remind us of the importance of implementing health in all policies (Rudolph et al., 2013) when undertaking sustainable development projects.AirThe central tenet of climate change is the forcing effects of so-called 'greenhouse' gasses including CO 2 and aerosols.", [["CO 2", "CHEMICAL", 270, 274], ["CO 2", "SIMPLE_CHEMICAL", 270, 274], ["CO", "TEST", 270, 272], ["central", "OBSERVATION_MODIFIER", 172, 179], ["tenet", "OBSERVATION_MODIFIER", 180, 185], ["climate change", "OBSERVATION", 189, 203]]], ["Forcing in this context means the impact that production of these gasses has on the balance of energy in the atmosphere.", [["these gasses", "PROBLEM", 60, 72]]], ["As greenhouse gasses increase in density, they tip the energy balance positively and positive forcing ensues.", [["the energy balance", "TEST", 51, 69], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["density", "OBSERVATION", 33, 40], ["tip", "OBSERVATION_MODIFIER", 47, 50], ["energy balance", "OBSERVATION", 55, 69]]], ["All climate models derive from this process and then simulate how varying degrees of forcing will affect global air and land surface temperatures.AirTropical climates are typically governed by the Intertropical Convergent Zone (ITCZ).", [["surface", "ANATOMY", 125, 132], ["global air and land surface temperatures", "PROBLEM", 105, 145], ["AirTropical climates", "PROBLEM", 146, 166]]], ["The ITCZ is a belt of low pressure surrounding the earth close to the equator that moves between the tropics of cancer and capricorn at different times of year.", [["cancer", "ANATOMY", 112, 118], ["ITCZ", "CHEMICAL", 4, 8], ["cancer", "DISEASE", 112, 118], ["cancer", "CANCER", 112, 118], ["capricorn", "CANCER", 123, 132], ["ITCZ", "PROTEIN", 4, 8], ["low pressure", "PROBLEM", 22, 34], ["cancer", "PROBLEM", 112, 118], ["capricorn", "TREATMENT", 123, 132], ["belt", "OBSERVATION_MODIFIER", 14, 18], ["low pressure", "OBSERVATION", 22, 34], ["equator", "ANATOMY_MODIFIER", 70, 77], ["tropics", "OBSERVATION_MODIFIER", 101, 108], ["cancer", "OBSERVATION", 112, 118]]], ["It is this movement that generates the characteristic dry and rainy seasons in countries located within the tropics (for animation click here): http://www2.palomar.edu/users/pdeen/animations/23_weatherpat.swf.AirThe dynamics and positioning of the ITCZ are highly sensitive to small changes in the global energy balance (Sachs et al., 2009; Schneider et al., 2014) .", [["ITCZ", "CHEMICAL", 248, 252], ["ITCZ", "GENE_OR_GENE_PRODUCT", 248, 252], ["ITCZ", "PROTEIN", 248, 252], ["small changes", "PROBLEM", 277, 290], ["small", "OBSERVATION_MODIFIER", 277, 282], ["global", "OBSERVATION_MODIFIER", 298, 304], ["energy balance", "OBSERVATION", 305, 319]]], ["Models struggle to predict the future dynamics of the ITCZ (Bony et al., 2015) , and until the models can project the future of the ITCZ in relation to climate scenarios it will be challenging to model the transmission of NTDs effectively.AirThe relationship between surface air temperature (as predicted by climate projections) is generally assumed to be correlated, over decadal scales, with the ground surface temperature, but over shorter time scales there may be considerable variability.", [["surface", "ANATOMY", 267, 274], ["surface", "ANATOMY", 405, 412], ["NTDs", "DISEASE", 222, 226], ["surface air temperature", "TEST", 267, 290], ["the ground surface temperature", "TEST", 394, 424], ["considerable variability", "PROBLEM", 468, 492], ["surface", "OBSERVATION_MODIFIER", 267, 274], ["air temperature", "OBSERVATION", 275, 290], ["may be", "UNCERTAINTY", 461, 467], ["considerable", "OBSERVATION_MODIFIER", 468, 480], ["variability", "OBSERVATION", 481, 492]]], ["Abiotic changes to the soil as a result to changes in air temperature may affect the natural history of a wide range of NTDS as diverse as trypanosomes and cestodes.ScaleDownscaling is a recently developed process, derived from subnational weather forecasting, to improve the spatial resolution of GCMs over limited areas (Dickinson et al., 1989) .", [["NTDS", "CHEMICAL", 120, 124], ["trypanosomes", "CELL", 139, 151], ["Abiotic changes", "PROBLEM", 0, 15], ["changes in air temperature", "PROBLEM", 43, 69], ["a wide range of NTDS", "TREATMENT", 104, 124], ["air temperature", "OBSERVATION", 54, 69], ["spatial", "OBSERVATION_MODIFIER", 276, 283], ["resolution", "OBSERVATION_MODIFIER", 284, 294], ["GCMs", "OBSERVATION_MODIFIER", 298, 302]]], ["A broad and accessible overview of the methodologies is available elsewhere (USAID, 2014) .", [["broad", "OBSERVATION_MODIFIER", 2, 7]]], ["Here I summarise some of the key methods.ScaleStatistical downscaling is a two-step process that involves understanding statistical relationships between observations at one point over time and GCM outputs at that location over the same time period, and correcting the GCM output to more closely resemble the observations (also known as bias correction).", [["GCM outputs", "TEST", 194, 205], ["the GCM output", "TEST", 265, 279]]], ["Statistical downscaling is computationally inexpensive but has low utility if the observations are scarce over time and space, and/or if the relationship between GCM and observations changes over time.ScaleDynamical downscaling (also known as generating regional climate models or RCM) is a process whereby a GCM is run and the lateral boundary outputs at the edge of the RCM region are used as the initial conditions of an RCM using the same physics-based model as the GCM but at a higher spatial resolution and over a relatively small area.", [["ScaleDynamical downscaling", "PROBLEM", 201, 227], ["the lateral boundary outputs", "TEST", 324, 352], ["lateral", "OBSERVATION_MODIFIER", 328, 335], ["boundary", "OBSERVATION_MODIFIER", 336, 344], ["outputs", "OBSERVATION_MODIFIER", 345, 352], ["edge", "ANATOMY_MODIFIER", 360, 364], ["RCM", "ANATOMY", 372, 375], ["region", "ANATOMY_MODIFIER", 376, 382], ["higher", "OBSERVATION_MODIFIER", 483, 489], ["spatial", "OBSERVATION_MODIFIER", 490, 497], ["resolution", "OBSERVATION_MODIFIER", 498, 508], ["relatively", "OBSERVATION_MODIFIER", 520, 530], ["small", "OBSERVATION_MODIFIER", 531, 536], ["area", "OBSERVATION_MODIFIER", 537, 541]]], ["The output of this computationally intensive process is a climate model at relatively high spatial resolution compared to the GCM (typically less than 0.5 degree).ScaleIn the context of understanding how climate change might affect local scale transmission of NTDs, RCMs arguably have greater utility than statistical models as they can be run on relatively sparse observations.", [["NTDs", "DISEASE", 260, 264], ["The output", "TEST", 0, 10], ["the GCM", "TEST", 122, 129], ["NTDs", "PROBLEM", 260, 264], ["output", "OBSERVATION_MODIFIER", 4, 10], ["climate model", "OBSERVATION_MODIFIER", 58, 71], ["high", "OBSERVATION_MODIFIER", 86, 90], ["spatial", "OBSERVATION_MODIFIER", 91, 98], ["resolution", "OBSERVATION_MODIFIER", 99, 109]]], ["Their disadvantage, apart from computing costs, is that each individual model can output widely differentiated products in regions with complex climates and widely varying but sparse observations (e.g. the tropical regions).", [["output", "OBSERVATION_MODIFIER", 82, 88], ["widely", "OBSERVATION_MODIFIER", 89, 95], ["differentiated", "OBSERVATION_MODIFIER", 96, 110], ["products", "OBSERVATION_MODIFIER", 111, 119], ["complex", "OBSERVATION_MODIFIER", 136, 143], ["climates", "OBSERVATION", 144, 152], ["widely", "OBSERVATION_MODIFIER", 157, 163], ["varying", "OBSERVATION_MODIFIER", 164, 171]]], ["For this reason, RCMs are often combined into ensembles with multiple outputs summarised into a single model that represents the average of all models in the ensemble.", [["RCMs", "PROBLEM", 17, 21], ["multiple", "OBSERVATION_MODIFIER", 61, 69], ["outputs", "OBSERVATION_MODIFIER", 70, 77]]], ["RCM ensembles, made available through the coordinated regional climate downscaling experiment have been used to model future precipitation over the African continent (Nikulin et al., 2012) .ScaleDespite recent advances, none of the current models predict or project temperature at a microgeographical scale, which is considered a major limitation in estimating how a particular organism may be vulnerable to a future climate (Scheffers et al., 2014; Storlie et al., 2014) .", [["a microgeographical scale", "TEST", 281, 306]]], ["Estimating precipitation continues to challenge the modelling community, due partly to the complex interaction between temperature and rainfall (Zhang et al., 2007) , including the influence of fine-scale drivers of cloud formation and rainfall.Absence vs Missing DataAll models are limited by the absence of data.", [["Estimating precipitation", "PROBLEM", 0, 24], ["cloud formation", "PROBLEM", 216, 231], ["Missing DataAll models", "PROBLEM", 256, 278], ["cloud formation", "OBSERVATION", 216, 231]]], ["In their attempts to address this issue when working on leishmaniasis, Carvalho et al. (2015) tested several ecological niche modelling algorithms and concluded that the inclusion of absence data improved model performance.", [["leishmaniasis", "DISEASE", 56, 69]]], ["A range of modelling approaches benefit from inclusion of absence data (Li and Guo, 2013) if a survey has been undertaken in the area and the absence has been confirmed by direct observation.", [["a survey", "TEST", 93, 101], ["direct observation", "TEST", 172, 190]]], ["The Maxent approach, as used by authors researching various parasites including leishmaniasis Peterson and Shaw (2003) and lymphatic filariasis (Slater and Michael, 2012 ) is a valuable tool for analysing presence-only data.", [["leishmaniasis", "DISEASE", 80, 93], ["lymphatic filariasis", "DISEASE", 123, 143], ["lymphatic filariasis", "PROBLEM", 123, 143], ["lymphatic", "ANATOMY", 123, 132], ["filariasis", "OBSERVATION", 133, 143]]], ["Process-based mapping issue, as used by Stensgaard et al. (2016) , can ameliorate the problem to an extent by predicting where the environment may be suitable for a vector or intermediate host based on the results of experimental observations.Uncertainty and BiasUncertainty is a fact of climate projections from which it is difficult to escape.", [["a vector", "TREATMENT", 163, 171]]], ["It is not possible to draw data from the future and there are many possible intermediate scenarios as depicted in Fig. 5 .", [["not possible", "UNCERTAINTY", 6, 18], ["intermediate scenarios", "OBSERVATION", 76, 98]]], ["The RCPs offer useful touch points for comparative purposes, but every projection of the impact of climate change must acknowledge the inherent uncertainty.Uncertainty and BiasTo illustrate the uncertainty regarding estimating the potential impact of climate change on NTDs, consider Fig. 6 .", [["NTDs", "DISEASE", 269, 273], ["comparative purposes", "TEST", 39, 59], ["climate change on NTDs", "PROBLEM", 251, 273]]], ["As surface temperatures warm there may be differential effects on transmission of NTD infections depending on regional environmental changes.", [["surface", "ANATOMY", 3, 10], ["infections", "DISEASE", 86, 96], ["surface temperatures warm", "PROBLEM", 3, 28], ["NTD infections", "PROBLEM", 82, 96], ["regional environmental changes", "PROBLEM", 110, 140], ["may be", "UNCERTAINTY", 35, 41], ["differential", "OBSERVATION_MODIFIER", 42, 54], ["infections", "OBSERVATION", 86, 96], ["environmental changes", "OBSERVATION", 119, 140]]], ["For example, in some places the regional climate may become too extreme to support vectors or zoonotic hosts, whereas in others an extreme flooding event may translocate vectors or zoonotic hosts from one part of a river system to another.", [["an extreme flooding event", "PROBLEM", 128, 153]]], ["This level of uncertainty places additional challenges on modelling future scenarios of not just schistosomes but all NTDs due to their tight association with specific environments.Uncertainty and BiasBias is another universal feature of climate models.", [["NTDs", "DISEASE", 118, 122], ["all NTDs", "PROBLEM", 114, 122]]], ["Future trends in warming and precipitation are based on simulations of historic events.", [["warming", "TREATMENT", 17, 24], ["precipitation", "TREATMENT", 29, 42], ["historic events", "PROBLEM", 71, 86]]], ["Generalised framework of how increases in global temperatures and regional changes to precipitation patterns may lead to increased, translocated or decreased transmission of NTDs.", [["NTDs", "DISEASE", 174, 178], ["global temperatures", "PROBLEM", 42, 61], ["regional changes to precipitation patterns", "PROBLEM", 66, 108], ["decreased transmission of NTDs", "PROBLEM", 148, 178], ["increases", "OBSERVATION_MODIFIER", 29, 38], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["decreased", "OBSERVATION_MODIFIER", 148, 157]]], ["Central column describes particular temperature and precipitation changes associated with climate change.", [["particular temperature", "PROBLEM", 25, 47], ["precipitation changes", "PROBLEM", 52, 73], ["column", "OBSERVATION_MODIFIER", 8, 14], ["precipitation", "OBSERVATION", 52, 65]]], ["Left column describes intermediary steps that might be expected to increase or translocate transmission.", [["column", "ANATOMY_MODIFIER", 5, 11], ["intermediary steps", "OBSERVATION", 22, 40], ["might be expected to", "UNCERTAINTY", 46, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75]]], ["Right column describes intermediary steps that could lead to reduced transmission.", [["reduced transmission", "PROBLEM", 61, 81], ["column", "ANATOMY_MODIFIER", 6, 12], ["intermediary steps", "OBSERVATION", 23, 41], ["could lead to", "UNCERTAINTY", 47, 60], ["reduced", "OBSERVATION_MODIFIER", 61, 68]]], ["Bias correction involves correcting the future simulations so that they more accurately predict the future.", [["Bias correction", "PROBLEM", 0, 15]]], ["There are several different types of bias correction available, which are detailed elsewhere (e.g. Teutschbein and Seibert, 2012) .MosquitoesSeveral genera of mosquitoes are involved in the life cycles of vector-borne NTDs.", [["NTDs", "DISEASE", 218, 222], ["mosquitoes", "ORGANISM", 159, 169], ["several", "OBSERVATION_MODIFIER", 10, 17], ["different", "OBSERVATION_MODIFIER", 18, 27], ["types", "OBSERVATION_MODIFIER", 28, 33], ["bias correction", "OBSERVATION", 37, 52]]], ["Here, I briefly describe factors affecting the life history traits of three of the main vectors-Aedes, Culex and Anopheles.", [["Anopheles", "ORGANISM", 113, 122], ["main vectors", "ANATOMY", 83, 95]]], ["For a more comprehensive review of oviposition, see Day (2016) .AedesThis urban dwelling mosquito is perhaps the most sensitive indicator of how environmental change can affect transmission of vector-borne diseases.", [["vector-borne diseases", "DISEASE", 193, 214], ["Aedes", "ORGANISM", 64, 69], ["mosquito", "ORGANISM", 89, 97], ["Aedes", "SPECIES", 64, 69], ["vector-borne diseases", "PROBLEM", 193, 214]]], ["Many different NTDs are transmitted by various species of Aedes.", [["NTDs", "DISEASE", 15, 19], ["Many different NTDs", "PROBLEM", 0, 19], ["different", "OBSERVATION_MODIFIER", 5, 14], ["NTDs", "OBSERVATION", 15, 19]]], ["Two of the most prominent Aedes species in terms of the number of diseases that can be transmitted via their feeding mechanism are Aedes albopictus and Aedes aegypti.", [["Aedes species", "ORGANISM", 26, 39], ["Aedes albopictus", "ORGANISM", 131, 147], ["Aedes aegypti", "ORGANISM", 152, 165], ["Aedes albopictus", "SPECIES", 131, 147], ["Aedes aegypti", "SPECIES", 152, 165], ["Aedes albopictus", "SPECIES", 131, 147], ["Aedes aegypti", "SPECIES", 152, 165], ["diseases", "PROBLEM", 66, 74], ["most prominent", "OBSERVATION_MODIFIER", 11, 25], ["Aedes species", "OBSERVATION", 26, 39], ["number", "OBSERVATION_MODIFIER", 56, 62], ["diseases", "OBSERVATION", 66, 74]]], ["A. albopictus has been observed to carry Yellow fever virus (YFV), Chikungunya viruses, West Nile virus, Eastern equine encephalitis, Japanese encephalitis.", [["Yellow fever", "DISEASE", 41, 53], ["Chikungunya viruses", "DISEASE", 67, 86], ["West Nile virus", "DISEASE", 88, 103], ["equine encephalitis", "DISEASE", 113, 132], ["Japanese encephalitis", "DISEASE", 134, 155], ["A. albopictus", "ORGANISM", 0, 13], ["Yellow fever virus", "ORGANISM", 41, 59], ["YFV", "ORGANISM", 61, 64], ["Chikungunya viruses", "ORGANISM", 67, 86], ["West Nile virus", "ORGANISM", 88, 103], ["Eastern equine encephalitis", "ORGANISM", 105, 132], ["A. albopictus", "SPECIES", 0, 13], ["Yellow fever virus", "SPECIES", 41, 59], ["Chikungunya", "SPECIES", 67, 78], ["West Nile virus", "SPECIES", 88, 103], ["equine", "SPECIES", 113, 119], ["A. albopictus", "SPECIES", 0, 13], ["Yellow fever virus", "SPECIES", 41, 59], ["YFV", "SPECIES", 61, 64], ["Chikungunya viruses", "SPECIES", 67, 86], ["West Nile virus", "SPECIES", 88, 103], ["Eastern equine encephalitis", "SPECIES", 105, 132], ["Yellow fever virus", "PROBLEM", 41, 59], ["Chikungunya viruses", "PROBLEM", 67, 86], ["West Nile virus", "PROBLEM", 88, 103], ["Eastern equine encephalitis", "PROBLEM", 105, 132], ["Japanese encephalitis", "PROBLEM", 134, 155], ["albopictus", "OBSERVATION", 3, 13], ["Chikungunya viruses", "OBSERVATION", 67, 86], ["encephalitis", "OBSERVATION", 143, 155]]], ["It can also transmit dog heartworm.", [["dog", "ORGANISM", 21, 24], ["heartworm", "ORGANISM_SUBDIVISION", 25, 34], ["dog", "SPECIES", 21, 24], ["dog heartworm", "SPECIES", 21, 34]]], ["A. aegypti can transmit both Dengue and YFV as well as Chikungunya, Zika virus and Mayaro virus.AedesSome information is available on how Aedes mosquitoes respond to pressures exerted by short-term environmental change.", [["Dengue", "DISEASE", 29, 35], ["Chikungunya", "DISEASE", 55, 66], ["A. aegypti", "ORGANISM", 0, 10], ["Dengue", "ORGANISM", 29, 35], ["YFV", "ORGANISM", 40, 43], ["Chikungunya", "ORGANISM", 55, 66], ["Zika virus", "ORGANISM", 68, 78], ["Mayaro virus", "ORGANISM", 83, 95], ["Aedes mosquitoes", "ORGANISM", 138, 154], ["A. aegypti", "SPECIES", 0, 10], ["Zika virus", "SPECIES", 68, 78], ["Mayaro virus", "SPECIES", 83, 95], ["A. aegypti", "SPECIES", 0, 10], ["YFV", "SPECIES", 40, 43], ["Zika virus", "SPECIES", 68, 78], ["Mayaro virus", "SPECIES", 83, 95], ["both Dengue and YFV", "PROBLEM", 24, 43], ["Chikungunya", "PROBLEM", 55, 66], ["Zika virus", "PROBLEM", 68, 78], ["Mayaro virus", "PROBLEM", 83, 95], ["pressures", "TREATMENT", 166, 175]]], ["For example, it is now known that gene flow is higher in wet than dry seasons due to transient selection pressures (Sayson et al., 2015) and that interaction between vectors and viruses that alters the carrying capacity of the mosquito to vary over time and space also likely to be important determinants of future transmission in particular locations (Lambrechts et al., 2009; Yee et al., 2012) .AedesA second important factor may be diapause (Jia et al., 2016 (Jia et al., , 2017 .", [["gene flow", "PROBLEM", 34, 43], ["transient selection pressures", "TREATMENT", 85, 114], ["gene flow", "OBSERVATION", 34, 43], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["pressures", "OBSERVATION_MODIFIER", 105, 114]]], ["This feature of Aedes mosquitoes natural history allows them to suspend development during adverse environmental conditions, such as cold weather (Brady et al., 2013) .", [["Aedes mosquitoes", "ORGANISM", 16, 32], ["Aedes mosquitoes", "SPECIES", 16, 32], ["adverse environmental conditions", "PROBLEM", 91, 123]]], ["Both temperature and photoperiodicity affect the length of dormancy (Yee et al., 2012) .", [["temperature", "OBSERVATION_MODIFIER", 5, 16], ["length", "OBSERVATION_MODIFIER", 49, 55]]], ["Photoperiodicity in particular has been identified as a target for potential intervention, with efforts underway to identify genes that produce potential targets for genetic or chemical disruption (Huang et al., 2015) .AedesA number of reasons have been cited as responsible for the lack of effectiveness of campaigns to eradicate Aedes mosquitoes historically, even after initial success.", [["Photoperiodicity", "DISEASE", 0, 16], ["Aedes mosquitoes", "ORGANISM", 331, 347], ["Aedes mosquitoes", "SPECIES", 331, 347], ["potential intervention", "TREATMENT", 67, 89], ["genetic or chemical disruption", "PROBLEM", 166, 196]]], ["Aedes spp. oviposit in a wide range of man-made containers (Tun-Lin et al., 2009 ), adapt oviposition rates to local water conditions (Wong et al., 2012) and rest after feeding in places that are difficult to reach with insecticides, including storm drains (Paploski et al., 2016) , and on dark wall surfaces across different rooms of houses (Chadee, 2013; Perich et al., 2000) .", [["Aedes spp", "ORGANISM", 0, 9], ["oviposit", "TREATMENT", 11, 19], ["adapt oviposition rates", "TREATMENT", 84, 107], ["storm drains", "TREATMENT", 244, 256], ["wide", "OBSERVATION_MODIFIER", 25, 29], ["wall", "ANATOMY_MODIFIER", 295, 299], ["surfaces", "ANATOMY_MODIFIER", 300, 308]]], ["One of the key challenges will be to consider how future rates of urbanisation and climate change connect with issues such as precipitation, water collection and drainage (Moore et al., 2016; Semadeni-Davies et al., 2008) .CulexAs with other mosquito vectors, Culex spp. all life stages are ectothermic and therefore climate sensitive.", [["CulexAs", "CHEMICAL", 223, 230], ["CulexAs", "GENE_OR_GENE_PRODUCT", 223, 230], ["Culex spp", "ORGANISM", 260, 269], ["urbanisation", "TREATMENT", 66, 78], ["drainage", "TREATMENT", 162, 170], ["CulexAs", "TEST", 223, 230], ["ectothermic", "OBSERVATION_MODIFIER", 291, 302]]], ["Species of Culex are currently distributed across the globe.", [["Species of Culex", "PROBLEM", 0, 16], ["Culex", "OBSERVATION", 11, 16], ["globe", "ANATOMY", 54, 59]]], ["Culex pipiens complex is the most widely distributed, with mosquitoes inhabiting latitudes as far apart as Northern Europe and the South Island of New Zealand (Farajollahi et al., 2011) .", [["Culex pipiens", "ORGANISM", 0, 13], ["Culex pipiens", "SPECIES", 0, 13], ["Culex pipiens", "SPECIES", 0, 13], ["Culex pipiens complex", "PROBLEM", 0, 21], ["most widely", "OBSERVATION_MODIFIER", 29, 40], ["New", "OBSERVATION_MODIFIER", 147, 150]]], ["In terms of the NTDs covered within this chapter, C. pipiens complex is responsible for transmission of Rift Valley fever and lymphatic filariasis.", [["lymphatic", "ANATOMY", 126, 135], ["NTDs", "DISEASE", 16, 20], ["Rift Valley fever", "DISEASE", 104, 121], ["lymphatic filariasis", "DISEASE", 126, 146], ["C. pipiens", "ORGANISM", 50, 60], ["Rift Valley fever", "ORGANISM", 104, 121], ["C. pipiens", "SPECIES", 50, 60], ["Rift Valley fever", "SPECIES", 104, 121], ["C. pipiens", "SPECIES", 50, 60], ["Rift Valley fever", "SPECIES", 104, 121], ["the NTDs", "PROBLEM", 12, 20], ["C. pipiens complex", "PROBLEM", 50, 68], ["Rift Valley fever", "PROBLEM", 104, 121], ["lymphatic filariasis", "PROBLEM", 126, 146], ["NTDs", "OBSERVATION", 16, 20], ["lymphatic", "ANATOMY", 126, 135], ["filariasis", "OBSERVATION", 136, 146]]], ["Culex quinquefasciatus is distributed across the tropics and subtopics and is responsible for the transmission of lymphatic filariasis and possibly Zika virus (Diallo et al., 2014) .CulexThe development of Culex mosquitoes has been demonstrated to correlate with temperature in a number of studies.", [["lymphatic", "ANATOMY", 114, 123], ["lymphatic filariasis", "DISEASE", 114, 134], ["Culex quinquefasciatus", "ORGANISM", 0, 22], ["lymphatic", "ORGAN", 114, 123], ["Zika virus", "ORGANISM", 148, 158], ["Culex mosquitoes", "ORGANISM", 206, 222], ["Culex quinquefasciatus", "SPECIES", 0, 22], ["Culex quinquefasciatus", "SPECIES", 0, 22], ["Zika virus", "SPECIES", 148, 158], ["Culex", "SPECIES", 182, 187], ["Culex mosquitoes", "SPECIES", 206, 222], ["Culex quinquefasciatus", "PROBLEM", 0, 22], ["lymphatic filariasis", "PROBLEM", 114, 134], ["Zika virus", "PROBLEM", 148, 158], ["Culex mosquitoes", "PROBLEM", 206, 222], ["lymphatic", "ANATOMY", 114, 123], ["filariasis", "OBSERVATION", 124, 134], ["possibly", "UNCERTAINTY", 139, 147], ["Culex mosquitoes", "OBSERVATION", 206, 222]]], ["Gunay et al. (2011) observed that body size of inbred C. quinquefasciatus decreased with increasing temperature (covering the range 20-27\u00b0C).", [["body", "ANATOMY", 34, 38], ["body", "ORGANISM_SUBDIVISION", 34, 38], ["C. quinquefasciatus", "ORGANISM", 54, 73], ["C. quinquefasciatus", "SPECIES", 54, 73], ["C. quinquefasciatus", "SPECIES", 54, 73], ["inbred C. quinquefasciatus", "PROBLEM", 47, 73], ["increasing temperature", "PROBLEM", 89, 111], ["size", "OBSERVATION_MODIFIER", 39, 43], ["increasing", "OBSERVATION_MODIFIER", 89, 99], ["temperature", "OBSERVATION_MODIFIER", 100, 111]]], ["This result echoed earlier work by Rueda et al. (1990) who also observed C. quinquefasciatus body size parameters (including head capsule width, larval body widths and weight) decreased with temperature (covering the range 15-34\u00b0C).", [["body", "ANATOMY", 93, 97], ["head capsule", "ANATOMY", 125, 137], ["body", "ANATOMY", 152, 156], ["C. quinquefasciatus", "ORGANISM", 73, 92], ["body", "ORGANISM_SUBDIVISION", 93, 97], ["head capsule", "MULTI-TISSUE_STRUCTURE", 125, 137], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["C. quinquefasciatus", "SPECIES", 73, 92], ["C. quinquefasciatus", "SPECIES", 73, 92], ["head capsule width", "TREATMENT", 125, 143], ["larval body widths", "TEST", 145, 163], ["weight", "TEST", 168, 174], ["temperature", "TEST", 191, 202]]], ["The parabolic nature of the relationship between temperature and survival was demonstrated also in that study, with the peak emergence occurring at temperatures between 20 and 30\u00b0C and high levels of mortality recorded at 15 and 34\u00b0C. A more comprehensive review of the relationship between temperature and Culex life history traits is available elsewhere (Ciota et al., 2014) .CulexObservations on the relationship between temperature and development of Culex mosquitoes have been used to inform investigations into the possible effects of climate change on the geographic distribution of Culex species.", [["C", "GENE_OR_GENE_PRODUCT", 179, 180], ["Culex mosquitoes", "ORGANISM", 455, 471], ["Culex species", "ORGANISM", 590, 603], ["Culex mosquitoes", "SPECIES", 455, 471], ["that study", "TEST", 99, 109], ["high levels of mortality", "PROBLEM", 185, 209], ["Culex mosquitoes", "TREATMENT", 455, 471], ["Culex species", "PROBLEM", 590, 603], ["parabolic", "OBSERVATION_MODIFIER", 4, 13], ["high", "OBSERVATION_MODIFIER", 185, 189], ["Culex species", "OBSERVATION", 590, 603]]], ["The results of their analysis suggest a pattern of regional changes that reflect the complex topography of the location under study, but also an overall trend towards a lengthier mosquito breeding season combined with a lower abundance in summer months.CulexFocusing on a more global picture, Samy et al. (2016) combined observed occurrence data of the contemporary distribution of C. quinquefasciatus with climatic projections of temperature based on the RCPs (covering RCP2.6, RCP4.5, RCP6.0 and RCP8.5) and a set of biolimactic variables containing monthly temperature and rainfall data.", [["C. quinquefasciatus", "ORGANISM", 382, 401], ["RCP2.6", "GENE_OR_GENE_PRODUCT", 471, 477], ["RCP4.5", "GENE_OR_GENE_PRODUCT", 479, 485], ["RCPs", "PROTEIN", 456, 460], ["RCP2.6", "DNA", 471, 477], ["RCP4.5", "PROTEIN", 479, 485], ["RCP6.0", "PROTEIN", 487, 493], ["RCP8", "PROTEIN", 498, 502], ["C. quinquefasciatus", "SPECIES", 382, 401], ["C. quinquefasciatus", "SPECIES", 382, 401], ["their analysis", "TEST", 15, 29], ["regional changes", "PROBLEM", 51, 67], ["the RCPs", "TEST", 452, 460], ["RCP8", "TREATMENT", 498, 502], ["biolimactic variables", "TREATMENT", 519, 540], ["rainfall data", "TEST", 576, 589], ["regional changes", "OBSERVATION", 51, 67]]], ["Current potential distribution of the mosquito was then estimated by first estimating, using an ecological niche model, which bioclimatic variables were contemporaneously associated with the distribution of Culex.", [["mosquito", "ORGANISM", 38, 46], ["distribution", "OBSERVATION_MODIFIER", 18, 30], ["niche model", "OBSERVATION", 107, 118]]], ["The conclusion from this work was that the limits of the geographical distribution would increase by up to 4.9% in the future (no specific date given) between RCP2.6 and RCP6.0 and then decrease under RCP8.5.AnophelesMosquitoes of the Anopheles genus are responsible for the transmission of malaria and as such have been studied relatively extensively in terms of their biology and life history.", [["AnophelesMosquitoes", "CHEMICAL", 208, 227], ["malaria", "DISEASE", 291, 298], ["RCP2.6", "GENE_OR_GENE_PRODUCT", 159, 165], ["RCP8", "GENE_OR_GENE_PRODUCT", 201, 205], ["Anopheles genus", "ORGANISM", 235, 250], ["RCP8", "PROTEIN", 201, 205], ["the Anopheles genus", "PROBLEM", 231, 250], ["malaria", "PROBLEM", 291, 298], ["malaria", "OBSERVATION", 291, 298]]], ["Information on this vector is included here due to its role in transmission of Wuchereria bancrofti and Brugia malayi (Bockarie et al., 2008) , but with the caveat that species-specific observations may not translate across species.AnophelesAnophelene mosquitoes generally lay their eggs singly onto water, and on hatching the larvae float horizontally to allow breathing.", [["Wuchereria bancrofti", "DISEASE", 79, 99], ["Brugia malayi", "DISEASE", 104, 117], ["Wuchereria bancrofti", "ORGANISM", 79, 99], ["Brugia malayi", "ORGANISM", 104, 117], ["AnophelesAnophelene mosquitoes", "ORGANISM", 232, 262], ["Wuchereria bancrofti", "SPECIES", 79, 99], ["Brugia malayi", "SPECIES", 104, 117], ["Wuchereria bancrofti", "SPECIES", 79, 99], ["Brugia malayi", "SPECIES", 104, 117], ["AnophelesAnophelene mosquitoes", "SPECIES", 232, 262], ["Wuchereria bancrofti", "PROBLEM", 79, 99], ["Brugia malayi", "PROBLEM", 104, 117], ["AnophelesAnophelene mosquitoes", "TREATMENT", 232, 262]]], ["Exceptionally, viable Anopheles gambiae eggs have been observed in both moist soil (Minakawa et al., 2001) , and dry soil (Bier et al.,) and treeholes (Omlin et al., 2007) .", [["Anopheles gambiae eggs", "ORGANISM", 22, 44], ["Anopheles gambiae", "SPECIES", 22, 39], ["Anopheles gambiae", "SPECIES", 22, 39]]], ["The larvae are amphibious and will move towards water (Miller et al., 2007) .AnophelesAs all stages of all species are poikilothermic, the life history traits of the organism are tightly controlled by environmental conditions from egg laying onwards (Davies et al., 2016; Lyons et al., 2013) .", [["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 231, 234], ["all species", "PROBLEM", 103, 114], ["poikilothermic", "PROBLEM", 119, 133], ["the organism", "PROBLEM", 162, 174], ["larvae", "ANATOMY", 4, 10], ["all species", "OBSERVATION", 103, 114]]], ["Several other environmental factors including pH, water flow and presence of algae are also important drivers of egg, larval, pupal and adult stage survival, larval feeding behaviour, larval-adult development time, gonotrophic cycle rate and population abundance (e.g. Ara\u00fajo et al., 2012; Gouagna et al., 2012; Kamara et al., 2015) .AnophelesUnderstanding the individual life history traits of individual species is necessary but not sufficient for modelling purposes.", [["egg", "ANATOMY", 113, 116], ["pupal", "ANATOMY", 126, 131], ["water", "SIMPLE_CHEMICAL", 50, 55], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 113, 116], ["pupal", "DEVELOPING_ANATOMICAL_STRUCTURE", 126, 131], ["Anopheles", "ORGANISM", 334, 343], ["Several other environmental factors", "PROBLEM", 0, 35], ["pH", "TEST", 46, 48], ["water flow", "TREATMENT", 50, 60], ["adult stage survival", "TREATMENT", 136, 156], ["gonotrophic cycle rate", "TEST", 215, 237], ["individual species", "PROBLEM", 395, 413]]], ["For example, a study in Nigeria by Lenhart et al. (2007) established that in Nigeria the relative contribution of A. gambiae, Anopheles arabiensis and Anopheles funestus to Wuchereria bancrofi transmission is likely to vary over a 12-month period.", [["Wuchereria bancrofi transmission", "DISEASE", 173, 205], ["A. gambiae", "ORGANISM", 114, 124], ["Anopheles arabiensis", "ORGANISM", 126, 146], ["Anopheles funestus", "ORGANISM", 151, 169], ["Wuchereria bancrofi", "ORGANISM", 173, 192], ["A. gambiae", "SPECIES", 114, 124], ["Anopheles arabiensis", "SPECIES", 126, 146], ["Anopheles funestus", "SPECIES", 151, 169], ["Wuchereria bancrofi", "SPECIES", 173, 192], ["A. gambiae", "SPECIES", 114, 124], ["Anopheles arabiensis", "SPECIES", 126, 146], ["Anopheles funestus", "SPECIES", 151, 169], ["Wuchereria bancrofi", "SPECIES", 173, 192], ["a study", "TEST", 13, 20], ["A. gambiae", "PROBLEM", 114, 124]]], ["Competition between sibling Anopheles species (Paaijmans et al., 2009) may be partly responsible for the dominance of particular species at different times, combine with changes to water and/or soil phases that favour the development of one species over another.AnophelesTaking into account all the possible abiotic and biotic factors that influence Anopheles life history, understanding how climate change might affect the populations of Anopheles mosquitoes and transmission of filarial infections is therefore challenging.", [["filarial infections", "DISEASE", 480, 499], ["Anopheles mosquitoes", "ORGANISM", 439, 459], ["filarial", "ORGANISM", 480, 488], ["Anopheles mosquitoes", "SPECIES", 439, 459], ["particular species", "PROBLEM", 118, 136], ["water and/or soil phases", "TREATMENT", 181, 205], ["Anopheles", "TREATMENT", 262, 271], ["abiotic and biotic factors", "PROBLEM", 308, 334], ["Anopheles mosquitoes", "TREATMENT", 439, 459], ["filarial infections", "PROBLEM", 480, 499], ["filarial", "ANATOMY", 480, 488], ["infections", "OBSERVATION", 489, 499]]], ["Evidence is nonetheless emerging that a mixture of anthropogenic activities related to land cover change, combined with increased temperatures, is shifting the species range in specific areas (e.g. Fuller et al., 2012; Kulkarni et al., 2016) and may either cause local extinction (Escobar et al., 2016) , or an overall increase in environmental suitability combined with seasonal and range shifts (e.g. Ryan et al., 2015) .BatsBats are either known, or suspected, to be vectors of many zoonotic infections (Olival et al., 2017) including several filoviruses and hepanaviruses (Moratelli and Calisher, 2015; Olival and Hayman, 2014) .", [["zoonotic infections", "DISEASE", 486, 505], ["BatsBats", "GENE_OR_GENE_PRODUCT", 423, 431], ["anthropogenic activities", "PROBLEM", 51, 75], ["land cover change", "PROBLEM", 87, 104], ["increased temperatures", "PROBLEM", 120, 142], ["many zoonotic infections", "PROBLEM", 481, 505], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["temperatures", "OBSERVATION_MODIFIER", 130, 142], ["overall", "OBSERVATION_MODIFIER", 311, 318], ["increase", "OBSERVATION_MODIFIER", 319, 327], ["zoonotic", "OBSERVATION_MODIFIER", 486, 494], ["infections", "OBSERVATION", 495, 505]]], ["Infections of humans via bats infected with filoviruses have tended to occur in outbreaks, which has been hypothesised to occur as a consequence of within-host dynamics (Plowright et al., 2016) .", [["Infections of humans via bats infected", "DISEASE", 0, 38], ["humans", "ORGANISM", 14, 20], ["filoviruses", "GENE_OR_GENE_PRODUCT", 44, 55], ["humans", "SPECIES", 14, 20], ["humans", "SPECIES", 14, 20], ["Infections of humans", "PROBLEM", 0, 20], ["filoviruses", "TREATMENT", 44, 55]]], ["Outbreaks of emerging viral infections, including filoviruses, have been increasing in recent decades (Smith et al., 2014) correlating with global environmental change.BatsLike many nonhuman mammals, bats are acutely susceptible to the impacts of environmental change, including climate change (Aguiar et al., 2016; Sherwin et al., 2013) .", [["viral infections", "DISEASE", 22, 38], ["filoviruses", "DISEASE", 50, 61], ["nonhuman mammals", "ORGANISM", 182, 198], ["bats", "ORGANISM", 200, 204], ["emerging viral infections", "PROBLEM", 13, 38], ["filoviruses", "PROBLEM", 50, 61], ["global environmental change", "PROBLEM", 140, 167], ["viral infections", "OBSERVATION", 22, 38], ["increasing", "OBSERVATION_MODIFIER", 73, 83], ["environmental change", "OBSERVATION", 147, 167], ["nonhuman mammals", "OBSERVATION", 182, 198]]], ["The direction of travel is less certain than the anticipation of change.", [["less certain", "OBSERVATION_MODIFIER", 27, 39]]], ["Published species-distribution models suggest that the fruit bat Pipistrellus kuhlii has extended its range over recent decades as global temperatures have increased (Ancillotto et al., 2016) .", [["Pipistrellus", "CHEMICAL", 65, 77], ["Pipistrellus kuhlii", "ORGANISM", 65, 84], ["Pipistrellus kuhlii", "SPECIES", 65, 84], ["Pipistrellus kuhlii", "SPECIES", 65, 84], ["the fruit bat Pipistrellus kuhlii", "PROBLEM", 51, 84], ["global temperatures", "TEST", 131, 150], ["increased", "OBSERVATION_MODIFIER", 156, 165]]], ["Extreme temperatures (>42\u00b0C) have been identified as fatal to flying foxes (Welbergen et al., 2008) .", [["Extreme temperatures", "TEST", 0, 20]]], ["A more complex, and localised, situation may exist across all species, given evidence that the call frequency is affected by temperature and humidity (Mutumi et al., 2016) and that efficiency of echolocation (and hence foraging success) is affected by temperature in a convex manner (Luo et al., 2014) .BatsKnown bat vectors of filoviruses include flying foxes and fruit bats (Table 1 ).", [["filoviruses", "GENE_OR_GENE_PRODUCT", 328, 339], ["A more complex, and localised, situation", "PROBLEM", 0, 40], ["echolocation", "PROBLEM", 195, 207], ["filoviruses", "TREATMENT", 328, 339], ["more complex", "OBSERVATION_MODIFIER", 2, 14]]], ["An attempt to predict which of the other existing 1116 bat species could possibly host filoviruses suggests that candidate species tend to produce more than 1 L per year of relatively large neonates, inhabit relatively large geographic ranges of high mammal density and live in larger roosts (Han et al., 2016) .", [["the other existing 1116 bat species", "PROBLEM", 31, 66], ["host filoviruses", "PROBLEM", 82, 98], ["relatively large neonates", "PROBLEM", 173, 198], ["high mammal density", "PROBLEM", 246, 265], ["relatively", "OBSERVATION_MODIFIER", 173, 183], ["large", "OBSERVATION_MODIFIER", 184, 189], ["neonates", "OBSERVATION", 190, 198], ["relatively", "OBSERVATION_MODIFIER", 208, 218], ["large", "OBSERVATION_MODIFIER", 219, 224], ["geographic", "OBSERVATION_MODIFIER", 225, 235], ["ranges", "OBSERVATION_MODIFIER", 236, 242], ["high", "OBSERVATION_MODIFIER", 246, 250], ["mammal density", "OBSERVATION", 251, 265], ["larger", "OBSERVATION_MODIFIER", 278, 284]]], ["One of the challenges in identifying bat vectors is the lack of pathology attributable to the viruses themselves, a situation that has led to the hypothesis that metabolic and internal temperature increases caused by flight may have led to the evolution of tolerance (O'Shea et al., 2014) .GoehelminthsAt the time of writing this chapter, there were no original research articles retrievable through PubMed specifically referring to climate change and hookworm infections, climate change and geohelminths, climate change and Ascaris lumbricoides infections or climate change and Trichuris trichiura infections.", [["hookworm infections", "DISEASE", 452, 471], ["geohelminths", "DISEASE", 492, 504], ["Ascaris lumbricoides infections", "DISEASE", 525, 556], ["Trichuris trichiura infections", "DISEASE", 579, 609], ["bat", "ORGANISM", 37, 40], ["Ascaris lumbricoides", "ORGANISM", 525, 545], ["Trichuris trichiura", "ORGANISM", 579, 598], ["Ascaris lumbricoides", "SPECIES", 525, 545], ["Trichuris trichiura", "SPECIES", 579, 598], ["Ascaris lumbricoides", "SPECIES", 525, 545], ["Trichuris trichiura", "SPECIES", 579, 598], ["bat vectors", "TREATMENT", 37, 48], ["the viruses themselves", "PROBLEM", 90, 112], ["internal temperature", "PROBLEM", 176, 196], ["hookworm infections", "PROBLEM", 452, 471], ["Ascaris lumbricoides infections", "PROBLEM", 525, 556], ["climate change", "PROBLEM", 560, 574], ["Trichuris trichiura infections", "PROBLEM", 579, 609], ["viruses", "OBSERVATION", 94, 101], ["hookworm", "OBSERVATION_MODIFIER", 452, 460], ["infections", "OBSERVATION", 461, 471], ["Ascaris", "OBSERVATION_MODIFIER", 525, 532], ["lumbricoides infections", "OBSERVATION", 533, 556], ["Trichuris trichiura", "OBSERVATION", 579, 598]]], ["I therefore summarise here what is known about the climate-sensitive stages of their life cycles to inform future efforts at statistical and/or dynamic modelling.TrichurisThe climate-sensitive stages of the Trichuris spp. life cycle are eggs deposited onto the ground within faecal matter.", [["faecal matter", "ANATOMY", 275, 288], ["Trichuris", "DISEASE", 162, 171], ["Trichuris spp", "DISEASE", 207, 220], ["Trichuris", "ORGANISM", 162, 171], ["Trichuris spp", "ORGANISM", 207, 220], ["faecal", "ORGANISM_SUBDIVISION", 275, 281], ["Trichuris spp", "SPECIES", 207, 220], ["their life cycles", "TREATMENT", 79, 96], ["Trichuris", "PROBLEM", 162, 171], ["the Trichuris spp", "PROBLEM", 203, 220], ["sensitive stages", "OBSERVATION_MODIFIER", 183, 199], ["Trichuris spp", "OBSERVATION", 207, 220], ["eggs", "OBSERVATION", 237, 241], ["ground", "ANATOMY_MODIFIER", 261, 267], ["faecal matter", "ANATOMY", 275, 288]]], ["Embryonation occurs at a pace dependent on temperature (Beer, 1973) , with an optimum rate of development at approximately 34\u00b0C. At this temperature, embryonation and development to infective stages take approximately 2 weeks.", [["Embryonation", "DISEASE", 0, 12], ["embryonation", "TREATMENT", 150, 162], ["infective stages", "PROBLEM", 182, 198], ["infective", "OBSERVATION", 182, 191]]], ["These and other experiments of temperature on embryonation of Trichuris suis indicate a lower threshold of 20\u00b0C and an upper threshold of approximately 40\u00b0C for development of the organism (Beer, 1973; Vejzagic et al., 2016) .", [["Trichuris suis", "ORGANISM", 62, 76], ["C", "GENE_OR_GENE_PRODUCT", 110, 111], ["C", "GENE_OR_GENE_PRODUCT", 155, 156], ["Trichuris suis", "SPECIES", 62, 76], ["Trichuris suis", "SPECIES", 62, 76], ["Trichuris suis", "PROBLEM", 62, 76], ["an upper threshold", "TEST", 116, 134], ["lower threshold", "OBSERVATION_MODIFIER", 88, 103], ["upper", "ANATOMY_MODIFIER", 119, 124]]], ["Increasing the pH of the soil can reduce the survivorship of eggs (O'Donnell et al., 1984) , in a temperature-dependent manner with a rapid reduction in survivorship under alkaline conditions (Ghiglietti et al., 1995) .TrichurisEgg survival periods of 2-6 years have been suggested in temperate conditions (Beer, 1973) .", [["a rapid reduction", "TREATMENT", 132, 149], ["rapid", "OBSERVATION_MODIFIER", 134, 139], ["reduction", "OBSERVATION_MODIFIER", 140, 149]]], ["The upper temperature boundary of approximately 40\u00b0C for development to infective stages is similar to that reported in prevalence studies among school-aged children, where evidence of transmission has been observed in communities with land surface temperatures up to 45\u00b0C (Brooker et al., 2004) .", [["surface", "ANATOMY", 241, 248], ["children", "ORGANISM", 157, 165], ["children", "SPECIES", 157, 165], ["The upper temperature boundary", "PROBLEM", 0, 30], ["infective stages", "PROBLEM", 72, 88], ["upper temperature", "OBSERVATION_MODIFIER", 4, 21], ["infective", "OBSERVATION", 72, 81]]], ["Other factors related to soil chemistry, including the level of quartz, may also be important in determining egg survival and viability-sandy soil channels may form down which the eggs fall to become incorporated into the subsoil and protected from environmental hazards (Brooker et al., 2004) .AscarisA. lumbricoides eggs, deposited onto soil within faecal matter, are the climatesensitive stage of this roundworm parasite.", [["egg", "ANATOMY", 109, 112], ["eggs", "ANATOMY", 318, 322], ["faecal matter", "ANATOMY", 351, 364], ["AscarisA", "CHEMICAL", 295, 303], ["egg", "ORGANISM_SUBDIVISION", 109, 112], ["lumbricoides", "ORGANISM", 305, 317], ["AscarisA", "PROTEIN", 295, 303], ["lumbricoides", "SPECIES", 305, 317], ["lumbricoides", "SPECIES", 305, 317], ["Other factors", "PROBLEM", 0, 13], ["soil chemistry", "TEST", 25, 39], ["sandy soil channels", "TREATMENT", 136, 155], ["the eggs", "PROBLEM", 176, 184], ["AscarisA", "PROBLEM", 295, 303], ["lumbricoides eggs", "PROBLEM", 305, 322], ["this roundworm parasite", "PROBLEM", 400, 423], ["faecal matter", "OBSERVATION", 351, 364], ["roundworm", "OBSERVATION_MODIFIER", 405, 414], ["parasite", "OBSERVATION", 415, 423]]], ["They are more robust to environmental perturbation than either Trichuris spp. eggs or hookworm larvae due to being coated in chitin (Meng et al., 1981) .", [["hookworm larvae", "DISEASE", 86, 101], ["Trichuris spp", "ORGANISM", 63, 76], ["eggs", "ORGANISM_SUBSTANCE", 78, 82], ["hookworm", "ORGANISM", 86, 94], ["chitin", "SIMPLE_CHEMICAL", 125, 131], ["Trichuris spp", "PROBLEM", 63, 76], ["hookworm larvae", "PROBLEM", 86, 101]]], ["Some studies have suggested the eggs may survive for several years in soil (Rudolfs in Storey and Phillips, 1985) .", [["eggs", "ANATOMY", 32, 36], ["Some studies", "TEST", 0, 12]]], ["Statistical analysis of bioclimatic data suggests that relatively moderate amounts of rain are associated with peak infection (Sch\u20ac ule et al., 2014) .AscarisChanges in relative humidity (RH) under experimental conditions reflect expected seasonal changes at certain latitudes, with much greater mortality under simulated field conditions that combined prolonged periods of simulated sunlight and dry soil conditions (Gaasenbeek and Borgsteede, 1998) .AscarisIn experimental studies, a major determinant of egg longevity has been reported to be the level of ammonia in the faecal matter (Jensen et al., 2009; Pecson et al., 2007) .", [["egg", "ANATOMY", 507, 510], ["faecal matter", "ANATOMY", 573, 586], ["infection", "DISEASE", 116, 125], ["ammonia", "CHEMICAL", 558, 565], ["ammonia", "CHEMICAL", 558, 565], ["Ascaris", "ORGANISM", 151, 158], ["egg", "ORGANISM_SUBDIVISION", 507, 510], ["ammonia", "SIMPLE_CHEMICAL", 558, 565], ["faecal", "ORGANISM_SUBDIVISION", 573, 579], ["Statistical analysis", "TEST", 0, 20], ["bioclimatic data", "TEST", 24, 40], ["relatively moderate amounts of rain", "PROBLEM", 55, 90], ["peak infection", "PROBLEM", 111, 125], ["AscarisChanges", "PROBLEM", 151, 165], ["expected seasonal changes", "PROBLEM", 230, 255], ["dry soil conditions", "PROBLEM", 397, 416], ["AscarisIn experimental studies", "TEST", 452, 482], ["egg longevity", "PROBLEM", 507, 520], ["relatively", "OBSERVATION_MODIFIER", 55, 65], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["amounts", "OBSERVATION_MODIFIER", 75, 82], ["rain", "OBSERVATION", 86, 90], ["peak", "OBSERVATION_MODIFIER", 111, 115], ["infection", "OBSERVATION", 116, 125], ["humidity", "OBSERVATION_MODIFIER", 178, 186], ["faecal matter", "ANATOMY", 573, 586]]], ["A combination of ammonia, temperature and pH is also deterministic, with the majority of eggs able to survive at pH 7 in low ammonia conditions at 20\u00b0C for several 100 days, whereas conditions combining high pH with high ammonia at 40\u00b0C kill the eggs within minutes (Pecson et al., 2007) .", [["eggs", "ANATOMY", 246, 250], ["ammonia", "CHEMICAL", 17, 24], ["ammonia", "CHEMICAL", 125, 132], ["ammonia", "CHEMICAL", 221, 228], ["ammonia", "CHEMICAL", 17, 24], ["ammonia", "CHEMICAL", 125, 132], ["ammonia", "CHEMICAL", 221, 228], ["ammonia", "SIMPLE_CHEMICAL", 17, 24], ["ammonia", "SIMPLE_CHEMICAL", 125, 132], ["ammonia", "SIMPLE_CHEMICAL", 221, 228], ["ammonia", "TEST", 17, 24], ["pH", "TEST", 42, 44], ["low ammonia conditions", "PROBLEM", 121, 143], ["high pH", "PROBLEM", 203, 210], ["high ammonia", "PROBLEM", 216, 228]]], ["In separate studies, it has been reported that egg survival is also sharply determined by relative survival, with a fall from almost 100% 8-week survival at 100% RH to almost 0% 8-week survival at 7.5% humidity (Gaasenbeek and Borgsteede, 1998) .HookwormsThe climate-sensitive stages of hookworm infection are the eggs and larval stages.", [["egg", "ANATOMY", 47, 50], ["eggs", "ANATOMY", 314, 318], ["Hookworms", "CHEMICAL", 246, 255], ["hookworm infection", "DISEASE", 287, 305], ["egg", "ORGANISM_SUBSTANCE", 47, 50], ["hookworm", "ORGANISM", 287, 295], ["Hookworms", "PROBLEM", 246, 255], ["hookworm infection", "PROBLEM", 287, 305], ["sensitive stages", "OBSERVATION_MODIFIER", 267, 283], ["hookworm", "OBSERVATION_MODIFIER", 287, 295], ["infection", "OBSERVATION", 296, 305]]], ["Like the other geohelminths the picture is still very incomplete, but nonetheless yields some relevant information.HookwormsThe presence of hookworm infection is associated with particular bioclimatic variables related to temperature and moisture.", [["hookworm infection", "DISEASE", 140, 158], ["hookworm", "ORGANISM", 140, 148], ["hookworm infection", "PROBLEM", 140, 158], ["hookworm", "OBSERVATION_MODIFIER", 140, 148], ["infection", "OBSERVATION", 149, 158]]], ["Efforts to map the ecological niche suggest arid areas and minimum temperatures of <20\u00b0C are inhibitory (Mudenda et al., 2012) , as are temperatures above 30\u00b0C (Udonsi and Atata, 1987) .", [["C", "GENE_OR_GENE_PRODUCT", 87, 88], ["arid areas", "PROBLEM", 44, 54], ["minimum temperatures", "TEST", 59, 79], ["temperatures", "TEST", 136, 148], ["arid", "OBSERVATION_MODIFIER", 44, 48]]], ["The dependence on environmental cues for the behaviour of the juvenile worms indicates that a changing environment which is predisposed to longer periods of dryness is likely to be detrimental.", [["worms", "SPECIES", 71, 76], ["dryness", "PROBLEM", 157, 164], ["dependence", "OBSERVATION_MODIFIER", 4, 14], ["likely to be", "UNCERTAINTY", 168, 180]]], ["Under stable and ideal soil conditions, the larvae may live for several weeks (Augustine, 1923) .", [["stable", "OBSERVATION_MODIFIER", 6, 12]]], ["If the soil becomes more clay like due to perturbation the larvae are not likely to survive (Payne, 1923) .", [["perturbation the larvae", "PROBLEM", 42, 65], ["not likely", "UNCERTAINTY", 70, 80]]], ["If there is rapid alteration of drying and moistening, the larvae will likewise not thrive (Beaver, 1953) .ToxocaraEggs of Toxocara species are deposited onto land by canids and other animals upon excretion of faecal matter.", [["faecal matter", "ANATOMY", 210, 223], ["ToxocaraEggs", "CHEMICAL", 107, 119], ["ToxocaraEggs", "SIMPLE_CHEMICAL", 107, 119], ["Toxocara species", "ORGANISM", 123, 139], ["faecal", "ORGANISM_SUBDIVISION", 210, 216], ["rapid alteration of drying and moistening", "PROBLEM", 12, 53], ["Toxocara species", "PROBLEM", 123, 139], ["faecal matter", "PROBLEM", 210, 223], ["rapid", "OBSERVATION_MODIFIER", 12, 17], ["alteration", "OBSERVATION_MODIFIER", 18, 28], ["drying", "OBSERVATION_MODIFIER", 32, 38], ["Toxocara species", "OBSERVATION", 123, 139], ["excretion", "OBSERVATION_MODIFIER", 197, 206], ["faecal matter", "OBSERVATION", 210, 223]]], ["The eggs are therefore directly sensitive to climate factors.", [["eggs", "ANATOMY", 4, 8]]], ["Like eggs of other soil-transmitted nematodes, the eggs of Toxocara spp. have evolved to withstand a range of changes in the abiotic and biotic features of the soil phase.", [["eggs", "ANATOMY", 51, 55], ["Toxocara spp", "DISEASE", 59, 71], ["eggs", "ORGANISM_SUBDIVISION", 51, 55], ["Toxocara spp", "ORGANISM", 59, 71], ["transmitted nematodes", "PROBLEM", 24, 45], ["Toxocara spp", "PROBLEM", 59, 71]]], ["Specifically in the case of Toxocara canis, the eggs are able withstand extremes of temperature ranging from below freezing (O'Lorcain, 1995) to over 30\u00b0C (Azam et al., 2012) .", [["eggs", "ANATOMY", 48, 52], ["Toxocara canis", "DISEASE", 28, 42], ["Toxocara canis", "ORGANISM", 28, 42], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 48, 52], ["Toxocara canis", "SPECIES", 28, 42], ["Toxocara canis", "SPECIES", 28, 42], ["Toxocara canis", "PROBLEM", 28, 42], ["temperature", "TEST", 84, 95], ["Toxocara canis", "OBSERVATION", 28, 42]]], ["Toxocara leonis, which rarely affects humans, has been historically present in artic foxes at very high latitudes of the Canadian Artic (Elmore et al., 2013) , indicating how this species of this genus have adapted to extreme environmental conditions before through selection pressures.ToxocaraThe microgeographical distribution of Toxocara eggs is affected by conditions including soil texture (Mizgajska, 1997) and oxygenation.", [["Toxocara leonis", "DISEASE", 0, 15], ["Toxocara", "DISEASE", 286, 294], ["Toxocara eggs", "DISEASE", 332, 345], ["Toxocara leonis", "ORGANISM", 0, 15], ["humans", "ORGANISM", 38, 44], ["artic foxes", "ORGANISM", 79, 90], ["Toxocara", "ORGANISM_SUBSTANCE", 286, 294], ["Toxocara", "ORGANISM", 332, 340], ["Toxocara leonis", "SPECIES", 0, 15], ["humans", "SPECIES", 38, 44], ["Toxocara leonis", "SPECIES", 0, 15], ["humans", "SPECIES", 38, 44], ["Toxocara leonis", "TEST", 0, 15], ["this genus", "PROBLEM", 191, 201], ["selection pressures", "TEST", 266, 285], ["Toxocara eggs", "PROBLEM", 332, 345], ["soil texture", "TEST", 382, 394], ["Mizgajska", "TEST", 396, 405], ["oxygenation", "TEST", 417, 428], ["microgeographical", "OBSERVATION_MODIFIER", 298, 315], ["distribution", "OBSERVATION_MODIFIER", 316, 328], ["Toxocara eggs", "OBSERVATION", 332, 345], ["oxygenation", "OBSERVATION_MODIFIER", 417, 428]]], ["Lower temperatures, lower humidity and low levels of oxygenation slow development times (Azam et al., 2012; Gamboa, 2005) leading to diversity in the rate of maturation depending on geographical location-typically maturation times are lower in tropical regions with all year transmission as a result (Macpherson, 2013) .ToxocaraEvidence for changing patterns of Toxocara infection globally is emerging from studies of zoonotic infections in northern latitudes lying well beyond tropical regions.", [["ToxocaraEvidence", "CHEMICAL", 320, 336], ["Toxocara infection", "DISEASE", 362, 380], ["zoonotic infections", "DISEASE", 418, 437], ["ToxocaraEvidence", "SIMPLE_CHEMICAL", 320, 336], ["Toxocara", "ORGANISM", 362, 370], ["Lower temperatures", "PROBLEM", 0, 18], ["lower humidity", "PROBLEM", 20, 34], ["ToxocaraEvidence", "TREATMENT", 320, 336], ["Toxocara infection", "PROBLEM", 362, 380], ["zoonotic infections", "PROBLEM", 418, 437], ["lower", "OBSERVATION_MODIFIER", 20, 25], ["humidity", "OBSERVATION_MODIFIER", 26, 34], ["low levels", "OBSERVATION_MODIFIER", 39, 49], ["lower", "OBSERVATION_MODIFIER", 235, 240], ["Toxocara infection", "OBSERVATION", 362, 380], ["zoonotic", "OBSERVATION_MODIFIER", 418, 426], ["infections", "OBSERVATION", 427, 437], ["tropical", "ANATOMY_MODIFIER", 478, 486], ["regions", "ANATOMY_MODIFIER", 487, 494]]], ["North-west Canada is sited at the southern limit of the discontinuous permafrost zone, overlapping with the Arctic circle (>60 degree latitude).", [["discontinuous", "OBSERVATION_MODIFIER", 56, 69], ["permafrost zone", "OBSERVATION", 70, 85], ["Arctic circle", "OBSERVATION", 108, 121]]], ["High levels of parasitic infection in Artic regions, excluding Toxocara, have been historically recorded (Hotez, 2010) .", [["parasitic infection", "DISEASE", 15, 34], ["Toxocara", "DISEASE", 63, 71], ["parasitic infection in Artic regions", "PROBLEM", 15, 51], ["Toxocara", "PROBLEM", 63, 71], ["parasitic", "OBSERVATION_MODIFIER", 15, 24], ["infection", "OBSERVATION", 25, 34], ["Artic regions", "OBSERVATION_MODIFIER", 38, 51], ["Toxocara", "OBSERVATION", 63, 71]]], ["This changed in 2006 when a survey of dogs recorded a prevalence of 5%-up from a prevalence of 0 in previous surveys at the same latitude (Salb et al., 2008) .", [["dogs", "ORGANISM", 38, 42], ["dogs", "SPECIES", 38, 42]]], ["More recent studies have confirmed that the prevalence of Toxocara in adults living in regions above 60 degree latitude is below 5% (Messier et al., 2012) .", [["Toxocara", "DISEASE", 58, 66], ["Toxocara", "ORGANISM", 58, 66], ["recent studies", "TEST", 5, 19], ["Toxocara", "PROBLEM", 58, 66], ["Toxocara", "OBSERVATION", 58, 66]]], ["In Northern Saskatchewan, however, the prevalence of T. canis in humans was recently recorded at 13.4% (Schurer et al., 2013) .ToxocaraNorthern Canada is facing a disproportionate increase in temperature changes and is therefore considered as a sentinel site for understanding how climate change might affect parasitic disease transmission (Jenkins et al., 2011) .", [["T. canis", "DISEASE", 53, 61], ["parasitic disease transmission", "DISEASE", 309, 339], ["T. canis", "ORGANISM", 53, 61], ["humans", "ORGANISM", 65, 71], ["T. canis", "SPECIES", 53, 61], ["humans", "SPECIES", 65, 71], ["T. canis", "SPECIES", 53, 61], ["humans", "SPECIES", 65, 71], ["T. canis", "PROBLEM", 53, 61], ["a disproportionate increase in temperature changes", "PROBLEM", 161, 211], ["a sentinel site", "PROBLEM", 243, 258], ["parasitic disease transmission", "PROBLEM", 309, 339], ["canis", "OBSERVATION", 56, 61], ["disproportionate", "OBSERVATION_MODIFIER", 163, 179], ["increase", "OBSERVATION_MODIFIER", 180, 188]]], ["In that review, Jenkins and colleagues suggest that a combination of migrating animal populations, including arctic fox, combined with increased survival of eggs over the winder period will result in a net increase in transmission despite the potential for higher summer temperatures to affect the eggs negatively.", [["eggs", "ANATOMY", 298, 302], ["arctic fox", "ORGANISM", 109, 119], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 298, 302], ["migrating animal populations", "PROBLEM", 69, 97], ["arctic fox", "TREATMENT", 109, 119], ["increased survival of eggs", "TREATMENT", 135, 161], ["a net increase in transmission", "PROBLEM", 200, 230], ["higher summer temperatures", "PROBLEM", 257, 283]]], ["There are no published studies that have projected how climate change may affect transmission and this issue remains to be investigated further through a combination of epidemiological surveys and modelling projects.LeprosyThe cause of leprosy, Mycobacterium leprae, is another example of an organism of public health importance for which there is a paucity of information available on its association with environmental factors (Franco-Paredes and Rodriguez-Morales, 2016).", [["Leprosy", "DISEASE", 216, 223], ["leprosy", "DISEASE", 236, 243], ["Mycobacterium leprae", "DISEASE", 245, 265], ["Mycobacterium leprae", "ORGANISM", 245, 265], ["Mycobacterium leprae", "SPECIES", 245, 265], ["Mycobacterium leprae", "SPECIES", 245, 265], ["published studies", "TEST", 13, 30], ["epidemiological surveys", "TEST", 169, 192], ["leprosy", "PROBLEM", 236, 243], ["Mycobacterium leprae", "PROBLEM", 245, 265], ["no", "UNCERTAINTY", 10, 12], ["cause of", "UNCERTAINTY", 227, 235], ["leprosy", "OBSERVATION", 236, 243], ["Mycobacterium leprae", "OBSERVATION", 245, 265]]], ["Long considered to be transmitted directly among individuals through nasal discharges and droplets, the role of the wider environment, including vector-borne transmission, remains cryptic (Franco-Paredes and Rodriguez-Morales, 2016).", [["nasal", "ANATOMY", 69, 74], ["nasal", "ORGANISM_SUBDIVISION", 69, 74], ["nasal discharges", "PROBLEM", 69, 85], ["cryptic", "PROBLEM", 180, 187], ["nasal", "ANATOMY", 69, 74], ["discharges", "OBSERVATION", 75, 85]]], ["Some climate-sensitive factors are considered below.SoilM. leprae bacteria survive in soil under specific laboratory conditions (Desikan and Sreevatsa, 1995) and have been found in soil in the natural environment close to human habitation (Turankar et al., 2012) .", [["SoilM. leprae", "ORGANISM", 52, 65], ["human", "ORGANISM", 222, 227], ["SoilM. leprae", "SPECIES", 52, 65], ["human", "SPECIES", 222, 227], ["SoilM. leprae", "SPECIES", 52, 65], ["human", "SPECIES", 222, 227], ["leprae bacteria", "PROBLEM", 59, 74], ["leprae bacteria", "OBSERVATION", 59, 74]]], ["It is therefore important to consider how soil conditions may be affected under conditions of a changing climate (see above).WaterM. leprae have been detected in water samples, using PCR, in India (Matsuoka et al., 1999) .", [["samples", "ANATOMY", 168, 175], ["WaterM. leprae", "ORGANISM", 125, 139], ["water samples", "ORGANISM_SUBSTANCE", 162, 175], ["WaterM. leprae", "SPECIES", 125, 139], ["WaterM. leprae", "SPECIES", 125, 139], ["WaterM", "PROBLEM", 125, 131], ["leprae", "PROBLEM", 133, 139], ["leprae", "OBSERVATION", 133, 139]]], ["The same study also reported an association between the presence of leprosy in water and the prevalence of leprosy in the population.WaterAt the time of writing, there were no original research articles available on how climate change might affect future incidence of Leprosy.Water9.", [["leprosy", "DISEASE", 68, 75], ["leprosy", "DISEASE", 107, 114], ["Leprosy", "DISEASE", 268, 275], ["The same study", "TEST", 0, 14], ["leprosy", "PROBLEM", 68, 75], ["leprosy", "PROBLEM", 107, 114], ["Leprosy", "PROBLEM", 268, 275], ["leprosy", "OBSERVATION", 68, 75], ["leprosy", "OBSERVATION", 107, 114], ["Leprosy", "OBSERVATION", 268, 275]]], ["PARASITES WITH INTERMEDIATE HOSTS 9.1 Trematodes 9.1.1 Schistosomes (S. mansoni, S. haematobium) The breadth of research undertaken on each aspect of this lesser-neglected NTD is sufficient to fill several books (Evans, 2015; Mahmoud, 2001; Secor and Colley, 2004) .", [["S. mansoni", "DISEASE", 69, 79], ["S. mansoni", "ORGANISM", 69, 79], ["S. haematobium", "ORGANISM", 81, 95], ["S. mansoni", "SPECIES", 69, 79], ["S. haematobium", "SPECIES", 81, 95], ["S. mansoni", "SPECIES", 69, 79], ["INTERMEDIATE HOSTS", "TEST", 15, 33], ["Trematodes", "TEST", 38, 48], ["haematobium", "OBSERVATION", 84, 95], ["breadth", "OBSERVATION_MODIFIER", 101, 108]]], ["Here, I focus on describing recent research relevant to modelling decadal climate change.WaterThe complex life cycles of schistosome species contain several climatesensitive stages (miracidia, sporocysts, cercaria and intermediate host snails).", [["sporocysts", "ANATOMY", 193, 203], ["cercaria", "ANATOMY", 205, 213], ["schistosome", "ORGANISM", 121, 132], ["sporocysts", "ORGANISM_SUBDIVISION", 193, 203], ["schistosome species", "PROBLEM", 121, 140], ["several climatesensitive stages (miracidia, sporocysts", "PROBLEM", 149, 203], ["complex", "OBSERVATION_MODIFIER", 98, 105], ["life cycles", "OBSERVATION_MODIFIER", 106, 117], ["schistosome species", "OBSERVATION", 121, 140], ["several", "OBSERVATION_MODIFIER", 149, 156], ["climatesensitive stages", "OBSERVATION_MODIFIER", 157, 180]]], ["Each of these components is affected temperature (reviewed by Kalinda et al., 2017) and a wide range of other environmental and physiochemical factors, depending on species, but which includes substrate type, flow velocity, water turbidity, metal content and chlorophyll content (Monde et al., 2016 ).WaterAn early attempt at modelling the future transmission of Schistosomiasis in the African context used a deterministic model of the entire life cycle, suggesting that higher temperatures (>30\u00b0C) could substantially reduce both prevalence and intensity of transmission (Mangal et al., 2008) .", [["metal", "CHEMICAL", 241, 246], ["chlorophyll", "CHEMICAL", 259, 270], ["Schistosomiasis", "DISEASE", 363, 378], ["chlorophyll", "CHEMICAL", 259, 270], ["water", "SIMPLE_CHEMICAL", 224, 229], ["metal", "SIMPLE_CHEMICAL", 241, 246], ["chlorophyll", "SIMPLE_CHEMICAL", 259, 270], ["affected temperature", "PROBLEM", 28, 48], ["water turbidity", "PROBLEM", 224, 239], ["Schistosomiasis", "PROBLEM", 363, 378], ["higher temperatures", "PROBLEM", 471, 490], ["components", "OBSERVATION_MODIFIER", 14, 24], ["affected", "OBSERVATION_MODIFIER", 28, 36], ["temperature", "OBSERVATION_MODIFIER", 37, 48], ["flow velocity", "OBSERVATION", 209, 222], ["water turbidity", "OBSERVATION", 224, 239], ["metal content", "OBSERVATION", 241, 254], ["chlorophyll content", "OBSERVATION", 259, 278], ["Schistosomiasis", "OBSERVATION", 363, 378]]], ["While it is clear that the temperature and the state of the aquatic ecosystem are a critical factor for snail and parasite development (Morley and Lewis, 2013) , the question of whether climate change alone will have a noticeably existential impact on the future transmission of schistosomiasis is still very uncertain (McCreesh and Booth, 2013; Stensgaard et al., 2016) .", [["schistosomiasis", "DISEASE", 279, 294], ["the temperature", "TEST", 23, 38], ["schistosomiasis", "PROBLEM", 279, 294], ["clear", "OBSERVATION", 12, 17], ["schistosomiasis", "OBSERVATION", 279, 294]]], ["Pedersen et al. (2014) and Stensgaard et al. (2013) used an ecological niche model to estimate potential changes to the macrodistribution of two snail species (Biomphalaria pfeifferi and Biomphalaria sudanica) in the African context.", [["Biomphalaria pfeifferi", "ORGANISM", 160, 182], ["Biomphalaria sudanica", "ORGANISM", 187, 208], ["Biomphalaria pfeifferi", "SPECIES", 160, 182], ["Biomphalaria sudanica", "SPECIES", 187, 208], ["Biomphalaria pfeifferi", "SPECIES", 160, 182], ["Biomphalaria sudanica", "SPECIES", 187, 208], ["an ecological niche model", "TREATMENT", 57, 82], ["two snail species", "PROBLEM", 141, 158], ["snail species", "OBSERVATION", 145, 158]]], ["The results of their studies hinted at the both the underlying complexity and uncertainty of this type of projection.", [["their studies", "TEST", 15, 28]]], ["Assuming all else remains equal; Stensgaard et al. (2013) predicted that snail range of B. pfeifferi could either contract by 43% by 2080 under the SRES A2 scenario while the range of B. sudanica could increase by 14% under the same scenario.", [["B. pfeifferi", "ORGANISM", 88, 100], ["B. sudanica", "ORGANISM", 184, 195], ["B. pfeifferi", "SPECIES", 88, 100], ["B. sudanica", "SPECIES", 184, 195], ["B. pfeifferi", "SPECIES", 88, 100], ["B. sudanica", "SPECIES", 184, 195], ["equal", "OBSERVATION", 26, 31]]], ["Their conclusion, that climate change is unlikely to have a uniform and unilateral effect, was borne out in a later study of S. mansoni in East Africa (McCreesh et al., 2015) .", [["S. mansoni", "DISEASE", 125, 135], ["S. mansoni", "ORGANISM", 125, 135], ["S. mansoni", "SPECIES", 125, 135], ["S. mansoni", "SPECIES", 125, 135], ["a uniform and unilateral effect", "PROBLEM", 58, 89], ["a later study", "TEST", 108, 121], ["uniform", "OBSERVATION_MODIFIER", 60, 67], ["unilateral", "OBSERVATION_MODIFIER", 72, 82], ["effect", "OBSERVATION_MODIFIER", 83, 89]]], ["Functional relationships drawn from the literature on B. pfeifferi were first used to model how a long-term trend towards warmer water may affect snail population biology (McCreesh and Booth, 2014) .", [["B. pfeifferi", "ORGANISM", 54, 66], ["B. pfeifferi", "SPECIES", 54, 66], ["B. pfeifferi", "SPECIES", 54, 66]]], ["Virtual miracidia were added into the model, with the output being virtual cercariae.", [["Virtual miracidia", "TREATMENT", 0, 17], ["the output", "TEST", 50, 60], ["cercariae", "OBSERVATION", 75, 84]]], ["Using this output as a measure of 'infection risk', combined with downscaled climate change projections for specific RCP scenarios allowed for mapping future transmission potential up to 2050 in Tanzania, Kenya, Uganda, Rwanda, Burundi and Zambia (McCreesh et al., 2015) .", [["infection", "DISEASE", 35, 44], ["this output", "TEST", 6, 17], ["'infection risk'", "PROBLEM", 34, 50], ["downscaled climate change projections", "TREATMENT", 66, 103]]], ["Owing to the nature of the functional relationships contained within the model it was observed that some areas are likely to become unsuitable either for the parasite or the host, whereas other areas would become more suitable.", [["the parasite", "PROBLEM", 154, 166]]], ["A later collaboration that combined the ecological niche and functional trait modelling reached a similar conclusion (Stensgaard et al., 2016) .", [["functional trait modelling", "PROBLEM", 61, 87]]], ["Fig. 7 summarises the steps taken in this project, which represented an application of a generalisable approach to assessing the effect climate change through considering how abiotic changes may affect functional traits of both intermediate hosts and parasites (Cizauskas et al., 2017) .Schistosoma japonicumEarly models of the potential for transmission of S. japonicum transmission to be altered by climate change focused on how projected changes in average temperature with China may affect the potential transmission area (e.g. Yang et al., 2005) .", [["S. japonicum transmission", "DISEASE", 358, 383], ["Schistosoma japonicumEarly", "ORGANISM", 287, 313], ["S. japonicum", "ORGANISM", 358, 370], ["S. japonicum", "SPECIES", 358, 370], ["S. japonicum", "SPECIES", 358, 370], ["a generalisable approach", "TREATMENT", 87, 111], ["how abiotic changes", "PROBLEM", 171, 190], ["S. japonicum transmission", "PROBLEM", 358, 383]]], ["A later effort extended this approach to include statistical modelling of the relationship between temperature and snail natural history to produce risk maps that illustrated the potential range shift in 2030 and 2050 (Zhou et al., 2008) .", [["this approach", "TREATMENT", 24, 37]]], ["An assessment by Moore et al. (2012) of the degree-day modelling approach used by Zhou et al. (2008) -as well as other publications (see table 2 Moore et al., 2012) cautioned against the use of the use of degree-day models due to their inability to deal effectively with parametric uncertainty.Food-Borne TrematodesThis is an important group of zoonotic trematodes transmitted to humans via poorly processed food, particularly fish, crustaceans and plants.", [["zoonotic trematodes", "DISEASE", 345, 364], ["humans", "ORGANISM", 380, 386], ["fish", "ORGANISM_SUBDIVISION", 427, 431], ["humans", "SPECIES", 380, 386], ["humans", "SPECIES", 380, 386], ["An assessment", "TEST", 0, 13]]], ["Included in this group is Clonorchiasis, Fascioliasis, Opisthorchiasis and Paragonimiasis (Keiser and Utzinger, 2009 ).", [["Clonorchiasis, Fascioliasis, Opisthorchiasis and Paragonimiasis", "DISEASE", 26, 89], ["Clonorchiasis", "PROBLEM", 26, 39], ["Fascioliasis", "PROBLEM", 41, 53], ["Opisthorchiasis", "PROBLEM", 55, 70], ["Paragonimiasis", "PROBLEM", 75, 89], ["Clonorchiasis", "OBSERVATION", 26, 39], ["Fascioliasis", "OBSERVATION", 41, 53], ["Opisthorchiasis", "OBSERVATION", 55, 70], ["Paragonimiasis", "OBSERVATION", 75, 89]]], ["The epidemiology, pathology and control of the parasites causing the first three diseases in the above list have been reviewed, in the SE Asia context, elsewhere (Sripa et al., 2010) .", [["SE", "DISEASE", 135, 137], ["the parasites", "PROBLEM", 43, 56]]], ["For Paragonimiasis, a recent comprehensive review is available (Blair, 2014) , and aspects of the evolution and phylogeography of all four genera have also been reviewed (Attwood, 2010) .", [["Paragonimiasis", "DISEASE", 4, 18], ["Paragonimiasis", "PROBLEM", 4, 18], ["Paragonimiasis", "OBSERVATION", 4, 18]]], ["At the time of writing, there was little published literature regarding decadal climate change and transmission of these infections.", [["infections", "DISEASE", 121, 131], ["decadal climate change", "PROBLEM", 72, 94], ["these infections", "PROBLEM", 115, 131], ["infections", "OBSERVATION", 121, 131]]], ["The discussion below summarises what is known about the relationship between environmental change and the climate-sensitive stages of the life cycles.Clonorchiasis and OpisthorchiasisThe life cycles of Clonorchis sinensis (endemic in Asia), Opisthorchis viverrini (endemic in SE Asia) and Opisthorchis felineus (endemic in Europe and Asia) involve open defaecation by a definitive host into fresh water, typically small ponds, containing vegetation and compatible snail hosts.", [["Clonorchiasis", "DISEASE", 150, 163], ["Opisthorchiasis", "DISEASE", 168, 183], ["Clonorchis sinensis", "DISEASE", 202, 221], ["Opisthorchis viverrini (endemic in SE Asia) and Opisthorchis felineus", "DISEASE", 241, 310], ["Clonorchis sinensis", "ORGANISM", 202, 221], ["Opisthorchis viverrini", "ORGANISM", 241, 263], ["SE Asia", "ORGANISM", 276, 283], ["Opisthorchis felineus", "ORGANISM", 289, 310], ["Clonorchis sinensis", "SPECIES", 202, 221], ["Opisthorchis viverrini", "SPECIES", 241, 263], ["Opisthorchis felineus", "SPECIES", 289, 310], ["Clonorchis sinensis", "SPECIES", 202, 221], ["Opisthorchis viverrini", "SPECIES", 241, 263], ["Opisthorchis felineus", "SPECIES", 289, 310], ["Clonorchiasis", "PROBLEM", 150, 163], ["Opisthorchiasis", "PROBLEM", 168, 183], ["Clonorchis sinensis", "PROBLEM", 202, 221], ["Opisthorchis viverrini", "PROBLEM", 241, 263], ["Opisthorchis felineus", "PROBLEM", 289, 310], ["open defaecation", "PROBLEM", 348, 364], ["vegetation", "PROBLEM", 438, 448], ["Opisthorchiasis", "OBSERVATION", 168, 183], ["Opisthorchis", "ANATOMY", 289, 301], ["small ponds", "OBSERVATION", 414, 425], ["vegetation", "OBSERVATION", 438, 448], ["snail hosts", "OBSERVATION", 464, 475]]], ["There are numerous species of snail that support the infections (Tang et al., 2016) , each of which may be restricted to specific habitats and possess its own set of attributes affected by abiotic and biotic characteristic properties of the water body (Petney et al., 2012) .", [["infections", "DISEASE", 53, 63], ["numerous species of snail", "PROBLEM", 10, 35], ["the infections", "PROBLEM", 49, 63], ["numerous", "OBSERVATION_MODIFIER", 10, 18], ["species", "OBSERVATION", 19, 26], ["infections", "OBSERVATION", 53, 63]]], ["Water temperature is crucial in terms of snail population size and dynamics-e.g., Parafossarulus manchouricus abundance-temperature relationship follows a convex curve, with the highest seasonal abundance associated with temperatures of between 24 and 26\u00b0C, and lowest abundance below 10-13\u00b0C (Chung et al., 1980) .", [["Parafossarulus manchouricus", "ORGANISM", 82, 109], ["Parafossarulus manchouricus", "SPECIES", 82, 109], ["Parafossarulus manchouricus", "SPECIES", 82, 109], ["Parafossarulus manchouricus abundance", "PROBLEM", 82, 119], ["a convex curve", "TEST", 153, 167], ["temperatures", "TEST", 221, 233], ["size", "OBSERVATION_MODIFIER", 58, 62]]], ["The second intermediate host is a freshwater (often a cyprinid) fish or crustacean that predates on the snail host.", [["intermediate host", "OBSERVATION_MODIFIER", 11, 28]]], ["Again, there are multiple species of fish or crustacean involved, depending on location (Tang et al., 2016) .", [["fish", "ORGANISM_SUBDIVISION", 37, 41], ["multiple", "OBSERVATION_MODIFIER", 17, 25], ["species", "OBSERVATION", 26, 33]]], ["The natural history of cyprinid fish, which are poikilothermic, is also affected by water temperature and hence likely to be affected by climate change (Ficke et al., 2007) .", [["cyprinid", "ORGANISM", 23, 31], ["fish", "ORGANISM_SUBDIVISION", 32, 36], ["cyprinid fish", "PROBLEM", 23, 36], ["cyprinid fish", "OBSERVATION", 23, 36], ["water temperature", "OBSERVATION_MODIFIER", 84, 101]]], ["Research into the effects of climate-induced changes suggest that population turnover (Buisson et al., 2008) , recruitment into rivers (Nunn et al., 2007) , species range (Comte et al., 2013) , body size and growth rates (Ruiz-Navarro et al., 2016) are all likely to be affected depending on species and habitats (Buisson and Grenouillet, 2009) .Clonorchiasis and OpisthorchiasisThe natural histories of both miracidia, cercariae and metacercariae of Clonorchis and Opisthoricis, and their relationship with snail and fish intermediate hosts, are acutely affected by the abiotic properties of the water bodies they inhabit.", [["body", "ANATOMY", 194, 198], ["Clonorchiasis", "DISEASE", 346, 359], ["Opisthorchiasis", "DISEASE", 364, 379], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["miracidia", "ORGANISM", 409, 418], ["cercariae", "ORGANISM", 420, 429], ["metacercariae of Clonorchis", "ORGANISM", 434, 461], ["Opisthoricis", "GENE_OR_GENE_PRODUCT", 466, 478], ["species range", "TEST", 157, 170], ["body size", "TEST", 194, 203], ["growth rates", "TEST", 208, 220], ["Ruiz", "TEST", 222, 226], ["Clonorchiasis", "PROBLEM", 346, 359], ["Opisthorchiasis", "PROBLEM", 364, 379], ["size", "OBSERVATION_MODIFIER", 199, 203], ["Opisthorchiasis", "OBSERVATION", 364, 379], ["Clonorchis", "OBSERVATION", 451, 461]]], ["For example, field and experimental observations of the Opisthorchis intermediate host, Bithynia siamensis goniomphalos, indicate that infection rate by miracidia of O. viverrini is minimised at water temperature of 16\u00b0C, maximised at 30-34\u00b0C, declines rapidly thereafter, and is more common in relatively small snails (Echaubard et al., 2017; Prasopdee et al., 2015) .", [["infection", "DISEASE", 135, 144], ["Opisthorchis", "ORGANISM", 56, 68], ["Bithynia siamensis goniomphalos", "ORGANISM", 88, 119], ["miracidia", "ORGANISM", 153, 162], ["O. viverrini", "ORGANISM", 166, 178], ["Bithynia siamensis goniomphalos", "SPECIES", 88, 119], ["O. viverrini", "SPECIES", 166, 178], ["Bithynia siamensis goniomphalos", "SPECIES", 88, 119], ["O. viverrini", "SPECIES", 166, 178], ["Bithynia siamensis goniomphalos", "PROBLEM", 88, 119], ["infection rate", "PROBLEM", 135, 149], ["Opisthorchis", "ANATOMY", 56, 68], ["infection", "OBSERVATION", 135, 144], ["more common", "OBSERVATION_MODIFIER", 280, 291]]], ["The convex nature of infectivity and survival of both snails and free-living parasites indicates that water bodies which exceed the upper temperature threshold over the coming years may become unsuitable habitats, whereas those water bodies that move from below 16\u00b0C towards 20\u00b0C or higher may become more suitable.Clonorchiasis and OpisthorchiasisEvidence of the downstream effect of warmer waters on transmission of the infections to humans is very limited, but one published study on Clonorchis from Guangzou city, China suggests a link (Li et al., 2014) .", [["Clonorchiasis", "DISEASE", 315, 328], ["infections", "DISEASE", 422, 432], ["C", "GENE_OR_GENE_PRODUCT", 278, 279], ["humans", "ORGANISM", 436, 442], ["Clonorchis", "ORGANISM", 487, 497], ["humans", "SPECIES", 436, 442], ["humans", "SPECIES", 436, 442], ["infectivity", "PROBLEM", 21, 32], ["both snails", "PROBLEM", 49, 60], ["free-living parasites", "PROBLEM", 65, 86], ["water bodies", "PROBLEM", 102, 114], ["the upper temperature threshold", "PROBLEM", 128, 159], ["Clonorchiasis", "PROBLEM", 315, 328], ["Opisthorchiasis", "PROBLEM", 333, 348], ["warmer waters", "TREATMENT", 385, 398], ["the infections", "PROBLEM", 418, 432], ["convex", "OBSERVATION_MODIFIER", 4, 10], ["infectivity", "OBSERVATION_MODIFIER", 21, 32], ["upper temperature", "OBSERVATION_MODIFIER", 132, 149], ["Opisthorchiasis", "OBSERVATION", 333, 348], ["downstream", "OBSERVATION_MODIFIER", 364, 374], ["effect", "OBSERVATION_MODIFIER", 375, 381], ["infections", "OBSERVATION", 422, 432]]], ["In that study, annual average 1\u00b0C increase was associated with an average 1.18% rise in monthly incidence from 2006 to 2012, a 1 mm change in rainfall was associated with 0.03% increase in incidence, and 1% rise in RH was associated with a 1.5% decrease in incidence.", [["a 1 mm change in rainfall", "PROBLEM", 125, 150], ["a 1.5% decrease in incidence", "PROBLEM", 238, 266], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["rise", "OBSERVATION_MODIFIER", 80, 84], ["increase", "OBSERVATION_MODIFIER", 177, 185]]], ["In contrast, projected impacts over several decades have been explored for Opisthorchis, specifically in Thailand (Suwannatrai et al., 2017) , where Maxent was used to model a potential future hazard distribution, using IPPC A2 scenarios to 2070.", [["Opisthorchis", "ORGANISM", 75, 87], ["Opisthorchis", "PROBLEM", 75, 87], ["Opisthorchis", "OBSERVATION", 75, 87]]], ["The conclusion from that study was that northern regions may become unsuitable for transmission.", [["that study", "TEST", 20, 30]]], ["The parasite life cycle is similar to other food-borne trematodes and schistosoma with one main difference.", [["schistosoma", "DISEASE", 70, 81], ["The parasite life cycle", "TREATMENT", 0, 23], ["borne trematodes", "PROBLEM", 49, 65], ["schistosoma", "PROBLEM", 70, 81], ["parasite", "OBSERVATION_MODIFIER", 4, 12], ["borne trematodes", "OBSERVATION", 49, 65], ["schistosoma", "OBSERVATION", 70, 81], ["one main", "OBSERVATION_MODIFIER", 87, 95]]], ["The snail intermediate hosts are air-breathing freshwater mollusks of the 'fossarine' group (family Lymnaeidae), most importantly Galba (formerly Lymnaea) trunculata, from which metacercaria emerge onto vegetation.", [["Galba", "ORGANISM", 130, 135], ["Lymnaea) trunculata", "ORGANISM", 146, 165], ["Lymnaea) trunculata", "SPECIES", 146, 165], ["Lymnaea) trunculata", "SPECIES", 146, 165], ["intermediate hosts", "OBSERVATION", 10, 28]]], ["This vegetation is ingested by the definitive host, which may include humans.", [["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76], ["This vegetation", "PROBLEM", 0, 15], ["vegetation", "OBSERVATION", 5, 15]]], ["The snails typically inhabit slow-moving or standing water bodies, often within marshy or muddy habitats, where they feed and lay eggs.", [["inhabit", "OBSERVATION_MODIFIER", 21, 28], ["slow", "OBSERVATION_MODIFIER", 29, 33]]], ["They can aestivate by burying into the substrate to survive drought conditions, with the period of aestivation decreasing with altitude (Goumghar et al., 2001) .Clonorchiasis and OpisthorchiasisThe global spread of the infection has been attributed to anthropocentric activities, related to domestication and transport of livestock, stretching back thousands of years (Mas-Coma et al., 2009 (Rapsch et al., 2008) .", [["Clonorchiasis", "DISEASE", 161, 174], ["Opisthorchiasis", "DISEASE", 179, 194], ["infection", "DISEASE", 219, 228], ["Clonorchiasis", "PROBLEM", 161, 174], ["Opisthorchiasis", "PROBLEM", 179, 194], ["the infection", "PROBLEM", 215, 228], ["anthropocentric activities", "PROBLEM", 252, 278], ["decreasing", "OBSERVATION_MODIFIER", 111, 121], ["Opisthorchiasis", "OBSERVATION", 179, 194], ["global", "OBSERVATION_MODIFIER", 198, 204], ["spread", "OBSERVATION_MODIFIER", 205, 211], ["infection", "OBSERVATION", 219, 228]]], ["Adaptations of snails and parasite to conditions associated with high altitude ($4000 m) have also been observed (Mas-Coma et al., 2001) .", [["snails", "OBSERVATION", 15, 21]]], ["Temperature above 30\u00b0C is associated with rapid reduction in egg survival, with the 'lethal' temperature depending on species (Harris and Charleston, 1977) .Clonorchiasis and OpisthorchiasisMiracidial development and hatching have been observed to depend on temperature of the water body, with early studies indicating that no development was possible at temperatures lower than 9\u00b0C or above 30\u00b0C (Kendall) .", [["egg", "ANATOMY", 61, 64], ["body", "ANATOMY", 283, 287], ["Clonorchiasis", "DISEASE", 157, 170], ["C", "GENE_OR_GENE_PRODUCT", 21, 22], ["egg", "ORGANISM_SUBDIVISION", 61, 64], ["Temperature", "TEST", 0, 11], ["rapid reduction in egg survival", "PROBLEM", 42, 73], ["the 'lethal' temperature", "PROBLEM", 80, 104], ["Clonorchiasis", "PROBLEM", 157, 170], ["OpisthorchiasisMiracidial development", "PROBLEM", 175, 212], ["early studies", "TEST", 294, 307], ["associated with", "UNCERTAINTY", 26, 41], ["rapid", "OBSERVATION_MODIFIER", 42, 47], ["reduction", "OBSERVATION_MODIFIER", 48, 57], ["egg survival", "OBSERVATION", 61, 73], ["Opisthorchiasis", "OBSERVATION", 175, 190]]], ["Cercarial shedding is also temperature dependent, with minimal shedding at 9\u00b0C (Kendall and McCullough, 1951) .", [["Cercarial", "ANATOMY", 0, 9], ["Cercarial shedding", "PROBLEM", 0, 18], ["temperature dependent", "PROBLEM", 27, 48], ["minimal shedding", "PROBLEM", 55, 71], ["temperature dependent", "OBSERVATION_MODIFIER", 27, 48], ["minimal", "OBSERVATION_MODIFIER", 55, 62]]], ["There is some disagreement over the optimal temperature.", [["some", "OBSERVATION_MODIFIER", 9, 13], ["disagreement", "OBSERVATION", 14, 26]]], ["The studies of Kendall and McCullough (1951) suggested ongoing shedding at 26\u00b0C. Subsequent observations have suggested not just that 20\u00b0C may be optimal, but also that the magnitude of the shedding may depend on susceptibility of the snail species and the degree of diurnal variation in temperature (Rondelaud et al., 2013) .Clonorchiasis and OpisthorchiasisAs a zoonotic infection affecting livestock of economic importance, Fasciola has received relatively more attention, in terms of environmental change research, than the other food-borne infections.", [["Clonorchiasis", "DISEASE", 326, 339], ["OpisthorchiasisAs", "CHEMICAL", 344, 361], ["zoonotic infection", "DISEASE", 364, 382], ["infections", "DISEASE", 545, 555], ["C", "GENE_OR_GENE_PRODUCT", 137, 138], ["The studies", "TEST", 0, 11], ["the shedding", "PROBLEM", 186, 198], ["the snail species", "PROBLEM", 231, 248], ["diurnal variation in temperature", "PROBLEM", 267, 299], ["Clonorchiasis", "PROBLEM", 326, 339], ["OpisthorchiasisAs", "TREATMENT", 344, 361], ["a zoonotic infection", "PROBLEM", 362, 382], ["borne infections", "PROBLEM", 539, 555], ["may be", "UNCERTAINTY", 139, 145], ["snail species", "OBSERVATION", 235, 248], ["diurnal variation", "OBSERVATION", 267, 284], ["zoonotic", "OBSERVATION_MODIFIER", 364, 372], ["infection", "OBSERVATION", 373, 382], ["infections", "OBSERVATION", 545, 555]]], ["It is known, for example, that contemporary weather patterns shape exposure among cattle in the European context, with the number of relatively warm days per annum, combined with relatively high average levels of within-farm precipitation (excluding within-year spikes) are positively associated with milkseropositivity (Charlier et al., 2016; Munita et al., 2016) .", [["cattle", "SPECIES", 82, 88], ["cattle", "SPECIES", 82, 88], ["relatively", "OBSERVATION_MODIFIER", 133, 143], ["warm", "OBSERVATION", 144, 148]]], ["Within-country spatial clustering is thereby associated with spatial variation in these meteorological factors (Selemetas and de Waal, 2015) .", [["spatial variation", "PROBLEM", 61, 78], ["spatial variation", "OBSERVATION", 61, 78]]], ["Enhanced vegetation (assessed remotely) has also been associated with increased risk of transmission in areas as regionally distant as Colombia (Valencia-L\u00f3pez et al., 2012) and Pakistan (Afshan et al., 2014) .Clonorchiasis and OpisthorchiasisSoil type, slope and treatment, along with the characteristics of the underlying water budget contribute significantly to determining spatial distribution.", [["Clonorchiasis", "DISEASE", 210, 223], ["Enhanced vegetation", "PROBLEM", 0, 19], ["transmission in areas", "PROBLEM", 88, 109], ["Clonorchiasis", "PROBLEM", 210, 223], ["OpisthorchiasisSoil type", "TREATMENT", 228, 252], ["treatment", "TREATMENT", 264, 273], ["vegetation", "OBSERVATION", 9, 19], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["Opisthorchiasis", "OBSERVATION", 228, 243], ["water budget", "OBSERVATION", 324, 336], ["spatial distribution", "OBSERVATION", 377, 397]]], ["In the tropical US context, hydric soils with poor drainage (Malone et al., 1992) or chenier soil with accumulated water that seeps out to provide a habitat for snails (Zukowski et al., 1993) is positively associated with exposure.", [["poor drainage", "PROBLEM", 46, 59]]], ["In the tropical African context, arid and/or acidic soils (<5.5 pH) are negatively associated with endemicity (Malone et al., 1998) .Clonorchiasis and OpisthorchiasisExposure within human communities is also associated with seasonal variation, as observed in Pakistan (Qureshi et al., 2016) .", [["Clonorchiasis", "DISEASE", 133, 146], ["Opisthorchiasis", "CHEMICAL", 151, 166], ["human", "ORGANISM", 182, 187], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["arid and/or acidic soils", "PROBLEM", 33, 57], ["Clonorchiasis", "PROBLEM", 133, 146], ["OpisthorchiasisExposure", "PROBLEM", 151, 174], ["seasonal variation", "PROBLEM", 224, 242], ["Opisthorchiasis", "OBSERVATION", 151, 166], ["seasonal variation", "OBSERVATION", 224, 242]]], ["Historic climate data have been used to map risk of human fascioliasis in Iran (Halimi et al., 2015) , with conclusions on the role of rainfall, temperature and vegetation that align with studies of the parasite in animal populations.Clonorchiasis and OpisthorchiasisThe wide window of available temperatures and habitat characteristics, as well as anthropocentric activities such as global travelling, highlights the potential for continued transmission of Fasciola infections under many climate change scenarios.", [["fascioliasis", "DISEASE", 58, 70], ["Clonorchiasis", "DISEASE", 234, 247], ["Opisthorchiasis", "DISEASE", 252, 267], ["Fasciola infections", "DISEASE", 458, 477], ["human", "ORGANISM", 52, 57], ["Fasciola", "ORGANISM", 458, 466], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["Historic climate data", "TEST", 0, 21], ["human fascioliasis", "PROBLEM", 52, 70], ["vegetation", "PROBLEM", 161, 171], ["Clonorchiasis", "PROBLEM", 234, 247], ["Opisthorchiasis", "PROBLEM", 252, 267], ["Fasciola infections", "PROBLEM", 458, 477], ["fascioliasis", "OBSERVATION", 58, 70], ["vegetation", "OBSERVATION", 161, 171], ["Opisthorchiasis", "OBSERVATION", 252, 267], ["wide window", "OBSERVATION_MODIFIER", 271, 282], ["Fasciola infections", "OBSERVATION", 458, 477]]], ["At the time of writing, the majority of literature related to environmental change consisted of articles as described earlier, mapping spatial heterogeneity in exposure or levels of infection through analysis of environmental covariates.", [["infection", "DISEASE", 182, 191], ["environmental change", "PROBLEM", 62, 82], ["infection", "PROBLEM", 182, 191], ["infection", "OBSERVATION", 182, 191]]], ["These include modelling snail habitat suitability in Zimbabwe up to 2099 using the SRES A1B scenario (Pedersen et al., 2014) ; modelling decadal exposure up to 2089 in the United Kingdom based on the SRES 1B scenario (Fox et al., 2011) and modelling infection risk in New Zealand up to 2090 using SRES A1B, A2 and B1 scenarios (Haydock et al., 2016) .ParagonimusThis food-borne parasite consists of over 40 species that infect a wide range of intermediate and definitive hosts (Blair et al., 1999) .", [["infection", "DISEASE", 250, 259], ["modelling infection risk", "PROBLEM", 240, 264], ["borne parasite", "PROBLEM", 372, 386], ["infection", "OBSERVATION", 250, 259]]], ["Nine species or species-complexes are known to affect humans (Blair, 2014; Chai, 2013) .", [["humans", "ORGANISM", 54, 60], ["humans", "SPECIES", 54, 60], ["humans", "SPECIES", 54, 60]]], ["The main focus of infection with species of the Paragonimus westermani complex is SE Asia, where multiple individual species within the complex infect intermediate hosts with low specificity (Doanh et al., 2013) .", [["infection", "DISEASE", 18, 27], ["SE", "DISEASE", 82, 84], ["Paragonimus westermani", "ORGANISM", 48, 70], ["SE Asia", "ORGANISM", 82, 89], ["Paragonimus westermani", "SPECIES", 48, 70], ["Paragonimus westermani", "SPECIES", 48, 70], ["infection", "PROBLEM", 18, 27], ["the Paragonimus westermani complex", "PROBLEM", 44, 78], ["multiple individual species", "PROBLEM", 97, 124], ["main", "OBSERVATION_MODIFIER", 4, 8], ["focus", "OBSERVATION_MODIFIER", 9, 14], ["infection", "OBSERVATION", 18, 27], ["Paragonimus", "ANATOMY", 48, 59], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["individual", "OBSERVATION_MODIFIER", 106, 116], ["species", "OBSERVATION_MODIFIER", 117, 124], ["complex", "OBSERVATION_MODIFIER", 136, 143], ["infect", "OBSERVATION_MODIFIER", 144, 150], ["intermediate hosts", "OBSERVATION", 151, 169]]], ["Other foci, consisting of highly distinct parasite species are located in West Africa (Paragonimus africanus and Paragonimus uterobilateralis) and (sub)-tropical parts of North, Central and South America (Paragonimus mexicanus and Paragonimus kellicotti).ParagonimusIn common with the other food-borne trematodes, the climate-sensitive stages of the Paragonimus life cycle are those contained in the water phase.", [["foci", "ANATOMY", 6, 10], ["ParagonimusIn", "CHEMICAL", 255, 268], ["West Africa", "ORGANISM", 74, 85], ["Paragonimus africanus", "ORGANISM", 87, 108], ["Paragonimus uterobilateralis", "ORGANISM", 113, 141], ["Paragonimus mexicanus", "ORGANISM", 205, 226], ["Paragonimus kellicotti", "ORGANISM", 231, 253], ["Paragonimus africanus", "SPECIES", 87, 108], ["Paragonimus uterobilateralis", "SPECIES", 113, 141], ["Paragonimus mexicanus", "SPECIES", 205, 226], ["Paragonimus kellicotti", "SPECIES", 231, 253], ["Paragonimus africanus", "SPECIES", 87, 108], ["Paragonimus uterobilateralis", "SPECIES", 113, 141], ["Paragonimus mexicanus", "SPECIES", 205, 226], ["Paragonimus kellicotti", "SPECIES", 231, 253], ["Other foci", "PROBLEM", 0, 10], ["highly distinct parasite species", "PROBLEM", 26, 58], ["ParagonimusIn", "TREATMENT", 255, 268], ["foci", "OBSERVATION", 6, 10], ["highly", "OBSERVATION_MODIFIER", 26, 32], ["distinct", "OBSERVATION_MODIFIER", 33, 41], ["parasite species", "OBSERVATION", 42, 58], ["Paragonimus", "ANATOMY", 87, 98], ["Paragonimus uterobilateralis", "ANATOMY", 113, 141], ["North", "ANATOMY_MODIFIER", 171, 176], ["Central", "ANATOMY_MODIFIER", 178, 185], ["Paragonimus", "ANATOMY", 205, 216], ["Paragonimus kellicotti", "ANATOMY", 231, 253]]], ["The second intermediate hosts are decapod crustaceans consisting drawn from several genera, depending on location and including Cambraoides crayfish (Kim et al., 2009) , the freshwater crabs Liberonautes and Sudanonautes (Aka et al., 2008) and Tehuana (Vargas-Arzola et al., 2014) .", [["Cambraoides crayfish", "ORGANISM", 128, 148], ["crabs", "ORGANISM", 185, 190], ["Cambraoides crayfish", "SPECIES", 128, 148], ["decapod crustaceans", "TREATMENT", 34, 53], ["the freshwater crabs Liberonautes", "TREATMENT", 170, 203]]], ["The list of susceptible hosts in these and other papers point to the extreme generalisation of this parasite, and thus indicate a major challenge to modelling future trends in transmission.ParagonimusIn the absence of available literature on climate change and paragonimiasis per se, it is nonetheless plausible to suggest that the contemporaneous distribution of Paragonimus species is shaped by a wide range of factors as described in previous sections.", [["sections", "ANATOMY", 446, 454], ["paragonimiasis", "DISEASE", 261, 275], ["Paragonimus species", "ORGANISM", 364, 383], ["paragonimiasis", "PROBLEM", 261, 275], ["Paragonimus species", "PROBLEM", 364, 383], ["paragonimiasis", "OBSERVATION", 261, 275], ["Paragonimus species", "OBSERVATION", 364, 383], ["shaped", "OBSERVATION_MODIFIER", 387, 393], ["wide", "OBSERVATION_MODIFIER", 399, 403]]], ["Future transmission of the infection may also be affected by climate-related changes to local ecosystems, food webs, zoonotic reservoirs, farming practices, consumption patterns, human behaviours related to sanitation and translocation of humans, intermediate and zoonotic hosts.", [["infection", "DISEASE", 27, 36], ["zoonotic reservoirs", "DISEASE", 117, 136], ["human", "ORGANISM", 179, 184], ["humans", "ORGANISM", 239, 245], ["human", "SPECIES", 179, 184], ["humans", "SPECIES", 239, 245], ["human", "SPECIES", 179, 184], ["humans", "SPECIES", 239, 245], ["the infection", "PROBLEM", 23, 36], ["human behaviours", "PROBLEM", 179, 195], ["translocation of humans", "PROBLEM", 222, 245], ["infection", "OBSERVATION", 27, 36]]], ["Long-distance translocation may have occurred to bring the parasite into South Africa, for example (Appleton, 2014) .Guinea WormAlthough scheduled for eradication due to the low number of recent cases, guinea worm may reemerge as a public health problem in the future due to the recent observations of infections in various animal hosts including dogs, fish and frogs (Eberhard et al., 2016; Ruiz-Tiben et al., 2014) .", [["infections", "DISEASE", 302, 312], ["guinea worm", "ORGANISM", 202, 213], ["dogs", "ORGANISM", 347, 351], ["fish", "ORGANISM", 353, 357], ["frogs", "ORGANISM_SUBDIVISION", 362, 367], ["guinea worm", "SPECIES", 202, 213], ["dogs", "SPECIES", 347, 351], ["Long-distance translocation", "PROBLEM", 0, 27], ["eradication", "TREATMENT", 151, 162], ["infections", "PROBLEM", 302, 312], ["infections", "OBSERVATION", 302, 312]]], ["The climatesensitive stages of Dracuncula are the L1 larvae released by the adult female worm, along with the L2 and L3 larvae contained within the poikilothermic copepods of the Metacyclops, Mesocylops and Thermocylops genera that act as the intermediate host.Guinea WormThere were no published papers available on climate change and guinea worm at the time of writing.", [["Dracuncula", "GENE_OR_GENE_PRODUCT", 31, 41], ["female worm", "ORGANISM", 82, 93], ["Metacyclops", "GENE_OR_GENE_PRODUCT", 179, 190], ["Mesocylops", "GENE_OR_GENE_PRODUCT", 192, 202], ["Thermocylops", "GENE_OR_GENE_PRODUCT", 207, 219], ["guinea worm", "ORGANISM", 335, 346], ["guinea worm", "SPECIES", 335, 346], ["Dracuncula", "PROBLEM", 31, 41], ["the L2 and L3 larvae", "TREATMENT", 106, 126], ["the Metacyclops", "TREATMENT", 175, 190], ["Mesocylops", "TREATMENT", 192, 202], ["Thermocylops genera", "TREATMENT", 207, 226], ["Dracuncula", "OBSERVATION", 31, 41], ["L1 larvae", "ANATOMY", 50, 59], ["L2", "ANATOMY", 110, 112], ["L3 larvae", "ANATOMY", 117, 126]]], ["Historically, guinea worm infections are known to occur seasonally (Bloch and Simonsen, 1998) , with peak infection tied to rainy seasons in countries at the southern fringe of the Sahara desert, and tied to dry seasons in those countries close to the Gulf of Guinea (reviewed by Ruiz-Tiben and Hopkins, 2006) .", [["guinea worm infections", "DISEASE", 14, 36], ["infection", "DISEASE", 106, 115], ["guinea worm", "ORGANISM", 14, 25], ["guinea worm", "SPECIES", 14, 25], ["guinea worm", "SPECIES", 14, 25], ["guinea worm infections", "PROBLEM", 14, 36], ["peak infection", "PROBLEM", 101, 115], ["infection", "OBSERVATION", 106, 115]]], ["In both regions, this has been attributed to the presence of stagnant freshwater used for drinking purposes rather than the population biology of the copepods or changes in ambient water temperature.Guinea WormThe thermal tolerance of warm-water copepods was established several decades ago.", [["Guinea Worm", "SPECIES", 199, 210], ["stagnant freshwater", "TREATMENT", 61, 80], ["warm-water copepods", "TREATMENT", 235, 254], ["both", "ANATOMY_MODIFIER", 3, 7], ["regions", "ANATOMY_MODIFIER", 8, 15], ["stagnant", "OBSERVATION_MODIFIER", 61, 69], ["freshwater", "OBSERVATION", 70, 80], ["thermal", "OBSERVATION_MODIFIER", 214, 221], ["tolerance", "OBSERVATION_MODIFIER", 222, 231]]], ["For example, the eggs of Thermocyclops spp. develop at a linear rate from 15 to 30\u00b0C, after which point there is a rapid downturn until 40\u00b0C, whereupon development ceases (Burgis, 1970) .", [["eggs", "ANATOMY", 17, 21], ["Thermocyclops spp", "ORGANISM", 25, 42], ["Thermocyclops spp", "PROBLEM", 25, 42], ["a linear rate", "TEST", 55, 68], ["a rapid downturn", "PROBLEM", 113, 129]]], ["Studies on the phenology of warm-water copepods suggest that increased temperatures can lead to increased fecundity and thereby increase population size at specific times of year (Gerten and Adrian, 2002; Wagner and Adrian, 2011) .", [["water copepods", "TREATMENT", 33, 47], ["increased temperatures", "PROBLEM", 61, 83], ["increased fecundity", "PROBLEM", 96, 115], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["fecundity", "OBSERVATION", 106, 115], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["population", "OBSERVATION_MODIFIER", 137, 147], ["size", "OBSERVATION_MODIFIER", 148, 152]]], ["Concern has been raised that the frequency of diurnal changes in the physiochemical environment could overwhelm the adaptability of copepods (Alm en et al., 2014) , and freshwater scarcity (see above) may also play a role in determining future abundance.Guinea WormGiven that cases among humans are an historically low point, but that copepod populations may be put under stress by environmental change, it is challenging to speculate how climate change will affect future Dracuncula transmission.", [["humans", "ORGANISM", 288, 294], ["Dracuncula", "SIMPLE_CHEMICAL", 473, 483], ["humans", "SPECIES", 288, 294], ["humans", "SPECIES", 288, 294], ["diurnal changes", "PROBLEM", 46, 61], ["copepod populations", "PROBLEM", 335, 354]]], ["History tells us that reduced efforts at controlling parasites can cause increases in transmission of parasites previously controlled (Ekwanzala et al., 1996) .", [["transmission of parasites", "PROBLEM", 86, 111], ["increases", "OBSERVATION_MODIFIER", 73, 82]]], ["This will need to be accompanied by continued awareness of the potential dangers of drinking copepodinfested water to ensure sustainable interruption of the parasite life cycle.EchinococcosisKey to understanding how climate change might affect the distribution of Echinococcus spp. in the future is a detailed understanding of all climatesensitive stages of the life cycle.", [["Echinococcus spp", "ORGANISM", 264, 280], ["the parasite life cycle", "TREATMENT", 153, 176], ["Echinococcus spp", "PROBLEM", 264, 280], ["Echinococcus spp", "OBSERVATION", 264, 280]]], ["The life cycle of Echinococcus spp. involves homeotherm mammals (including humans).", [["Echinococcus spp", "ORGANISM", 18, 34], ["humans", "ORGANISM", 75, 81], ["Echinococcus spp", "SPECIES", 18, 34], ["humans", "SPECIES", 75, 81], ["Echinococcus spp", "SPECIES", 18, 34], ["humans", "SPECIES", 75, 81], ["Echinococcus spp", "PROBLEM", 18, 34], ["Echinococcus spp", "OBSERVATION", 18, 34]]], ["Only one life stage-the eggs deposited with faecal matter from the definitive host-is essentially poikilothermic.", [["eggs", "ANATOMY", 24, 28], ["faecal matter", "ANATOMY", 44, 57], ["eggs", "ORGANISM_SUBDIVISION", 24, 28], ["faecal", "ORGANISM_SUBDIVISION", 44, 50], ["the eggs", "PROBLEM", 20, 28], ["faecal matter", "PROBLEM", 44, 57], ["essentially poikilothermic", "PROBLEM", 86, 112], ["faecal matter", "OBSERVATION_MODIFIER", 44, 57], ["essentially", "OBSERVATION_MODIFIER", 86, 97], ["poikilothermic", "OBSERVATION", 98, 112]]], ["Typically, these eggs are deposited onto soil through open defecation of dogs and other canidae.", [["eggs", "ANATOMY", 17, 21], ["dogs", "ORGANISM", 73, 77], ["dogs", "SPECIES", 73, 77], ["open defecation of dogs", "TREATMENT", 54, 77]]], ["Eggs are therefore most likely to be directly affected by abiotic or biotic factors that affect the soil.EchinococcosisEchinococcus multilocularis is confined to northern latitudes and its eggs can survive freezing temperatures, with an optimal temperature range of 0-10\u00b0C and are viable only for a few hours at temperatures >25\u00b0C (Veit et al., 1995) .", [["Eggs", "ANATOMY", 0, 4], ["eggs", "ANATOMY", 189, 193], ["EchinococcosisEchinococcus multilocularis", "DISEASE", 105, 146], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["Echinococcosis", "ORGANISM", 105, 119], ["Echinococcus multilocularis", "ORGANISM", 119, 146], ["C", "GENE_OR_GENE_PRODUCT", 271, 272], ["Echinococcus multilocularis", "SPECIES", 119, 146], ["Echinococcus multilocularis", "SPECIES", 119, 146], ["Eggs", "TREATMENT", 0, 4], ["abiotic or biotic factors", "PROBLEM", 58, 83], ["EchinococcosisEchinococcus multilocularis", "PROBLEM", 105, 146], ["an optimal temperature range", "TEST", 234, 262], ["most likely", "UNCERTAINTY", 19, 30], ["biotic factors", "OBSERVATION", 69, 83]]], ["Echinococcus granulosus is responsible for the majority of morbidity in humans and has a wider distribution including tropical and temperate regions (McManus et al., 2003) .", [["Echinococcus granulosus", "DISEASE", 0, 23], ["Echinococcus granulosus", "ORGANISM", 0, 23], ["humans", "ORGANISM", 72, 78], ["Echinococcus granulosus", "SPECIES", 0, 23], ["humans", "SPECIES", 72, 78], ["Echinococcus granulosus", "SPECIES", 0, 23], ["humans", "SPECIES", 72, 78], ["Echinococcus granulosus", "PROBLEM", 0, 23], ["tropical and temperate regions", "PROBLEM", 118, 148], ["granulosus", "OBSERVATION", 13, 23], ["morbidity", "OBSERVATION", 59, 68], ["wider", "OBSERVATION_MODIFIER", 89, 94], ["distribution", "OBSERVATION_MODIFIER", 95, 107], ["tropical", "OBSERVATION_MODIFIER", 118, 126]]], ["It is clear from this latter fact alone that the eggs of E. granulosus must have historically adapted to a wide range of temperatures above 0\u00b0C. This has been reported by a very small number of studies at the time of writing.", [["E. granulosus", "ORGANISM", 57, 70], ["E. granulosus", "SPECIES", 57, 70], ["E. granulosus", "SPECIES", 57, 70], ["E. granulosus", "PROBLEM", 57, 70], ["clear", "OBSERVATION", 6, 11], ["granulosus", "OBSERVATION", 60, 70]]], ["Wachira et al. (1991) tested the viability of E. granulosus eggs under various conditions in a semiarid region of Kenya.", [["eggs", "ANATOMY", 60, 64], ["E. granulosus", "ORGANISM", 46, 59], ["eggs", "ORGANISM", 60, 64], ["E. granulosus", "SPECIES", 46, 59], ["E. granulosus", "SPECIES", 46, 59], ["E. granulosus eggs", "TREATMENT", 46, 64]]], ["After placing eggs in suspension, samples were positioned on open ground, near a house or near a water hole.", [["eggs", "ANATOMY", 14, 18], ["samples", "ANATOMY", 34, 41], ["eggs in suspension", "TREATMENT", 14, 32], ["a water hole", "TREATMENT", 95, 107], ["water hole", "OBSERVATION", 97, 107]]], ["Only the eggs near the water hole were observed to be viable after 10 days, where the average temperature was approximately 29\u00b0C. Most recently, Thevenet et al. (2005) observed that eggs of the parasite kept outdoors on deposited stool samples from canines were viable after 41 months exposure to the elements in an arid region of Pategonia.", [["eggs", "ANATOMY", 9, 13], ["eggs", "ANATOMY", 182, 186], ["stool samples", "ANATOMY", 230, 243], ["eggs", "ORGAN", 9, 13], ["stool samples", "ORGANISM_SUBSTANCE", 230, 243], ["canines", "ORGAN", 249, 256], ["the eggs near the water hole", "TREATMENT", 5, 33], ["the average temperature", "TEST", 82, 105], ["deposited stool samples", "TEST", 220, 243], ["Pategonia", "PROBLEM", 331, 340], ["water hole", "OBSERVATION", 23, 33], ["Pategonia", "OBSERVATION", 331, 340]]], ["During the exposure period, the eggs were subject to a temperature variation of \u00c03 to +37\u00b0C and low rainfall (<300 mm per annum).", [["eggs", "ANATOMY", 32, 36], ["a temperature variation", "TEST", 53, 76], ["C and low rainfall", "PROBLEM", 90, 108], ["low", "OBSERVATION_MODIFIER", 96, 99], ["rainfall", "OBSERVATION_MODIFIER", 100, 108]]], ["At the end of the exposure period, the eggs were still viable in terms of producing cysts in Texel ovines.", [["eggs", "ANATOMY", 39, 43], ["cysts", "ANATOMY", 84, 89], ["cysts", "DISEASE", 84, 89], ["cysts", "PATHOLOGICAL_FORMATION", 84, 89], ["Texel ovines", "SPECIES", 93, 105], ["the eggs", "PROBLEM", 35, 43], ["cysts in Texel ovines", "PROBLEM", 84, 105], ["cysts", "OBSERVATION", 84, 89]]], ["Together, these studies, combined with a few earlier studies cited by Wachira et al. (1991) , suggest that eggs of E. granulosus may be viable when deposited onto the ground at temperatures not yet reached by more temperate areas.EchinococcosisAt the time of writing, there have been no published studies in terms of modelling the potential future transmission of Echinococcus spp. under specific climate change scenarios.", [["Echinococcus spp", "DISEASE", 364, 380], ["E. granulosus", "ORGANISM", 115, 128], ["Echinococcus spp", "ORGANISM", 364, 380], ["E. granulosus", "SPECIES", 115, 128], ["E. granulosus", "SPECIES", 115, 128], ["Echinococcus spp", "SPECIES", 364, 380], ["these studies", "TEST", 10, 23], ["E. granulosus", "PROBLEM", 115, 128], ["published studies", "TEST", 287, 304], ["Echinococcus spp", "PROBLEM", 364, 380], ["granulosus", "OBSERVATION", 118, 128], ["Echinococcus spp", "OBSERVATION", 364, 380]]], ["Much research has covered the myriad environmental factors that shape the contemporary geographic distribution (Atkinson et al., 2013) .", [["geographic", "OBSERVATION_MODIFIER", 87, 97], ["distribution", "OBSERVATION_MODIFIER", 98, 110]]], ["It is also made clear in that review that there is a lack of evidence on the role of anthropogenic factors.EchinococcosisAnthropogenic changes that are likely to affect the contemporary transmission of Echinococcus are those which modify the habitat, range and/or behaviour of predator and prey animals.", [["Echinococcosis", "DISEASE", 107, 121], ["Echinococcus", "DISEASE", 202, 214], ["Echinococcus", "ORGANISM", 202, 214], ["anthropogenic factors", "PROTEIN", 85, 106], ["anthropogenic factors", "PROBLEM", 85, 106], ["EchinococcosisAnthropogenic changes", "PROBLEM", 107, 142], ["Echinococcus", "PROBLEM", 202, 214], ["Echinococcus", "OBSERVATION", 202, 214]]], ["The modifying effects of climate change on anthropogenic influences presents a further, as yet unexplored, challenge.Taeniasis-CysticercosisCysticercosis is a disease, mainly endemic in low-to-middle income countries (LMICs), which is considered to be responsible for approximately 30% of all epilepsy cases in endemic countries (Ndimubanzi et al., 2010) .", [["Taeniasis-CysticercosisCysticercosis", "DISEASE", 117, 153], ["epilepsy", "DISEASE", 293, 301], ["climate change", "PROBLEM", 25, 39], ["anthropogenic influences", "TREATMENT", 43, 67], ["Taeniasis", "PROBLEM", 117, 126], ["CysticercosisCysticercosis", "PROBLEM", 127, 153], ["a disease", "PROBLEM", 157, 166], ["anthropogenic", "OBSERVATION", 43, 56], ["CysticercosisCysticercosis", "OBSERVATION", 127, 153], ["disease", "OBSERVATION", 159, 166], ["mainly", "OBSERVATION_MODIFIER", 168, 174], ["endemic", "OBSERVATION_MODIFIER", 175, 182], ["low-to-", "OBSERVATION_MODIFIER", 186, 193], ["middle", "ANATOMY_MODIFIER", 193, 199]]], ["The primary risk factor is consumption of pigs infected by Taenia solium.", [["Taenia solium", "DISEASE", 59, 72], ["pigs", "ORGANISM", 42, 46], ["Taenia solium", "ORGANISM", 59, 72], ["pigs", "SPECIES", 42, 46], ["Taenia solium", "SPECIES", 59, 72], ["pigs", "SPECIES", 42, 46], ["Taenia solium", "SPECIES", 59, 72], ["Taenia solium", "PROBLEM", 59, 72]]], ["The WHO updated its map of T. solium distribution in 2015 (Donadeu et al., 2016) , highlighting how the import of infected pigs leads to cases in countries without comprehensive screening protocols.Taeniasis-CysticercosisThe life cycle of Taenia parasites includes a climate-sensitive stage and its future transmission potential may therefore depend partly on how soil phases change in the future.", [["Cysticercosis", "DISEASE", 208, 221], ["Taenia parasites", "DISEASE", 239, 255], ["T. solium", "ORGANISM", 27, 36], ["pigs", "ORGANISM", 123, 127], ["Taenia parasites", "ORGANISM", 239, 255], ["T. solium", "SPECIES", 27, 36], ["pigs", "SPECIES", 123, 127], ["T. solium", "SPECIES", 27, 36], ["comprehensive screening protocols", "TEST", 164, 197], ["Taeniasis", "PROBLEM", 198, 207], ["Cysticercosis", "PROBLEM", 208, 221], ["Taenia parasites", "PROBLEM", 239, 255], ["a climate-sensitive stage", "PROBLEM", 265, 290], ["Cysticercosis", "OBSERVATION", 208, 221], ["Taenia parasites", "OBSERVATION", 239, 255]]], ["This review is therefore restricted to reviewing existing literature that has explored how environmental variables affect the survival and viability of the eggs shed by the definitive hosts.Taeniasis-CysticercosisIn common with other parasites, the majority of work related to the natural history of taenid eggs was comprehensively investigated several decades ago (reviewed Lawson and Gemmell, 1983 ; see also Willis and Herbert, 1984 regarding Taenia multiceps).", [["Taenia multiceps", "DISEASE", 446, 462], ["taenid eggs", "ORGANISM", 300, 311], ["Taenia multiceps", "ORGANISM", 446, 462], ["Taenia multiceps", "SPECIES", 446, 462], ["Taenia multiceps", "SPECIES", 446, 462], ["Taeniasis", "PROBLEM", 190, 199], ["other parasites", "PROBLEM", 228, 243], ["taenid eggs", "PROBLEM", 300, 311], ["parasites", "OBSERVATION", 234, 243]]], ["The aim of these studies was to understand the abiotic and biotic factors that affect the survival of eggs either under in vitro or field conditions, covering a range of species including Taenia pisiformis, Taenia ovis, Taenia hydatigena and T. multiceps.", [["eggs", "ANATOMY", 102, 106], ["Taenia pisiformis", "DISEASE", 188, 205], ["Taenia ovis", "DISEASE", 207, 218], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 102, 106], ["Taenia pisiformis", "ORGANISM", 188, 205], ["Taenia ovis", "ORGANISM", 207, 218], ["Taenia hydatigena", "ORGANISM", 220, 237], ["T. multiceps", "ORGANISM", 242, 254], ["Taenia pisiformis", "SPECIES", 188, 205], ["Taenia ovis", "SPECIES", 207, 218], ["Taenia hydatigena", "SPECIES", 220, 237], ["T. multiceps", "SPECIES", 242, 254], ["Taenia pisiformis", "SPECIES", 188, 205], ["Taenia ovis", "SPECIES", 207, 218], ["Taenia hydatigena", "SPECIES", 220, 237], ["T. multiceps", "SPECIES", 242, 254], ["these studies", "TEST", 11, 24], ["the abiotic and biotic factors", "PROBLEM", 43, 73], ["Taenia pisiformis", "PROBLEM", 188, 205], ["Taenia ovis", "PROBLEM", 207, 218], ["Taenia hydatigena", "PROBLEM", 220, 237]]], ["The in vitro experiments examined the effects of varying temperature and/or humidity or surface moisture on egg survival.", [["surface", "ANATOMY", 88, 95], ["egg", "ANATOMY", 108, 111], ["egg", "ORGANISM_SUBSTANCE", 108, 111], ["varying temperature", "TREATMENT", 49, 68], ["humidity", "TREATMENT", 76, 84], ["surface moisture on egg survival", "TREATMENT", 88, 120]]], ["Field experiments have focused more on the distribution and survival of eggs (e.g. Wachira et al., 1991) and uptake of eggs by animals under controlled conditions.Taeniasis-CysticercosisIn terms of temperature, eggs have recorded to withstand freeing conditions of up to \u00c020\u00b0C without any effect on hatching (Willis and Herbert, 1984) , while surviving for just 4 days at 21\u00b0C (Gemmell, 1977) and for just a few hours, if at all at 37\u00b0C (Coman, 1975; Gemmell, 1977) .", [["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 76], ["uptake of eggs", "PROBLEM", 109, 123], ["Taeniasis", "PROBLEM", 163, 172], ["without", "UNCERTAINTY", 277, 284]]], ["In terms of humidity and surface water, the evidence suggests that conditions of low RH can dramatically affect the survival of eggs.", [["surface", "ANATOMY", 25, 32], ["eggs", "ANATOMY", 128, 132], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 128, 132], ["surface water", "TREATMENT", 25, 38], ["low RH", "PROBLEM", 81, 87]]], ["Laws (1968) reported that only T. hydatigena eggs could survive RH levels below 60%, while Gemmell (1977) observed that a lack of surface moisture reduced hatching to almost 0% after 4 days, irrespective of species and storage temperature.", [["surface", "ANATOMY", 130, 137], ["T. hydatigena eggs", "ORGANISM", 31, 49], ["T. hydatigena", "SPECIES", 31, 44], ["T. hydatigena", "SPECIES", 31, 44], ["T. hydatigena eggs", "PROBLEM", 31, 49], ["RH levels", "TEST", 64, 73], ["surface moisture reduced hatching", "PROBLEM", 130, 163]]], ["Similar observations were made by S\u00e1nchez Thevenet et al. (2017) who again concluded from laboratory studies of T. hydatigena that low RH values are inimical to eggs of this parasite.", [["T. hydatigena", "ORGANISM", 112, 125], ["T. hydatigena", "SPECIES", 112, 125], ["T. hydatigena", "SPECIES", 112, 125], ["laboratory studies", "TEST", 90, 108], ["T. hydatigena", "PROBLEM", 112, 125], ["low RH values", "PROBLEM", 131, 144], ["this parasite", "PROBLEM", 169, 182]]], ["The inferences from all these studies are that dryer environments cause higher rates of mortality, possibly due to the desiccation of the keratin shell leading to shrinkage and increased hydrostatic pressure on the embryo, leading to its demise (Laws, 1968) .Taeniasis-CysticercosisRisks to humans as a result of climate change are currently challenging to estimate.", [["embryo", "ANATOMY", 215, 221], ["keratin", "GENE_OR_GENE_PRODUCT", 138, 145], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 215, 221], ["humans", "ORGANISM", 291, 297], ["humans", "SPECIES", 291, 297], ["humans", "SPECIES", 291, 297], ["the keratin shell", "TREATMENT", 134, 151], ["shrinkage", "PROBLEM", 163, 172], ["increased hydrostatic pressure", "PROBLEM", 177, 207], ["the embryo", "PROBLEM", 211, 221], ["Taeniasis", "PROBLEM", 259, 268], ["possibly due to", "UNCERTAINTY", 99, 114], ["shrinkage", "OBSERVATION_MODIFIER", 163, 172], ["increased", "OBSERVATION_MODIFIER", 177, 186], ["hydrostatic pressure", "OBSERVATION", 187, 207]]], ["There are two routes to infection-either the consumption of infected pork or ingestion of eggs, e.g., by eating food stuffs fertilised with contaminated faeces.", [["faeces", "ANATOMY", 153, 159], ["infection", "DISEASE", 24, 33], ["pork", "ORGANISM_SUBDIVISION", 69, 73], ["faeces", "ORGANISM_SUBDIVISION", 153, 159], ["pork", "SPECIES", 69, 73], ["infection", "PROBLEM", 24, 33], ["infected pork", "PROBLEM", 60, 73], ["ingestion of eggs", "PROBLEM", 77, 94], ["infection", "OBSERVATION", 24, 33], ["infected", "OBSERVATION", 60, 68]]], ["Pigs can be treated and meat can be screened to prevent that particular route of infection (Gabriel et al., 2015) , and there is no a priori reason to expect that would be directly affected by a changing climate.Taeniasis-CysticercosisIt is more likely that changing climate conditions will affect the ingestion of eggs.", [["meat", "ANATOMY", 24, 28], ["infection", "DISEASE", 81, 90], ["Cysticercosis", "DISEASE", 222, 235], ["Pigs", "ORGANISM", 0, 4], ["meat", "ORGANISM_SUBDIVISION", 24, 28], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 315, 319], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["infection", "PROBLEM", 81, 90], ["Taeniasis", "PROBLEM", 212, 221], ["Cysticercosis", "PROBLEM", 222, 235], ["changing climate conditions", "PROBLEM", 258, 285], ["infection", "OBSERVATION", 81, 90], ["Cysticercosis", "OBSERVATION", 222, 235], ["more likely", "UNCERTAINTY", 241, 252]]], ["Changes to the soil phase that supports the eggs may have localised effects depending on a combination of soil temperature and soil moisture.", [["eggs", "ANATOMY", 44, 48], ["soil temperature", "PROBLEM", 106, 122], ["soil moisture", "TREATMENT", 127, 140]]], ["Given the evidence from the studies summarised earlier, it is possible only to speculate that areas where a combination of increased humidity and only moderate increases in temperature may experience a greater percentage of egg survival.", [["egg", "ORGANISM_SUBDIVISION", 224, 227], ["the studies", "TEST", 24, 35], ["increased humidity", "PROBLEM", 123, 141], ["moderate increases in temperature", "PROBLEM", 151, 184], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["humidity", "OBSERVATION_MODIFIER", 133, 141], ["moderate", "OBSERVATION_MODIFIER", 151, 159], ["increases", "OBSERVATION_MODIFIER", 160, 169], ["greater", "OBSERVATION_MODIFIER", 202, 209], ["egg survival", "OBSERVATION", 224, 236]]], ["This may translate into a localised hazard function for modelling purposes, but this function will need to be modified by other risk factors associated with the vulnerability of associated human populations that may or may not alter depending on which climate change scenario is realised.Taeniasis-CysticercosisAnother factor that will need to be considered is the potential for insects to distribute the eggs over extended distances through coming into contact with contaminated faecal matter.", [["eggs", "ANATOMY", 405, 409], ["faecal matter", "ANATOMY", 480, 493], ["Cysticercosis", "DISEASE", 298, 311], ["human", "ORGANISM", 189, 194], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["modelling purposes", "TEST", 56, 74], ["associated human populations", "PROBLEM", 178, 206], ["Taeniasis", "PROBLEM", 288, 297], ["Cysticercosis", "PROBLEM", 298, 311], ["Cysticercosis", "OBSERVATION", 298, 311]]], ["It has been previously suggested that blow flies could distribute eggs (Lawson and Gemmell, 1990 ) but this has not been demonstrated other than experimentally with dead flies being ingested by lambs (Lawson and Gemmell, 1990) .", [["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 66, 70], ["lambs", "ORGANISM", 194, 199], ["lambs", "SPECIES", 194, 199], ["blow flies", "PROBLEM", 38, 48]]], ["More recently, Ammophorus rubripes, a dung beetle, has been implemented as a potential carrier through experiments that demonstrated carriage of viable eggs by the beetles for up to 24 days (Gomez-Puerta et al., 2014) .", [["eggs", "ANATOMY", 152, 156], ["Ammophorus rubripes", "ORGANISM", 15, 34], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 152, 156], ["Ammophorus rubripes", "SPECIES", 15, 34], ["Ammophorus rubripes", "SPECIES", 15, 34]]], ["A broad range of synergistic and competing factors is likely to affect the ecology of any organism capable of dispersing eggs, leading perhaps to localised extinction (Brook et al., 2008) , among other effects related to anthropogenic disruption of established ecosystems (Cable et al., 2017) .CoronovirusesMiddle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS) are two coronaviruses on the list of WHO priority diseases due to the lack of preparedness for future outbreaks.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 307, 351], ["acute respiratory syndrome", "DISEASE", 374, 400], ["SARS", "DISEASE", 402, 406], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 121, 125], ["CoronovirusesMiddle East respiratory syndrome coronavirus", "ORGANISM", 294, 351], ["MERS-CoV", "ORGANISM", 353, 361], ["MERS-CoV", "SPECIES", 353, 361], ["Middle East respiratory syndrome coronavirus", "SPECIES", 307, 351], ["MERS-CoV", "SPECIES", 353, 361], ["Coronoviruses", "PROBLEM", 294, 307], ["Middle East respiratory syndrome", "PROBLEM", 307, 339], ["coronavirus", "PROBLEM", 340, 351], ["severe acute respiratory syndrome", "PROBLEM", 367, 400], ["WHO priority diseases", "PROBLEM", 445, 466], ["broad", "OBSERVATION_MODIFIER", 2, 7], ["anthropogenic disruption", "OBSERVATION", 221, 245], ["Middle", "ANATOMY_MODIFIER", 307, 313], ["respiratory syndrome", "OBSERVATION", 319, 339], ["severe", "OBSERVATION_MODIFIER", 367, 373], ["acute", "OBSERVATION_MODIFIER", 374, 379], ["respiratory syndrome", "OBSERVATION", 380, 400]]], ["Bats are the major suspects in terms of zoonotic origin of both SARS and MERS-CoV (Anthony et al., 2017; Drexler et al., 2014) .CoronovirusesPerson-to-person transmission of aerosolised virus is the predominant risk factor for infection post-spillover.", [["SARS", "DISEASE", 64, 68], ["infection", "DISEASE", 227, 236], ["Bats", "CELL", 0, 4], ["MERS-CoV", "ORGANISM", 73, 81], ["aerosolised virus", "ORGANISM", 174, 191], ["person", "SPECIES", 151, 157], ["MERS-CoV", "SPECIES", 73, 81], ["CoronovirusesPerson", "TREATMENT", 128, 147], ["aerosolised virus", "PROBLEM", 174, 191], ["infection post-spillover", "PROBLEM", 227, 251], ["zoonotic", "OBSERVATION_MODIFIER", 40, 48], ["infection", "OBSERVATION", 227, 236]]], ["As with all other respiratory viruses, a range of environmental factors facilitate or inhibit the transmission, including temperature, precipitation, RH and airflow (reviewed by Pica and Bouvier, 2012) .", [["respiratory viruses", "DISEASE", 18, 37], ["all other respiratory viruses", "PROBLEM", 8, 37], ["respiratory", "ANATOMY", 18, 29], ["viruses", "OBSERVATION", 30, 37], ["airflow", "ANATOMY", 157, 164]]], ["Relatively few investigations have been undertaken on SARS or MERS-CoV specifically.", [["SARS", "DISEASE", 54, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["MERS-CoV", "SPECIES", 62, 70], ["SARS", "PROBLEM", 54, 58]]], ["From the available literature, it is possible to deduce that both SARS and MERS-CoV persistence in the environment decreases at temperatures >20\u00b0C, at a rate dependent on a convex humiditytemperature interaction (Casanova et al., 2010; Chan et al., 2011; van Doremalen et al., 2013) .CoronovirusesAt the time of writing, there were no original research papers available on the potential for climate change to affect transmission.", [["SARS", "DISEASE", 66, 70], ["MERS-CoV", "ORGANISM", 75, 83], ["both SARS and MERS", "PROBLEM", 61, 79], ["decreases", "OBSERVATION_MODIFIER", 115, 124]]], ["Given the earlier observations, it may be possible to speculate that both MERS-CoV and SARS are likely to be less common in tropical and tropical areas in the future.Nipah and HendraNipah henipavirus is a recently discovered member of the Henipavirus genus and is closely related to Hendra henipavirus (Ksiazek et al., 2011) .", [["SARS", "DISEASE", 87, 91], ["Nipah", "DISEASE", 166, 171], ["henipavirus", "CHEMICAL", 188, 199], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 74, 82], ["Nipah", "ORGANISM", 166, 171], ["HendraNipah henipavirus", "ORGANISM", 176, 199], ["Hendra henipavirus", "ORGANISM", 283, 301], ["Nipah", "SPECIES", 166, 171], ["MERS-CoV", "SPECIES", 74, 82], ["HendraNipah henipavirus", "SPECIES", 176, 199], ["Hendra henipavirus", "SPECIES", 283, 301], ["CoV", "PROBLEM", 79, 82], ["SARS", "PROBLEM", 87, 91], ["Nipah", "TREATMENT", 166, 171], ["may be possible", "UNCERTAINTY", 35, 50], ["likely to be", "UNCERTAINTY", 96, 108], ["tropical", "OBSERVATION_MODIFIER", 137, 145], ["areas", "OBSERVATION", 146, 151]]], ["Both Hendra and Nipah are on the WHO list of priority diseases, are highly pathogenic, affect populations in southeast Asia and are zoonotic.", [["Hendra and Nipah", "DISEASE", 5, 21], ["Nipah", "ORGANISM", 16, 21], ["Nipah", "SPECIES", 16, 21], ["priority diseases", "PROBLEM", 45, 62], ["Hendra", "OBSERVATION", 5, 11], ["Nipah", "OBSERVATION", 16, 21], ["highly", "OBSERVATION_MODIFIER", 68, 74], ["pathogenic", "OBSERVATION", 75, 85]]], ["Fruit bats have been confirmed as the main zoonotic hosts of Nipah (Yob et al., 2001) and Hendra (Halpin et al., 2000) .", [["Nipah", "DISEASE", 61, 66], ["Nipah", "ORGANISM", 61, 66], ["Hendra", "ORGANISM", 90, 96], ["Nipah", "SPECIES", 61, 66]]], ["Food-borne transmission is possible given observations of cases who reported drinking palm sap from containers previously accessed by fruit bats in Bangladesh (Islam et al., 2016; Luby et al., 2006) .Nipah and HendraAt the time of writing, there were no original papers in the literature on the potential for decadal climate change to affect Henipavirus transmission.", [["Nipah", "DISEASE", 200, 205], ["palm", "ORGANISM_SUBDIVISION", 86, 90], ["sap", "ORGANISM_SUBDIVISION", 91, 94], ["Nipah", "ORGANISM", 200, 205], ["Henipavirus", "SIMPLE_CHEMICAL", 342, 353], ["Nipah", "SPECIES", 200, 205], ["decadal climate change", "PROBLEM", 309, 331]]], ["Under experimental conditions, both Nipah and Hendra can tolerate conditions with pH of 3-4 to 11, can survive more than 4 days in bat urine kept at 22\u00b0C, but are rapidly inactivated under conditions of desiccation (Fogarty et al., 2008) .Nipah and HendraIn epidemiological studies, seasonality of Nipah spillover into human populations has been observed in Bangladesh (Luby et al., 2009 ) outside the typhoon season.", [["urine", "ANATOMY", 135, 140], ["Nipah", "DISEASE", 36, 41], ["Nipah", "DISEASE", 239, 244], ["Nipah spillover", "DISEASE", 298, 313], ["Nipah", "ORGANISM", 36, 41], ["Hendra", "ORGANISM", 46, 52], ["bat", "ORGANISM", 131, 134], ["urine", "ORGANISM_SUBSTANCE", 135, 140], ["Nipah", "ORGANISM", 298, 303], ["human", "ORGANISM", 319, 324], ["human", "SPECIES", 319, 324], ["human", "SPECIES", 319, 324], ["pH", "TEST", 82, 84], ["bat urine", "TEST", 131, 140], ["Nipah", "TREATMENT", 239, 244], ["HendraIn epidemiological studies", "TEST", 249, 281], ["Nipah spillover", "OBSERVATION", 298, 313]]], ["In terms of understanding which environmental factors are associated with Nipah spillover risk, Walsh (2015) identified bat density and a derived variable termed 'human footprint' as key factors, but excluded vegetation cover and pig density.", [["Nipah spillover", "DISEASE", 74, 89], ["human", "ORGANISM", 163, 168], ["pig", "ORGANISM_SUBDIVISION", 230, 233], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["pig", "SPECIES", 230, 233], ["a derived variable termed 'human footprint'", "TREATMENT", 136, 179], ["vegetation", "PROBLEM", 209, 219], ["pig density", "PROBLEM", 230, 241], ["pig density", "OBSERVATION", 230, 241]]], ["Seasonality has also been observed in terms of viral antibody dynamics in bats (Baker et al., 2014) .", [["viral antibody", "PROTEIN", 47, 61], ["viral antibody", "OBSERVATION", 47, 61]]], ["Taken together, these observations hint that the risk of spillover events is determined by an interacting combination of bioclimatic factors and bat ecology.Ebola and MarburgThe filoviruses (Ebola and Marburg) are highly pathogenic NTDs (MacNeil and Rollin, 2012) that affect human populations in outbreaks associated with a spillover event from zoonotic hosts.", [["Ebola", "DISEASE", 157, 162], ["Ebola and Marburg)", "DISEASE", 191, 209], ["NTDs", "DISEASE", 232, 236], ["Ebola", "ORGANISM", 157, 162], ["Marburg", "ORGANISM", 167, 174], ["filoviruses", "GENE_OR_GENE_PRODUCT", 178, 189], ["Ebola", "ORGANISM", 191, 196], ["Marburg", "ORGANISM", 201, 208], ["human", "ORGANISM", 276, 281], ["bioclimatic factors", "PROTEIN", 121, 140], ["human", "SPECIES", 276, 281], ["Marburg", "SPECIES", 167, 174], ["human", "SPECIES", 276, 281], ["spillover events", "PROBLEM", 57, 73], ["a spillover event", "PROBLEM", 323, 340], ["spillover", "OBSERVATION", 57, 66], ["Marburg", "OBSERVATION", 167, 174], ["filoviruses", "OBSERVATION", 178, 189]]], ["Bats are speculated to be primarily responsible for these spillover events, where the infections persist, possibly due to biannual birth pulses (Hayman, 2014) .", [["infections", "DISEASE", 86, 96], ["Bats", "CELL", 0, 4], ["these spillover events", "PROBLEM", 52, 74], ["the infections", "PROBLEM", 82, 96], ["biannual birth pulses", "TEST", 122, 143], ["spillover", "OBSERVATION", 58, 67], ["infections", "OBSERVATION", 86, 96], ["possibly due to", "UNCERTAINTY", 106, 121]]], ["Epidemiological evidence of spillover phenomenon comes from observations of seasonal variation in the prevalence of Marburg virus coinciding with the onset of outbreaks (Amman et al., 2012) .", [["Marburg virus", "DISEASE", 116, 129], ["Marburg virus", "ORGANISM", 116, 129], ["Marburg virus", "SPECIES", 116, 129], ["spillover phenomenon", "PROBLEM", 28, 48], ["seasonal variation", "PROBLEM", 76, 94], ["Marburg virus", "PROBLEM", 116, 129], ["spillover phenomenon", "OBSERVATION", 28, 48]]], ["The majority of human infection after the spillover is through direct contact with cases.Ebola and MarburgAt the time of writing, there were no original research papers available that have modelled future climate change-related projections of either of these filoviruses.", [["infection", "DISEASE", 22, 31], ["Ebola", "DISEASE", 89, 94], ["filoviruses", "DISEASE", 259, 270], ["human", "ORGANISM", 16, 21], ["Ebola", "ORGANISM", 89, 94], ["filoviruses", "GENE_OR_GENE_PRODUCT", 259, 270], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["human infection", "PROBLEM", 16, 31], ["these filoviruses", "PROBLEM", 253, 270], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["human", "OBSERVATION_MODIFIER", 16, 21], ["infection", "OBSERVATION", 22, 31], ["filoviruses", "OBSERVATION", 259, 270]]], ["All attempts at modelling the risk of infection has instead focused on the near term.", [["infection", "DISEASE", 38, 47], ["infection", "PROBLEM", 38, 47], ["infection", "OBSERVATION", 38, 47]]], ["Bats have received some attention in the literature in relation to both Ebola and Marburg, particularly in terms of modelling interactions between bat ecology and environmental factors.", [["Ebola", "DISEASE", 72, 77], ["Marburg", "DISEASE", 82, 89], ["Bats", "CELL", 0, 4], ["Ebola", "ORGANISM", 72, 77], ["Ebola", "OBSERVATION", 72, 77]]], ["Taken together, the current models suggest that infected bats migrate to resource rich areas (Buceta and Johnson, 2017) but are limited in their geographic distribution by a combination of temperature, evapotranspiration and elevation (Pigott et al., 2014 (Pigott et al., , 2015 .", [["bats", "ORGANISM", 57, 61], ["infected bats", "PROBLEM", 48, 61], ["infected", "OBSERVATION", 48, 56], ["elevation", "OBSERVATION_MODIFIER", 225, 234]]], ["Areas that combine relatively high human population density with high vegetation coverage are at relatively high risk of outbreak (Walsh and Haseeb, 2015) , presumably as this increases the rate of contact between bats and humans.", [["human", "ORGANISM", 35, 40], ["humans", "ORGANISM", 223, 229], ["human", "SPECIES", 35, 40], ["humans", "SPECIES", 223, 229], ["human", "SPECIES", 35, 40], ["humans", "SPECIES", 223, 229], ["relatively high human population density", "PROBLEM", 19, 59], ["high vegetation coverage", "PROBLEM", 65, 89], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["high", "OBSERVATION_MODIFIER", 30, 34], ["human", "OBSERVATION_MODIFIER", 35, 40], ["population", "OBSERVATION_MODIFIER", 41, 51], ["density", "OBSERVATION", 52, 59], ["high vegetation", "OBSERVATION", 65, 80]]], ["It remains to be seen whether climate change will significantly alter the interactions between these risk factors.Lassa FeverLassa mammarenavirus (the aetiological agent of Lassa Fever) is a member of the Arenaviridae family of viruses (Yun and Walker, 2012) .", [["Lassa Fever", "DISEASE", 173, 184], ["Lassa FeverLassa mammarenavirus", "ORGANISM", 114, 145], ["Lassa Fever", "ORGANISM", 173, 184], ["Arenaviridae", "GENE_OR_GENE_PRODUCT", 205, 217], ["Lassa FeverLassa mammarenavirus", "SPECIES", 114, 145], ["Lassa FeverLassa mammarenavirus", "SPECIES", 114, 145], ["Lassa FeverLassa mammarenavirus", "PROBLEM", 114, 145], ["Lassa Fever", "PROBLEM", 173, 184]]], ["Up to 37 million people, mainly living in West Africa, may currently live in areas where the environment is suitable to support the main zoonotic host of Lassa Fever, the Natal multimammate rat, Mastomys natalensis (Fichet-Calvet et al., 2009; Mylne et al., 2015) .", [["Lassa Fever", "DISEASE", 154, 165], ["people", "ORGANISM", 17, 23], ["Lassa Fever", "ORGANISM", 154, 165], ["multimammate rat", "ORGANISM", 177, 193], ["Mastomys natalensis", "ORGANISM", 195, 214], ["people", "SPECIES", 17, 23], ["rat", "SPECIES", 190, 193], ["Mastomys natalensis", "SPECIES", 195, 214], ["Mastomys natalensis", "SPECIES", 195, 214], ["Lassa Fever", "PROBLEM", 154, 165]]], ["Human-to-human transmission is considered to be account for between 5% and 20% of all cases, possibly due to 'super-spreaders' (Lo Iacono et al., 2015) .", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 9, 14], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["Transmission occurs when humans come into close contact with the mouse specifically through ingestion or inhalation of mouse urine, faeces or blood.", [["urine", "ANATOMY", 125, 130], ["faeces", "ANATOMY", 132, 138], ["blood", "ANATOMY", 142, 147], ["humans", "ORGANISM", 25, 31], ["mouse", "ORGANISM", 65, 70], ["mouse", "ORGANISM", 119, 124], ["urine", "ORGANISM_SUBSTANCE", 125, 130], ["faeces", "ORGANISM_SUBSTANCE", 132, 138], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["humans", "SPECIES", 25, 31], ["mouse", "SPECIES", 65, 70], ["mouse", "SPECIES", 119, 124], ["humans", "SPECIES", 25, 31], ["mouse", "SPECIES", 65, 70], ["mouse", "SPECIES", 119, 124], ["mouse urine", "PROBLEM", 119, 130], ["blood", "PROBLEM", 142, 147]]], ["Risk factors include living in close proximity to the mice, butchering and consumption (Bonwitt et al., 2016 (Bonwitt et al., , 2017 .Lassa FeverAs with other zoonotic NTDs, a consideration of the life history traits and population biology of the zoonotic host is essential to understanding how climate change may affect future transmission patterns.", [["zoonotic NTDs", "DISEASE", 159, 172], ["mice", "ORGANISM", 54, 58], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["Risk factors", "PROBLEM", 0, 12], ["other zoonotic NTDs", "PROBLEM", 153, 172]]], ["M. natalensis is an endotherm and as such its gestation period is not directly affected by external temperatures.", [["M. natalensis", "ORGANISM", 0, 13], ["M. natalensis", "SPECIES", 0, 13], ["M. natalensis", "SPECIES", 0, 13]]], ["In contrast, the population abundance of this organism is characterised by clearly definable and high-amplitude fluctuations.Lassa FeverPublished field studies have consistently observed that these fluctuations are predictably associated with seasonal rainfall patterns (Coetzee, 1975; Makundi et al., 2007; Sluydts et al., 2007; Stenseth et al., 1997) .", [["high-amplitude fluctuations", "PROBLEM", 97, 124], ["Lassa FeverPublished field studies", "TEST", 125, 159], ["high", "OBSERVATION_MODIFIER", 97, 101], ["amplitude fluctuations", "OBSERVATION", 102, 124]]], ["Typically, M. natalensis breed during rainy seasons and are most abundant in the proceeding dry season (Christensen, 1993) .", [["M. natalensis", "ORGANISM", 11, 24], ["M. natalensis", "SPECIES", 11, 24], ["M. natalensis", "SPECIES", 11, 24], ["natalensis breed", "OBSERVATION", 14, 30]]], ["Specific rainfall events, including so-called 'short rains' have been associated with rapid growth in population, termed outbreaks (Mwanjabe et al., 2002) .", [["Specific rainfall events", "PROBLEM", 0, 24], ["rapid growth in population", "PROBLEM", 86, 112], ["rapid", "OBSERVATION_MODIFIER", 86, 91], ["growth", "OBSERVATION_MODIFIER", 92, 98]]], ["This phenomenon is the result of more rapid development of the pups (Leirs et al., 1990) , a process triggered by the rains and the consequential lifting of food restrictions (Christensen, 1993) , and leads to both parents and their offspring breeding within relatively short periods of time.Lassa FeverAlthough known as an opportunistic species able to occupy a wide range of habitats, several natural environment factors nonetheless limit the spatial distribution of M. natalensis.", [["pups", "ORGANISM_SUBDIVISION", 63, 67], ["Lassa", "ORGANISM", 292, 297], ["M. natalensis", "ORGANISM", 469, 482], ["M. natalensis", "SPECIES", 469, 482], ["M. natalensis", "SPECIES", 469, 482], ["This phenomenon", "PROBLEM", 0, 15], ["an opportunistic species", "PROBLEM", 321, 345], ["more", "OBSERVATION_MODIFIER", 33, 37], ["rapid", "OBSERVATION_MODIFIER", 38, 43], ["M. natalensis", "OBSERVATION", 469, 482]]], ["The type of soil appears important, with higher abundance observed in regions with high vegetation cover and sandy (Massawe et al., 2005 (Massawe et al., , 2008 .", [["high vegetation", "PROBLEM", 83, 98], ["high vegetation", "OBSERVATION", 83, 98]]], ["Both these environmental factors can be naturally and anthropogenically determined, thus farming practice and land use are also likely to affect the population biology of the rodent .Lassa FeverSurvival of the virus in the environment is also key to completing the transmission cycle.", [["rodent", "ORGANISM", 175, 181], ["Lassa", "ORGANISM", 183, 188], ["rodent", "SPECIES", 175, 181], ["the virus", "PROBLEM", 206, 215], ["virus", "OBSERVATION", 210, 215]]], ["Once an infected mouse has urinated or defecated, there is a finite period over which the virus is viable.", [["mouse", "ORGANISM", 17, 22], ["mouse", "SPECIES", 17, 22], ["mouse", "SPECIES", 17, 22], ["the virus", "PROBLEM", 86, 95], ["infected", "OBSERVATION", 8, 16], ["virus", "OBSERVATION", 90, 95]]], ["Laboratory investigations indicate that aerosolised virus is inactivated within 60 min at temperatures >24\u00b0C (Stephenson et al., 1984) and that dark, dry conditions (Sagripanti et al., 2010) are associated with rapid decay of the virus.Lassa FeverThe potential effects of climate change on the transmission of Lassa fever to humans have so far received limited attention in the literature.", [["Lassa Fever", "DISEASE", 236, 247], ["Lassa fever", "DISEASE", 310, 321], ["Lassa", "ORGANISM", 236, 241], ["Lassa fever", "ORGANISM", 310, 321], ["humans", "ORGANISM", 325, 331], ["Lassa fever", "SPECIES", 310, 321], ["humans", "SPECIES", 325, 331], ["Lassa Fever", "SPECIES", 236, 247], ["humans", "SPECIES", 325, 331], ["Laboratory investigations", "TEST", 0, 25], ["aerosolised virus", "PROBLEM", 40, 57], ["dark, dry conditions", "PROBLEM", 144, 164], ["the virus", "PROBLEM", 226, 235], ["Lassa Fever", "PROBLEM", 236, 247], ["climate change", "PROBLEM", 272, 286], ["Lassa fever", "PROBLEM", 310, 321], ["aerosolised virus", "OBSERVATION", 40, 57]]], ["Given the well-known propensity of the mouse to undergo population outbreaks, historic attention has been given to either mapping contemporary risk (Fichet-Calvet et al., 2009) or forecasting over short periods (Leirs et al., 1996) .", [["mouse", "ORGANISM", 39, 44], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44]]], ["One study has focused on the issue of estimating the effect of global change, including climate change (Redding et al., 2016) .", [["One study", "TEST", 0, 9], ["global change", "PROBLEM", 63, 76], ["global", "OBSERVATION_MODIFIER", 63, 69], ["change", "OBSERVATION", 70, 76]]], ["The results of this simulation suggest that more extreme scenarios of both temperature increase and landuse change are likely to increase the rate of spillover events from animals to humans.RabiesDog-transmitted rabies are present in 150 countries including all of Africa, parts of Latin America and all of Asia (Hampson et al., 2015) .", [["RabiesDog-transmitted rabies", "DISEASE", 190, 218], ["humans", "ORGANISM", 183, 189], ["Rabies", "ORGANISM", 190, 196], ["Dog", "ORGANISM", 196, 199], ["rabies", "ORGANISM", 212, 218], ["humans", "SPECIES", 183, 189], ["Rabies", "SPECIES", 190, 196], ["humans", "SPECIES", 183, 189], ["RabiesDog-transmitted rabies", "SPECIES", 190, 218], ["this simulation", "TEST", 15, 30], ["both temperature increase", "PROBLEM", 70, 95], ["landuse change", "PROBLEM", 100, 114], ["spillover events", "PROBLEM", 150, 166], ["transmitted rabies", "PROBLEM", 200, 218]]], ["As a vaccine preventable, zoonotic disease, most research is focused on contemporary issues related to these two domains of enquiry.", [["zoonotic disease", "DISEASE", 26, 42], ["a vaccine", "TREATMENT", 3, 12], ["zoonotic disease", "PROBLEM", 26, 42]]], ["Efforts to understand the environmental component of transmission are geared towards operational aspects of vaccine delivery, e.g., in relation to landscape features (Russell et al., 2006) , the delivery of vaccines to wildlife (Rupprecht et al., 2004) .", [["vaccine delivery", "TREATMENT", 108, 124], ["the delivery of vaccines", "TREATMENT", 191, 215]]], ["There is little attention in the literature on how environmental change (including climate change) might affect transmission decades in to the future.", [["little", "OBSERVATION_MODIFIER", 9, 15], ["attention", "OBSERVATION_MODIFIER", 16, 25]]], ["To date, the focus on climate change and rabies has been confined to arctic areas (Huettmann et al., 2017; Kim et al., 2014) .VECTOR-BORNE INFECTIONSIn contrast to direct life cycle infections, there has been more attention given to the vector-borne diseases (e.g. Parham et al., 2015; Rogers and Randolph, 2006) .", [["rabies", "DISEASE", 41, 47], ["infections", "DISEASE", 182, 192], ["rabies", "SPECIES", 41, 47], ["rabies", "PROBLEM", 41, 47], ["direct life cycle infections", "PROBLEM", 164, 192]]], ["This reflects both the larger number of actors working in the field of vector-borne disease, and a relatively early realisation that climate can have a profound impact on the distribution of vector species, particularly mosquitoes.Helminths11.1.1 Lymphatic Filariasis W. bancrofti, the parasite that causes LF, is transmitted by mosquitoes of the Anopheles, Culex and Aedes genera.", [["vector-borne disease", "DISEASE", 71, 91], ["Filariasis W. bancrofti", "DISEASE", 257, 280], ["W. bancrofti", "ORGANISM", 268, 280], ["Aedes genera", "ORGANISM", 368, 380], ["W. bancrofti", "SPECIES", 268, 280], ["W. bancrofti", "SPECIES", 268, 280], ["borne disease", "PROBLEM", 78, 91], ["vector species", "PROBLEM", 191, 205], ["Lymphatic Filariasis", "PROBLEM", 247, 267], ["bancrofti", "PROBLEM", 271, 280], ["the parasite", "PROBLEM", 282, 294], ["LF", "PROBLEM", 307, 309], ["larger", "OBSERVATION_MODIFIER", 23, 29], ["number", "OBSERVATION_MODIFIER", 30, 36], ["profound", "OBSERVATION_MODIFIER", 152, 160], ["impact", "OBSERVATION", 161, 167], ["vector species", "OBSERVATION", 191, 205], ["Lymphatic", "ANATOMY", 247, 256], ["Filariasis", "OBSERVATION", 257, 267], ["LF", "ANATOMY", 307, 309]]], ["The potential effects of climate change on the transmission of this infection (assuming all else remains equal) therefore depends primarily on how the vectors respond to the biotic and abiotic shifts associated with changing climates.", [["infection", "DISEASE", 68, 77], ["this infection", "PROBLEM", 63, 77], ["infection", "OBSERVATION", 68, 77], ["abiotic shifts", "OBSERVATION", 185, 199]]], ["See sections earlier for more information on each of these species.HelminthsThe potential impact of climate change on the parasite itself has not been comprehensively studied.", [["sections", "ANATOMY", 4, 12], ["Helminths", "DISEASE", 67, 76], ["climate change", "PROBLEM", 100, 114], ["climate change", "OBSERVATION", 100, 114]]], ["There is some evidence that ambient temperature can affect the density of the symbiotic Wolbachia density (Mouton et al., 2007) , particularly in terms of the interaction between host genotype and Wolbachia strain.", [["ambient temperature", "PROBLEM", 28, 47], ["the symbiotic Wolbachia density", "PROBLEM", 74, 105], ["Wolbachia strain", "PROBLEM", 197, 213], ["ambient temperature", "OBSERVATION", 28, 47], ["density", "OBSERVATION_MODIFIER", 63, 70], ["symbiotic", "OBSERVATION_MODIFIER", 78, 87], ["Wolbachia density", "OBSERVATION", 88, 105], ["Wolbachia strain", "OBSERVATION", 197, 213]]], ["This may reflect local adaptability to changing temperatures over short timescales.", [["changing temperatures", "PROBLEM", 39, 60], ["may reflect", "UNCERTAINTY", 5, 16], ["local adaptability", "OBSERVATION", 17, 35], ["temperatures", "OBSERVATION_MODIFIER", 48, 60]]], ["A less direct effect may be possible through competition for resources as the availability of food changes over a longer period of time (Ross et al., 2016) , with evidence that certain Wolbachia strains (wMel, wMelPop and wAlbB) can reduce the survival times of Aedes larvae under starvation conditions.", [["Wolbachia strains", "ORGANISM", 185, 202], ["wAlbB", "GENE_OR_GENE_PRODUCT", 222, 227], ["Aedes larvae", "ORGANISM", 262, 274], ["certain Wolbachia strains", "PROBLEM", 177, 202], ["starvation conditions", "TREATMENT", 281, 302]]], ["In the context of using Wolbachia to control populations of Aedes mosquitoes, high temperatures (e.g. 30-40\u00b0C over several days) have been observed to reduce bacterial levels, at least in the short term (Ulrich et al., 2016) .", [["Aedes mosquitoes", "ORGANISM", 60, 76], ["Aedes mosquitoes", "SPECIES", 60, 76], ["Wolbachia", "TREATMENT", 24, 33], ["Aedes mosquitoes", "PROBLEM", 60, 76], ["high temperatures", "PROBLEM", 78, 95], ["bacterial levels", "PROBLEM", 158, 174], ["Wolbachia", "OBSERVATION", 24, 33]]], ["Such information may emerge from longer-term studies over multiple generations of vector kept at constantly higher temperatures.OnchocerciasisOnchocerca is transmitted by the blackfly Simulium damnosum complex and is therefore a parasite with a life cycle that is sensitive to climate change.", [["OnchocerciasisOnchocerca", "CHEMICAL", 128, 152], ["blackfly Simulium damnosum", "ORGANISM", 175, 201], ["Simulium damnosum", "SPECIES", 184, 201], ["Simulium damnosum", "SPECIES", 184, 201], ["longer-term studies", "TREATMENT", 33, 52], ["multiple generations of vector", "TREATMENT", 58, 88], ["the blackfly Simulium damnosum complex", "PROBLEM", 171, 209]]], ["Here I summarise work that has been conducted on the potential impact of climate change in particular.OnchocerciasisThe fact that over 60 sibling species or cytoforms have been identified (Adler et al., 2010) , each with different life history parameters, makes any attempt at projecting the effects of climate change highly challenging.", [["Onchocerciasis", "DISEASE", 102, 116], ["cytoforms", "CANCER", 157, 166], ["Onchocerciasis", "PROBLEM", 102, 116], ["cytoforms", "PROBLEM", 157, 166], ["climate", "OBSERVATION", 73, 80]]], ["Nonetheless it has been possible, as with other NTDs, to estimate how changing temperatures can affect the development of each stage of the vector, the development of Onchocerca within the fly, fly fecundity and the mortality rate of the fly (Cheke et al., 2015; Takaoka et al., 1982) .", [["Onchocerca", "ORGANISM", 167, 177], ["other NTDs", "PROBLEM", 42, 52], ["changing temperatures", "PROBLEM", 70, 91], ["Onchocerca", "OBSERVATION", 167, 177]]], ["Unlike some other vector species, there appears to be no threshold temperature (within the range 15-32\u00b0C) at which point either fly mortality increases or the rate of development of the parasite decreases (Cheke et al., 2015) .", [["some other vector species", "PROBLEM", 7, 32], ["threshold temperature", "PROBLEM", 57, 78], ["the parasite decreases", "PROBLEM", 182, 204], ["vector species", "OBSERVATION", 18, 32], ["appears to be", "UNCERTAINTY", 40, 53], ["temperature", "OBSERVATION_MODIFIER", 67, 78], ["parasite", "OBSERVATION_MODIFIER", 186, 194], ["decreases", "OBSERVATION_MODIFIER", 195, 204]]], ["Fluctuations in daily temperatures may affect the overall development time, corresponding to seasonal fluctuations in fly abundance (Zarroug et al., 2016) .OnchocerciasisImportantly, temperature is not the only driver of the ecology of Simulium.", [["Fluctuations in daily temperatures", "PROBLEM", 0, 34]]], ["A crucial feedback mechanism may lie in the phenomenon of aggregated oviposition, which is the process by which gravid Simulium females select existing egg masses to lay their eggs upon (McCall et al., 1994) .", [["egg masses", "ANATOMY", 152, 162], ["Simulium females", "ORGANISM", 119, 135], ["egg masses", "MULTI-TISSUE_STRUCTURE", 152, 162], ["A crucial feedback mechanism", "PROBLEM", 0, 28], ["egg masses", "PROBLEM", 152, 162], ["masses", "OBSERVATION", 156, 162]]], ["The stabilising effect on the population of the vector possibly comes from a higher rate of egg mortality with increasing egg mass (Kyorku and Raybould, 1987) .", [["egg", "ANATOMY", 92, 95], ["egg mass", "ANATOMY", 122, 130], ["egg", "ORGANISM_SUBDIVISION", 92, 95], ["egg", "ORGANISM_SUBDIVISION", 122, 125], ["increasing egg mass", "PROBLEM", 111, 130], ["stabilising", "OBSERVATION_MODIFIER", 4, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22], ["increasing", "OBSERVATION_MODIFIER", 111, 121], ["egg mass", "OBSERVATION", 122, 130]]], ["When incorporated into a mathematical model, this feedback produced a sharply convex curve when plotting temperature against the abundance of both parous and nulliparous flies, peaking at 29\u00b0C (Cheke et al., 2015) .OnchocerciasisAt the time of writing, there were no original research publications available that considered the potential for long-term climate change to influence future transmission of this NTD.DengueOf all the NTDs, Dengue infections have been considered more often in terms of climate than all other infections, with over 200 publications available at the time of writing.", [["NTD", "DISEASE", 408, 411], ["NTDs", "DISEASE", 429, 433], ["Dengue infections", "DISEASE", 435, 452], ["infections", "DISEASE", 520, 530], ["Dengue", "ORGANISM", 435, 441], ["a sharply convex curve", "PROBLEM", 68, 90], ["plotting temperature", "PROBLEM", 96, 116], ["long-term climate change", "TREATMENT", 342, 366], ["this NTD", "PROBLEM", 403, 411], ["Dengue infections", "PROBLEM", 435, 452], ["all other infections", "PROBLEM", 510, 530], ["infections", "OBSERVATION", 520, 530]]], ["A recent review on the subject by Ebi and Nealon (2016) revealed that most of this literature is concerned with identifying risk factors for contemporary transmission, with only a handful of studies devoted specifically to estimating the effects of decadal-scale climate change on Dengue transmission.", [["Dengue", "DISEASE", 281, 287], ["Dengue", "ORGANISM", 281, 287], ["Dengue transmission", "TREATMENT", 281, 300]]], ["These studies have employed a range of modelling techniques (reviewed by Messina et al., 2015) , with varying results in terms of where in the world Dengue infections are likely or not to be transmitted under particular scenarios.", [["Dengue infections", "DISEASE", 149, 166], ["Dengue", "ORGANISM", 149, 155], ["These studies", "TEST", 0, 13], ["Dengue infections", "PROBLEM", 149, 166], ["infections", "OBSERVATION", 156, 166]]], ["Messina et al. (2015) attempted to unify the field by writing a statistical modelling framework for future projections that relies on capturing spatially explicit information at high spatial resolution to map the contemporary distribution before replacing the existing values of covariates (e.g. temperature, precipitation) with projected values based on different RCPs.DengueMost of the existing models project that Dengue is likely to increase its range in the coming decades as global temperatures rise.", [["Dengue", "DISEASE", 417, 423], ["Dengue", "ORGANISM", 417, 423], ["projected values", "TEST", 329, 345], ["Dengue", "PROBLEM", 417, 423], ["global temperatures rise", "PROBLEM", 481, 505], ["is likely", "UNCERTAINTY", 424, 433], ["increase", "OBSERVATION_MODIFIER", 437, 445]]], ["Where they differ is the amount of uncertainty in their outputs (Messina et al., 2015) .", [["amount", "OBSERVATION_MODIFIER", 25, 31]]], ["Neither the individual projects nor any unifying frameworks consider the possibility that selection pressures acting on the Aedes vector or the dengue virus itself could affect future transmission.", [["dengue", "DISEASE", 144, 150], ["dengue virus", "ORGANISM", 144, 156], ["dengue virus", "SPECIES", 144, 156], ["selection pressures", "TREATMENT", 90, 109], ["the Aedes vector", "TREATMENT", 120, 136], ["the dengue virus", "PROBLEM", 140, 156], ["pressures", "OBSERVATION_MODIFIER", 100, 109], ["dengue virus", "OBSERVATION", 144, 156]]], ["General evolutionary features of the dengue virus in relation to climate change and urban vs sylvatic cycles of the Aedes mosquitoes are reviewed elsewhere (Tabachnick, 2016) , with the conclusion that past evidence of evolution warns us to expect future adaptation.DengueStudies of how temperature change affects host-virus interactions are few in number, with most evidence emerging in the context of investigating how Wolbachia bacteria may be used to control populations of dengue-transmitting mosquitoes.", [["dengue", "DISEASE", 37, 43], ["dengue", "DISEASE", 478, 484], ["dengue virus", "ORGANISM", 37, 49], ["Aedes mosquitoes", "ORGANISM", 116, 132], ["Wolbachia bacteria", "ORGANISM", 421, 439], ["mosquitoes", "ORGANISM", 498, 508], ["dengue virus", "SPECIES", 37, 49], ["Aedes mosquitoes", "SPECIES", 116, 132], ["dengue", "SPECIES", 478, 484], ["the dengue virus", "PROBLEM", 33, 49], ["Wolbachia bacteria", "PROBLEM", 421, 439], ["dengue", "PROBLEM", 478, 484], ["dengue virus", "OBSERVATION", 37, 49], ["sylvatic cycles", "OBSERVATION", 93, 108], ["few", "OBSERVATION_MODIFIER", 342, 345]]], ["In that context, ambient temperature has been observed to affect DENV infection rate in A. aegypti mosquitoes (Sgr\u00f2 et al., 2016) .Yellow FeverYFV is a member of the Flaviviridae family, closely related to Dengue and also transmitted by Aedes mosquitoes.", [["infection", "DISEASE", 70, 79], ["FeverYFV", "CHEMICAL", 138, 146], ["Dengue and also transmitted by Aedes mosquitoes", "DISEASE", 206, 253], ["DENV", "ORGANISM", 65, 69], ["A. aegypti", "ORGANISM", 88, 98], ["mosquitoes", "ORGANISM", 99, 109], ["FeverYFV", "GENE_OR_GENE_PRODUCT", 138, 146], ["Dengue", "ORGANISM", 206, 212], ["Aedes mosquitoes", "ORGANISM", 237, 253], ["A. aegypti", "SPECIES", 88, 98], ["DENV", "SPECIES", 65, 69], ["A. aegypti", "SPECIES", 88, 98], ["Yellow FeverYFV", "SPECIES", 131, 146], ["Aedes mosquitoes", "SPECIES", 237, 253], ["ambient temperature", "TEST", 17, 36], ["DENV infection rate", "PROBLEM", 65, 84], ["Dengue", "PROBLEM", 206, 212]]], ["It is predominantly observed in Africa and South America.", [["predominantly", "OBSERVATION_MODIFIER", 6, 19], ["Africa", "OBSERVATION_MODIFIER", 32, 38]]], ["Unlike other most other VBDs, yellow fever has been historically partially controlled through successful vaccination campaigns , combined with visa restrictions on travellers who have not been vaccinated.", [["yellow fever", "DISEASE", 30, 42], ["yellow fever", "ORGANISM", 30, 42], ["yellow fever", "PROBLEM", 30, 42], ["successful vaccination campaigns", "TREATMENT", 94, 126]]], ["Control efforts have not been entirely successful, with recent estimates putting the death toll at approximately 78,000 in Africa during 2013 alone (Garske et al., 2014) .Yellow FeverOutbreaks of yellow fever have highlighted a number of issues, predominantly related to lack of vaccination campaigns in East and Central Africa, and large-scale urbanisation (Kraemer et al., 2017) .", [["death", "DISEASE", 85, 90], ["yellow fever", "DISEASE", 196, 208], ["yellow fever", "ORGANISM", 196, 208], ["yellow fever", "PROBLEM", 196, 208], ["yellow fever", "OBSERVATION", 196, 208], ["Central", "ANATOMY_MODIFIER", 313, 320], ["large", "OBSERVATION_MODIFIER", 333, 338]]], ["One expressed fear is that this outbreak will facilitate world-wide distribution of the virus due to the establishment of direct air travel routes from east Africa into areas with susceptible mosquito populations (Wasserman et al., 2016) .", [["the virus", "PROBLEM", 84, 93]]], ["Notable in this regard is the recent observation that Australian strains of A. aegypti are susceptible to YFV infection (Higgs et al., 2011) that European populations of A. albopictus can carry YFV (Amraoui et al., 2016) , and that either A. albopictus or A. aegypti is present in numerous US states (Kraemer et al., 2015b) .Yellow FeverThe reasons for the absence of YFV in SE Asia are unknown.", [["YFV infection", "DISEASE", 106, 119], ["Fever", "DISEASE", 332, 337], ["YFV", "DISEASE", 368, 371], ["SE", "DISEASE", 375, 377], ["A. aegypti", "ORGANISM", 76, 86], ["YFV", "ORGANISM", 106, 109], ["A. albopictus", "ORGANISM", 170, 183], ["YFV", "ORGANISM", 194, 197], ["A. albopictus", "ORGANISM", 239, 252], ["A. aegypti", "ORGANISM", 256, 266], ["YFV", "ORGANISM", 368, 371], ["A. aegypti", "SPECIES", 76, 86], ["A. albopictus", "SPECIES", 170, 183], ["A. albopictus", "SPECIES", 239, 252], ["A. aegypti", "SPECIES", 256, 266], ["A. aegypti", "SPECIES", 76, 86], ["YFV", "SPECIES", 106, 109], ["A. albopictus", "SPECIES", 170, 183], ["YFV", "SPECIES", 194, 197], ["A. albopictus", "SPECIES", 239, 252], ["A. aegypti", "SPECIES", 256, 266], ["Yellow Fever", "SPECIES", 325, 337], ["YFV", "SPECIES", 368, 371], ["A. aegypti", "PROBLEM", 76, 86], ["YFV infection", "PROBLEM", 106, 119], ["Yellow Fever", "PROBLEM", 325, 337], ["YFV", "PROBLEM", 368, 371], ["aegypti", "OBSERVATION", 259, 266], ["Fever", "OBSERVATION", 332, 337]]], ["Hypotheses have been established that include a lack of carrying capacity among Asian strains of Aedes, an historic lack of travel from endemic areas to Asia, crossimmunity related to Dengue infection, a lack of a sylvatic cycle in Asia and the lack of a slave trade in Asia (Cathey and Marr, 2014; Rogers et al., 2006; Wasserman et al., 2016) .", [["crossimmunity", "DISEASE", 159, 172], ["Dengue infection", "DISEASE", 184, 200], ["Dengue", "ORGANISM", 184, 190], ["carrying capacity", "PROBLEM", 56, 73], ["Dengue infection", "PROBLEM", 184, 200], ["infection", "OBSERVATION", 191, 200]]], ["Given uncertainty about current reasons for lack of transmission, it is even more uncertain how climate change might affect future transmission of YVF in Asia.", [["YVF", "DISEASE", 147, 150], ["YVF", "SPECIES", 147, 150]]], ["Aedes mosquitoes are susceptible to selection pressures as a result of climate change (see above), and may therefore disseminate due to certain environments becoming more suitable.", [["Aedes mosquitoes", "ORGANISM", 0, 16], ["Aedes mosquitoes", "SPECIES", 0, 16], ["selection pressures", "TEST", 36, 55], ["climate change", "PROBLEM", 71, 85]]], ["The establishment of susceptible Aedes from Australia into parts of SE Asia where the environment has become more suitable is possible through international trade (Benedict et al., 2007) .Yellow FeverThe same hypothesis can be applied to other areas where the environment may become suitable for species or strains of Aedes that are capable of carrying YFV, contemporaneously with the transport of the virus through globalised air travel of people and cargo.", [["SE", "DISEASE", 68, 70], ["Fever", "DISEASE", 195, 200], ["YFV", "ORGANISM", 353, 356], ["people", "ORGANISM", 441, 447], ["cargo", "CELLULAR_COMPONENT", 452, 457], ["people", "SPECIES", 441, 447], ["Yellow Fever", "SPECIES", 188, 200], ["YFV", "SPECIES", 353, 356], ["susceptible Aedes", "PROBLEM", 21, 38], ["Yellow Fever", "PROBLEM", 188, 200], ["The same hypothesis", "PROBLEM", 200, 219], ["species", "PROBLEM", 296, 303], ["strains of Aedes", "PROBLEM", 307, 323], ["carrying YFV", "PROBLEM", 344, 356], ["susceptible", "OBSERVATION_MODIFIER", 21, 32], ["Aedes", "OBSERVATION", 33, 38], ["Fever", "OBSERVATION", 195, 200]]], ["For example, as the tropics expand (see above), it may be expected that some areas will become more humid and vegetative cover may increase.Yellow FeverLike Dengue, YFV transmission may be affected by climate change due to the fact that Aedes mosquitoes are the vectors.", [["Dengue", "DISEASE", 157, 163], ["YFV", "DISEASE", 165, 168], ["Yellow FeverLike Dengue", "ORGANISM", 140, 163], ["YFV", "ORGANISM", 165, 168], ["Aedes mosquitoes", "ORGANISM", 237, 253], ["YFV", "SPECIES", 165, 168], ["Aedes mosquitoes", "SPECIES", 237, 253], ["Yellow FeverLike Dengue", "PROBLEM", 140, 163], ["FeverLike", "OBSERVATION_MODIFIER", 147, 156], ["Dengue", "OBSERVATION", 157, 163]]], ["It cannot be assumed, however, that the direction of change will be the same for all these infections.", [["infections", "DISEASE", 91, 101], ["all these infections", "PROBLEM", 81, 101], ["cannot be assumed", "UNCERTAINTY", 3, 20], ["infections", "OBSERVATION", 91, 101]]], ["This is due to the fact that each virus has at least two types of transmission cycle involving partly overlapping combinations of vectors or nonhuman hosts Tabachnick, 2016) .", [["each virus", "PROBLEM", 29, 39], ["transmission cycle", "TREATMENT", 66, 84]]], ["The sylvatic cycle is particularly important in YFV epidemiology, contrasting with the urban cycle being predominant in terms of Dengue transmission.", [["Dengue", "DISEASE", 129, 135], ["YFV", "ORGANISM", 48, 51], ["Dengue", "ORGANISM", 129, 135], ["YFV", "SPECIES", 48, 51], ["Dengue transmission", "PROBLEM", 129, 148], ["sylvatic cycle", "OBSERVATION", 4, 18], ["Dengue", "OBSERVATION", 129, 135]]], ["Thus, we have to consider how the different cycles of each infection may be affected by global environmental change.", [["infection", "DISEASE", 59, 68], ["each infection", "PROBLEM", 54, 68], ["infection", "OBSERVATION", 59, 68], ["global", "OBSERVATION_MODIFIER", 88, 94], ["environmental change", "OBSERVATION", 95, 115]]], ["Rogers et al. (2006) offer some insights into the differential effects of environmental variation on transmission of Dengue and YFV.", [["Dengue", "DISEASE", 117, 123], ["YFV", "DISEASE", 128, 131], ["Dengue", "ORGANISM", 117, 123], ["YFV", "ORGANISM", 128, 131], ["YFV", "SPECIES", 128, 131], ["Dengue", "PROBLEM", 117, 123]]], ["They attempted to map the global risk of Dengue and YBF by considering which environmental variables (including land surface temperature and normalised difference vegetation index) are associated with known outbreaks.", [["surface", "ANATOMY", 117, 124], ["Dengue", "DISEASE", 41, 47], ["YBF", "DISEASE", 52, 55], ["Dengue", "ORGANISM", 41, 47], ["Dengue and YBF", "PROBLEM", 41, 55], ["land surface temperature", "PROBLEM", 112, 136], ["normalised difference vegetation index", "PROBLEM", 141, 179], ["Dengue", "OBSERVATION", 41, 47]]], ["They concluded that YFV transmission is predominantly associated with changes in vegetation cover and humidity, whereas Dengue virus transmission is more closely associated with changes in temperature.", [["YFV", "DISEASE", 20, 23], ["Dengue", "DISEASE", 120, 126], ["YFV", "ORGANISM", 20, 23], ["Dengue virus", "ORGANISM", 120, 132], ["YFV", "SPECIES", 20, 23], ["Dengue virus", "SPECIES", 120, 132], ["YFV transmission", "PROBLEM", 20, 36], ["vegetation cover", "TREATMENT", 81, 97], ["humidity", "TREATMENT", 102, 110], ["Dengue virus transmission", "PROBLEM", 120, 145], ["changes in temperature", "PROBLEM", 178, 200], ["predominantly associated with", "UNCERTAINTY", 40, 69], ["vegetation", "OBSERVATION", 81, 91]]], ["The maps produced by Rogers et al. (2006) also suggest that environmental conditions are suitable for transmission for YFV in SE Asia despite an absence of the virus in that region.Yellow FeverThe effects of climate change on sylvatic cycles of either Dengue or Yellow fever transmission have not been directly studied.", [["YFV", "DISEASE", 119, 122], ["SE", "DISEASE", 126, 128], ["Fever", "DISEASE", 188, 193], ["Dengue", "DISEASE", 252, 258], ["Yellow fever", "DISEASE", 262, 274], ["YFV", "ORGANISM", 119, 122], ["SE Asia", "ORGANISM", 126, 133], ["Dengue", "ORGANISM", 252, 258], ["Yellow fever", "ORGANISM", 262, 274], ["YFV", "SPECIES", 119, 122], ["Yellow Fever", "SPECIES", 181, 193], ["The maps", "TEST", 0, 8], ["environmental conditions", "PROBLEM", 60, 84], ["YFV", "PROBLEM", 119, 122], ["the virus", "PROBLEM", 156, 165], ["Yellow Fever", "PROBLEM", 181, 193], ["climate change", "PROBLEM", 208, 222], ["sylvatic cycles", "TREATMENT", 226, 241], ["Dengue", "PROBLEM", 252, 258], ["Yellow fever transmission", "PROBLEM", 262, 287], ["virus", "OBSERVATION", 160, 165], ["Fever", "OBSERVATION", 188, 193], ["climate", "OBSERVATION_MODIFIER", 208, 215], ["change", "OBSERVATION_MODIFIER", 216, 222], ["sylvatic cycles", "OBSERVATION", 226, 241]]], ["Again, we must infer the likelihood of climate having a significant impact based on what is already known about the ecology and the natural history of the organisms within each cycle.", [["the organisms", "PROBLEM", 151, 164]]], ["For example, toque macaques (Macaca sinica) are known hosts of Dengue in Sri Lanka.", [["Dengue", "DISEASE", 63, 69], ["toque macaques", "ORGANISM", 13, 27], ["Macaca sinica", "ORGANISM", 29, 42], ["Dengue", "ORGANISM", 63, 69], ["Sri Lanka", "ORGANISM", 73, 82], ["macaques", "SPECIES", 19, 27], ["Macaca sinica", "SPECIES", 29, 42], ["toque macaques", "SPECIES", 13, 27], ["Macaca sinica", "SPECIES", 29, 42], ["Dengue", "PROBLEM", 63, 69]]], ["The genus Macaca is also known for its plastic characteristics in terms of its ability to adapt to changing food availability caused by anthropogenic activities (Riley, 2007) .", [["Macaca", "ORGANISM", 10, 16], ["genus Macaca", "OBSERVATION", 4, 16]]], ["The macaques adapt their foraging strategy by moving beyond their home range if food becomes scarce in one particular area.", [["macaques", "ORGANISM", 4, 12], ["macaques", "SPECIES", 4, 12]]], ["This range extension could occur as a result of decreasing availability of natural foodstuffs in areas with altered patterns of agriculture, forcing the monkeys into new areas (including urban settings) where food is more available.", [["natural foodstuffs", "TREATMENT", 75, 93], ["natural foodstuffs", "OBSERVATION", 75, 93]]], ["Toque macaques are already found in urban settings in Sri Lanka and are exploited in a number of ways-as pets, performer and for ritual activities (Radhakrishna et al., 2014) .Rift Valley Fever (RVF)RVF is a vaccine preventable, epizootic and zoonotic disease that has a complex natural history involving dozens of mosquito species as vectors (Pepin et al., 2010) .", [["Rift Valley Fever", "DISEASE", 176, 193], ["RVF", "DISEASE", 195, 198], ["RVF", "DISEASE", 199, 202], ["zoonotic disease", "DISEASE", 243, 259], ["Toque macaques", "ORGANISM", 0, 14], ["Rift Valley Fever", "ORGANISM", 176, 193], ["Toque macaques", "SPECIES", 0, 14], ["Rift Valley Fever (", "SPECIES", 176, 195], ["RVF", "SPECIES", 195, 198], ["RVF", "SPECIES", 199, 202], ["Rift Valley Fever (RVF)RVF", "PROBLEM", 176, 202], ["a vaccine", "TREATMENT", 206, 215], ["epizootic and zoonotic disease", "PROBLEM", 229, 259], ["zoonotic disease", "OBSERVATION", 243, 259]]], ["Aedes and Culex spp. have been implicated as the main vector genera, with the former acting to transmit RVF in the interepidemic period and the latter acting as an amplifier species during epidemics (Pepin et al., 2010) .Rift Valley Fever (RVF)Epidemics of RVF are closely associated with excessive rainfall and El Nino events (Linthicum et al., 1999) .", [["RVF", "DISEASE", 104, 107], ["Rift Valley Fever", "DISEASE", 221, 238], ["RVF", "DISEASE", 240, 243], ["RVF", "DISEASE", 257, 260], ["Aedes", "ORGANISM", 0, 5], ["Culex spp", "ORGANISM", 10, 19], ["Rift Valley Fever", "ORGANISM", 221, 238], ["Rift Valley Fever (", "SPECIES", 221, 240], ["RVF", "SPECIES", 240, 243], ["RVF", "SPECIES", 257, 260], ["Rift Valley Fever", "PROBLEM", 221, 238], ["RVF", "PROBLEM", 257, 260], ["excessive rainfall and El Nino events", "PROBLEM", 289, 326], ["RVF", "OBSERVATION", 257, 260]]], ["Additional large-scale determinants include the presence of irrigation schemes, a high level of cultivation, higher population density (Redding et al., 2017) .", [["irrigation schemes", "TREATMENT", 60, 78], ["a high level of cultivation", "PROBLEM", 80, 107], ["higher population density", "PROBLEM", 109, 134], ["large", "OBSERVATION_MODIFIER", 11, 16], ["-scale", "OBSERVATION_MODIFIER", 16, 22], ["irrigation schemes", "OBSERVATION", 60, 78], ["higher", "OBSERVATION_MODIFIER", 109, 115], ["population", "OBSERVATION_MODIFIER", 116, 126], ["density", "OBSERVATION", 127, 134]]], ["At a local scale, a critical factor is the nature of the local habitats-they must be suitable for supporting mosquito populations.", [["mosquito populations", "CELL", 109, 129]]], ["In this context, Sang et al. (2010) collected both Aedes and Culex mosquitoes associated with RVF from a diverse range of habitats in Garissa, Kenya, including human settlements near flooded wetlands, mixed forest close to mangrove swamps and livestock holding areas.", [["RVF", "DISEASE", 94, 97], ["Culex mosquitoes", "ORGANISM", 61, 77], ["human", "ORGANISM", 160, 165], ["human", "SPECIES", 160, 165], ["Culex mosquitoes", "SPECIES", 61, 77], ["RVF", "SPECIES", 94, 97], ["human", "SPECIES", 160, 165], ["RVF", "PROBLEM", 94, 97], ["mangrove swamps", "TREATMENT", 223, 238]]], ["Elsewhere, Culex tritaeniorhynchus-a vector of RVF in Saudi Arabia, prefers wet, muddy substrates with a low total dissolved salts content (Sallam et al., 2013) .Rift Valley Fever (RVF)Mathematical models of RVF typically focus on identifying factors that can be used to forecast or mitigate the next epidemic (e.g. Leedale et al., 2016; Mpeshe et al., 2011; Pedro et al., 2016) .", [["RVF", "DISEASE", 47, 50], ["Rift Valley Fever", "DISEASE", 162, 179], ["RVF", "DISEASE", 181, 184], ["RVF", "DISEASE", 208, 211], ["Culex tritaeniorhynchus", "ORGANISM", 11, 34], ["RVF", "ORGANISM", 47, 50], ["Saudi Arabia", "ORGANISM", 54, 66], ["salts", "SIMPLE_CHEMICAL", 125, 130], ["Rift Valley Fever", "ORGANISM", 162, 179], ["Culex tritaeniorhynchus", "SPECIES", 11, 34], ["Culex tritaeniorhynchus", "SPECIES", 11, 34], ["RVF", "SPECIES", 47, 50], ["Rift Valley Fever (", "SPECIES", 162, 181], ["RVF", "SPECIES", 181, 184], ["RVF", "PROBLEM", 47, 50], ["muddy substrates", "PROBLEM", 81, 97], ["a low total dissolved salts content", "PROBLEM", 103, 138], ["Rift Valley Fever (RVF)", "PROBLEM", 162, 185], ["RVF", "PROBLEM", 208, 211], ["RVF", "OBSERVATION", 208, 211]]], ["The repeated observation of the importance of precipitation and water availability at specific locations, combined with the differentiated natural history of the main vectors, means that attempting to predict longer-term transmission of RVF under projected climate change scenarios is inherently more challenging than for a disease that has only one vector.", [["RVF", "DISEASE", 237, 240], ["RVF", "SPECIES", 237, 240], ["precipitation", "TREATMENT", 46, 59], ["RVF", "PROBLEM", 237, 240], ["a disease", "PROBLEM", 322, 331]]], ["This aspect of disease has been explored by Taylor et al. (2016) who constructed an overall risk map of future RVF outbreaks in East Africa that comprised the deterministic RVF model of Leedale et al. (2016) , downscaled RCP projections and several expert-weighted indicators of social vulnerability.Rift Valley Fever (RVF)Like all attempts to capture future transmission potential of an NTD, a number of assumptions have to be made.", [["RVF", "DISEASE", 111, 114], ["Rift Valley Fever", "DISEASE", 300, 317], ["RVF", "DISEASE", 319, 322], ["Rift Valley Fever", "ORGANISM", 300, 317], ["Rift Valley Fever (", "SPECIES", 300, 319], ["RVF", "SPECIES", 319, 322], ["disease", "PROBLEM", 15, 22], ["Rift Valley Fever (RVF)", "PROBLEM", 300, 323], ["an NTD", "PROBLEM", 385, 391], ["disease", "OBSERVATION", 15, 22], ["NTD", "OBSERVATION", 388, 391]]], ["It was also assumed that neither the mosquito vectors nor the virus itself will evolve as a result of selection pressures from climate change.Crimean Congo Haemorrhagic Fever (CCHF)A tick-borne infection, the CCHF virus is a member of the Bunyaviridae family.", [["Crimean Congo Haemorrhagic Fever", "DISEASE", 142, 174], ["CCHF", "DISEASE", 176, 180], ["tick-borne infection", "DISEASE", 183, 203], ["CCHF", "DISEASE", 209, 213], ["Bunyaviridae", "DISEASE", 239, 251], ["Crimean Congo Haemorrhagic Fever", "ORGANISM", 142, 174], ["CCHF virus", "ORGANISM", 209, 219], ["Crimean Congo Haemorrhagic Fever (CCHF)", "SPECIES", 142, 181], ["CCHF virus", "SPECIES", 209, 219], ["the mosquito vectors", "PROBLEM", 33, 53], ["the virus", "PROBLEM", 58, 67], ["selection pressures", "TEST", 102, 121], ["Crimean Congo Haemorrhagic Fever", "PROBLEM", 142, 174], ["CCHF", "PROBLEM", 176, 180], ["A tick-borne infection", "PROBLEM", 181, 203], ["the CCHF virus", "PROBLEM", 205, 219], ["virus", "OBSERVATION", 62, 67], ["Haemorrhagic", "OBSERVATION_MODIFIER", 156, 168], ["Fever", "OBSERVATION", 169, 174], ["infection", "OBSERVATION", 194, 203]]], ["Many tick species, especially members of the Hylalomma genus, can act as vectors.", [["Hylalomma genus", "ORGANISM", 45, 60], ["Many tick species", "PROBLEM", 0, 17], ["the Hylalomma genus", "PROBLEM", 41, 60], ["tick species", "OBSERVATION", 5, 17], ["Hylalomma genus", "ANATOMY", 45, 60]]], ["Both domestic animals and wildlife, particularly birds, can act as reservoir populations.Crimean Congo Haemorrhagic Fever (CCHF)The geographic distribution of infection is currently limited to the countries within Africa, the Middle East, Southern-Eastern Europe and Southern Asia (Dreshaj et al., 2016; Erg\u20ac on\u20ac ul, 2006) .", [["Crimean Congo Haemorrhagic Fever", "DISEASE", 89, 121], ["CCHF", "DISEASE", 123, 127], ["infection", "DISEASE", 159, 168], ["Crimean Congo Haemorrhagic Fever", "PROBLEM", 89, 121], ["CCHF", "PROBLEM", 123, 127], ["infection", "PROBLEM", 159, 168], ["Haemorrhagic", "OBSERVATION_MODIFIER", 103, 115], ["Fever", "OBSERVATION", 116, 121], ["geographic", "OBSERVATION_MODIFIER", 132, 142], ["distribution", "OBSERVATION_MODIFIER", 143, 155], ["infection", "OBSERVATION", 159, 168], ["Middle", "ANATOMY_MODIFIER", 226, 232]]], ["Not all populations within each country affected by CCHF are at risk due to factors such as limited environmental suitability for the ticks (Messina et al., 2015) or the restricted distribution of zoonotic reservoirs including cattle and goats (Mostafavi et al., 2013) .", [["CCHF", "DISEASE", 52, 56], ["cattle", "ORGANISM", 227, 233], ["goats", "ORGANISM", 238, 243], ["cattle", "SPECIES", 227, 233], ["goats", "SPECIES", 238, 243], ["cattle", "SPECIES", 227, 233], ["goats", "SPECIES", 238, 243], ["CCHF", "PROBLEM", 52, 56], ["all", "OBSERVATION_MODIFIER", 4, 7], ["populations", "OBSERVATION", 8, 19], ["CCHF", "OBSERVATION", 52, 56], ["zoonotic reservoirs", "OBSERVATION", 197, 216]]], ["Concerns have been raised that countries such as Turkey and those in former Yugoslavia can act as portals for exporting cases into neighbouring countries (Mahzounieh et al., 2012; Mild et al., 2010) , due to the ability of the vectors to be transported across boundaries.Crimean Congo Haemorrhagic Fever (CCHF)Retrospective analyses of incidence data from human cases in Europe have observed distinct seasonality and correlations with environmental factors including increased vegetation (grass, scrubland and herbaceous) cover, medium-high level fragmentation of landscapes and warmer temperatures (Vescio et al., 2012) .", [["Haemorrhagic Fever", "DISEASE", 285, 303], ["CCHF", "DISEASE", 305, 309], ["human", "ORGANISM", 356, 361], ["human", "SPECIES", 356, 361], ["human", "SPECIES", 356, 361], ["the vectors", "TREATMENT", 223, 234], ["Crimean Congo Haemorrhagic Fever", "PROBLEM", 271, 303], ["incidence data", "TEST", 336, 350], ["environmental factors", "PROBLEM", 435, 456], ["increased vegetation (grass", "PROBLEM", 467, 494], ["high level fragmentation of landscapes", "PROBLEM", 536, 574], ["Haemorrhagic", "OBSERVATION_MODIFIER", 285, 297], ["increased", "OBSERVATION_MODIFIER", 467, 476], ["vegetation", "OBSERVATION", 477, 487], ["high level", "OBSERVATION_MODIFIER", 536, 546], ["fragmentation", "OBSERVATION_MODIFIER", 547, 560]]], ["Similar conclusions regarding high temperatures were reached in a study of cases in Pakistan (Abbas et al., 2017) .Crimean Congo Haemorrhagic Fever (CCHF)Efforts to estimate the potential impact of climate change on future transmission of CCHF have, to date, focused on the role of migratory birds spreading the infection further into livestock of Europe (Gale et al., 2012) .", [["Fever", "DISEASE", 142, 147], ["CCHF", "DISEASE", 149, 153], ["CCHF", "DISEASE", 239, 243], ["infection", "DISEASE", 312, 321], ["birds", "ORGANISM", 292, 297], ["high temperatures", "PROBLEM", 30, 47], ["a study", "TEST", 64, 71], ["Crimean Congo Haemorrhagic Fever (CCHF)", "PROBLEM", 115, 154], ["climate change", "PROBLEM", 198, 212], ["CCHF", "PROBLEM", 239, 243], ["the infection", "PROBLEM", 308, 321], ["high temperatures", "OBSERVATION_MODIFIER", 30, 47], ["Haemorrhagic", "OBSERVATION_MODIFIER", 129, 141], ["infection", "OBSERVATION", 312, 321]]], ["In that context, it has been concluded that climate change will not have a substantial impact by 2084.Crimean Congo Haemorrhagic Fever (CCHF)The absence of a contribution from birds does not preclude other organisms from affecting potential future transmission.", [["Haemorrhagic Fever", "DISEASE", 116, 134], ["CCHF", "DISEASE", 136, 140], ["birds", "ORGANISM", 176, 181], ["Crimean Congo Haemorrhagic Fever", "PROBLEM", 102, 134], ["CCHF", "PROBLEM", 136, 140], ["other organisms", "PROBLEM", 200, 215], ["Haemorrhagic", "OBSERVATION_MODIFIER", 116, 128], ["Fever", "OBSERVATION", 129, 134]]], ["The role of climate in affecting tick ecology is likely to be highly significant given the sensitivity of tick development and mortality to temperature, water availability and vapour deficit (Estrada-Pe\u00f1a et al., 2015) .", [["tick development", "PROBLEM", 106, 122], ["vapour deficit", "PROBLEM", 176, 190]]], ["In common with other infections included in this review, the relationship between success of the organism and temperature is nonlinear due to the differential effects on development, transovarial transmission, egg survival and mortality of the adult ticks (Estrada-Pe\u00f1a et al., 2013) .", [["egg", "ANATOMY", 210, 213], ["infections", "DISEASE", 21, 31], ["egg", "ORGANISM_SUBDIVISION", 210, 213], ["other infections", "PROBLEM", 15, 31], ["the organism", "PROBLEM", 93, 105], ["transovarial transmission", "TREATMENT", 183, 208], ["infections", "OBSERVATION", 21, 31]]], ["11.2.5 Severe Fever With Thrombocytopenia Syndrome (SFTS) SFTS is caused by a phlebovirus from the Bunyaviridae family, first reported in 2009 in China (Yu et al., 2011) .", [["Fever", "DISEASE", 14, 19], ["Thrombocytopenia", "DISEASE", 25, 41], ["SFTS", "DISEASE", 52, 56], ["SFTS", "DISEASE", 58, 62], ["Bunyaviridae", "DISEASE", 99, 111], ["Severe Fever", "PROBLEM", 7, 19], ["Thrombocytopenia Syndrome", "PROBLEM", 25, 50], ["SFTS) SFTS", "PROBLEM", 52, 62], ["a phlebovirus", "PROBLEM", 76, 89], ["Severe", "OBSERVATION_MODIFIER", 7, 13], ["Fever", "OBSERVATION", 14, 19], ["Thrombocytopenia Syndrome", "OBSERVATION", 25, 50], ["phlebovirus", "OBSERVATION", 78, 89]]], ["Haemaphysalis longicornis ticks are reservoir hosts of SFTS (Luo et al., 2015) .", [["Haemaphysalis longicornis ticks", "ORGANISM", 0, 31], ["Haemaphysalis longicornis", "SPECIES", 0, 25], ["Haemaphysalis longicornis", "SPECIES", 0, 25], ["Haemaphysalis longicornis ticks", "TREATMENT", 0, 31], ["SFTS", "PROBLEM", 55, 59]]], ["Antibodies to the virus have been detected in goats, cattle, dogs and chickens (Ding et al., 2014; Zhao et al., 2012) .", [["goats", "ORGANISM", 46, 51], ["cattle", "ORGANISM", 53, 59], ["dogs", "ORGANISM", 61, 65], ["chickens", "ORGANISM", 70, 78], ["goats", "SPECIES", 46, 51], ["cattle", "SPECIES", 53, 59], ["dogs", "SPECIES", 61, 65], ["chickens", "SPECIES", 70, 78], ["goats", "SPECIES", 46, 51], ["cattle", "SPECIES", 53, 59], ["chickens", "SPECIES", 70, 78], ["Antibodies", "TREATMENT", 0, 10], ["the virus", "PROBLEM", 14, 23]]], ["The virus is on the list of WHO priority diseases.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["Elderly agricultural workers inhabiting rural, shrub or forested areas are at the greatest risk at specific times of year, according to epidemiological surveys (Liu et al., 2014) .Crimean Congo Haemorrhagic Fever (CCHF)At the time of writing, there were no original research publications on the potential for climate change to affect transmission in the future.", [["Fever", "DISEASE", 207, 212], ["CCHF", "DISEASE", 214, 218], ["Crimean Congo Haemorrhagic Fever", "PROBLEM", 180, 212], ["CCHF", "PROBLEM", 214, 218], ["Haemorrhagic", "OBSERVATION_MODIFIER", 194, 206], ["Fever", "OBSERVATION", 207, 212]]], ["A current hypothesis is that ticks have historically distributed the infection around China, South Korea and Japan by attachment to migrating birds (Li et al., 2016; Zhang and Xu, 2016) .Zika VirusZika virus is an arbovirus of the Flaviviridae family, known to be transmitted to humans through the bite of Aedes mosquitoes (Marchette et al., 1969) .", [["infection", "DISEASE", 69, 78], ["arbovirus of the Flaviviridae", "DISEASE", 214, 243], ["ticks", "ORGANISM", 29, 34], ["Zika VirusZika virus", "ORGANISM", 187, 207], ["humans", "ORGANISM", 279, 285], ["Aedes mosquitoes", "ORGANISM", 306, 322], ["Zika VirusZika virus", "SPECIES", 187, 207], ["humans", "SPECIES", 279, 285], ["Zika VirusZika virus", "SPECIES", 187, 207], ["humans", "SPECIES", 279, 285], ["Aedes mosquitoes", "SPECIES", 306, 322], ["A current hypothesis", "PROBLEM", 0, 20], ["the infection", "PROBLEM", 65, 78], ["Zika VirusZika virus", "PROBLEM", 187, 207], ["infection", "OBSERVATION", 69, 78]]], ["Culex has been assessed as a vector but appears refractory .", [["refractory", "OBSERVATION_MODIFIER", 48, 58]]], ["Historically, the infection has been known to be endemic in parts of Africa (particularly Nigeria) and parts of southeast Asia (including Borneo and the Philippines).", [["infection", "DISEASE", 18, 27], ["the infection", "PROBLEM", 14, 27], ["Africa", "PROBLEM", 69, 75], ["infection", "OBSERVATION", 18, 27], ["endemic", "OBSERVATION_MODIFIER", 49, 56]]], ["It was the emergence of Zika virus as a public health problem in Latin America in 2015 that created disquiet among global public health practitioners.", [["Zika virus", "DISEASE", 24, 34], ["Zika virus", "ORGANISM", 24, 34], ["Zika virus", "SPECIES", 24, 34], ["Zika virus", "PROBLEM", 24, 34]]], ["The potential importance of the infection was recognised by WHO, which declared a public health emergency in February 2016 as the infection was observed to spread across 69 countries and territories, causing thousands of cases of microcephaly (World Health Organisation, 2016b).", [["infection", "DISEASE", 32, 41], ["infection", "DISEASE", 130, 139], ["microcephaly", "DISEASE", 230, 242], ["the infection", "PROBLEM", 28, 41], ["the infection", "PROBLEM", 126, 139], ["microcephaly", "PROBLEM", 230, 242], ["infection", "OBSERVATION", 32, 41], ["infection", "OBSERVATION", 130, 139], ["microcephaly", "OBSERVATION", 230, 242]]], ["At the time of writing, Zika virus was placed on the list of priority diseases for research and development to prevent epidemics.Zika VirusIt has been speculated that climate variation was partly responsible for the rapid expansion of Zika during 2015 (Ali et al., 2017; Paz and Semenza, 2016) .", [["Zika virus", "ORGANISM", 24, 34], ["Zika Virus", "ORGANISM", 129, 139], ["Zika virus", "SPECIES", 24, 34], ["Zika Virus", "SPECIES", 129, 139], ["Zika virus", "PROBLEM", 24, 34], ["epidemics", "PROBLEM", 119, 128], ["Zika Virus", "PROBLEM", 129, 139], ["the rapid expansion of Zika", "PROBLEM", 212, 239], ["partly responsible for", "UNCERTAINTY", 189, 211], ["rapid", "OBSERVATION_MODIFIER", 216, 221], ["expansion", "OBSERVATION_MODIFIER", 222, 231]]], ["The reason for the rapid rise from 2015 onwards has been attributed to the El Nino event of 2015 (Caminade et al., 2017) , due to the rise in temperatures increasing the biting rate of the mosquito vectors.Zika VirusA few modelling studies have been published to estimate the contemporary risk of transmission of Zika virus, using ecological niche models to estimate environmental suitability for the two main vectors, A. albopictus and A. aegypti (Messina et al., 2016) ; or estimates of R0 for South America (Perkins et al., 2016) .", [["Zika virus", "ORGANISM", 313, 323], ["A. albopictus", "ORGANISM", 419, 432], ["A. aegypti", "ORGANISM", 437, 447], ["A. albopictus", "SPECIES", 419, 432], ["A. aegypti", "SPECIES", 437, 447], ["Zika virus", "SPECIES", 313, 323], ["A. albopictus", "SPECIES", 419, 432], ["A. aegypti", "SPECIES", 437, 447], ["the rise in temperatures", "PROBLEM", 130, 154], ["Zika VirusA few modelling studies", "TEST", 206, 239], ["Zika virus", "PROBLEM", 313, 323], ["rise", "OBSERVATION_MODIFIER", 134, 138]]], ["At the time of writing, there were no published original research studies on the potential for decadal changes in climate to affect transmission of Zika virus on a local or global scale.", [["Zika virus", "ORGANISM", 148, 158], ["Zika virus", "SPECIES", 148, 158], ["decadal changes", "PROBLEM", 95, 110], ["Zika virus", "PROBLEM", 148, 158]]], ["As with other vectorborne diseases, a key factor will be the effect of environmental change on the ecology of the vectors (see above), modified by the vectoral capacity of the two vectors (Gardner et al., 2017) .TrachomaThere have been several papers published that have considered whether or not transmission of trachoma (Chlamydia trachomatis) is associated with abiotic factors including temperature, rainfall, RH and sunshine fraction (reviewed by Ramesh et al., 2013) .", [["vectorborne diseases", "DISEASE", 14, 34], ["trachoma", "DISEASE", 313, 321], ["Chlamydia trachomatis", "DISEASE", 323, 344], ["trachoma", "ORGANISM", 313, 321], ["Chlamydia trachomatis", "ORGANISM", 323, 344], ["Chlamydia trachomatis", "SPECIES", 323, 344], ["Chlamydia trachomatis", "SPECIES", 323, 344], ["other vectorborne diseases", "PROBLEM", 8, 34], ["trachoma (Chlamydia trachomatis", "PROBLEM", 313, 344], ["abiotic factors", "PROBLEM", 365, 380], ["trachoma", "OBSERVATION", 313, 321]]], ["Of the various factors considered, rainfall and temperature (or altitude as a proxy for temperature) were most consistently reported (in mainly cross-sectional studies) to be associated with variation in the prevalence of active Trachoma.", [["Trachoma", "DISEASE", 229, 237], ["the various factors", "PROBLEM", 3, 22], ["active Trachoma", "PROBLEM", 222, 237], ["active", "OBSERVATION_MODIFIER", 222, 228], ["Trachoma", "OBSERVATION", 229, 237]]], ["Clements et al. (2010) incorporated land cover and land use in a geostatistical model with the conclusion that transmission is higher in savannah and grassland compared to areas with higher precipitation or high water-table (wetlands).TrachomaC. trachomatis can be transmitted directly from person to person or through fomites.", [["TrachomaC", "CHEMICAL", 235, 244], ["trachomatis", "DISEASE", 246, 257], ["trachomatis", "ORGANISM", 246, 257], ["trachomatis", "SPECIES", 246, 257], ["person", "SPECIES", 291, 297], ["person", "SPECIES", 301, 307], ["trachomatis", "SPECIES", 246, 257], ["land cover", "TREATMENT", 36, 46], ["a geostatistical model", "TREATMENT", 63, 85], ["TrachomaC", "TREATMENT", 235, 244], ["trachomatis", "PROBLEM", 246, 257], ["higher", "OBSERVATION_MODIFIER", 127, 133]]], ["From a climate change perspective, it will be important to identify all potential fomites and consider how they may be affected in the future.", [["fomites", "CANCER", 82, 89]]], ["The most widely implicated are fabrics that can come into contact with faces-towels, bedlinen, etc. But exudates from the eyes are often wiped away with fingers which then come into contact with a wide range of surfaces and objects touched by others.", [["exudates", "ANATOMY", 104, 112], ["eyes", "ANATOMY", 122, 126], ["bedlinen", "SIMPLE_CHEMICAL", 85, 93], ["eyes", "ORGAN", 122, 126], ["fingers", "ORGANISM_SUBDIVISION", 153, 160], ["exudates", "PROBLEM", 104, 112], ["most widely", "OBSERVATION_MODIFIER", 4, 15], ["fabrics", "OBSERVATION", 31, 38], ["exudates", "OBSERVATION", 104, 112], ["eyes", "ANATOMY", 122, 126], ["fingers", "ANATOMY", 153, 160]]], ["Some of these may be associated with climate-sensitive factors in ways that are poorly understood.TrachomaFor example, there is a known link between inclusion conjunctivitis and genital chlamyidia (caused also by C. trachomatis), whereby contaminated genital secretions are transferred by hand to the eye either through autoinoculation or from a partner.", [["genital chlamyidia", "ANATOMY", 178, 196], ["genital secretions", "ANATOMY", 251, 269], ["hand", "ANATOMY", 289, 293], ["eye", "ANATOMY", 301, 304], ["conjunctivitis", "DISEASE", 159, 173], ["genital chlamyidia", "DISEASE", 178, 196], ["C. trachomatis", "DISEASE", 213, 227], ["genital chlamyidia", "ORGANISM", 178, 196], ["C. trachomatis", "ORGANISM", 213, 227], ["genital secretions", "ORGAN", 251, 269], ["hand", "ORGANISM_SUBDIVISION", 289, 293], ["eye", "ORGAN", 301, 304], ["C. trachomatis", "SPECIES", 213, 227], ["C. trachomatis", "SPECIES", 213, 227], ["a known link between inclusion conjunctivitis", "PROBLEM", 128, 173], ["genital chlamyidia", "PROBLEM", 178, 196], ["C. trachomatis", "PROBLEM", 213, 227], ["contaminated genital secretions", "PROBLEM", 238, 269], ["inclusion", "OBSERVATION_MODIFIER", 149, 158], ["conjunctivitis", "OBSERVATION", 159, 173], ["genital chlamyidia", "ANATOMY", 178, 196], ["secretions", "OBSERVATION", 259, 269], ["eye", "ANATOMY", 301, 304]]], ["Contaminated fingers may or may not be washed depending on the availability of water.", [["fingers", "ANATOMY", 13, 20], ["fingers", "ORGANISM_SUBDIVISION", 13, 20], ["Contaminated fingers", "PROBLEM", 0, 20]]], ["In areas of water scarcity, hand washing is likely to be less frequent.", [["hand", "ANATOMY", 28, 32], ["hand", "ORGANISM_SUBDIVISION", 28, 32], ["water scarcity", "TREATMENT", 12, 26], ["hand washing", "TREATMENT", 28, 40], ["areas", "OBSERVATION_MODIFIER", 3, 8], ["water scarcity", "OBSERVATION", 12, 26], ["hand", "ANATOMY", 28, 32], ["washing", "OBSERVATION", 33, 40], ["likely to be", "UNCERTAINTY", 44, 56], ["less", "OBSERVATION_MODIFIER", 57, 61]]], ["Blinding trachoma is a major problem in countries with a high level of desertification, including Egypt and Chad.", [["trachoma", "DISEASE", 9, 17], ["Blinding trachoma", "PROBLEM", 0, 17], ["trachoma", "OBSERVATION", 9, 17]]], ["Although speculative, it is possible that blinding trachoma in such areas is partly associated with both the presence of genital chlamydia and lack of water for hand washing.TrachomaAn understanding of the ecology of the vector-borne route is of critical importance when considering climate change.", [["hand", "ANATOMY", 161, 165], ["trachoma", "DISEASE", 51, 59], ["genital chlamydia", "DISEASE", 121, 138], ["genital", "ORGANISM_SUBDIVISION", 121, 128], ["hand", "ORGANISM_SUBDIVISION", 161, 165], ["blinding trachoma", "PROBLEM", 42, 59], ["genital chlamydia", "PROBLEM", 121, 138], ["hand washing", "TREATMENT", 161, 173], ["is possible", "UNCERTAINTY", 25, 36], ["blinding", "OBSERVATION_MODIFIER", 42, 50], ["trachoma", "OBSERVATION", 51, 59], ["genital", "ANATOMY", 121, 128], ["chlamydia", "OBSERVATION", 129, 138]]], ["Musca sorbens, a major vector of trachoma, lays its eggs on (preferably human) faeces (Emerson et al., 2001) .", [["eggs", "ANATOMY", 52, 56], ["trachoma", "DISEASE", 33, 41], ["Musca sorbens", "ORGANISM", 0, 13], ["human", "ORGANISM", 72, 77], ["faeces", "ORGANISM_SUBDIVISION", 79, 85], ["Musca sorbens", "SPECIES", 0, 13], ["human", "SPECIES", 72, 77], ["Musca sorbens", "SPECIES", 0, 13], ["human", "SPECIES", 72, 77], ["trachoma", "PROBLEM", 33, 41], ["trachoma", "OBSERVATION", 33, 41]]], ["Factors affecting the probability of emergence include whether or not the environment around the faeces leads to crust formation (making it harder to emerge), whether or not the faeces is removed by dung beetles, or whether fly predators such as the dermapateran Labidura riparia or histerid beetles such as Atholus rothkirchi Berkhardt, predate the larvae prior to emergence (Toyama and Ikeda, 1981) .", [["faeces", "ANATOMY", 97, 103], ["faeces", "ANATOMY", 178, 184], ["faeces", "ORGANISM_SUBDIVISION", 97, 103], ["crust", "TISSUE", 113, 118], ["faeces", "ORGANISM_SUBDIVISION", 178, 184], ["dermapateran", "ORGANISM", 250, 262], ["Labidura riparia", "ORGANISM", 263, 279], ["histerid beetles", "ORGANISM", 283, 299], ["Atholus rothkirchi Berkhardt", "ORGANISM", 308, 336], ["Labidura riparia", "SPECIES", 263, 279], ["Atholus rothkirchi", "SPECIES", 308, 326], ["Labidura riparia", "SPECIES", 263, 279], ["Atholus rothkirchi", "SPECIES", 308, 326], ["the dermapateran Labidura riparia", "PROBLEM", 246, 279], ["histerid beetles", "PROBLEM", 283, 299], ["Atholus rothkirchi Berkhardt", "TREATMENT", 308, 336]]], ["When considering how climate change may affect trachoma transmission it is therefore necessary to consider how dung beetles, and arthropod fly predators will also be affected.", [["trachoma", "DISEASE", 47, 55], ["trachoma transmission", "PROBLEM", 47, 68]]], ["Furthermore, although M. sorbens appears to prefer human faeces, the fly will also settle and lay eggs on dung of animals such as cows.", [["faeces", "ANATOMY", 57, 63], ["M. sorbens", "ORGANISM", 22, 32], ["human", "ORGANISM", 51, 56], ["faeces", "ORGANISM_SUBDIVISION", 57, 63], ["dung", "ORGANISM_SUBDIVISION", 106, 110], ["cows", "ORGANISM_SUBDIVISION", 130, 134], ["M. sorbens", "SPECIES", 22, 32], ["human", "SPECIES", 51, 56], ["cows", "SPECIES", 130, 134], ["M. sorbens", "SPECIES", 22, 32], ["human", "SPECIES", 51, 56]]], ["So it also important to consider how humans and animals will deposit faeces, and what happens to the faeces once deposited, under conditions of a changing climate which may include increasingly long periods of extreme conditions.", [["humans", "ORGANISM", 37, 43], ["faeces", "ORGANISM_SUBDIVISION", 69, 75], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["extreme conditions", "PROBLEM", 210, 228]]], ["In a recent attempt to understand better how climate affects trachoma transmission, Ramesh et al. (2013) reviewed studies of abiotic factors associated with M. sorbens ecology.", [["trachoma", "DISEASE", 61, 69], ["M. sorbens", "ORGANISM", 157, 167], ["abiotic factors", "PROTEIN", 125, 140], ["M. sorbens", "SPECIES", 157, 167], ["M. sorbens", "SPECIES", 157, 167], ["abiotic factors", "PROBLEM", 125, 140]]], ["First implicated as a vector at the turn of the 21st century (Emerson et al., 2000) , the fly is known to be affected by temperature and humidity, but the limited number of relevant studies makes modelling of the future transmission potential highly challenging (Ramesh et al., 2013) .TrachomaThe lack of empirical data to support dynamic models is of particular concern.", [["Trachoma", "DISEASE", 285, 293], ["Trachoma", "PROBLEM", 285, 293], ["empirical data", "TEST", 305, 319]]], ["The WHO strategy of combining mass antibiotic distribution, facial cleanliness and environmental hygiene (known as SAFE), has been scaled up in recent years, and blinding trachoma is one of the conditions scheduled for global elimination by 2020.", [["facial", "ANATOMY", 60, 66], ["trachoma", "DISEASE", 171, 179], ["combining mass antibiotic distribution", "PROBLEM", 20, 58], ["facial cleanliness", "PROBLEM", 60, 78], ["blinding trachoma", "PROBLEM", 162, 179], ["mass", "OBSERVATION", 30, 34], ["facial", "ANATOMY", 60, 66], ["trachoma", "OBSERVATION", 171, 179]]], ["Given the paucity of information on the epidemiology of blinding trachoma, its links to genital chlamydia, water insecurities, land use change and other potential ecological variances, it is still an uncertain future.Buruli UlcerBuruli ulcer is a debilitating and disfiguring infection of tropical regions caused by Mycobacterium ulcerans.", [["UlcerBuruli ulcer", "ANATOMY", 224, 241], ["trachoma", "DISEASE", 65, 73], ["genital chlamydia", "DISEASE", 88, 105], ["ulcer", "DISEASE", 236, 241], ["infection", "DISEASE", 276, 285], ["Mycobacterium ulcerans", "DISEASE", 316, 338], ["genital", "ORGANISM_SUBDIVISION", 88, 95], ["Mycobacterium ulcerans", "ORGANISM", 316, 338], ["Mycobacterium ulcerans", "SPECIES", 316, 338], ["Mycobacterium ulcerans", "SPECIES", 316, 338], ["blinding trachoma", "PROBLEM", 56, 73], ["genital chlamydia", "PROBLEM", 88, 105], ["Buruli UlcerBuruli ulcer", "PROBLEM", 217, 241], ["a debilitating", "PROBLEM", 245, 259], ["disfiguring infection of tropical regions", "PROBLEM", 264, 305], ["Mycobacterium ulcerans", "PROBLEM", 316, 338], ["trachoma", "OBSERVATION", 65, 73], ["ulcer", "OBSERVATION", 236, 241], ["debilitating", "OBSERVATION_MODIFIER", 247, 259], ["disfiguring", "OBSERVATION_MODIFIER", 264, 275], ["infection", "OBSERVATION", 276, 285], ["tropical regions", "OBSERVATION_MODIFIER", 289, 305], ["Mycobacterium ulcerans", "OBSERVATION", 316, 338]]], ["For a recent review of the pathology of Buruli ulcer, see Yotsu et al. (2015) .", [["Buruli ulcer", "DISEASE", 40, 52], ["Buruli ulcer", "PROBLEM", 40, 52], ["Buruli ulcer", "OBSERVATION", 40, 52]]], ["Within that review is a list of known or suspected vectors of M. ulcerans that includes insects, mammals, fish and shellfish.", [["M. ulcerans", "ORGANISM", 62, 73], ["fish", "ORGANISM", 106, 110], ["shellfish", "ORGANISM_SUBDIVISION", 115, 124], ["M. ulcerans", "SPECIES", 62, 73], ["M. ulcerans", "SPECIES", 62, 73], ["M. ulcerans", "PROBLEM", 62, 73], ["M. ulcerans", "OBSERVATION", 62, 73]]], ["One of the key suspects is Naucoridae water bugs (Portaels et al., 2008) , which have been demonstrated to be able to transfer the bacterium to mice through biting-the bacterium being located in the salivary glands (Marsollier et al., 2002) .", [["salivary glands", "ANATOMY", 199, 214], ["mice", "ORGANISM", 144, 148], ["salivary glands", "ORGAN", 199, 214], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["the bacterium", "PROBLEM", 164, 177], ["salivary glands", "ANATOMY", 199, 214]]], ["There is also evidence that certain types of water body (e.g. swamps) are associated with increased risk of exposure to the bacterium, but no evidence that direct water contact is a risk factor (Williamson et al., 2012) .", [["body", "ANATOMY", 51, 55], ["water body (e.g. swamps)", "PROBLEM", 45, 69], ["the bacterium", "PROBLEM", 120, 133], ["certain", "OBSERVATION_MODIFIER", 28, 35], ["types", "OBSERVATION_MODIFIER", 36, 41], ["water body", "OBSERVATION_MODIFIER", 45, 55], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["no evidence", "UNCERTAINTY", 139, 150]]], ["The reason for proximity to water being a risk factor may be partly due to the presence of the water bugs.", [["a risk factor", "PROBLEM", 40, 53], ["the water bugs", "PROBLEM", 91, 105]]], ["Linking the abundance of water bugs to the risk of infection has proven challenging-various studies have identified that carriage of the bacterium in in the mouthparts of the water bugs changes at specific times of year (Marion et al., 2010) , but also that unidentified environmental factors can better explain spatiotemporal variation in disease when compared to spatiotemporal variation of M. ulcerans presence in the environment (Garchitorena et al., 2016) .Buruli UlcerCases of the Buruli ulcer are predominantly found in West Africa (Yotsu et al., 2015) , but also in other tropical countries including Japan (Yotsu et al., 2012) and northern parts of Australia (Lavender et al., 2012) .", [["Buruli ulcer", "ANATOMY", 487, 499], ["infection", "DISEASE", 51, 60], ["Buruli ulcer", "DISEASE", 487, 499], ["M. ulcerans", "ORGANISM", 393, 404], ["ulcer", "PATHOLOGICAL_FORMATION", 494, 499], ["M. ulcerans", "SPECIES", 393, 404], ["M. ulcerans", "SPECIES", 393, 404], ["infection", "PROBLEM", 51, 60], ["various studies", "TEST", 84, 99], ["the bacterium", "PROBLEM", 133, 146], ["spatiotemporal variation in disease", "PROBLEM", 312, 347], ["M. ulcerans", "PROBLEM", 393, 404], ["Buruli UlcerCases", "PROBLEM", 462, 479], ["the Buruli ulcer", "PROBLEM", 483, 499], ["abundance", "OBSERVATION_MODIFIER", 12, 21], ["infection", "OBSERVATION", 51, 60], ["water bugs", "OBSERVATION", 175, 185], ["ulcerans", "OBSERVATION", 396, 404], ["Buruli ulcer", "OBSERVATION", 487, 499], ["predominantly", "OBSERVATION_MODIFIER", 504, 517]]], ["Anthropocentric activities such as dam building have been implicated in terms of establishing new sites of infection (Marion et al., 2011) .", [["infection", "DISEASE", 107, 116], ["infection", "PROBLEM", 107, 116], ["new", "OBSERVATION_MODIFIER", 94, 97], ["infection", "OBSERVATION", 107, 116]]], ["A recent case report suggests the bacterium is also found in Honduras (Southern, 2016) .", [["the bacterium", "PROBLEM", 30, 43]]], ["Buruli ulcer is classified as an emerging disease.", [["Buruli ulcer", "ANATOMY", 0, 12], ["Buruli ulcer", "DISEASE", 0, 12], ["Buruli ulcer", "PROBLEM", 0, 12], ["an emerging disease", "PROBLEM", 30, 49], ["ulcer", "OBSERVATION", 7, 12], ["disease", "OBSERVATION", 42, 49]]], ["The number of cases per country fluctuates and there is no clear temporal trend over the previous decade (Yotsu et al., 2015) .Buruli UlcerEvidence is emerging of landscape factors driving spatiotemporal variation in abundance of M. ulcerans cases- (Aboagye et al., 2017-presence of bacterial DNA in the environment; Landier et al., 2014; Merritt et al., 2010) .", [["Buruli", "DISEASE", 127, 133], ["M. ulcerans", "ORGANISM", 230, 241], ["DNA", "CELLULAR_COMPONENT", 293, 296], ["M. ulcerans", "SPECIES", 230, 241], ["M. ulcerans", "SPECIES", 230, 241], ["Buruli UlcerEvidence", "PROBLEM", 127, 147], ["bacterial DNA", "PROBLEM", 283, 296], ["no", "UNCERTAINTY", 56, 58], ["clear", "OBSERVATION_MODIFIER", 59, 64], ["temporal", "OBSERVATION_MODIFIER", 65, 73], ["trend", "OBSERVATION_MODIFIER", 74, 79], ["M. ulcerans", "OBSERVATION", 230, 241]]], ["At the time of writing, there were no original research articles on the potential for decadal climate change to affect transmission patterns.LeishmaniaFor a review of papers published on this subject before 2008, see Ready (2008) .LeishmaniaSeveral species of Phlebotomus and Lutzomyia sandflies, distributed and segregated geographically across the tropics, have been identified as major vectors of leishmanial parasites (Bates, 2007) .", [["leishmanial parasites", "DISEASE", 400, 421], ["Phlebotomus", "ORGANISM", 260, 271], ["Lutzomyia sandflies", "ORGANISM", 276, 295], ["leishmanial", "ORGANISM", 400, 411], ["decadal climate change", "TREATMENT", 86, 108], ["LeishmaniaSeveral species", "PROBLEM", 231, 256], ["Phlebotomus", "PROBLEM", 260, 271], ["Lutzomyia sandflies", "PROBLEM", 276, 295], ["Phlebotomus", "OBSERVATION", 260, 271], ["Lutzomyia sandflies", "OBSERVATION", 276, 295], ["segregated", "OBSERVATION_MODIFIER", 313, 323], ["geographically", "OBSERVATION_MODIFIER", 324, 338], ["leishmanial parasites", "OBSERVATION", 400, 421]]], ["While it has been recognised since the turn of the century that climate change may have a significant impact on the distribution of both the vectors and the disease (Peterson and Shaw, 2003) , the general direction of travel is less well specified due to the fact that sandfly populations are affected on a microgeographical scale.LeishmaniaIn the European context, it has been demonstrated that the density of Phlebotomus ariasi at a particular sampling location is affected by both minimum and maximum temperatures and to some extent by RH (Prudhomme et al., 2015) .", [["Phlebotomus ariasi", "ORGANISM", 411, 429], ["Phlebotomus ariasi", "SPECIES", 411, 429], ["Phlebotomus ariasi", "SPECIES", 411, 429], ["sandfly populations", "PROBLEM", 269, 288], ["a microgeographical scale", "TREATMENT", 305, 330], ["Phlebotomus ariasi", "PROBLEM", 411, 429], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["impact", "OBSERVATION_MODIFIER", 102, 108], ["disease", "OBSERVATION", 157, 164], ["density", "OBSERVATION_MODIFIER", 400, 407], ["Phlebotomus ariasi", "OBSERVATION", 411, 429], ["both", "OBSERVATION_MODIFIER", 479, 483], ["minimum", "OBSERVATION_MODIFIER", 484, 491], ["maximum", "OBSERVATION_MODIFIER", 496, 503], ["temperatures", "OBSERVATION_MODIFIER", 504, 516]]], ["South facing slopes, wall vegetation, soil type and neighbouring land cover precipitation may also be important factors in determining local abundance of this and other species (Ballart et al., 2014) .", [["wall vegetation", "PROBLEM", 21, 36], ["soil type", "PROBLEM", 38, 47], ["neighbouring land cover precipitation", "TREATMENT", 52, 89], ["wall", "ANATOMY_MODIFIER", 21, 25], ["vegetation", "OBSERVATION", 26, 36]]], ["Effects of individual explanatory factors disaggregate among species of sandfly, indicating a need to consider not just how climate change might affect individual ecological drivers of abundance and site-specific vector density, but how individual species of vector might be affected.LeishmaniaIn the South American context, the relatively early models of Peterson and Shaw (2003) , using a combination of ecological niche modelling and a general circulation model, predicted that by 2055 conditions in parts of Brazil may become more favourable for transmission due largely to anticipated increases in temperature.", [["individual explanatory factors", "PROBLEM", 11, 41], ["specific vector density", "PROBLEM", 204, 227], ["increases in temperature", "PROBLEM", 590, 614], ["vector density", "OBSERVATION", 213, 227]]], ["A more refined conclusion was reached by Carvalho et al. (2015) , working with an ensemble of ecological niche models and downscaled (344 km 2 ) general circulation models, projected to 2041-60.", [["general circulation models", "TEST", 145, 171]]], ["In that study, the simulations indicate that southern and eastern parts of Brazil are likely to become more suitable in terms of the environment a simulation model of climate change scenarios on the distribution of leishmanial vectors in the Colombian context, it was suggested that spatial range could decrease under minimally disruptive scenarios through to maximally disruptive scenarios (Gonz\u00e1lez et al., 2014) .Chagas DiseaseThe organism responsible for Chagas disease is Trypanasoma cruzi.", [["Chagas Disease", "DISEASE", 416, 430], ["Chagas disease", "DISEASE", 459, 473], ["Trypanasoma cruzi", "DISEASE", 477, 494], ["Trypanasoma cruzi", "ORGANISM", 477, 494], ["Trypanasoma cruzi", "SPECIES", 477, 494], ["Chagas Disease", "SPECIES", 416, 430], ["Trypanasoma cruzi", "SPECIES", 477, 494], ["that study", "TEST", 3, 13], ["minimally disruptive scenarios", "PROBLEM", 318, 348], ["Chagas Disease", "PROBLEM", 416, 430], ["The organism", "PROBLEM", 430, 442], ["Chagas disease", "PROBLEM", 459, 473], ["Trypanasoma cruzi", "PROBLEM", 477, 494], ["leishmanial vectors", "OBSERVATION", 215, 234], ["responsible for", "UNCERTAINTY", 443, 458], ["Chagas disease", "OBSERVATION", 459, 473]]], ["This protozoan parasite is distributed widely across Latin America and is estimated to infect 6-8 million people of all ages (Rassi et al., 2010) .", [["protozoan parasite", "DISEASE", 5, 23], ["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["This protozoan parasite", "PROBLEM", 0, 23], ["protozoan", "OBSERVATION_MODIFIER", 5, 14], ["parasite", "OBSERVATION", 15, 23], ["distributed", "OBSERVATION_MODIFIER", 27, 38], ["widely", "OBSERVATION_MODIFIER", 39, 45]]], ["The climate-sensitive stage of the parasite is in the insect vector, members of the Triatominae subfamily.Chagas DiseaseThe evolution, natural history and ecology of many Triatominae vectors are described in detail elsewhere (Abad-Franch et al., 2015; Galvao and Justi, 2015; Teixeira et al., 2009) .", [["Chagas Disease", "DISEASE", 106, 120], ["Triatominae", "GENE_OR_GENE_PRODUCT", 84, 95], ["Triatominae subfamily", "PROTEIN", 84, 105], ["Chagas Disease", "SPECIES", 106, 120], ["Chagas Disease", "PROBLEM", 106, 120], ["sensitive stage", "OBSERVATION_MODIFIER", 12, 27], ["parasite", "OBSERVATION", 35, 43], ["Triatominae vectors", "OBSERVATION", 171, 190]]], ["What has emerged from these and other studies is that many Triaotominae species have evolved to be closely associated with specific natural environments involving vertebrates such as birds, bats and rodents (Galvao and Justi, 2015) from which they derive blood meals.", [["blood", "ANATOMY", 255, 260], ["Triaotominae species", "ORGANISM", 59, 79], ["blood", "ORGANISM_SUBSTANCE", 255, 260], ["other studies", "TEST", 32, 45], ["many Triaotominae species", "PROBLEM", 54, 79]]], ["The large number of species means that there are a corresponding large number of potential niches, each of which may respond differently to changing climates.Chagas DiseaseIt is becoming increasingly apparent that these traditional niches are being disturbed by anthropogenic changes affecting life history traits, species composition in specific locations and habitat availability (Gottdenker et al., 2012) .", [["Chagas DiseaseIt", "DISEASE", 158, 174], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["species", "OBSERVATION", 20, 27], ["large", "OBSERVATION_MODIFIER", 65, 70], ["number", "OBSERVATION_MODIFIER", 71, 77], ["potential niches", "OBSERVATION", 81, 97]]], ["Several studies have reported that normally sylvatic species are increasingly invading urban domestic properties, for example in Bolivia (Rojas-Cortez et al., 2016) and Brazil (Ribeiro et al., 2015) .", [["Several studies", "TEST", 0, 15], ["normally sylvatic species", "PROBLEM", 35, 60], ["sylvatic species", "OBSERVATION", 44, 60]]], ["Reasons for expansion of the vector range into human habitations have speculated to include the increasing availability of electrical light.", [["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52]]], ["Many insect species are attracted to the blue light fraction of electrical light and several studies have observed clustering of Triatomine species around artificial light sources, both in sylvatic (Castro et al., 2010) and urban (Pacheco-Tucuch et al., 2012) settings.", [["Triatomine", "CHEMICAL", 129, 139], ["Many insect species", "PROBLEM", 0, 19], ["several studies", "TEST", 85, 100], ["Triatomine species", "PROBLEM", 129, 147], ["insect species", "OBSERVATION", 5, 19], ["Triatomine species", "OBSERVATION", 129, 147]]], ["Economic activities associated with the availability of electric light have also been suggested to underlie recent epidemics of T. cruzi in new areas.Chagas DiseaseThe anthropogenic influences above demonstrate that Triatominae adapt rapidly to new opportunities and/or pressures.", [["T. cruzi", "DISEASE", 128, 136], ["Chagas Disease", "DISEASE", 150, 164], ["T. cruzi", "ORGANISM", 128, 136], ["Triatominae", "SIMPLE_CHEMICAL", 216, 227], ["T. cruzi", "SPECIES", 128, 136], ["T. cruzi", "SPECIES", 128, 136], ["Chagas Disease", "SPECIES", 150, 164], ["T. cruzi", "PROBLEM", 128, 136], ["Chagas Disease", "PROBLEM", 150, 164], ["pressures", "TEST", 270, 279], ["new", "OBSERVATION_MODIFIER", 140, 143], ["anthropogenic", "OBSERVATION", 168, 181]]], ["The potential for climate change to affect transmission patterns of T. cruzi over much longer periods, through long-term effects on the soil and water phases, is less well understood but has received some attention in the literature, specifically through attempts to model the future suitability of habitats to support vectors.", [["T. cruzi", "ORGANISM", 68, 76], ["T. cruzi", "SPECIES", 68, 76], ["T. cruzi", "SPECIES", 68, 76], ["climate change", "PROBLEM", 18, 32], ["T. cruzi", "PROBLEM", 68, 76], ["long-term effects", "OBSERVATION_MODIFIER", 111, 128]]], ["Two separate studies have focused on how projected warming scenarios may affect the geographic distribution of Rhodnius prolixus and Triatoma infestans in Venezuala and Argentina (Medone et al., 2015) , and the geographic distribution of Eratyrus mucronatus, Panstrongylus geniculatus, R. prolixus, Rhodnius robustus and Triatoma maculata in Venezuala (Ceccarelli et al., 2015) .Chagas DiseaseA common output of these studies was that the distribution of infection is likely to change over the coming decades.", [["Chagas DiseaseA", "DISEASE", 379, 394], ["infection", "DISEASE", 455, 464], ["Rhodnius prolixus", "ORGANISM", 111, 128], ["Triatoma infestans", "ORGANISM", 133, 151], ["Eratyrus mucronatus", "ORGANISM", 238, 257], ["Panstrongylus geniculatus", "ORGANISM", 259, 284], ["R. prolixus", "ORGANISM", 286, 297], ["Rhodnius robustus", "ORGANISM", 299, 316], ["Triatoma maculata", "ORGANISM", 321, 338], ["Rhodnius prolixus", "SPECIES", 111, 128], ["Triatoma infestans", "SPECIES", 133, 151], ["Eratyrus mucronatus", "SPECIES", 238, 257], ["Panstrongylus geniculatus", "SPECIES", 259, 284], ["R. prolixus", "SPECIES", 286, 297], ["Rhodnius robustus", "SPECIES", 299, 316], ["Triatoma maculata", "SPECIES", 321, 338], ["Rhodnius prolixus", "SPECIES", 111, 128], ["Triatoma infestans", "SPECIES", 133, 151], ["Eratyrus mucronatus", "SPECIES", 238, 257], ["Panstrongylus geniculatus", "SPECIES", 259, 284], ["R. prolixus", "SPECIES", 286, 297], ["Rhodnius robustus", "SPECIES", 299, 316], ["Triatoma maculata", "SPECIES", 321, 338], ["Two separate studies", "TEST", 0, 20], ["Rhodnius prolixus", "PROBLEM", 111, 128], ["Triatoma infestans", "PROBLEM", 133, 151], ["Eratyrus mucronatus", "PROBLEM", 238, 257], ["Panstrongylus geniculatus", "PROBLEM", 259, 284], ["R. prolixus", "PROBLEM", 286, 297], ["Rhodnius robustus", "PROBLEM", 299, 316], ["these studies", "TEST", 412, 425], ["infection", "PROBLEM", 455, 464], ["Rhodnius prolixus", "OBSERVATION", 111, 128], ["Eratyrus mucronatus", "OBSERVATION", 238, 257], ["Rhodnius robustus", "OBSERVATION", 299, 316], ["Triatoma maculata", "OBSERVATION", 321, 338], ["infection", "OBSERVATION", 455, 464]]], ["Specifically, the distribution of infection is expected to reduce in the countries studied due to environments becoming unsuitable for the vectors.", [["infection", "DISEASE", 34, 43], ["infection", "PROBLEM", 34, 43], ["distribution", "OBSERVATION_MODIFIER", 18, 30], ["infection", "OBSERVATION", 34, 43]]], ["Neither of these studies considered other changes to the niches that will be affected by climate change.", [["these studies", "TEST", 11, 24]]], ["Palm trees, bromeliads, bird and rodent nests, hollow trees and mammal burrows are among the sylvatic ecotopes occupied by the vectors of T. cruzi.", [["bromeliads", "ANATOMY", 12, 22], ["hollow trees", "MULTI-TISSUE_STRUCTURE", 47, 59], ["T. cruzi", "ORGANISM", 138, 146], ["rodent", "SPECIES", 33, 39], ["T. cruzi", "SPECIES", 138, 146], ["T. cruzi", "SPECIES", 138, 146], ["mammal burrows", "PROBLEM", 64, 78], ["the sylvatic ecotopes", "PROBLEM", 89, 110], ["hollow trees", "OBSERVATION", 47, 59], ["mammal burrows", "OBSERVATION", 64, 78]]], ["Climate change is likely to impact on each ecotype in ways that we do not yet fully understand and which will be challenging to project given the potential for multidimensional interactions among biotic and abiotic domains.Human African Trypanosomiasis (HAT)The life cycle of HAT involves humans, wildlife and over 20 species of Glossina, the Tsetse fly.", [["Human", "ORGANISM", 223, 228], ["humans", "ORGANISM", 289, 295], ["Tsetse fly", "ORGANISM", 343, 353], ["Human", "SPECIES", 223, 228], ["humans", "SPECIES", 289, 295], ["humans", "SPECIES", 289, 295], ["Tsetse fly", "SPECIES", 343, 353], ["Human African Trypanosomiasis (HAT)", "TREATMENT", 223, 258], ["likely to", "UNCERTAINTY", 18, 27]]], ["The most climate-sensitive stage of the lifecycle is in the flies.", [["lifecycle", "OBSERVATION_MODIFIER", 40, 49]]], ["It is well established that Tsetse natural history dynamics are shaped by environmental factors-as far back as 1940 studies were being undertaken into the role of humidity on the population of Glossina pallidipes, Glossina austeni and Glossina brevipalpis in Kenya (Moggridge, 1949) .", [["Glossina pallidipes", "ORGANISM", 193, 212], ["Glossina austeni", "ORGANISM", 214, 230], ["Glossina brevipalpis", "ORGANISM", 235, 255], ["Glossina pallidipes", "SPECIES", 193, 212], ["Glossina austeni", "SPECIES", 214, 230], ["Glossina brevipalpis", "SPECIES", 235, 255], ["Glossina pallidipes", "SPECIES", 193, 212], ["Glossina austeni", "SPECIES", 214, 230], ["Glossina brevipalpis", "SPECIES", 235, 255], ["Glossina pallidipes", "PROBLEM", 193, 212], ["shaped", "OBSERVATION_MODIFIER", 64, 70], ["Glossina pallidipes", "OBSERVATION", 193, 212]]], ["Readers are referred to Leak (1999) for a comprehensive overview of Tsetse biology and ecology, and Rogers (2000) for an introduction into the use of satellite imagery to map the distribution of Tsetse flies.Human African Trypanosomiasis (HAT)More recently, Pagabeleguem et al. (2016) have investigated the fecundity and survival of three strains of G.p. gambiensis under conditions of varying temperature at constant RH (25-35\u00b0C at 60% RH) and varying RH at constant temperature (40%-75% RH at 25\u00b0C).", [["Human", "ORGANISM", 208, 213], ["G.p. gambiensis", "ORGANISM", 350, 365], ["Human", "SPECIES", 208, 213], ["G.p. gambiensis", "SPECIES", 350, 365], ["Tsetse flies", "SPECIES", 195, 207], ["G.p. gambiensis", "SPECIES", 350, 365], ["Leak", "TEST", 24, 28], ["satellite imagery", "TREATMENT", 150, 167], ["Human African Trypanosomiasis (HAT)", "TREATMENT", 208, 243], ["varying temperature", "PROBLEM", 386, 405], ["Leak", "OBSERVATION", 24, 28], ["Tsetse flies", "OBSERVATION", 195, 207]]], ["The effect of changing temperature on the survival was dramatic.", [["changing temperature", "PROBLEM", 14, 34]]], ["Peak survival of all three strains was estimated to occur at 25\u00b0C, with rapid declines thereafter and a median survival time of less than 5 days at 32\u00b0C.Human African Trypanosomiasis (HAT)In terms of the potential for climate change to alter current transmission patterns, there has been one published study.", [["Human", "ORGANISM", 153, 158], ["Human", "SPECIES", 153, 158], ["all three strains", "PROBLEM", 17, 34], ["rapid declines", "PROBLEM", 72, 86], ["Human African Trypanosomiasis (HAT)", "TREATMENT", 153, 188], ["one published study", "TEST", 288, 307], ["rapid", "OBSERVATION_MODIFIER", 72, 77], ["declines", "OBSERVATION_MODIFIER", 78, 86]]], ["Moore et al. (2012) used a deterministic model based on a series of ordinary differential equations that described the rate at which tsetse flies become susceptible, exposed, infected and recovered.", [["ordinary differential equations", "PROBLEM", 68, 99], ["infected", "OBSERVATION", 175, 183]]], ["The effect of changing temperature on the basic reproductive rate (R0) was then estimated from published studies on the effect of temperature change on mortality, biting rate, parasite-biting rate and population growth rate.", [["changing temperature", "PROBLEM", 14, 34], ["published studies", "TEST", 95, 112], ["temperature change", "PROBLEM", 130, 148], ["biting rate", "TEST", 163, 174], ["parasite", "PROBLEM", 176, 184], ["population growth rate", "TEST", 201, 223]]], ["Changes in temperature over future decades were drawn from the IPCC scenarios B1 and A2 to 2090.", [["Changes in temperature", "PROBLEM", 0, 22]]], ["Population was assumed to remain constant.", [["constant", "OBSERVATION_MODIFIER", 33, 41]]], ["Moore et al. (2012) predicted that rather than expansion of the tseste fly population under conditions set by the IPCC scenarios, there may be a shift of up to 60% in the geographical extent of the range.", [["may be", "UNCERTAINTY", 136, 142]]], ["Under the A2 scenario, there is likely to be range contraction by 2090 due to some regions of eastern Africa becoming too hot to support the fly population.Human African Trypanosomiasis (HAT)In recognising the limits of their study, Moore et al. (2012) highlight a point relevant to all modelling studies-namely that the modelling exercise itself sets a framework for future projects rather than making any definitive statements.CONCLUSIONSIn writing this review, I examined the published peer-reviewed literature for articles that represent interests in climate change and NTDs.", [["NTDs", "DISEASE", 574, 578], ["Human", "ORGANISM", 156, 161], ["Human", "SPECIES", 156, 161], ["eastern Africa", "PROBLEM", 94, 108], ["their study", "TEST", 220, 231], ["all modelling studies", "TEST", 283, 304], ["NTDs", "PROBLEM", 574, 578], ["A2 scenario", "OBSERVATION", 10, 21], ["likely to be", "UNCERTAINTY", 32, 44], ["range contraction", "OBSERVATION", 45, 62]]], ["Climate change in this context primarily concerns forward looking, decadal-scale changes and is therefore distinct from near or mid-term forecasting which typically concerns within-decade timescales.CONCLUSIONSIt is clear from reviewing the published literature that there is a relative abundance of literature from previous decades, as well as more recently, regarding the environmental factors that underpin the natural history of several NTDs.", [["NTDs", "DISEASE", 441, 445], ["the environmental factors", "PROBLEM", 370, 395], ["several NTDs", "PROBLEM", 433, 445], ["distinct", "OBSERVATION_MODIFIER", 106, 114], ["clear", "OBSERVATION", 216, 221]]], ["In contrast, there is a paucity of forward-looking research being conducted on the decadal timescale for the majority of infections.", [["infections", "DISEASE", 121, 131], ["the decadal timescale", "TREATMENT", 79, 100], ["infections", "PROBLEM", 121, 131], ["paucity", "OBSERVATION_MODIFIER", 24, 31], ["infections", "OBSERVATION", 121, 131]]], ["This document therefore serves as a gap analysis as much as a review of the state of the art.CONCLUSIONSOne conclusion that is nonetheless shared among all research outputs is that a changing climate is associated with spatiotemporal variation in exposure and transmission of each species of infection.", [["infection", "DISEASE", 292, 301], ["a gap analysis", "TEST", 34, 48], ["spatiotemporal variation", "PROBLEM", 219, 243], ["infection", "PROBLEM", 292, 301], ["associated with", "UNCERTAINTY", 203, 218], ["spatiotemporal variation", "OBSERVATION", 219, 243], ["infection", "OBSERVATION", 292, 301]]], ["Along with other aspects of global change (reviewed by Cable et al., 2017) , it can be concluded that there are likely to be profound yet hard-to-discern changes to global patterns of NTD transmission in the near, mid-and long term.", [["global change", "PROBLEM", 28, 41], ["NTD transmission", "PROBLEM", 184, 200], ["global", "OBSERVATION_MODIFIER", 28, 34], ["change", "OBSERVATION", 35, 41], ["NTD", "OBSERVATION", 184, 187], ["mid", "ANATOMY_MODIFIER", 214, 217]]], ["Some of these changes may be extreme enough to cause elimination or extinction of parasites, vectors and zoonotic hosts in localised, regional or global contexts (Cable et al., 2017; Cizauskas et al., 2017) .CONCLUSIONSThe future can only be imagined and modelled, as we cannot draw data down from the future.", [["extinction of parasites", "PROBLEM", 68, 91]]], ["No model can capture every potential interaction, and the increasingly fragmented nature of ecosystems (Haddad et al., 2015) is an ongoing challenge in terms of providing mitigation and/or adaptation (Villard and Metzger, 2014) .CONCLUSIONSIn the absence of sureties regarding the future, combined with recognition of the inherent complexities facing humanity, a viable response may be to increase intersectoral collaboration so that, e.g., emerging knowledge in one domain can be assessed for its utility in another domain.", [["fragmented", "OBSERVATION_MODIFIER", 71, 81]]], ["The 'One Health' concept is a potential avenue down which colleagues working on NTDs from many disciplines could travel together (Webster et al., 2016) .", [["NTDs", "DISEASE", 80, 84]]], ["A complementary approach may be to improve surveillance and adaptation efforts (Ebi et al., 2013; Parham et al., 2015; Wilby and Dessai, 2010) .", [["A complementary approach", "TREATMENT", 0, 24]]], ["It has been advocated that these new approaches should be community-based (Ebi and Semenza, 2008) and combine capacity building in modelling with decision support tools that are sufficiently flexible and adaptive to emerging conditions (Booth and Clements, 2018) .", [["new", "OBSERVATION_MODIFIER", 33, 36]]]], "96454b22b4c649398a3d7763603fec0faa9beb4f": [["INTRODUCTIONExpression of coronavirus genes occurs through the synthesis of a 3\u0408 coterminal nested set of mRNAs.", [["coronavirus", "ORGANISM", 26, 37], ["coronavirus genes", "DNA", 26, 43], ["3\u0408 coterminal nested set", "RNA", 78, 102], ["mRNAs", "RNA", 106, 111], ["coronavirus genes", "PROBLEM", 26, 43], ["a 3\u0408 coterminal nested set of mRNAs", "TREATMENT", 76, 111], ["coronavirus genes", "OBSERVATION", 26, 43]]], ["Although coronavirus mRNAs are structurally polycistronic (the 3\u0408-most mRNA in many but not all viral species is monocistronic), evidence from studies of translation both in vitro and in vivo has suggested that most function as monocistronic messages.", [["coronavirus", "ORGANISM", 9, 20], ["coronavirus mRNAs", "RNA", 9, 26], ["3\u0408-most mRNA", "RNA", 63, 75], ["monocistronic", "DNA", 113, 126], ["coronavirus mRNAs", "PROBLEM", 9, 26], ["structurally polycistronic", "PROBLEM", 31, 57], ["all viral species", "PROBLEM", 92, 109], ["coronavirus mRNAs", "OBSERVATION", 9, 26], ["polycistronic", "OBSERVATION_MODIFIER", 44, 57]]], ["That is, despite their polycistronic configuration, usually only the 5\u0408-terminal ORF on each is abundantly translated (reviewed in Lai and Cavanagh, 1997, and Luytjes, 1995) .", [["5\u0408-terminal ORF", "DNA", 69, 84], ["polycistronic configuration", "OBSERVATION", 23, 50]]], ["The location of some coronavirus genes, however, is not 5\u0408-terminal on any mRNA, which would require that the gene, if expressed, be translated by a mechanism allowing translation reinitiation, leaky scanning, frameshifting, or a downstream entry of ribosomes.", [["ribosomes", "ANATOMY", 250, 259], ["coronavirus", "ORGANISM", 21, 32], ["ribosomes", "CELLULAR_COMPONENT", 250, 259], ["coronavirus genes", "DNA", 21, 38], ["5\u0408-terminal", "DNA", 56, 67], ["mRNA", "RNA", 75, 79], ["some coronavirus genes", "PROBLEM", 16, 38], ["translation reinitiation", "TREATMENT", 168, 192], ["leaky scanning", "TEST", 194, 208], ["some", "OBSERVATION_MODIFIER", 16, 20], ["coronavirus genes", "OBSERVATION", 21, 38]]], ["Examples of such genes include (1) ORF 1b on mRNA 1, from which a polyprotein is synthesized following \u03ea1 ribosomal frameshifting (Brierly et al., 1987; Eleouet et al., 1995) ; (2) ORFs 3b and 3c on avian infectious bronchitis virus mRNA 3 (Boursnell et al., 1985) , from which 7.4-and 12.4-kDa proteins are synthesized following leaky scanning and internal ribosomal entry, respectively (Liu et al., 1991; Liu and Inglis, 1992; Le et al., 1995) ; (3) ORF 5b on mouse hepatitis virus mRNA 5 (Skinner et al., 1985) , from which a 9.6-kDa protein(the E protein) is synthesized (Budzilowicz and Weiss, 1987; Leibowitz et al., 1988) , by an apparent internal ribosomal entry mechanism (Thiel and Siddell, 1994) ; and (4) the I ORF in mRNA 7 of the bovine and mouse hepatitis coronaviruses, from which the I protein is made in the \u03e91 reading frame relative to N (Senanayake et al., 1992; Fischer et al., 1997) following ribosomal scanning (Senanayake and Brian, 1997) .INTRODUCTIONIn this study, we examine the mechanism by which gene 3b is expressed from mRNA 3 in the Purdue strain of TGEV and demonstrate that, surprisingly, it may be approached by ribosomes entering internally and not necessarily through a leaky scanning step as would be predicted from mRNA 3 sequence.", [["ribosomal", "ANATOMY", 106, 115], ["ribosomal", "ANATOMY", 358, 367], ["ribosomal", "ANATOMY", 655, 664], ["ribosomal", "ANATOMY", 915, 924], ["infectious bronchitis", "DISEASE", 205, 226], ["hepatitis virus", "DISEASE", 468, 483], ["hepatitis coronaviruses", "DISEASE", 761, 784], ["(1) ORF 1b", "GENE_OR_GENE_PRODUCT", 31, 41], ["mRNA 1", "GENE_OR_GENE_PRODUCT", 45, 51], ["avian infectious bronchitis virus", "ORGANISM", 199, 232], ["ribosomal", "CELLULAR_COMPONENT", 358, 367], ["ORF 5b", "GENE_OR_GENE_PRODUCT", 452, 458], ["mouse hepatitis virus", "ORGANISM", 462, 483], ["ribosomal", "CELLULAR_COMPONENT", 655, 664], ["bovine", "ORGANISM", 744, 750], ["mouse hepatitis coronaviruses", "ORGANISM", 755, 784], ["ribosomal", "CELLULAR_COMPONENT", 915, 924], ["gene 3b", "GENE_OR_GENE_PRODUCT", 1025, 1032], ["3", "GENE_OR_GENE_PRODUCT", 1056, 1057], ["Purdue strain", "ORGANISM", 1065, 1078], ["TGEV", "ORGANISM", 1082, 1086], ["ribosomes", "CELLULAR_COMPONENT", 1147, 1156], ["ORF 1b", "DNA", 35, 41], ["mRNA 1", "RNA", 45, 51], ["ORFs", "DNA", 181, 185], ["ORF 5b", "DNA", 452, 458], ["9.6-kDa protein", "PROTEIN", 529, 544], ["E protein", "PROTEIN", 549, 558], ["I ORF", "DNA", 721, 726], ["mRNA 7", "RNA", 730, 736], ["I protein", "PROTEIN", 801, 810], ["\u03e91 reading frame", "DNA", 826, 842], ["gene 3b", "DNA", 1025, 1032], ["mRNA 3", "RNA", 1051, 1057], ["mRNA 3 sequence", "DNA", 1254, 1269], ["avian infectious bronchitis virus", "SPECIES", 199, 232], ["mouse", "SPECIES", 462, 467], ["hepatitis virus", "SPECIES", 468, 483], ["bovine", "SPECIES", 744, 750], ["mouse", "SPECIES", 755, 760], ["infectious bronchitis virus", "SPECIES", 205, 232], ["mouse hepatitis virus", "SPECIES", 462, 483], ["mouse hepatitis coronaviruses", "SPECIES", 755, 784], ["TGEV", "SPECIES", 1082, 1086], ["such genes", "PROBLEM", 12, 22], ["a polyprotein", "TREATMENT", 64, 77], ["\u03ea1 ribosomal frameshifting", "PROBLEM", 103, 129], ["ORFs", "TEST", 181, 185], ["avian infectious bronchitis virus mRNA", "PROBLEM", 199, 237], ["kDa proteins", "TEST", 291, 303], ["leaky scanning", "TEST", 330, 344], ["internal ribosomal entry", "TEST", 349, 373], ["Le et al.", "TEST", 429, 438], ["ORF 5b", "TEST", 452, 458], ["mouse hepatitis virus mRNA", "PROBLEM", 462, 488], ["the E protein", "TEST", 545, 558], ["the I ORF", "PROBLEM", 717, 726], ["the bovine", "TREATMENT", 740, 750], ["mouse hepatitis coronaviruses", "PROBLEM", 755, 784], ["the I protein", "TEST", 797, 810], ["ribosomal scanning", "TEST", 915, 933], ["this study", "TEST", 979, 989], ["TGEV", "PROBLEM", 1082, 1086], ["a leaky scanning step", "TEST", 1205, 1226], ["mRNA 3 sequence", "TEST", 1254, 1269], ["ribosomal frameshifting", "OBSERVATION", 106, 129], ["infectious", "OBSERVATION_MODIFIER", 205, 215], ["bronchitis", "OBSERVATION", 216, 226], ["internal ribosomal", "ANATOMY", 349, 367], ["ribosomal entry", "OBSERVATION", 655, 670], ["hepatitis coronaviruses", "OBSERVATION", 761, 784]]], ["Gene 3b in TGEV is unusual in that for one strain of virus, the virulent Miller strain (Wesley et al., 1989) , it is expressed as the 5\u0408terminal ORF on mRNA 3-1, whereas in three other strains, the virulent British FS772/70 and Taiwanese TFI strains and the avirulent Purdue-116 strain, it is expressed as the second ORF on mRNA 3 (Britton et al., 1989; Chen et al., 1995; this study) (note mRNA structures in Fig. 1A ).", [["Gene 3b", "GENE_OR_GENE_PRODUCT", 0, 7], ["TGEV", "ORGANISM", 11, 15], ["Miller strain", "ORGANISM", 73, 86], ["3-1", "GENE_OR_GENE_PRODUCT", 157, 160], ["British FS772/70", "ORGANISM", 207, 223], ["Purdue-116 strain", "ORGANISM", 268, 285], ["Gene 3b", "DNA", 0, 7], ["5\u0408terminal ORF", "DNA", 134, 148], ["mRNA 3-1", "DNA", 152, 160], ["ORF", "DNA", 317, 320], ["TGEV", "SPECIES", 11, 15], ["Purdue-116", "SPECIES", 268, 278], ["virus", "PROBLEM", 53, 58], ["Taiwanese TFI strains", "PROBLEM", 228, 249], ["the avirulent Purdue", "TEST", 254, 274], ["this study", "TEST", 373, 383]]], ["The differences in transcription patterns appear to be a function of the canonical TGEV UCUAAAC intergenic sequence positioned 18 nt upstream of gene 3b in the genome, which in the Miller virus totally conforms to the canonical sequence but in the British FS772/70 and Purdue-116 strains is UCUAAAU and in the Taiwanese TFI strain is ACAAAAC.", [["TGEV", "ORGANISM", 83, 87], ["gene 3b", "GENE_OR_GENE_PRODUCT", 145, 152], ["Miller virus", "ORGANISM", 181, 193], ["Purdue-116 strains", "ORGANISM", 269, 287], ["UCUAAAU", "CANCER", 291, 298], ["TGEV UCUAAAC intergenic sequence", "DNA", 83, 115], ["18 nt upstream of gene 3b", "DNA", 127, 152], ["TGEV", "SPECIES", 83, 87], ["Miller virus", "SPECIES", 181, 193], ["Purdue-116", "SPECIES", 269, 279], ["Purdue", "TEST", 269, 275], ["genome", "ANATOMY", 160, 166]]], ["The nonconforming intergenic sequences apparently fail to promote synthe- sis of a subgenomic mRNA.", [["nonconforming intergenic sequences", "DNA", 4, 38], ["subgenomic mRNA", "RNA", 83, 98], ["The nonconforming intergenic sequences", "PROBLEM", 0, 38], ["a subgenomic mRNA", "PROBLEM", 81, 98], ["subgenomic mRNA", "OBSERVATION", 83, 98]]], ["Translation from ORF 3b when it occurs as the second ORF on mRNA 3 must, therefore, require either a reinitiation of translation after translation of the upstream ORF, a leaky scanning by ribosomes over a long distance (431 nt; Fig. 1B ), or a downstream entry of ribosomes.INTRODUCTIONBecause gene 3b is not intact in some strains of TGEV (i.e., it is either severely truncated by frameshift mutations as in the Purdue-115 strain [Rasschaert et al., 1987] or by deletions as in the avirulent Miller strain [Wesley et al., 1990 [Wesley et al., , 1991 ) and cannot produce a full-length product, it has been suggested that its product fulfills a specialized function, perhaps during animal infection (reviewed in Enjuanes et al., 1995) , and is not required for virus replication.", [["ribosomes", "ANATOMY", 264, 273], ["infection", "DISEASE", 689, 698], ["ribosomes", "CELLULAR_COMPONENT", 188, 197], ["ribosomes", "CELLULAR_COMPONENT", 264, 273], ["INTRODUCTIONBecause gene 3b", "GENE_OR_GENE_PRODUCT", 274, 301], ["TGEV", "ORGANISM", 335, 339], ["Purdue-115 strain", "ORGANISM", 413, 430], ["Miller strain", "ORGANISM", 493, 506], ["ORF 3b", "DNA", 17, 23], ["ORF", "DNA", 53, 56], ["mRNA 3", "RNA", 60, 66], ["upstream ORF", "DNA", 154, 166], ["INTRODUCTIONBecause gene 3b", "DNA", 274, 301], ["TGEV", "SPECIES", 335, 339], ["a leaky scanning", "TEST", 168, 184], ["TGEV", "PROBLEM", 335, 339], ["severely truncated by frameshift mutations", "PROBLEM", 360, 402], ["animal infection", "PROBLEM", 682, 698], ["virus replication", "TREATMENT", 761, 778], ["not", "UNCERTAINTY", 305, 308], ["intact", "OBSERVATION", 309, 315], ["infection", "OBSERVATION", 689, 698]]], ["Similar conclusions were reached after revelations of a truncated gene 3b in strains of the closely related porcine epidemic diarrhea virus (Vaughn et al., 1995) .", [["porcine epidemic diarrhea", "DISEASE", 108, 133], ["truncated gene 3b", "GENE_OR_GENE_PRODUCT", 56, 73], ["porcine epidemic diarrhea virus", "ORGANISM", 108, 139], ["truncated gene 3b", "DNA", 56, 73], ["porcine epidemic diarrhea virus", "SPECIES", 108, 139], ["porcine epidemic diarrhea virus", "SPECIES", 108, 139], ["a truncated gene 3b", "PROBLEM", 54, 73], ["the closely related porcine epidemic diarrhea virus", "PROBLEM", 88, 139], ["porcine", "OBSERVATION_MODIFIER", 108, 115], ["epidemic", "OBSERVATION_MODIFIER", 116, 124]]], ["It might therefore be assumed that gene 3b is not translated when it occurs as a downstream ORF as in mRNA 3.", [["gene 3b", "GENE_OR_GENE_PRODUCT", 35, 42], ["gene 3b", "DNA", 35, 42], ["downstream ORF", "DNA", 81, 95], ["mRNA 3", "RNA", 102, 108], ["a downstream ORF", "PROBLEM", 79, 95]]], ["However, a product from gene 3b is made in cells infected with the Purdue-116 strain of virus (O'Connor and Brian, 1999) , indicating a mechanism must exist for its synthesis from mRNA 3.", [["cells", "ANATOMY", 43, 48], ["gene 3b", "GENE_OR_GENE_PRODUCT", 24, 31], ["cells", "CELL", 43, 48], ["Purdue-116 strain", "ORGANISM", 67, 84], ["gene 3b", "DNA", 24, 31], ["mRNA 3", "RNA", 180, 186], ["Purdue-116", "SPECIES", 67, 77], ["a product from gene 3b", "PROBLEM", 9, 31], ["the Purdue", "TEST", 63, 73]]], ["Here we report that, whereas mRNA 3 has a sequence predicting leaky scanning for the translation of ORF 3b by the model of Kozak (1989) , experimental results with mutant constructs suggested downstream entry of ribosomes might also be used.", [["ribosomes", "CELLULAR_COMPONENT", 212, 221], ["mRNA 3", "RNA", 29, 35], ["ORF 3b", "DNA", 100, 106], ["mutant constructs", "DNA", 164, 181], ["a sequence predicting leaky scanning", "TEST", 40, 76], ["mutant constructs", "PROBLEM", 164, 181]]], ["Furthermore, deletion analysis indicated that the internal entry of ribosomes did not depend on an immediate upstream internal ribosomal entry structure (IRES) and suggested ribosomes are entering very close to the ORF 3b start site by a mechanism resembling shunting.RESULTSmRNA 3, but not mRNA 3-1, is made in cells infected with the Purdue-116 strain of TGEV Northern analyses of Purdue-116 virus-infected cells carried out previously in our laboratory with oligonucleotide probes specific for the 3\u0408 end of the genome (i.e., a sequence from within the 3\u0408-proximal HP ORF) had identified eight species of mRNA, leading us to conclude that ORFs encoding the 7.7-kDa (gene 3a) and 27.7-kDa (gene 3b) proteins are each 5\u0408-terminal on separate mRNA species (Sethna et al., 1989) .", [["ribosomes", "ANATOMY", 68, 77], ["ribosomal", "ANATOMY", 127, 136], ["ribosomes", "ANATOMY", 174, 183], ["cells", "ANATOMY", 312, 317], ["cells", "ANATOMY", 409, 414], ["Purdue-116", "CHEMICAL", 383, 393], ["ribosomes", "CELLULAR_COMPONENT", 68, 77], ["ribosomal", "CELLULAR_COMPONENT", 127, 136], ["ribosomes", "CELLULAR_COMPONENT", 174, 183], ["RESULTSmRNA 3", "GENE_OR_GENE_PRODUCT", 268, 281], ["mRNA 3-1", "GENE_OR_GENE_PRODUCT", 291, 299], ["cells", "CELL", 312, 317], ["Purdue-116 strain", "ORGANISM", 336, 353], ["TGEV", "ORGANISM", 357, 361], ["Purdue-116 virus", "ORGANISM", 383, 399], ["cells", "CELL", 409, 414], ["genome", "CELLULAR_COMPONENT", 515, 521], ["gene 3b", "GENE_OR_GENE_PRODUCT", 692, 699], ["immediate upstream internal ribosomal entry structure", "DNA", 99, 152], ["IRES", "DNA", 154, 158], ["ORF 3b start site", "DNA", 215, 232], ["RESULTSmRNA 3", "DNA", 268, 281], ["mRNA 3", "RNA", 291, 297], ["3\u0408 end", "DNA", 501, 507], ["3\u0408-proximal HP ORF", "DNA", 556, 574], ["mRNA", "RNA", 608, 612], ["ORFs", "DNA", 642, 646], ["7.7-kDa (gene 3a", "DNA", 660, 676], ["5\u0408-terminal", "DNA", 719, 730], ["Purdue-116", "SPECIES", 336, 346], ["TGEV", "SPECIES", 357, 361], ["Purdue-116 virus", "SPECIES", 383, 399], ["deletion analysis", "TEST", 13, 30], ["the internal entry of ribosomes", "PROBLEM", 46, 77], ["ribosomes", "PROBLEM", 174, 183], ["shunting", "PROBLEM", 259, 267], ["RESULTSmRNA", "TEST", 268, 279], ["mRNA", "TEST", 291, 295], ["the Purdue", "TEST", 332, 342], ["Purdue", "TEST", 383, 389], ["infected cells", "PROBLEM", 400, 414], ["oligonucleotide probes", "TREATMENT", 461, 483], ["a sequence", "TEST", 529, 539], ["ORFs", "TEST", 642, 646], ["kDa (gene 3b) proteins", "TEST", 687, 709], ["internal", "OBSERVATION_MODIFIER", 118, 126], ["ribosomal", "OBSERVATION", 127, 136], ["entry structure", "OBSERVATION", 137, 152], ["shunting", "OBSERVATION", 259, 267]]], ["To test this conclusion, separate Northern analyses were done with probes specific for the 90-nt leader and for genes 3a and 3b.", [["90-nt leader", "DNA", 91, 103], ["genes 3a and 3b", "DNA", 112, 127], ["Northern analyses", "TEST", 34, 51]]], ["Our rationale was that mRNA species 3 and 3-1 would be distinguishable with probes binding within ORFs 3a and 3b because transcripts of 3875 and 3561 nt (or even 4075 and 3761 nt if they included poly A tails of 200 nt in length) are resolvable on a gel of 1% agarose.", [["3-1", "GENE_OR_GENE_PRODUCT", 42, 45], ["agarose", "SIMPLE_CHEMICAL", 260, 267], ["mRNA species", "RNA", 23, 35], ["ORFs", "DNA", 98, 102], ["3875 and 3561 nt", "DNA", 136, 152], ["poly A tails", "DNA", 196, 208], ["mRNA species", "TEST", 23, 35], ["poly A tails", "TREATMENT", 196, 208], ["a gel of 1% agarose", "TREATMENT", 248, 267]]], ["Northern analyses with the separate probes revealed bands with identical mobilities, indicating the presence of mRNA 3, but not mRNA 3-1, in RNA from Purdue-116 virus-infected cells ( Fig. 2A, lanes 4-9) .RESULTSTo test this conclusion by a second method, RT-PCR analysis was done with oligonucleotide primers specific to gene 3b and the minus strand of the leader.", [["cells", "ANATOMY", 176, 181], ["3", "GENE_OR_GENE_PRODUCT", 117, 118], ["mRNA 3-1", "GENE_OR_GENE_PRODUCT", 128, 136], ["Purdue-116 virus", "ORGANISM", 150, 166], ["cells", "CELL", 176, 181], ["mRNA 3", "RNA", 112, 118], ["mRNA 3", "RNA", 128, 134], ["infected cells", "CELL_TYPE", 167, 181], ["oligonucleotide primers", "DNA", 286, 309], ["gene 3b", "DNA", 322, 329], ["Purdue-116 virus", "SPECIES", 150, 166], ["Northern analyses", "TEST", 0, 17], ["the separate probes", "TEST", 23, 42], ["bands with identical mobilities", "PROBLEM", 52, 83], ["mRNA 3", "PROBLEM", 112, 118], ["mRNA", "TEST", 128, 132], ["Purdue", "TEST", 150, 156], ["infected cells", "PROBLEM", 167, 181], ["lanes", "TEST", 193, 198], ["a second method", "TEST", 239, 254], ["RT-PCR analysis", "TEST", 256, 271], ["oligonucleotide primers", "TREATMENT", 286, 309], ["infected cells", "OBSERVATION", 167, 181]]], ["Amplified products of 463 and 876 nt would be expected from mRNAs 3-1 and 3, respectively.", [["mRNAs", "TEST", 60, 65]]], ["A product of 5248 nt Northern blot analysis using gene-specific probes.", [["blot analysis", "TEST", 30, 43]]], ["(B) RT-PCR analysis of RNA from Purdue or Miller virus-infected cells using a plus-strand-detecting oligonucleotide from within ORF 3b as the first primer (for RT and subsequent amplification) and a minus-strand-detecting oligonucleotide from within the leader sequence for amplification.", [["cells", "ANATOMY", 64, 69], ["Miller virus", "ORGANISM", 42, 54], ["cells", "CELL", 64, 69], ["ORF 3b", "DNA", 128, 134], ["minus-strand", "DNA", 199, 211], ["leader sequence", "DNA", 254, 269], ["Miller virus", "SPECIES", 42, 54], ["RT-PCR analysis", "TEST", 4, 19], ["RNA", "PROBLEM", 23, 26], ["Miller virus", "PROBLEM", 42, 54], ["infected cells", "PROBLEM", 55, 69], ["a plus-strand-detecting oligonucleotide", "TREATMENT", 76, 115], ["RT and subsequent amplification", "TREATMENT", 160, 191], ["infected cells", "OBSERVATION", 55, 69]]], ["Products were electrophoresed on a gel of 1% agarose and stained with EtBr. might also be found from mRNA 2, the mRNA encoding the spike protein.", [["agarose", "SIMPLE_CHEMICAL", 45, 52], ["EtBr.", "GENE_OR_GENE_PRODUCT", 70, 75], ["EtBr.", "PROTEIN", 70, 75], ["mRNA 2", "RNA", 101, 107], ["mRNA", "RNA", 113, 117], ["spike protein", "PROTEIN", 131, 144], ["a gel of 1% agarose", "TREATMENT", 33, 52], ["the spike protein", "PROBLEM", 127, 144]]], ["From RT-PCR analysis only a single product of 876 nt with the proper sequence as determined by cloning and sequencing was obtained (Fig. 2B , lane 3; sequencing data not shown), indicating the presence of mRNA 3 but not mRNA 3-1.", [["3-1", "GENE_OR_GENE_PRODUCT", 225, 228], ["mRNA 3", "RNA", 205, 211], ["mRNA 3", "RNA", 220, 226], ["RT-PCR analysis", "TEST", 5, 20], ["sequencing data", "TEST", 150, 165], ["mRNA 3", "PROBLEM", 205, 211], ["mRNA", "TEST", 220, 224]]], ["To establish that the experimental protocol would have detected mRNA 3-1 if present, RNA was extracted from Miller virus-infected cells and used in parallel.", [["cells", "ANATOMY", 130, 135], ["3-1", "GENE_OR_GENE_PRODUCT", 69, 72], ["Miller virus", "ORGANISM", 108, 120], ["cells", "CELL", 130, 135], ["mRNA 3", "RNA", 64, 70], ["infected cells", "CELL_TYPE", 121, 135], ["Miller virus", "SPECIES", 108, 120], ["the experimental protocol", "TREATMENT", 18, 43], ["mRNA", "TEST", 64, 68], ["Miller virus", "PROBLEM", 108, 120], ["infected cells", "PROBLEM", 121, 135], ["infected cells", "OBSERVATION", 121, 135]]], ["From this, the expected 463-nt mRNA 3-1-derived product was obtained (Fig. 2B , lane 4).", [["nt mRNA", "TEST", 28, 35]]], ["No product was obtained with RNA from uninfected cells (Fig. 2B, lane 2) .RESULTSGenes 3a and 3b, but not gene 4, are translated in vitro from synthetic mRNA 3-like transcripts containing all three ORFsRESULTSTo test by in vitro translation whether the 27.7-and 20-kDa gene 3b products (O'Connor and Brian, 1999) are synthesized when ORF 3b is positioned downstream of ORF 3a (beginning at base 337) on synthetic transcripts, uncapped transcripts of pORF3a-3b-4 DNA linearized at the BamHI site 50 nt downstream from the stop codon of gene 4 (Fig. 1C) were translated in either wheat germ extract or rabbit reticulocyte lysate.", [["cells", "ANATOMY", 49, 54], ["germ extract", "ANATOMY", 584, 596], ["reticulocyte lysate", "ANATOMY", 607, 626], ["cells", "CELL", 49, 54], ["RESULTSGenes 3a", "GENE_OR_GENE_PRODUCT", 74, 89], ["3b", "GENE_OR_GENE_PRODUCT", 94, 96], ["gene 4", "GENE_OR_GENE_PRODUCT", 106, 112], ["3", "GENE_OR_GENE_PRODUCT", 158, 159], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 334, 340], ["ORF 3", "GENE_OR_GENE_PRODUCT", 369, 374], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 450, 461], ["DNA", "CELLULAR_COMPONENT", 462, 465], ["BamHI", "GENE_OR_GENE_PRODUCT", 484, 489], ["wheat germ extract", "ORGANISM_SUBSTANCE", 578, 596], ["rabbit", "ORGANISM", 600, 606], ["reticulocyte lysate", "ORGANISM_SUBSTANCE", 607, 626], ["uninfected cells", "CELL_TYPE", 38, 54], ["RESULTSGenes 3a and 3b, but not gene 4", "DNA", 74, 112], ["synthetic mRNA 3", "RNA", 143, 159], ["ORF 3b", "DNA", 334, 340], ["ORF 3", "DNA", 369, 374], ["base 337", "DNA", 390, 398], ["synthetic transcripts", "RNA", 403, 424], ["pORF3a-3b-4 DNA", "DNA", 450, 465], ["BamHI site", "DNA", 484, 494], ["stop codon", "DNA", 521, 531], ["gene 4", "DNA", 535, 541], ["wheat", "SPECIES", 578, 583], ["rabbit", "SPECIES", 600, 606], ["wheat", "SPECIES", 578, 583], ["rabbit", "SPECIES", 600, 606], ["synthetic transcripts", "TREATMENT", 403, 424], ["pORF3a", "TEST", 450, 456], ["the BamHI site", "TREATMENT", 480, 494], ["rabbit reticulocyte lysate", "TEST", 600, 626], ["uninfected cells", "OBSERVATION", 38, 54], ["rabbit reticulocyte lysate", "OBSERVATION", 600, 626]]], ["In both, products from genes 3a (the 7.7-kDa protein containing one methionine) and 3b (the 27.7-kDa form of the protein containing eight methionines and the 20-kDa form presumably containing seven methionines), but not gene 4 (the 9.2-kDa E protein containing four methionines), were obtained (results for wheat germ extract are shown in Fig. 3A , lane 5; note the marker positions in lanes 2-4 and the absence of endogenous product in lane 1).", [["germ extract", "ANATOMY", 313, 325], ["methionine", "CHEMICAL", 68, 78], ["methionine", "CHEMICAL", 68, 78], ["methionines", "CHEMICAL", 138, 149], ["methionines", "CHEMICAL", 198, 209], ["methionines", "CHEMICAL", 266, 277], ["methionine", "SIMPLE_CHEMICAL", 68, 78], ["methionines", "GENE_OR_GENE_PRODUCT", 266, 277], ["genes 3a", "DNA", 23, 31], ["methionines", "PROTEIN", 138, 149], ["methionines", "PROTEIN", 198, 209], ["gene 4", "DNA", 220, 226], ["E protein", "PROTEIN", 240, 249], ["endogenous product", "PROTEIN", 415, 433], ["wheat", "SPECIES", 307, 312], ["wheat", "SPECIES", 307, 312], ["the 7.7-kDa protein", "TREATMENT", 33, 52], ["one methionine", "TREATMENT", 64, 78], ["the protein containing eight methionines", "TREATMENT", 109, 149], ["wheat germ extract", "PROBLEM", 307, 325]]], ["Because a nearly 27-kDa protein was also synthesized from an endogenous transcript in (some) rabbit reticulocyte lysates and the presence of abundant globin protein in the lysate interfered with the resolution of small proteins (data not shown), all subsequent studies described were carried out in wheat germ extract.", [["reticulocyte lysates", "ANATOMY", 100, 120], ["lysate", "ANATOMY", 172, 178], ["germ extract", "ANATOMY", 305, 317], ["rabbit", "ORGANISM", 93, 99], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 100, 120], ["globin", "GENE_OR_GENE_PRODUCT", 150, 156], ["wheat", "ORGANISM", 299, 304], ["germ extract", "ORGANISM_SUBSTANCE", 305, 317], ["Da protein", "PROTEIN", 21, 31], ["globin protein", "PROTEIN", 150, 164], ["small proteins", "PROTEIN", 213, 227], ["rabbit", "SPECIES", 93, 99], ["wheat", "SPECIES", 299, 304], ["rabbit", "SPECIES", 93, 99], ["wheat", "SPECIES", 299, 304], ["an endogenous transcript in (some) rabbit reticulocyte lysates", "PROBLEM", 58, 120], ["abundant globin protein in the lysate", "PROBLEM", 141, 178], ["small proteins", "PROBLEM", 213, 227], ["all subsequent studies", "TEST", 246, 268], ["endogenous transcript", "OBSERVATION", 61, 82], ["rabbit reticulocyte lysates", "OBSERVATION", 93, 120], ["abundant globin protein", "OBSERVATION", 141, 164], ["small", "OBSERVATION_MODIFIER", 213, 218]]], ["Thus, from uncapped transcripts bearing similarity to mRNA 3 the first methionine codon in gene 3b (for synthesis of the 27.7-kDa protein) and also the second (assuming synthesis of the 20-kDa protein initiates at the second methionine codon [O'Connor and Brian, 1999] ) are accessed for translation.", [["methionine", "CHEMICAL", 71, 81], ["methionine", "CHEMICAL", 71, 81], ["methionine", "CHEMICAL", 225, 235], ["methionine codon in gene 3b", "GENE_OR_GENE_PRODUCT", 71, 98], ["uncapped transcripts", "RNA", 11, 31], ["mRNA 3", "RNA", 54, 60], ["gene 3b", "DNA", 91, 98], ["20-kDa protein", "PROTEIN", 186, 200], ["mRNA", "TEST", 54, 58], ["the first methionine codon", "TREATMENT", 61, 87], ["synthesis", "TEST", 104, 113], ["synthesis", "TEST", 169, 178]]], ["There was no evidence of a 9.2-kDa E protein from ORF 4 in this (Fig. 3A , lane 5) or in subsequent experiments, indicating ribosomal accessibility of ORF 3b was probably not the result of template fragmentation.RESULTSAn upstream leader-containing sequence in transcripts of pLORF3a-3b-4 ( Fig. 1C) , although containing an additional 14 nts not found on mRNA 3, had only a small effect on the rate of translation from ORF 3b relative to 3a (Fig. 3A , lane 7, and Fig. 3C ), indicating the leader se-quence may not strongly influence translation from the downstream ORF; however, this needs confirmation with transcripts precisely mimicking the 5\u0408 end of mRNA 3.", [["ribosomal", "ANATOMY", 124, 133], ["ribosomal", "CELLULAR_COMPONENT", 124, 133], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 151, 157], ["pLORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 276, 288], ["Fig. 1C", "GENE_OR_GENE_PRODUCT", 291, 298], ["Fig. 3C", "GENE_OR_GENE_PRODUCT", 465, 472], ["E protein", "PROTEIN", 35, 44], ["ORF 4", "DNA", 50, 55], ["ORF 3b", "DNA", 151, 157], ["upstream leader-containing sequence", "DNA", 222, 257], ["pLORF3a-3b-4", "DNA", 276, 288], ["mRNA 3", "RNA", 356, 362], ["ORF 3b", "DNA", 420, 426], ["leader se-quence", "DNA", 491, 507], ["downstream ORF", "DNA", 556, 570], ["5\u0408 end", "RNA", 646, 652], ["mRNA 3", "RNA", 656, 662], ["kDa E protein", "TEST", 31, 44], ["ORF", "TEST", 50, 53], ["ribosomal accessibility of ORF", "PROBLEM", 124, 154], ["template fragmentation", "PROBLEM", 189, 211], ["pLORF3a", "TEST", 276, 283], ["a small effect", "PROBLEM", 373, 387], ["no evidence of", "UNCERTAINTY", 10, 24], ["ribosomal accessibility", "OBSERVATION", 124, 147], ["probably not the result of", "UNCERTAINTY", 162, 188], ["template fragmentation", "OBSERVATION", 189, 211], ["small", "OBSERVATION_MODIFIER", 375, 380], ["effect", "OBSERVATION", 381, 387]]], ["As with transcripts of pORF3a-3b-4, no product was evident from ORF 4.RESULTSTranslation of gene 3b from mRNA 3-like transcripts shows a pattern not fully consistent with a leaky scanning model From precedents in eukaryotic mRNAs, it is unlikely that ribosomes would approach ORF 3b on mRNA 3 by a mechanism of translation reinitiation, since three inframe strong stop codons follow ORF 3a (Fig. 1B) .", [["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 23, 34], ["RESULTSTranslation of gene 3b", "GENE_OR_GENE_PRODUCT", 70, 99], ["3", "GENE_OR_GENE_PRODUCT", 110, 111], ["ribosomes", "CELLULAR_COMPONENT", 251, 260], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 276, 282], ["mRNA 3", "GENE_OR_GENE_PRODUCT", 286, 292], ["pORF3a", "PROTEIN", 23, 29], ["ORF 4", "DNA", 64, 69], ["gene 3b", "DNA", 92, 99], ["mRNA 3", "RNA", 105, 111], ["eukaryotic mRNAs", "RNA", 213, 229], ["ORF 3b", "DNA", 276, 282], ["mRNA 3", "RNA", 286, 292], ["inframe strong stop codons", "DNA", 349, 375], ["ORF 3", "DNA", 383, 388], ["pORF3a", "TEST", 23, 29], ["mRNA", "TEST", 105, 109], ["a leaky scanning model", "PROBLEM", 171, 193], ["translation reinitiation", "TREATMENT", 311, 335], ["leaky", "OBSERVATION", 173, 178], ["eukaryotic mRNAs", "OBSERVATION", 213, 229], ["unlikely", "UNCERTAINTY", 237, 245]]], ["However, an approach by leaky scanning according to the model of Kozak (1989 Kozak ( , 1991a ,b) might be expected, since the initiator codon for ORF 3a (UGUA123UGG, in the Quantitation of products from the indicated constructs as determined from AMBIS radioanalytic imager scans of the gel shown in (A).", [["Kozak", "DNA", 65, 70], ["initiator codon", "DNA", 126, 141], ["ORF 3", "DNA", 146, 151], ["leaky scanning", "TEST", 24, 38], ["the initiator codon", "TREATMENT", 122, 141]]], ["Note that only detected proteins are represented in the bar graph. * denotes a putative aggregate of the ORF 3b product; \u2020 indicates plasmid DNA was linearized at the ScaI site within ORF 3b before transcription. same reading frame as ORF 3b) and for three other potential small ORFs within gene 3a (UAGA167UGC, CAUA283UGC, and UCCA424UGC, all in the \u03e91 reading frame relative to ORF 3b) are within contexts considered weak for initiation, whereas that for ORF 3b (AAAA432UGA) is considered relatively strong.", [["DNA", "CELLULAR_COMPONENT", 141, 144], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 184, 190], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 457, 463], ["ORF 3b product", "PROTEIN", 105, 119], ["plasmid DNA", "DNA", 133, 144], ["ScaI site", "DNA", 167, 176], ["ORF 3b", "DNA", 184, 190], ["same reading frame", "DNA", 213, 231], ["ORF 3b", "DNA", 235, 241], ["ORFs", "DNA", 279, 283], ["gene 3", "DNA", 291, 297], ["UAGA167UGC", "DNA", 300, 310], ["CAUA283UGC", "DNA", 312, 322], ["UCCA424UGC", "DNA", 328, 338], ["\u03e91 reading frame", "DNA", 351, 367], ["ORF 3b", "DNA", 380, 386], ["ORF 3b", "DNA", 457, 463], ["AAAA432UGA", "DNA", 465, 475], ["plasmid DNA", "PROBLEM", 133, 144], ["small ORFs", "PROBLEM", 273, 283], ["CAUA283UGC", "TEST", 312, 322], ["ORF", "TEST", 457, 460], ["plasmid DNA", "OBSERVATION", 133, 144], ["small", "OBSERVATION_MODIFIER", 273, 278], ["ORFs", "OBSERVATION", 279, 283], ["strong", "OBSERVATION", 502, 508]]], ["To test for ribosomal scanning on mRNA 3-like transcripts, three approaches were taken.", [["ribosomal", "ANATOMY", 12, 21], ["ribosomal", "CELLULAR_COMPONENT", 12, 21], ["mRNA 3", "RNA", 34, 40], ["ribosomal scanning", "TEST", 12, 30], ["mRNA", "TEST", 34, 38]]], ["In the first, the effect of a 5\u0408 cap on the synthesis of 3a and 3b gene products was measured.", [["3b", "GENE_OR_GENE_PRODUCT", 64, 66], ["3a and 3b gene products", "PROTEIN", 57, 80], ["a 5\u0408 cap", "TREATMENT", 28, 36], ["the synthesis of 3a", "TREATMENT", 40, 59], ["3b gene products", "TREATMENT", 64, 80]]], ["Increased synthesis from both would be expected if 5\u0408 cap-dependent entry followed by leaky scanning were used (Kozak, 1989 (Kozak, , 1991a .", [["Increased synthesis", "PROBLEM", 0, 19], ["leaky scanning", "TEST", 86, 100]]], ["Increased synthesis from 3b might also be expected if a cap-dependent shunting mechanism were used (Jackson, 1996; Mathews, 1996) .", [["Increased synthesis", "PROBLEM", 0, 19], ["a cap-dependent shunting mechanism", "PROBLEM", 54, 88], ["shunting", "OBSERVATION", 70, 78]]], ["3B and 3C, enhanced translation of both ORFs 3a and 3b resulted when capped transcripts of pORF3a-3b-4 and pLORF3a-3b-4 were translated.", [["3b", "GENE_OR_GENE_PRODUCT", 52, 54], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 91, 102], ["pLORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 107, 119], ["ORFs 3a and 3b", "DNA", 40, 54], ["pORF3a-3b-4 and pLORF3a-3b-4", "DNA", 91, 119], ["pORF3a", "TEST", 91, 97], ["pLORF3a", "TEST", 107, 114], ["both", "ANATOMY_MODIFIER", 35, 39], ["ORFs 3a", "OBSERVATION", 40, 47]]], ["These results are therefore consistent with the mechanisms of leaky scanning and cap-enhanced ribosomal shunting.RESULTSIn the second approach, the competitive effect of a soluble cap analog on the translation of ORFs 3a and 3b from capped transcripts of pORF3a-3b-4 was measured.", [["ribosomal", "ANATOMY", 94, 103], ["ribosomal", "CELLULAR_COMPONENT", 94, 103], ["ORFs 3a", "GENE_OR_GENE_PRODUCT", 213, 220], ["3b", "GENE_OR_GENE_PRODUCT", 225, 227], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 255, 266], ["ORFs 3a and 3b", "DNA", 213, 227], ["pORF3a", "PROTEIN", 255, 261], ["leaky scanning", "PROBLEM", 62, 76], ["cap-enhanced ribosomal shunting", "PROBLEM", 81, 112], ["a soluble cap analog", "TREATMENT", 170, 190], ["ORFs 3a", "TREATMENT", 213, 220], ["pORF3a", "TEST", 255, 261], ["consistent with", "UNCERTAINTY", 28, 43], ["leaky scanning", "OBSERVATION", 62, 76], ["ribosomal shunting", "OBSERVATION", 94, 112]]], ["With either leaky scanning or cap-dependent shunting, but not with cap-independent internal entry, competitive inhibition of translation from both ORFs would be expected (Iizuka et al., 1994; Jackson, 1996; Mathews, 1996) .", [["ORFs", "DNA", 147, 151], ["leaky scanning", "TEST", 12, 26], ["cap-dependent shunting", "PROBLEM", 30, 52], ["leaky", "OBSERVATION", 12, 17], ["cap", "OBSERVATION_MODIFIER", 30, 33], ["dependent", "OBSERVATION_MODIFIER", 34, 43], ["shunting", "OBSERVATION", 44, 52]]], ["4A and 4C), indicating either mechanism of capdependent entry could be functioning in the translation for ORF 3b.RESULTSIn the third approach, the sequence context surrounding the 3a start codon in transcripts of pORF3a-3b-4 was modified to become strongly favorable for translation (GCCGCCATGG) (Kozak, 1991b) and the relative amounts of 3a and 3b gene products were measured.", [["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 213, 224], ["3b", "GENE_OR_GENE_PRODUCT", 346, 348], ["ORF 3b", "DNA", 106, 112], ["3a start codon", "DNA", 180, 194], ["pORF3a-3b-4", "DNA", 213, 224], ["pORF3a", "TEST", 213, 219], ["3b gene products", "TREATMENT", 346, 362]]], ["With leaky scanning, a diminished synthesis from 3b relative to 3a would be expected regardless of the capped status of the transcripts (Kozak, 1991b) , whereas with shunting a change in the relative amounts would not necessarily be expected.", [["leaky scanning", "TEST", 5, 19], ["a diminished synthesis", "PROBLEM", 21, 43], ["shunting", "TREATMENT", 166, 174], ["leaky", "OBSERVATION", 5, 10], ["diminished", "OBSERVATION_MODIFIER", 23, 33], ["shunting", "OBSERVATION", 166, 174]]], ["5A and 5B, whereas the accumulation of 3a product increased almost 20% relative to 3b with the improved Kozak consensus for capped transcripts, no increase was observed with uncapped transcripts.", [["Kozak consensus", "DNA", 104, 119], ["capped transcripts", "RNA", 124, 142], ["uncapped transcripts", "RNA", 174, 194], ["3a product", "TREATMENT", 39, 49], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["no", "UNCERTAINTY", 144, 146], ["increase", "OBSERVATION_MODIFIER", 147, 155]]], ["Intriguingly, the absolute amount of gene 3b product appeared nearly identical under all conditions of translation.", [["3b", "GENE_OR_GENE_PRODUCT", 42, 44], ["gene 3b product", "PROTEIN", 37, 52], ["absolute", "OBSERVATION_MODIFIER", 18, 26], ["amount", "OBSERVATION_MODIFIER", 27, 33]]], ["These results, therefore, are not fully consistent with the leaky scanning model for ORF 3b Translation of ORF 3b is not blocked by the upstream insertion of an 884-nt-long sequence containing three sequential ORFsRESULTSTo test for an internal entry of ribosomes onto ORF 3b, pORF3a-3b-4 was modified to psCATORF3a-3b-4 by the placement of an 884-nt-long sequence containing three sequential ORFs upstream of ORF 3a (Fig. 1C ) and the products of translation were quantitated.", [["ribosomes", "ANATOMY", 254, 263], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 107, 113], ["ribosomes", "CELLULAR_COMPONENT", 254, 263], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 277, 288], ["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 305, 320], ["ORF 3b", "DNA", 85, 91], ["ORF 3b", "DNA", 107, 113], ["884-nt-long sequence", "DNA", 161, 181], ["ORFsRESULTSTo", "DNA", 210, 223], ["ORF 3b", "DNA", 269, 275], ["pORF3a-3b-4", "DNA", 277, 288], ["psCATORF3a-3b-4", "DNA", 305, 320], ["884-nt-long sequence", "DNA", 344, 364], ["ORFs", "DNA", 393, 397], ["ORF 3", "DNA", 410, 415], ["the leaky scanning model", "TEST", 56, 80], ["ORF", "PROBLEM", 85, 88], ["an 884-nt-long sequence", "TREATMENT", 158, 181], ["three sequential ORFsRESULTSTo test", "TEST", 193, 228], ["pORF3a", "TEST", 277, 283], ["psCATORF3a", "TEST", 305, 315], ["an 884-nt-long sequence", "TREATMENT", 341, 364], ["ORF", "TEST", 410, 413]]], ["An internal entry of ribosomes, either directed by an IRES element or by a shunting mechanism, would typically not be blocked by the presence of upstream ORFs of this dimension (reviewed in Jackson et al., 1995; Jackson, 1996; Mathews, 1996) .", [["ribosomes", "ANATOMY", 21, 30], ["ribosomes", "CELLULAR_COMPONENT", 21, 30], ["IRES element", "DNA", 54, 66], ["upstream ORFs", "DNA", 145, 158], ["An internal entry of ribosomes", "TREATMENT", 0, 30], ["a shunting mechanism", "TREATMENT", 73, 93], ["internal", "OBSERVATION_MODIFIER", 3, 11], ["entry", "OBSERVATION", 12, 17], ["ribosomes", "OBSERVATION", 21, 30], ["IRES", "OBSERVATION", 54, 58], ["shunting", "OBSERVATION", 75, 83]]], ["Transcripts of psCATORF3a-3b-4 possessed a 5\u0408 UTR of 59 nt; a five-methionine-containing 450-nt sCAT ORF beginning within an excellent Kozak context (AAAATGG) at base 60; a five-methionine-con-taining 4.4-kDa protein-encoding ORF beginning within a fair Kozak context (ATCATGC) at base 534; a one-methionine-containing 4.5-kDa protein-encoding ORF beginning within a fair Kozak context (CGGATGA) at base 685; and ORF 3a beginning at base 944, ORF 3b beginning at base 1253, and ORF 4 beginning at base 1974.", [["methionine", "CHEMICAL", 67, 77], ["methionine", "CHEMICAL", 178, 188], ["one-methionine", "CHEMICAL", 293, 307], ["methionine", "CHEMICAL", 67, 77], ["methionine", "CHEMICAL", 178, 188], ["methionine", "CHEMICAL", 297, 307], ["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 15, 30], ["methionine", "SIMPLE_CHEMICAL", 67, 77], ["methionine", "SIMPLE_CHEMICAL", 297, 307], ["psCATORF3a-3b-4", "DNA", 15, 30], ["5\u0408 UTR", "DNA", 43, 49], ["450-nt sCAT ORF", "DNA", 89, 104], ["Kozak context", "DNA", 135, 148], ["ORF", "DNA", 226, 229], ["ORF", "DNA", 344, 347], ["base 685", "DNA", 399, 407], ["ORF 3", "DNA", 413, 418], ["base 944", "DNA", 433, 441], ["ORF 3b", "DNA", 443, 449], ["base 1253", "DNA", 463, 472], ["ORF 4", "DNA", 478, 483], ["psCATORF3a", "TEST", 15, 25], ["methionine", "TREATMENT", 67, 77], ["nt sCAT ORF", "PROBLEM", 93, 104], ["methionine", "TEST", 178, 188], ["encoding ORF", "PROBLEM", 217, 229], ["methionine", "TREATMENT", 297, 307], ["encoding ORF", "PROBLEM", 335, 347], ["CGGATGA", "TEST", 387, 394], ["ORF", "TEST", 413, 416], ["ORF", "TEST", 443, 446], ["ORF", "TEST", 478, 481]]], ["In addition, there is a 66-kDa protein-encoding ORF beginning within a fair Kozak context (TCCATGA) at base 346 within the sCAT ORF (in the \u03e91 reading frame relative to sCAT).", [["sCAT", "GENE_OR_GENE_PRODUCT", 123, 127], ["66-kDa protein", "PROTEIN", 24, 38], ["ORF", "DNA", 48, 51], ["base 346", "DNA", 103, 111], ["sCAT ORF", "DNA", 123, 131], ["\u03e91 reading frame", "DNA", 140, 156], ["sCAT", "DNA", 169, 173], ["encoding ORF", "PROBLEM", 39, 51], ["the sCAT ORF", "TEST", 119, 131], ["sCAT ORF", "OBSERVATION", 123, 131]]], ["All in all, 29 AUG codons exist upstream of ORF 3b.", [["AUG codons", "DNA", 15, 25], ["ORF 3b", "DNA", 44, 50]]], ["When transcripts of psCATORF3a-3b-4 were translated the following features were noted:RESULTS1.", [["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 20, 35], ["psCATORF3a-3b-4", "DNA", 20, 35], ["RESULTS1", "DNA", 86, 94], ["psCATORF3a", "TEST", 20, 30]]], ["From uncapped transcripts, only products from the sCAT and 3b ORFs, in a molar ratio of approximately 1:0.15, were obtained (Fig. 3A, lane 9; Fig. 3D ), indicating that among the downstream ORFs, translation from ORF 3b had been a selective one and was probably not the result of initiation on fragmented transcripts.RESULTS2.", [["ORF 3b", "GENE_OR_GENE_PRODUCT", 213, 219], ["sCAT and 3b ORFs", "DNA", 50, 66], ["downstream ORFs", "DNA", 179, 194], ["ORF 3b", "DNA", 213, 219], ["fragmented transcripts", "RNA", 294, 316], ["the sCAT", "TEST", 46, 54], ["a molar ratio", "TEST", 71, 84], ["the downstream ORFs", "PROBLEM", 175, 194], ["uncapped transcripts", "OBSERVATION", 5, 25], ["sCAT", "ANATOMY", 50, 54]]], ["From capped transcripts, an enhanced accumulation from the sCAT ORF was observed but not from the 3b ORF (Fig. 3A, lane 10; Fig. 3D ), unless an inexplicable putative aggregated form of ORF 3b (identified by an asterisk in Fig. 3A , lane 10, and noted earlier [O'Connor and Brian, 1999] ) was included in the total.", [["sCAT", "GENE_OR_GENE_PRODUCT", 59, 63], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 186, 192], ["sCAT ORF", "DNA", 59, 67], ["3b ORF", "DNA", 98, 104], ["ORF 3b", "DNA", 186, 192], ["an enhanced accumulation", "PROBLEM", 25, 49], ["the sCAT ORF", "PROBLEM", 55, 67], ["capped transcripts", "OBSERVATION", 5, 23], ["enhanced", "OBSERVATION_MODIFIER", 28, 36], ["accumulation", "OBSERVATION_MODIFIER", 37, 49]]], ["From capped transcripts in the presence of soluble cap, a similar rate of inhibition was observed for products of both the sCAT and 3b ORFs (50-70% with 0.1 mM and 80-90% with 0.2 mM cap analog; Figs.", [["sCAT", "SIMPLE_CHEMICAL", 123, 127], ["soluble cap", "TREATMENT", 43, 54], ["3b ORFs", "TEST", 132, 139], ["capped transcripts", "OBSERVATION", 5, 23], ["sCAT", "ANATOMY", 123, 127]]], ["4B and 4D), mirroring the results with mRNA 3-like transcripts of pORF3a-3b-4 (Figs.", [["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 66, 77], ["mRNA 3", "RNA", 39, 45], ["pORF3a", "PROTEIN", 66, 72], ["mRNA", "TEST", 39, 43], ["pORF3a", "TEST", 66, 72]]], ["No translation of the remaining five ORFs was observed from either uncapped or capped transcripts.RESULTSThese results show that translation of ORF 3b positioned 1263 nt downstream from the 5\u0408 terminus in the synthetic construct is initiated by some form of internal entry of ribosomes and not by scanning, is influenced by a cap, and is not the result of a fragmented template.Deletion analysis failed to identify a postulated IRESlike element within the upstream gene 3aAlthough no universally identifying primary or secondary structural features of IRES elements are known, certain secondary structural features do appear necessary for IRES function (reviewed in Jackson, 1996) .", [["ribosomes", "ANATOMY", 276, 285], ["ribosomes", "CELLULAR_COMPONENT", 276, 285], ["ORFs", "DNA", 37, 41], ["uncapped or capped transcripts", "RNA", 67, 97], ["ORF 3b", "DNA", 144, 150], ["1263 nt downstream", "DNA", 162, 180], ["5\u0408 terminus", "DNA", 190, 201], ["ribosomes", "PROTEIN", 276, 285], ["IRESlike element", "DNA", 428, 444], ["upstream gene 3aAlthough", "DNA", 456, 480], ["IRES elements", "DNA", 552, 565], ["IRES", "DNA", 639, 643], ["the remaining five ORFs", "PROBLEM", 18, 41], ["a fragmented template", "PROBLEM", 356, 377], ["Deletion analysis", "TEST", 378, 395], ["a postulated IRESlike element", "PROBLEM", 415, 444], ["secondary structural features of IRES elements", "PROBLEM", 519, 565], ["secondary structural features", "PROBLEM", 585, 614], ["IRES function", "TEST", 639, 652], ["cap", "OBSERVATION", 326, 329], ["fragmented", "OBSERVATION", 358, 368], ["IRES elements", "OBSERVATION", 552, 565]]], ["Within TGEV gene 3a, secondary structures can be predicted (Figs.", [["TGEV", "ORGANISM", 7, 11], ["TGEV gene 3", "DNA", 7, 18], ["TGEV", "SPECIES", 7, 11]]], ["6A and 6B) that share features with the putative IRES element in IBV mRNA 3 (Liu and Inglis, 1992; Le et al., 1995) , leading us to postulate that gene 3a might contain an IRES.", [["6B", "GENE_OR_GENE_PRODUCT", 7, 9], ["IBV", "ORGANISM", 65, 68], ["gene 3a", "GENE_OR_GENE_PRODUCT", 147, 154], ["IRES element", "DNA", 49, 61], ["gene 3a", "DNA", 147, 154], ["IRES", "DNA", 172, 176], ["IBV", "SPECIES", 65, 68], ["IRES", "OBSERVATION", 172, 176]]], ["The predicted structures are five stemloops (I-V), four of which can be drawn as components of pseudoknots.", [["I-V", "GENE_OR_GENE_PRODUCT", 45, 48], ["pseudoknots", "PROBLEM", 95, 106], ["five", "OBSERVATION_MODIFIER", 29, 33], ["stemloops", "OBSERVATION", 34, 43], ["pseudoknots", "OBSERVATION", 95, 106]]], ["The free energies of these are calculated to be, respectively, \u03ea6.8, \u03e96.0, \u03ea3.8, \u03ea0.8, and \u03e95. are relatively unstable and suggest a low probability for their existence in viral RNA.", [["viral RNA", "RNA", 172, 181], ["a low probability", "PROBLEM", 131, 148], ["viral RNA", "PROBLEM", 172, 181], ["free energies", "OBSERVATION", 4, 17], ["relatively", "OBSERVATION_MODIFIER", 99, 109], ["unstable", "OBSERVATION", 110, 118], ["low probability", "OBSERVATION_MODIFIER", 133, 148], ["viral RNA", "OBSERVATION", 172, 181]]], ["Nevertheless, to test whether gene 3a might function as an IRES for translation of ORF 3b, deletions within it were prepared and tested.", [["gene 3a", "GENE_OR_GENE_PRODUCT", 30, 37], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 83, 89], ["gene 3a", "DNA", 30, 37], ["IRES", "DNA", 59, 63], ["ORF 3b", "DNA", 83, 89], ["translation of ORF", "TREATMENT", 68, 86], ["deletions", "PROBLEM", 91, 100]]], ["These were (mostly) bidirectional for distances of 16, 86, 74, 192, 314, 337, 334, and 523 nt, and represented 3\u0408-ward deletions of 11, 41, 44, 120, 140, 149, 289 , and 534 nt from the first nucleotide in gene 3a, respectively, for which the mutants were named.", [["nucleotide", "CHEMICAL", 191, 201], ["nucleotide", "CHEMICAL", 191, 201], ["16, 86, 74, 192, 314, 337, 334", "RNA", 51, 81], ["nt", "TEST", 91, 93]]], ["Results shown in Fig. 6C and summarized in Fig. 6D indicate that the relative molar amounts of sCAT and the 27.7-kDa gene 3b products (\u03f31:0.12) remained essentially unchanged between wild-type and \u232c149.", [["sCAT", "GENE_OR_GENE_PRODUCT", 95, 99], ["sCAT", "PROTEIN", 95, 99], ["sCAT", "TEST", 95, 99], ["kDa gene 3b products", "TREATMENT", 113, 133], ["Fig", "OBSERVATION", 17, 20], ["molar", "OBSERVATION_MODIFIER", 78, 83], ["amounts", "OBSERVATION_MODIFIER", 84, 91], ["sCAT", "ANATOMY", 95, 99], ["essentially", "OBSERVATION_MODIFIER", 153, 164], ["unchanged", "OBSERVATION_MODIFIER", 165, 174]]], ["The only exception was for \u232c41, for which the molar ratio was 1:0.56 along with an inexplicable enhancement of an uncharacterized band with an approximate molecular weight of 6 kDa.", [["the molar ratio", "TEST", 42, 57], ["an inexplicable enhancement", "PROBLEM", 80, 107], ["uncharacterized", "OBSERVATION_MODIFIER", 114, 129], ["band", "OBSERVATION_MODIFIER", 130, 134]]], ["For \u232c289, which leaves only 17 nt upstream of the ORF 3b start codon, the relative amounts were surprisingly 1:0.07 and not 1:0, as expected.", [["17 nt upstream", "DNA", 28, 42], ["ORF 3b start codon", "DNA", 50, 68], ["the ORF", "TREATMENT", 46, 53], ["amounts", "OBSERVATION_MODIFIER", 83, 90]]], ["For \u232c534, there was abundant synthesis of the sCAT protein but no synthesis of the 27.7-kDa protein; however, there was synthesis of the 20-kDa gene 3b product (O'Connor and Brian, 1999) (Fig. 6D) .", [["sCAT", "GENE_OR_GENE_PRODUCT", 46, 50], ["sCAT protein", "PROTEIN", 46, 58], ["27.7-kDa protein", "PROTEIN", 83, 99], ["the sCAT protein", "TEST", 42, 58], ["synthesis", "TEST", 66, 75], ["synthesis", "TEST", 120, 129]]], ["These results are not consistent with a mechanism of ribosomal entry within gene 3a but rather with one in which ribosomes enter within 50 nt from the start codon of gene 3b.", [["ribosomal", "ANATOMY", 53, 62], ["ribosomes", "ANATOMY", 113, 122], ["ribosomal", "CELLULAR_COMPONENT", 53, 62], ["ribosomes", "CELLULAR_COMPONENT", 113, 122], ["50 nt", "DNA", 136, 141], ["start codon of gene 3b", "DNA", 151, 173], ["not consistent with", "UNCERTAINTY", 18, 37], ["ribosomal entry", "OBSERVATION", 53, 68]]], ["Because the 20-kDa gene 3b product is found with mutant \u232c534, the intriguing possibility exists that ribosomes are entering at or downstream of the gene 3b start site and are scanning in the upstream direction to reach the start codon.DISCUSSIONBased on precedents in eukaryotes (reviewed in Mathews, 1996) , four mechanistic possibilities should be considered as explanations for how ribosomes approach the downstream ORF 3b on TGEV mRNA 3 for translation: Ribosomes could (1) translate the upstream ORF and then reinitiate synthesis on the downstream ORF, (2) scan through the upstream ORF(s) without the act of translation in a manner known as leaky scanning, (3) bypass the upstream ORF(s) by using an internal ribosomal entry site similar to that used by picornaviruses and flaviviruses on genomic RNA, or (4) bypass the upstream ORF(s) after first binding to the mRNA in a cap-dependent manner and then undergo shunting to a downstream site on the mRNA.", [["ribosomes", "ANATOMY", 101, 110], ["ribosomal", "ANATOMY", 715, 724], ["3b", "GENE_OR_GENE_PRODUCT", 24, 26], ["ribosomes", "CELLULAR_COMPONENT", 101, 110], ["ribosomes", "CELLULAR_COMPONENT", 385, 394], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 419, 425], ["TGEV mRNA 3", "GENE_OR_GENE_PRODUCT", 429, 440], ["Ribosomes", "GENE_OR_GENE_PRODUCT", 458, 467], ["ribosomal", "CELLULAR_COMPONENT", 715, 724], ["20-kDa gene 3b product", "PROTEIN", 12, 34], ["mutant \u232c534", "PROTEIN", 49, 60], ["gene 3b start site", "DNA", 148, 166], ["start codon", "DNA", 223, 234], ["downstream ORF 3b", "DNA", 408, 425], ["TGEV mRNA 3", "RNA", 429, 440], ["upstream ORF", "DNA", 492, 504], ["downstream ORF", "DNA", 542, 556], ["upstream ORF", "DNA", 579, 591], ["upstream ORF", "DNA", 678, 690], ["internal ribosomal entry site", "DNA", 706, 735], ["genomic RNA", "RNA", 795, 806], ["upstream ORF", "DNA", 826, 838], ["mRNA", "RNA", 869, 873], ["downstream site", "DNA", 931, 946], ["mRNA", "RNA", 954, 958], ["TGEV", "SPECIES", 429, 433], ["the upstream ORF", "PROBLEM", 488, 504], ["synthesis", "TREATMENT", 525, 534], ["scan", "TEST", 562, 566], ["leaky scanning", "TEST", 647, 661], ["bypass", "TREATMENT", 667, 673], ["an internal ribosomal entry site", "TREATMENT", 703, 735], ["picornaviruses", "PROBLEM", 760, 774], ["flaviviruses on genomic RNA", "PROBLEM", 779, 806], ["bypass", "TREATMENT", 815, 821], ["shunting", "TREATMENT", 917, 925], ["entry site", "OBSERVATION", 725, 735], ["picornaviruses", "OBSERVATION", 760, 774], ["shunting", "OBSERVATION", 917, 925]]], ["Among these, shunting is the most recently recognized and is exemplified by translation on pregenomic RNA of the cauliflower mosaic virus (Futterer et al., 1993) and rice tungro bacilliform virus (Futterer et al., 1996) , both pararetroviruses, on adenovirus mRNA (Yueh and Schneider, 1996) , and on Sendai paramyxovirus mRNA Kolakovsky, 1988, 1989; Latorre et al., 1998) .DISCUSSIONWe conclude that ORF 3b is translated from mRNA 3, and that the likelihood is high that an internal entry of ribosomes is used, possibly one with shuntlike features, and perhaps in conjunction with leaky ribosomal scanning through ORF 3a.", [["ribosomes", "ANATOMY", 492, 501], ["ribosomal", "ANATOMY", 587, 596], ["cauliflower mosaic virus", "ORGANISM", 113, 137], ["rice", "ORGANISM", 166, 170], ["tungro bacilliform virus", "ORGANISM", 171, 195], ["adenovirus", "ORGANISM", 248, 258], ["Sendai paramyxovirus", "ORGANISM", 300, 320], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 400, 406], ["ribosomes", "CELLULAR_COMPONENT", 492, 501], ["ribosomal", "CELLULAR_COMPONENT", 587, 596], ["pregenomic RNA", "RNA", 91, 105], ["adenovirus mRNA", "RNA", 248, 263], ["ORF 3b", "DNA", 400, 406], ["mRNA 3", "RNA", 426, 432], ["ribosomes", "RNA", 492, 501], ["ORF 3", "DNA", 614, 619], ["cauliflower mosaic virus", "SPECIES", 113, 137], ["rice", "SPECIES", 166, 170], ["tungro bacilliform virus", "SPECIES", 171, 195], ["Sendai paramyxovirus", "SPECIES", 300, 320], ["cauliflower mosaic virus", "SPECIES", 113, 137], ["rice tungro bacilliform virus", "SPECIES", 166, 195], ["pregenomic RNA", "PROBLEM", 91, 105], ["the cauliflower mosaic virus", "PROBLEM", 109, 137], ["rice tungro bacilliform virus", "PROBLEM", 166, 195], ["shuntlike features", "PROBLEM", 529, 547], ["leaky ribosomal scanning", "TEST", 581, 605], ["shunting", "OBSERVATION", 13, 21], ["high", "OBSERVATION_MODIFIER", 461, 465]]], ["The relative contribution of each mechanism on mRNA 3 could not be established by the experiments performed here.", [["mRNA 3", "RNA", 47, 53]]], ["However, an internal entry of ribosomes was demonstrated by the use of constructs, in which four extensive ORFs within an 884-nt sequence were placed upstream of ORF 3a and synthesis from ORF 3b was shown to remain approximately one-eighth to one-fifth of that from the 5\u0408-terminal ORF.", [["ribosomes", "CELLULAR_COMPONENT", 30, 39], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 188, 194], ["ORFs", "DNA", 107, 111], ["884-nt sequence", "DNA", 122, 137], ["ORF 3", "DNA", 162, 167], ["ORF 3b", "DNA", 188, 194], ["5\u0408-terminal ORF", "DNA", 270, 285], ["an internal entry of ribosomes", "PROBLEM", 9, 39], ["an 884-nt sequence", "TREATMENT", 119, 137], ["internal", "OBSERVATION_MODIFIER", 12, 20], ["terminal", "ANATOMY_MODIFIER", 273, 281], ["ORF", "OBSERVATION", 282, 285]]], ["The internal entry showed some properties of shunting in that (1) no IRES element of the type directing internal entry in picornaviruses and togaviruses could be demonstrated within sequence upstream of gene 3b and (2) translation of ORF 3b in capped transcripts from the synthetic multicistronic psCATORF3a-3b-4 showed some inhibition by a competing soluble cap in the translation mix.", [["psCATORF3a-3b-4", "CHEMICAL", 297, 312], ["togaviruses", "CANCER", 141, 152], ["ORF 3b", "GENE_OR_GENE_PRODUCT", 234, 240], ["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 297, 312], ["IRES element", "DNA", 69, 81], ["ORF 3b", "DNA", 234, 240], ["synthetic multicistronic psCATORF3a-3b-4", "DNA", 272, 312], ["picornaviruses", "PROBLEM", 122, 136], ["translation of ORF", "TREATMENT", 219, 237], ["the synthetic multicistronic psCATORF3a", "TEST", 268, 307], ["a competing soluble cap", "TREATMENT", 339, 362], ["shunting", "OBSERVATION", 45, 53], ["picornaviruses", "OBSERVATION", 122, 136]]], ["That is, internal entry in the multicistronic transcript may follow a cap-dependent step as described for shunting in the adenoviruses, pararetroviruses, and paramyxoviruses.DISCUSSIONIn general, the mechanistic features of ribosomal shunting, so far described for only viral mRNAs (Jackson, 1996; Mathews, 1996) , remain to be clarified.", [["ribosomal", "ANATOMY", 224, 233], ["adenoviruses", "ORGANISM", 122, 134], ["pararetroviruses", "GENE_OR_GENE_PRODUCT", 136, 152], ["ribosomal", "CELLULAR_COMPONENT", 224, 233], ["multicistronic transcript", "RNA", 31, 56], ["viral mRNAs", "RNA", 270, 281], ["a cap-dependent step", "PROBLEM", 68, 88], ["shunting in the adenoviruses", "PROBLEM", 106, 134], ["pararetroviruses", "PROBLEM", 136, 152], ["paramyxoviruses", "PROBLEM", 158, 173], ["ribosomal shunting", "PROBLEM", 224, 242], ["internal", "OBSERVATION_MODIFIER", 9, 17], ["entry", "OBSERVATION_MODIFIER", 18, 23], ["shunting", "OBSERVATION", 106, 114], ["adenoviruses", "OBSERVATION", 122, 134], ["ribosomal shunting", "OBSERVATION", 224, 242]]], ["In the case of adenovirus and pararetrovirus mRNAs, an upstream donor structure appears necessary for the shunting step.", [["adenovirus", "ORGANISM", 15, 25], ["pararetrovirus", "GENE_OR_GENE_PRODUCT", 30, 44], ["adenovirus and pararetrovirus mRNAs", "RNA", 15, 50], ["adenovirus", "SPECIES", 15, 25], ["adenovirus", "PROBLEM", 15, 25], ["pararetrovirus mRNAs", "PROBLEM", 30, 50], ["an upstream donor structure", "PROBLEM", 52, 79], ["the shunting step", "PROBLEM", 102, 119], ["adenovirus", "OBSERVATION", 15, 25], ["shunting", "OBSERVATION", 106, 114]]], ["In pararetrovirus, this appears to be a stable hairpin preceded by a short open reading frame (Hemmings-Mieszczak and Hohn, 1999) .", [["short open reading frame", "DNA", 69, 93], ["a stable hairpin", "PROBLEM", 38, 54], ["appears to be", "UNCERTAINTY", 24, 37], ["stable", "OBSERVATION_MODIFIER", 40, 46], ["hairpin", "OBSERVATION", 47, 54], ["short", "OBSERVATION_MODIFIER", 69, 74]]], ["In the case of TGEV ORF 3b shunting reported here, a requirement for an upstream structure seems unlikely, since shunting took place in the presence of foreign sequence (psCATORF3a-3b-4) as well as (relatively) native sequence (pORF3a-3b-4) at the 5\u0408 terminus.", [["TGEV", "ORGANISM", 15, 19], ["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 170, 185], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 228, 239], ["foreign sequence", "DNA", 152, 168], ["psCATORF3a-3b-4", "DNA", 170, 185], ["pORF3a-3b-4", "DNA", 228, 239], ["5\u0408 terminus", "DNA", 248, 259], ["TGEV", "SPECIES", 15, 19], ["TGEV ORF", "PROBLEM", 15, 23], ["an upstream structure", "PROBLEM", 69, 90], ["shunting", "PROBLEM", 113, 121], ["foreign sequence", "TEST", 152, 168], ["psCATORF3a", "TEST", 170, 180], ["pORF3a", "TEST", 228, 234], ["shunting", "OBSERVATION", 27, 35], ["seems unlikely", "UNCERTAINTY", 91, 105], ["shunting", "OBSERVATION", 113, 121]]], ["In this respect, the TGEV ORF 3b shunting pathway bears similarity to that in paramyxovirus mRNA, for which no apparent requirement for a donor structure was found (Latorre et al., 1998) .", [["TGEV", "ORGANISM", 21, 25], ["paramyxovirus", "ORGANISM", 78, 91], ["TGEV ORF 3b", "DNA", 21, 32], ["paramyxovirus mRNA", "RNA", 78, 96], ["TGEV", "SPECIES", 21, 25], ["the TGEV ORF", "TEST", 17, 29], ["shunting pathway", "PROBLEM", 33, 49], ["paramyxovirus mRNA", "PROBLEM", 78, 96], ["apparent requirement", "PROBLEM", 111, 131], ["a donor structure", "PROBLEM", 136, 153], ["paramyxovirus mRNA", "OBSERVATION", 78, 96]]], ["Likewise, it is not clear what determines the landing site in a ribosomal shunt.", [["ribosomal", "ANATOMY", 64, 73], ["ribosomal", "CELLULAR_COMPONENT", 64, 73], ["landing site", "DNA", 46, 58], ["a ribosomal shunt", "TREATMENT", 62, 79], ["clear", "OBSERVATION", 20, 25], ["ribosomal shunt", "OBSERVATION", 64, 79]]], ["Certainly in the experiments reported here it is not apparent how ribosomes might have been directed to land so close to the 3b initiation codon in TGEV mRNA 3.", [["ribosomes", "CELLULAR_COMPONENT", 66, 75], ["TGEV", "ORGANISM", 148, 152], ["3b initiation codon", "DNA", 125, 144], ["TGEV mRNA 3", "RNA", 148, 159], ["TGEV", "SPECIES", 148, 152]]], ["It is clearly not the postulated secondary structures within gene 3a, because internal entry took place after these had been removed or disrupted (\u232c149, Figs.", [["gene 3", "DNA", 61, 67]]], ["One possibility is that ribosomes are directed to land at or near the start site of gene 3b by specific sequences or by higher-order structures situated very near the landing site.", [["ribosomes", "ANATOMY", 24, 33], ["ribosomes", "CELLULAR_COMPONENT", 24, 33], ["gene 3b", "GENE_OR_GENE_PRODUCT", 84, 91], ["start site", "DNA", 70, 80], ["gene 3b", "DNA", 84, 91], ["landing site", "DNA", 167, 179], ["landing site", "OBSERVATION", 167, 179]]], ["Precedents for this are found in Sendai virus, wherein sequences both upstream and downstream of the Y1 ORF are required for shunt landing (Latorre et al., 1998) , and in Hepatitis C virus, wherein sequences extending 28 nt into the ORF are required for IRES-directed landing (Reynolds et al., 1995) .", [["Hepatitis C", "DISEASE", 171, 182], ["Sendai virus", "ORGANISM", 33, 45], ["Y1 ORF", "GENE_OR_GENE_PRODUCT", 101, 107], ["Hepatitis C virus", "ORGANISM", 171, 188], ["Y1 ORF", "DNA", 101, 107], ["28 nt", "DNA", 218, 223], ["ORF", "DNA", 233, 236], ["IRES", "DNA", 254, 258], ["Hepatitis C virus", "SPECIES", 171, 188], ["Sendai virus", "SPECIES", 33, 45], ["Hepatitis C virus", "SPECIES", 171, 188], ["Sendai virus", "PROBLEM", 33, 45], ["shunt landing", "TREATMENT", 125, 138], ["Hepatitis C virus", "PROBLEM", 171, 188], ["IRES", "TREATMENT", 254, 258], ["Sendai virus", "OBSERVATION", 33, 45]]], ["Curiously, such a landing site might require that ribosomes backscan to find the gene 3b start codon, a process postulated to explain the translation of certain SV40 and influenza virus transcripts (Peabody et al., 1986; Williams and Lamb, 1989) .DISCUSSIONOur findings were particularly intriguing because some evidence had suggested the existence of IRESdirected, cap-independent translation for the third ORF in tricistronic IBV mRNA 3 (Liu and Inglis, 1992; Le et al., 1995) and for the second ORF in the bicistronic MHV mRNA 5 (Thiel and Siddell, 1994) .", [["SV40", "GENE_OR_GENE_PRODUCT", 161, 165], ["influenza virus", "ORGANISM", 170, 185], ["landing site", "DNA", 18, 30], ["gene 3b start codon", "DNA", 81, 100], ["ORF", "DNA", 408, 411], ["ORF", "DNA", 498, 501], ["influenza virus", "SPECIES", 170, 185], ["MHV", "SPECIES", 521, 524], ["a landing site", "PROBLEM", 16, 30], ["ribosomes backscan", "TREATMENT", 50, 68], ["certain SV40", "PROBLEM", 153, 165], ["influenza virus transcripts", "PROBLEM", 170, 197], ["the third ORF", "PROBLEM", 398, 411], ["the second ORF", "PROBLEM", 487, 501], ["bicistronic MHV", "ANATOMY", 509, 524]]], ["The influence of the cap, however, was not examined in the MHV studies, and the possibility remains that a form of shunting might also be exhibited during the translation of these mRNAs.DISCUSSIONThe consequences of an internal ribosomal entry onto gene 3b for virus replication are not immediately apparent, but one might be that it enables a constitutive synthesis of 3b protein because, in principle, any of the viral mRNAs containing gene 3b (mRNAs 1, 2, and 3) could serve as templates.MATERIALS AND METHODSCells and virus.", [["ribosomal", "ANATOMY", 228, 237], ["ribosomal", "CELLULAR_COMPONENT", 228, 237], ["gene 3b", "GENE_OR_GENE_PRODUCT", 249, 256], ["3b", "GENE_OR_GENE_PRODUCT", 370, 372], ["gene 3b", "GENE_OR_GENE_PRODUCT", 438, 445], ["2", "GENE_OR_GENE_PRODUCT", 456, 457], ["3", "GENE_OR_GENE_PRODUCT", 463, 464], ["mRNAs", "RNA", 180, 185], ["gene 3b", "DNA", 249, 256], ["viral mRNAs", "RNA", 415, 426], ["gene 3b", "DNA", 438, 445], ["mRNAs 1, 2, and 3", "DNA", 447, 464], ["MHV", "SPECIES", 59, 62], ["the cap", "TEST", 17, 24], ["the MHV studies", "TEST", 55, 70], ["shunting", "PROBLEM", 115, 123], ["an internal ribosomal entry onto gene 3b for virus replication", "TREATMENT", 216, 278], ["a constitutive synthesis of 3b protein", "PROBLEM", 342, 380], ["the viral mRNAs", "TEST", 411, 426], ["mRNAs", "TEST", 447, 452], ["METHODSCells", "TREATMENT", 505, 517], ["virus", "PROBLEM", 522, 527], ["cap", "OBSERVATION_MODIFIER", 21, 24], ["shunting", "OBSERVATION", 115, 123], ["viral mRNAs", "OBSERVATION", 415, 426]]], ["The Purdue-116 and Miller strains of TGEV were obtained from E. Bohl, Ohio State University.", [["Purdue-116", "CELL", 4, 14], ["TGEV", "ORGANISM", 37, 41], ["TGEV", "SPECIES", 37, 41], ["TGEV", "SPECIES", 37, 41], ["The Purdue", "TEST", 0, 10], ["TGEV", "PROBLEM", 37, 41]]], ["Purdue-116 virus was plaque-purified from infectious genomic RNA, grown on swine testicle (ST) cells in medium containing 10% fetal calf serum (Atlanta Biologicals), and used within eight passages of plaque purification (Brian et al., 1980; Kapke and Brian, 1986) .", [["plaque", "ANATOMY", 21, 27], ["testicle (ST) cells", "ANATOMY", 81, 100], ["fetal calf serum", "ANATOMY", 126, 142], ["plaque", "ANATOMY", 200, 206], ["Purdue-116 virus", "ORGANISM", 0, 16], ["swine", "ORGANISM", 75, 80], ["testicle (ST) cells", "CELL", 81, 100], ["calf", "ORGANISM", 132, 136], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["infectious genomic RNA", "RNA", 42, 64], ["swine testicle (ST) cells", "CELL_TYPE", 75, 100], ["swine", "SPECIES", 75, 80], ["calf", "SPECIES", 132, 136], ["Purdue-116 virus", "SPECIES", 0, 16], ["swine", "SPECIES", 75, 80], ["plaque", "PROBLEM", 21, 27], ["infectious genomic RNA", "PROBLEM", 42, 64], ["swine testicle (ST) cells in medium", "PROBLEM", 75, 110], ["fetal calf serum", "TEST", 126, 142], ["plaque purification", "TREATMENT", 200, 219], ["plaque", "OBSERVATION", 21, 27], ["infectious", "OBSERVATION_MODIFIER", 42, 52], ["genomic RNA", "OBSERVATION", 53, 64], ["testicle", "ANATOMY", 81, 89], ["fetal calf", "ANATOMY", 126, 136], ["plaque", "OBSERVATION", 200, 206]]], ["Miller virus was similarly grown but was plaque-purified twice from infectious virus on ST cells and used within 10 passages of plaque purification.MATERIALS AND METHODSNorthern analysis of TGEV mRNAs.", [["plaque", "ANATOMY", 41, 47], ["ST cells", "ANATOMY", 88, 96], ["plaque", "ANATOMY", 128, 134], ["Miller virus", "ORGANISM", 0, 12], ["ST cells", "CELL", 88, 96], ["plaque", "PATHOLOGICAL_FORMATION", 128, 134], ["TGEV", "ORGANISM", 190, 194], ["ST cells", "CELL_TYPE", 88, 96], ["TGEV mRNAs", "RNA", 190, 200], ["TGEV", "SPECIES", 190, 194], ["Miller virus", "PROBLEM", 0, 12], ["plaque", "PROBLEM", 41, 47], ["infectious virus", "PROBLEM", 68, 84], ["ST cells", "TREATMENT", 88, 96], ["plaque purification", "TREATMENT", 128, 147], ["METHODSNorthern analysis", "TEST", 162, 186], ["TGEV mRNAs", "PROBLEM", 190, 200], ["virus", "OBSERVATION", 7, 12], ["grown", "OBSERVATION_MODIFIER", 27, 32], ["plaque", "OBSERVATION", 41, 47], ["infectious", "OBSERVATION_MODIFIER", 68, 78], ["plaque", "OBSERVATION", 128, 134], ["TGEV mRNAs", "OBSERVATION", 190, 200]]], ["Northern analyses were performed as described (Sethna et al., 1989) and quantitation was done with the AMBIS Photoanalytic Imaging System (AMBIS, San Diego, CA).", [["Northern analyses", "TEST", 0, 17], ["quantitation", "TEST", 72, 84], ["the AMBIS", "TEST", 99, 108]]], ["Cells were infected with TGEV at a multiplicity of infection (m.o.i.) of 10 and total RNA was extracted at 6 and 9 h postinfection (hpi).", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 51, 60], ["Cells", "CELL", 0, 5], ["TGEV", "ORGANISM", 25, 29], ["TGEV", "SPECIES", 25, 29], ["TGEV", "PROBLEM", 25, 29], ["infection", "PROBLEM", 51, 60], ["total RNA", "TEST", 80, 89], ["infection", "OBSERVATION", 51, 60]]], ["Blots were probed with radiolabeled synthetic oligodeoxynucleotide specific for the leader (oligonucleotide L3\u03e9, 5\u0408CGGGATCCTCGGGTTTAGTTCGAGTTGGTG-TCCGAAGACAAAATCTAGCACAAGGCTAGTTAAAGT-AAAAGAAGAGATAT3\u0408), gene 3a (oligonucleotide 7.7, 5\u0408GTTCGTCAAGTACAGCATCTACGG3\u0408), or gene 3b (oligonucleotide 4, 5\u0408CTTCTCATAAACGGTGCAGCTCT-GCC3\u0408).", [["oligodeoxynucleotide", "CHEMICAL", 46, 66], ["5\u0408CGGGATCCTCGGGTTTAGTTCGAGTTGGTG-TCCGAAGACAAAATCTAGCACAAGGCTAGTTAAAGT-AAAAGAAGAGATAT3\u0408), gene 3a", "GENE_OR_GENE_PRODUCT", 113, 209], ["5\u0408CTTCTCATAAACGGTGCAGCTCT-GCC3\u0408", "GENE_OR_GENE_PRODUCT", 294, 325], ["gene 3a", "DNA", 202, 209], ["gene 3b", "DNA", 266, 273], ["oligonucleotide 4", "DNA", 275, 292], ["GCC3\u0408", "DNA", 320, 325], ["Blots", "TEST", 0, 5], ["radiolabeled synthetic oligodeoxynucleotide", "TREATMENT", 23, 66], ["oligonucleotide L3\u03e9", "TEST", 92, 111], ["oligonucleotide", "TEST", 211, 226], ["5\u0408GTTCGTCAAGTACAGCATCTACGG3\u0408)", "TREATMENT", 232, 261], ["gene 3b (oligonucleotide", "TREATMENT", 266, 290]]], ["Probes were radiolabeled to a specific activity of 1.5 to 3.5 \u03eb 10 6 cpm/pmol by the forward reaction.MATERIALS AND METHODSConstruction of plasmids.", [["plasmids", "ANATOMY", 139, 147], ["Probes", "ORGANISM_SUBSTANCE", 0, 6], ["plasmids", "DNA", 139, 147], ["the forward reaction", "PROBLEM", 81, 101], ["METHODSConstruction of plasmids", "TREATMENT", 116, 147]]], ["TGEV Purdue sequences used in this study have been published (Kapke, et al., 1988a; Sethna et al., 1991) .", [["TGEV", "ORGANISM", 0, 4], ["TGEV Purdue sequences", "DNA", 0, 21], ["TGEV", "SPECIES", 0, 4], ["TGEV Purdue sequences", "TEST", 0, 21], ["this study", "TEST", 30, 40]]], ["The construction of pORF3b-4 ( Fig. 1C) , formerly called pORF2, has been described (O'Connor and Brian, 1999) . pORF3b-4 carries genes 3b and 4 and 308 nt of gene 5 in vector pGEM-4Z (Promega Biotech) (a sequence obtained from cDNA clone pFT44 [ Fig. 1A] ). pORF4 (Fig. 1C) was made from pORF3b-4 by first removing the 291-nt M-containing SphI fragment, religating, and then removing the 716-nt HindIII-BbsI fragment and religating after blunt-ending with mung bean nuclease. pORF3a-3b-4 (Fig. 1C) , which carries genes 3a, 3b, and 4 downstream of the T7 RNA polymerase promoter in pGEM-3Z (Promega Biotech), was made in three steps.", [["pORF3b-4", "GENE_OR_GENE_PRODUCT", 20, 28], ["Fig. 1C", "GENE_OR_GENE_PRODUCT", 31, 38], ["pORF2", "GENE_OR_GENE_PRODUCT", 58, 63], ["pORF3b-4", "GENE_OR_GENE_PRODUCT", 113, 121], ["pGEM-4Z", "GENE_OR_GENE_PRODUCT", 176, 183], ["Promega Biotech", "GENE_OR_GENE_PRODUCT", 185, 200], ["pORF3b-4", "GENE_OR_GENE_PRODUCT", 289, 297], ["SphI", "GENE_OR_GENE_PRODUCT", 340, 344], ["HindIII", "GENE_OR_GENE_PRODUCT", 396, 403], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 477, 488], ["Fig. 1C", "GENE_OR_GENE_PRODUCT", 490, 497], ["3b", "GENE_OR_GENE_PRODUCT", 525, 527], ["4", "GENE_OR_GENE_PRODUCT", 533, 534], ["pGEM-3Z", "GENE_OR_GENE_PRODUCT", 583, 590], ["pORF3b", "PROTEIN", 20, 26], ["pORF2", "DNA", 58, 63], ["pORF3b-4", "DNA", 113, 121], ["genes 3b and 4", "DNA", 130, 144], ["308 nt of gene 5", "DNA", 149, 165], ["pGEM", "DNA", 176, 180], ["4Z", "DNA", 181, 183], ["Promega Biotech", "DNA", 185, 200], ["cDNA clone pFT44", "DNA", 228, 244], ["pORF4", "PROTEIN", 259, 264], ["pORF3b", "PROTEIN", 289, 295], ["291-nt M-", "DNA", 320, 329], ["SphI fragment", "DNA", 340, 353], ["716-nt HindIII-BbsI fragment", "DNA", 389, 417], ["mung bean nuclease", "PROTEIN", 457, 475], ["pORF3a", "PROTEIN", 477, 483], ["3b-4", "DNA", 484, 488], ["genes 3a, 3b, and 4", "DNA", 515, 534], ["T7 RNA polymerase promoter", "DNA", 553, 579], ["pGEM", "DNA", 583, 587], ["3Z", "DNA", 588, 590], ["Promega Biotech", "DNA", 592, 607], ["mung bean", "SPECIES", 457, 466], ["pORF3b", "TEST", 20, 26], ["pORF3b", "TEST", 113, 119], ["a sequence", "TEST", 203, 213], ["nt M-containing SphI fragment", "TREATMENT", 324, 353], ["BbsI fragment", "PROBLEM", 404, 417], ["blunt", "PROBLEM", 439, 444], ["mung bean nuclease", "TREATMENT", 457, 475], ["pORF3a", "TEST", 477, 483], ["the T7 RNA polymerase promoter", "TREATMENT", 549, 579], ["SphI fragment", "OBSERVATION", 340, 353], ["BbsI fragment", "OBSERVATION", 404, 417], ["T7", "ANATOMY", 553, 555]]], ["First, pSP6ORF3a, from which gene 3a and 591 nt of gene 3b can be transcribed with RNA polymerase SP6, was created by ligating the 1111 bp NsiI-PstI fragment from clone pFT39 (a clone containing nucleotides 3968 to 5449 from the genome 3\u0408 end [ Fig. 1A ; Tung et al., 1992] , prepared as described in Kapke et al., 1988a,b) into the PstI site of pGEM-3Z.", [["pGEM-3Z.", "CHEMICAL", 346, 354], ["nucleotides", "CHEMICAL", 195, 206], ["pSP6ORF3a", "GENE_OR_GENE_PRODUCT", 7, 16], ["gene 3b", "GENE_OR_GENE_PRODUCT", 51, 58], ["SP6", "GENE_OR_GENE_PRODUCT", 98, 101], ["PstI", "GENE_OR_GENE_PRODUCT", 144, 148], ["pFT39", "GENE_OR_GENE_PRODUCT", 169, 174], ["PstI", "GENE_OR_GENE_PRODUCT", 333, 337], ["pSP6ORF3a", "PROTEIN", 7, 16], ["591 nt of gene 3b", "DNA", 41, 58], ["RNA polymerase SP6", "DNA", 83, 101], ["1111 bp NsiI-PstI fragment", "DNA", 131, 157], ["clone pFT39", "DNA", 163, 174], ["nucleotides 3968 to 5449", "DNA", 195, 219], ["genome 3\u0408 end", "DNA", 229, 242], ["PstI site", "DNA", 333, 342], ["pGEM", "PROTEIN", 346, 350], ["RNA polymerase SP6", "TREATMENT", 83, 101], ["bp", "TEST", 136, 138], ["PstI fragment", "PROBLEM", 144, 157], ["clone pFT39", "TEST", 163, 174], ["a clone containing nucleotides", "TREATMENT", 176, 206], ["pGEM", "TEST", 346, 350]]], ["Second, pSP6ORF3a-3b-4 was created by ligating the 925-bp BsrGI-EcoRI fragment from pORF3b-4 into the 4048-nt vector-containing EcoRI-BsrGI-linearized fragment of pSP6ORF3a.", [["pSP6ORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 8, 22], ["pORF3b-4", "GENE_OR_GENE_PRODUCT", 84, 92], ["EcoRI", "GENE_OR_GENE_PRODUCT", 128, 133], ["pSP6ORF3a", "GENE_OR_GENE_PRODUCT", 163, 172], ["pSP6ORF3a-3b-4", "DNA", 8, 22], ["925-bp BsrGI-EcoRI fragment", "DNA", 51, 78], ["pORF3b-4", "DNA", 84, 92], ["4048-nt vector", "DNA", 102, 116], ["EcoRI-BsrGI-linearized fragment", "DNA", 128, 159], ["pSP6ORF3a", "DNA", 163, 172], ["pSP6ORF3a", "TEST", 8, 17], ["bp BsrGI", "TEST", 55, 63], ["EcoRI fragment", "TEST", 64, 78], ["pORF3b", "TEST", 84, 90], ["EcoRI", "TEST", 128, 133], ["linearized fragment of pSP6ORF3a", "PROBLEM", 140, 172], ["linearized fragment", "OBSERVATION", 140, 159]]], ["Third, the entire 1340-nt SphI-HinfI insert from pSP6ORF3a-3b-4, after blunt-ending with T4 DNA polymerase, was ligated in the reverse orientation into similarly blunt-ended EcoRI-SacI-linearized pGEM-3Z.MATERIALS AND METHODSTo place the viral leader upstream of ORF 3a, pLORF3a-3b-4 ( Fig. 1C ) was constructed by a previously published procedure (Sethna et al., 1991; Hofmann et al., 1993) .", [["pSP6ORF3a-3b-4", "CHEMICAL", 49, 63], ["pGEM-3Z", "CHEMICAL", 196, 203], ["SphI", "GENE_OR_GENE_PRODUCT", 26, 30], ["HinfI", "GENE_OR_GENE_PRODUCT", 31, 36], ["pSP6ORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 49, 63], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["EcoRI", "GENE_OR_GENE_PRODUCT", 174, 179], ["SacI", "GENE_OR_GENE_PRODUCT", 180, 184], ["pGEM-3Z", "GENE_OR_GENE_PRODUCT", 196, 203], ["pLORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 271, 283], ["1340-nt SphI-HinfI insert", "DNA", 18, 43], ["pSP6ORF3a-3b-4", "DNA", 49, 63], ["T4 DNA polymerase", "PROTEIN", 89, 106], ["blunt-ended EcoRI-SacI-linearized pGEM-3Z", "DNA", 162, 203], ["viral leader upstream", "DNA", 238, 259], ["ORF 3", "DNA", 263, 268], ["pLORF3a-3b-4", "DNA", 271, 283], ["nt SphI-HinfI insert", "TREATMENT", 23, 43], ["pSP6ORF3a", "TEST", 49, 58], ["blunt", "PROBLEM", 71, 76], ["T4 DNA polymerase", "PROBLEM", 89, 106], ["EcoRI", "TEST", 174, 179], ["ORF", "TEST", 263, 266], ["pLORF3a", "TEST", 271, 278]]], ["Briefly, cDNA was made from the 5\u0408 end of mRNA 3 with a primer specific to gene 3b (oligo 4(\u03e9) [5\u0408CTTCT-CATAAACGGTGCAGCTCTGCC3\u0408]), and amplified by PCR using oligo 4(\u03e9) and oligo leaderGAC(\u03ea) (5\u0408GCGGGC-CCGGGACTTTTAAAGTAAAG3, which binds to the minus-strand of the leader), to create a leader-containing fragment.", [["oligo 4(\u03e9)", "GENE_OR_GENE_PRODUCT", 84, 94], ["oligo 4", "GENE_OR_GENE_PRODUCT", 158, 165], ["cDNA", "DNA", 9, 13], ["5\u0408 end", "DNA", 32, 38], ["mRNA 3", "RNA", 42, 48], ["gene 3b", "DNA", 75, 82], ["oligo 4", "DNA", 84, 91], ["oligo 4", "DNA", 158, 165], ["oligo leaderGAC", "DNA", 173, 188], ["\u03ea", "DNA", 189, 190], ["minus-strand", "DNA", 244, 256], ["leader-containing fragment", "DNA", 285, 311], ["oligo", "TEST", 84, 89], ["oligo", "TREATMENT", 158, 163], ["oligo leaderGAC(\u03ea) (5\u0408GCGGGC-CCGGGACTTTTAAAGTAAAG3", "TREATMENT", 173, 223], ["fragment", "OBSERVATION_MODIFIER", 303, 311]]], ["The product was digested with SmaI and BsrGI, and the large fragment was ligated in a three-way ligation reaction with the 590-nt BsrGI-SphI fragment of pORF3a-3b, and with pGEM-4Z that had been linearized with HindIII, blunt-ended with T4 DNA polymerase, and digested with SphI.MATERIALS AND METHODSTo create a strong Kozak context for the 3a start codon, thus creating pORF3a(K)-3b-4, an overlap PCR mutagenesis procedure (Horton et al., 1990) was used.", [["SmaI", "GENE_OR_GENE_PRODUCT", 30, 34], ["BsrGI", "GENE_OR_GENE_PRODUCT", 39, 44], ["SphI", "GENE_OR_GENE_PRODUCT", 136, 140], ["pORF3a-3", "GENE_OR_GENE_PRODUCT", 153, 161], ["pGEM-4Z", "GENE_OR_GENE_PRODUCT", 173, 180], ["HindIII", "GENE_OR_GENE_PRODUCT", 211, 218], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["SphI", "GENE_OR_GENE_PRODUCT", 274, 278], ["pORF3a(K)-3b-4", "GENE_OR_GENE_PRODUCT", 371, 385], ["SmaI", "DNA", 30, 34], ["BsrGI", "DNA", 39, 44], ["590-nt BsrGI-SphI fragment", "DNA", 123, 149], ["pORF3a-3b", "DNA", 153, 162], ["pGEM", "DNA", 173, 177], ["4Z", "DNA", 178, 180], ["HindIII", "DNA", 211, 218], ["T4 DNA polymerase", "PROTEIN", 237, 254], ["SphI", "DNA", 274, 278], ["3a start codon", "DNA", 341, 355], ["pORF3a(K)-3b-4", "DNA", 371, 385], ["SmaI and BsrGI", "PROBLEM", 30, 44], ["the large fragment", "PROBLEM", 50, 68], ["a three-way ligation reaction", "TREATMENT", 84, 113], ["pORF3a", "TEST", 153, 159], ["pGEM", "TEST", 173, 177], ["blunt", "PROBLEM", 220, 225], ["T4 DNA polymerase", "PROBLEM", 237, 254], ["an overlap PCR mutagenesis procedure", "TREATMENT", 387, 423], ["large", "OBSERVATION_MODIFIER", 54, 59], ["fragment", "OBSERVATION", 60, 68], ["ligated", "OBSERVATION_MODIFIER", 73, 80], ["ligation", "OBSERVATION", 96, 104]]], ["For this, complementary mutagenesis primers 7.7Kozak(\u03e9) (5\u0408CAA-TGTCAATGGTGGCCCTGTAATGAC3\u0408) and 7.7Kozak(\u03ea) (5\u0408GTCATTACAGGGCCACCATGGACATTG3\u0408), and primers oligo 5(\u03e9) (5\u0408TGCCACCATACAATGTGACA3\u0408, which binds to bases 465-484 within ORF 3b) and pGEM3Zf(\u03ea)NdeI(\u03ea) (5\u0408GAGAGTGCACCATATGCGGTGT3\u0408, which binds to bases 2498-2519 within pGEM-3Z), were used together in the overlap procedure to amplify a 1066-nt product from pORF3a-3b-4 DNA.", [["pGEM3Zf(\u03ea)NdeI(\u03ea)", "GENE_OR_GENE_PRODUCT", 240, 257], ["pGEM-3Z", "GENE_OR_GENE_PRODUCT", 325, 332], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 413, 424], ["DNA", "CELLULAR_COMPONENT", 425, 428], ["complementary mutagenesis primers", "DNA", 10, 43], ["primers oligo 5", "DNA", 146, 161], ["ORF 3b", "DNA", 228, 234], ["pGEM3Zf(\u03ea)NdeI(\u03ea)", "DNA", 240, 257], ["bases 2498-2519", "DNA", 302, 317], ["pGEM", "DNA", 325, 329], ["3Z", "DNA", 330, 332], ["pORF3a-3b-4 DNA", "DNA", 413, 428], ["complementary mutagenesis primers", "TEST", 10, 43], ["Kozak", "TEST", 47, 52], ["5\u0408CAA", "TEST", 57, 62], ["Kozak(\u03ea) (5\u0408GTCATTACAGGGCCACCATGGACATTG3\u0408)", "TREATMENT", 98, 140], ["primers oligo 5(\u03e9) (5\u0408TGCCACCATACAATGTGACA3\u0408", "TREATMENT", 146, 190], ["pORF3a", "TEST", 413, 419]]], ["After digestion with restriction enzymes NarI and BsrGI, the 932-nt product was cloned into NarI-BsrGI-linearized pORF3a-3b-4.MATERIALS AND METHODSTo create pCATORF3a-3b-4 (Fig. 1C) , the ORF3a-3b-4containing 1534-nt SphI fragment from pORF3a-3b-4 was placed into the SphI site of pCAT (Fig. 1C) , which was made by cloning the BamHI fragment from pCM4 (Pharmacia) into the BamHI site of pGEM-3Z.", [["pORF3a-3b-4", "CHEMICAL", 236, 247], ["pGEM-3Z.", "CHEMICAL", 388, 396], ["NarI", "GENE_OR_GENE_PRODUCT", 41, 45], ["BsrGI", "GENE_OR_GENE_PRODUCT", 50, 55], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 114, 125], ["pCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 157, 171], ["ORF3a-3b", "GENE_OR_GENE_PRODUCT", 188, 196], ["SphI", "GENE_OR_GENE_PRODUCT", 217, 221], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 236, 247], ["SphI", "GENE_OR_GENE_PRODUCT", 268, 272], ["pCAT", "GENE_OR_GENE_PRODUCT", 281, 285], ["Fig. 1C", "GENE_OR_GENE_PRODUCT", 287, 294], ["BamHI", "GENE_OR_GENE_PRODUCT", 328, 333], ["pCM4", "GENE_OR_GENE_PRODUCT", 348, 352], ["BamHI", "GENE_OR_GENE_PRODUCT", 374, 379], ["restriction enzymes", "PROTEIN", 21, 40], ["NarI", "PROTEIN", 41, 45], ["BsrGI", "PROTEIN", 50, 55], ["932-nt product", "PROTEIN", 61, 75], ["NarI-BsrGI-linearized pORF3a-3b-4", "DNA", 92, 125], ["pCATORF3a", "DNA", 157, 166], ["3b-4", "DNA", 167, 171], ["ORF3a-3b-4containing 1534-nt SphI fragment", "DNA", 188, 230], ["pORF3a-3b-4", "DNA", 236, 247], ["SphI site", "DNA", 268, 277], ["pCAT", "DNA", 281, 285], ["BamHI fragment", "DNA", 328, 342], ["pCM4", "DNA", 348, 352], ["BamHI site", "DNA", 374, 384], ["pGEM", "DNA", 388, 392], ["enzymes", "TEST", 33, 40], ["NarI", "TEST", 41, 45], ["BsrGI", "TEST", 50, 55], ["nt product", "TREATMENT", 65, 75], ["pCATORF3a", "TEST", 157, 166], ["the ORF3a", "TEST", 184, 193], ["nt SphI fragment", "TREATMENT", 214, 230], ["pORF3a", "TEST", 236, 242], ["the BamHI fragment from pCM4 (Pharmacia", "TREATMENT", 324, 363], ["pGEM", "TEST", 388, 392], ["BamHI", "ANATOMY", 374, 379]]], ["For better size resolution of the large proteins, the CAT gene in pCATORF3a-3b-4 was truncated by 91 nt on its 3\u0408 end by digestions with NcoI and nuclease Bal 31, thus forming psCATORF3a-3b-4 (Fig. 1C) .", [["CAT", "GENE_OR_GENE_PRODUCT", 54, 57], ["pCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 66, 80], ["NcoI", "GENE_OR_GENE_PRODUCT", 137, 141], ["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 176, 191], ["CAT gene", "DNA", 54, 62], ["pCATORF3a-3b-4", "DNA", 66, 80], ["3\u0408 end", "DNA", 111, 117], ["NcoI", "DNA", 137, 141], ["nuclease Bal 31", "PROTEIN", 146, 161], ["psCATORF3a-3b-4", "DNA", 176, 191], ["the large proteins", "PROBLEM", 30, 48], ["the CAT gene", "TEST", 50, 62], ["pCATORF3a", "TEST", 66, 75], ["NcoI", "TEST", 137, 141], ["nuclease Bal", "TEST", 146, 158], ["psCATORF3a", "TEST", 176, 186], ["size", "OBSERVATION_MODIFIER", 11, 15], ["large", "OBSERVATION_MODIFIER", 34, 39], ["proteins", "OBSERVATION", 40, 48]]], ["This, along with a frameshift, resulted in a total shortening of the CAT protein (now called sCAT) by 46 aa.MATERIALS AND METHODSThe junctions of all constructs were confirmed by sequencing plasmid DNA.MATERIALS AND METHODSPreparation of nested deletions within gene 3a, the postulated internal ribosomal entry region.", [["plasmid", "ANATOMY", 190, 197], ["ribosomal", "ANATOMY", 295, 304], ["CAT", "GENE_OR_GENE_PRODUCT", 69, 72], ["sCAT", "GENE_OR_GENE_PRODUCT", 93, 97], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["ribosomal", "CELLULAR_COMPONENT", 295, 304], ["CAT protein", "PROTEIN", 69, 80], ["sCAT", "PROTEIN", 93, 97], ["plasmid DNA", "DNA", 190, 201], ["gene 3", "DNA", 262, 268], ["internal ribosomal entry region", "DNA", 286, 317], ["a total shortening of the CAT protein", "PROBLEM", 43, 80], ["METHODSThe junctions of all constructs", "TREATMENT", 122, 160], ["METHODSPreparation of nested deletions", "TREATMENT", 216, 254], ["internal", "ANATOMY_MODIFIER", 286, 294], ["ribosomal entry", "OBSERVATION", 295, 310]]], ["To obtain deletions within gene 3a, psCATORF3a-3b-4 DNA was linearized at base 7 of ORF 3a with Tth111 I, treated with Bal 31 and mung bean nucleases, purified by electrophoresis, and religated.", [["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 36, 51], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["Tth111 I", "GENE_OR_GENE_PRODUCT", 96, 104], ["gene 3a", "DNA", 27, 34], ["psCATORF3a-3b-4 DNA", "DNA", 36, 55], ["base 7", "DNA", 74, 80], ["ORF 3a", "DNA", 84, 90], ["Tth111 I", "DNA", 96, 104], ["Bal 31", "DNA", 119, 125], ["mung bean nucleases", "DNA", 130, 149], ["mung bean", "SPECIES", 130, 139], ["psCATORF3a", "TEST", 36, 46], ["Tth", "TEST", 96, 99], ["Bal", "TEST", 119, 122], ["mung bean nucleases", "TREATMENT", 130, 149], ["electrophoresis", "TEST", 163, 178]]], ["Transformants were screened for deletions by PCR and the sequenced constructs were named for the number of bases deleted downstream of the gene 3a start site (the total number of deleted bases is also noted).MATERIALS AND METHODSIn vitro translation and analysis of products.", [["Transformants", "ANATOMY", 0, 13], ["Transformants", "CELL", 0, 13], ["gene 3", "DNA", 139, 145], ["start site", "DNA", 147, 157], ["deletions", "PROBLEM", 32, 41], ["PCR", "TEST", 45, 48], ["METHODSIn vitro translation", "TREATMENT", 222, 249], ["bases", "ANATOMY_MODIFIER", 187, 192]]], ["In vitro transcription with T7 RNA polymerase was carried out on linearized plasmid DNAs as recommended (Promega Biotech). pORF3b-4 was linearized with EcoRI, pORF3a-3b-4 with ScaI or BamHI, as indicated, and psCATORF3a-3b-4 with AseI.", [["DNAs", "ANATOMY", 84, 88], ["pORF3b-4", "GENE_OR_GENE_PRODUCT", 123, 131], ["EcoRI", "GENE_OR_GENE_PRODUCT", 152, 157], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 159, 170], ["ScaI", "GENE_OR_GENE_PRODUCT", 176, 180], ["BamHI", "GENE_OR_GENE_PRODUCT", 184, 189], ["psCATORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 209, 224], ["AseI", "GENE_OR_GENE_PRODUCT", 230, 234], ["T7 RNA polymerase", "PROTEIN", 28, 45], ["linearized plasmid DNAs", "DNA", 65, 88], ["pORF3b-4", "DNA", 123, 131], ["EcoRI, pORF3a-3b-4", "DNA", 152, 170], ["ScaI", "DNA", 176, 180], ["BamHI", "DNA", 184, 189], ["psCATORF3a-3b-4", "DNA", 209, 224], ["AseI", "DNA", 230, 234], ["T7 RNA polymerase", "TREATMENT", 28, 45], ["linearized plasmid DNAs", "TREATMENT", 65, 88], ["pORF3b", "TEST", 123, 129], ["EcoRI", "TEST", 152, 157], ["pORF3a", "TEST", 159, 165], ["BamHI", "TEST", 184, 189], ["psCATORF3a", "TEST", 209, 219]]], ["The 1274-nt DNA fragment from ScaIlinearized pORF3a-3b-4 was purified by affinity chromatography (Geneclean; Bio 101) to ensure transcription of only ORF 3a.", [["pORF3a-3b-4", "CHEMICAL", 45, 56], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["pORF3a-3b-4", "GENE_OR_GENE_PRODUCT", 45, 56], ["1274-nt DNA fragment", "DNA", 4, 24], ["ScaIlinearized pORF3a-3b-4", "DNA", 30, 56], ["ORF 3", "DNA", 150, 155], ["nt DNA fragment", "PROBLEM", 9, 24], ["ScaIlinearized pORF3a", "TEST", 30, 51], ["affinity chromatography", "TEST", 73, 96]]], ["For preparation of capped RNA transcripts, 0.5 mM m7G(5\u0408)ppp(5\u0408)G and 0.25 mM GTP replaced 2.5 mM GTP in the transcription mix (Promega Biotech).", [["GTP", "CHEMICAL", 78, 81], ["GTP", "CHEMICAL", 98, 101], ["m7G(5\u0408)ppp(5\u0408)G", "CHEMICAL", 50, 65], ["GTP", "CHEMICAL", 78, 81], ["GTP", "CHEMICAL", 98, 101], ["GTP", "SIMPLE_CHEMICAL", 78, 81], ["GTP", "SIMPLE_CHEMICAL", 98, 101], ["capped RNA transcripts", "RNA", 19, 41], ["preparation of capped RNA transcripts", "TREATMENT", 4, 41], ["ppp", "TEST", 57, 60], ["0.25 mM GTP", "TREATMENT", 70, 81], ["2.5 mM GTP", "TREATMENT", 91, 101], ["the transcription mix", "TREATMENT", 105, 126]]], ["Each preparation of RNA was purified by Biospin column chromatography (Bio-Rad), quantitated by spectrophotometry, and monitored for degradation by agarose gel electrophoresis.", [["agarose", "SIMPLE_CHEMICAL", 148, 155], ["Biospin column chromatography", "TEST", 40, 69], ["agarose gel electrophoresis", "TEST", 148, 175]]], ["In vitro translation was carried out in methionine-depleted wheat germ extracts or rabbit reticulocyte lysates as recommended by the manufacturers (Promega Biotech and Ambion, Inc.).", [["germ extracts", "ANATOMY", 66, 79], ["reticulocyte lysates", "ANATOMY", 90, 110], ["methionine", "CHEMICAL", 40, 50], ["methionine", "CHEMICAL", 40, 50], ["methionine", "SIMPLE_CHEMICAL", 40, 50], ["wheat", "ORGANISM", 60, 65], ["germ extracts", "ORGANISM_SUBSTANCE", 66, 79], ["rabbit", "ORGANISM", 83, 89], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 90, 110], ["wheat", "SPECIES", 60, 65], ["rabbit", "SPECIES", 83, 89], ["wheat", "SPECIES", 60, 65], ["rabbit", "SPECIES", 83, 89], ["methionine", "TREATMENT", 40, 50], ["wheat germ extracts", "TREATMENT", 60, 79], ["rabbit reticulocyte lysates", "TREATMENT", 83, 110]]], ["In some preparations, translation products were treated with RNase A before electrophoresis as recommended by Ambion, Inc., to remove a 27-kDa endogenous band caused by the binding of charged tRNA to proteins.", [["RNase", "GENE_OR_GENE_PRODUCT", 61, 66], ["translation products", "PROTEIN", 22, 42], ["RNase A", "PROTEIN", 61, 68], ["translation products", "TREATMENT", 22, 42], ["RNase A before electrophoresis", "TREATMENT", 61, 91]]], ["Fifty-microliter reaction volumes contained 50 Ci 35 S-methionine (1000 Ci/mmol; ICN) and 1.0 g of RNA transcript.", [["Ci 35 S-methionine", "CHEMICAL", 47, 65], ["Ci 35 S-methionine", "CHEMICAL", 47, 65], ["ICN", "CHEMICAL", 81, 84], ["RNA transcript", "RNA", 99, 113], ["microliter reaction volumes", "TEST", 6, 33], ["methionine", "TREATMENT", 55, 65], ["RNA transcript", "TREATMENT", 99, 113]]], ["To test for inhibition of translation by exogenous methylated cap analog, m7G(5\u0408)ppp(5\u0408)G (New England Biolabs) was added to the translation mix to final concentrations of 0.1, 0.2, 0.4, and 0.8 mM.", [["Biolabs", "GENE_OR_GENE_PRODUCT", 103, 110], ["inhibition of translation", "TREATMENT", 12, 37], ["exogenous methylated cap analog", "TREATMENT", 41, 72], ["New England Biolabs)", "TREATMENT", 91, 111]]], ["Radioactivity in the separated products was quantitated by scanning dried gels with the AMBIS Photoanalytic Imaging System (San Diego, CA) or by scanning autoradiograms of the gels with the Bio-Rad Imaging Spectrophotometer (Bio-Rad).", [["scanning dried gels", "TREATMENT", 59, 78], ["scanning autoradiograms", "TEST", 145, 168], ["the Bio", "TEST", 186, 193]]], ["Each experiment depicted was done minimally on three separate preparations of transcript RNA.", [["transcript RNA", "RNA", 78, 92], ["transcript RNA", "TREATMENT", 78, 92], ["transcript RNA", "OBSERVATION", 78, 92]]], ["Standard deviation measurements were made from the results of three separate experiments.", [["Standard deviation measurements", "TEST", 0, 31], ["deviation", "OBSERVATION", 9, 18]]]], "f938a5e23a8cf22f4d43683c54f10cd39fe93467": [["millennia, he also relocates an ethics developed in the area of the desires (food, diet, sex) to the area of technology.", [["millennia", "PROBLEM", 0, 9]]]], "0454c71b0d75bbcc30a6d699cda9fd97bddfcd81": [["Correspondence barb.nik@uky.eduIn BriefWe uncovered a dominant Th17 inflammaging profile made by CD4 + T cells.", [["CD4 + T cells", "ANATOMY", 97, 110], ["Th17", "CELL", 63, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD4", "PROTEIN", 97, 100], ["T cells", "CELL_TYPE", 103, 110], ["dominant", "OBSERVATION_MODIFIER", 54, 62], ["Th17", "OBSERVATION", 63, 67]]], ["Knockdown of autophagy in T cells from young subjects activates this profile.", [["T cells", "ANATOMY", 26, 33], ["T cells", "CELL", 26, 33], ["T cells", "CELL_TYPE", 26, 33], ["autophagy in T cells", "PROBLEM", 13, 33], ["autophagy", "OBSERVATION", 13, 22]]], ["In vitro metformin improves autophagy and mitochondrial function in parallel to ameliorate Th17 inflammaging.", [["mitochondrial", "ANATOMY", 42, 55], ["metformin", "CHEMICAL", 9, 18], ["metformin", "CHEMICAL", 9, 18], ["metformin", "SIMPLE_CHEMICAL", 9, 18], ["mitochondrial", "CELLULAR_COMPONENT", 42, 55], ["Th17", "CELL", 91, 95], ["vitro metformin", "TREATMENT", 3, 18], ["autophagy", "PROBLEM", 28, 37], ["mitochondrial function", "TEST", 42, 64], ["mitochondrial function", "OBSERVATION", 42, 64]]], ["Oral metformin intervention improves T cell autophagy in people, indicating potential use for age-associated inflammation.INTRODUCTIONAging-associated inflammation, or inflammaging, plays roles in increased risk of insulin resistance, type 2 diabetes (T2D), and cardiovascular diseases with age.", [["Oral", "ANATOMY", 0, 4], ["T cell", "ANATOMY", 37, 43], ["cardiovascular", "ANATOMY", 262, 276], ["metformin", "CHEMICAL", 5, 14], ["inflammation", "DISEASE", 109, 121], ["inflammation", "DISEASE", 151, 163], ["inflammaging", "DISEASE", 168, 180], ["type 2 diabetes", "DISEASE", 235, 250], ["T2D", "DISEASE", 252, 255], ["cardiovascular diseases", "DISEASE", 262, 285], ["metformin", "CHEMICAL", 5, 14], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["metformin", "SIMPLE_CHEMICAL", 5, 14], ["T cell", "CELL", 37, 43], ["people", "ORGANISM", 57, 63], ["insulin", "GENE_OR_GENE_PRODUCT", 215, 222], ["cardiovascular", "ANATOMICAL_SYSTEM", 262, 276], ["people", "SPECIES", 57, 63], ["Oral metformin intervention", "TREATMENT", 0, 27], ["age-associated inflammation", "PROBLEM", 94, 121], ["associated inflammation", "PROBLEM", 140, 163], ["inflammaging", "PROBLEM", 168, 180], ["insulin resistance", "PROBLEM", 215, 233], ["type 2 diabetes (T2D)", "PROBLEM", 235, 256], ["cardiovascular diseases", "PROBLEM", 262, 285], ["inflammation", "OBSERVATION", 109, 121], ["inflammation", "OBSERVATION", 151, 163], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["insulin resistance", "OBSERVATION", 215, 233], ["diabetes", "OBSERVATION", 242, 250], ["cardiovascular", "ANATOMY", 262, 276], ["diseases", "OBSERVATION", 277, 285]]], ["Inflammaging thereby limits the length of one's lifespan spent in good health (Mueller and Rose, 1996; Franceschi and Campisi, 2014; Franceschi et al., 2017; Bharath et al., 2017b) .", [["Inflammaging", "DISEASE", 0, 12]]], ["Aging-associated inflammation has been defined based on cytokines, such as TNFa and IL-6 (Bruunsgaard et al., 2000; Roubenoff et al., 1998; Ferrucci et al., 2005; Piber et al., 2019) , without consideration of the relative importance of the many sources of what is collectively labeled ''inflammation.''", [["inflammation", "DISEASE", 17, 29], ["inflammation", "DISEASE", 288, 300], ["TNFa", "GENE_OR_GENE_PRODUCT", 75, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["cytokines", "PROTEIN", 56, 65], ["TNFa", "PROTEIN", 75, 79], ["associated inflammation", "PROBLEM", 6, 29], ["cytokines", "TREATMENT", 56, 65], ["inflammation", "PROBLEM", 288, 300], ["inflammation", "OBSERVATION", 17, 29], ["inflammation", "OBSERVATION", 288, 300]]], ["T cells are a major source of inflammatory cytokines in settings characterized by chronic low-level inflammation, and multiple lines of evidence showed that one particular T cell subset, Th17s, characterizes and mathematically predicts T2D (Ip et al., 2016) .", [["T cells", "ANATOMY", 0, 7], ["T cell", "ANATOMY", 172, 178], ["inflammation", "DISEASE", 100, 112], ["T2D", "DISEASE", 236, 239], ["T cells", "CELL", 0, 7], ["T cell", "CELL", 172, 178], ["Th17s", "GENE_OR_GENE_PRODUCT", 187, 192], ["T cells", "CELL_TYPE", 0, 7], ["inflammatory cytokines", "PROTEIN", 30, 52], ["T cell subset", "CELL_TYPE", 172, 185], ["Th17s", "CELL_TYPE", 187, 192], ["inflammatory cytokines", "PROBLEM", 30, 52], ["chronic low-level inflammation", "PROBLEM", 82, 112], ["inflammatory", "OBSERVATION_MODIFIER", 30, 42], ["cytokines", "OBSERVATION", 43, 52], ["chronic", "OBSERVATION_MODIFIER", 82, 89], ["low-level", "OBSERVATION_MODIFIER", 90, 99], ["inflammation", "OBSERVATION", 100, 112], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["lines", "OBSERVATION", 127, 132], ["cell subset", "OBSERVATION", 174, 185]]], ["Th17s also promote arguably the most prevelant inflammatory disease in the world, periodontal disease, which fuels cardiovascular and other more deadly diseases (Abusleme and Moutsopoulos, 2017).", [["periodontal", "ANATOMY", 82, 93], ["cardiovascular", "ANATOMY", 115, 129], ["periodontal disease", "DISEASE", 82, 101], ["cardiovascular and other more deadly diseases", "DISEASE", 115, 160], ["Th17s", "GENE_OR_GENE_PRODUCT", 0, 5], ["the most prevelant inflammatory disease", "PROBLEM", 28, 67], ["periodontal disease", "PROBLEM", 82, 101], ["most prevelant", "OBSERVATION_MODIFIER", 32, 46], ["inflammatory", "OBSERVATION_MODIFIER", 47, 59], ["disease", "OBSERVATION", 60, 67], ["periodontal", "ANATOMY", 82, 93], ["disease", "OBSERVATION", 94, 101]]], ["Similarly defining age-associated T cell inflammation will significantly enhance our current appreciation of inflammaging toward the goal of improving health span.INTRODUCTIONMultiple mediators of cell maintenance are known to decline in aging, raising the possibility that age-associated changes in processes, such as macroautophagy, herein ''autophagy,'' and mitochondrial bioenergetics (Sun et al., 2016) both parallel and promote inflammaging.", [["T cell", "ANATOMY", 34, 40], ["cell", "ANATOMY", 197, 201], ["mitochondrial", "ANATOMY", 361, 374], ["inflammaging", "DISEASE", 434, 446], ["T cell", "CELL", 34, 40], ["cell", "CELL", 197, 201], ["mitochondrial", "CELLULAR_COMPONENT", 361, 374], ["associated T cell inflammation", "PROBLEM", 23, 53], ["cell maintenance", "TREATMENT", 197, 213], ["cell inflammation", "OBSERVATION", 36, 53], ["cell maintenance", "OBSERVATION", 197, 213], ["decline", "OBSERVATION_MODIFIER", 227, 234], ["raising the possibility", "UNCERTAINTY", 245, 268]]], ["Autophagy has multiple immunomodulatory effects, including broad coordination of general immune cell responses, as evidenced by the importance of autophagy in development and function of anti-inflammatory regulatory T cells (Tregs) (Wei et al., 2016; Le Texier et al., 2016) .", [["immune cell", "ANATOMY", 89, 100], ["anti-inflammatory regulatory T cells", "ANATOMY", 187, 223], ["Tregs", "ANATOMY", 225, 230], ["immune cell", "CELL", 89, 100], ["regulatory T cells", "CELL", 205, 223], ["Tregs", "CELL", 225, 230], ["anti-inflammatory regulatory T cells", "CELL_TYPE", 187, 223], ["Tregs", "CELL_TYPE", 225, 230], ["multiple immunomodulatory effects", "PROBLEM", 14, 47], ["anti-inflammatory regulatory T cells", "TREATMENT", 187, 223], ["multiple", "OBSERVATION_MODIFIER", 14, 22], ["immunomodulatory effects", "OBSERVATION", 23, 47], ["immune cell", "OBSERVATION", 89, 100]]], ["Autophagy controls immune cell function in part by regulating mitochondrial bioenergetics, as shown by demonstrations that CD4 + T cell autophagy negatively regulates glucose metabolism in Tregs (Kabat et al., 2016) .", [["immune cell", "ANATOMY", 19, 30], ["mitochondrial", "ANATOMY", 62, 75], ["CD4 + T cell", "ANATOMY", 123, 135], ["Tregs", "ANATOMY", 189, 194], ["glucose", "CHEMICAL", 167, 174], ["glucose", "CHEMICAL", 167, 174], ["immune cell", "CELL", 19, 30], ["mitochondrial", "CELLULAR_COMPONENT", 62, 75], ["CD4", "GENE_OR_GENE_PRODUCT", 123, 126], ["glucose", "SIMPLE_CHEMICAL", 167, 174], ["Tregs", "CELL", 189, 194], ["CD4", "PROTEIN", 123, 126], ["Tregs", "CELL_TYPE", 189, 194], ["CD4", "TEST", 123, 126], ["T cell autophagy", "TEST", 129, 145], ["immune cell function", "OBSERVATION", 19, 39], ["mitochondrial bioenergetics", "OBSERVATION", 62, 89]]], ["Given that ATP generation through mitochondrial oxidative phosphorylation (OXPHOS) versus non-mitochondrial glycolysis (deemed ''glycolysis'' herein) can determine T cell function (Kominsky et al., 2010; Priyadharshini et al., 2018) , these findings suggest that autophagy enhancement may alter the mitochondrial response of T cells to stimulation, and thereby ameliorate inflammaging to prolong health span.", [["mitochondrial", "ANATOMY", 34, 47], ["T cell", "ANATOMY", 164, 170], ["mitochondrial", "ANATOMY", 299, 312], ["T cells", "ANATOMY", 325, 332], ["ATP", "CHEMICAL", 11, 14], ["ATP", "CHEMICAL", 11, 14], ["ATP", "SIMPLE_CHEMICAL", 11, 14], ["mitochondrial", "CELLULAR_COMPONENT", 34, 47], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 75, 81], ["T cell", "CELL", 164, 170], ["mitochondrial", "CELLULAR_COMPONENT", 299, 312], ["T cells", "CELL", 325, 332], ["T cells", "CELL_TYPE", 325, 332], ["ATP generation through mitochondrial oxidative phosphorylation (OXPHOS", "TREATMENT", 11, 81], ["non-mitochondrial glycolysis", "TREATMENT", 90, 118], ["''glycolysis'' herein", "TREATMENT", 127, 148], ["autophagy enhancement", "PROBLEM", 263, 284], ["autophagy enhancement", "OBSERVATION", 263, 284]]], ["Arguably, the top candidate drug for activating autophagy over the immediate term is metformin, a well-tolerated T2D drug that improves glycemic control and, in some studies, chronic inflammation (Cameron et al., 2016; Mal\u00ednsk\u00e1 et al., 2016) .", [["metformin", "CHEMICAL", 85, 94], ["T2D", "DISEASE", 113, 116], ["inflammation", "DISEASE", 183, 195], ["metformin", "CHEMICAL", 85, 94], ["metformin", "SIMPLE_CHEMICAL", 85, 94], ["activating autophagy", "PROBLEM", 37, 57], ["metformin", "TREATMENT", 85, 94], ["T2D drug", "TREATMENT", 113, 121], ["glycemic control", "TREATMENT", 136, 152], ["chronic inflammation", "PROBLEM", 175, 195], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["inflammation", "OBSERVATION", 183, 195]]], ["Putative effects of metformin on age-associated T cell inflammation justify targeted pre-clinical work to identify metformin-sensitive mechanisms that ameliorate a more sophisticated profile of inflammaging.INTRODUCTIONData herein show that a combinatorial Th17 cytokine profile differentiated CD4 + T cell inflammation in healthy sexagenarians compared to $30-year-old subjects.", [["T cell", "ANATOMY", 48, 54], ["CD4 + T cell", "ANATOMY", 294, 306], ["metformin", "CHEMICAL", 20, 29], ["inflammation", "DISEASE", 55, 67], ["metformin", "CHEMICAL", 115, 124], ["inflammaging", "DISEASE", 194, 206], ["inflammation", "DISEASE", 307, 319], ["metformin", "CHEMICAL", 20, 29], ["metformin", "CHEMICAL", 115, 124], ["metformin", "SIMPLE_CHEMICAL", 20, 29], ["T cell", "CELL", 48, 54], ["metformin", "SIMPLE_CHEMICAL", 115, 124], ["Th17", "CELL", 257, 261], ["CD4", "GENE_OR_GENE_PRODUCT", 294, 297], ["subjects", "ORGANISM", 370, 378], ["Th17 cytokine", "PROTEIN", 257, 270], ["CD4", "PROTEIN", 294, 297], ["metformin", "TREATMENT", 20, 29], ["T cell inflammation", "PROBLEM", 48, 67], ["metformin", "TREATMENT", 115, 124], ["inflammaging", "PROBLEM", 194, 206], ["a combinatorial Th17 cytokine profile", "TEST", 241, 278], ["T cell inflammation in healthy sexagenarians", "PROBLEM", 300, 344], ["cell inflammation", "OBSERVATION", 50, 67], ["cell inflammation", "OBSERVATION", 302, 319]]], ["Physiologically achievable concentrations of metformin lowered overall T cell cytokine production ex vivo in samples from all subjects, but the Th17 profile was disproportionately susceptible in samples from older (O) subjects.", [["T cell", "ANATOMY", 71, 77], ["samples", "ANATOMY", 109, 116], ["samples", "ANATOMY", 195, 202], ["metformin", "CHEMICAL", 45, 54], ["metformin", "CHEMICAL", 45, 54], ["metformin", "SIMPLE_CHEMICAL", 45, 54], ["T cell", "CELL", 71, 77], ["cytokine", "PROTEIN", 78, 86], ["metformin", "TREATMENT", 45, 54], ["T cell cytokine production", "TREATMENT", 71, 97]]], ["By contrast, metformin reduced a Th2 profile in cells from younger (Y) subjects.", [["cells", "ANATOMY", 48, 53], ["metformin", "CHEMICAL", 13, 22], ["metformin", "CHEMICAL", 13, 22], ["metformin", "SIMPLE_CHEMICAL", 13, 22], ["cells", "CELL", 48, 53], ["metformin", "TREATMENT", 13, 22]]], ["Metformin increased autophagy in CD4 + T cells from older subjects and shifted measures of mitochondrial bioenergetics and T cell inflammation to values indistinguishable from young subjects' cells. siRNA-mediated impairment of autophagy, but not mitophagy, in cells from younger subjects compromised mitochondrial function and activated a Th17 profile indistinguishable from T cell profiles produced by cells from older subjects.", [["CD4 + T cells", "ANATOMY", 33, 46], ["mitochondrial", "ANATOMY", 91, 104], ["T cell", "ANATOMY", 123, 129], ["cells", "ANATOMY", 192, 197], ["cells", "ANATOMY", 261, 266], ["mitochondrial", "ANATOMY", 301, 314], ["T cell", "ANATOMY", 376, 382], ["cells", "ANATOMY", 404, 409], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["mitochondrial", "CELLULAR_COMPONENT", 91, 104], ["T cell", "CELL", 123, 129], ["cells", "CELL", 192, 197], ["cells", "CELL", 261, 266], ["mitochondrial", "CELLULAR_COMPONENT", 301, 314], ["T cell", "CELL", 376, 382], ["cells", "CELL", 404, 409], ["CD4", "PROTEIN", 33, 36], ["T cells", "CELL_TYPE", 39, 46], ["Metformin", "TREATMENT", 0, 9], ["mitochondrial bioenergetics", "PROBLEM", 91, 118], ["T cell inflammation", "PROBLEM", 123, 142], ["siRNA", "TEST", 199, 204], ["impairment of autophagy", "PROBLEM", 214, 237], ["mitophagy", "PROBLEM", 247, 256], ["compromised mitochondrial function", "PROBLEM", 289, 323], ["a Th17 profile", "TEST", 338, 352], ["T cell profiles", "TEST", 376, 391], ["mitochondrial bioenergetics", "OBSERVATION", 91, 118], ["cell inflammation", "OBSERVATION", 125, 142]]], ["We conclude metformin-sensitive defects in immune cell autophagy (1) accompany natural aging in people, (2) shift mitochondrial bioenergetics, and (3) fuel a previously unappreciated Th17 inflammaging profile.", [["immune cell", "ANATOMY", 43, 54], ["mitochondrial", "ANATOMY", 114, 127], ["metformin", "CHEMICAL", 12, 21], ["metformin", "CHEMICAL", 12, 21], ["metformin", "SIMPLE_CHEMICAL", 12, 21], ["immune cell", "CELL", 43, 54], ["people", "ORGANISM", 96, 102], ["mitochondrial", "CELLULAR_COMPONENT", 114, 127], ["Th17", "CELL", 183, 187], ["people", "SPECIES", 96, 102], ["metformin", "TREATMENT", 12, 21], ["sensitive defects", "PROBLEM", 22, 39], ["immune cell autophagy", "PROBLEM", 43, 64], ["shift mitochondrial bioenergetics", "PROBLEM", 108, 141], ["immune cell autophagy", "OBSERVATION", 43, 64]]], ["Our findings highlight cause-and-effect relationships among defects in non-mitochondrial autophagy, mitochondrial function, and inflammaging to justify clinical trials to extend health span with metformin.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismTo define an age-associated T cell cytokine profile, we quantified cytokines produced by aCD3/aCD28-stimulated CD4 + T cells from O and Y subjects (Table S1) by bioplex.", [["non-mitochondrial", "ANATOMY", 71, 88], ["mitochondrial", "ANATOMY", 100, 113], ["CD4 + T Cell", "ANATOMY", 230, 242], ["T cell", "ANATOMY", 339, 345], ["aCD3/aCD28", "ANATOMY", 400, 410], ["CD4 + T cells", "ANATOMY", 422, 435], ["metformin", "CHEMICAL", 195, 204], ["Metformin", "CHEMICAL", 282, 291], ["metformin", "CHEMICAL", 195, 204], ["Metformin", "CHEMICAL", 282, 291], ["mitochondrial", "CELLULAR_COMPONENT", 100, 113], ["metformin", "SIMPLE_CHEMICAL", 195, 204], ["CD4", "GENE_OR_GENE_PRODUCT", 230, 233], ["Metformin", "SIMPLE_CHEMICAL", 282, 291], ["T cell", "CELL", 339, 345], ["aCD3", "GENE_OR_GENE_PRODUCT", 400, 404], ["aCD28", "GENE_OR_GENE_PRODUCT", 405, 410], ["CD4", "GENE_OR_GENE_PRODUCT", 422, 425], ["CD4", "PROTEIN", 230, 233], ["T cell cytokine", "PROTEIN", 339, 354], ["cytokines", "PROTEIN", 378, 387], ["aCD3", "PROTEIN", 400, 404], ["aCD28", "PROTEIN", 405, 410], ["CD4", "PROTEIN", 422, 425], ["T cells", "CELL_TYPE", 428, 435], ["defects in non-mitochondrial autophagy", "PROBLEM", 60, 98], ["metformin", "TREATMENT", 195, 204], ["A Th17 Profile", "TEST", 205, 219], ["CD4", "TEST", 230, 233], ["a Metformin", "TREATMENT", 280, 291], ["T cell cytokine profile", "PROBLEM", 339, 362], ["quantified cytokines", "TEST", 367, 387], ["aCD3", "TEST", 400, 404], ["aCD28", "TEST", 405, 410]]], ["O cells produced higher amounts of most classically defined Th17-associated/ supportive cytokines (IL-6, IL-17A, IL-17F, IL-21, and IL-23) but similar amounts of cytokines typically produced by other CD4 + T cell subsets (Figures 1A and S1A-S1D).", [["O cells", "ANATOMY", 0, 7], ["CD4 + T cell", "ANATOMY", 200, 212], ["O cells", "CELL", 0, 7], ["Th17", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["IL-17A", "GENE_OR_GENE_PRODUCT", 105, 111], ["IL-17F", "GENE_OR_GENE_PRODUCT", 113, 119], ["IL-21", "GENE_OR_GENE_PRODUCT", 121, 126], ["IL-23", "GENE_OR_GENE_PRODUCT", 132, 137], ["CD4", "GENE_OR_GENE_PRODUCT", 200, 203], ["S1A-S1D", "GENE_OR_GENE_PRODUCT", 237, 244], ["O cells", "CELL_TYPE", 0, 7], ["Th17", "PROTEIN", 60, 64], ["cytokines", "PROTEIN", 88, 97], ["IL", "PROTEIN", 105, 107], ["17F", "PROTEIN", 116, 119], ["IL", "PROTEIN", 121, 123], ["IL", "PROTEIN", 132, 134], ["cytokines", "PROTEIN", 162, 171], ["CD4 + T cell subsets", "CELL_TYPE", 200, 220], ["S1A", "PROTEIN", 237, 240], ["S1D", "PROTEIN", 241, 244], ["supportive cytokines", "TREATMENT", 77, 97], ["IL", "TEST", 99, 101], ["IL", "TEST", 105, 107], ["IL", "TEST", 113, 115], ["IL", "TEST", 121, 123], ["IL", "TEST", 132, 134], ["cytokines", "PROBLEM", 162, 171], ["Figures", "TEST", 222, 229], ["higher amounts", "OBSERVATION_MODIFIER", 17, 31], ["cytokines", "OBSERVATION", 162, 171], ["cell subsets", "OBSERVATION", 208, 220]]], ["Age-associated shifts in CD4 + T cell subset distribution in our cohort was as previously published (Figures 1B and S1E) , including CD57 + terminal effectors that were almost unique to samples from O subjects and fewer central memory T cells in Y samples.", [["CD4 + T cell", "ANATOMY", 25, 37], ["samples", "ANATOMY", 186, 193], ["central memory T cells", "ANATOMY", 220, 242], ["Y samples", "ANATOMY", 246, 255], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["S1E", "GENE_OR_GENE_PRODUCT", 116, 119], ["CD57", "GENE_OR_GENE_PRODUCT", 133, 137], ["central memory T cells", "CELL", 220, 242], ["Y samples", "CELL", 246, 255], ["CD4", "PROTEIN", 25, 28], ["CD57", "PROTEIN", 133, 137], ["central memory T cells", "CELL_TYPE", 220, 242], ["Age-associated shifts", "PROBLEM", 0, 21], ["CD4", "TEST", 25, 28], ["T cell subset distribution", "PROBLEM", 31, 57], ["CD57", "TEST", 133, 137], ["terminal effectors", "PROBLEM", 140, 158], ["shifts", "OBSERVATION_MODIFIER", 15, 21], ["CD4 + T cell", "OBSERVATION", 25, 37], ["subset", "OBSERVATION_MODIFIER", 38, 44], ["distribution", "OBSERVATION_MODIFIER", 45, 57], ["terminal effectors", "OBSERVATION", 140, 158]]], ["These results were consistent with recent work showing that Th17 frequency does not increase with age (Alpert et al., 2019) .", [["consistent with", "UNCERTAINTY", 19, 34], ["increase", "OBSERVATION_MODIFIER", 84, 92]]], ["Ageassociated changes in CD8 + T cell subsets were also as expected ( Figure S1F ).", [["CD8 + T cell", "ANATOMY", 25, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8 + T cell subsets", "CELL_TYPE", 25, 45], ["Ageassociated changes", "PROBLEM", 0, 21], ["CD8", "TEST", 25, 28], ["T cell subsets", "PROBLEM", 31, 45], ["cell subsets", "OBSERVATION", 33, 45]]], ["Partial least squares discriminant analysis (PLSDA) models, which combine all cytokines from one sample into a compendium multi-dimensional value for ''inflammation,'' showed that cytokine production differentiates O and Y samples ( Figure 1C ).", [["Y samples", "ANATOMY", 221, 230], ["inflammation", "DISEASE", 152, 164], ["cytokines", "PROTEIN", 78, 87], ["cytokine", "PROTEIN", 180, 188], ["''inflammation", "PROBLEM", 150, 164], ["cytokine production", "PROBLEM", 180, 199]]], ["Variable importance projection (VIP) calculations, which rank cytokines based on their overall importance for separating cytokine data clouds, showed almost all Th17 cytokines were disproportionately important for identifying higher overall inflammation produced by O-derived CD4 + T cells (VIP > 1.0, bracket in Figure 1D , red bars highlight classical Th17 cytokines).", [["O-derived CD4 + T cells", "ANATOMY", 266, 289], ["inflammation", "DISEASE", 241, 253], ["cytokines", "PROTEIN", 62, 71], ["cytokine", "PROTEIN", 121, 129], ["Th17 cytokines", "PROTEIN", 161, 175], ["O-derived CD4 + T cells", "CELL_TYPE", 266, 289], ["classical Th17 cytokines", "PROTEIN", 344, 368], ["separating cytokine data clouds", "TEST", 110, 141], ["higher overall inflammation", "PROBLEM", 226, 253], ["VIP", "TEST", 291, 294], ["bracket in Figure 1D", "TREATMENT", 302, 322], ["classical Th17 cytokines", "TREATMENT", 344, 368], ["inflammation", "OBSERVATION", 241, 253]]], ["We conclude that a comprehensive Th17 profile defines and mathematically predicts age-related T cell inflammation.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismThe glycemic control drug metformin variably impacts inflammation and inflammatory comorbidities like T2D in part through undefined age-associated mechanisms (Chakraborty et al., 2011; Smith et al., 2010; Fidan et al., 2011) .", [["T cell", "ANATOMY", 94, 100], ["CD4 + T Cell", "ANATOMY", 139, 151], ["inflammation", "DISEASE", 101, 113], ["Metformin", "CHEMICAL", 191, 200], ["metformin", "CHEMICAL", 246, 255], ["inflammation", "DISEASE", 273, 285], ["T2D", "DISEASE", 322, 325], ["Metformin", "CHEMICAL", 191, 200], ["metformin", "CHEMICAL", 246, 255], ["T cell", "CELL", 94, 100], ["CD4", "GENE_OR_GENE_PRODUCT", 139, 142], ["Metformin", "SIMPLE_CHEMICAL", 191, 200], ["metformin", "SIMPLE_CHEMICAL", 246, 255], ["CD4", "PROTEIN", 139, 142], ["T cell inflammation", "PROBLEM", 94, 113], ["A Th17 Profile", "TEST", 114, 128], ["CD4", "TEST", 139, 142], ["a Metformin", "TREATMENT", 189, 200], ["The glycemic control drug metformin", "TREATMENT", 220, 255], ["impacts inflammation", "PROBLEM", 265, 285], ["inflammatory comorbidities", "PROBLEM", 290, 316], ["T2D", "PROBLEM", 322, 325], ["cell inflammation", "OBSERVATION", 96, 113], ["inflammatory", "OBSERVATION_MODIFIER", 290, 302]]], ["We tested the effect of physiologically achievable metformin (100 mM) (Madiraju et al., 2019) added coincidence with T cell-targeted stimuli on the newly defined age-related inflammation profile.", [["T cell", "ANATOMY", 117, 123], ["metformin", "CHEMICAL", 51, 60], ["inflammation", "DISEASE", 174, 186], ["metformin", "CHEMICAL", 51, 60], ["metformin", "SIMPLE_CHEMICAL", 51, 60], ["T cell", "CELL", 117, 123], ["physiologically achievable metformin", "TREATMENT", 24, 60], ["T cell", "TREATMENT", 117, 123], ["related inflammation profile", "PROBLEM", 166, 194], ["inflammation", "OBSERVATION", 174, 186]]], ["Metformin specifically decreased production of Th17 cytokines but failed to decrease most Th2 cytokines (IL-4, IL-5, and IL-10) by O cells (O + met), as indicated by single cytokine (Figures 1A and S1A-S1D) or PLSDA (Figures 1E and 1F) analysis.", [["O cells", "ANATOMY", 131, 138], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["IL-4", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL-5", "GENE_OR_GENE_PRODUCT", 111, 115], ["IL-10", "GENE_OR_GENE_PRODUCT", 121, 126], ["O cells", "CELL", 131, 138], ["O +", "SIMPLE_CHEMICAL", 140, 143], ["S1A-S1D", "GENE_OR_GENE_PRODUCT", 198, 205], ["Th17 cytokines", "PROTEIN", 47, 61], ["Th2 cytokines", "PROTEIN", 90, 103], ["IL-4", "PROTEIN", 105, 109], ["IL", "PROTEIN", 111, 113], ["IL", "PROTEIN", 121, 123], ["O cells", "CELL_TYPE", 131, 138], ["cytokine", "PROTEIN", 173, 181], ["S1A", "PROTEIN", 198, 201], ["S1D", "PROTEIN", 202, 205], ["PLSDA", "PROTEIN", 210, 215], ["Metformin", "TREATMENT", 0, 9], ["Th17 cytokines", "TREATMENT", 47, 61], ["Th2 cytokines", "TEST", 90, 103], ["IL", "TEST", 105, 107], ["IL", "TEST", 111, 113], ["IL", "TEST", 121, 123], ["Figures", "TEST", 183, 190], ["S1A", "TEST", 198, 201], ["analysis", "TEST", 236, 244], ["decreased", "OBSERVATION_MODIFIER", 23, 32]]], ["In contrast, single cytokine analyses showed metformin did not change cytokine production by Y-derived ll Article T cells (Y + met; Figures 1A and S1A-S1D), while PLSDA showed metformin ameliorated a Th2/type 2 immune profile produced by Y cells Figures 1G and 1H) .", [["ll Article T cells", "ANATOMY", 103, 121], ["Y cells", "ANATOMY", 238, 245], ["metformin", "CHEMICAL", 45, 54], ["metformin", "CHEMICAL", 176, 185], ["metformin", "CHEMICAL", 45, 54], ["metformin", "CHEMICAL", 176, 185], ["metformin", "SIMPLE_CHEMICAL", 45, 54], ["Y-derived ll Article T cells", "CELL", 93, 121], ["S1A-S1D", "GENE_OR_GENE_PRODUCT", 147, 154], ["PLSDA", "SIMPLE_CHEMICAL", 163, 168], ["metformin", "SIMPLE_CHEMICAL", 176, 185], ["Y cells", "CELL", 238, 245], ["cytokine", "PROTEIN", 20, 28], ["cytokine", "PROTEIN", 70, 78], ["Y-derived ll Article T cells", "CELL_LINE", 93, 121], ["S1A", "PROTEIN", 147, 150], ["PLSDA", "PROTEIN", 163, 168], ["Y cells", "CELL_TYPE", 238, 245], ["single cytokine analyses", "TEST", 13, 37], ["metformin", "TREATMENT", 45, 54], ["cytokine production", "TEST", 70, 89], ["Y", "TEST", 123, 124], ["Figures", "TEST", 132, 139], ["S1A", "TEST", 147, 150], ["PLSDA", "TEST", 163, 168], ["metformin", "TEST", 176, 185], ["Figures", "TEST", 246, 253]]], ["Cytokine profiles from O + met cultures were indistinguishable from profile produced in Y cultures as indicated by statistically similar profiles (p > 0.05), no VIP cytokines with values >1.0, and a non-predictive value in ''leave-one-out'' analysis of p = 0.15 (data not shown).", [["cultures", "ANATOMY", 31, 39], ["Y cultures", "ANATOMY", 88, 98], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["O +", "SIMPLE_CHEMICAL", 23, 26], ["Y cultures", "CELL", 88, 98], ["VIP", "GENE_OR_GENE_PRODUCT", 161, 164], ["Cytokine", "PROTEIN", 0, 8], ["Y cultures", "CELL_LINE", 88, 98], ["VIP cytokines", "PROTEIN", 161, 174], ["Cytokine profiles", "TEST", 0, 17], ["met cultures", "TEST", 27, 39], ["Y cultures", "TEST", 88, 98], ["VIP cytokines", "TEST", 161, 174], ["values", "TEST", 180, 186], ["a non-predictive value", "TEST", 197, 219], ["p", "TEST", 253, 254]]], ["We conclude that metformin restores age-related T cell inflammation to profiles generated by Y cells.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismMitochondria Dysfunction in CD4 + T Cells Is Regulated by an Age-Related, Metformin-Sensitive Mechanism To identify metformin-sensitive mechanisms that control Th17 inflammaging, we quantified indicators of mitochondrial function that promote pro-inflammatory T cells (De Rosa et al., 2015; Hong et al., 2013; Bharath et al., 2017a) using a mito stress test in extracellular flux (XF, Seahorse). aCD3/aCD28-stimulated CD4 + T cells from O subjects had higher OXPHOS (OXPHOS/oxygen consumption rate [OCR] ; baseline and maximal), extracellular acidification rate ratio (OCR:ECAR), and proton leak.", [["T cell", "ANATOMY", 48, 54], ["Y cells", "ANATOMY", 93, 100], ["CD4 + T Cell", "ANATOMY", 126, 138], ["CD4 + T Cells", "ANATOMY", 235, 248], ["mitochondrial", "ANATOMY", 414, 427], ["T cells", "ANATOMY", 467, 474], ["extracellular", "ANATOMY", 568, 581], ["CD4 + T cells", "ANATOMY", 625, 638], ["extracellular", "ANATOMY", 736, 749], ["metformin", "CHEMICAL", 17, 26], ["Metformin", "CHEMICAL", 178, 187], ["Metformin", "CHEMICAL", 281, 290], ["metformin", "CHEMICAL", 323, 332], ["oxygen", "CHEMICAL", 681, 687], ["metformin", "CHEMICAL", 17, 26], ["Metformin", "CHEMICAL", 178, 187], ["Metformin", "CHEMICAL", 281, 290], ["metformin", "CHEMICAL", 323, 332], ["oxygen", "CHEMICAL", 681, 687], ["metformin", "SIMPLE_CHEMICAL", 17, 26], ["T cell", "CELL", 48, 54], ["Y cells", "CELL", 93, 100], ["CD4", "GENE_OR_GENE_PRODUCT", 126, 129], ["Metformin", "SIMPLE_CHEMICAL", 178, 187], ["Metformin", "SIMPLE_CHEMICAL", 281, 290], ["metformin", "SIMPLE_CHEMICAL", 323, 332], ["Th17", "CELL", 367, 371], ["mitochondrial", "CELLULAR_COMPONENT", 414, 427], ["T cells", "CELL", 467, 474], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 568, 581], ["aCD3", "GENE_OR_GENE_PRODUCT", 603, 607], ["aCD28", "GENE_OR_GENE_PRODUCT", 608, 613], ["CD4", "GENE_OR_GENE_PRODUCT", 625, 628], ["oxygen", "SIMPLE_CHEMICAL", 681, 687], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 736, 749], ["Y cells", "CELL_TYPE", 93, 100], ["CD4", "PROTEIN", 126, 129], ["CD4", "PROTEIN", 235, 238], ["pro-inflammatory T cells", "CELL_TYPE", 450, 474], ["aCD3", "PROTEIN", 603, 607], ["aCD28", "PROTEIN", 608, 613], ["CD4", "PROTEIN", 625, 628], ["T cells", "CELL_TYPE", 631, 638], ["OXPHOS", "PROTEIN", 666, 672], ["metformin", "TREATMENT", 17, 26], ["T cell inflammation", "PROBLEM", 48, 67], ["A Th17 Profile", "TEST", 101, 115], ["CD4", "TEST", 126, 129], ["a Metformin", "TREATMENT", 176, 187], ["Sensitive MechanismMitochondria Dysfunction", "PROBLEM", 188, 231], ["T Cells", "PROBLEM", 241, 248], ["Metformin", "TREATMENT", 281, 290], ["metformin", "TREATMENT", 323, 332], ["mitochondrial function", "PROBLEM", 414, 436], ["a mito stress test", "TEST", 546, 564], ["aCD3", "TEST", 603, 607], ["aCD28", "TEST", 608, 613], ["higher OXPHOS", "PROBLEM", 659, 672], ["OXPHOS", "TEST", 674, 680], ["oxygen consumption rate", "TEST", 681, 704], ["extracellular acidification rate ratio", "TEST", 736, 774], ["proton leak", "PROBLEM", 791, 802], ["cell inflammation", "OBSERVATION", 50, 67], ["proton leak", "OBSERVATION", 791, 802]]], ["Spare respiratory capacity was similar between O and Y cells.", [["respiratory", "ANATOMY", 6, 17], ["Y cells", "ANATOMY", 53, 60], ["Y cells", "CELL", 53, 60], ["O and Y cells", "CELL_LINE", 47, 60], ["Spare respiratory capacity", "PROBLEM", 0, 26], ["respiratory capacity", "OBSERVATION", 6, 26]]], ["CD4 + T cells from O compared Y subjects produced less lactate Cytokine production was assessed in T cells from BMI-matched normoglycemic Y and O subjects following 40 h aCD3/aCD28 stimulation \u00b1 100 mm metformin (MET).", [["CD4 + T cells", "ANATOMY", 0, 13], ["T cells", "ANATOMY", 99, 106], ["lactate", "CHEMICAL", 55, 62], ["metformin", "CHEMICAL", 202, 211], ["lactate", "CHEMICAL", 55, 62], ["metformin", "CHEMICAL", 202, 211], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["lactate", "SIMPLE_CHEMICAL", 55, 62], ["Cytokine", "GENE_OR_GENE_PRODUCT", 63, 71], ["T cells", "CELL", 99, 106], ["aCD28", "GENE_OR_GENE_PRODUCT", 175, 180], ["metformin", "SIMPLE_CHEMICAL", 202, 211], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["Cytokine", "PROTEIN", 63, 71], ["T cells", "CELL_TYPE", 99, 106], ["aCD28", "PROTEIN", 175, 180], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 6, 13], ["less lactate Cytokine production", "PROBLEM", 50, 82], ["BMI", "TEST", 112, 115], ["aCD3/aCD28 stimulation", "TREATMENT", 170, 192], ["metformin", "TREATMENT", 202, 211]]], ["(A) Concentrations of IL-17A, IL-17F, IL-21, and IL-6 as indicated.", [["IL-17A", "GENE_OR_GENE_PRODUCT", 22, 28], ["IL-17F", "GENE_OR_GENE_PRODUCT", 30, 36], ["IL-21", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["IL", "PROTEIN", 22, 24], ["IL-6", "PROTEIN", 49, 53], ["IL", "TEST", 22, 24], ["IL", "TEST", 30, 32], ["IL", "TEST", 38, 40], ["IL", "TREATMENT", 49, 51]]], ["For all panels, each n (i.e., each dot) represents T cells isolated from one subject. p < 0.05 by two-tailed t test.", [["T cells", "ANATOMY", 51, 58], ["T cells", "CELL", 51, 58], ["T cells", "CELL_TYPE", 51, 58], ["all panels", "TEST", 4, 14], ["T cells", "PROBLEM", 51, 58], ["tailed t test", "TEST", 102, 115]]], ["(C, E, and G) PLSDA shows compendium measures of ''inflammation'' generated by combining all cytokines measured by (C) Y (blue) or O (green) CD4 + T cells, (E) CD4 + cells from O subjects stimulated in the presence (orange) or absence (green) of metformin (100 mM), or (G) CD4 + cells from Y subjects stimulated in the presence (purple) or absence (blue) of metformin (100 mM).", [["O (green) CD4 + T cells", "ANATOMY", 131, 154], ["E) CD4 + cells", "ANATOMY", 157, 171], ["CD4 + cells", "ANATOMY", 273, 284], ["inflammation", "DISEASE", 51, 63], ["metformin", "CHEMICAL", 246, 255], ["metformin", "CHEMICAL", 358, 367], ["metformin", "CHEMICAL", 246, 255], ["metformin", "CHEMICAL", 358, 367], ["G) PLSDA", "SIMPLE_CHEMICAL", 11, 19], ["metformin", "SIMPLE_CHEMICAL", 246, 255], ["metformin", "SIMPLE_CHEMICAL", 358, 367], ["cytokines", "PROTEIN", 93, 102], ["O (green) CD4 + T cells", "CELL_TYPE", 131, 154], ["CD4", "PROTEIN", 160, 163], ["CD4", "PROTEIN", 273, 276], ["(C, E, and G) PLSDA", "TEST", 0, 19], ["''inflammation", "PROBLEM", 49, 63], ["all cytokines", "TEST", 89, 102], ["T cells", "TEST", 147, 154], ["CD4 + cells", "PROBLEM", 160, 171], ["metformin", "TREATMENT", 246, 255], ["metformin", "TREATMENT", 358, 367]]], ["(D, F, and H) Bar graphs show VIP scores, which rank cytokines as most (leftmost) or least (rightmost) important for differentiating overall cytokine profiles between the groups indicated in key.", [["VIP", "GENE_OR_GENE_PRODUCT", 30, 33], ["cytokines", "PROTEIN", 53, 62], ["cytokine", "PROTEIN", 141, 149], ["(D, F, and H) Bar graphs", "TEST", 0, 24], ["VIP scores", "TEST", 30, 40]]], ["A VIP score >1 (bracket) is considered important for differentiating inflammatory profiles between groups.", [["A VIP score", "TEST", 0, 11], ["considered important for", "UNCERTAINTY", 28, 52], ["inflammatory", "OBSERVATION", 69, 81]]], ["All VIP cytokines indicated also differed in post hoc analyses (p < 0.05). n = 10-14.", [["VIP", "GENE_OR_GENE_PRODUCT", 4, 7], ["VIP cytokines", "PROTEIN", 4, 17], ["All VIP cytokines", "TEST", 0, 17], ["hoc analyses", "TEST", 50, 62]]], ["See also Figure S1 . and had lower ECAR (Figures 2A-2D and S2A-S2D).", [["S2A-S2D", "GENE_OR_GENE_PRODUCT", 59, 66], ["ECAR", "PROTEIN", 35, 39], ["S2A", "PROTEIN", 59, 62], ["S2D", "PROTEIN", 63, 66], ["lower ECAR", "PROBLEM", 29, 39], ["lower", "ANATOMY_MODIFIER", 29, 34]]], ["Mitochondrial membrane potential (MMP) was lower in O cells, as measured by tetramethylrhodamine, ethyl ester (TMRE) ( Figure 2E ), perhaps in part due to intrinsically lower membrane potential differences in O compared with Y cells (Figure 2F) .", [["Mitochondrial membrane", "ANATOMY", 0, 22], ["O cells", "ANATOMY", 52, 59], ["membrane", "ANATOMY", 175, 183], ["Y cells", "ANATOMY", 225, 232], ["tetramethylrhodamine, ethyl ester", "CHEMICAL", 76, 109], ["TMRE", "CHEMICAL", 111, 115], ["tetramethylrhodamine", "CHEMICAL", 76, 96], ["ethyl ester", "CHEMICAL", 98, 109], ["TMRE", "CHEMICAL", 111, 115], ["Mitochondrial membrane", "CELLULAR_COMPONENT", 0, 22], ["O cells", "CELL", 52, 59], ["tetramethylrhodamine", "SIMPLE_CHEMICAL", 76, 96], ["ethyl ester", "SIMPLE_CHEMICAL", 98, 109], ["TMRE", "SIMPLE_CHEMICAL", 111, 115], ["Y cells", "CELL", 225, 232], ["O cells", "CELL_TYPE", 52, 59], ["Y cells", "CELL_TYPE", 225, 232], ["Mitochondrial membrane potential (MMP)", "PROBLEM", 0, 38], ["lower in O cells", "PROBLEM", 43, 59], ["intrinsically lower membrane potential differences", "PROBLEM", 155, 205]]], ["Addition of metformin (100 mM) concomitant with stimulation decreased basal and maximal OCR, OCR:ECAR ratio, and proton leak of CD4 + T cells from O subjects (Figures 2A, 2B , 2D, S2A, and S2B).", [["CD4 + T cells", "ANATOMY", 128, 141], ["metformin", "CHEMICAL", 12, 21], ["metformin", "CHEMICAL", 12, 21], ["metformin", "SIMPLE_CHEMICAL", 12, 21], ["OCR", "SIMPLE_CHEMICAL", 93, 96], ["ECAR", "SIMPLE_CHEMICAL", 97, 101], ["CD4", "GENE_OR_GENE_PRODUCT", 128, 131], ["S2A", "GENE_OR_GENE_PRODUCT", 180, 183], ["S2B", "GENE_OR_GENE_PRODUCT", 189, 192], ["CD4", "PROTEIN", 128, 131], ["T cells", "CELL_TYPE", 134, 141], ["S2A", "PROTEIN", 180, 183], ["S2B", "PROTEIN", 189, 192], ["metformin", "TREATMENT", 12, 21], ["ECAR ratio", "TEST", 97, 107], ["proton leak", "TEST", 113, 124], ["T cells", "PROBLEM", 134, 141], ["Figures", "TEST", 159, 166], ["proton leak", "OBSERVATION", 113, 124]]], ["Metformin increased lactate production and ECAR ( Figures 2C and S2C ) and supported a trend toward increase in MMP in CD4 + T cells from O subjects ( Figure 2E ; p = 0.055).", [["CD4 + T cells", "ANATOMY", 119, 132], ["Metformin", "CHEMICAL", 0, 9], ["lactate", "CHEMICAL", 20, 27], ["Metformin", "CHEMICAL", 0, 9], ["lactate", "CHEMICAL", 20, 27], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["lactate", "SIMPLE_CHEMICAL", 20, 27], ["MMP", "GENE_OR_GENE_PRODUCT", 112, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 119, 122], ["ECAR", "PROTEIN", 43, 47], ["MMP", "PROTEIN", 112, 115], ["CD4", "PROTEIN", 119, 122], ["T cells", "CELL_TYPE", 125, 132], ["Metformin", "TREATMENT", 0, 9], ["lactate production", "PROBLEM", 20, 38], ["MMP", "TEST", 112, 115]]], ["Metformin action on mitochondrial bioenergetics was independent of AMPK, as indicated by similar outcomes from cells treated with AMPK-specific or scrambled siRNA prior to stimulation and extracellular flux (XF) analysis (Figures S2E and S2F) .", [["mitochondrial", "ANATOMY", 20, 33], ["cells", "ANATOMY", 111, 116], ["extracellular", "ANATOMY", 188, 201], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["mitochondrial", "CELLULAR_COMPONENT", 20, 33], ["AMPK", "GENE_OR_GENE_PRODUCT", 67, 71], ["cells", "CELL", 111, 116], ["AMPK", "GENE_OR_GENE_PRODUCT", 130, 134], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["AMPK", "PROTEIN", 67, 71], ["AMPK", "PROTEIN", 130, 134], ["Metformin", "TREATMENT", 0, 9], ["mitochondrial bioenergetics", "TREATMENT", 20, 47], ["AMPK", "TEST", 67, 71], ["AMPK", "TREATMENT", 130, 134], ["scrambled siRNA", "PROBLEM", 147, 162], ["extracellular flux (XF) analysis", "TEST", 188, 220], ["Figures", "TEST", 222, 229]]], ["Metformin had no effect on the mitochondrial function of T cells from Y subjects (Figures 2A-2E and S2A-S2D).", [["mitochondrial", "ANATOMY", 31, 44], ["T cells", "ANATOMY", 57, 64], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["mitochondrial", "CELLULAR_COMPONENT", 31, 44], ["T cells", "CELL", 57, 64], ["S2A-S2D", "GENE_OR_GENE_PRODUCT", 100, 107], ["T cells", "CELL_TYPE", 57, 64], ["S2A", "PROTEIN", 100, 103], ["Metformin", "TREATMENT", 0, 9], ["Figures", "TEST", 82, 89]]], ["We conclude that higher OXPHOS corresponds with lower glycolysis and Th17 inflammation in T cells from O compared with Y subjects, and that metformin shifts O cells to recapitulate characteristics of Y cells.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismAlthough inflammation is traditionally fueled by glycolysis, our data showing association between mitochondrial respiration and inflammation in CD4 + T cells from O subjects raise the possibility that O cells ineffectively shift to glycolysis to fuel inflammation.", [["T cells", "ANATOMY", 90, 97], ["O cells", "ANATOMY", 157, 164], ["Y cells", "ANATOMY", 200, 207], ["CD4 + T Cell", "ANATOMY", 233, 245], ["mitochondrial", "ANATOMY", 412, 425], ["CD4 + T cells", "ANATOMY", 458, 471], ["O cells", "ANATOMY", 515, 522], ["inflammation", "DISEASE", 74, 86], ["metformin", "CHEMICAL", 140, 149], ["Metformin", "CHEMICAL", 285, 294], ["inflammation", "DISEASE", 323, 335], ["inflammation", "DISEASE", 442, 454], ["inflammation", "DISEASE", 565, 577], ["metformin", "CHEMICAL", 140, 149], ["Metformin", "CHEMICAL", 285, 294], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 24, 30], ["T cells", "CELL", 90, 97], ["Y subjects", "ORGANISM", 119, 129], ["metformin", "SIMPLE_CHEMICAL", 140, 149], ["O cells", "CELL", 157, 164], ["Y cells", "CELL", 200, 207], ["CD4", "GENE_OR_GENE_PRODUCT", 233, 236], ["Metformin", "SIMPLE_CHEMICAL", 285, 294], ["mitochondrial", "CELLULAR_COMPONENT", 412, 425], ["CD4", "GENE_OR_GENE_PRODUCT", 458, 461], ["O cells", "CELL", 515, 522], ["OXPHOS", "PROTEIN", 24, 30], ["T cells", "CELL_TYPE", 90, 97], ["O cells", "CELL_TYPE", 157, 164], ["Y cells", "CELL_TYPE", 200, 207], ["CD4", "PROTEIN", 233, 236], ["CD4 + T cells", "CELL_TYPE", 458, 471], ["O cells", "CELL_TYPE", 515, 522], ["higher OXPHOS", "PROBLEM", 17, 30], ["lower glycolysis", "PROBLEM", 48, 64], ["Th17 inflammation in T cells", "PROBLEM", 69, 97], ["metformin shifts O cells", "TREATMENT", 140, 164], ["A Th17 Profile", "TEST", 208, 222], ["CD4", "TEST", 233, 236], ["a Metformin", "TREATMENT", 283, 294], ["Sensitive MechanismAlthough inflammation", "PROBLEM", 295, 335], ["our data", "TEST", 375, 383], ["mitochondrial respiration", "PROBLEM", 412, 437], ["inflammation", "PROBLEM", 442, 454], ["CD4 + T cells", "PROBLEM", 458, 471], ["O cells", "PROBLEM", 515, 522], ["fuel inflammation", "PROBLEM", 560, 577], ["lower glycolysis", "OBSERVATION_MODIFIER", 48, 64], ["Cell", "OBSERVATION", 241, 245], ["inflammation", "OBSERVATION", 323, 335], ["mitochondrial respiration", "OBSERVATION", 412, 437], ["inflammation", "OBSERVATION", 442, 454], ["fuel inflammation", "OBSERVATION", 560, 577]]], ["To begin testing this possibility, we quantified protein levels of glycolytic pathway enzymes.", [["glycolytic pathway enzymes", "GENE_OR_GENE_PRODUCT", 67, 93], ["glycolytic pathway enzymes", "PROTEIN", 67, 93], ["glycolytic pathway enzymes", "TEST", 67, 93]]], ["CD4 + T cells from O subjects had lower expression of lactate dehydrogenase A (LDH), which catalyzes pyruvate 4 lactate ( Figure 2G ), providing a mechanistic explanation for low lactate in O cells ( Figure 2C ).", [["CD4 + T cells", "ANATOMY", 0, 13], ["O cells", "ANATOMY", 190, 197], ["lactate", "CHEMICAL", 54, 61], ["pyruvate", "CHEMICAL", 101, 109], ["lactate", "CHEMICAL", 112, 119], ["lactate", "CHEMICAL", 179, 186], ["lactate", "CHEMICAL", 54, 61], ["pyruvate", "CHEMICAL", 101, 109], ["lactate", "CHEMICAL", 112, 119], ["lactate", "CHEMICAL", 179, 186], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["lactate dehydrogenase A", "GENE_OR_GENE_PRODUCT", 54, 77], ["LDH", "GENE_OR_GENE_PRODUCT", 79, 82], ["pyruvate 4 lactate", "SIMPLE_CHEMICAL", 101, 119], ["Figure 2G", "GENE_OR_GENE_PRODUCT", 122, 131], ["lactate", "SIMPLE_CHEMICAL", 179, 186], ["O cells", "CELL", 190, 197], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["lactate dehydrogenase A", "PROTEIN", 54, 77], ["LDH", "PROTEIN", 79, 82], ["O cells", "CELL_TYPE", 190, 197], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 6, 13], ["lactate dehydrogenase A (LDH)", "PROBLEM", 54, 83], ["lactate", "TEST", 112, 119], ["low lactate in O cells", "PROBLEM", 175, 197]]], ["Expression of enzymes that regulate pyruvate production from glucose, including hexokinase and pyruvate kinase M2 (PKM2), was higher or equivalent, respectively, in CD4 + T cells from O compared with Y subjects (Figures S2G and S2H), suggesting age did not change pyruvate production to limit lactate.", [["CD4 + T cells", "ANATOMY", 165, 178], ["pyruvate", "CHEMICAL", 36, 44], ["glucose", "CHEMICAL", 61, 68], ["pyruvate", "CHEMICAL", 95, 103], ["pyruvate", "CHEMICAL", 264, 272], ["lactate", "CHEMICAL", 293, 300], ["pyruvate", "CHEMICAL", 36, 44], ["glucose", "CHEMICAL", 61, 68], ["pyruvate", "CHEMICAL", 95, 103], ["pyruvate", "CHEMICAL", 264, 272], ["lactate", "CHEMICAL", 293, 300], ["pyruvate", "SIMPLE_CHEMICAL", 36, 44], ["glucose", "SIMPLE_CHEMICAL", 61, 68], ["hexokinase", "GENE_OR_GENE_PRODUCT", 80, 90], ["pyruvate kinase M2", "GENE_OR_GENE_PRODUCT", 95, 113], ["PKM2", "GENE_OR_GENE_PRODUCT", 115, 119], ["CD4", "GENE_OR_GENE_PRODUCT", 165, 168], ["pyruvate", "SIMPLE_CHEMICAL", 264, 272], ["lactate", "SIMPLE_CHEMICAL", 293, 300], ["hexokinase", "PROTEIN", 80, 90], ["pyruvate kinase M2", "PROTEIN", 95, 113], ["PKM2", "PROTEIN", 115, 119], ["CD4", "PROTEIN", 165, 168], ["T cells", "CELL_TYPE", 171, 178], ["enzymes", "TEST", 14, 21], ["pyruvate production", "TEST", 36, 55], ["glucose", "TEST", 61, 68], ["hexokinase", "TEST", 80, 90], ["pyruvate kinase M2", "TEST", 95, 113], ["PKM2", "TEST", 115, 119], ["pyruvate production", "PROBLEM", 264, 283], ["lactate", "TEST", 293, 300], ["higher", "OBSERVATION_MODIFIER", 126, 132]]], ["In contrast to lower glycolysis, pyruvate hydrolysis through the citric acid cycle was not likely compromised by age-dependent changes in citric acid cycle enzymes, as suggested by protein levels of isocitrate dehydrogenase (IDH2) and oxoglutarate dehydrogenase (OGDH) (Figures S2I and S2J ).", [["pyruvate", "CHEMICAL", 33, 41], ["citric acid", "CHEMICAL", 65, 76], ["citric acid", "CHEMICAL", 138, 149], ["oxoglutarate", "CHEMICAL", 235, 247], ["pyruvate", "CHEMICAL", 33, 41], ["citric acid", "CHEMICAL", 65, 76], ["citric acid", "CHEMICAL", 138, 149], ["isocitrate", "CHEMICAL", 199, 209], ["oxoglutarate", "CHEMICAL", 235, 247], ["pyruvate", "SIMPLE_CHEMICAL", 33, 41], ["citric acid", "SIMPLE_CHEMICAL", 65, 76], ["citric acid", "SIMPLE_CHEMICAL", 138, 149], ["isocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 199, 223], ["IDH2", "GENE_OR_GENE_PRODUCT", 225, 229], ["oxoglutarate dehydrogenase", "GENE_OR_GENE_PRODUCT", 235, 261], ["OGDH", "GENE_OR_GENE_PRODUCT", 263, 267], ["citric acid cycle enzymes", "PROTEIN", 138, 163], ["isocitrate dehydrogenase", "PROTEIN", 199, 223], ["IDH2", "PROTEIN", 225, 229], ["oxoglutarate dehydrogenase", "PROTEIN", 235, 261], ["OGDH", "PROTEIN", 263, 267], ["S2I", "PROTEIN", 278, 281], ["S2J", "PROTEIN", 286, 289], ["pyruvate hydrolysis", "PROBLEM", 33, 52], ["the citric acid cycle", "TEST", 61, 82], ["dependent changes", "PROBLEM", 117, 134], ["citric acid cycle enzymes", "TEST", 138, 163], ["protein levels", "TEST", 181, 195], ["isocitrate dehydrogenase (IDH2)", "PROBLEM", 199, 230], ["oxoglutarate dehydrogenase (OGDH)", "PROBLEM", 235, 268], ["lower", "ANATOMY_MODIFIER", 15, 20], ["pyruvate hydrolysis", "OBSERVATION", 33, 52], ["not likely", "UNCERTAINTY", 87, 97]]], ["NADH:ubiquinone oxidoreductase (mitochondrial respiratory complex 1) was quantitatively equal in CD4 + T cells from O and Y subjects, although western blots suggested an age-related post-translational modification ( Figure S2K ).", [["mitochondrial", "ANATOMY", 32, 45], ["CD4 + T cells", "ANATOMY", 97, 110], ["NADH", "CHEMICAL", 0, 4], ["ubiquinone", "CHEMICAL", 5, 15], ["NADH", "CHEMICAL", 0, 4], ["ubiquinone", "CHEMICAL", 5, 15], ["NADH", "SIMPLE_CHEMICAL", 0, 4], ["ubiquinone oxidoreductase", "GENE_OR_GENE_PRODUCT", 5, 30], ["mitochondrial respiratory complex 1", "GENE_OR_GENE_PRODUCT", 32, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["NADH:ubiquinone oxidoreductase", "PROTEIN", 0, 30], ["mitochondrial respiratory complex 1", "PROTEIN", 32, 67], ["CD4", "PROTEIN", 97, 100], ["T cells", "CELL_TYPE", 103, 110], ["S2K", "PROTEIN", 223, 226], ["ubiquinone oxidoreductase (mitochondrial respiratory complex", "PROBLEM", 5, 65], ["western blots", "TEST", 143, 156], ["ubiquinone oxidoreductase", "OBSERVATION", 5, 30]]], ["Metformin increased protein levels of LDH ( Figure 2G ) and OGDH ( Figure S2J ) in CD4 + T cells from O subjects but had no effect on the other enzymes measured.", [["CD4 + T cells", "ANATOMY", 83, 96], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["LDH", "GENE_OR_GENE_PRODUCT", 38, 41], ["Figure 2G", "GENE_OR_GENE_PRODUCT", 44, 53], ["OGDH", "SIMPLE_CHEMICAL", 60, 64], ["CD4", "GENE_OR_GENE_PRODUCT", 83, 86], ["LDH", "PROTEIN", 38, 41], ["OGDH", "PROTEIN", 60, 64], ["CD4", "PROTEIN", 83, 86], ["T cells", "CELL_TYPE", 89, 96], ["enzymes", "PROTEIN", 144, 151], ["Metformin", "TREATMENT", 0, 9], ["protein levels", "TEST", 20, 34], ["LDH", "TEST", 38, 41], ["Figure", "TEST", 44, 50], ["OGDH", "PROBLEM", 60, 64], ["CD4 + T cells", "PROBLEM", 83, 96], ["the other enzymes", "TEST", 134, 151]]], ["We conclude age-related decreases in LDH, which are sensitive to metformin, mechanistically explain lower glycolysis and may thereby promote compensatory OXPHOS in CD4 + T cells from O subjects.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismTo test causal relationships between low LDH expression in O cells and the Th17 inflammaging profile, we pharmacologically inhibited LDH activity in CD4 + T cells from Y subjects with 20 mM oxamic acid (OA; Figure S2L ).", [["CD4 + T cells", "ANATOMY", 164, 177], ["CD4 + T Cell", "ANATOMY", 219, 231], ["O cells", "ANATOMY", 359, 366], ["CD4 + T cells", "ANATOMY", 449, 462], ["metformin", "CHEMICAL", 65, 74], ["Metformin", "CHEMICAL", 271, 280], ["oxamic acid", "CHEMICAL", 490, 501], ["metformin", "CHEMICAL", 65, 74], ["Metformin", "CHEMICAL", 271, 280], ["oxamic acid", "CHEMICAL", 490, 501], ["LDH", "GENE_OR_GENE_PRODUCT", 37, 40], ["metformin", "SIMPLE_CHEMICAL", 65, 74], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 154, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 164, 167], ["CD4", "GENE_OR_GENE_PRODUCT", 219, 222], ["Metformin", "SIMPLE_CHEMICAL", 271, 280], ["LDH", "GENE_OR_GENE_PRODUCT", 341, 344], ["O cells", "CELL", 359, 366], ["Th17", "CELL", 375, 379], ["LDH", "GENE_OR_GENE_PRODUCT", 433, 436], ["CD4", "GENE_OR_GENE_PRODUCT", 449, 452], ["oxamic acid", "SIMPLE_CHEMICAL", 490, 501], ["LDH", "PROTEIN", 37, 40], ["OXPHOS", "PROTEIN", 154, 160], ["CD4 + T cells", "CELL_TYPE", 164, 177], ["CD4", "PROTEIN", 219, 222], ["LDH", "PROTEIN", 341, 344], ["O cells", "CELL_TYPE", 359, 366], ["LDH", "PROTEIN", 433, 436], ["CD4", "PROTEIN", 449, 452], ["T cells", "CELL_TYPE", 455, 462], ["decreases in LDH", "PROBLEM", 24, 40], ["metformin", "TREATMENT", 65, 74], ["lower glycolysis", "PROBLEM", 100, 116], ["compensatory OXPHOS", "PROBLEM", 141, 160], ["A Th17 Profile", "TEST", 194, 208], ["CD4", "TEST", 219, 222], ["a Metformin", "TEST", 269, 280], ["low LDH expression in O cells", "PROBLEM", 337, 366], ["the Th17 inflammaging profile", "TEST", 371, 400], ["LDH activity", "TEST", 433, 445], ["CD4", "TEST", 449, 452], ["Y subjects", "TEST", 468, 478], ["20 mM oxamic acid (OA", "TREATMENT", 484, 505], ["decreases", "OBSERVATION_MODIFIER", 24, 33], ["low LDH", "OBSERVATION_MODIFIER", 337, 344]]], ["Some Th17-associated cytokines, including IL-21 and the Th17 supporters IL-6 and IL-23, were activated by OA ( Figure S2M ).", [["Th17", "GENE_OR_GENE_PRODUCT", 5, 9], ["IL-21", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-6", "GENE_OR_GENE_PRODUCT", 72, 76], ["IL-23", "GENE_OR_GENE_PRODUCT", 81, 86], ["OA", "SIMPLE_CHEMICAL", 106, 108], ["Th17", "PROTEIN", 5, 9], ["cytokines", "PROTEIN", 21, 30], ["IL-21", "PROTEIN", 42, 47], ["IL-23", "PROTEIN", 81, 86], ["IL", "TEST", 42, 44], ["the Th17 supporters IL", "TREATMENT", 52, 74], ["IL", "TEST", 81, 83], ["Th17", "OBSERVATION", 5, 9], ["cytokines", "OBSERVATION", 21, 30]]], ["However, PLSDA showed that the majority of Th17 signature cytokines (IL-17A, IL-17F IL-6, and IL-21; Figure 1F ) were not important for distinguishing compendium cytokine profiles from LDH inhibitor-treated Y cells.", [["Y cells", "ANATOMY", 207, 214], ["PLSDA", "SIMPLE_CHEMICAL", 9, 14], ["Th17", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-17A", "GENE_OR_GENE_PRODUCT", 69, 75], ["IL-17F", "GENE_OR_GENE_PRODUCT", 77, 83], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL-21", "GENE_OR_GENE_PRODUCT", 94, 99], ["Figure 1F", "GENE_OR_GENE_PRODUCT", 101, 110], ["LDH", "GENE_OR_GENE_PRODUCT", 185, 188], ["Y cells", "CELL", 207, 214], ["PLSDA", "PROTEIN", 9, 14], ["Th17 signature cytokines", "PROTEIN", 43, 67], ["IL", "PROTEIN", 94, 96], ["cytokine", "PROTEIN", 162, 170], ["LDH inhibitor-treated Y cells", "CELL_LINE", 185, 214], ["PLSDA", "TEST", 9, 14], ["Th17 signature cytokines", "TEST", 43, 67], ["IL", "TEST", 69, 71], ["IL", "TEST", 77, 79], ["IL", "TEST", 84, 86], ["IL", "TEST", 94, 96], ["cytokine profiles", "TEST", 162, 179], ["LDH inhibitor", "TEST", 185, 198]]], ["Exceptions were IL-22 and IL-23, highlighted as important by this method ( Figure 2H ).", [["IL-22", "GENE_OR_GENE_PRODUCT", 16, 21], ["IL-23", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-22", "PROTEIN", 16, 21], ["IL", "PROTEIN", 26, 28], ["IL", "TEST", 16, 18], ["IL", "TEST", 26, 28]]], ["We conclude that changes in glycolytic machinery do not play critical roles in Th17 inflammaging.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismMitochondrial Dysfunction Disrupts Redox Balance to Support Th17 Cytokine Production by CD4 + T Cells from O Subjects and Is Corrected by Metformin Higher OXPHOS in the absence of parallel increases in anti-oxidants can generate excess oxidative stress, as measured by reactive oxygen species (ROS), which in turn can support Th17 number and function (Zhi et al., 2012; Ungvari et al., 2009; Murphy, 2009; Liu et al., 2002) .", [["CD4 + T Cell", "ANATOMY", 122, 134], ["CD4 + T Cells", "ANATOMY", 291, 304], ["Metformin", "CHEMICAL", 174, 183], ["Metformin", "CHEMICAL", 341, 350], ["oxygen", "CHEMICAL", 481, 487], ["ROS", "CHEMICAL", 497, 500], ["Metformin", "CHEMICAL", 174, 183], ["Metformin", "CHEMICAL", 341, 350], ["oxygen", "CHEMICAL", 481, 487], ["Th17", "CELL", 79, 83], ["CD4", "GENE_OR_GENE_PRODUCT", 122, 125], ["Metformin", "SIMPLE_CHEMICAL", 174, 183], ["CD4", "GENE_OR_GENE_PRODUCT", 291, 294], ["Metformin", "SIMPLE_CHEMICAL", 341, 350], ["anti-oxidants", "SIMPLE_CHEMICAL", 405, 418], ["reactive oxygen species", "SIMPLE_CHEMICAL", 472, 495], ["ROS", "SIMPLE_CHEMICAL", 497, 500], ["CD4", "PROTEIN", 122, 125], ["Cytokine", "PROTEIN", 268, 276], ["CD4", "PROTEIN", 291, 294], ["OXPHOS", "PROTEIN", 358, 364], ["glycolytic machinery", "TREATMENT", 28, 48], ["A Th17 Profile", "TEST", 97, 111], ["CD4", "TEST", 122, 125], ["a Metformin", "TREATMENT", 172, 183], ["Sensitive MechanismMitochondrial Dysfunction", "PROBLEM", 184, 228], ["Th17 Cytokine Production", "TREATMENT", 263, 287], ["Metformin", "TREATMENT", 341, 350], ["parallel increases in anti-oxidants", "TREATMENT", 383, 418], ["excess oxidative stress", "PROBLEM", 432, 455], ["reactive oxygen species", "PROBLEM", 472, 495], ["excess oxidative stress", "OBSERVATION", 432, 455], ["reactive", "OBSERVATION_MODIFIER", 472, 480], ["oxygen species", "OBSERVATION", 481, 495]]], ["CD4 + T cells from O subjects had more ROS than Y counterparts, as measured by DCFDA (Figure 3A) , and consistent with higher ATP-linked respiration ( Figure 3B ).", [["CD4 + T cells", "ANATOMY", 0, 13], ["ATP", "CHEMICAL", 126, 129], ["ATP", "CHEMICAL", 126, 129], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["ROS", "SIMPLE_CHEMICAL", 39, 42], ["Y counterparts", "CELL", 48, 62], ["ATP", "SIMPLE_CHEMICAL", 126, 129], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["CD4", "TEST", 0, 3], ["T cells", "TEST", 6, 13], ["higher ATP-linked respiration", "PROBLEM", 119, 148], ["consistent with", "UNCERTAINTY", 103, 118]]], ["Lower glutathione (GSH) and more nicotinamide nucleotide transhydrogenase (NNT) in O compared with Y cells indicated that less antioxidant, perhaps in response to ''reverse'' NNT function (Nickel et al., 2015) , contributed to higher oxidative stress ( Figures 3C and 3D ).", [["Y cells", "ANATOMY", 99, 106], ["glutathione", "CHEMICAL", 6, 17], ["GSH", "CHEMICAL", 19, 22], ["nicotinamide", "CHEMICAL", 33, 45], ["glutathione", "CHEMICAL", 6, 17], ["GSH", "CHEMICAL", 19, 22], ["nicotinamide", "CHEMICAL", 33, 45], ["nucleotide", "CHEMICAL", 46, 56], ["glutathione", "SIMPLE_CHEMICAL", 6, 17], ["GSH", "SIMPLE_CHEMICAL", 19, 22], ["nicotinamide nucleotide transhydrogenase", "GENE_OR_GENE_PRODUCT", 33, 73], ["NNT", "SIMPLE_CHEMICAL", 75, 78], ["Y cells", "CELL", 99, 106], ["nicotinamide nucleotide transhydrogenase", "PROTEIN", 33, 73], ["Y cells", "CELL_TYPE", 99, 106], ["Lower glutathione (GSH)", "PROBLEM", 0, 23], ["more nicotinamide nucleotide transhydrogenase", "TREATMENT", 28, 73], ["higher oxidative stress", "PROBLEM", 227, 250], ["less antioxidant", "OBSERVATION_MODIFIER", 122, 138]]], ["Lower expression of mitochondrial manganese superoxide dismutase (MnSOD/ SOD2) in T cells from O subjects ( Figure 3E ) was also consistent with higher ROS, despite age-independent expression of the anti-oxidants SOD1 and PRDX2 ( Figures S3A and S3B ), all of which associated with lower MMP ( Figure 3F ).", [["mitochondrial", "ANATOMY", 20, 33], ["T cells", "ANATOMY", 82, 89], ["superoxide", "CHEMICAL", 44, 54], ["ROS", "CHEMICAL", 152, 155], ["manganese", "CHEMICAL", 34, 43], ["superoxide", "CHEMICAL", 44, 54], ["mitochondrial", "CELLULAR_COMPONENT", 20, 33], ["manganese superoxide dismutase", "GENE_OR_GENE_PRODUCT", 34, 64], ["MnSOD", "GENE_OR_GENE_PRODUCT", 66, 71], ["SOD2", "GENE_OR_GENE_PRODUCT", 73, 77], ["T cells", "CELL", 82, 89], ["O subjects", "CELL", 95, 105], ["ROS", "SIMPLE_CHEMICAL", 152, 155], ["SOD1", "GENE_OR_GENE_PRODUCT", 213, 217], ["PRDX2", "GENE_OR_GENE_PRODUCT", 222, 227], ["Figures S3A", "GENE_OR_GENE_PRODUCT", 230, 241], ["S3B", "GENE_OR_GENE_PRODUCT", 246, 249], ["mitochondrial manganese superoxide dismutase", "PROTEIN", 20, 64], ["MnSOD", "PROTEIN", 66, 71], ["SOD2", "PROTEIN", 73, 77], ["T cells", "CELL_TYPE", 82, 89], ["SOD1", "PROTEIN", 213, 217], ["PRDX2", "PROTEIN", 222, 227], ["S3A", "PROTEIN", 238, 241], ["S3B", "PROTEIN", 246, 249], ["MMP", "PROTEIN", 288, 291], ["mitochondrial manganese superoxide dismutase (MnSOD/ SOD2) in T cells", "PROBLEM", 20, 89], ["higher ROS", "PROBLEM", 145, 155], ["the anti-oxidants SOD1", "PROBLEM", 195, 217], ["PRDX2", "TREATMENT", 222, 227], ["lower MMP", "PROBLEM", 282, 291], ["mitochondrial manganese", "OBSERVATION", 20, 43], ["superoxide dismutase", "OBSERVATION", 44, 64]]], ["Metformin increased the expression of GSH and SOD1 (Figures 3C and S3A), decreased ROS and NNT ( Figures 3A and 3D ), and showed a trend toward increased MnSOD ( Figure 3E ; p = 0.062) in cells from O subjects.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismTo explore the possibility that metformin regulates the Th17 inflammaging profile through effects on ROS, we tested the ability of the ROS-specific scavenger Tempol to recapitulate metformin effects on CD4 + T cells from O subjects.", [["cells", "ANATOMY", 188, 193], ["CD4 + T Cell", "ANATOMY", 235, 247], ["CD4 + T cells", "ANATOMY", 518, 531], ["Metformin", "CHEMICAL", 0, 9], ["GSH", "CHEMICAL", 38, 41], ["ROS", "CHEMICAL", 83, 86], ["Metformin", "CHEMICAL", 287, 296], ["metformin", "CHEMICAL", 348, 357], ["ROS", "CHEMICAL", 451, 454], ["Tempol", "CHEMICAL", 474, 480], ["metformin", "CHEMICAL", 497, 506], ["Metformin", "CHEMICAL", 0, 9], ["GSH", "CHEMICAL", 38, 41], ["Metformin", "CHEMICAL", 287, 296], ["metformin", "CHEMICAL", 348, 357], ["Tempol", "CHEMICAL", 474, 480], ["metformin", "CHEMICAL", 497, 506], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["GSH", "SIMPLE_CHEMICAL", 38, 41], ["SOD1", "GENE_OR_GENE_PRODUCT", 46, 50], ["Figures 3C", "GENE_OR_GENE_PRODUCT", 52, 62], ["S3A", "GENE_OR_GENE_PRODUCT", 67, 70], ["ROS", "SIMPLE_CHEMICAL", 83, 86], ["MnSOD", "GENE_OR_GENE_PRODUCT", 154, 159], ["cells", "CELL", 188, 193], ["CD4", "GENE_OR_GENE_PRODUCT", 235, 238], ["Metformin", "SIMPLE_CHEMICAL", 287, 296], ["metformin", "SIMPLE_CHEMICAL", 348, 357], ["ROS", "SIMPLE_CHEMICAL", 417, 420], ["ROS", "SIMPLE_CHEMICAL", 451, 454], ["Tempol", "SIMPLE_CHEMICAL", 474, 480], ["metformin", "SIMPLE_CHEMICAL", 497, 506], ["CD4", "GENE_OR_GENE_PRODUCT", 518, 521], ["SOD1", "PROTEIN", 46, 50], ["S3A", "PROTEIN", 67, 70], ["MnSOD", "PROTEIN", 154, 159], ["CD4", "PROTEIN", 235, 238], ["CD4", "PROTEIN", 518, 521], ["T cells", "CELL_TYPE", 524, 531], ["Metformin", "TREATMENT", 0, 9], ["Figures 3C and S3A)", "TREATMENT", 52, 71], ["decreased ROS", "PROBLEM", 73, 86], ["increased MnSOD", "PROBLEM", 144, 159], ["A Th17 Profile", "TEST", 210, 224], ["CD4", "TEST", 235, 238], ["a Metformin", "TREATMENT", 285, 296], ["metformin", "TREATMENT", 348, 357], ["specific scavenger Tempol", "TREATMENT", 455, 480], ["metformin effects", "PROBLEM", 497, 514], ["CD4", "TEST", 518, 521]]], ["Tempol (H) VIP scores, which rank cytokines as most (leftmost) or least (rightmost) important for differentiating overall cytokine profiles between CD4 + T cells from young subjects stimulated \u00b1 the LDH inhibitor OA in an orthagonalized model.", [["CD4 + T cells", "ANATOMY", 148, 161], ["Tempol", "CHEMICAL", 0, 6], ["Tempol", "CHEMICAL", 0, 6], ["Tempol", "SIMPLE_CHEMICAL", 0, 6], ["H) VIP", "GENE_OR_GENE_PRODUCT", 8, 14], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["LDH", "GENE_OR_GENE_PRODUCT", 199, 202], ["cytokines", "PROTEIN", 34, 43], ["cytokine", "PROTEIN", 122, 130], ["CD4", "PROTEIN", 148, 151], ["T cells", "CELL_TYPE", 154, 161], ["Tempol", "TREATMENT", 0, 6], ["VIP scores", "TEST", 11, 21], ["cytokine profiles", "TEST", 122, 139], ["CD4 + T cells", "PROBLEM", 148, 161], ["young subjects", "PROBLEM", 167, 181], ["the LDH inhibitor OA", "PROBLEM", 195, 215], ["an orthagonalized model", "TREATMENT", 219, 242]]], ["A VIP score >1 (bracket) is considered important for differentiating inflammatory profiles between groups.", [["A VIP score", "TEST", 0, 11], ["considered important for", "UNCERTAINTY", 28, 52], ["inflammatory", "OBSERVATION", 69, 81]]], ["All VIP cytokines indicated also differed in post hoc analyses (p < 0.05).", [["VIP", "GENE_OR_GENE_PRODUCT", 4, 7], ["VIP cytokines", "PROTEIN", 4, 17], ["All VIP cytokines", "TEST", 0, 17], ["hoc analyses", "TEST", 50, 62]]], ["Fold change is compared to Y or Y + FCCP.", [["FCCP", "CHEMICAL", 36, 40], ["FCCP", "CHEMICAL", 36, 40], ["FCCP", "SIMPLE_CHEMICAL", 36, 40], ["Fold change", "PROBLEM", 0, 11], ["change", "OBSERVATION", 5, 11]]], ["See also Figure S2 . ll Article reduced ROS and trended toward increased MMP (TMRE, p = 0.058) in CD4 + T cells from O subjects ( Figures 3F and 3G ), but perhaps more importantly, Tempol uniformly decreased Th17 profile cytokines in O cells with no effect on Y cells, though effects on other cytokines somewhat differed from effects of metformin .", [["CD4 + T cells", "ANATOMY", 98, 111], ["O cells", "ANATOMY", 234, 241], ["Y cells", "ANATOMY", 260, 267], ["ROS", "CHEMICAL", 40, 43], ["Tempol", "CHEMICAL", 181, 187], ["metformin", "CHEMICAL", 337, 346], ["Tempol", "CHEMICAL", 181, 187], ["metformin", "CHEMICAL", 337, 346], ["ROS", "SIMPLE_CHEMICAL", 40, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 98, 101], ["Tempol", "SIMPLE_CHEMICAL", 181, 187], ["O cells", "CELL", 234, 241], ["Y cells", "CELL", 260, 267], ["metformin", "SIMPLE_CHEMICAL", 337, 346], ["MMP", "PROTEIN", 73, 76], ["CD4", "PROTEIN", 98, 101], ["T cells", "CELL_TYPE", 104, 111], ["cytokines", "PROTEIN", 221, 230], ["O cells", "CELL_TYPE", 234, 241], ["Y cells", "CELL_TYPE", 260, 267], ["cytokines", "PROTEIN", 293, 302], ["ll Article reduced ROS", "PROBLEM", 21, 43], ["increased MMP", "PROBLEM", 63, 76], ["TMRE", "TEST", 78, 82], ["p", "TEST", 84, 85], ["Tempol uniformly decreased Th17 profile cytokines in O cells", "PROBLEM", 181, 241], ["effect on Y cells", "PROBLEM", 250, 267], ["other cytokines", "PROBLEM", 287, 302], ["metformin", "TREATMENT", 337, 346], ["decreased", "OBSERVATION_MODIFIER", 198, 207], ["no", "UNCERTAINTY", 247, 249]]], ["Tempol and metformin together increased TMRE signal more than either alone in O cells ( Figure 3F ), further indicating overlapping but non-identical effects of ROS scavenging and metformin, but consistent with previous demonstrations that ROS dissipation is a mechanism of metformin action (Madiraju et al., 2019) .", [["O cells", "ANATOMY", 78, 85], ["Tempol", "CHEMICAL", 0, 6], ["metformin", "CHEMICAL", 11, 20], ["ROS", "CHEMICAL", 161, 164], ["metformin", "CHEMICAL", 180, 189], ["ROS", "CHEMICAL", 240, 243], ["metformin", "CHEMICAL", 274, 283], ["Tempol", "CHEMICAL", 0, 6], ["metformin", "CHEMICAL", 11, 20], ["metformin", "CHEMICAL", 180, 189], ["metformin", "CHEMICAL", 274, 283], ["Tempol", "SIMPLE_CHEMICAL", 0, 6], ["metformin", "SIMPLE_CHEMICAL", 11, 20], ["TMRE", "SIMPLE_CHEMICAL", 40, 44], ["O cells", "CELL", 78, 85], ["ROS", "SIMPLE_CHEMICAL", 161, 164], ["metformin", "SIMPLE_CHEMICAL", 180, 189], ["ROS", "SIMPLE_CHEMICAL", 240, 243], ["metformin", "SIMPLE_CHEMICAL", 274, 283], ["TMRE", "PROTEIN", 40, 44], ["O cells", "CELL_TYPE", 78, 85], ["Tempol", "TREATMENT", 0, 6], ["metformin", "TREATMENT", 11, 20], ["increased TMRE signal", "PROBLEM", 30, 51], ["ROS scavenging", "TREATMENT", 161, 175], ["metformin", "TREATMENT", 180, 189], ["ROS dissipation", "PROBLEM", 240, 255], ["metformin action", "TREATMENT", 274, 290], ["ROS scavenging", "OBSERVATION", 161, 175]]], ["We conclude mitochondrial OXPHOS in O cells coincides with lower antioxidant to cause oxidative stress and a ROS-downstream Th17 profile.", [["mitochondrial", "ANATOMY", 12, 25], ["O cells", "ANATOMY", 36, 43], ["ROS", "CHEMICAL", 109, 112], ["mitochondrial", "CELLULAR_COMPONENT", 12, 25], ["O cells", "CELL", 36, 43], ["ROS", "SIMPLE_CHEMICAL", 109, 112], ["mitochondrial OXPHOS", "PROTEIN", 12, 32], ["O cells", "CELL_TYPE", 36, 43], ["mitochondrial OXPHOS in O cells", "PROBLEM", 12, 43], ["oxidative stress", "PROBLEM", 86, 102], ["a ROS", "TEST", 107, 112], ["mitochondrial OXPHOS", "OBSERVATION", 12, 32]]], ["Metformin-sensitive pathways that are partially redundant with mitochondrial ROS-scavenging re-establish redox balance to ameliorate T cell inflammaging.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismAutophagy Defects in CD4 + T Cells from O Subjects Are Corrected by Metformin Accumulation of defective mitochondria stemming from general age-related declines in autophagy may, in part, explain excessive OXPHOS and thus redox imbalance in CD4 + T cells from O subjects.", [["mitochondrial", "ANATOMY", 63, 76], ["T cell", "ANATOMY", 133, 139], ["CD4 + T Cell", "ANATOMY", 178, 190], ["CD4 + T Cells", "ANATOMY", 280, 293], ["mitochondria", "ANATOMY", 363, 375], ["CD4 + T cells", "ANATOMY", 499, 512], ["Metformin", "CHEMICAL", 0, 9], ["ROS", "CHEMICAL", 77, 80], ["Metformin", "CHEMICAL", 230, 239], ["Metformin", "CHEMICAL", 327, 336], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 230, 239], ["Metformin", "CHEMICAL", 327, 336], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["mitochondrial", "CELLULAR_COMPONENT", 63, 76], ["ROS", "SIMPLE_CHEMICAL", 77, 80], ["T cell", "CELL", 133, 139], ["CD4", "GENE_OR_GENE_PRODUCT", 178, 181], ["Metformin", "SIMPLE_CHEMICAL", 230, 239], ["Metformin", "SIMPLE_CHEMICAL", 327, 336], ["mitochondria", "CELLULAR_COMPONENT", 363, 375], ["OXPHOS", "GENE_OR_GENE_PRODUCT", 464, 470], ["CD4", "GENE_OR_GENE_PRODUCT", 499, 502], ["CD4", "PROTEIN", 178, 181], ["CD4", "PROTEIN", 280, 283], ["OXPHOS", "PROTEIN", 464, 470], ["CD4 + T cells", "CELL_TYPE", 499, 512], ["Metformin", "TREATMENT", 0, 9], ["sensitive pathways", "PROBLEM", 10, 28], ["mitochondrial ROS", "PROBLEM", 63, 80], ["T cell inflammaging", "PROBLEM", 133, 152], ["A Th17 Profile", "TEST", 153, 167], ["CD4", "TEST", 178, 181], ["a Metformin", "TREATMENT", 228, 239], ["Sensitive MechanismAutophagy Defects", "PROBLEM", 240, 276], ["T Cells", "PROBLEM", 286, 293], ["Metformin", "TREATMENT", 327, 336], ["defective mitochondria stemming", "PROBLEM", 353, 384], ["excessive OXPHOS", "PROBLEM", 454, 470], ["redox imbalance", "PROBLEM", 480, 495], ["defective mitochondria", "OBSERVATION", 353, 375]]], ["We quantified mitochondrial accumulation in CD4 + T cells with Mitotracker green fluorescence and flow cytometry.", [["mitochondrial", "ANATOMY", 14, 27], ["CD4 + T cells", "ANATOMY", 44, 57], ["Mitotracker green", "CHEMICAL", 63, 80], ["Mitotracker green", "CHEMICAL", 63, 80], ["mitochondrial", "CELLULAR_COMPONENT", 14, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["Mitotracker", "SIMPLE_CHEMICAL", 63, 74], ["CD4", "PROTEIN", 44, 47], ["T cells", "CELL_TYPE", 50, 57], ["mitochondrial accumulation", "PROBLEM", 14, 40], ["CD4 + T cells", "PROBLEM", 44, 57], ["Mitotracker green fluorescence", "TEST", 63, 93], ["flow cytometry", "TEST", 98, 112], ["mitochondrial accumulation", "OBSERVATION", 14, 40], ["CD4 + T cells", "OBSERVATION", 44, 57], ["flow cytometry", "OBSERVATION", 98, 112]]], ["Cells from O subjects had more mitochondrial mass and mitochondrial matrix proteins, such as m-aconitase, consistent with mitochondrial accumulation.", [["Cells", "ANATOMY", 0, 5], ["mitochondrial", "ANATOMY", 31, 44], ["mitochondrial matrix", "ANATOMY", 54, 74], ["mitochondrial", "ANATOMY", 122, 135], ["Cells", "CELL", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 31, 44], ["mitochondrial matrix", "CELLULAR_COMPONENT", 54, 74], ["m-aconitase", "GENE_OR_GENE_PRODUCT", 93, 104], ["mitochondrial", "CELLULAR_COMPONENT", 122, 135], ["mitochondrial matrix proteins", "PROTEIN", 54, 83], ["m-aconitase", "PROTEIN", 93, 104], ["mitochondrial mass", "PROBLEM", 31, 49], ["mitochondrial matrix proteins", "PROBLEM", 54, 83], ["mitochondrial accumulation", "PROBLEM", 122, 148], ["mass", "OBSERVATION", 45, 49], ["mitochondrial matrix proteins", "OBSERVATION", 54, 83], ["consistent with", "UNCERTAINTY", 106, 121], ["mitochondrial accumulation", "OBSERVATION", 122, 148]]], ["Metformin decreased mitochondrial accumulation in O, but not Y cells ( Figures 4A-4D ).", [["mitochondrial", "ANATOMY", 20, 33], ["Y cells", "ANATOMY", 61, 68], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["mitochondrial", "CELLULAR_COMPONENT", 20, 33], ["Y cells", "CELL", 61, 68], ["O, but not Y cells", "CELL_LINE", 50, 68], ["Metformin", "TREATMENT", 0, 9], ["mitochondrial accumulation", "PROBLEM", 20, 46], ["mitochondrial accumulation", "OBSERVATION", 20, 46]]], ["Metformin action was redundant with Tempol-mediated decrease in mitochondrial mass ( Figure 4D ), raising the possibility that metformin corrects age-related changes in autophagy that impact redox balance that in turn drives T cell inflammaging.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismTo more broadly test the possibility that age-related autophagy defects impact CD4 + T cells and thereby age-related inflammation, we quantified autophagy indicators in CD4 + T cells from O subjects.", [["mitochondrial", "ANATOMY", 64, 77], ["T cell", "ANATOMY", 225, 231], ["CD4 + T Cell", "ANATOMY", 270, 282], ["CD4 + T cells", "ANATOMY", 430, 443], ["CD4 + T cells", "ANATOMY", 520, 533], ["Metformin", "CHEMICAL", 0, 9], ["Tempol", "CHEMICAL", 36, 42], ["metformin", "CHEMICAL", 127, 136], ["Metformin", "CHEMICAL", 322, 331], ["inflammation", "DISEASE", 468, 480], ["Metformin", "CHEMICAL", 0, 9], ["Tempol", "CHEMICAL", 36, 42], ["metformin", "CHEMICAL", 127, 136], ["Metformin", "CHEMICAL", 322, 331], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["Tempol", "SIMPLE_CHEMICAL", 36, 42], ["mitochondrial", "CELLULAR_COMPONENT", 64, 77], ["metformin", "SIMPLE_CHEMICAL", 127, 136], ["T cell", "CELL", 225, 231], ["CD4", "GENE_OR_GENE_PRODUCT", 270, 273], ["Metformin", "SIMPLE_CHEMICAL", 322, 331], ["CD4", "GENE_OR_GENE_PRODUCT", 430, 433], ["CD4", "GENE_OR_GENE_PRODUCT", 520, 523], ["CD4", "PROTEIN", 270, 273], ["CD4", "PROTEIN", 430, 433], ["T cells", "CELL_TYPE", 436, 443], ["CD4", "PROTEIN", 520, 523], ["T cells", "CELL_TYPE", 526, 533], ["Metformin action", "TREATMENT", 0, 16], ["Tempol", "TREATMENT", 36, 42], ["mitochondrial mass", "PROBLEM", 64, 82], ["metformin", "TREATMENT", 127, 136], ["changes in autophagy", "PROBLEM", 158, 178], ["redox balance", "PROBLEM", 191, 204], ["A Th17 Profile", "TEST", 245, 259], ["CD4", "TEST", 270, 273], ["a Metformin", "TREATMENT", 320, 331], ["autophagy defects", "PROBLEM", 405, 422], ["T cells", "PROBLEM", 436, 443], ["related inflammation", "PROBLEM", 460, 480], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["mitochondrial", "ANATOMY", 64, 77], ["mass", "OBSERVATION", 78, 82], ["raising the possibility", "UNCERTAINTY", 98, 121], ["autophagy defects", "OBSERVATION", 405, 422], ["inflammation", "OBSERVATION", 468, 480]]], ["O cells had less robust autophagy than Y counterparts, as shown by lower LC3II, p62 accumulation, and fewer LC3IIlabeled puncta.", [["O cells", "ANATOMY", 0, 7], ["puncta", "ANATOMY", 121, 127], ["O cells", "CELL", 0, 7], ["Y counterparts", "CELL", 39, 53], ["LC3II", "GENE_OR_GENE_PRODUCT", 73, 78], ["p62", "GENE_OR_GENE_PRODUCT", 80, 83], ["puncta", "CELLULAR_COMPONENT", 121, 127], ["O cells", "CELL_TYPE", 0, 7], ["Y counterparts", "CELL_TYPE", 39, 53], ["LC3II", "PROTEIN", 73, 78], ["p62", "PROTEIN", 80, 83], ["less robust", "OBSERVATION_MODIFIER", 12, 23], ["p62 accumulation", "OBSERVATION", 80, 96], ["puncta", "OBSERVATION", 121, 127]]], ["Metformin improved all measures of autophagy in O cells ( Figures 4E-4H ).", [["O cells", "ANATOMY", 48, 55], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["O cells", "CELL", 48, 55], ["O cells", "CELL_TYPE", 48, 55], ["Metformin", "TREATMENT", 0, 9]]], ["More LC3II in cells treated with metformin + bafilomycin A1 (BAF A1, autophagy inhibitor) indicated that metformin enhanced autophagosome flux rather than stalled cargo degradation ( Figure 4I ).", [["cells", "ANATOMY", 14, 19], ["autophagosome", "ANATOMY", 124, 137], ["metformin", "CHEMICAL", 33, 42], ["bafilomycin A1", "CHEMICAL", 45, 59], ["metformin", "CHEMICAL", 105, 114], ["metformin", "CHEMICAL", 33, 42], ["bafilomycin A1", "CHEMICAL", 45, 59], ["BAF A1", "CHEMICAL", 61, 67], ["metformin", "CHEMICAL", 105, 114], ["LC3II", "GENE_OR_GENE_PRODUCT", 5, 10], ["cells", "CELL", 14, 19], ["metformin", "SIMPLE_CHEMICAL", 33, 42], ["bafilomycin A1", "SIMPLE_CHEMICAL", 45, 59], ["BAF A1", "SIMPLE_CHEMICAL", 61, 67], ["metformin", "SIMPLE_CHEMICAL", 105, 114], ["autophagosome", "SIMPLE_CHEMICAL", 124, 137], ["LC3II", "PROTEIN", 5, 10], ["metformin", "TREATMENT", 33, 42], ["bafilomycin A1 (BAF A1", "TREATMENT", 45, 67], ["autophagy inhibitor", "TREATMENT", 69, 88], ["metformin enhanced autophagosome flux", "PROBLEM", 105, 142], ["autophagosome flux", "OBSERVATION", 124, 142], ["cargo degradation", "OBSERVATION", 163, 180]]], ["In addition, O cells had less co-localization of the mitochondrial protein translocase of outer membrane 20 protein (TOM20) and the lysosomal protein lysosome associated membrane protein 1 (LAMP1) than Y cells had, definitively confirming defective mitochondrial turnover was restored by metformin (Figures 4J and 4K) .", [["O cells", "ANATOMY", 13, 20], ["mitochondrial", "ANATOMY", 53, 66], ["Y cells", "ANATOMY", 202, 209], ["mitochondrial", "ANATOMY", 249, 262], ["metformin", "CHEMICAL", 288, 297], ["metformin", "CHEMICAL", 288, 297], ["O cells", "CELL", 13, 20], ["mitochondrial", "CELLULAR_COMPONENT", 53, 66], ["outer membrane 20 protein", "GENE_OR_GENE_PRODUCT", 90, 115], ["TOM20", "GENE_OR_GENE_PRODUCT", 117, 122], ["lysosomal protein lysosome associated membrane protein 1", "GENE_OR_GENE_PRODUCT", 132, 188], ["LAMP1", "GENE_OR_GENE_PRODUCT", 190, 195], ["Y cells", "CELL", 202, 209], ["mitochondrial", "CELLULAR_COMPONENT", 249, 262], ["metformin", "SIMPLE_CHEMICAL", 288, 297], ["O cells", "CELL_TYPE", 13, 20], ["mitochondrial protein translocase", "PROTEIN", 53, 86], ["outer membrane 20 protein", "PROTEIN", 90, 115], ["TOM20", "PROTEIN", 117, 122], ["lysosomal protein lysosome associated membrane protein 1", "PROTEIN", 132, 188], ["LAMP1", "PROTEIN", 190, 195], ["Y cells", "CELL_TYPE", 202, 209], ["the lysosomal protein lysosome", "TEST", 128, 158], ["membrane protein", "TEST", 170, 186], ["defective mitochondrial turnover", "PROBLEM", 239, 271], ["metformin", "TREATMENT", 288, 297], ["mitochondrial turnover", "OBSERVATION", 249, 271]]], ["Metformin similarly increased expression of the mitochondrial fission protein dynamin related protein 1 (Drp1), a mitochondrial indicator of improved health span in Drosophila (Rana et al., 2017) in cells from O subjects ( Figure 4L ).", [["mitochondrial", "ANATOMY", 48, 61], ["mitochondrial", "ANATOMY", 114, 127], ["cells", "ANATOMY", 199, 204], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["mitochondrial", "CELLULAR_COMPONENT", 48, 61], ["dynamin related protein 1", "GENE_OR_GENE_PRODUCT", 78, 103], ["Drp1", "GENE_OR_GENE_PRODUCT", 105, 109], ["mitochondrial", "CELLULAR_COMPONENT", 114, 127], ["cells", "CELL", 199, 204], ["mitochondrial fission protein", "PROTEIN", 48, 77], ["dynamin related protein 1", "PROTEIN", 78, 103], ["Drp1", "PROTEIN", 105, 109], ["Drosophila", "SPECIES", 165, 175], ["Drosophila", "SPECIES", 165, 175], ["Metformin", "TREATMENT", 0, 9], ["the mitochondrial fission protein dynamin", "PROBLEM", 44, 85], ["protein", "TEST", 94, 101], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["mitochondrial fission protein dynamin", "OBSERVATION", 48, 85], ["improved", "OBSERVATION_MODIFIER", 141, 149]]], ["Metformin did not affect general indicators of autophagy, nor specific mitophagy indicators in Y cells , and also failed to impact age-related decreases in humanin and prohibitin (Figures S4A and S4B) , two mitokines that regulate inflammation in some circumstances (Conte et al., 2019; Zapa1a et al., 2010; Kathiria et al., 2012) .", [["Y cells", "ANATOMY", 95, 102], ["Metformin", "CHEMICAL", 0, 9], ["inflammation", "DISEASE", 231, 243], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["Y cells", "CELL", 95, 102], ["humanin", "GENE_OR_GENE_PRODUCT", 156, 163], ["prohibitin", "GENE_OR_GENE_PRODUCT", 168, 178], ["Figures S4A", "GENE_OR_GENE_PRODUCT", 180, 191], ["S4B", "GENE_OR_GENE_PRODUCT", 196, 199], ["mitokines", "GENE_OR_GENE_PRODUCT", 207, 216], ["Y cells", "CELL_TYPE", 95, 102], ["humanin", "PROTEIN", 156, 163], ["prohibitin", "PROTEIN", 168, 178], ["S4A", "PROTEIN", 188, 191], ["S4B", "PROTEIN", 196, 199], ["Metformin", "TREATMENT", 0, 9], ["autophagy", "PROBLEM", 47, 56], ["humanin", "TREATMENT", 156, 163], ["prohibitin", "TREATMENT", 168, 178], ["inflammation", "PROBLEM", 231, 243], ["decreases", "OBSERVATION_MODIFIER", 143, 152], ["inflammation", "OBSERVATION", 231, 243]]], ["We conclude that mitochondrial turnover is defective in CD4 + T cells from older people, and that this defect, but not age-related declines in mitokines, is neutralized by metformin.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismTo test the clinical significance of our in vitro demonstration that metformin improves CD4 + T cell autophagy, we collected cells from obese, pre-diabetes subjects (Table S2) before and 3 months after clinically indicated metformin (1,000 mg/ day).", [["mitochondrial", "ANATOMY", 17, 30], ["CD4 + T cells", "ANATOMY", 56, 69], ["CD4 + T Cell", "ANATOMY", 207, 219], ["CD4 + T cell", "ANATOMY", 376, 388], ["cells", "ANATOMY", 413, 418], ["metformin", "CHEMICAL", 172, 181], ["Metformin", "CHEMICAL", 259, 268], ["metformin", "CHEMICAL", 357, 366], ["pre-diabetes", "DISEASE", 431, 443], ["metformin", "CHEMICAL", 511, 520], ["metformin", "CHEMICAL", 172, 181], ["Metformin", "CHEMICAL", 259, 268], ["metformin", "CHEMICAL", 357, 366], ["metformin", "CHEMICAL", 511, 520], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["people", "ORGANISM", 81, 87], ["mitokines", "GENE_OR_GENE_PRODUCT", 143, 152], ["metformin", "SIMPLE_CHEMICAL", 172, 181], ["CD4", "GENE_OR_GENE_PRODUCT", 207, 210], ["Metformin", "SIMPLE_CHEMICAL", 259, 268], ["metformin", "SIMPLE_CHEMICAL", 357, 366], ["CD4", "GENE_OR_GENE_PRODUCT", 376, 379], ["cells", "CELL", 413, 418], ["metformin", "SIMPLE_CHEMICAL", 511, 520], ["CD4", "PROTEIN", 56, 59], ["T cells", "CELL_TYPE", 62, 69], ["CD4", "PROTEIN", 207, 210], ["CD4", "PROTEIN", 376, 379], ["people", "SPECIES", 81, 87], ["mitochondrial turnover", "PROBLEM", 17, 39], ["this defect", "PROBLEM", 98, 109], ["mitokines", "TREATMENT", 143, 152], ["metformin", "TREATMENT", 172, 181], ["A Th17 Profile", "TEST", 182, 196], ["CD4", "TEST", 207, 210], ["a Metformin", "TREATMENT", 257, 268], ["metformin", "TREATMENT", 357, 366], ["CD4", "TEST", 376, 379], ["T cell autophagy", "PROBLEM", 382, 398], ["obese", "PROBLEM", 424, 429], ["pre-diabetes subjects", "PROBLEM", 431, 452], ["metformin", "TREATMENT", 511, 520], ["defect", "OBSERVATION", 103, 109], ["Cell", "OBSERVATION", 215, 219], ["cell autophagy", "OBSERVATION", 384, 398]]], ["Metformin activated autophagy in purified CD4 + T cells from these subjects, after cells were stimulated (without additional metformin) ex vivo, as indicated by more LC3II and multiple indicators of organelle clearance (less m-aconitase and GRP78, indicating mitochondrial and endoplasmic reticulum [ER] clearance; Figures 4M-4O ).", [["CD4 + T cells", "ANATOMY", 42, 55], ["cells", "ANATOMY", 83, 88], ["organelle", "ANATOMY", 199, 208], ["mitochondrial", "ANATOMY", 259, 272], ["endoplasmic reticulum", "ANATOMY", 277, 298], ["ER", "ANATOMY", 300, 302], ["Metformin", "CHEMICAL", 0, 9], ["metformin", "CHEMICAL", 125, 134], ["Metformin", "CHEMICAL", 0, 9], ["metformin", "CHEMICAL", 125, 134], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["cells", "CELL", 83, 88], ["metformin", "SIMPLE_CHEMICAL", 125, 134], ["LC3II", "SIMPLE_CHEMICAL", 166, 171], ["organelle", "CELLULAR_COMPONENT", 199, 208], ["GRP78", "GENE_OR_GENE_PRODUCT", 241, 246], ["mitochondrial", "CELLULAR_COMPONENT", 259, 272], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 277, 298], ["ER", "GENE_OR_GENE_PRODUCT", 300, 302], ["CD4", "PROTEIN", 42, 45], ["T cells", "CELL_TYPE", 48, 55], ["LC3II", "PROTEIN", 166, 171], ["m-aconitase", "PROTEIN", 225, 236], ["GRP78", "PROTEIN", 241, 246], ["Metformin", "TREATMENT", 0, 9], ["T cells", "PROBLEM", 48, 55], ["metformin", "TREATMENT", 125, 134], ["organelle clearance", "TEST", 199, 218], ["GRP78", "TEST", 241, 246], ["mitochondrial and endoplasmic reticulum", "PROBLEM", 259, 298], ["endoplasmic reticulum", "OBSERVATION", 277, 298]]], ["These data indicate that metformin intervention in older subjects is likely to improve autophagy and autophagy-downstream effects of aging on CD4 + T cells.A Th17 Profile Dominates CD4 + T Cell Function from Older Subjects through a Metformin-Sensitive MechanismTo begin testing the possibility that metformin-sensitive defects in autophagy, alone or in combination with fundamental changes in mitochondria, fuel Th17 inflammaging, we activated CD4 + T cells from Y subjects in the presence of the autophagy activator trehalose, or the fatty acid oxidation inhibitor trimetazidine (to induce partial mitochondrial dysfunction), alone or in combination.", [["CD4 + T cells", "ANATOMY", 142, 155], ["CD4 + T Cell", "ANATOMY", 181, 193], ["mitochondria", "ANATOMY", 394, 406], ["CD4 + T cells", "ANATOMY", 445, 458], ["mitochondrial", "ANATOMY", 600, 613], ["metformin", "CHEMICAL", 25, 34], ["Metformin", "CHEMICAL", 233, 242], ["metformin", "CHEMICAL", 300, 309], ["trehalose", "CHEMICAL", 518, 527], ["fatty acid", "CHEMICAL", 536, 546], ["trimetazidine", "CHEMICAL", 567, 580], ["mitochondrial dysfunction", "DISEASE", 600, 625], ["metformin", "CHEMICAL", 25, 34], ["Metformin", "CHEMICAL", 233, 242], ["metformin", "CHEMICAL", 300, 309], ["trehalose", "CHEMICAL", 518, 527], ["fatty acid", "CHEMICAL", 536, 546], ["trimetazidine", "CHEMICAL", 567, 580], ["metformin", "SIMPLE_CHEMICAL", 25, 34], ["CD4", "GENE_OR_GENE_PRODUCT", 142, 145], ["CD4", "GENE_OR_GENE_PRODUCT", 181, 184], ["Metformin", "SIMPLE_CHEMICAL", 233, 242], ["metformin", "SIMPLE_CHEMICAL", 300, 309], ["mitochondria", "CELLULAR_COMPONENT", 394, 406], ["CD4", "GENE_OR_GENE_PRODUCT", 445, 448], ["trehalose", "SIMPLE_CHEMICAL", 518, 527], ["fatty acid", "SIMPLE_CHEMICAL", 536, 546], ["trimetazidine", "SIMPLE_CHEMICAL", 567, 580], ["mitochondrial", "CELLULAR_COMPONENT", 600, 613], ["CD4 + T cells", "CELL_TYPE", 142, 155], ["CD4", "PROTEIN", 181, 184], ["CD4", "PROTEIN", 445, 448], ["T cells", "CELL_TYPE", 451, 458], ["metformin intervention", "TREATMENT", 25, 47], ["autophagy", "PROBLEM", 87, 96], ["autophagy", "PROBLEM", 101, 110], ["CD4 + T cells", "PROBLEM", 142, 155], ["A Th17 Profile", "TEST", 156, 170], ["CD4", "TEST", 181, 184], ["a Metformin", "TREATMENT", 231, 242], ["metformin", "TREATMENT", 300, 309], ["sensitive defects in autophagy", "PROBLEM", 310, 340], ["fundamental changes in mitochondria", "PROBLEM", 371, 406], ["the autophagy activator trehalose", "TREATMENT", 494, 527], ["the fatty acid oxidation inhibitor trimetazidine", "TREATMENT", 532, 580], ["partial mitochondrial dysfunction", "PROBLEM", 592, 625], ["likely to", "UNCERTAINTY", 69, 78], ["mitochondrial dysfunction", "OBSERVATION", 600, 625]]], ["Trimetazidine increased production of the Th17 cytokines IL-17A/F, IL-21, and IL-23 as previously reported in peripheral blood mononuclear cells (PBMCs) (Nicholas et al., 2019) , although, in contrast to PBMCs, trimetazidine also activated Th1 cytokine production by CD4 + T cells (Figures 5A and S4C-S4E).", [["peripheral blood mononuclear cells", "ANATOMY", 110, 144], ["PBMCs", "ANATOMY", 146, 151], ["PBMCs", "ANATOMY", 204, 209], ["CD4 + T cells", "ANATOMY", 267, 280], ["Trimetazidine", "CHEMICAL", 0, 13], ["trimetazidine", "CHEMICAL", 211, 224], ["Trimetazidine", "CHEMICAL", 0, 13], ["trimetazidine", "CHEMICAL", 211, 224], ["Trimetazidine", "SIMPLE_CHEMICAL", 0, 13], ["IL-17A", "GENE_OR_GENE_PRODUCT", 57, 63], ["F", "GENE_OR_GENE_PRODUCT", 64, 65], ["IL-21", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL-23", "GENE_OR_GENE_PRODUCT", 78, 83], ["peripheral blood mononuclear cells", "CELL", 110, 144], ["PBMCs", "CELL", 146, 151], ["PBMCs", "CELL", 204, 209], ["trimetazidine", "SIMPLE_CHEMICAL", 211, 224], ["Th1", "GENE_OR_GENE_PRODUCT", 240, 243], ["CD4", "GENE_OR_GENE_PRODUCT", 267, 270], ["S4C", "GENE_OR_GENE_PRODUCT", 297, 300], ["Th17 cytokines", "PROTEIN", 42, 56], ["IL", "PROTEIN", 57, 59], ["IL-23", "PROTEIN", 78, 83], ["peripheral blood mononuclear cells", "CELL_TYPE", 110, 144], ["PBMCs", "CELL_TYPE", 146, 151], ["PBMCs", "CELL_TYPE", 204, 209], ["Th1 cytokine", "PROTEIN", 240, 252], ["CD4", "PROTEIN", 267, 270], ["T cells", "CELL_TYPE", 273, 280], ["S4C", "PROTEIN", 297, 300], ["S4E", "PROTEIN", 301, 304], ["Trimetazidine", "TREATMENT", 0, 13], ["the Th17 cytokines IL", "TEST", 38, 59], ["IL", "TEST", 67, 69], ["IL", "TEST", 78, 80], ["PBMCs", "TEST", 204, 209], ["trimetazidine", "TREATMENT", 211, 224], ["Th1 cytokine production", "TEST", 240, 263], ["CD4", "TEST", 267, 270], ["Figures", "TEST", 282, 289], ["5A", "TEST", 290, 292], ["S4C", "TEST", 297, 300], ["peripheral", "ANATOMY_MODIFIER", 110, 120], ["blood", "ANATOMY", 121, 126], ["mononuclear cells", "OBSERVATION", 127, 144]]], ["Trehalose did not affect cytokine production, as expected from the inability of metformin or other manipulations to alter Y cells.", [["Y cells", "ANATOMY", 122, 129], ["Trehalose", "CHEMICAL", 0, 9], ["metformin", "CHEMICAL", 80, 89], ["Trehalose", "CHEMICAL", 0, 9], ["metformin", "CHEMICAL", 80, 89], ["Trehalose", "SIMPLE_CHEMICAL", 0, 9], ["metformin", "SIMPLE_CHEMICAL", 80, 89], ["Y cells", "CELL", 122, 129], ["cytokine", "PROTEIN", 25, 33], ["Y cells", "CELL_TYPE", 122, 129], ["Trehalose", "TREATMENT", 0, 9], ["cytokine production", "PROBLEM", 25, 44], ["metformin", "TREATMENT", 80, 89]]], ["However, trehalose partially blocked trimetazi-dine-activated cytokine production (Figures 5A and S4C-S4E), supporting the conclusion that autophagy improvement cannot entirely prevent inflammatory cytokine production by cells with compromised mitochondrial function.Genetic Disruption of Autophagy in T Cells from Y Subjects Recapitulates Traits of T Cells from O Subjects and Prevents Metformin-Mediated RepairTo more definitively test the possibility that metformin-mediated autophagy ameliorates age-related Th17 inflammation, we knocked down autophagy in CD4 + T cells from Y subjects using siRNA specific for autophagy related protein 3 (Atg3; Figure S5A).", [["cells", "ANATOMY", 221, 226], ["mitochondrial", "ANATOMY", 244, 257], ["T Cells", "ANATOMY", 302, 309], ["T Cells", "ANATOMY", 350, 357], ["Th17", "ANATOMY", 512, 516], ["CD4 + T cells", "ANATOMY", 560, 573], ["trehalose", "CHEMICAL", 9, 18], ["trimetazi-dine", "CHEMICAL", 37, 51], ["Metformin", "CHEMICAL", 387, 396], ["metformin", "CHEMICAL", 459, 468], ["inflammation", "DISEASE", 517, 529], ["trehalose", "CHEMICAL", 9, 18], ["trimetazi-dine", "CHEMICAL", 37, 51], ["Metformin", "CHEMICAL", 387, 396], ["metformin", "CHEMICAL", 459, 468], ["trehalose", "SIMPLE_CHEMICAL", 9, 18], ["trimetazi-dine", "SIMPLE_CHEMICAL", 37, 51], ["S4C-S4E", "GENE_OR_GENE_PRODUCT", 98, 105], ["cells", "CELL", 221, 226], ["mitochondrial", "CELLULAR_COMPONENT", 244, 257], ["T Cells", "CELL", 302, 309], ["T Cells", "CELL", 350, 357], ["Metformin", "SIMPLE_CHEMICAL", 387, 396], ["metformin", "SIMPLE_CHEMICAL", 459, 468], ["Th17", "CELL", 512, 516], ["CD4", "GENE_OR_GENE_PRODUCT", 560, 563], ["autophagy related protein 3", "GENE_OR_GENE_PRODUCT", 615, 642], ["Atg3; Figure S5A", "GENE_OR_GENE_PRODUCT", 644, 660], ["cytokine", "PROTEIN", 62, 70], ["S4C", "PROTEIN", 98, 101], ["S4E", "PROTEIN", 102, 105], ["cytokine", "PROTEIN", 198, 206], ["T Cells", "CELL_TYPE", 302, 309], ["T Cells", "CELL_TYPE", 350, 357], ["CD4", "PROTEIN", 560, 563], ["T cells", "CELL_TYPE", 566, 573], ["autophagy related protein 3", "PROTEIN", 615, 642], ["Atg3", "PROTEIN", 644, 648], ["Figure S5A", "PROTEIN", 650, 660], ["trehalose", "TEST", 9, 18], ["activated cytokine production", "TREATMENT", 52, 81], ["inflammatory cytokine production", "PROBLEM", 185, 217], ["compromised mitochondrial function", "PROBLEM", 232, 266], ["Autophagy in T Cells", "PROBLEM", 289, 309], ["Metformin", "TREATMENT", 387, 396], ["metformin", "TREATMENT", 459, 468], ["Th17 inflammation", "PROBLEM", 512, 529], ["T cells", "PROBLEM", 566, 573], ["siRNA", "TREATMENT", 596, 601], ["autophagy related protein", "PROBLEM", 615, 640], ["mitochondrial function", "OBSERVATION", 244, 266], ["Th17 inflammation", "OBSERVATION", 512, 529]]], ["Atg3 siRNA, but not scrambled siRNA, decreased LC3II and increased m-aconitase ( Figures S5B and S5C ), indicating compromised autophagy.", [["Atg3", "GENE_OR_GENE_PRODUCT", 0, 4], ["LC3II", "GENE_OR_GENE_PRODUCT", 47, 52], ["m-aconitase", "GENE_OR_GENE_PRODUCT", 67, 78], ["Figures S5B", "GENE_OR_GENE_PRODUCT", 81, 92], ["S5C", "GENE_OR_GENE_PRODUCT", 97, 100], ["LC3II", "PROTEIN", 47, 52], ["m-aconitase", "PROTEIN", 67, 78], ["S5C", "PROTEIN", 97, 100], ["Atg3 siRNA", "PROBLEM", 0, 10], ["scrambled siRNA", "PROBLEM", 20, 35], ["decreased LC3II", "PROBLEM", 37, 52], ["increased m-aconitase", "TREATMENT", 57, 78], ["compromised autophagy", "PROBLEM", 115, 136], ["compromised autophagy", "OBSERVATION", 115, 136]]], ["Atg3 knockdown in CD4 + T cells from Y subjects increased basal OCR, maximal OCR, OCR:ECAR ratio, and ROS to values indistinguishable from those of CD4 + T cells from O subjects ( Figures 5B-5D ). ll Article Furthermore, Atg3 knockdown in CD4 + T cells from Y subjects resulted in higher Th17 cytokine production (IL-17A, IL-17F, and IL-21) that was indistinguishable from Th17 cytokines produced by O cells ( Figure S5D ).", [["CD4 + T cells", "ANATOMY", 18, 31], ["CD4 + T cells", "ANATOMY", 148, 161], ["CD4 + T cells", "ANATOMY", 239, 252], ["O cells", "ANATOMY", 400, 407], ["Atg3", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD4", "GENE_OR_GENE_PRODUCT", 18, 21], ["OCR", "SIMPLE_CHEMICAL", 82, 85], ["ECAR", "SIMPLE_CHEMICAL", 86, 90], ["ROS", "SIMPLE_CHEMICAL", 102, 105], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["Atg3", "GENE_OR_GENE_PRODUCT", 221, 225], ["CD4", "GENE_OR_GENE_PRODUCT", 239, 242], ["IL-17A", "GENE_OR_GENE_PRODUCT", 314, 320], ["IL-17F", "GENE_OR_GENE_PRODUCT", 322, 328], ["IL-21", "GENE_OR_GENE_PRODUCT", 334, 339], ["Th17", "CELL", 373, 377], ["O cells", "CELL", 400, 407], ["Atg3", "PROTEIN", 0, 4], ["CD4", "PROTEIN", 18, 21], ["T cells", "CELL_TYPE", 24, 31], ["CD4", "PROTEIN", 148, 151], ["T cells", "CELL_TYPE", 154, 161], ["Atg3", "PROTEIN", 221, 225], ["CD4", "PROTEIN", 239, 242], ["T cells", "CELL_TYPE", 245, 252], ["Th17 cytokine", "PROTEIN", 288, 301], ["Th17 cytokines", "PROTEIN", 373, 387], ["O cells", "CELL_TYPE", 400, 407], ["Atg3 knockdown", "TEST", 0, 14], ["CD4", "TEST", 18, 21], ["Y subjects", "TEST", 37, 47], ["increased basal OCR", "PROBLEM", 48, 67], ["maximal OCR", "TEST", 69, 80], ["ECAR ratio", "TEST", 86, 96], ["CD4", "TEST", 148, 151], ["Atg3 knockdown", "TEST", 221, 235], ["CD4", "TEST", 239, 242], ["Y subjects", "TEST", 258, 268], ["higher Th17 cytokine production", "PROBLEM", 281, 312], ["IL", "TEST", 314, 316], ["IL", "TEST", 322, 324], ["IL", "TEST", 334, 336], ["Th17 cytokines", "PROBLEM", 373, 387], ["basal OCR", "OBSERVATION", 58, 67], ["higher", "OBSERVATION_MODIFIER", 281, 287], ["Th17 cytokine", "OBSERVATION", 288, 301]]], ["CCL-20 and GMCSF, two cytokines produced by both Th17 and Th1 cells, increased with Atg3 knockdown ( Figure S5D ).", [["Th17", "ANATOMY", 49, 53], ["Th1 cells", "ANATOMY", 58, 67], ["CCL-20", "GENE_OR_GENE_PRODUCT", 0, 6], ["GMCSF", "GENE_OR_GENE_PRODUCT", 11, 16], ["Th17", "CELL", 49, 53], ["Th1 cells", "CELL", 58, 67], ["Atg3", "GENE_OR_GENE_PRODUCT", 84, 88], ["CCL-20", "PROTEIN", 0, 6], ["GMCSF", "PROTEIN", 11, 16], ["cytokines", "PROTEIN", 22, 31], ["Th17", "CELL_TYPE", 49, 53], ["Th1 cells", "CELL_TYPE", 58, 67], ["Atg3", "PROTEIN", 84, 88], ["CCL", "TEST", 0, 3], ["GMCSF", "TEST", 11, 16], ["two cytokines", "TEST", 18, 31], ["Atg3 knockdown", "TREATMENT", 84, 98], ["both", "ANATOMY_MODIFIER", 44, 48], ["Th17", "ANATOMY", 49, 53], ["Th1 cells", "OBSERVATION", 58, 67], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["Other cytokines generally produced by other CD4 + T cell subsets variably changed with knockdown ( Figure S5E ).", [["CD4 + T cell", "ANATOMY", 44, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["cytokines", "PROTEIN", 6, 15], ["CD4 + T cell subsets", "CELL_TYPE", 44, 64], ["Other cytokines", "PROBLEM", 0, 15], ["T cell subsets", "TREATMENT", 50, 64], ["cytokines", "OBSERVATION", 6, 15], ["cell subsets", "OBSERVATION", 52, 64]]], ["PLSDA analysis showed that Atg3 siRNA treatment of CD4 + T cells from Y subjects induced VIP cytokines that were very similar to the Th17 profile produced by cells from O subjects, and that the Th17 profile induced by siAtg3 was minimally changed by metformin ( Figures 5E-5H ; compare Figure 5F with Figure 1D ).Genetic Disruption of Autophagy in T Cells from Y Subjects Recapitulates Traits of T Cells from O Subjects and Prevents Metformin-Mediated RepairAutophagy blockade with Atg3-knockdown increased mitochondrial ROS in CD4 + cells from Y subjects ( Figure 5I ).", [["CD4 + T cells", "ANATOMY", 51, 64], ["cells", "ANATOMY", 158, 163], ["T Cells", "ANATOMY", 348, 355], ["T Cells", "ANATOMY", 396, 403], ["mitochondrial", "ANATOMY", 507, 520], ["CD4 + cells", "ANATOMY", 528, 539], ["Atg3", "CHEMICAL", 27, 31], ["siAtg3", "CHEMICAL", 218, 224], ["metformin", "CHEMICAL", 250, 259], ["Metformin", "CHEMICAL", 433, 442], ["ROS", "CHEMICAL", 521, 524], ["metformin", "CHEMICAL", 250, 259], ["Metformin", "CHEMICAL", 433, 442], ["Atg3", "GENE_OR_GENE_PRODUCT", 27, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 51, 54], ["VIP", "GENE_OR_GENE_PRODUCT", 89, 92], ["cells", "CELL", 158, 163], ["siAtg3", "SIMPLE_CHEMICAL", 218, 224], ["metformin", "SIMPLE_CHEMICAL", 250, 259], ["T Cells", "CELL", 348, 355], ["T Cells", "CELL", 396, 403], ["Metformin", "SIMPLE_CHEMICAL", 433, 442], ["RepairAutophagy", "SIMPLE_CHEMICAL", 452, 467], ["Atg3", "GENE_OR_GENE_PRODUCT", 482, 486], ["mitochondrial", "CELLULAR_COMPONENT", 507, 520], ["ROS", "SIMPLE_CHEMICAL", 521, 524], ["CD4", "PROTEIN", 51, 54], ["T cells", "CELL_TYPE", 57, 64], ["VIP cytokines", "PROTEIN", 89, 102], ["T Cells", "CELL_TYPE", 348, 355], ["T Cells", "CELL_TYPE", 396, 403], ["Atg3", "PROTEIN", 482, 486], ["CD4", "PROTEIN", 528, 531], ["PLSDA analysis", "TEST", 0, 14], ["Atg3 siRNA treatment", "TREATMENT", 27, 47], ["CD4 + T cells", "PROBLEM", 51, 64], ["Y subjects", "PROBLEM", 70, 80], ["VIP cytokines", "TEST", 89, 102], ["metformin", "TREATMENT", 250, 259], ["Autophagy in T Cells", "PROBLEM", 335, 355], ["Metformin", "TREATMENT", 433, 442], ["Mediated RepairAutophagy blockade", "TREATMENT", 443, 476], ["Atg3", "TREATMENT", 482, 486], ["increased mitochondrial ROS", "PROBLEM", 497, 524], ["mitochondrial ROS", "OBSERVATION", 507, 524]]], ["Given that ROS mitigation is a major action of metformin, we tested the impact of MitoTempo, a mitochondrial ROS-specific scavenger, on mitochondrial ROS in Atg3-knockdown cells.", [["mitochondrial", "ANATOMY", 95, 108], ["mitochondrial", "ANATOMY", 136, 149], ["cells", "ANATOMY", 172, 177], ["ROS", "CHEMICAL", 11, 14], ["metformin", "CHEMICAL", 47, 56], ["MitoTempo", "CHEMICAL", 82, 91], ["ROS", "CHEMICAL", 109, 112], ["ROS", "CHEMICAL", 150, 153], ["metformin", "CHEMICAL", 47, 56], ["MitoTempo", "CHEMICAL", 82, 91], ["ROS", "SIMPLE_CHEMICAL", 11, 14], ["metformin", "SIMPLE_CHEMICAL", 47, 56], ["MitoTempo", "SIMPLE_CHEMICAL", 82, 91], ["mitochondrial", "CELLULAR_COMPONENT", 95, 108], ["ROS", "SIMPLE_CHEMICAL", 109, 112], ["mitochondrial", "CELLULAR_COMPONENT", 136, 149], ["ROS", "SIMPLE_CHEMICAL", 150, 153], ["Atg3", "GENE_OR_GENE_PRODUCT", 157, 161], ["cells", "CELL", 172, 177], ["Atg3-knockdown cells", "CELL_LINE", 157, 177], ["metformin", "TREATMENT", 47, 56], ["MitoTempo", "TREATMENT", 82, 91], ["a mitochondrial ROS", "TEST", 93, 112], ["mitochondrial ROS", "TEST", 136, 153], ["knockdown cells", "OBSERVATION", 162, 177]]], ["Mito-Tempo added 3 h after aCD3/aCD28 stimulation decreased mitochondrial ROS of Atg3-knockdown cells to baseline levels ( Figure 5I ) and had no effect on activation of Th17-associated cytokines in the absence of autophagy ( Figure 5J ).", [["mitochondrial", "ANATOMY", 60, 73], ["cells", "ANATOMY", 96, 101], ["Mito-Tempo", "CHEMICAL", 0, 10], ["ROS", "CHEMICAL", 74, 77], ["aCD3", "GENE_OR_GENE_PRODUCT", 27, 31], ["aCD28", "GENE_OR_GENE_PRODUCT", 32, 37], ["mitochondrial", "CELLULAR_COMPONENT", 60, 73], ["ROS", "SIMPLE_CHEMICAL", 74, 77], ["Atg3", "GENE_OR_GENE_PRODUCT", 81, 85], ["cells", "CELL", 96, 101], ["Th17", "GENE_OR_GENE_PRODUCT", 170, 174], ["aCD3", "PROTEIN", 27, 31], ["aCD28", "PROTEIN", 32, 37], ["Atg3-knockdown cells", "CELL_LINE", 81, 101], ["Th17", "PROTEIN", 170, 174], ["cytokines", "PROTEIN", 186, 195], ["aCD3/aCD28 stimulation", "TREATMENT", 27, 49], ["mitochondrial ROS", "TEST", 60, 77], ["Atg3", "TEST", 81, 85], ["knockdown cells", "PROBLEM", 86, 101], ["baseline levels", "TEST", 105, 120]]], ["Addition of Mi-toTempo concurrent with stimulation resulted in cell death; thus, we cannot eliminate the possibility that an initial burst of mitochondrial ROS initiates measurable production of Th17 cytokines 40 h later.", [["cell", "ANATOMY", 63, 67], ["mitochondrial", "ANATOMY", 142, 155], ["Mi-toTempo", "CHEMICAL", 12, 22], ["death", "DISEASE", 68, 73], ["ROS", "CHEMICAL", 156, 159], ["Mi-toTempo", "CHEMICAL", 12, 22], ["Mi-toTempo", "SIMPLE_CHEMICAL", 12, 22], ["cell", "CELL", 63, 67], ["mitochondrial", "CELLULAR_COMPONENT", 142, 155], ["ROS", "SIMPLE_CHEMICAL", 156, 159], ["Th17 cytokines", "PROTEIN", 195, 209], ["Mi-toTempo", "TREATMENT", 12, 22], ["stimulation", "TREATMENT", 39, 50], ["cell death", "PROBLEM", 63, 73], ["mitochondrial ROS", "PROBLEM", 142, 159], ["Th17 cytokines", "TREATMENT", 195, 209], ["cell death", "OBSERVATION", 63, 73], ["mitochondrial ROS", "OBSERVATION", 142, 159]]], ["We conclude that mitochondrial ROS does not drive the Th17 signature in cells with compromised autophagy.Genetic Disruption of Autophagy in T Cells from Y Subjects Recapitulates Traits of T Cells from O Subjects and Prevents Metformin-Mediated RepairTaken together, our data suggest that age-related autophagy decline may activate Th17 inflammaging through a metforminsensitive mechanism.", [["mitochondrial", "ANATOMY", 17, 30], ["cells", "ANATOMY", 72, 77], ["T Cells", "ANATOMY", 140, 147], ["T Cells", "ANATOMY", 188, 195], ["ROS", "CHEMICAL", 31, 34], ["Metformin", "CHEMICAL", 225, 234], ["Metformin", "CHEMICAL", 225, 234], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["ROS", "SIMPLE_CHEMICAL", 31, 34], ["cells", "CELL", 72, 77], ["T Cells", "CELL", 140, 147], ["T Cells", "CELL", 188, 195], ["Metformin", "SIMPLE_CHEMICAL", 225, 234], ["Th17", "GENE_OR_GENE_PRODUCT", 331, 335], ["T Cells", "CELL_TYPE", 140, 147], ["T Cells", "CELL_TYPE", 188, 195], ["mitochondrial ROS", "PROBLEM", 17, 34], ["compromised autophagy", "PROBLEM", 83, 104], ["Autophagy in T Cells", "PROBLEM", 127, 147], ["Metformin", "TREATMENT", 225, 234], ["autophagy decline", "PROBLEM", 300, 317], ["Autophagy", "OBSERVATION_MODIFIER", 127, 136]]], ["Corroborating evidence for this model includes metformin-sensitive under-expression of PINK-1, a key regulator of mitochondrial autophagy (mitophagy; Geisler et al., 2010) , in CD4 + T cells from O compared with Y subjects (Figure S6A ).", [["mitochondrial", "ANATOMY", 114, 127], ["CD4 + T cells", "ANATOMY", 177, 190], ["metformin", "CHEMICAL", 47, 56], ["metformin", "CHEMICAL", 47, 56], ["metformin", "SIMPLE_CHEMICAL", 47, 56], ["PINK-1", "GENE_OR_GENE_PRODUCT", 87, 93], ["mitochondrial", "CELLULAR_COMPONENT", 114, 127], ["CD4", "GENE_OR_GENE_PRODUCT", 177, 180], ["PINK-1", "PROTEIN", 87, 93], ["CD4", "PROTEIN", 177, 180], ["T cells", "CELL_TYPE", 183, 190], ["metformin", "TREATMENT", 47, 56], ["PINK", "TEST", 87, 91], ["mitochondrial autophagy", "PROBLEM", 114, 137]]], ["We used PINK-1 knockdown in CD4 + T cell from Y subjects ( Figure S6B ) to determine whether compromised mitophagy, rather than general macroautophagy, was a critical driver of the (A) Th17-associated cytokine production by CD4 + T cells from Y subjects, with cells stimulated 40 h aCD3/aCD28 in the presence of trimetazidine, a fatty acid oxidation inhibitor; alone; or in combination with trehalose, an autophagy activator. n = 4. p < 0.05 versus Y by SHORE (Nicholas et al., 2017) (B) or one-way ANOVA (C and D). =p<0.05 v. Y and #=p<0.05 v. O by one-way ANOVA.", [["CD4 + T cell", "ANATOMY", 28, 40], ["CD4 + T cells", "ANATOMY", 224, 237], ["cells", "ANATOMY", 260, 265], ["trimetazidine", "CHEMICAL", 312, 325], ["fatty acid", "CHEMICAL", 329, 339], ["trehalose", "CHEMICAL", 391, 400], ["trimetazidine", "CHEMICAL", 312, 325], ["fatty acid", "CHEMICAL", 329, 339], ["trehalose", "CHEMICAL", 391, 400], ["PINK-1", "GENE_OR_GENE_PRODUCT", 8, 14], ["CD4", "GENE_OR_GENE_PRODUCT", 28, 31], ["Th17", "GENE_OR_GENE_PRODUCT", 185, 189], ["CD4", "GENE_OR_GENE_PRODUCT", 224, 227], ["cells", "CELL", 260, 265], ["aCD28", "GENE_OR_GENE_PRODUCT", 287, 292], ["trimetazidine", "SIMPLE_CHEMICAL", 312, 325], ["fatty acid", "SIMPLE_CHEMICAL", 329, 339], ["trehalose", "SIMPLE_CHEMICAL", 391, 400], ["PINK", "PROTEIN", 8, 12], ["CD4", "PROTEIN", 28, 31], ["cytokine", "PROTEIN", 201, 209], ["CD4", "PROTEIN", 224, 227], ["T cells", "CELL_TYPE", 230, 237], ["aCD3", "PROTEIN", 282, 286], ["aCD28", "PROTEIN", 287, 292], ["autophagy activator", "PROTEIN", 405, 424], ["PINK", "TEST", 8, 12], ["compromised mitophagy", "PROBLEM", 93, 114], ["cytokine production", "PROBLEM", 201, 220], ["cells", "TEST", 260, 265], ["trimetazidine", "TREATMENT", 312, 325], ["a fatty acid oxidation inhibitor", "TREATMENT", 327, 359], ["trehalose", "TREATMENT", 391, 400], ["an autophagy activator", "TREATMENT", 402, 424], ["PINK", "OBSERVATION_MODIFIER", 8, 12]]], ["Fold change is compared to Y. LC3II, (C) m-aconitase, and (D-E) cytokines (grouped according to dominant CD4 + T cell subset source) after genetic inhibition of autophagy by Atg3-targeted siRNA or control (scrambled) siRNA.", [["CD4 + T cell", "ANATOMY", 105, 117], ["(C) m-aconitase", "GENE_OR_GENE_PRODUCT", 37, 52], ["CD4", "GENE_OR_GENE_PRODUCT", 105, 108], ["Atg3", "GENE_OR_GENE_PRODUCT", 174, 178], ["Y. LC3II, (C) m-aconitase", "PROTEIN", 27, 52], ["cytokines", "PROTEIN", 64, 73], ["CD4", "PROTEIN", 105, 108], ["Atg3", "PROTEIN", 174, 178], ["Fold change", "PROBLEM", 0, 11], ["m-aconitase", "TEST", 41, 52], ["D-E) cytokines", "TREATMENT", 59, 73], ["T cell subset source", "PROBLEM", 111, 131], ["autophagy", "PROBLEM", 161, 170], ["change", "OBSERVATION", 5, 11], ["siRNA", "ANATOMY", 217, 222]]], ["In panels A-C N=5-9, with one representative Western blot shown.", [["A-C N", "TEST", 10, 15]]], ["In panels D&E N=8-9.", [["N", "TEST", 14, 15]]], ["Shown are avg. and SEM in all bar graphs. * p<0.05 vs. control siRNA treated T cells from Y subjects by one-way ANOVA.", [["T cells", "ANATOMY", 77, 84], ["T cells", "CELL", 77, 84], ["T cells", "CELL_TYPE", 77, 84], ["control siRNA treated T cells", "TREATMENT", 55, 84], ["avg", "OBSERVATION", 10, 13], ["SEM", "OBSERVATION", 19, 22]]], ["Fold change is compared to control siRNA.", [["Fold change", "PROBLEM", 0, 11], ["change", "OBSERVATION", 5, 11]]], ["(F&G) mitophagy as measured by TOM20/LAMP1 co-localization and quatification, respectively; (H) LC3II to indicate total autophagy; or (I) cytokines as indicated.", [["TOM20", "GENE_OR_GENE_PRODUCT", 31, 36], ["LAMP1", "GENE_OR_GENE_PRODUCT", 37, 42], ["TOM20", "PROTEIN", 31, 36], ["LAMP1", "PROTEIN", 37, 42], ["LC3II", "PROTEIN", 96, 101], ["cytokines", "PROTEIN", 138, 147], ["quatification", "TEST", 63, 76], ["total autophagy", "PROBLEM", 114, 129]]], ["In panel C, N=5, 3 cells/field and 4-5 fields/slide were imaged using 40X magnification in Zeiss microscope.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["panel C", "TEST", 3, 10], ["N", "TEST", 12, 13], ["cells/field", "TEST", 19, 30]]], ["One representative cell or Western blot is shown at the top of panels A,B,D,F,H. All bar graphs show avg. and SEM.", [["cell", "ANATOMY", 19, 23], ["cell", "CELL", 19, 23], ["B", "GENE_OR_GENE_PRODUCT", 72, 73], ["B", "PROTEIN", 72, 73], ["Western blot", "TEST", 27, 39], ["All bar graphs", "TEST", 81, 95], ["cell", "OBSERVATION", 19, 23], ["avg", "OBSERVATION", 101, 104], ["SEM", "OBSERVATION", 110, 113]]], ["3 cells/field and 2-3 fields/slide were imaged using 63X oil immersion for panels F and G. Subjects gave two samples for pre-vs post-metformin analysis.", [["cells", "ANATOMY", 2, 7], ["samples", "ANATOMY", 109, 116], ["cells", "CELL", 2, 7], ["Subjects", "ORGANISM", 91, 99], ["pre-vs post-metformin analysis", "TEST", 121, 151]]], ["The first sample was given before taking metformin (na\u00efve) and the second three months after metformin administration.", [["sample", "ANATOMY", 10, 16], ["metformin", "CHEMICAL", 41, 50], ["metformin", "CHEMICAL", 93, 102], ["metformin", "CHEMICAL", 41, 50], ["metformin", "CHEMICAL", 93, 102], ["metformin", "SIMPLE_CHEMICAL", 41, 50], ["metformin", "SIMPLE_CHEMICAL", 93, 102], ["metformin", "TREATMENT", 41, 50], ["metformin administration", "TREATMENT", 93, 117]]]], "7fd503fedde433097518106a86124c301d46c3ef": [["IntroductionCoronavirus disease is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly discovered coronavirus, which leads to respiratory illness and can be transmitted from person to person.", [["respiratory", "ANATOMY", 176, 187], ["Coronavirus disease", "DISEASE", 12, 31], ["infectious disease", "DISEASE", 38, 56], ["acute respiratory syndrome coronavirus", "DISEASE", 74, 112], ["coronavirus", "DISEASE", 148, 159], ["respiratory illness", "DISEASE", 176, 195], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 67, 114], ["SARS-CoV-2", "ORGANISM", 116, 126], ["coronavirus", "ORGANISM", 148, 159], ["CoV-2", "SPECIES", 121, 126], ["person", "SPECIES", 224, 230], ["person", "SPECIES", 234, 240], ["severe acute respiratory syndrome coronavirus", "SPECIES", 67, 112], ["SARS-CoV-2", "SPECIES", 116, 126], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["an infectious disease", "PROBLEM", 35, 56], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 67, 112], ["SARS-CoV", "TEST", 116, 124], ["a newly discovered coronavirus", "PROBLEM", 129, 159], ["respiratory illness", "PROBLEM", 176, 195], ["Coronavirus disease", "OBSERVATION", 12, 31], ["infectious", "OBSERVATION_MODIFIER", 38, 48], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["respiratory syndrome", "OBSERVATION", 80, 100], ["coronavirus", "OBSERVATION", 148, 159], ["respiratory illness", "OBSERVATION", 176, 195]]], ["Ever since December 2019, when the first case of COVID-19 in Wuhan, P. R. China (or mainland China) was reported, the novel coronavirus has hit most of the countries in the world, with the United States (U.S.) being the one having the largest number of confirmed cases (Worldometer, 2020) .", [["coronavirus", "DISEASE", 124, 135], ["coronavirus", "ORGANISM", 124, 135], ["COVID", "TEST", 49, 54]]], ["As of May 9, 2020, the WHO has reported a total of 3,855,788 confirmed cases all over the world and the total number of deaths has reached 265,862.IntroductionThe COVID-19 pandemic has significant negative impacts on both the global health and the economy.", [["deaths", "DISEASE", 120, 126], ["The COVID", "TEST", 159, 168], ["significant", "OBSERVATION_MODIFIER", 185, 196], ["negative", "OBSERVATION", 197, 205], ["impacts", "OBSERVATION_MODIFIER", 206, 213]]], ["In the U.S., for example, the unemployment rate has jumped up to 14.7% in April, 2020, reaching the highest rate and the largest monthly increase since January 1948 (U.S. Bureau of Labor Statistics, https://www.bls.gov/bls/newsrels.htm).", [["the unemployment rate", "TEST", 26, 47], ["largest", "OBSERVATION_MODIFIER", 121, 128]]], ["Continuous efforts have been made by every country in the world to slow the spread of the disease and mitigate the associated negative impacts on various aspects of the society.IntroductionSo far, great amount of scientific research has been conducted on COVID-19, ranging from ongoing clinical trials that evaluate potential treatments to statistical analyses on the characteristics of this infectious disease.", [["infectious disease", "DISEASE", 392, 410], ["the disease", "PROBLEM", 86, 97], ["COVID", "TEST", 255, 260], ["potential treatments", "TREATMENT", 316, 336], ["this infectious disease", "PROBLEM", 387, 410], ["disease", "OBSERVATION", 90, 97], ["negative", "OBSERVATION", 126, 134], ["impacts", "OBSERVATION_MODIFIER", 135, 142], ["great", "OBSERVATION_MODIFIER", 197, 202], ["amount", "OBSERVATION_MODIFIER", 203, 209], ["infectious", "OBSERVATION", 392, 402]]], ["With more and more COVID-19 data and studies available, it is vitally important to aggregate the information and pool the statistical findings.", [["studies", "TEST", 37, 44]]], ["Hence, here we conduct a meta-analysis based on published studies of the COVID-19 outbreak in mainland China.IntroductionOur meta-analysis that accounts for between-study heterogeneity concentrates on four common epidemic metrics that characterize the transmission of the COVID-19:Introduction1.", [["a meta-analysis", "TEST", 23, 38], ["published studies", "TEST", 48, 65], ["the COVID", "TEST", 69, 78], ["IntroductionOur meta-analysis", "TEST", 109, 138], ["Introduction1", "TREATMENT", 281, 294]]], ["Basic reproduction number : Often referred to as R 0 , the basic reproduction number measures the contagiousness or transmissibility of infectious agents and is interpreted as the expected number of infections caused directly by one case in a completely susceptible population.Introductionof the quarantine period.Introduction3.", [["infections", "DISEASE", 199, 209], ["infectious agents", "TREATMENT", 136, 153], ["infections", "PROBLEM", 199, 209], ["infectious", "OBSERVATION", 136, 146], ["infections", "OBSERVATION", 199, 209], ["quarantine period", "OBSERVATION", 296, 313]]], ["Serial interval : Defined as the time between the start of symptoms in the primary patient (infector) and onset of symptoms in the patient being infected by the infector (the infectee), the serial interval is critical in the calculation of R 0 .Epidemic doubling time:This metric measures the period of time needed for the total number of cases in the epidemic to double, and is an important factor that reflects the speed at which the COVID-19 is spreading.Epidemic doubling time:The rest of this manuscript is organized as follows.", [["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 131, 138], ["symptoms", "PROBLEM", 59, 67], ["symptoms", "PROBLEM", 115, 123], ["infected", "OBSERVATION", 145, 153], ["spreading", "OBSERVATION_MODIFIER", 448, 457]]], ["Then in Section 3, we introduce the key ingredients for a meta-analysis, where the modeling and estimation methods are outlined.", [["a meta-analysis", "TEST", 56, 71]]], ["Statistical results from the meta-analysis are reported in Section 5, and sensitivity analysis is given in Section 6.", [["the meta-analysis", "TEST", 25, 42], ["sensitivity analysis", "TEST", 74, 94]]], ["Concluding remarks are then disclosed in Section 7.Study selectionWe conduct a comprehensive literature screening for the articles published on scientific journals (including early versions) or preprint platforms like medRxiv and bioRxiv.", [["Study selectionWe", "TEST", 51, 68], ["a comprehensive literature screening", "TEST", 77, 113], ["early versions", "TREATMENT", 175, 189], ["preprint platforms", "TREATMENT", 194, 212], ["medRxiv", "TREATMENT", 218, 225], ["bioRxiv", "TREATMENT", 230, 237], ["med", "ANATOMY", 218, 221]]], ["The key words of our searching are COVID-19 (SARS-CoV-2 or 2019-nCOV), the epidemic characteristics of interest (basic reproduction number, incubation period, serial interval and epidemic doubling time), and China, where the selection criteria is relaxed for regional labels.", [["COVID", "TEST", 35, 40], ["CoV", "TEST", 50, 53]]], ["Specifically, we include the studies on the whole country of China, China except for Hubei province (when the city of Wuhan is located), a list of provinces and municipalities, a collection of cities or even a specific region, in order to increase the sample size and the potential statistical power.", [["the studies", "TEST", 25, 36], ["size", "OBSERVATION_MODIFIER", 259, 263]]], ["The variability and heterogeneity across the selected studies are accounted when adopting appropriate methodologies in the meta-analysis.Study selectionIn addition, we only include the studies reporting unambiguous estimates and the associated 95% confidence intervals or standard deviations.", [["the selected studies", "TEST", 41, 61], ["Study selection", "TEST", 137, 152], ["the studies", "TEST", 181, 192], ["standard deviations", "PROBLEM", 272, 291], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["heterogeneity", "OBSERVATION_MODIFIER", 20, 33]]], ["If the standard deviation of an estimator is given, we calculate the 95% confidence interval under the assumption of normal approximation provided that the fitted model is valid.", [["normal", "OBSERVATION", 117, 123]]], ["This selection criterion is needed to ensure the consistency of analysis results.Study selectionSome studies included here provide more than one estimates that are obtained from various methods or models.", [["This selection criterion", "TEST", 0, 24], ["Study selectionSome studies", "TEST", 81, 108]]], ["For those studies, we select one estimate and its associated confidence interval in our analysis.", [["those studies", "TEST", 4, 17], ["our analysis", "TEST", 84, 96]]], ["We illustrate our choices and the corresponding reasons in details in Section 5.Meta-analysisMeta-analysis is a statistical procedure aiming to combine scientific results from multiple comparable studies or trials.", [["a statistical procedure", "TREATMENT", 110, 133], ["multiple comparable studies", "TEST", 176, 203]]], ["It is one of the most popular analytical tools in the statistical analysis, which derives a pooled estimate by aggregating relevant information, thus increasing the statistical power.", [["the statistical analysis", "TEST", 50, 74]]], ["In particular, when comparing different studies addressing the same question, the crux is to measure the standardized difference across various results, i.e. the effect size.", [["different studies", "TEST", 30, 47], ["effect", "OBSERVATION_MODIFIER", 162, 168], ["size", "OBSERVATION_MODIFIER", 169, 173]]], ["In this sense, we rely on meta-analysis to improve the estimates of the effect size of an intervention or an association and examine variability to detect inconsistent results across studies.Meta-analysisIn general, there are two methods to pool effect sizes from multiple studies: the fixed-effects model (FEM) and the random-effects model (REM).", [["meta-analysis", "TREATMENT", 26, 39], ["an intervention", "TREATMENT", 87, 102], ["multiple studies", "TEST", 264, 280], ["the fixed-effects model (FEM)", "TREATMENT", 282, 311], ["size", "OBSERVATION_MODIFIER", 79, 83], ["sizes", "OBSERVATION_MODIFIER", 253, 258], ["FEM", "ANATOMY", 307, 310]]], ["A FEM assumes all included studies come from the same population, whereas a REM is constructed based on the assumption that data collected comes from different population.", [["A FEM assumes", "TEST", 0, 13], ["studies", "TEST", 27, 34], ["FEM", "ANATOMY", 2, 5]]], ["Although we restrict our searching of COVID-19 research with data only from mainland China, difference in the population may still exist, due to possible variations in the data samples as well as sampling errors.", [["COVID", "TEST", 38, 43], ["variations in the data samples", "PROBLEM", 154, 184], ["sampling errors", "TEST", 196, 211]]], ["Hence, we choose to adopt the REM in our analysis.Meta-analysisLet k index the selected studies and Y k be the estimator of the k-th study.", [["our analysis", "TEST", 37, 49], ["Meta-analysis", "TEST", 50, 63], ["the selected studies", "TEST", 75, 95], ["Y k", "TEST", 100, 103], ["the k-th study", "TEST", 124, 138]]], ["A REM assumes a normal-normal hierarchical model:Meta-analysisHere \u03b8 k is the parameter of interest, and s 2 k is the variance of Y k .", [["REM", "OBSERVATION", 2, 5]]], ["The hyper-parameters \u00b5 and \u03c4 2 correspond to the true effect and the across-study variance that reflects heterogeneity of the population, respectively.Meta-analysisThe inference for REM is done sequentially: we first estimate the heterogeneity variance \u03c4 2 (denoted as\u03c4 2 ), then with\u03c4 2 given, we obtain estimates of the effect \u00b5.", [["The hyper-parameters \u00b5 and \u03c4 2", "PROBLEM", 0, 30], ["the across-study variance", "TEST", 65, 90], ["the heterogeneity variance", "PROBLEM", 226, 252], ["hyper", "OBSERVATION", 4, 9], ["true effect", "OBSERVATION", 49, 60], ["heterogeneity", "OBSERVATION_MODIFIER", 105, 118], ["population", "OBSERVATION_MODIFIER", 126, 136]]], ["There are a variety of estimation methods for \u03c4 2 ; see Veroniki et al. (2016) for a concise survey.", [["variety", "OBSERVATION_MODIFIER", 12, 19]]], ["We adopt the Hartung-Knapp-Sidik-Jonkman (HKSJ) method (Hartung and Knapp, 2001; Sidik and Jonkman, 2002) , which is shown to be more robust when the number of studies is small and there is a substantial heterogeneity in the population.Meta-analysisGiven\u03c4 2 , the conditional maximum-likelihood of effect estimate become\u015dMeta-analysiswhere the weights are specified asMeta-analysisThen we use the normal approximation to construct confidence intervals, where the standard deviation of\u03bc is given b\u01775.", [["b\u01775", "PROTEIN", 495, 498], ["a substantial heterogeneity in the population", "PROBLEM", 190, 235], ["small", "OBSERVATION_MODIFIER", 171, 176], ["substantial", "OBSERVATION_MODIFIER", 192, 203], ["heterogeneity", "OBSERVATION", 204, 217]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)5Later in Section 5, we also provide prediction intervals, which are equally significant components in a meta-analysis.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["a meta-analysis", "TEST", 305, 320], ["med", "ANATOMY", 105, 108]]], ["In the presence of a substantial across-study heterogeneity, prediction intervals are preferred as they not only quantitatively provide a range for the effect size of a new study, but also measure the uncertainty of the estimate in a way that acknowledges the heterogeneity.Epidemic characteristicsIn this section, we briefly introduce the epidemic characteristics that are investigated in this manuscript.Epidemic characteristicsBasic reproduction number In epidemiology, the basic reproduction number, denoted R 0 , is the expected number of cases caused by one case in a completely susceptible population.", [["a substantial across-study heterogeneity", "PROBLEM", 19, 59], ["a new study", "TEST", 167, 178], ["substantial", "OBSERVATION_MODIFIER", 21, 32], ["across", "OBSERVATION_MODIFIER", 33, 39], ["size", "OBSERVATION_MODIFIER", 159, 163], ["new", "OBSERVATION_MODIFIER", 169, 172], ["heterogeneity", "OBSERVATION", 260, 273]]], ["It is a critical metric to describe the contagiousness or transmissibility of infectious diseases (Delamater et al., 2019) .", [["contagiousness", "DISEASE", 40, 54], ["infectious diseases", "DISEASE", 78, 97], ["infectious diseases", "PROBLEM", 78, 97], ["infectious", "OBSERVATION_MODIFIER", 78, 88]]], ["The estimation of R 0 is primarily based on compartmental models, where the susceptible-infectious-recovered (SIR) model and its extensions are the most commonly used.", [["infectious", "OBSERVATION", 88, 98]]], ["For the users of statistical software R, the package R0 includes most standard methods for the estimation of R 0 .Epidemic characteristicsSince the outbreak of COVID-19, R 0 has been one of the most critical metrics receiving substantial interest in the community, as it provides a basic benchmark (with threshold 1) to define a pandemic.", [["R 0", "GENE_OR_GENE_PRODUCT", 170, 173], ["the package R0", "TREATMENT", 41, 55], ["COVID", "TEST", 160, 165], ["a pandemic", "PROBLEM", 327, 337], ["substantial", "OBSERVATION_MODIFIER", 226, 237], ["interest", "OBSERVATION", 238, 246], ["pandemic", "OBSERVATION", 329, 337]]], ["Besides, R 0 helps indicating the potential severity of an epidemic outbreak.", [["an epidemic outbreak", "PROBLEM", 56, 76], ["epidemic", "OBSERVATION_MODIFIER", 59, 67], ["outbreak", "OBSERVATION", 68, 76]]], ["It is evident that R 0 is closely related to the fraction of the number of infected individuals out of a population once the outbreak ends (Holme and Masuda, 2015) .", [["R 0", "GENE_OR_GENE_PRODUCT", 19, 22], ["number", "OBSERVATION_MODIFIER", 65, 71], ["infected", "OBSERVATION", 75, 83]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["R 0 is an indispensable component when estimating the effective reproduction numbers (denoted as R t ), which are often used to assess the effectiveness of the intervention procedure to mitigate the spread of an epidemic.(which was not certified by peer review)Incubation period The second characteristic that we investigate here is the incubation period.", [["an indispensable component", "PROBLEM", 7, 33], ["the intervention procedure", "TREATMENT", 156, 182], ["indispensable", "OBSERVATION_MODIFIER", 10, 23], ["component", "OBSERVATION_MODIFIER", 24, 33], ["effective", "OBSERVATION_MODIFIER", 54, 63]]], ["The incubation period of an epidemic is the period from the time of the contact of a transmission source (susceptible or confirmed infector) and the time of symptom onset.", [["epidemic", "OBSERVATION", 28, 36]]], ["The incubation period provides important information during an outbreak, as it helps to determine when the infected individuals who are symptomatic are most likely to spread the disease, and signal necessary public health activities such as monitoring, surveillance and intervention.(which was not certified by peer review)From a statistical perspective, the incubation period is a crucial factor to model the current and future trends of an epidemic, as well as evaluate intervention strategies.", [["individuals", "ORGANISM", 116, 127], ["symptomatic", "PROBLEM", 136, 147], ["the disease", "PROBLEM", 174, 185], ["surveillance", "TEST", 253, 265], ["intervention", "TREATMENT", 270, 282], ["intervention strategies", "TREATMENT", 472, 495], ["most likely", "UNCERTAINTY", 152, 163]]], ["One of the biggest challenges of estimating the incubation period is that data are often coarsely observed, in addition to several other issues such as censoring and selection bias.", [["several other issues", "PROBLEM", 123, 143], ["censoring and selection bias", "PROBLEM", 152, 180], ["biggest", "OBSERVATION_MODIFIER", 11, 18]]], ["The estimation of incubation period is generally based on the methods developed in Reich et al. (2009) and the extensions.Serial intervalThe serial interval is defined as the time duration between the onset of symptoms in the primary patient and the onset of symptoms in the secondary patient who receives the disease from that primary one (Lipsitch et al., 2003) .", [["patient", "ORGANISM", 234, 241], ["patient", "ORGANISM", 285, 292], ["patient", "SPECIES", 234, 241], ["patient", "SPECIES", 285, 292], ["symptoms", "PROBLEM", 210, 218], ["symptoms", "PROBLEM", 259, 267], ["the disease", "PROBLEM", 306, 317]]], ["It is the sum of the latent period and the duration of infectiousness.", [["infectiousness", "PROBLEM", 55, 69], ["latent", "OBSERVATION_MODIFIER", 21, 27], ["period", "OBSERVATION_MODIFIER", 28, 34]]], ["Being another crucial factor for constructing epidemiological models, the serial interval is one of the fundamentals for computing and estimating R 0 ; see Fine (2003) for a summary of the importance of serial interval in epidemiological studies.Serial intervalThe estimation of serial interval is based on the generation time distribution, which is closely related to the infection rate of a epidemic.", [["infection", "DISEASE", 373, 382], ["epidemiological studies", "TEST", 222, 245], ["the infection rate", "PROBLEM", 369, 387], ["a epidemic", "PROBLEM", 391, 401], ["infection", "OBSERVATION", 373, 382]]], ["Standard estimation procedures are given in Diekmann et al. (2013, Chapter 13 ).", [["Standard estimation procedures", "TREATMENT", 0, 30]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . practice, the R package R0 collects functions that estimate serial intervals via maximum likelihood methods (White et al., 2009) and the estimation of serial interval in the package EpiEstim is based on the method developed in Cori et al. (2013) .(which was not certified by peer review)Epidemic doubling time The epidemic doubling time (or simply doubling time) is another important index in epidemic studies, as it measures the length of the period during which the number of confirmed cases is doubled.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the R package R0", "TREATMENT", 286, 302], ["serial interval in the package EpiEstim", "TREATMENT", 427, 466], ["epidemic studies", "TEST", 669, 685], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["epidemic", "OBSERVATION_MODIFIER", 590, 598]]], ["It is evident that the doubling time is reversely related to another epidemic parameters of interest: case-fatality rate.", [["fatality rate", "TEST", 107, 120]]], ["Hence, learning doubling time helps epidemiologists not only understand the transmissiblity of an infection disease but also evaluate its severity.", [["infection", "DISEASE", 98, 107], ["an infection disease", "PROBLEM", 95, 115], ["infection", "OBSERVATION", 98, 107]]], ["In the course of pathology, the doubling time is useful for analyzing the growth rate of viruses and antigens.", [["antigens", "PROTEIN", 101, 109], ["pathology", "OBSERVATION", 17, 26]]], ["Doubling time also can be used to assess the effectiveness of public health interventions and protocols, as an increase in the doubling time usually indicates a slowdown in epidemic transmission.(which was not certified by peer review)The estimation of the epidemic doubling time is generally model based, where exponential growth models are the most frequently adopted (Galvani et al., 2003; Du et al., 2020b) .", [["public health interventions", "TREATMENT", 62, 89], ["protocols", "TREATMENT", 94, 103], ["exponential growth models", "PROBLEM", 312, 337], ["increase", "OBSERVATION_MODIFIER", 111, 119], ["slowdown", "OBSERVATION_MODIFIER", 161, 169]]], ["In this manuscript, we conduct a meta-analysis on the doubling time to gauge the growth rate of COVID-19.ResultsIn this section, we apply the methods introduced in Section 3 to estimate the epidemic characteristics of interest listed in Section 4.", [["COVID-19", "CHEMICAL", 96, 104], ["the growth rate", "TEST", 77, 92], ["COVID", "TEST", 96, 101], ["the methods", "TREATMENT", 138, 149]]], ["The analysis is primarily done in R, where several standard packages for meta-analysis are utilized; for instance, meta, metafor, dmetar among others.ResultsBasic reproduction number Relevant studies used for our meta-analysis are summarized in Table 2 , where a total of 12 research articles are included.Results8 .", [["The analysis", "TEST", 0, 12], ["meta-analysis", "TEST", 73, 86], ["our meta-analysis", "TEST", 209, 226]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. .(which was not certified by peer review)Note that the sample size is not large, so we depict a funnel plot in Figure 1 to see whether there is any bias owing to the small sample size.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the sample size", "TEST", 325, 340], ["a funnel plot", "TEST", 368, 381], ["any bias", "PROBLEM", 418, 426], ["med", "ANATOMY", 105, 108], ["size", "OBSERVATION_MODIFIER", 336, 340], ["not", "UNCERTAINTY", 344, 347], ["large", "OBSERVATION_MODIFIER", 348, 353], ["bias", "OBSERVATION", 422, 426], ["small", "OBSERVATION_MODIFIER", 440, 445], ["sample", "OBSERVATION_MODIFIER", 446, 452], ["size", "OBSERVATION_MODIFIER", 453, 457]]], ["In a funnel plot, a significantly asymmetry pattern indicates publication bias.", [["a funnel plot", "TEST", 3, 16], ["a significantly asymmetry pattern", "PROBLEM", 18, 51], ["publication bias", "PROBLEM", 62, 78], ["funnel plot", "OBSERVATION", 5, 16], ["publication bias", "OBSERVATION", 62, 78]]], ["A more rigorous method is to exploit the Egger's test (Egger et al., 1997) , for which a small p-value suggests rejecting the null hypothesis (i.e., some bias caused by the small sample size does exist).", [["the Egger's test", "TEST", 37, 53], ["a small p-value", "PROBLEM", 87, 102], ["the null hypothesis", "PROBLEM", 122, 141], ["some bias", "PROBLEM", 149, 158], ["the small sample size", "PROBLEM", 169, 190], ["small", "OBSERVATION_MODIFIER", 89, 94], ["null hypothesis", "OBSERVATION", 126, 141], ["small", "OBSERVATION_MODIFIER", 173, 178]]], ["The p-value here is 0.47, showing that no further procedure is needed for correcting the effect size for the present meta-analysis.(which was not certified by peer review)Using the estimation procedure demonstrated in Section 3, we see that the estimate of R 0 is 3.16 with a 95% confidence interval [2.60, 3.72] and a 95% prediction interval [1.25, 5.08].", [["The p-value", "TEST", 0, 11], ["further procedure", "TREATMENT", 42, 59], ["the effect size", "PROBLEM", 85, 100], ["the estimation procedure", "TREATMENT", 177, 201]]], ["The associated forest plot is presented in Figure 2 .", [["The associated forest plot", "PROBLEM", 0, 26], ["forest plot", "OBSERVATION", 15, 26]]], ["The index of heterogeneity, I 2 , which ranges from 0 to 1, is used to quantify the dispersion of effect sizes.", [["index", "OBSERVATION_MODIFIER", 4, 9], ["heterogeneity", "OBSERVATION", 13, 26], ["dispersion", "OBSERVATION_MODIFIER", 84, 94], ["effect", "OBSERVATION_MODIFIER", 98, 104], ["sizes", "OBSERVATION_MODIFIER", 105, 110]]], ["Here we have I 2 = 97%, indicating a substantial heterogeneity in the population.", [["a substantial heterogeneity in the population", "PROBLEM", 35, 80], ["substantial", "OBSERVATION_MODIFIER", 37, 48], ["heterogeneity", "OBSERVATION", 49, 62], ["population", "OBSERVATION_MODIFIER", 70, 80]]], ["The conclusion from I 2 is also consistent with a small p-value from the Cochran's Q test (less than 10 \u22124 ).", [["a small p-value", "PROBLEM", 48, 63], ["the Cochran's Q test", "TEST", 69, 89], ["consistent with", "UNCERTAINTY", 32, 47], ["small", "OBSERVATION_MODIFIER", 50, 55], ["p-value", "OBSERVATION", 56, 63]]], ["Hence, the REM is indeed more appropriate than the FEM for our meta-analysis.(which was not certified by peer review)With high heterogeneity in the underlying population, prediction intervals that incorporates heterogeneity is more informative than confidence intervals which focuses only on summary estimates.", [["high heterogeneity in the underlying population", "PROBLEM", 122, 169], ["FEM", "ANATOMY", 51, 54], ["high", "OBSERVATION_MODIFIER", 122, 126], ["heterogeneity", "OBSERVATION", 127, 140], ["population", "OBSERVATION", 159, 169]]], ["We hence recommend using the prediction interval as an interval estimator when inferring R 0 .(which was not certified by peer review)Based on the results from our meta-analysis, we conclude that the basic reproduction number (R 0 ) of COVID-19 appears to be greater than that of SARS (point estimate around 3), as reported by WHO in \"Consensus document on the epidemiology of severe acute respiratory syndrome (SARS)\".", [["SARS", "DISEASE", 280, 284], ["acute respiratory syndrome", "DISEASE", 384, 410], ["SARS", "DISEASE", 412, 416], ["an interval estimator", "TREATMENT", 52, 73], ["our meta-analysis", "TEST", 160, 177], ["COVID", "TEST", 236, 241], ["SARS", "PROBLEM", 280, 284], ["severe acute respiratory syndrome", "PROBLEM", 377, 410], ["greater", "OBSERVATION_MODIFIER", 259, 266], ["severe", "OBSERVATION_MODIFIER", 377, 383], ["acute", "OBSERVATION_MODIFIER", 384, 389], ["respiratory syndrome", "OBSERVATION", 390, 410]]], ["However, it is not as large as an average-based estimate (3.28) for COVID-19 reported in Liu et al. (2020b) .", [["COVID", "TEST", 68, 73], ["not as", "UNCERTAINTY", 15, 21], ["large", "OBSERVATION_MODIFIER", 22, 27]]], ["Compared with the results from other two meta-analyses on COVID-19, our estimate is slightly greater than 3.15 reported in He et al. (2020a) , and moderately greater than 3.05 reported in Dong et al. (2020) .", [["COVID", "TEST", 58, 63], ["slightly", "OBSERVATION_MODIFIER", 84, 92], ["greater", "OBSERVATION_MODIFIER", 93, 100], ["moderately", "OBSERVATION_MODIFIER", 147, 157], ["greater", "OBSERVATION_MODIFIER", 158, 165]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . difference in either case.(which was not certified by peer review)Incubation period Analogous to the previous part, we give the funnel plot in Figure 3 , from which a (roughly) symmetric pattern is observed.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the funnel plot", "TEST", 400, 415], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This is consistent with the p-value (0.915) from the Egger's test.", [["the p-value", "TEST", 24, 35], ["the Egger's test", "TEST", 49, 65], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Hence, again, publication bias is not present here.(which was not certified by peer review)The estimate of the incubation period of COVID-19 based on our meta analysis is 5.35 (days), with a 95% confidence interval [4.29, 6.42] and a 95% prediction interval [1.97, 8.73 ]; see Figure 4 .", [["COVID", "TEST", 132, 137], ["our meta analysis", "TEST", 150, 167]]], ["Our result is greater than the median (4 with interquartile range (IQR) from 2 to 7) of the incubation period estimated by Guan et al. (2020) , which is not included in our meta-analysis as no 95% confidence interval is provided therein.", [["greater", "OBSERVATION_MODIFIER", 14, 21]]], ["One possible reason is that the study period of Guan et al. (2020) is between December 11, 2019 and January 29, 2020, which is considered as a relatively early stage of the COVID-19 outbreak in mainland China.", [["the study", "TEST", 28, 37], ["the COVID", "TEST", 169, 178]]], ["Besides, our estimate is larger than that (5.08) from another meta-analysis in He et al. (2020a) .(which was not certified by peer review)Our meta-analysis also suggests that the incubation period of COVID-19 is a bit longer than that of SARS (commonly ranging from 3 to 5 according to WHO), and our finding is close to the estimate of the incubation period of COVID-19 by the U.S. Centers for Disease Control and Prevention (CDC).", [["SARS", "DISEASE", 238, 242], ["COVID-19", "CHEMICAL", 200, 208], ["Our meta-analysis", "TEST", 138, 155], ["COVID", "TEST", 200, 205], ["SARS", "PROBLEM", 238, 242], ["COVID", "TEST", 361, 366], ["Disease Control", "TREATMENT", 394, 409], ["larger", "OBSERVATION_MODIFIER", 25, 31]]], ["Our result provides evidence in support of the 14-day monitoring and quarantine periods in implementation.(which was not certified by peer review)Serial interval For this part, we collect 12 studies to proceed along our meta-analysis.", [["quarantine periods", "TREATMENT", 69, 87], ["our meta-analysis", "TEST", 216, 233]]], ["Albeit the funnel plot in Figure 5 displaying an asymmetric pattern, the p-value from the Egger's test is 0.29, suggesting that it is not required to implement a correction procedure.", [["the funnel plot", "TEST", 7, 22], ["an asymmetric pattern", "PROBLEM", 46, 67], ["the p-value", "TEST", 69, 80], ["the Egger's test", "TEST", 86, 102], ["a correction procedure", "TREATMENT", 160, 182], ["funnel plot", "OBSERVATION", 11, 22], ["asymmetric", "OBSERVATION_MODIFIER", 49, 59], ["pattern", "OBSERVATION_MODIFIER", 60, 67]]], ["The estimate of the serial interval is 5.35 with a 95% confidence interval [4.63, 6.07] and a 95% prediction interval [3.13, 7.57] .(which was not certified by peer review)The estimate of the serial interval of COVID-19 based on our metaanalysis is close to that of SARS (5-6 days according to WHO's report in 10 .", [["SARS", "DISEASE", 266, 270], ["COVID", "TEST", 211, 216], ["our metaanalysis", "TEST", 229, 245]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["\"Consensus document on the epidemiology of severe acute respiratory syndrome (SARS)\").", [["acute respiratory syndrome", "DISEASE", 50, 76], ["SARS", "DISEASE", 78, 82], ["severe acute respiratory syndrome", "PROBLEM", 43, 76], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory syndrome", "OBSERVATION", 56, 76]]], ["A shorter serial interval of COVID-19, together with a shorter mean incubation period, suggests higher possibility that a transmission is completed before the onset of symptoms.", [["COVID", "TEST", 29, 34], ["symptoms", "PROBLEM", 168, 176], ["higher possibility", "OBSERVATION_MODIFIER", 96, 114]]], ["Therefore, reducing the source of transmission (by hospitalizing infected individuals or implementing \"stay-at-home\" protocols to susceptible individuals) and reasonably extending the quarantine period are extensively helpful to slow the progression of COVID-19.(which was not certified by peer review)Epidemic doubling time The number of the collected studies for epidemic doubling time is 8 (less than 10).", [["COVID", "TEST", 253, 258], ["the collected studies", "TEST", 339, 360], ["epidemic doubling time", "TEST", 365, 387]]], ["As a small sample size is likely to cause bias in meta-analysis (Lin, 2018), the visualization of the funnel plot in Figure 7 exhibits asymmetry.(which was not certified by peer review)We consider the trim-and-fill procedure (Duval and Richard, 2000) based on the imputations to reduce the bias owing to a small sample size, and the estimation results before and after implementing the trim-and-fill procedure are given in Figure 8 .", [["a small sample size", "PROBLEM", 3, 22], ["the funnel plot", "TEST", 98, 113], ["asymmetry", "PROBLEM", 135, 144], ["the bias", "PROBLEM", 286, 294], ["the trim-and-fill procedure", "TREATMENT", 382, 409], ["small", "OBSERVATION_MODIFIER", 5, 10], ["sample size", "OBSERVATION_MODIFIER", 11, 22], ["likely to cause", "UNCERTAINTY", 26, 41], ["bias", "OBSERVATION", 42, 46], ["funnel plot", "OBSERVATION", 102, 113], ["small", "OBSERVATION_MODIFIER", 306, 311], ["size", "OBSERVATION_MODIFIER", 319, 323]]], ["The estimate without correction is 4.86 (with a 95% confidence interval [3.26, 6.45]), which is larger than the trimmed estimate of value 3.48 (with a 95% confidence interval [1.60, 5.35]).", [["larger", "OBSERVATION_MODIFIER", 96, 102]]], ["Hence, even though the p-value of the Egger's test is not significant, a remedy is still necessary, as an extensively small sample size usually jeopardizes the statistical power of the Egger's test.", [["the Egger's test", "TEST", 34, 50], ["an extensively small sample size", "PROBLEM", 103, 135], ["the Egger's test", "TEST", 181, 197], ["small", "OBSERVATION_MODIFIER", 118, 123], ["sample", "OBSERVATION_MODIFIER", 124, 130], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["In contrast, when we apply the trim-and-fill procedure to the previous three epidemic metrics, no significant difference has been detected.(which was not certified by peer review)Although there seems to be no official report on the epidemic doubling time of SARS from WHO or CDC, we find that an estimate of the doubling time of SARS from a published article (Galvani et al., 2003) is 16.3 through literature search.", [["SARS", "DISEASE", 258, 262], ["SARS", "DISEASE", 329, 333], ["significant difference", "PROBLEM", 98, 120], ["SARS", "PROBLEM", 258, 262], ["SARS", "PROBLEM", 329, 333], ["no", "UNCERTAINTY", 95, 97], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["difference", "OBSERVATION", 110, 120]]], ["The estimate of the doubling time of SARS is three times more than the counterpart of COVID-19 based on our analysis, suggesting that COVID-19 is a more contagious disease.11.", [["SARS", "DISEASE", 37, 41], ["SARS", "PROBLEM", 37, 41], ["COVID", "TEST", 86, 91], ["our analysis", "TEST", 104, 116], ["COVID", "TEST", 134, 139], ["a more contagious disease", "PROBLEM", 146, 171], ["contagious disease", "OBSERVATION", 153, 171]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint Meta-analysis and sensitivity analysis usually go hand in hand.", [["hand", "ANATOMY", 392, 396], ["hand", "ANATOMY", 400, 404], ["CC", "CHEMICAL", 0, 2], ["hand", "ORGANISM_SUBDIVISION", 392, 396], ["hand", "ORGANISM_SUBDIVISION", 400, 404], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint Meta-analysis", "TREATMENT", 325, 355], ["sensitivity analysis", "TEST", 360, 380], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["hand", "ANATOMY", 400, 404]]], ["Meta analysis places focus on the summary of a systematic review of relevant studies, whereas the sensitivity analysis is used to assess the robustness of the results from the meta-analysis.", [["Meta analysis", "TEST", 0, 13], ["relevant studies", "TEST", 68, 84], ["the sensitivity analysis", "TEST", 94, 118], ["the meta-analysis", "TEST", 172, 189]]], ["In practice, the sensitivity analysis is a repeat of the meta-analysis, substituting alternative studies or the results from unclear studies.", [["the sensitivity analysis", "TEST", 13, 37], ["the meta-analysis", "TEST", 53, 70], ["alternative studies", "TEST", 85, 104]]], ["In other words, the goal of sensitivity analysis is to explore the impact of the meta-analysis by including or excluding studies in the metaanalysis based on some criteria as in Higgins et al. (2019, Section 9 .7).", [["sensitivity analysis", "TEST", 28, 48], ["the metaanalysis", "TEST", 132, 148]]], ["In this section, we present a couple of sensitivity analyses for the basic reproduction number R 0 .", [["sensitivity analyses", "TEST", 40, 60]]], ["Analogous studies can be carried out for other epidemic characteristics, done mutatis mutandis.", [["Analogous studies", "TEST", 0, 17]]], ["For the sake of brevity, we present the details about the sensitivity analysis of R 0 only in this section.(which was not certified by peer review)In the first sensitivity analysis, we only include the published articles (a total number of 7 left) in the new analysis, by leaving out preprints that have not yet been through the peer review process.", [["the sensitivity analysis", "TEST", 54, 78], ["the first sensitivity analysis", "TEST", 150, 180], ["the new analysis", "TEST", 251, 267], ["new", "OBSERVATION_MODIFIER", 255, 258]]], ["The new estimate of R 0 is 2.80 with a 95% confidence interval [2.05, 3.54].", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["It is unnecessary to use the prediction interval for inference in the new analysis since we have I 2 = 19%, which is interpreted as unimportant to estimation consistency (Higgins et al., 2019, Section 9.5).(which was not certified by peer review)Having observed a small I 2 , we conduct a follow-up sensitivity analysis which includes only the 7 published articles and fit a FEM.", [["the new analysis", "TEST", 66, 82], ["a follow-up sensitivity analysis", "TEST", 287, 319], ["a FEM", "TREATMENT", 373, 378], ["small", "OBSERVATION_MODIFIER", 264, 269], ["FEM", "ANATOMY", 375, 378]]], ["Now instead of leaving out ambiguous results, we expand the scope of our study to the East Asia.", [["our study", "TEST", 69, 78]]], ["We add several studies from Japan, Korea and the Diamond Princess Cruise, which are listed in Table 6 .", [["several studies", "TEST", 7, 22]]], ["The estimate of R 0 for this analysis is 2.80 with a 95% confidence interval [2.05, 3.54] and a prediction interval [0.92, 4.69].", [["this analysis", "TEST", 24, 37], ["a prediction interval", "TEST", 94, 115]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi. org/10.1101 org/10. /2020 In this meta-analysis, we study a collection of recent studies on the COVID-19 pandemic, focusing mainly on four epidemic characteristics: R 0 or the basic reproduction number, the incubation period, the serial interval, and the doubling time of the epidemic.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["recent studies", "TEST", 363, 377], ["the COVID", "TEST", 381, 390], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We summarize our numerical findings in Table 1 and include corresponding comparisons with SARS, which is also a viral respiratory illness caused by a coronavirus in 2003.", [["SARS", "DISEASE", 90, 94], ["viral respiratory illness", "DISEASE", 112, 137], ["coronavirus", "DISEASE", 150, 161], ["SARS", "PROBLEM", 90, 94], ["a viral respiratory illness", "PROBLEM", 110, 137], ["a coronavirus", "PROBLEM", 148, 161]]], ["From Table 1 we see that compared to SARS, the COVID-19 has a larger R 0 , a longer incubation period and much shorter doubling time, thus suggesting this novel coronavirus be more contagious and stringent public health strategies be necessary.(which was not certified by peer review)The numerical results also provide insights on further studies.", [["SARS", "DISEASE", 37, 41], ["coronavirus", "ORGANISM", 161, 172], ["COVID-19", "DNA", 47, 55], ["the COVID", "TEST", 43, 52], ["this novel coronavirus", "PROBLEM", 150, 172], ["further studies", "TEST", 331, 346], ["larger", "OBSERVATION_MODIFIER", 62, 68]]], ["For example, with pooled estimates of R 0 and the doubling time available, we can then compare them with the effective reproduction number (or R t ) or the doubling time after the nationwide lockdown protocol has been implemented in China to see the effectiveness of the public health strategies.", [["the nationwide lockdown protocol", "TREATMENT", 176, 208]]], ["The estimates of the incubation period and the serial interval reassure the necessity of reinforcing a 14-day quarantine period to prevent the spread of the disease.(which was not certified by peer review)It is also worthwhile noting the potential limitations of the current metaanalysis.", [["the disease", "PROBLEM", 153, 164], ["disease", "OBSERVATION", 157, 164]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 publications that report estimates with a 90% confidence interval or estimates with quartiles.", [["CC", "CHEMICAL", 0, 2], ["https: //doi.org/10.1101 //doi.org/10", "SPECIES", 276, 313], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This may lead to some loss of precision or publication bias for our estimates in meta-analysis.", [["some loss of precision", "PROBLEM", 17, 39]]], ["Meanwhile, the study on the COVID-19 may not be only restricted to the four characteristics listed in the manuscript.", [["COVID-19", "DNA", 28, 36], ["the study", "TEST", 11, 20], ["the COVID", "TEST", 24, 33]]], ["Other metrics, e.g., the case-to fatality rate and the testing capacity, and factors, e.g., significant clusters and patients' underlying chronic medical conditions, are also of great importance in the future endeavors to mitigate the negative impacts of the COVID-19 pandemic.(which was not certified by peer review).", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["fatality rate", "TEST", 33, 46], ["the testing capacity", "TEST", 51, 71], ["significant clusters and patients' underlying chronic medical conditions", "PROBLEM", 92, 164], ["the COVID", "TEST", 255, 264], ["pandemic", "PROBLEM", 268, 276], ["chronic", "OBSERVATION_MODIFIER", 138, 145]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020.15.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 325, 341], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 325, 341], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. .20029983.Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., Kuss, O., Higgins, J. P. T., Langan, D. and Salanti, G. (2016) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["R.", "ANATOMY", 339, 341]]], ["Methods to estimate the between-study variance and its uncertainty in meta-analysis.", [["Methods", "TREATMENT", 0, 7], ["study variance", "TEST", 32, 46]]], ["Research Synthesis Methods, 7, 55-79.20029983.Volz, E., Baguelin, M., Bhatia, S., Boonyasiri, A., Cori, A., Cucunub\u00e1, Z., Cuomo-Dannenburg, G., Donnelly, C. A., Dorigatti, I., FitzJohn, R., Fu, H., Gaythorpe, K., Ghani, A., Hamlet, A., Hinsley, W., Imai, N., Laydon, D., Nedjati-Gilani, G., Okell, L., Riley, S. Van Elsland, S., Wang, H., Wang, Y., Xi, X. and Ferguson, N. M. (2020) .", [["Volz", "TEST", 46, 50], ["Baguelin", "TEST", 56, 64], ["Bhatia", "TEST", 70, 76], ["Boonyasiri", "TEST", 82, 92], ["Cucunub\u00e1", "TEST", 108, 116], ["R.", "ANATOMY", 186, 188], ["L.", "OBSERVATION_MODIFIER", 298, 300]]], ["Report 5: Phylogenetic analysis of SARS-CoV-2.", [["SARS-CoV-2", "ORGANISM", 35, 45], ["SARS-CoV", "SPECIES", 35, 43], ["Phylogenetic analysis", "TEST", 10, 31], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020 . . https://doi.org/10.1101 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020 . . https://doi.org/10.1101 Basic reproduction number We list the sources that are utilized for estimating R 0 via meta-analysis in Table 2 .", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 277, 300], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108]]], ["We picked the confidence interval under the utilization of log-normal.Serial intervalWe list the sources that are utilized for estimating incubation period via meta-analysis in Table 4 .", [["normal", "OBSERVATION", 63, 69]]], ["In You et al. (2020) , the authors considered three models (maximum likelihood, exponential growth rate and 24 .", [["exponential growth rate", "TEST", 80, 103]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Figure 1 : Funnel plot of meta-analysis for R 0 stochastic SIR) and estimated serial intervals for mainland China and a number of provinces.", [["Funnel plot", "TEST", 11, 22], ["meta-analysis", "TEST", 26, 39]]], ["In Lau et al. (2020) , the authors reported two estimates of epidemic doubling time and their confidence intervals, respectively before and after imposing lockdown in mainland China; we adopt the latter in the analysis.", [["the analysis", "TEST", 206, 218]]], ["In Muniz-Rodriguez et al. (2020) , the authors estimated epidemic doubling times for 31 provinces and municipalities in mainland China; we pick the one for \"mainland China (except for Hubei province)\" in our study since it is the most comprehensive 25 .", [["our study", "TEST", 204, 213]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprintSensitivity analysisWe list the sources that are utilized for estimating basic reproduction number in sensitivity analysis in Table 6 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The added studies include recent research in Japan, South Korea and Diamond Princess Cruise.26.", [["The added studies", "TEST", 0, 17], ["Diamond Princess", "OBSERVATION", 68, 84]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint 28 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint29.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprint29", "TREATMENT", 366, 384], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)29The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint Figure 6 : Forest plot of meta-analysis for serial interval30.", [["CC", "CHEMICAL", 0, 2], ["interval30", "PROTEIN", 396, 406], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)30The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)30The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.1101/2020.05.31.20118448 doi: medRxiv preprint Figure 8 : Forest plots of meta-analysis for epidemic doubling time before (top) and after (bottom) implementing the trim-and-fill procedure 32 .", [["CC", "CHEMICAL", 0, 2], ["CC", "CHEMICAL", 345, 347], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["The copyright holder", "TREATMENT", 549, 569], ["meta-analysis", "TREATMENT", 717, 730], ["epidemic", "PROBLEM", 735, 743], ["the trim-and-fill procedure", "TREATMENT", 803, 830], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 450, 453]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)30The copyright holder for this preprint this version posted June 3, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["med", "ANATOMY", 105, 108]]]], "a99927909867bf30530558770197e81e8efe398c": [["Severe acute respiratory syndrome corona virus 2 (SARS CoV2) emerged in late 2019 as a new virus causing severe respiratory illness and the COVID19 syndrome.", [["respiratory", "ANATOMY", 112, 123], ["acute respiratory syndrome corona virus", "DISEASE", 7, 46], ["respiratory illness", "DISEASE", 112, 131], ["Severe acute respiratory syndrome corona virus 2", "ORGANISM", 0, 48], ["Severe acute respiratory syndrome corona virus", "SPECIES", 0, 46], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["corona virus", "PROBLEM", 34, 46], ["a new virus", "PROBLEM", 85, 96], ["severe respiratory illness", "PROBLEM", 105, 131], ["the COVID19 syndrome", "PROBLEM", 136, 156], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["corona virus", "OBSERVATION", 34, 46], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["respiratory illness", "OBSERVATION", 112, 131]]], ["As the outbreak evolved into a worldwide pandemic, it became evident that infection with SARS CoV2 results in multi organ disease, with a high incidence of acute kidney injury (AKI).", [["organ", "ANATOMY", 116, 121], ["kidney", "ANATOMY", 162, 168], ["infection", "DISEASE", 74, 83], ["SARS", "DISEASE", 89, 93], ["multi organ disease", "DISEASE", 110, 129], ["acute kidney injury", "DISEASE", 156, 175], ["AKI", "DISEASE", 177, 180], ["organ", "ORGAN", 116, 121], ["kidney", "ORGAN", 162, 168], ["infection", "PROBLEM", 74, 83], ["SARS CoV2", "PROBLEM", 89, 98], ["multi organ disease", "PROBLEM", 110, 129], ["acute kidney injury", "PROBLEM", 156, 175], ["AKI", "PROBLEM", 177, 180], ["infection", "OBSERVATION", 74, 83], ["multi organ disease", "OBSERVATION", 110, 129], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["kidney", "ANATOMY", 162, 168], ["injury", "OBSERVATION", 169, 175], ["AKI", "OBSERVATION", 177, 180]]], ["Early reports from China did not describe the incidence and aetiology of AKI in COVID19.", [["AKI", "DISEASE", 73, 76], ["AKI", "PROBLEM", 73, 76], ["AKI", "OBSERVATION", 73, 76]]], ["However, subsequent studies from China, the USA and the UK report an incidence of AKI ranging from 17% to 43% in hospitalized patients.", [["AKI", "DISEASE", 82, 85], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["AKI", "PROBLEM", 82, 85], ["AKI", "OBSERVATION", 82, 85]]], ["In critically ill patients, the incidence of AKI is remarkably higher, ranging from 61% to 76% 1 .", [["critically ill", "DISEASE", 3, 17], ["AKI", "DISEASE", 45, 48], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["AKI", "PROBLEM", 45, 48], ["AKI", "OBSERVATION", 45, 48], ["higher", "OBSERVATION_MODIFIER", 63, 69]]], ["Now, Braun et al. report an association between SARS CoV2 infection of kidney cells and clinical outcomes in patients with COVID19 (ref.", [["kidney cells", "ANATOMY", 71, 83], ["SARS CoV2 infection", "DISEASE", 48, 67], ["CoV2", "GENE_OR_GENE_PRODUCT", 53, 57], ["kidney cells", "CELL", 71, 83], ["patients", "ORGANISM", 109, 117], ["kidney cells", "CELL_TYPE", 71, 83], ["patients", "SPECIES", 109, 117], ["SARS CoV2 infection of kidney cells", "PROBLEM", 48, 83], ["COVID19 (ref", "TREATMENT", 123, 135], ["kidney", "ANATOMY", 71, 77]]]], "PMC7405315": [["IntroductionCD19-directed chimeric antigen receptor (CAR) T cell is a major breakthrough that has revolutionized the treatment paradigm of relapsed/refractory (RR) diffuse large B cell lymphoma (DLBCL) over the past recent years1,2.", [["chimeric antigen receptor (CAR) T cell", "ANATOMY", 26, 64], ["diffuse large B cell lymphoma", "ANATOMY", 164, 193], ["DLBCL", "ANATOMY", 195, 200], ["large B cell lymphoma", "DISEASE", 172, 193], ["DLBCL", "DISEASE", 195, 200], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 26, 51], ["diffuse large B cell lymphoma", "CANCER", 164, 193], ["DLBCL", "CANCER", 195, 200], ["IntroductionCD19", "PROTEIN", 0, 16], ["chimeric antigen receptor (CAR) T cell", "CELL_TYPE", 26, 64], ["IntroductionCD19", "TEST", 0, 16], ["the treatment paradigm", "TREATMENT", 113, 135], ["refractory (RR)", "PROBLEM", 148, 163], ["diffuse large B cell lymphoma", "PROBLEM", 164, 193], ["DLBCL", "PROBLEM", 195, 200], ["diffuse", "OBSERVATION_MODIFIER", 164, 171], ["large", "OBSERVATION_MODIFIER", 172, 177], ["B cell lymphoma", "OBSERVATION", 178, 193]]], ["Despite the significant anti-lymphoma activity, CD19 CAR T cells possess unique toxicities.", [["CD19 CAR T cells", "ANATOMY", 48, 64], ["toxicities", "DISEASE", 80, 90], ["anti-lymphoma", "CANCER", 24, 37], ["CD19", "GENE_OR_GENE_PRODUCT", 48, 52], ["CD19 CAR T cells", "CELL_TYPE", 48, 64], ["the significant anti-lymphoma activity", "PROBLEM", 8, 46], ["CD19 CAR T cells", "TREATMENT", 48, 64], ["unique toxicities", "PROBLEM", 73, 90], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["anti-lymphoma activity", "OBSERVATION", 24, 46]]], ["Besides immune-mediated toxicities, B cell aplasia, and resultant hypogammaglobulinemia are common consequences of CD19 CAR T cell therapy, which put patients at risk for infectious complications3,4.", [["B cell", "ANATOMY", 36, 42], ["T cell", "ANATOMY", 124, 130], ["toxicities", "DISEASE", 24, 34], ["aplasia", "DISEASE", 43, 50], ["hypogammaglobulinemia", "DISEASE", 66, 87], ["B cell", "CELL", 36, 42], ["CD19", "GENE_OR_GENE_PRODUCT", 115, 119], ["patients", "ORGANISM", 150, 158], ["CD19", "PROTEIN", 115, 119], ["patients", "SPECIES", 150, 158], ["immune-mediated toxicities", "PROBLEM", 8, 34], ["B cell aplasia", "PROBLEM", 36, 50], ["resultant hypogammaglobulinemia", "PROBLEM", 56, 87], ["CD19 CAR T cell therapy", "TREATMENT", 115, 138], ["infectious complications", "PROBLEM", 171, 195], ["toxicities", "OBSERVATION", 24, 34], ["B cell aplasia", "OBSERVATION", 36, 50], ["resultant", "OBSERVATION_MODIFIER", 56, 65], ["hypogammaglobulinemia", "OBSERVATION", 66, 87], ["infectious", "OBSERVATION", 171, 181]]], ["Although there have been some initial reports on the infectious complications of CAR T cell therapy, most studies included patients treated in clinical trials or with multiple underlying B cell malignancies5\u201310.", [["T cell", "ANATOMY", 85, 91], ["B cell", "ANATOMY", 187, 193], ["CAR T cell", "CELL", 81, 91], ["patients", "ORGANISM", 123, 131], ["B cell malignancies5\u201310", "CELL", 187, 210], ["patients", "SPECIES", 123, 131], ["the infectious complications", "PROBLEM", 49, 77], ["CAR T cell therapy", "TREATMENT", 81, 99], ["multiple underlying B cell malignancies5", "TREATMENT", 167, 207], ["infectious", "OBSERVATION_MODIFIER", 53, 63], ["B cell malignancies5", "OBSERVATION", 187, 207]]], ["Currently, there are limited real-world data on infectious risks in patients treated with CD19 CAR T cell therapy for DLBCL.", [["T cell", "ANATOMY", 99, 105], ["DLBCL", "ANATOMY", 118, 123], ["DLBCL", "DISEASE", 118, 123], ["patients", "ORGANISM", 68, 76], ["CD19", "GENE_OR_GENE_PRODUCT", 90, 94], ["DLBCL", "CANCER", 118, 123], ["CD19", "PROTEIN", 90, 94], ["patients", "SPECIES", 68, 76], ["CD19 CAR T cell therapy", "TREATMENT", 90, 113], ["DLBCL", "PROBLEM", 118, 123]]], ["Moreover, little is known about proper prophylaxis and management strategies for these patients.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["proper prophylaxis", "TREATMENT", 32, 50], ["management strategies", "TREATMENT", 55, 76]]], ["Herein, we describe the pattern, incidence, impact of infections, including infection prophylactic strategies, in patients with DLBCL who received FDA-approved CAR T cell therapy at Memorial Sloan Kettering Cancer Center (MSKCC).Statistical analysis ::: Sample and methodsWe reported continuous variables using median and range.", [["DLBCL", "ANATOMY", 128, 133], ["T cell", "ANATOMY", 164, 170], ["infections", "DISEASE", 54, 64], ["infection", "DISEASE", 76, 85], ["DLBCL", "DISEASE", 128, 133], ["Cancer", "DISEASE", 207, 213], ["patients", "ORGANISM", 114, 122], ["DLBCL", "CANCER", 128, 133], ["CAR T cell", "CELL", 160, 170], ["patients", "SPECIES", 114, 122], ["infections", "PROBLEM", 54, 64], ["infection prophylactic strategies", "TREATMENT", 76, 109], ["DLBCL", "PROBLEM", 128, 133], ["FDA", "TREATMENT", 147, 150], ["CAR T cell therapy", "TREATMENT", 160, 178], ["Sample", "TEST", 254, 260], ["methods", "TEST", 265, 272], ["infections", "OBSERVATION", 54, 64], ["infection", "OBSERVATION", 76, 85]]], ["Categorical data were presented as a percentage.", [["Categorical data", "TEST", 0, 16]]], ["Overall survival was analyzed by Kaplan\u2013Meier methodology and infections were treated as time-dependent covariates.", [["infections", "DISEASE", 62, 72], ["infections", "PROBLEM", 62, 72]]], ["Cumulative incidence of time to the first infection was evaluated with progression of disease, relapse, and death from non-infection causes as competing events.", [["infection", "DISEASE", 42, 51], ["death", "DISEASE", 108, 113], ["the first infection", "PROBLEM", 32, 51], ["disease", "PROBLEM", 86, 93], ["relapse", "PROBLEM", 95, 102], ["death", "PROBLEM", 108, 113], ["non-infection", "PROBLEM", 119, 132], ["infection", "OBSERVATION", 42, 51], ["disease", "OBSERVATION", 86, 93]]], ["Factors associated with infection were identified by univariate analysis using cause-specific hazard ratios and 95% confidence intervals.", [["infection", "DISEASE", 24, 33], ["infection", "PROBLEM", 24, 33], ["univariate analysis", "TEST", 53, 72], ["specific hazard ratios", "PROBLEM", 85, 107], ["infection", "OBSERVATION", 24, 33]]], ["CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), corticosteroid, tocilizumab, and intravenous immunoglobulin (IVIG) were treated as time-dependent covariates.", [["immune effector cell", "ANATOMY", 5, 25], ["intravenous", "ANATOMY", 102, 113], ["CRS", "DISEASE", 0, 3], ["neurotoxicity", "DISEASE", 37, 50], ["ICANS", "DISEASE", 61, 66], ["tocilizumab", "CHEMICAL", 85, 96], ["immune effector cell", "CELL", 5, 25], ["corticosteroid", "SIMPLE_CHEMICAL", 69, 83], ["tocilizumab", "SIMPLE_CHEMICAL", 85, 96], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 102, 128], ["IVIG", "SIMPLE_CHEMICAL", 130, 134], ["intravenous immunoglobulin", "PROTEIN", 102, 128], ["CRS", "PROBLEM", 0, 3], ["immune effector cell", "PROBLEM", 5, 25], ["neurotoxicity syndrome", "PROBLEM", 37, 59], ["ICANS)", "TREATMENT", 61, 67], ["corticosteroid", "TREATMENT", 69, 83], ["tocilizumab", "TREATMENT", 85, 96], ["intravenous immunoglobulin (IVIG", "TREATMENT", 102, 134], ["immune effector cell", "OBSERVATION", 5, 25], ["neurotoxicity syndrome", "OBSERVATION", 37, 59]]], ["P-values less than 0.10 were considered for multivariate analysis using cause-specific hazard ratios.", [["P-values", "TEST", 0, 8], ["multivariate analysis", "TEST", 44, 65]]], ["All statistical analyses were performed by R program version 3.6.0.", [["All statistical analyses", "TEST", 0, 24]]], ["The cmprsk package was used for the cumulative incidence of infection.", [["infection", "DISEASE", 60, 69], ["cmprsk package", "DNA", 4, 18], ["The cmprsk package", "TREATMENT", 0, 18], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["The institutional review board and the ethic committee of MSKCC granted approval for conducting the study.Baseline clinical characteristics ::: ResultsTable 2 summarizes the baseline clinical characteristics of the 60 patients in this cohort.", [["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["conducting the study", "TEST", 85, 105]]], ["The median age at the time of CAR T treatment was 63 years (19.5\u201385.9 years).", [["CAR T treatment", "TREATMENT", 30, 45]]], ["Thirty-five patients (58%) had de novo DLBCL.", [["DLBCL", "ANATOMY", 39, 44], ["DLBCL", "DISEASE", 39, 44], ["patients", "ORGANISM", 12, 20], ["DLBCL", "CANCER", 39, 44], ["patients", "SPECIES", 12, 20], ["de novo DLBCL", "PROBLEM", 31, 44], ["DLBCL", "OBSERVATION", 39, 44]]], ["Patients had a median of 42\u20139 prior lines of treatment before CAR T cells, and 16 (26.7%) underwent prior hematopoietic cell transplantation.", [["CAR T cells", "ANATOMY", 62, 73], ["hematopoietic cell", "ANATOMY", 106, 124], ["Patients", "ORGANISM", 0, 8], ["CAR T cells", "CELL", 62, 73], ["hematopoietic cell", "CELL", 106, 124], ["CAR T cells", "CELL_TYPE", 62, 73], ["Patients", "SPECIES", 0, 8], ["prior lines of treatment", "TREATMENT", 30, 54], ["CAR T cells", "TEST", 62, 73], ["prior hematopoietic cell transplantation", "TREATMENT", 100, 140], ["hematopoietic cell transplantation", "OBSERVATION", 106, 140]]], ["Thirty-eight patients (63.3%) received bridging therapy before CAR T cells (4 radiation therapy, 33 immunochemotherapy and 1 combined modality).", [["CAR T cells", "ANATOMY", 63, 74], ["patients", "ORGANISM", 13, 21], ["CAR T cells", "CELL", 63, 74], ["CAR T cells", "CELL_TYPE", 63, 74], ["patients", "SPECIES", 13, 21], ["bridging therapy", "TREATMENT", 39, 55], ["CAR T cells", "TREATMENT", 63, 74], ["4 radiation therapy", "TREATMENT", 76, 95], ["33 immunochemotherapy", "TREATMENT", 97, 118], ["1 combined modality", "TREATMENT", 123, 142]]], ["Forty-three patients (71.7%) were treated with axicabtagene ciloleucel, and 17 (28.3%) received tisagenlecleucel.", [["axicabtagene ciloleucel", "CHEMICAL", 47, 70], ["tisagenlecleucel", "CHEMICAL", 96, 112], ["tisagenlecleucel", "CHEMICAL", 96, 112], ["patients", "ORGANISM", 12, 20], ["tisagenlecleucel", "SIMPLE_CHEMICAL", 96, 112], ["patients", "SPECIES", 12, 20], ["axicabtagene ciloleucel", "TREATMENT", 47, 70], ["tisagenlecleucel", "TREATMENT", 96, 112]]], ["The median length of hospital stay for CAR T cell admission was 17 days (0\u201372 days).", [["T cell", "ANATOMY", 43, 49], ["CAR T cell", "CELL", 39, 49], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17]]], ["Thirteen patients (21.7%) received CAR T cell therapy after the institutional antimicrobial prophylactic protocol was implemented.Baseline infection and antimicrobial prophylaxis ::: ResultsNineteen patients (31.7%) received systemic antibacterial treatment for an infection within 30 days before the CAR T cell infusion.", [["T cell", "ANATOMY", 39, 45], ["T cell", "ANATOMY", 305, 311], ["infection", "DISEASE", 139, 148], ["infection", "DISEASE", 265, 274], ["patients", "ORGANISM", 9, 17], ["CAR T cell", "CELL", 35, 45], ["patients", "ORGANISM", 199, 207], ["CAR T cell", "CELL", 301, 311], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 199, 207], ["CAR T cell therapy", "TREATMENT", 35, 53], ["the institutional antimicrobial prophylactic protocol", "TREATMENT", 60, 113], ["Baseline infection", "PROBLEM", 130, 148], ["antimicrobial prophylaxis", "TREATMENT", 153, 178], ["systemic antibacterial treatment", "TREATMENT", 225, 257], ["an infection", "PROBLEM", 262, 274], ["the CAR T cell infusion", "TREATMENT", 297, 320], ["infection", "OBSERVATION", 139, 148], ["antimicrobial prophylaxis", "OBSERVATION", 153, 178], ["infection", "OBSERVATION", 265, 274]]], ["Three of these patients continued antibiotics through the admission of CAR T cell therapy.", [["T cell", "ANATOMY", 75, 81], ["patients", "ORGANISM", 15, 23], ["CAR T cell", "CELL", 71, 81], ["patients", "SPECIES", 15, 23], ["antibiotics", "TREATMENT", 34, 45], ["CAR T cell therapy", "TREATMENT", 71, 89], ["cell therapy", "OBSERVATION", 77, 89]]], ["Thirty-one patients (51.7%) received antibacterial prophylaxis (Supplementary Table S1).", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["antibacterial prophylaxis", "TREATMENT", 37, 62]]], ["All patients received antiviral prophylaxis for HSV, and 6 received entecavir due to the positive hepatitis B core antibody.", [["entecavir", "CHEMICAL", 68, 77], ["hepatitis B", "DISEASE", 98, 109], ["entecavir", "CHEMICAL", 68, 77], ["patients", "ORGANISM", 4, 12], ["HSV", "ORGANISM", 48, 51], ["entecavir", "SIMPLE_CHEMICAL", 68, 77], ["positive hepatitis B core antibody", "PROTEIN", 89, 123], ["patients", "SPECIES", 4, 12], ["HSV", "SPECIES", 48, 51], ["antiviral prophylaxis", "TREATMENT", 22, 43], ["HSV", "PROBLEM", 48, 51], ["entecavir", "TREATMENT", 68, 77], ["the positive hepatitis B core antibody", "PROBLEM", 85, 123], ["hepatitis", "OBSERVATION", 98, 107]]], ["Fifty-five patients (91.7%) were given prophylaxis for Pneumocytis jiroveci.", [["Pneumocytis jiroveci", "DISEASE", 55, 75], ["patients", "ORGANISM", 11, 19], ["Pneumocytis jiroveci", "ORGANISM", 55, 75], ["patients", "SPECIES", 11, 19], ["Pneumocytis jiroveci", "SPECIES", 55, 75], ["Pneumocytis jiroveci", "SPECIES", 55, 75], ["prophylaxis", "TREATMENT", 39, 50], ["Pneumocytis jiroveci", "PROBLEM", 55, 75], ["jiroveci", "OBSERVATION", 67, 75]]], ["Forty-eight patients (80%) received antifungal prophylaxis, 26 were initiated before CAR T cell infusion whereas the other 22 had antifungal prophylaxis started once absolute neutrophil count (ANC) was less than 500 \u00b5/mL (median time from CAR T infusion to antifungal prophylaxis initiation of 7 days).Recovery of leukocytes and immunoglobulin levels (Table 3Tab3table) ::: ResultsBaseline median ANC and absolute lymphocyte counts (ALC) before LD chemotherapy were 3850 (200\u201310,600) and 600 (100\u20132700) cells/\u00b5L, respectively.", [["T cell", "ANATOMY", 89, 95], ["neutrophil", "ANATOMY", 175, 185], ["leukocytes", "ANATOMY", 314, 324], ["lymphocyte", "ANATOMY", 414, 424], ["cells", "ANATOMY", 503, 508], ["patients", "ORGANISM", 12, 20], ["CAR T cell", "CELL", 85, 95], ["neutrophil", "CELL", 175, 185], ["leukocytes", "CELL", 314, 324], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 329, 343], ["lymphocyte", "CELL", 414, 424], ["leukocytes", "CELL_TYPE", 314, 324], ["immunoglobulin", "PROTEIN", 329, 343], ["patients", "SPECIES", 12, 20], ["antifungal prophylaxis", "TREATMENT", 36, 58], ["CAR T cell infusion", "TREATMENT", 85, 104], ["antifungal prophylaxis", "TREATMENT", 130, 152], ["absolute neutrophil count", "TEST", 166, 191], ["ANC", "TEST", 193, 196], ["CAR T infusion", "TREATMENT", 239, 253], ["antifungal prophylaxis", "TREATMENT", 257, 279], ["leukocytes", "TEST", 314, 324], ["immunoglobulin levels", "TEST", 329, 350], ["median ANC", "TEST", 390, 400], ["absolute lymphocyte counts", "TEST", 405, 431], ["ALC", "TEST", 433, 436], ["LD chemotherapy", "TREATMENT", 445, 460], ["cells", "TEST", 503, 508], ["leukocytes", "OBSERVATION", 314, 324], ["absolute lymphocyte counts", "OBSERVATION", 405, 431]]], ["Two patients had grade 4 neutropenia (ANC < 500 cells/\u00b5L) before LD therapy, as defined by CTCAE version 5.012.", [["cells", "ANATOMY", 48, 53], ["neutropenia", "DISEASE", 25, 36], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["grade 4 neutropenia", "PROBLEM", 17, 36], ["ANC", "TEST", 38, 41], ["LD therapy", "TREATMENT", 65, 75], ["CTCAE version", "TEST", 91, 104], ["grade 4", "OBSERVATION_MODIFIER", 17, 24], ["neutropenia", "OBSERVATION", 25, 36]]], ["Forty-seven of the remaining 58 patients (81.0%) developed neutropenia grade 4 after LD therapy.", [["neutropenia", "DISEASE", 59, 70], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["neutropenia grade 4", "PROBLEM", 59, 78], ["LD therapy", "TREATMENT", 85, 95], ["neutropenia", "OBSERVATION", 59, 70]]], ["The median duration of neutropenia grade 4 was 12 days (3\u201366 days).", [["neutropenia", "DISEASE", 23, 34], ["neutropenia grade", "PROBLEM", 23, 40], ["median", "OBSERVATION_MODIFIER", 4, 10], ["neutropenia", "OBSERVATION", 23, 34]]], ["Ten patients had grade 4 neutropenia after day 30 (5 of which had persistent grade 4 neutropenia from the first 30 days).", [["neutropenia", "DISEASE", 25, 36], ["neutropenia", "DISEASE", 85, 96], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["grade 4 neutropenia", "PROBLEM", 17, 36], ["persistent grade 4 neutropenia", "PROBLEM", 66, 96], ["grade 4", "OBSERVATION_MODIFIER", 17, 24], ["neutropenia", "OBSERVATION", 25, 36], ["persistent", "OBSERVATION_MODIFIER", 66, 76], ["grade 4", "OBSERVATION_MODIFIER", 77, 84], ["neutropenia", "OBSERVATION", 85, 96]]], ["Thirty patients required at least one dose of growth factor support after CAR T cell therapy.", [["T cell", "ANATOMY", 78, 84], ["patients", "ORGANISM", 7, 15], ["CAR T cell", "CELL", 74, 84], ["growth factor", "PROTEIN", 46, 59], ["CAR", "PROTEIN", 74, 77], ["patients", "SPECIES", 7, 15], ["growth factor support", "TREATMENT", 46, 67], ["CAR T cell therapy", "TREATMENT", 74, 92]]], ["Grade 3\u20135 lymphopenia beyond day 30 after CAR T cell was observed in 35 patients (58.3%).", [["T cell", "ANATOMY", 46, 52], ["lymphopenia", "DISEASE", 10, 21], ["CAR T cell", "CELL", 42, 52], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Grade 3\u20135 lymphopenia", "PROBLEM", 0, 21], ["CAR T cell", "TEST", 42, 52], ["3\u20135", "OBSERVATION_MODIFIER", 6, 9], ["lymphopenia", "OBSERVATION", 10, 21]]], ["Of 19 patients who had lymphocyte subset analysis at day 30, all had B cell aplasia and the median CD4+ lymphocyte count was 116 cells/\u00b5L (41\u2013630 cells/\u00b5L).", [["lymphocyte", "ANATOMY", 23, 33], ["B cell", "ANATOMY", 69, 75], ["CD4+ lymphocyte", "ANATOMY", 99, 114], ["cells", "ANATOMY", 129, 134], ["cells", "ANATOMY", 146, 151], ["aplasia", "DISEASE", 76, 83], ["patients", "ORGANISM", 6, 14], ["lymphocyte", "CELL", 23, 33], ["B cell", "CELL", 69, 75], ["lymphocyte", "CELL", 104, 114], ["CD4", "PROTEIN", 99, 102], ["patients", "SPECIES", 6, 14], ["lymphocyte subset analysis", "TEST", 23, 49], ["B cell aplasia", "PROBLEM", 69, 83], ["the median CD4", "TEST", 88, 102], ["lymphocyte count", "TEST", 104, 120], ["cells", "TEST", 129, 134], ["\u00b5L", "TEST", 135, 137], ["cells", "TEST", 146, 151], ["cell aplasia", "OBSERVATION", 71, 83]]], ["Supplementary Table S2 summarizes the status of leukocyte subset reconstitution after CAR T cell infusion.Recovery of leukocytes and immunoglobulin levels (Table 3Tab3table) ::: ResultsIn 59 patients with available baseline IgG level before LD chemotherapy, the median IgG level was 487 mg/dL (163\u20131399 mg/dL), and 15 patients (25%) had baseline hypogammaglobulinemia (IgG \u2264 400 mg/dL).", [["leukocyte", "ANATOMY", 48, 57], ["T cell", "ANATOMY", 90, 96], ["leukocytes", "ANATOMY", 118, 128], ["hypogammaglobulinemia", "DISEASE", 346, 367], ["leukocyte", "CELL", 48, 57], ["CAR T cell", "CELL", 86, 96], ["leukocytes", "CELL", 118, 128], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 133, 147], ["patients", "ORGANISM", 191, 199], ["IgG", "GENE_OR_GENE_PRODUCT", 224, 227], ["IgG", "GENE_OR_GENE_PRODUCT", 269, 272], ["patients", "ORGANISM", 318, 326], ["leukocytes", "CELL_TYPE", 118, 128], ["immunoglobulin", "PROTEIN", 133, 147], ["IgG", "PROTEIN", 224, 227], ["IgG", "PROTEIN", 269, 272], ["IgG", "PROTEIN", 369, 372], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 318, 326], ["leukocyte subset reconstitution", "TREATMENT", 48, 79], ["CAR T cell infusion", "TREATMENT", 86, 105], ["leukocytes", "TEST", 118, 128], ["immunoglobulin levels", "TEST", 133, 154], ["available baseline IgG level", "PROBLEM", 205, 233], ["LD chemotherapy", "TREATMENT", 241, 256], ["the median IgG level", "TEST", 258, 278], ["baseline hypogammaglobulinemia", "PROBLEM", 337, 367], ["IgG", "TEST", 369, 372], ["leukocytes", "OBSERVATION", 118, 128], ["hypogammaglobulinemia", "OBSERVATION", 346, 367]]], ["Immunoglobulin levels were checked at day 30 after CAR T cell therapy in 32 patients; 14 (43.8%) had hypogammaglobulinemia.", [["T cell", "ANATOMY", 55, 61], ["hypogammaglobulinemia", "DISEASE", 101, 122], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["CAR T cell", "CELL", 51, 61], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Immunoglobulin levels", "TEST", 0, 21], ["CAR T cell therapy", "TREATMENT", 51, 69], ["hypogammaglobulinemia", "PROBLEM", 101, 122], ["hypogammaglobulinemia", "OBSERVATION", 101, 122]]], ["An additional 12 patients (37.5%) developed hypogammaglobulinemia at later follow-up timepoints.", [["hypogammaglobulinemia", "DISEASE", 44, 65], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["hypogammaglobulinemia", "PROBLEM", 44, 65], ["hypogammaglobulinemia", "OBSERVATION", 44, 65]]], ["Nineteen patients (31.7%) received at least 1 dose of IVIG replacement, including 10 (52.6%) who had IVIG after history of recurrent infections.", [["infections", "DISEASE", 133, 143], ["patients", "ORGANISM", 9, 17], ["IVIG", "SIMPLE_CHEMICAL", 54, 58], ["patients", "SPECIES", 9, 17], ["IVIG replacement", "TREATMENT", 54, 70], ["IVIG", "TREATMENT", 101, 105], ["recurrent infections", "PROBLEM", 123, 143], ["recurrent", "OBSERVATION_MODIFIER", 123, 132], ["infections", "OBSERVATION", 133, 143]]], ["Figure 1 illustrates patterns of leukocyte and IgG level during the CD19 CAR T cell treatment course.CRS and ICANS ::: ResultsCRS was observed in 48 patients (80%) (grade \u2265 3 in 7 patients; 11.7%) at a median onset of 2 days after CAR T cell infusion (0\u201311 days).", [["leukocyte", "ANATOMY", 33, 42], ["CD19 CAR T cell", "ANATOMY", 68, 83], ["T cell", "ANATOMY", 235, 241], ["CRS", "DISEASE", 101, 104], ["leukocyte", "CELL", 33, 42], ["IgG", "GENE_OR_GENE_PRODUCT", 47, 50], ["CD19", "GENE_OR_GENE_PRODUCT", 68, 72], ["patients", "ORGANISM", 149, 157], ["patients", "ORGANISM", 180, 188], ["CAR T cell", "CELL", 231, 241], ["IgG", "PROTEIN", 47, 50], ["CD19", "PROTEIN", 68, 72], ["CAR", "PROTEIN", 231, 234], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 180, 188], ["leukocyte", "TEST", 33, 42], ["IgG level", "TEST", 47, 56], ["the CD19 CAR T cell treatment course", "TREATMENT", 64, 100], ["CRS", "TEST", 101, 104], ["ICANS", "TEST", 109, 114], ["ResultsCRS", "TEST", 119, 129], ["CAR T cell infusion", "TREATMENT", 231, 250], ["leukocyte", "ANATOMY", 33, 42]]], ["ICANS was observed in 24 patients (40%) and was grade \u22653 in 13 patients.", [["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 63, 71], ["ICANS", "TEST", 0, 5]]], ["The median onset of ICANS was 5 days after infusion.", [["infusion", "TREATMENT", 43, 51], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["Of patients who developed CRS or ICANS, 25 (53.2%) received systemic corticosteroid with a median duration of 4 days (1\u201358 days).", [["CRS", "DISEASE", 26, 29], ["ICANS", "DISEASE", 33, 38], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["CRS", "PROBLEM", 26, 29], ["ICANS", "TEST", 33, 38], ["systemic corticosteroid", "TREATMENT", 60, 83]]], ["The median prednisone equivalent dose intensity of corticosteroid was 1.12 mg/kg/day (0.33\u20134.23 mg/kg/day) with the corresponding median cumulative dose of 380 mg (66.7\u20134586 mg) or 8.1 mg/kg (0.33\u201369.6 mg/kg) prednisone equivalent.", [["prednisone", "CHEMICAL", 11, 21], ["prednisone", "CHEMICAL", 209, 219], ["prednisone", "CHEMICAL", 11, 21], ["prednisone", "CHEMICAL", 209, 219], ["prednisone", "SIMPLE_CHEMICAL", 11, 21], ["corticosteroid", "SIMPLE_CHEMICAL", 51, 65], ["prednisone", "SIMPLE_CHEMICAL", 209, 219], ["The median prednisone equivalent dose intensity of corticosteroid", "TREATMENT", 0, 65], ["prednisone equivalent", "TREATMENT", 209, 230]]], ["Patients who received systemic corticosteroid had longer median hospital stay than patients who did not (27 days vs. 14 days, P < 0.001).CRS and ICANS ::: ResultsBaseline c-reactive protein, procalcitonin, and IL-6 before CAR T cell infusion were elevated in 52 (86.7%), 4 (7.4%), and 38 (63.3%) patients, respectively.", [["T cell", "ANATOMY", 226, 232], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 83, 91], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 191, 204], ["IL-6", "GENE_OR_GENE_PRODUCT", 210, 214], ["CAR T cell", "CELL", 222, 232], ["patients", "ORGANISM", 296, 304], ["ResultsBaseline c-reactive protein", "PROTEIN", 155, 189], ["procalcitonin", "PROTEIN", 191, 204], ["IL-6", "PROTEIN", 210, 214], ["CAR", "PROTEIN", 222, 225], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 296, 304], ["systemic corticosteroid", "TREATMENT", 22, 45], ["CRS", "TEST", 137, 140], ["ICANS", "TEST", 145, 150], ["c-reactive protein", "TEST", 171, 189], ["procalcitonin", "TEST", 191, 204], ["IL", "TEST", 210, 212], ["CAR T cell infusion", "TREATMENT", 222, 241]]], ["The median peak procalcitonin level was 0.46 (0.05\u201327.65) \u00b5g/L. The trends of procalcitonin and IL-6 are shown in Supplementary Figs.", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 16, 29], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 78, 91], ["IL-6", "GENE_OR_GENE_PRODUCT", 96, 100], ["procalcitonin", "PROTEIN", 78, 91], ["IL-6", "PROTEIN", 96, 100], ["The median peak procalcitonin level", "TEST", 0, 35], ["procalcitonin and IL", "TREATMENT", 78, 98], ["Supplementary Figs", "OBSERVATION", 114, 132]]], ["S1 and S2, respectively.Incidence, characteristics, and patterns of infection after CAR T cell therapy ::: ResultsFifty-two of 60 patients (86.7%) developed neutropenic fever within the first 30 days after CAR T cell infusion.", [["T cell", "ANATOMY", 88, 94], ["T cell", "ANATOMY", 210, 216], ["infection", "DISEASE", 68, 77], ["fever", "DISEASE", 169, 174], ["S2", "GENE_OR_GENE_PRODUCT", 7, 9], ["CAR T cell", "CELL", 84, 94], ["patients", "ORGANISM", 130, 138], ["CAR T cell", "CELL", 206, 216], ["S1", "PROTEIN", 0, 2], ["S2", "PROTEIN", 7, 9], ["patients", "SPECIES", 130, 138], ["infection", "PROBLEM", 68, 77], ["CAR T cell therapy", "TREATMENT", 84, 102], ["neutropenic fever", "PROBLEM", 157, 174], ["CAR T cell infusion", "TREATMENT", 206, 225], ["S2", "ANATOMY", 7, 9], ["infection", "OBSERVATION", 68, 77], ["neutropenic", "OBSERVATION_MODIFIER", 157, 168], ["fever", "OBSERVATION", 169, 174]]], ["With the median follow-up of 6 months (0.8\u201312 months), after excluding neutropenic fever without identified pathogen or localizing organ, there was a total of 101 infection events (60 bacterial, 38 viral, 2 fungal, and 1 protozoal) in 40 patients during the entire study period.", [["organ", "ANATOMY", 131, 136], ["fever", "DISEASE", 83, 88], ["infection", "DISEASE", 163, 172], ["organ", "ORGAN", 131, 136], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["neutropenic fever", "PROBLEM", 71, 88], ["pathogen", "PROBLEM", 108, 116], ["101 infection events", "PROBLEM", 159, 179], ["bacterial", "TEST", 184, 193], ["viral", "TEST", 198, 203], ["fungal", "TEST", 207, 213], ["pathogen", "OBSERVATION", 108, 116], ["infection", "OBSERVATION", 163, 172]]], ["Pathogenic organism were identified in 73 infection events (72%) (60% of bacterial, 92.1% of viral, 50% of fungal, and 100% of protozoal infection).", [["infection", "DISEASE", 42, 51], ["protozoal infection", "DISEASE", 127, 146], ["Pathogenic organism", "PROBLEM", 0, 19], ["73 infection events", "PROBLEM", 39, 58], ["bacterial", "TEST", 73, 82], ["viral", "TEST", 93, 98], ["fungal", "TEST", 107, 113], ["protozoal infection", "PROBLEM", 127, 146], ["infection", "OBSERVATION_MODIFIER", 42, 51], ["protozoal", "OBSERVATION_MODIFIER", 127, 136], ["infection", "OBSERVATION", 137, 146]]], ["Thirty-seven infection episodes (34.6%) occurred within the first 30 days after CAR T cell therapy.", [["T cell", "ANATOMY", 84, 90], ["infection", "DISEASE", 13, 22], ["CAR T cell", "CELL", 80, 90], ["Thirty-seven infection episodes", "PROBLEM", 0, 31], ["CAR T cell therapy", "TREATMENT", 80, 98], ["infection", "OBSERVATION", 13, 22], ["cell therapy", "OBSERVATION", 86, 98]]], ["Of 101 events, 23 (22.8)% infections were classified as severe, 1 (1.0%) as life-threatening (Escherichia coli biliary sepsis), and 1 (1.0%) fatal (influenza A pneumonia).", [["biliary", "ANATOMY", 111, 118], ["infections", "DISEASE", 26, 36], ["Escherichia coli biliary sepsis", "DISEASE", 94, 125], ["influenza A pneumonia", "DISEASE", 148, 169], ["Escherichia coli", "ORGANISM", 94, 110], ["biliary", "ORGAN", 111, 118], ["Escherichia coli", "SPECIES", 94, 110], ["Escherichia coli", "SPECIES", 94, 110], ["infections", "PROBLEM", 26, 36], ["Escherichia coli biliary sepsis", "PROBLEM", 94, 125], ["fatal (influenza A pneumonia)", "PROBLEM", 141, 170], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["Escherichia coli", "OBSERVATION", 94, 110], ["biliary", "ANATOMY", 111, 118], ["sepsis", "OBSERVATION", 119, 125], ["pneumonia", "OBSERVATION", 160, 169]]], ["Of all 101 infection events, 32 occurred during the initial CAR T cell admission.", [["T cell", "ANATOMY", 64, 70], ["infection", "DISEASE", 11, 20], ["all 101 infection events", "PROBLEM", 3, 27], ["infection", "OBSERVATION", 11, 20]]], ["Among the other 69 infection episodes (bacterial; n = 42, viral; n = 26, fungal; n = 1), which occurred following hospital discharge from CAR T cell therapy, 21 (bacterial; n = 14, viral; n = 6, fungal; n = 1) required hospital readmission with the median hospital stay of 5 (2\u201337) days.Incidence, characteristics, and patterns of infection after CAR T cell therapy ::: ResultsFigure 2 shows the distribution of bacterial or viral infection at each period post-CAR T cell infusion.", [["T cell", "ANATOMY", 142, 148], ["T cell", "ANATOMY", 351, 357], ["T cell", "ANATOMY", 465, 471], ["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 331, 340], ["infection", "DISEASE", 431, 440], ["CAR T cell", "CELL", 138, 148], ["CAR T cell", "CELL", 347, 357], ["T cell", "CELL", 465, 471], ["the other 69 infection episodes", "PROBLEM", 6, 37], ["bacterial", "TEST", 39, 48], ["viral", "TEST", 58, 63], ["fungal", "PROBLEM", 73, 79], ["CAR T cell therapy", "TREATMENT", 138, 156], ["bacterial", "TEST", 162, 171], ["viral", "TEST", 181, 186], ["fungal", "PROBLEM", 195, 201], ["infection", "PROBLEM", 331, 340], ["CAR T cell therapy", "TREATMENT", 347, 365], ["bacterial or viral infection", "PROBLEM", 412, 440], ["T cell infusion", "TREATMENT", 465, 480], ["infection", "OBSERVATION", 19, 28], ["infection", "OBSERVATION", 331, 340], ["distribution", "OBSERVATION_MODIFIER", 396, 408], ["bacterial", "OBSERVATION_MODIFIER", 412, 421], ["viral", "OBSERVATION_MODIFIER", 425, 430], ["infection", "OBSERVATION", 431, 440]]], ["The distribution of organ involvement and causative organism of bacterial infection are shown in Fig. 3 and Supplementary Table S3.", [["organ", "ANATOMY", 20, 25], ["bacterial infection", "DISEASE", 64, 83], ["organ", "ORGAN", 20, 25], ["organ involvement", "PROBLEM", 20, 37], ["bacterial infection", "PROBLEM", 64, 83], ["organ", "ANATOMY", 20, 25], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 74, 83]]], ["The 1-year cumulative incidence of all infections, bacterial, viral, and fungal infections were 63.3, 57.2, 44.7%, and 4.0%, respectively (Fig. 4, Table 4).Infection within the first 30 days of CAR T cell infusion ::: ResultsOf 37 infection episodes that occurred within the first 30 days after CAR T cell infusion (Supplementary Tables S3\u2013S6), bacterial infections were the most frequent with 25 events (15 moderate, 10 severe) in 20 patients.", [["T cell", "ANATOMY", 198, 204], ["T cell", "ANATOMY", 299, 305], ["infections", "DISEASE", 39, 49], ["bacterial, viral, and fungal infections", "DISEASE", 51, 90], ["infection", "DISEASE", 231, 240], ["bacterial infections", "DISEASE", 345, 365], ["CAR T cell", "CELL", 194, 204], ["CAR T cell", "CELL", 295, 305], ["patients", "ORGANISM", 435, 443], ["patients", "SPECIES", 435, 443], ["all infections", "PROBLEM", 35, 49], ["bacterial, viral, and fungal infections", "PROBLEM", 51, 90], ["Infection", "PROBLEM", 156, 165], ["CAR T cell infusion", "TREATMENT", 194, 213], ["37 infection episodes", "PROBLEM", 228, 249], ["CAR T cell infusion", "TREATMENT", 295, 314], ["Supplementary Tables S3\u2013S6", "TREATMENT", 316, 342], ["bacterial infections", "PROBLEM", 345, 365], ["all", "OBSERVATION_MODIFIER", 35, 38], ["infections", "OBSERVATION", 39, 49], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["viral", "OBSERVATION_MODIFIER", 62, 67], ["fungal", "OBSERVATION_MODIFIER", 73, 79], ["infections", "OBSERVATION", 80, 90], ["infection", "OBSERVATION", 231, 240], ["bacterial", "OBSERVATION_MODIFIER", 345, 354], ["infections", "OBSERVATION", 355, 365]]], ["The median onset of the first bacterial infection was day 12 (0\u201330).", [["bacterial infection", "DISEASE", 30, 49], ["the first bacterial infection", "PROBLEM", 20, 49], ["median onset", "OBSERVATION_MODIFIER", 4, 16], ["bacterial", "OBSERVATION_MODIFIER", 30, 39], ["infection", "OBSERVATION", 40, 49]]], ["A total of 15 events were organ-specific infections, whereas 10 were primary bacteremias.", [["organ", "ANATOMY", 26, 31], ["infections", "DISEASE", 41, 51], ["primary bacteremias", "DISEASE", 69, 88], ["organ", "ORGAN", 26, 31], ["specific infections", "PROBLEM", 32, 51], ["primary bacteremias", "PROBLEM", 69, 88], ["infections", "OBSERVATION", 41, 51], ["bacteremias", "OBSERVATION", 77, 88]]], ["Organisms were identified in 19 definite infectious episodes with Clostridium difficile (colitis) being the most common causative bacterial pathogen (n = 7).", [["Clostridium difficile", "DISEASE", 66, 87], ["colitis", "DISEASE", 89, 96], ["Clostridium difficile", "ORGANISM", 66, 87], ["colitis", "PATHOLOGICAL_FORMATION", 89, 96], ["Clostridium difficile", "SPECIES", 66, 87], ["Clostridium difficile", "SPECIES", 66, 87], ["Organisms", "PROBLEM", 0, 9], ["19 definite infectious episodes", "PROBLEM", 29, 60], ["Clostridium difficile (colitis", "PROBLEM", 66, 96], ["causative bacterial pathogen", "PROBLEM", 120, 148], ["19 definite", "OBSERVATION_MODIFIER", 29, 40], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["Clostridium difficile", "OBSERVATION", 66, 87], ["colitis", "OBSERVATION", 89, 96], ["most common", "OBSERVATION_MODIFIER", 108, 119], ["bacterial", "OBSERVATION_MODIFIER", 130, 139], ["pathogen", "OBSERVATION", 140, 148]]], ["The other 6 events were probable infections (including 3 lobar pneumonia, 3 soft tissue infection).", [["lobar", "ANATOMY", 57, 62], ["soft tissue", "ANATOMY", 76, 87], ["infections", "DISEASE", 33, 43], ["pneumonia", "DISEASE", 63, 72], ["soft tissue infection", "DISEASE", 76, 97], ["tissue", "TISSUE", 81, 87], ["infections", "PROBLEM", 33, 43], ["3 lobar pneumonia", "PROBLEM", 55, 72], ["3 soft tissue infection", "PROBLEM", 74, 97], ["probable", "UNCERTAINTY", 24, 32], ["infections", "OBSERVATION", 33, 43], ["lobar", "OBSERVATION_MODIFIER", 57, 62], ["pneumonia", "OBSERVATION", 63, 72], ["soft tissue", "OBSERVATION_MODIFIER", 76, 87], ["infection", "OBSERVATION", 88, 97]]], ["Piperacillin/tazobactam was the most common empirical anti-bacterial agent for neutropenic fever during the first 30 days in 38 patients (63.3%), followed by cefepime in 7 patients.Infection within the first 30 days of CAR T cell infusion ::: ResultsTen viral infections occurred during the first 30 days (8 mild, 2 moderate) with the median onset at day 8 (0\u201326 days).", [["T cell", "ANATOMY", 223, 229], ["Piperacillin/tazobactam", "CHEMICAL", 0, 23], ["neutropenic fever", "DISEASE", 79, 96], ["cefepime", "CHEMICAL", 158, 166], ["viral infections", "DISEASE", 254, 270], ["Piperacillin", "CHEMICAL", 0, 12], ["tazobactam", "CHEMICAL", 13, 23], ["cefepime", "CHEMICAL", 158, 166], ["Piperacillin/tazobactam", "SIMPLE_CHEMICAL", 0, 23], ["patients", "ORGANISM", 128, 136], ["cefepime", "SIMPLE_CHEMICAL", 158, 166], ["patients", "ORGANISM", 172, 180], ["CAR T cell", "CELL", 219, 229], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 172, 180], ["Piperacillin", "TREATMENT", 0, 12], ["tazobactam", "TREATMENT", 13, 23], ["empirical anti-bacterial agent", "TREATMENT", 44, 74], ["neutropenic fever", "PROBLEM", 79, 96], ["cefepime", "TREATMENT", 158, 166], ["Infection", "PROBLEM", 181, 190], ["CAR T cell infusion", "TREATMENT", 219, 238], ["ResultsTen viral infections", "PROBLEM", 243, 270], ["viral", "OBSERVATION_MODIFIER", 254, 259], ["infections", "OBSERVATION", 260, 270]]], ["Viral pathogens included respiratory syncytial virus (n = 5), cytomegalovirus (n = 2), polyoma BK virus (n = 2), and norovirus (n = 1).", [["Viral pathogens", "DISEASE", 0, 15], ["respiratory syncytial virus", "DISEASE", 25, 52], ["cytomegalovirus", "DISEASE", 62, 77], ["polyoma BK", "DISEASE", 87, 97], ["norovirus", "DISEASE", 117, 126], ["respiratory syncytial virus", "ORGANISM", 25, 52], ["cytomegalovirus", "ORGANISM", 62, 77], ["polyoma BK virus", "ORGANISM", 87, 103], ["respiratory syncytial virus", "SPECIES", 25, 52], ["polyoma BK virus", "SPECIES", 87, 103], ["respiratory syncytial virus", "SPECIES", 25, 52], ["polyoma BK virus", "SPECIES", 87, 103], ["Viral pathogens", "PROBLEM", 0, 15], ["respiratory syncytial virus", "PROBLEM", 25, 52], ["cytomegalovirus", "PROBLEM", 62, 77], ["polyoma BK virus", "PROBLEM", 87, 103], ["norovirus", "PROBLEM", 117, 126], ["respiratory syncytial virus", "OBSERVATION", 25, 52], ["norovirus", "OBSERVATION", 117, 126]]], ["Both cytomegalovirus infection were viremia without end organ involvement.", [["organ", "ANATOMY", 56, 61], ["cytomegalovirus infection", "DISEASE", 5, 30], ["viremia", "DISEASE", 36, 43], ["cytomegalovirus", "ORGANISM", 5, 20], ["organ", "ORGAN", 56, 61], ["Both cytomegalovirus infection", "PROBLEM", 0, 30], ["viremia", "PROBLEM", 36, 43], ["end organ involvement", "PROBLEM", 52, 73], ["cytomegalovirus", "OBSERVATION_MODIFIER", 5, 20], ["infection", "OBSERVATION", 21, 30], ["viremia", "OBSERVATION", 36, 43]]], ["There was 1 probable invasive aspergillosis pulmonary infection (elevated serum galactomannan antigen and consistent radiographic imaging), and 1 protozoal infection (Cryptosporidium parvum).Infection after day 30 post CAR T cell infusion ::: ResultsThirty-five bacterial infections were observed in 16 patients after day 30, including 12 events during day 31\u2013100, 7 during day 101\u2013180, and 16 beyond day 180 (Supplementary Tables S3\u2013S6).", [["pulmonary", "ANATOMY", 44, 53], ["serum", "ANATOMY", 74, 79], ["T cell", "ANATOMY", 223, 229], ["aspergillosis pulmonary infection", "DISEASE", 30, 63], ["protozoal infection", "DISEASE", 146, 165], ["Cryptosporidium parvum", "DISEASE", 167, 189], ["bacterial infections", "DISEASE", 262, 282], ["pulmonary", "ORGAN", 44, 53], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["galactomannan antigen", "GENE_OR_GENE_PRODUCT", 80, 101], ["Cryptosporidium parvum", "ORGANISM", 167, 189], ["CAR T cell", "CELL", 219, 229], ["patients", "ORGANISM", 303, 311], ["serum galactomannan antigen", "PROTEIN", 74, 101], ["S6", "PROTEIN", 434, 436], ["Cryptosporidium parvum", "SPECIES", 167, 189], ["patients", "SPECIES", 303, 311], ["Cryptosporidium parvum", "SPECIES", 167, 189], ["invasive aspergillosis pulmonary infection", "PROBLEM", 21, 63], ["elevated serum galactomannan antigen", "PROBLEM", 65, 101], ["radiographic imaging", "TEST", 117, 137], ["1 protozoal infection (Cryptosporidium parvum", "PROBLEM", 144, 189], ["Infection", "PROBLEM", 191, 200], ["CAR T cell infusion", "TREATMENT", 219, 238], ["ResultsThirty", "TEST", 243, 256], ["five bacterial infections", "PROBLEM", 257, 282], ["probable", "UNCERTAINTY", 12, 20], ["invasive", "OBSERVATION_MODIFIER", 21, 29], ["aspergillosis", "OBSERVATION", 30, 43], ["pulmonary", "ANATOMY", 44, 53], ["infection", "OBSERVATION", 54, 63], ["protozoal", "OBSERVATION_MODIFIER", 146, 155], ["infection", "OBSERVATION", 156, 165], ["bacterial", "OBSERVATION_MODIFIER", 262, 271], ["infections", "OBSERVATION", 272, 282]]], ["Six of these 16 patients had previous bacterial infection within the first 30 days.", [["bacterial infection", "DISEASE", 38, 57], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["previous bacterial infection", "PROBLEM", 29, 57], ["bacterial", "OBSERVATION_MODIFIER", 38, 47], ["infection", "OBSERVATION", 48, 57]]], ["Among 35 bacterial infections, there were 26 moderate, 8 severe, and 1 fatal infection.", [["bacterial infections", "DISEASE", 9, 29], ["infection", "DISEASE", 77, 86], ["35 bacterial infections", "PROBLEM", 6, 29], ["moderate, 8 severe, and 1 fatal infection", "PROBLEM", 45, 86], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["26 moderate", "OBSERVATION_MODIFIER", 42, 53], ["8 severe", "OBSERVATION_MODIFIER", 55, 63], ["fatal", "OBSERVATION_MODIFIER", 71, 76], ["infection", "OBSERVATION", 77, 86]]], ["Ninety-seven percent were organ-specific infections with urinary tract infection being the most common presentation (n = 11).", [["organ", "ANATOMY", 26, 31], ["urinary tract", "ANATOMY", 57, 70], ["infections", "DISEASE", 41, 51], ["urinary tract infection", "DISEASE", 57, 80], ["organ", "ORGAN", 26, 31], ["urinary tract", "ORGANISM_SUBDIVISION", 57, 70], ["specific infections", "PROBLEM", 32, 51], ["urinary tract infection", "PROBLEM", 57, 80], ["organ", "ANATOMY", 26, 31], ["infections", "OBSERVATION", 41, 51], ["urinary tract", "ANATOMY", 57, 70], ["infection", "OBSERVATION", 71, 80], ["most common", "OBSERVATION_MODIFIER", 91, 102]]], ["Of 28 viral infections, 10 occurred during day 31\u2013100, 8 occurred during day 101\u2013180, and 10 occurred after day 180.", [["viral infections", "DISEASE", 6, 22], ["28 viral infections", "PROBLEM", 3, 22], ["28 viral", "OBSERVATION_MODIFIER", 3, 11], ["infections", "OBSERVATION", 12, 22]]], ["Approximately 50% of viral infections were of mild severity (n = 17).", [["viral infections", "DISEASE", 21, 37], ["viral infections", "PROBLEM", 21, 37], ["mild severity", "PROBLEM", 46, 59], ["viral", "OBSERVATION_MODIFIER", 21, 26], ["infections", "OBSERVATION", 27, 37], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["severity", "OBSERVATION_MODIFIER", 51, 59]]], ["Respiratory tract infections (n = 21) were the most common with rhinovirus being the most frequently recovered.", [["Respiratory tract", "ANATOMY", 0, 17], ["Respiratory tract infections", "DISEASE", 0, 28], ["Respiratory tract", "ORGANISM_SUBDIVISION", 0, 17], ["rhinovirus", "ORGANISM", 64, 74], ["Respiratory tract infections", "PROBLEM", 0, 28], ["rhinovirus", "PROBLEM", 64, 74], ["tract", "OBSERVATION_MODIFIER", 12, 17], ["infections", "OBSERVATION", 18, 28], ["rhinovirus", "OBSERVATION", 64, 74]]], ["There were 1 cytomegalovirus reactivation (viremia without organ dysfunction), 2 BK virus cystitis, and 2 herpes zoster reactivation (both of whom were on acyclovir prophylaxis).", [["organ", "ANATOMY", 59, 64], ["cytomegalovirus reactivation", "DISEASE", 13, 41], ["viremia", "DISEASE", 43, 50], ["organ dysfunction", "DISEASE", 59, 76], ["cystitis", "DISEASE", 90, 98], ["herpes zoster", "DISEASE", 106, 119], ["acyclovir", "CHEMICAL", 155, 164], ["acyclovir", "CHEMICAL", 155, 164], ["cytomegalovirus", "ORGANISM", 13, 28], ["organ", "ORGAN", 59, 64], ["BK virus", "ORGANISM", 81, 89], ["herpes zoster", "ORGANISM", 106, 119], ["acyclovir", "SIMPLE_CHEMICAL", 155, 164], ["BK virus", "SPECIES", 81, 89], ["herpes zoster", "SPECIES", 106, 119], ["1 cytomegalovirus reactivation", "PROBLEM", 11, 41], ["viremia", "PROBLEM", 43, 50], ["organ dysfunction", "PROBLEM", 59, 76], ["2 BK virus cystitis", "PROBLEM", 79, 98], ["2 herpes zoster reactivation", "PROBLEM", 104, 132], ["acyclovir prophylaxis", "TREATMENT", 155, 176], ["cytomegalovirus reactivation", "OBSERVATION", 13, 41], ["virus cystitis", "OBSERVATION", 84, 98], ["herpes", "OBSERVATION_MODIFIER", 106, 112], ["zoster reactivation", "OBSERVATION", 113, 132]]], ["Pneumocystis jiroveci infection was identified in 1 patient at 9 months after CAR T cell infusion (4 months after pentamidine prophylaxis discontinuation).Risk factors associated with infection ::: ResultsIn the univariate analysis, impaired baseline performance status, ICANS grade \u22652, and systemic corticosteroid exposure after CAR T cell infusion were associated with a higher incidence of overall infection (Table 5).", [["T cell", "ANATOMY", 82, 88], ["T cell", "ANATOMY", 334, 340], ["Pneumocystis jiroveci infection", "DISEASE", 0, 31], ["pentamidine", "CHEMICAL", 114, 125], ["infection", "DISEASE", 184, 193], ["infection", "DISEASE", 401, 410], ["pentamidine", "CHEMICAL", 114, 125], ["Pneumocystis jiroveci", "ORGANISM", 0, 21], ["patient", "ORGANISM", 52, 59], ["CAR T cell", "CELL", 78, 88], ["pentamidine", "SIMPLE_CHEMICAL", 114, 125], ["CAR T cell", "CELL", 330, 340], ["CAR", "PROTEIN", 330, 333], ["Pneumocystis jiroveci", "SPECIES", 0, 21], ["patient", "SPECIES", 52, 59], ["Pneumocystis jiroveci", "SPECIES", 0, 21], ["Pneumocystis jiroveci infection", "PROBLEM", 0, 31], ["CAR T cell infusion", "TREATMENT", 78, 97], ["pentamidine prophylaxis discontinuation", "TREATMENT", 114, 153], ["infection", "PROBLEM", 184, 193], ["the univariate analysis", "TEST", 208, 231], ["impaired baseline performance status", "PROBLEM", 233, 269], ["ICANS grade \u22652", "PROBLEM", 271, 285], ["systemic corticosteroid exposure", "TREATMENT", 291, 323], ["CAR T cell infusion", "TREATMENT", 330, 349], ["overall infection", "PROBLEM", 393, 410], ["jiroveci", "OBSERVATION", 13, 21], ["infection", "OBSERVATION", 184, 193], ["systemic", "OBSERVATION_MODIFIER", 291, 299], ["corticosteroid exposure", "OBSERVATION", 300, 323], ["higher", "OBSERVATION_MODIFIER", 373, 379], ["overall", "OBSERVATION_MODIFIER", 393, 400], ["infection", "OBSERVATION", 401, 410]]], ["In multivariate analysis, systemic corticosteroid was the only risk factor of infectious complications.", [["multivariate analysis", "TEST", 3, 24], ["systemic corticosteroid", "TREATMENT", 26, 49], ["infectious complications", "PROBLEM", 78, 102], ["infectious", "OBSERVATION", 78, 88]]], ["Impaired performance status and previous infection 30 days before LD chemotherapy was independent predictors for severe bacterial infection (HR 3.98, 95% CI 1.3\u201312.2).", [["infection", "DISEASE", 41, 50], ["bacterial infection", "DISEASE", 120, 139], ["Impaired performance status", "PROBLEM", 0, 27], ["previous infection", "PROBLEM", 32, 50], ["LD chemotherapy", "TREATMENT", 66, 81], ["severe bacterial infection", "PROBLEM", 113, 139], ["HR", "TEST", 141, 143], ["CI", "TEST", 154, 156], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["infection", "OBSERVATION", 130, 139]]], ["Patients with low IgG before LD chemotherapy had higher risk of viral infection after CAR T cells (HR 5.7, 95% CI 2.3\u201314.3; Supplementary Table S7), however, IVIG replacement did not decrease the incidence of infection.", [["CAR T cells", "ANATOMY", 86, 97], ["viral infection", "DISEASE", 64, 79], ["infection", "DISEASE", 209, 218], ["Patients", "ORGANISM", 0, 8], ["CAR T cells", "CELL", 86, 97], ["IVIG", "SIMPLE_CHEMICAL", 158, 162], ["IgG", "PROTEIN", 18, 21], ["CAR T cells", "CELL_TYPE", 86, 97], ["Patients", "SPECIES", 0, 8], ["low IgG", "PROBLEM", 14, 21], ["LD chemotherapy", "TREATMENT", 29, 44], ["viral infection", "PROBLEM", 64, 79], ["CAR T cells", "TEST", 86, 97], ["HR", "TEST", 99, 101], ["CI", "TEST", 111, 113], ["IVIG replacement", "TREATMENT", 158, 174], ["infection", "PROBLEM", 209, 218], ["low IgG", "OBSERVATION_MODIFIER", 14, 21], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["infection", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 209, 218]]], ["CRS, tocilizumab administration, and procalcitonin were not associated with infection or severe bacterial infection.", [["CRS", "DISEASE", 0, 3], ["tocilizumab", "CHEMICAL", 5, 16], ["infection", "DISEASE", 76, 85], ["bacterial infection", "DISEASE", 96, 115], ["tocilizumab", "SIMPLE_CHEMICAL", 5, 16], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 37, 50], ["CRS", "TEST", 0, 3], ["tocilizumab administration", "TREATMENT", 5, 31], ["procalcitonin", "TREATMENT", 37, 50], ["infection", "PROBLEM", 76, 85], ["severe bacterial infection", "PROBLEM", 89, 115], ["not associated with", "UNCERTAINTY", 56, 75], ["infection", "OBSERVATION", 76, 85], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["infection", "OBSERVATION", 106, 115]]], ["The incidence of infection was comparable between 47 patients who received CAR T cell therapy before March 2019 and 13 patients who were treated with CAR T cells after March 2019, when the standardized antimicrobial prophylaxis guideline was implemented (HR 1.22, 95% CI 0.6\u20132.5).Impact of infection on patients\u2019 survival outcomes ::: ResultsOf all infectious complications, one resulted in death attributed to influenza pneumonia despite a 10-day course of oseltamivir treatment.", [["T cell", "ANATOMY", 79, 85], ["T cells", "ANATOMY", 154, 161], ["infection", "DISEASE", 17, 26], ["infection", "DISEASE", 290, 299], ["death", "DISEASE", 391, 396], ["pneumonia", "DISEASE", 421, 430], ["oseltamivir", "CHEMICAL", 458, 469], ["oseltamivir", "CHEMICAL", 458, 469], ["patients", "ORGANISM", 53, 61], ["CAR T cell", "CELL", 75, 85], ["patients", "ORGANISM", 119, 127], ["CAR T cells", "CELL", 150, 161], ["patients", "ORGANISM", 303, 311], ["oseltamivir", "SIMPLE_CHEMICAL", 458, 469], ["CAR", "PROTEIN", 75, 78], ["CAR T cells", "CELL_TYPE", 150, 161], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 303, 311], ["infection", "PROBLEM", 17, 26], ["CAR T cell therapy", "TREATMENT", 75, 93], ["CAR T cells", "TREATMENT", 150, 161], ["the standardized antimicrobial prophylaxis guideline", "TREATMENT", 185, 237], ["HR", "TEST", 255, 257], ["CI", "TEST", 268, 270], ["infection", "PROBLEM", 290, 299], ["all infectious complications", "PROBLEM", 345, 373], ["death", "PROBLEM", 391, 396], ["influenza pneumonia", "PROBLEM", 411, 430], ["oseltamivir treatment", "TREATMENT", 458, 479], ["infection", "OBSERVATION", 17, 26], ["infection", "OBSERVATION", 290, 299], ["infectious", "OBSERVATION_MODIFIER", 349, 359], ["influenza", "OBSERVATION_MODIFIER", 411, 420], ["pneumonia", "OBSERVATION", 421, 430]]], ["There was no association between infectious complications and mortality risk in CAR T cell-treated patients when analyzed by univariate cox regression.DiscussionOur study reported comprehensive real-world data on infectious complications in DLBCL patients treated with commercially available CD19 CAR T cell products.", [["T cell", "ANATOMY", 84, 90], ["DLBCL", "ANATOMY", 241, 246], ["T cell", "ANATOMY", 301, 307], ["infectious complications", "DISEASE", 33, 57], ["DLBCL", "DISEASE", 241, 246], ["CAR T cell", "CELL", 80, 90], ["patients", "ORGANISM", 99, 107], ["DLBCL", "CANCER", 241, 246], ["patients", "ORGANISM", 247, 255], ["CD19", "GENE_OR_GENE_PRODUCT", 292, 296], ["CD19 CAR T cell products", "PROTEIN", 292, 316], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 247, 255], ["infectious complications", "PROBLEM", 33, 57], ["univariate cox regression", "PROBLEM", 125, 150], ["DiscussionOur study", "TEST", 151, 170], ["infectious complications", "PROBLEM", 213, 237], ["CD19 CAR T cell products", "TREATMENT", 292, 316], ["no association between", "UNCERTAINTY", 10, 32], ["infectious", "OBSERVATION_MODIFIER", 33, 43], ["infectious", "OBSERVATION_MODIFIER", 213, 223]]], ["Data from the pivotal studies of CD19 CAR T cell therapy in DLBCL demonstrated an incidence of 15\u201330% for severe infection13\u201315.", [["T cell", "ANATOMY", 42, 48], ["DLBCL", "ANATOMY", 60, 65], ["DLBCL", "DISEASE", 60, 65], ["infection", "DISEASE", 113, 122], ["CD19", "GENE_OR_GENE_PRODUCT", 33, 37], ["DLBCL", "CANCER", 60, 65], ["CD19", "PROTEIN", 33, 37], ["the pivotal studies", "TEST", 10, 29], ["CD19 CAR T cell therapy", "TREATMENT", 33, 56], ["DLBCL", "PROBLEM", 60, 65], ["severe infection", "PROBLEM", 106, 122], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["infection", "OBSERVATION", 113, 122]]], ["The incidence of overall infection in our study was comparable to these landmark trials.", [["infection", "DISEASE", 25, 34], ["overall infection", "PROBLEM", 17, 34], ["our study", "TEST", 38, 47], ["overall", "OBSERVATION_MODIFIER", 17, 24], ["infection", "OBSERVATION", 25, 34]]], ["Moreover, the patterns of infection in our cohort were similar to the findings from previous reports5,7,10.", [["infection", "DISEASE", 26, 35], ["infection", "PROBLEM", 26, 35], ["infection", "OBSERVATION", 26, 35]]], ["Bacterial and viral infections were commonly observed, with bacteria being the most common pathogen, especially during the first 30 days5,7,10.", [["Bacterial and viral infections", "DISEASE", 0, 30], ["Bacterial and viral infections", "PROBLEM", 0, 30], ["bacteria", "PROBLEM", 60, 68], ["viral infections", "OBSERVATION", 14, 30], ["most common", "OBSERVATION_MODIFIER", 79, 90]]], ["Recently, Cordeiro and colleagues reported the incidence of adverse events beyond day 90 from CAR T cell infusion16 and described a relatively low incidence of late infections (2.08 per patient-year), with most being of mild to moderate severity.", [["T cell", "ANATOMY", 98, 104], ["infections", "DISEASE", 165, 175], ["CAR T cell", "CELL", 94, 104], ["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 186, 193], ["adverse events", "PROBLEM", 60, 74], ["CAR T cell infusion16", "TREATMENT", 94, 115], ["late infections", "PROBLEM", 160, 175], ["mild to moderate severity", "PROBLEM", 220, 245], ["low incidence", "OBSERVATION_MODIFIER", 143, 156], ["late", "OBSERVATION_MODIFIER", 160, 164], ["infections", "OBSERVATION", 165, 175], ["mild", "OBSERVATION_MODIFIER", 220, 224], ["moderate", "OBSERVATION_MODIFIER", 228, 236], ["severity", "OBSERVATION_MODIFIER", 237, 245]]], ["Our study observed similar results with 71% of all infections considered mild to moderate.", [["infections", "DISEASE", 51, 61], ["Our study", "TEST", 0, 9], ["all infections", "PROBLEM", 47, 61], ["infections", "OBSERVATION", 51, 61], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["moderate", "OBSERVATION_MODIFIER", 81, 89]]], ["Upper respiratory tract infections were the most common infectious events.", [["Upper respiratory tract", "ANATOMY", 0, 23], ["respiratory tract infections", "DISEASE", 6, 34], ["Upper respiratory tract", "ORGANISM_SUBDIVISION", 0, 23], ["Upper respiratory tract infections", "PROBLEM", 0, 34], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34], ["most common", "OBSERVATION_MODIFIER", 44, 55], ["infectious", "OBSERVATION", 56, 66]]], ["Serious infections occurred in 23.4% of DLBCL patients treated with commercial CD19 CAR T cell products; nonetheless, most infections were manageable and infection-related mortality was low similar to the results of previous reports5,7,17.", [["DLBCL", "ANATOMY", 40, 45], ["T cell", "ANATOMY", 88, 94], ["infections", "DISEASE", 8, 18], ["DLBCL", "DISEASE", 40, 45], ["infections", "DISEASE", 123, 133], ["infection", "DISEASE", 154, 163], ["DLBCL", "CANCER", 40, 45], ["patients", "ORGANISM", 46, 54], ["CD19", "GENE_OR_GENE_PRODUCT", 79, 83], ["CD19", "PROTEIN", 79, 83], ["patients", "SPECIES", 46, 54], ["Serious infections", "PROBLEM", 0, 18], ["DLBCL", "PROBLEM", 40, 45], ["commercial CD19 CAR T cell products", "TREATMENT", 68, 103], ["most infections", "PROBLEM", 118, 133], ["infection", "PROBLEM", 154, 163], ["infections", "OBSERVATION", 8, 18]]], ["In our study, one patient died from influenza A pneumonia at day +159 despite treatment with oseltamivir.", [["influenza A pneumonia", "DISEASE", 36, 57], ["oseltamivir", "CHEMICAL", 93, 104], ["oseltamivir", "CHEMICAL", 93, 104], ["patient", "ORGANISM", 18, 25], ["oseltamivir", "SIMPLE_CHEMICAL", 93, 104], ["patient", "SPECIES", 18, 25], ["our study", "TEST", 3, 12], ["influenza A pneumonia", "PROBLEM", 36, 57], ["oseltamivir", "TREATMENT", 93, 104], ["influenza", "OBSERVATION", 36, 45], ["pneumonia", "OBSERVATION", 48, 57]]], ["Fungal infection was uncommon in patients treated with CAR T cells likely due to short duration of neutropenia5,18.", [["T cells", "ANATOMY", 59, 66], ["Fungal infection", "DISEASE", 0, 16], ["neutropenia5", "CHEMICAL", 99, 111], ["patients", "ORGANISM", 33, 41], ["CAR T cells", "CELL", 55, 66], ["CAR T cells", "CELL_TYPE", 55, 66], ["patients", "SPECIES", 33, 41], ["Fungal infection", "PROBLEM", 0, 16], ["CAR T cells", "TREATMENT", 55, 66], ["neutropenia5", "TEST", 99, 111], ["infection", "OBSERVATION", 7, 16]]], ["One patient had Pneumocystis jirovecii pneumonia 4 months after pentamidine prophylaxis was stopped.", [["Pneumocystis jirovecii pneumonia", "DISEASE", 16, 48], ["pentamidine", "CHEMICAL", 64, 75], ["pentamidine", "CHEMICAL", 64, 75], ["patient", "ORGANISM", 4, 11], ["Pneumocystis jirovecii", "ORGANISM", 16, 38], ["pentamidine", "SIMPLE_CHEMICAL", 64, 75], ["patient", "SPECIES", 4, 11], ["Pneumocystis jirovecii", "SPECIES", 16, 38], ["Pneumocystis jirovecii", "SPECIES", 16, 38], ["Pneumocystis jirovecii pneumonia", "PROBLEM", 16, 48], ["pentamidine prophylaxis", "TREATMENT", 64, 87], ["Pneumocystis", "OBSERVATION_MODIFIER", 16, 28], ["jirovecii", "OBSERVATION", 29, 38]]], ["Retrospectively, the patient\u2019s CD4 count was 44 cells/\u00b5L at the time of infection, thus emphasizing the importance of implementing immune monitoring protocols to guide the duration of antimicrobial prophylaxis in these patients.DiscussionGeneral practice for infection prophylaxis in patients treated with CAR T cell are heterogeneous and vary by institutions19.", [["cells", "ANATOMY", 48, 53], ["T cell", "ANATOMY", 310, 316], ["infection", "DISEASE", 72, 81], ["infection", "DISEASE", 259, 268], ["patient", "ORGANISM", 21, 28], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["cells", "CELL", 48, 53], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 284, 292], ["CAR T cell", "CELL", 306, 316], ["CD4", "PROTEIN", 31, 34], ["CAR T cell", "CELL_TYPE", 306, 316], ["patient", "SPECIES", 21, 28], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 284, 292], ["the patient\u2019s CD4 count", "TEST", 17, 40], ["cells", "TEST", 48, 53], ["infection", "PROBLEM", 72, 81], ["immune monitoring protocols", "TREATMENT", 131, 158], ["antimicrobial prophylaxis", "TREATMENT", 184, 209], ["infection prophylaxis", "TREATMENT", 259, 280], ["CAR T cell", "TREATMENT", 306, 316], ["infection", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 259, 268], ["heterogeneous", "OBSERVATION_MODIFIER", 321, 334]]], ["The recent European guidelines for antimicrobial prophylaxis and IVIG replacement in patients treated with CAR T cells20 was primarily based on the evidence from SCT patients21.", [["IVIG", "SIMPLE_CHEMICAL", 65, 69], ["patients", "ORGANISM", 85, 93], ["CAR T cells20", "GENE_OR_GENE_PRODUCT", 107, 120], ["patients", "ORGANISM", 166, 174], ["CAR T cells20", "PROTEIN", 107, 120], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 166, 174], ["The recent European guidelines", "TREATMENT", 0, 30], ["antimicrobial prophylaxis", "TREATMENT", 35, 60], ["IVIG replacement", "TREATMENT", 65, 81], ["CAR T cells20", "TREATMENT", 107, 120]]], ["Currently, the appropriate prophylactic approach in these patients remains unknown and requires further understanding of the immune reconstitution pattern and longer follow-up data.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["the appropriate prophylactic approach", "TREATMENT", 11, 48], ["the immune reconstitution pattern", "TREATMENT", 121, 154]]], ["B cell aplasia is a well-known \u201coff tumor and on target\u201d phenomenon after CD19 CAR T cell therapy contributing to hypogammaglobulinemia in these patients.", [["B cell", "ANATOMY", 0, 6], ["tumor", "ANATOMY", 36, 41], ["T cell", "ANATOMY", 83, 89], ["aplasia", "DISEASE", 7, 14], ["tumor", "DISEASE", 36, 41], ["hypogammaglobulinemia", "DISEASE", 114, 135], ["B cell", "CELL", 0, 6], ["tumor", "CANCER", 36, 41], ["CD19", "GENE_OR_GENE_PRODUCT", 74, 78], ["patients", "ORGANISM", 145, 153], ["CD19", "PROTEIN", 74, 78], ["patients", "SPECIES", 145, 153], ["B cell aplasia", "PROBLEM", 0, 14], ["tumor", "PROBLEM", 36, 41], ["target\u201d phenomenon", "TREATMENT", 49, 67], ["CD19 CAR T cell therapy", "TREATMENT", 74, 97], ["hypogammaglobulinemia", "PROBLEM", 114, 135], ["cell aplasia", "OBSERVATION", 2, 14], ["tumor", "OBSERVATION", 36, 41], ["hypogammaglobulinemia", "OBSERVATION", 114, 135]]], ["A quarter of patients in our cohort had IgG < 400 mg/dL, and 60% had IgG < 600 mg/dL.", [["patients", "ORGANISM", 13, 21], ["IgG", "PROTEIN", 40, 43], ["IgG", "PROTEIN", 69, 72], ["patients", "SPECIES", 13, 21], ["IgG", "TEST", 40, 43], ["IgG", "TEST", 69, 72]]], ["This finding was comparable to data from the JULIET trial14, which highlighted the baseline humoral immune defect in these patients.", [["patients", "ORGANISM", 123, 131], ["JULIET trial14", "DNA", 45, 59], ["patients", "SPECIES", 123, 131], ["the JULIET trial14", "TEST", 41, 59], ["the baseline humoral immune defect", "PROBLEM", 79, 113], ["humoral immune defect", "OBSERVATION", 92, 113]]], ["However, there are data showing persistent long-lived plasma cells after CAR T cell therapy22.", [["plasma cells", "ANATOMY", 54, 66], ["T cell", "ANATOMY", 77, 83], ["plasma cells", "CELL", 54, 66], ["CAR T cell", "CELL", 73, 83], ["plasma cells", "CELL_TYPE", 54, 66], ["CAR T cell therapy22", "PROTEIN", 73, 93], ["persistent long-lived plasma cells", "PROBLEM", 32, 66], ["CAR T cell therapy22", "TREATMENT", 73, 93], ["persistent", "OBSERVATION_MODIFIER", 32, 42], ["long", "OBSERVATION_MODIFIER", 43, 47]]], ["In addition, Hill and colleagues recently demonstrated preserved anti-viral humoral immune response in patients treated with CD19 CAR T cells23.", [["CD19 CAR T cells", "ANATOMY", 125, 141], ["patients", "ORGANISM", 103, 111], ["CD19", "GENE_OR_GENE_PRODUCT", 125, 129], ["CD19", "PROTEIN", 125, 129], ["patients", "SPECIES", 103, 111], ["CD19 CAR T cells", "TREATMENT", 125, 141], ["anti-viral humoral immune response", "OBSERVATION", 65, 99]]], ["The authors reported sustained anti-measle IgG level independent of the total IgG level in 95% of patients.", [["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgG", "GENE_OR_GENE_PRODUCT", 78, 81], ["patients", "ORGANISM", 98, 106], ["anti-measle IgG", "PROTEIN", 31, 46], ["IgG", "PROTEIN", 78, 81], ["patients", "SPECIES", 98, 106], ["sustained anti-measle IgG level", "PROBLEM", 21, 52], ["the total IgG level", "TEST", 68, 87]]], ["Moreover, overall anti-virome was preserved in most patients.", [["anti-virome", "SIMPLE_CHEMICAL", 18, 29], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["Moreover, there was a low incidence of viral infection after day 90.", [["viral infection", "DISEASE", 39, 54], ["viral infection", "PROBLEM", 39, 54], ["low incidence", "OBSERVATION_MODIFIER", 22, 35], ["viral", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 45, 54]]], ["In our study, there were 18 viral infectious episodes in 15 patients after day 100 with mild respiratory tract infection as the most common presentation similar to previous reports.", [["respiratory tract", "ANATOMY", 93, 110], ["viral infectious episodes", "DISEASE", 28, 53], ["respiratory tract infection", "DISEASE", 93, 120], ["patients", "ORGANISM", 60, 68], ["tract", "ORGANISM_SUBDIVISION", 105, 110], ["patients", "SPECIES", 60, 68], ["our study", "TEST", 3, 12], ["18 viral infectious episodes", "PROBLEM", 25, 53], ["mild respiratory tract infection", "PROBLEM", 88, 120], ["infectious", "OBSERVATION_MODIFIER", 34, 44], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["respiratory tract", "ANATOMY", 93, 110], ["infection", "OBSERVATION", 111, 120]]], ["Interestingly, we observed an increased risk of viral infection in patients with hypogammaglobulinemia, but no such correlation was seen with other types of infection (supplementary data).", [["viral infection", "DISEASE", 48, 63], ["hypogammaglobulinemia", "DISEASE", 81, 102], ["infection", "DISEASE", 157, 166], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["viral infection", "PROBLEM", 48, 63], ["hypogammaglobulinemia", "PROBLEM", 81, 102], ["infection", "PROBLEM", 157, 166], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["infection", "OBSERVATION", 54, 63], ["hypogammaglobulinemia", "OBSERVATION", 81, 102], ["infection", "OBSERVATION", 157, 166]]], ["We hypothesize that IgG deficiency at baseline might indicate pre-existing depleted plasma cell and antibody repertoire, which may have a more critical impact on the ability to mount viral-specific neutralizing IgG and predispose patients to infection after CAR T cell therapy.", [["plasma cell", "ANATOMY", 84, 95], ["T cell", "ANATOMY", 262, 268], ["IgG deficiency", "DISEASE", 20, 34], ["infection", "DISEASE", 242, 251], ["IgG", "GENE_OR_GENE_PRODUCT", 20, 23], ["plasma cell", "CELL", 84, 95], ["IgG", "GENE_OR_GENE_PRODUCT", 211, 214], ["patients", "ORGANISM", 230, 238], ["CAR T cell", "CELL", 258, 268], ["IgG", "PROTEIN", 20, 23], ["antibody repertoire", "PROTEIN", 100, 119], ["neutralizing IgG", "PROTEIN", 198, 214], ["patients", "SPECIES", 230, 238], ["IgG deficiency", "PROBLEM", 20, 34], ["pre-existing depleted plasma cell and antibody repertoire", "PROBLEM", 62, 119], ["specific neutralizing IgG", "PROBLEM", 189, 214], ["infection", "PROBLEM", 242, 251], ["CAR T cell therapy", "TREATMENT", 258, 276], ["IgG deficiency", "OBSERVATION", 20, 34], ["depleted plasma cell", "OBSERVATION", 75, 95]]], ["The significance of hypogammaglobulinemia on the risk of infection in patients treated with CD19 CAR T cells warrants further study.", [["CD19 CAR T cells", "ANATOMY", 92, 108], ["hypogammaglobulinemia", "DISEASE", 20, 41], ["infection", "DISEASE", 57, 66], ["patients", "ORGANISM", 70, 78], ["CD19", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD19 CAR T cells", "CELL_TYPE", 92, 108], ["patients", "SPECIES", 70, 78], ["hypogammaglobulinemia", "PROBLEM", 20, 41], ["infection", "PROBLEM", 57, 66], ["CD19 CAR T cells", "TREATMENT", 92, 108], ["further study", "TEST", 118, 131], ["hypogammaglobulinemia", "OBSERVATION", 20, 41], ["infection", "OBSERVATION", 57, 66]]], ["In the ELIANA trial, all pediatric patients with precursor B acute lymphoblastic leukemia (ALL) received IVIG replacement.", [["precursor B acute lymphoblastic leukemia", "ANATOMY", 49, 89], ["ALL", "ANATOMY", 91, 94], ["precursor B acute lymphoblastic leukemia", "DISEASE", 49, 89], ["ALL", "DISEASE", 91, 94], ["patients", "ORGANISM", 35, 43], ["precursor B acute lymphoblastic leukemia", "CANCER", 49, 89], ["ALL", "CANCER", 91, 94], ["IVIG", "SIMPLE_CHEMICAL", 105, 109], ["patients", "SPECIES", 35, 43], ["precursor B acute lymphoblastic leukemia", "PROBLEM", 49, 89], ["IVIG replacement", "TREATMENT", 105, 121], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["lymphoblastic leukemia", "OBSERVATION", 67, 89]]], ["In contrast, the proportion of IVIG replacement among DLBCL patients treated in pivotal studies was lower and ranged around 20\u201360%14,15,24.", [["DLBCL", "ANATOMY", 54, 59], ["DLBCL", "DISEASE", 54, 59], ["IVIG", "SIMPLE_CHEMICAL", 31, 35], ["DLBCL", "CANCER", 54, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["IVIG replacement", "TREATMENT", 31, 47], ["pivotal studies", "TEST", 80, 95], ["IVIG replacement", "OBSERVATION", 31, 47]]], ["Only 30% of our patients received IVIG replacement, of which half had a history of preceding recurrent infection after CAR T cell therapy.", [["T cell", "ANATOMY", 123, 129], ["infection", "DISEASE", 103, 112], ["patients", "ORGANISM", 16, 24], ["IVIG", "SIMPLE_CHEMICAL", 34, 38], ["CAR T cell", "CELL", 119, 129], ["patients", "SPECIES", 16, 24], ["IVIG replacement", "TREATMENT", 34, 50], ["preceding recurrent infection", "PROBLEM", 83, 112], ["CAR T cell therapy", "TREATMENT", 119, 137], ["recurrent", "OBSERVATION_MODIFIER", 93, 102], ["infection", "OBSERVATION", 103, 112], ["cell therapy", "OBSERVATION", 125, 137]]], ["The primary malignancy probably has a critical contribution to the risk of infection attributed to underlying immune function and kinetics of immune recovery.", [["primary malignancy", "ANATOMY", 4, 22], ["malignancy", "DISEASE", 12, 22], ["infection", "DISEASE", 75, 84], ["malignancy", "CANCER", 12, 22], ["The primary malignancy", "PROBLEM", 0, 22], ["infection", "PROBLEM", 75, 84], ["underlying immune function", "PROBLEM", 99, 125], ["immune recovery", "TREATMENT", 142, 157], ["primary", "OBSERVATION_MODIFIER", 4, 11], ["malignancy", "OBSERVATION", 12, 22], ["infection", "OBSERVATION", 75, 84], ["immune function", "OBSERVATION", 110, 125]]], ["Data from patients with B-ALL indicated that CD8+ lymphocyte recovered early whereas CD4+ lymphocyte had delayed recovery after CAR T cell therapy25.", [["B-ALL", "ANATOMY", 24, 29], ["CD8+ lymphocyte", "ANATOMY", 45, 60], ["CD4+ lymphocyte", "ANATOMY", 85, 100], ["T cell", "ANATOMY", 132, 138], ["ALL", "DISEASE", 26, 29], ["patients", "ORGANISM", 10, 18], ["B-ALL", "CANCER", 24, 29], ["CD8", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["CAR T cell therapy25", "GENE_OR_GENE_PRODUCT", 128, 148], ["CD8", "PROTEIN", 45, 48], ["CD4", "PROTEIN", 85, 88], ["CAR", "PROTEIN", 128, 131], ["patients", "SPECIES", 10, 18], ["CD8", "TEST", 45, 48], ["lymphocyte", "TEST", 50, 60], ["CD4", "TEST", 85, 88], ["CAR T cell therapy25", "TREATMENT", 128, 148], ["lymphocyte", "ANATOMY", 50, 60], ["lymphocyte", "ANATOMY", 90, 100]]], ["Further studies on infection prophylaxis, immunization, and immune reconstitution in CAR T cell-treated patients are warranted.DiscussionIn our study, we identified systemic corticosteroid as a predictor for infection after CAR T cell therapy whereas history of infection within 30 days before CAR T cell infusion was associated with severe bacterial infection, which may contribute to longer hospital stays in these patients.", [["T cell", "ANATOMY", 89, 95], ["T cell", "ANATOMY", 228, 234], ["T cell", "ANATOMY", 298, 304], ["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 208, 217], ["infection", "DISEASE", 262, 271], ["bacterial infection", "DISEASE", 341, 360], ["CAR T cell", "CELL", 85, 95], ["patients", "ORGANISM", 104, 112], ["CAR T cell", "CELL", 224, 234], ["CAR T cell", "CELL", 294, 304], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 417, 425], ["Further studies", "TEST", 0, 15], ["infection prophylaxis", "TREATMENT", 19, 40], ["immunization", "TREATMENT", 42, 54], ["immune reconstitution", "TREATMENT", 60, 81], ["CAR T cell-treated patients", "TREATMENT", 85, 112], ["our study", "TEST", 140, 149], ["systemic corticosteroid", "TREATMENT", 165, 188], ["infection", "PROBLEM", 208, 217], ["CAR T cell therapy", "TREATMENT", 224, 242], ["infection", "PROBLEM", 262, 271], ["CAR T cell infusion", "TREATMENT", 294, 313], ["severe bacterial infection", "PROBLEM", 334, 360], ["infection", "OBSERVATION", 262, 271], ["severe", "OBSERVATION_MODIFIER", 334, 340], ["bacterial", "OBSERVATION_MODIFIER", 341, 350], ["infection", "OBSERVATION", 351, 360]]], ["This observation is similar to another previous retrospective study8.", [["another previous retrospective study8", "TEST", 31, 68]]], ["We did not see an association between CRS and infectious complications in our lymphoma cohort.", [["lymphoma", "ANATOMY", 78, 86], ["CRS", "DISEASE", 38, 41], ["infectious complications", "DISEASE", 46, 70], ["lymphoma", "DISEASE", 78, 86], ["lymphoma", "CANCER", 78, 86], ["CRS", "PROBLEM", 38, 41], ["infectious complications", "PROBLEM", 46, 70], ["our lymphoma cohort", "PROBLEM", 74, 93], ["infectious", "OBSERVATION_MODIFIER", 46, 56], ["lymphoma", "OBSERVATION", 78, 86]]], ["Park and colleagues previously demonstrated severe CRS (grade \u2265 3) as a risk factor for bacterial infection in adult B-ALL treated with CD19 CAR T cells7,10.", [["B-ALL", "ANATOMY", 117, 122], ["CD19 CAR T cells", "ANATOMY", 136, 152], ["CRS", "DISEASE", 51, 54], ["bacterial infection", "DISEASE", 88, 107], ["B-ALL", "DISEASE", 117, 122], ["B-ALL", "CANCER", 117, 122], ["CD19", "GENE_OR_GENE_PRODUCT", 136, 140], ["CD19", "PROTEIN", 136, 140], ["severe CRS (grade \u2265 3", "PROBLEM", 44, 65], ["a risk factor", "PROBLEM", 70, 83], ["bacterial infection", "PROBLEM", 88, 107], ["CD19 CAR T cells", "TREATMENT", 136, 152], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["bacterial", "OBSERVATION_MODIFIER", 88, 97], ["infection", "OBSERVATION", 98, 107]]], ["Other risk factors for infection after CAR T cell therapy shown by previous studies included higher number of prior treatments, higher doses of CAR T cells, older age, previous history of infection, and CD22-specific CAR T cells5,8.", [["T cell", "ANATOMY", 43, 49], ["T cells", "ANATOMY", 148, 155], ["CAR T cells", "ANATOMY", 217, 228], ["infection", "DISEASE", 23, 32], ["infection", "DISEASE", 188, 197], ["CAR T cell", "CELL", 39, 49], ["CAR T cells", "CELL", 144, 155], ["CD22", "GENE_OR_GENE_PRODUCT", 203, 207], ["CAR T cells", "CELL_TYPE", 144, 155], ["CD22", "PROTEIN", 203, 207], ["CAR T cells", "CELL_TYPE", 217, 228], ["Other risk factors", "PROBLEM", 0, 18], ["infection", "PROBLEM", 23, 32], ["CAR T cell therapy", "TREATMENT", 39, 57], ["previous studies", "TEST", 67, 83], ["prior treatments", "TREATMENT", 110, 126], ["CAR T cells", "TREATMENT", 144, 155], ["infection", "PROBLEM", 188, 197], ["CD22", "TEST", 203, 207], ["infection", "OBSERVATION", 188, 197]]], ["Finally, a recent study described the association between double peak IL-6 pattern (second surge of serum IL-6 after initial normalization) and life-threatening infection26.", [["serum", "ANATOMY", 100, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 70, 74], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL", "PROTEIN", 70, 72], ["serum IL-6", "PROTEIN", 100, 110], ["a recent study", "TEST", 9, 23], ["double peak IL", "TEST", 58, 72], ["serum IL", "TEST", 100, 108], ["life-threatening infection26", "PROBLEM", 144, 172]]], ["Along with the current interest of anti-IL6 therapy in severe acute respiratory syndrome coronavirus 2 patients with respiratory failure27\u201334, it is at least worth noting that we did not observe an association between the use of tocilizumab and infections in this cohort.DiscussionOur study has unique strengths.", [["anti-IL6", "CHEMICAL", 35, 43], ["acute respiratory syndrome coronavirus", "DISEASE", 62, 100], ["respiratory failure27\u201334", "DISEASE", 117, 141], ["tocilizumab", "CHEMICAL", 229, 240], ["infections", "DISEASE", 245, 255], ["anti-IL6", "SIMPLE_CHEMICAL", 35, 43], ["patients", "ORGANISM", 103, 111], ["tocilizumab", "SIMPLE_CHEMICAL", 229, 240], ["patients", "SPECIES", 103, 111], ["severe acute respiratory syndrome coronavirus", "SPECIES", 55, 100], ["anti-IL6 therapy", "TREATMENT", 35, 51], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 55, 100], ["respiratory failure27\u201334", "PROBLEM", 117, 141], ["tocilizumab", "TREATMENT", 229, 240], ["infections", "PROBLEM", 245, 255], ["DiscussionOur study", "TEST", 271, 290], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome", "OBSERVATION", 68, 88], ["respiratory failure27\u201334", "OBSERVATION", 117, 141]]], ["We comprehensively analyzed the real-world data on patterns of infection, detailed information on relevant immune status and prophylactic strategies during the first year after CAR T cell therapy in patients with DLBCL from a dedicated lymphoma patient cohort.", [["T cell", "ANATOMY", 181, 187], ["DLBCL", "ANATOMY", 213, 218], ["lymphoma", "ANATOMY", 236, 244], ["infection", "DISEASE", 63, 72], ["DLBCL", "DISEASE", 213, 218], ["lymphoma", "DISEASE", 236, 244], ["CAR T cell", "CELL", 177, 187], ["patients", "ORGANISM", 199, 207], ["DLBCL", "CANCER", 213, 218], ["lymphoma", "CANCER", 236, 244], ["patient", "ORGANISM", 245, 252], ["patients", "SPECIES", 199, 207], ["patient", "SPECIES", 245, 252], ["infection", "PROBLEM", 63, 72], ["prophylactic strategies", "TREATMENT", 125, 148], ["CAR T cell therapy", "TREATMENT", 177, 195], ["DLBCL", "PROBLEM", 213, 218], ["a dedicated lymphoma patient cohort", "TREATMENT", 224, 259], ["infection", "OBSERVATION", 63, 72], ["lymphoma", "OBSERVATION", 236, 244]]], ["We acknowledge several limitations of this study.", [["this study", "TEST", 38, 48]]], ["Besides its retrospective nature, immune function monitoring and infection prophylaxis were not prospectively studied in a systematic manner.", [["infection", "DISEASE", 65, 74], ["immune function monitoring", "TEST", 34, 60], ["infection prophylaxis", "TREATMENT", 65, 86]]], ["Lastly, the relatively small number of patients included in the study could limit its statistical power.DiscussionIn summary, infection is common in DLBCL patients treated with CD19 CAR T cells.", [["DLBCL", "ANATOMY", 149, 154], ["CD19 CAR T cells", "ANATOMY", 177, 193], ["infection", "DISEASE", 126, 135], ["DLBCL", "DISEASE", 149, 154], ["patients", "ORGANISM", 39, 47], ["DLBCL", "CANCER", 149, 154], ["patients", "ORGANISM", 155, 163], ["CD19", "GENE_OR_GENE_PRODUCT", 177, 181], ["CD19 CAR T cells", "CELL_TYPE", 177, 193], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 155, 163], ["the study", "TEST", 60, 69], ["infection", "PROBLEM", 126, 135], ["CD19 CAR T cells", "TREATMENT", 177, 193], ["relatively", "OBSERVATION_MODIFIER", 12, 22], ["small", "OBSERVATION_MODIFIER", 23, 28], ["number", "OBSERVATION_MODIFIER", 29, 35], ["infection", "OBSERVATION", 126, 135]]], ["However, most events occurred early after CAR T cell therapy and were largely manageable.", [["T cell", "ANATOMY", 46, 52], ["CAR T cell", "CELL", 42, 52], ["CAR T cell therapy", "TREATMENT", 42, 60], ["manageable", "OBSERVATION_MODIFIER", 78, 88]]], ["The mechanism of infection in these patients is complex and multifactorial.", [["infection", "DISEASE", 17, 26], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["infection", "PROBLEM", 17, 26], ["infection", "OBSERVATION", 17, 26]]], ["Appropriate infection prophylaxis in these patients remain to be determined, and prospective clinical trials are warranted.", [["infection", "DISEASE", 12, 21], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Appropriate infection prophylaxis", "TREATMENT", 0, 33], ["infection", "OBSERVATION", 12, 21]]]], "9a10a6987343e532af5fec63470acee2629008a6": [["shows the observed and predicted total VOCs concentrations (in the unit 1 of ppbC) before and after the shutdown.", [["VOCs", "CHEMICAL", 39, 43]]], ["The predicted total VOCs concentrations 2 agree well with observed concentrations, and the difference between predictions and 3 observations is less than 10% in both periods.", [["The predicted total VOCs concentrations", "TREATMENT", 0, 39]]], ["The changes in total VOCs 4 concentrations are also well predicted, with observed 8% decrease vs. predicted 10% 5 decrease.", [["The changes in total VOCs 4 concentrations", "PROBLEM", 0, 42]]], ["Fig. S1b shows the relative changes in different VOC species.", [["S1b", "PROTEIN", 5, 8], ["different VOC species", "PROBLEM", 39, 60], ["relative", "OBSERVATION_MODIFIER", 19, 27], ["changes", "OBSERVATION_MODIFIER", 28, 35], ["different", "OBSERVATION_MODIFIER", 39, 48], ["VOC species", "OBSERVATION", 49, 60]]], ["Different 6 species show different changes and the model generally predicts well the decreasing 7 trends of most species, although a few species show relatively large discrepancy such 8 as some alkanes and aromatics.9The changes of meteorological conditions in Shanghai before and during the 10 lockdown are shown in Fig. S3 .", [["alkanes", "CHEMICAL", 194, 201], ["aromatics", "CHEMICAL", 206, 215], ["alkanes", "CHEMICAL", 194, 201], ["aromatics", "CHEMICAL", 206, 215], ["alkanes", "SIMPLE_CHEMICAL", 194, 201], ["aromatics", "SIMPLE_CHEMICAL", 206, 215], ["S3", "GENE_OR_GENE_PRODUCT", 322, 324], ["Different 6 species", "PROBLEM", 0, 19], ["different changes", "PROBLEM", 25, 42], ["most species", "PROBLEM", 108, 120], ["a few species", "PROBLEM", 131, 144], ["meteorological conditions", "PROBLEM", 232, 257], ["different changes", "OBSERVATION", 25, 42], ["decreasing", "OBSERVATION_MODIFIER", 85, 95], ["most species", "OBSERVATION_MODIFIER", 108, 120], ["relatively", "OBSERVATION_MODIFIER", 150, 160], ["large", "OBSERVATION_MODIFIER", 161, 166], ["discrepancy", "OBSERVATION", 167, 178], ["meteorological conditions", "OBSERVATION", 232, 257]]], ["Compared to the conditions before the lockdown, 2m 11 temperature increased by 2 K, PBLH increased by 44%, RH decreased by 23%, and 12 more north and east winds with 0.7 m/s slightly higher mean wind speed.", [["temperature", "TEST", 54, 65], ["PBLH", "TEST", 84, 88], ["RH", "TEST", 107, 109], ["decreased", "OBSERVATION_MODIFIER", 110, 119]]], ["The relative 13 changes of PM2.5 and O3 due to variation of meteorological conditions show obvious 14 difference.", [["PM2.5", "CHEMICAL", 27, 32], ["O3", "CHEMICAL", 37, 39], ["PM2.5", "CHEMICAL", 27, 32], ["O3", "CHEMICAL", 37, 39], ["PM2.5", "SIMPLE_CHEMICAL", 27, 32], ["O3", "SIMPLE_CHEMICAL", 37, 39], ["PM2.5", "TREATMENT", 27, 32], ["O3", "TREATMENT", 37, 39], ["meteorological conditions", "TEST", 60, 85], ["obvious 14 difference", "PROBLEM", 91, 112], ["13 changes", "OBSERVATION_MODIFIER", 13, 23]]], ["16 However, higher temperature, higher PBLH and lower RH partly compensate the 17 PM2.5 increase due to transport.", [["higher temperature", "PROBLEM", 12, 30], ["higher PBLH", "PROBLEM", 32, 43], ["lower RH", "PROBLEM", 48, 56], ["higher temperature", "OBSERVATION_MODIFIER", 12, 30]]], ["On contrary, these changes in the meteorological 18 conditions are conducive to more formation and less titration of O3.", [["O3", "CHEMICAL", 117, 119], ["O3", "CHEMICAL", 117, 119], ["O3", "SIMPLE_CHEMICAL", 117, 119]]], ["119The results suggest that O3 is strongly VOC-limited in the four cities during the 20 winter episode.", [["O3", "CHEMICAL", 28, 30], ["VOC", "CHEMICAL", 43, 46], ["O3", "CHEMICAL", 28, 30], ["O3", "SIMPLE_CHEMICAL", 28, 30]]], ["The VOC-limited situation has been reported in YRD in summer Figure S4 ) confirm that the 24 VOC-limited situation during the studying period, and indicate that the O3-NOx 25 relationship is approximately linear in this study case.", [["VOC", "CHEMICAL", 4, 7], ["O3", "CHEMICAL", 165, 167], ["NOx", "CHEMICAL", 168, 171], ["O3-NOx 25", "CHEMICAL", 165, 174], ["O3", "SIMPLE_CHEMICAL", 165, 167], ["approximately", "OBSERVATION_MODIFIER", 191, 204], ["linear", "OBSERVATION_MODIFIER", 205, 211]]], ["This is also proved by the data the lockdown (OBS is mean observation; PRE is mean prediction; NMB is 48 normalized mean bias; NME is normalized mean error).", [["NMB", "TEST", 95, 98]]], ["Figure S1 . (a)Observed and predicted total VOCs concentrations (ppbC) before and after the 54 lockdown in Shanghai; (b) Observed and predicted relative changes in different VOC species due 5519to COVID-19 lockdown in Shanghai.", [["VOCs", "CHEMICAL", 44, 48], ["relative changes in different VOC species", "PROBLEM", 144, 185], ["COVID", "TEST", 197, 202], ["VOC species", "OBSERVATION", 174, 185]]], ["Spatial distributions of predicted PM2.5 and MDA8 O3 and changes 58 between S0 and S1 in February 2020.", [["O3", "CHEMICAL", 50, 52], ["O3", "CHEMICAL", 50, 52], ["MDA8 O3", "TREATMENT", 45, 52]]]], "PMC7253048": [["FREQUENT CHECKS FOR SYMPTOMS SUCH AS FEVER, COUGH, DYSPNEA, OR RHINORRHEA IN PATIENTS OR STAFFThe coronavirus disease is believed to be highly contagious and symptomatic, although silent transmission of asymptomatic cases has also been reported.", [["coronavirus disease", "DISEASE", 98, 117], ["coronavirus", "ORGANISM", 98, 109], ["coronavirus", "SPECIES", 98, 109], ["FREQUENT CHECKS", "TEST", 0, 15], ["SYMPTOMS", "PROBLEM", 20, 28], ["FEVER", "PROBLEM", 37, 42], ["COUGH", "PROBLEM", 44, 49], ["DYSPNEA", "PROBLEM", 51, 58], ["RHINORRHEA", "PROBLEM", 63, 73], ["The coronavirus disease", "PROBLEM", 94, 117], ["symptomatic", "PROBLEM", 158, 169], ["asymptomatic cases", "PROBLEM", 203, 221], ["RHINORRHEA", "OBSERVATION", 63, 73], ["coronavirus disease", "OBSERVATION", 98, 117], ["believed to be", "UNCERTAINTY", 121, 135], ["highly", "OBSERVATION_MODIFIER", 136, 142], ["contagious", "OBSERVATION", 143, 153], ["symptomatic", "OBSERVATION_MODIFIER", 158, 169]]], ["Frequent symptom check in patients or medical staff before rehabilitation can minimize the spread of the virus in confined spaces such as physical therapy rooms.MASK WEARING DURING TREATMENTThe novel coronavirus has been reported to spread through droplets and airborne transmission.2,3 These two main routes of 2019-nCoV infections are categorized by particle size.", [["2,3", "CHEMICAL", 283, 286], ["infections", "DISEASE", 322, 332], ["patients", "ORGANISM", 26, 34], ["coronavirus", "ORGANISM", 200, 211], ["2,3", "SIMPLE_CHEMICAL", 283, 286], ["patients", "SPECIES", 26, 34], ["Frequent symptom", "PROBLEM", 0, 16], ["rehabilitation", "TREATMENT", 59, 73], ["the virus", "PROBLEM", 101, 110], ["TREATMENT", "TREATMENT", 181, 190], ["The novel coronavirus", "PROBLEM", 190, 211], ["nCoV infections", "PROBLEM", 317, 332], ["coronavirus", "OBSERVATION", 200, 211], ["main", "OBSERVATION_MODIFIER", 297, 301], ["infections", "OBSERVATION", 322, 332], ["particle", "OBSERVATION_MODIFIER", 352, 360], ["size", "OBSERVATION_MODIFIER", 361, 365]]], ["Droplet infection is defined when large droplets that carry the infectious agent (>5 \u03bcm in diameter) become an infection source.4 By contrast, airborne infection is defined when the infection usually occurs via the respiratory route, with the agent present in aerosols (infectious particles of <5 \u03bcm in diameter).4 The droplets tend to be heavy and thus do not go far and stay around the patient (within 2 m of indoor air), mainly causing close-contact transmission.", [["respiratory", "ANATOMY", 215, 226], ["infection", "DISEASE", 8, 17], ["infection", "DISEASE", 111, 120], ["airborne infection", "DISEASE", 143, 161], ["infection", "DISEASE", 182, 191], ["patient", "ORGANISM", 388, 395], ["patient", "SPECIES", 388, 395], ["Droplet infection", "PROBLEM", 0, 17], ["large droplets", "PROBLEM", 34, 48], ["the infectious agent", "PROBLEM", 60, 80], ["an infection source", "PROBLEM", 108, 127], ["airborne infection", "PROBLEM", 143, 161], ["the infection", "PROBLEM", 178, 191], ["the respiratory route", "TREATMENT", 211, 232], ["the agent", "TREATMENT", 239, 248], ["infection", "OBSERVATION", 8, 17], ["large", "OBSERVATION_MODIFIER", 34, 39], ["droplets", "OBSERVATION", 40, 48], ["infectious", "OBSERVATION_MODIFIER", 64, 74], ["infection", "OBSERVATION", 111, 120], ["infection", "OBSERVATION", 152, 161], ["infection", "OBSERVATION", 182, 191], ["infectious", "OBSERVATION_MODIFIER", 270, 280]]], ["On the other hand, aerosols float through the air and can cause both long-distance contactless infections and close-contact transmission.", [["infections", "DISEASE", 95, 105], ["both long-distance contactless infections", "PROBLEM", 64, 105]]], ["Preliminary studies have shown that the main transmission route of 2019-nCoV is through respiratory droplets, although airborne transmission cannot be completely excluded.", [["respiratory droplets", "ANATOMY", 88, 108], ["Preliminary studies", "TEST", 0, 19], ["respiratory droplets", "PROBLEM", 88, 108], ["airborne transmission", "PROBLEM", 119, 140], ["main", "OBSERVATION_MODIFIER", 40, 44], ["respiratory droplets", "OBSERVATION", 88, 108], ["cannot be completely excluded", "UNCERTAINTY", 141, 170]]], ["The size of coronavirus is approximately 0.12\u20130.15 \u03bcm5; thus, the 2019-nCoV is not easy to directly filter except with a mask such as N95, which has filtration efficiencies for most penetrating particles sized 0.1\u20130.3 \u03bcm.6 However, wearing a mask such as a surgical or dental mask, as well as the N95 mask, has been reported to have an effect of blocking viral transmissions because the mask filters droplets or aerosols containing virus particles rather than the virus itself.7 The surgical mask is also designed to filter 99.9% of aerosols of 3 \u03bcm in size that contain bacteria or viruses.", [["coronavirus", "DISEASE", 12, 23], ["coronavirus", "ORGANISM", 12, 23], ["2019-nCoV", "DNA", 66, 75], ["N95", "CELL_LINE", 134, 137], ["a mask", "TREATMENT", 119, 125], ["N95", "TREATMENT", 134, 137], ["filtration efficiencies", "TREATMENT", 149, 172], ["most penetrating particles sized", "TREATMENT", 177, 209], ["a mask", "TREATMENT", 240, 246], ["a surgical or dental mask", "TREATMENT", 255, 280], ["the N95 mask", "TREATMENT", 293, 305], ["blocking viral transmissions", "TREATMENT", 346, 374], ["the mask filters droplets", "TREATMENT", 383, 408], ["aerosols containing virus particles", "PROBLEM", 412, 447], ["The surgical mask", "TREATMENT", 479, 496], ["filter", "TEST", 517, 523], ["aerosols", "TEST", 533, 541], ["bacteria", "PROBLEM", 571, 579], ["viruses", "PROBLEM", 583, 590], ["size", "OBSERVATION_MODIFIER", 4, 8], ["coronavirus", "OBSERVATION", 12, 23], ["approximately", "OBSERVATION_MODIFIER", 27, 40], ["filter", "OBSERVATION", 100, 106], ["filtration efficiencies", "OBSERVATION", 149, 172], ["N95 mask", "OBSERVATION", 297, 305], ["virus particles", "OBSERVATION", 432, 447], ["surgical mask", "OBSERVATION", 483, 496], ["size", "OBSERVATION_MODIFIER", 553, 557], ["bacteria", "OBSERVATION", 571, 579], ["viruses", "OBSERVATION", 583, 590]]], ["Considering this, not only N95 masks but also surgical masks can also filter out all droplets that contain large amounts of viruses entering or leaving the respiratory tract and a significant amount of aerosols.", [["respiratory tract", "ANATOMY", 156, 173], ["respiratory tract", "ORGANISM_SUBDIVISION", 156, 173], ["N95 masks", "TREATMENT", 27, 36], ["surgical masks", "TREATMENT", 46, 60], ["all droplets", "TREATMENT", 81, 93], ["large amounts of viruses", "PROBLEM", 107, 131], ["the respiratory tract", "PROBLEM", 152, 173], ["large", "OBSERVATION_MODIFIER", 107, 112], ["amounts", "OBSERVATION_MODIFIER", 113, 120], ["viruses", "OBSERVATION", 124, 131], ["respiratory tract", "ANATOMY", 156, 173], ["significant", "OBSERVATION_MODIFIER", 180, 191], ["amount", "OBSERVATION_MODIFIER", 192, 198], ["aerosols", "OBSERVATION", 202, 210]]], ["Considering that a significant amount of viral penetration is required for virus infection, mask wearing for both the therapist and the patient during rehabilitation treatment is believed to show a reduction effect on the transmission of 2019-nCoV.AVOIDING FACE-TO-FACE CONVERSATIONS BETWEEN MEDICAL STAFF AND PATIENTSAs seen in the 2019-nCoV infection cases in South Korea, droplets and aerosols, which are produced during conversations, prayers, and singing among people who sit densely in a limited space such as religious facilities like churches, seem to be the main cause of COVID-19 propagation.", [["infection", "DISEASE", 81, 90], ["infection", "DISEASE", 343, 352], ["patient", "ORGANISM", 136, 143], ["people", "ORGANISM", 466, 472], ["patient", "SPECIES", 136, 143], ["people", "SPECIES", 466, 472], ["viral penetration", "PROBLEM", 41, 58], ["virus infection", "PROBLEM", 75, 90], ["mask wearing", "TREATMENT", 92, 104], ["rehabilitation treatment", "TREATMENT", 151, 175], ["a reduction effect", "PROBLEM", 196, 214], ["COVID", "TEST", 581, 586], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["viral penetration", "OBSERVATION", 41, 58], ["reduction", "OBSERVATION", 198, 207], ["infection", "OBSERVATION", 343, 352]]], ["In addition, COVID-19 can also spread through having a meal and conversation together, as can be observed in many countries.", [["COVID-19", "CHEMICAL", 13, 21], ["COVID", "TEST", 13, 18]]], ["Therefore, avoiding talking and having a meal together while facing each other not only between patients and medical staff but also among medical staff may help prevent the spread of COVID-19.CHANGING THE REHABILITATIVE METHODS FOR PATIENTS WITH SYMPTOMS OR CONTACT HISTORY WITH COVID-19 PATIENTSHigh false-negative rates in real-time polymerase chain reaction tests for 2019-nCoV have been reported.8 Therefore, if the patient has symptoms or contact with a COVID-19 patient, careful observation and changing to bedside physical therapy in isolation for at least 2 weeks may be helpful in decreasing the COVID-19 propagation rate even if real-time polymerase chain reaction results are negative.CHANGING THE REHABILITATIVE METHODS FOR PATIENTS WITH SYMPTOMS OR CONTACT HISTORY WITH COVID-19 PATIENTSThe COVID-19 outbreak will cause many limitations in the rehabilitation department and other hospital facilities.", [["COVID-19", "CHEMICAL", 183, 191], ["patients", "ORGANISM", 96, 104], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 371, 380], ["patient", "ORGANISM", 420, 427], ["patient", "ORGANISM", 468, 475], ["patients", "SPECIES", 96, 104], ["patient", "SPECIES", 420, 427], ["patient", "SPECIES", 468, 475], ["COVID", "TEST", 183, 188], ["SYMPTOMS", "PROBLEM", 246, 254], ["COVID", "TEST", 279, 284], ["symptoms", "PROBLEM", 432, 440], ["careful observation", "TEST", 477, 496], ["bedside physical therapy", "TREATMENT", 513, 537], ["the COVID", "TEST", 601, 610], ["propagation rate", "TEST", 614, 630], ["polymerase chain reaction", "TEST", 649, 674], ["SYMPTOMS", "PROBLEM", 750, 758]]], ["Protocols for patient management and treatment plans for patients with COVID-19 in the rehabilitation department must begin in full force before the disease spreads further.", [["patient", "ORGANISM", 14, 21], ["patients", "ORGANISM", 57, 65], ["patient", "SPECIES", 14, 21], ["patients", "SPECIES", 57, 65], ["patient management", "TREATMENT", 14, 32], ["treatment plans", "TREATMENT", 37, 52], ["COVID", "TREATMENT", 71, 76], ["disease", "OBSERVATION", 149, 156]]]]}